<SEC-DOCUMENT>0001564590-18-005876.txt : 20180315
<SEC-HEADER>0001564590-18-005876.hdr.sgml : 20180315
<ACCEPTANCE-DATETIME>20180315171053
ACCESSION NUMBER:		0001564590-18-005876
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180315
DATE AS OF CHANGE:		20180315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UroGen Pharma Ltd.
		CENTRAL INDEX KEY:			0001668243
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38079
		FILM NUMBER:		18693289

	BUSINESS ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
		BUSINESS PHONE:		972 9 770 7601

	MAIL ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>urgn-20f_20171231.htm
<DESCRIPTION>20-F
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-20f_20171231.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:33.33%;margin-right:33.33%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 20-F</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:33.33%;margin-right:33.33%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:MS Mincho;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-size:10pt;font-family:MS Mincho;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2017</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for the transition period from&#160;<font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;to <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of event requiring this shell company report</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number 001-38079</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Translation of Registrant&#8217;s name into English)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Israel </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Jurisdiction of incorporation)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9 Ha&#8217;Ta&#8217;asiya Street</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ra&#8217;anana 4365007, Israel</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(address of principal executive offices)</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ron Bentsur</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9 Ha&#8217;Ta&#8217;asiya Street</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ra&#8217;anana 4365007, Israel</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tel: +972 (9) 770-7601</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fax: +972 (77) 417-1410</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:33.33%;margin-right:33.33%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered or to be registered, pursuant to Section&#160;12(b) of the Act</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="middle"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary Shares, par value NIS 0.01 per share</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Market</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered or to be registered pursuant to Section&#160;12(g) of the Act. None </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Title of Class)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities for which there is a reporting obligation pursuant to Section&#160;15(d) of the Act. None</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Title of Class)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="color:#000000;">&#9746;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934. &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="color:#000000;font-family:MS Mincho;">&#9746;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="color:#000000;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). &#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="color:#000000;">&#9746;</font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
<td valign="top"  style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font></p></td>
<td valign="top"  style="width:25%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<font style="color:#000000;font-family:MS Mincho;">&#9746;</font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8201;&#8224; provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="color:#000000;">&#9746;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#8201;The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.&#160;GAAP&#160;&#160;<font style="color:#000000;font-family:MS Mincho;">&#9746;</font></p></td>
<td valign="top"  style="width:59.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International Financial Reporting Standards as issued</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by the International Accounting Standards Board&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
<td valign="top"  style="width:20.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow.&#160;&#160;&#160;&#160;Item&#160;17&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;Item&#160;18&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="color:#000000;">&#9746;</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital stock or common stock as of the close of business as of December 31, 2017. &#160;13,751,390&#160;Ordinary Shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:left;margin-top:0pt;border-top:Double 2.25pt;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.06%;margin-right:0.93%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#INTRODUCTION"><font style="text-decoration:underline;">INTRODUCTION</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"><font style="text-decoration:underline;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:underline;">PART I</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_IDENTITY_DIRECTORS_SENIOR_MANAGEM"><font style="text-decoration:underline;">Item 1. Identity of Directors, Senior Management and Advisers</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_FER_STATISTICS_EXPECTED_TIMETABLE"><font style="text-decoration:underline;">Item 2. Offer Statistics and Expected Timetable</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_KEY_INFORMATION"><font style="text-decoration:underline;">Item 3. Key Information</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">A.&#160;&#160;Selected financial data</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_3B"><font style="text-decoration:underline;">B.&#160;&#160;Capitalization and indebtedness</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_3C"><font style="text-decoration:underline;">C.&#160;&#160;Reasons for the offer and use of proceeds</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_3D"><font style="text-decoration:underline;">D.&#160;&#160;Risk factors</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4"><font style="text-decoration:underline;">Item 4 Information on the Company</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4A"><font style="text-decoration:underline;">A.&#160;&#160;History and development of the company</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4B"><font style="text-decoration:underline;">B.&#160;&#160;Business overview</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4C"><font style="text-decoration:underline;">C.&#160;&#160;Organizational structure</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4D"><font style="text-decoration:underline;">D.&#160;&#160;Property, plants and equipment</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_4_A"><font style="text-decoration:underline;">Item 4A. Unresolved Staff Comments</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5"><font style="text-decoration:underline;">Item 5. Operating and Financial Review and Prospects</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5A"><font style="text-decoration:underline;">A.&#160;&#160;Operating results</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5B"><font style="text-decoration:underline;">B.&#160;&#160;Liquidity and capital resources</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5C"><font style="text-decoration:underline;">C.&#160;&#160;Research and development, patents and licenses, etc.</font></a><font style="text-decoration:none;color:#auto;"> </font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5D"><font style="text-decoration:underline;">D.&#160;&#160;Trend information</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5E"><font style="text-decoration:underline;">E.&#160;&#160;Off-balance sheet arrangements</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5F"><font style="text-decoration:underline;">F.&#160;&#160;Tabular disclosure of contractual obligations</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_5G"><font style="text-decoration:underline;">G.&#160;&#160;Safe harbor</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_6"><font style="text-decoration:underline;">Item 6. Directors, Senior Management and Employees</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_6A"><font style="text-decoration:underline;">A.&#160;&#160;Directors and senior management</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_6B"><font style="text-decoration:underline;">B.&#160;&#160;Compensation</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_6C"><font style="text-decoration:underline;">C.&#160;&#160;Board Practices</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_6D"><font style="text-decoration:underline;">D.&#160;&#160;Employees</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_6E"><font style="text-decoration:underline;">E.&#160;&#160;Share ownership</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MAJOR_SHAREHOLDERS_RELATED_PARTY_"><font style="text-decoration:underline;">Item 7. Major Shareholders and Related Party Transactions</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#A_MAJOR_SHAREHOLDERS"><font style="text-decoration:underline;">A.&#160;&#160;Major shareholders</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#RELATED_PARTY_TRANSACTIONS"><font style="text-decoration:underline;">B.&#160;&#160;Related party transactions</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#C_INTERESTS_EXPERTS_COUNSEL"><font style="text-decoration:underline;">C.&#160;&#160;Interests of experts and counsel</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#_Item_8._Financial"><font style="text-decoration:underline;">Item 8. Financial Information</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#A_CONSOLIDATED_STATEMENTS_OR_FINANCIAL_I"><font style="text-decoration:underline;">A.&#160;&#160;Consolidated Statements and Other Financial Information</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#B_SIGNIFICANT_CHANGES"><font style="text-decoration:underline;">B.&#160;&#160;Significant Changes</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_FER_LISTING"><font style="text-decoration:underline;">Item 9. The Offer and Listing</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#A_FER_LISTING_DETAILS"><font style="text-decoration:underline;">A.&#160;&#160;Offer and listing details</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#B_PLAN_DISTRIBUTION"><font style="text-decoration:underline;">B.&#160;&#160;Plan of distribution</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#C_MARKETS"><font style="text-decoration:underline;">C.&#160;&#160;Markets</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#D_SELLING_SHAREHOLDERS"><font style="text-decoration:underline;">D.&#160;&#160;Selling shareholders</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#E_DILUTION"><font style="text-decoration:underline;">E.&#160;&#160;Dilution</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#F_EXPENSES__ISSUE"><font style="text-decoration:underline;">F.&#160;&#160;Expenses of the issue</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_ADDITIONAL_INFORMATION"><font style="text-decoration:underline;">Item 10. Additional Information</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#A_SHARE_CAPITAL"><font style="text-decoration:underline;">A.&#160;&#160;Share capital</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#B_MEMORUM_ARTICLES_ASSOCIATION"><font style="text-decoration:underline;">B.&#160;&#160;Memorandum and articles of association</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#C_MATERIAL_CONTRACTS"><font style="text-decoration:underline;">C.&#160;&#160;Material contracts</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#D_EXCHANGE_CONTROLS"><font style="text-decoration:underline;">D.&#160;&#160;Exchange controls</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#E_TAXATION"><font style="text-decoration:underline;">E.&#160;&#160;Taxation</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#F_DIVIDENDS_PAYING_AGENTS"><font style="text-decoration:underline;">F.&#160;&#160;Dividends and paying agents</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#G_STATEMENT_BY_EXPERTS"><font style="text-decoration:underline;">G.&#160;&#160;Statement by experts</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#H_DOCUMENTS_ON_DISPLAY"><font style="text-decoration:underline;">H.&#160;&#160;Documents on display</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#I_SUBSIDIARY_INFORMATION"><font style="text-decoration:underline;">I.&#160;&#160;Subsidiary Information</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.06%;margin-right:0.93%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.06%;margin-right:0.93%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(continued)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Item 11. Quantitative and Qualitative Disclosures About Market Risk</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_DESCRIPTION_SECURITIES_OR_THAN_E"><font style="text-decoration:underline;">Item 12. Description of Securities Other than Equity Securities</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#DEBT_SECURITIES"><font style="text-decoration:underline;">A.&#160;&#160;Debt Securities</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#B_WARRANTS_RIGHTS"><font style="text-decoration:underline;">B.&#160;&#160;Warrants and Rights</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#C_OR_SECURITIES"><font style="text-decoration:underline;">C.&#160;&#160;Other Securities</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#D_AMERICAN_DEPOSITARY_SHARES"><font style="text-decoration:underline;">D.&#160;&#160;American Depositary Shares</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:underline;">PART II</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_DEFAULTS_DIVIDEND_ARREARAGES_DEL"><font style="text-decoration:underline;">Item 13. Defaults, Dividend Arrearages and Delinquencies</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_MATERIAL_MODIFICATIONS_TO_RIGHTS"><font style="text-decoration:underline;">Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Item 15. Controls and Procedures</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_RESERVED"><font style="text-decoration:underline;">Item 16. [Reserved]</font></a><font style="text-decoration:none;color:#auto;"> </font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16A_AUDIT_COMMITTEE_FINANCIAL_EXPER"><font style="text-decoration:underline;">Item 16A. Audit committee financial expert</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16B_CODE_ETHICS"><font style="text-decoration:underline;">Item 16B. Code of Ethics</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16C_PRINCIPAL_ACCOUNTANT_FEES_SERVI"><font style="text-decoration:underline;">Item 16C. Principal Accountant Fees and Services</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16D_EXEMPTIONS_FROM_LISTING_STARDS_"><font style="text-decoration:underline;">Item 16D. Exemptions from the Listing Standards for Audit Committees</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16E_PURCHASES_EQUITY_SECURITIES_BY_"><font style="text-decoration:underline;">Item 16E Purchases of Equity Securities by the Issuer and Affiliated Purchasers</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFYIN"><font style="text-decoration:underline;">Item 16F. Change in Registrant&#8217;s Certifying Accountant</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16G_CORPORATE_GOVERNANCE"><font style="text-decoration:underline;">Item 16G. Corporate Governance</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16H_MINE_SAFETY_DISCLOSURE"><font style="text-decoration:underline;">Item 16H. Mine Safety Disclosure</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:underline;">PART III</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_17_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Item 17. Financial Statements</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_18_FINANCIAL_STATEMENTS"><font style="text-decoration:underline;">Item 18. Financial Statements</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:49pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_19"><font style="text-decoration:underline;">Item 19. Exhibits</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-ii-</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="Presentation_Financial_Info"></a><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><a name="INTRODUCTION"></a><font style="font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="INTRODUCTION"></a>Introd</font><font style="font-weight:bold;font-size:10pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">uction</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise indicated, &#8220;UroGen Pharma,&#8221; &#8220;the Company,&#8221; &#8220;our Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to UroGen Pharma Ltd.&nbsp;&nbsp;and its subsidiary, Urogen Pharma, Inc. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MitoGel, VesiGel, Vesimune, UroGen and RTGel are trademarks of ours that we use in this annual report. This annual report also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this annual report appear without the &#174; or &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain our books and records in U.S. dollars, and prepare our financial statements in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms &#8220;shekel,&#8221; &#8220;Israeli shekel&#8221; and &#8220;NIS&#8221; refer to New Israeli Shekels, the lawful currency of the State of Israel, and the terms &#8220;dollar,&#8221; &#8220;U.S. dollar&#8221; or &#8220;$&#8221; refer to United States dollars, the lawful currency of the United States. All references to &#8220;shares&#8221; in this annual report refer to ordinary shares of UroGen Pharma Ltd., par value NIS 0.01 per share.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have made rounding adjustments to some of the figures included in this annual report.&#160;Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><a name="CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CAUTIONARY_STATEMENT_REGARDING_FORWARDLO"></a>CAUTIONARY STATEMENT REGARDIN</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">G FORWARD-LOOKING STATEMENTS</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and conduct of our clinical trials of MitoGel, VesiGel and our other product candidates, including statements regarding the timing, progress and results of current and future preclinical studies and clinical trials, and our research and development programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of MitoGel, VesiGel and our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our plans regarding utilization of regulatory pathways that would allow for accelerated marketing approval in the United States;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding timing for application for and receipt of regulatory approval for any of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ongoing and planned discovery and development of product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding future growth, including our ability to develop, and obtain regulatory approval for, new product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to maintain our collaboration with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, enter into and successfully complete other collaborations, licensing arrangements or in-license or acquire rights to other products, product candidates or technologies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our plans to develop and commercialize our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our estimates regarding the market opportunity for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our estimates regarding expenses, future revenues, capital requirements and the need for additional financing; our planned level of capital expenditures and our belief that our existing cash, cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the impact of our research and development expenses as we continue developing product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our expectations regarding the maintenance of our foreign private issuer status; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the impact of government laws and regulations.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should refer to the section of this annual report titled &#8220;Item 3.D&#8212;Risk Factors&#8221; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this annual report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read this annual report and the documents that we reference in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report may contain market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this annual report is generally reliable, such information is inherently imprecise.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><a name="PART_I"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>PAR</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T I</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_IDENTITY_DIRECTORS_SENIOR_MANAGEM"></a><a name="ITEM_1_IDENTITY_DIRECTORS_SENIOR_MANAGEM"></a>Item 1. Identity of Directors, Senior Management and Advisers</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_FER_STATISTICS_EXPECTED_TIMETABLE"></a><a name="ITEM_2_FER_STATISTICS_EXPECTED_TIMETABLE"></a>Item 2. Offer Statistics and Expected Timetable </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_KEY_INFORMATION"></a><a name="ITEM_3_KEY_INFORMATION"></a>Item 3. Key Information </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="SELECTED_FINANCIAL_DATA"></a><a name="SELECTED_FINANCIAL_DATA"></a>Selected financial data.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have derived the selected consolidated statements of operations data for the years ended December 31, 2017, 2016 and 2015 and the selected consolidated balance sheet data as of December 31, 2017 and 2016 from our audited consolidated financial statements included elsewhere in this annual report. The December 31, 2015 balance sheet has been derived from our consolidated financial statements not included elsewhere in this annual report. . This data should be read together with, and is qualified in its entirety by reference to, &#8220;Item 5. Operating and Financial Review and Prospects&#8221; as well as our financial statements and notes thereto appearing elsewhere in this annual report. Our historical results are not necessarily indicative of the results to be expected in the future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We present the audited consolidated financial statements in U.S. dollars and in accordance with U.S. GAAP.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653228"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Statements of operations data:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenue</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,558</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,502</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,697</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,515</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,811</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,417</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating (loss) income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,410</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,739</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,981</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss per ordinary share, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding used in computing loss per share</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,716,790</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300,959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance sheet data:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,362</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,975</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,437</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,904</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,894</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,056</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,390</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,035</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,749</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,109</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total shareholders&#8217; equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,515</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,307</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%; vertical-align:top">(1)</sup>&nbsp;&nbsp;Working capital is defined as total current assets minus total current liabilities.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_3B"></a>Capitalization and indebtedness. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_3C"></a><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reasons for the offer and use of proceeds. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_3D"></a>D.<font style="margin-left:36pt;"></font>Risk factors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the United States Securities and Exchange Commission, or the SEC, including the following risk factors which we face, and which are faced by our industry. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this annual report and our other SEC filings. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; above.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and have incurred net losses in each period since we commenced operations in 2004, including net losses of $20.0 million and $1.9 million for the years ended December 31, 2017 and 2016, respectively. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our ability to ultimately achieve recurring revenues and profitability is dependent upon our ability to successfully complete the development of our product candidates and obtain necessary regulatory approvals for and successfully manufacture, market and commercialize our products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we will continue to expend substantial resources in the foreseeable future for the clinical development of our current product candidates or any additional product candidates and indications that we may choose to pursue in the future. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, and payments for third-party manufacturing and supply, as well as sales and marketing of any of our product candidates that are approved for sale by regulatory agencies. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our clinical stage and preclinical drug candidates and any other drug candidates that we may develop in the future. Other unanticipated costs may also arise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of, and the costs involved in, clinical development and obtaining regulatory approvals for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in regulatory requirements during the development phase that can delay or force us to stop our activities related to any of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of commercialization activities if our products are approved for sale, including marketing, sales and distribution costs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of third-party manufacturing of our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the number and characteristics of any other product candidates we develop or acquire; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements, and the terms and timing of such arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent and rate of market acceptance of any approved products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the expenses needed to attract and retain skilled personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs associated with being a public company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent and other intellectual property claims, including potential litigation costs, and the outcome of such litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing, receipt and amount of sales of, or royalties on, future approved products, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-family:Times New Roman;">any product liability or other lawsuits related to our products; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">scientific breakthroughs in the field of urothelial cancer treatment and diagnosis that could significantly diminish the need for our product candidates or make them obsolete; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in reimbursement policies that could have a negative impact on our future revenue stream. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Drug development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any material revenue from product sales.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, almost all our resources have been dedicated to the preclinical and clinical development of our lead product candidates, MitoGel and VesiGel. As of December 31, 2017, we had cash and cash equivalents of $37 million and short-term investments of $36 million, for aggregate cash, cash equivalents and short-term investments of $73.0 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, we completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for approximately $64 million net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&#8217; option to purchase an additional 219,512 ordinary shares at the public offering price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe we have sufficient cash, cash equivalents and short-term investments to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We expect that we will require additional capital to complete clinical trials, obtain regulatory approval for and commercialize our product candidates. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity, convertible debt or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. In any event, we will require additional capital to pursue preclinical and clinical activities, and pursue regulatory approval for, and to commercialize, our pipeline product candidates. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any additional fundraising efforts may divert the attention of our management from day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may negatively impact the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility of such issuance may cause the market price of our shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than would be desirable and we may be required to relinquish rights to some of our technologies, intellectual property or product candidates or otherwise agree to terms unfavorable to us, any of which may harm our business, financial condition, cash flows, operating results and prospects.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If adequate funds are not available to us on a timely basis, we may be required or choose to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product candidates or any of our future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delay, limit, reduce or terminate our other research and development activities; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delay, limit, reduce or terminate our establishment or expansion of manufacturing, sales and marketing or distribution capabilities or other activities that may be necessary to commercialize MitoGel, VesiGel or any of our other product candidates. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could harm our business, financial condition, cash flows and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity, convertible debt or debt financings, as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not currently have any committed external source of funds other than funding under the existing exclusive license agreement we entered into with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, in October 2016, or the Allergan Agreement. Under the Allergan Agreement, we may receive additional material milestone payments upon the successful completion of certain development, regulatory and commercial milestones and royalties with respect to future sales of collaboration products by Allergan. Allergan may unilaterally terminate our existing collaboration for any reason upon advance notice. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring and distributing dividends, and may be secured by all or a portion of our assets.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds by selectively continuing to enter into additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish additional valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity, convertible debt or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If we are unable to raise additional funds through other collaborations, strategic alliances or licensing arrangements, we may be required to terminate product development or future commercialization efforts or to cease operations altogether.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business and Strategy</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are dependent on the success of our lead product candidates, including obtaining regulatory approval to market our product candidates in the United States.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have invested almost all our efforts and financial resources in the research and development of our lead product candidates, MitoGel and VesiGel. Our future success depends on our ability to market and sell these product candidates. However, these drugs are in various stages of clinical development and each of these drugs has yet to receive marketing approval from the U.S. Food and Drug Administration, or the FDA, or any other regulatory agency. Our product candidates&#8217; marketability is subject to significant risks associated with successfully completing current and future clinical trials, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s timely acceptance of our investigational new drug, or IND, filing for VesiGel, which we intend to submit in the first half of 2018, and our other product candidates for which we plan to file an IND. Without such IND acceptances, we will be unable to commence clinical trials in the United States; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s acceptance of our parameters for regulatory approval relating to MitoGel, VesiGel and our other product candidates, including our proposed indications, primary and secondary endpoint assessments and measurements, safety evaluations and regulatory pathways; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to successfully complete the clinical trials of our product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of the product candidates undergoing such clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s timely acceptance of our NDA for MitoGel, following our expected submission in the first quarter of 2019, and our eligibility for priority review of our NDA submission by the FDA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to complete in a timely fashion the single pivotal Phase 3 clinical trial for MitoGel for the treatment of low-grade upper tract urothelial carcinoma, or UTUC, and that the single pivotal Phase 3 clinical trial, even if successfully completed, will be sufficient to support a New Drug Application, or NDA, submission and subsequently, FDA approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to successfully complete the FDA requirements related to chemistry, manufacturing and control (CMC) for our MitoGel, VesiGel and our other product candidates, and if completed, will it be sufficient to support a New Drug Application, or NDA;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the FDA&#8217;s acceptance of the sufficiency of the data we collected from our preclinical studies and our Phase 2a clinical trial with VesiGel in low-grade non-muscle invasive bladder cancer, or NMIBC, and expect to collect from toxicological studies that we may conduct to support the submission of an IND without requiring additional preclinical studies or clinical trials, and our ability to commence a Phase 2b clinical trial in the United States for VesiGel in low-grade NMIBC following an IND application, if accepted; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s need to schedule an advisory committee meeting, and to conduct such meeting, in a timely manner to evaluate and decide on the approval of our potential future NDAs for MitoGel and VesiGel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the recommendation of the FDA&#8217;s advisory committee to approve our applications to market MitoGel and VesiGel and our other product candidates in the United States, without limiting the approved labeling, specifications, distribution or use of the products, or imposing other restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s satisfaction with the safety and efficacy of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of adverse events associated with our product candidates as there were no drugs and related drug administration procedures approved for LG UTUC or LG NMIBC that are based on RTGel technology; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timely and satisfactory performance by third-party contractors of their obligations in relation to our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our success in educating physicians and patients about the benefits, administration and use of our product candidates, if approved, particularly in light of the fact that there are currently no drugs approved by the FDA for the treatment of UTUC and the FDA has not approved a drug for the treatment of NMIBC in more than 15 years; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to secure supply of the raw materials from TAPI (Teva Active Pharmaceutical Ingredients) or other suppliers for our product candidates to support the clinical trial and commercial use;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to obtain, protect and enforce our intellectual property rights with respect to our product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to properly train physicians or nurses for the skillful administration of our products, including MitoGel and VesiGel, and our ability to develop a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of these clinical, regulatory and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance any of our product candidates through clinical development, or to obtain regulatory approval of or commercialize any of our product candidates. If we fail to achieve these objectives or overcome the challenges presented above, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, we may not be able to generate sufficient revenues through the sale of our product candidates to enable us to continue our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to obtain regulatory approval for our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA, and by foreign regulatory authorities in other countries. These regulations differ from country to country. To gain approval to market our product candidates, we must provide clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. We have not yet obtained regulatory approval to market any of our product candidates in the United States or any other country. Our business depends upon obtaining these regulatory approvals. There are currently no drugs approved by the FDA for the treatment of UTUC and only three drugs have been approved by the FDA for NMIBC, with the last approval having occurred over 15 years ago. The FDA can delay, limit or deny approval of our product candidates for many reasons, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to satisfactorily demonstrate that the product candidates are safe and effective for the target indication; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s disagreement with our trial protocol, the interpretation of data from preclinical studies or clinical trials or conduct and control of clinical trials; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the patient population studied in the clinical trial may not be sufficiently large, broad or representative to assess efficacy and safety in the patient population for which we seek approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s determination that the 505(b)(2) regulatory pathway is not available for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s determination that additional preclinical studies or clinical trials are required; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s determination that the Fast Track Designation, or FTD, for MitoGel is no longer accepted or our trial results do not meet the criteria for FTD;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s determination that the Orphan Drug Designation, or ODD, for MMC for UTUC is no longer accepted;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s determination that the quality of our drug substance or drug product, formulation, labeling or the specifications of our product candidates is insufficient for approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA&#8217;s failure to accept the manufacturing processes or facilities of third-party manufacturers with which we contract; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">resistance to approval from the FDA&#8217;s advisory committee for any reason including safety or efficacy concerns. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval contingent on the performance of costly and potentially time-consuming additional post-approval clinical trials or subject to restrictive Risk Evaluation and Mitigation Strategies. The FDA may also approve our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would thus negatively impact our business, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">To date, we have only generated limited clinical data for our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Positive results in preclinical testing and early clinical trials do not ensure that later clinical trials will be successful. A number of pharmaceutical companies have suffered significant setbacks in clinical trials, including in Phase 3 clinical trials, after promising results in preclinical testing and early clinical trials. These setbacks have included negative safety and efficacy observations in later clinical trials, including previously unreported adverse effects. For example, we enrolled only 22 patients into the recently completed UTUC Compassionate Use program of MitoGel. In the Compassionate Use Program, of the 18 patients confirmed with low-grade UTUC disease, only 13 patients had completed the six-weekly administration treatment regimen were evaluated for response, and eight of the 13 patients achieved a complete response and the remaining five achieved a partial response at the primary evaluation time. Of the eight patients who achieved a complete response at the primary evaluation time, three have subsequently experienced recurrences to date. The data generated by our Compassionate Use program may not be as reliable as data generated from a clinical trial. For instance, consistent with the nature of Compassionate Use programs, our Compassionate Use program is investigator-initiated and driven, with no uniform protocol with respect to dosing, primary endpoint or frequency or timing of follow-up evaluations. The data collected in our Compassionate Use program is based on individual physician reports and has not undergone independent monitoring or quality assurance. The follow-up evaluation plan for patients is determined by each individual investigator and varies from patient to patient, and some patients have not undergone follow-up evaluation or have been lost to follow-up. Due to the intricate anatomy of the renal pelvis and the calyceal system, we also face the risk that MitoGel may not reach all tumors. To date in our preclinical testing, Compassionate Use program and clinical trials, we have observed several adverse events and serious adverse events, consisting primarily of burning sensation, rash, flank pain, kidney swelling, kidney infection, urgency in urination and pain during urination. In addition, we have observed transient perturbation of laboratory measures of renal and hematopoietic function as well as renal stricture and stenosis. No study participants have required medical intervention to address these changes. These adverse events are known MMC, or procedure-related adverse events and many are indicated as potential side effects of MMC usage on the MMC label. However, we cannot assure you that adverse events related to MitoGel and VesiGel that are not directly attributable to MMC specifically will not occur. In addition, this trial may not be successful. If our clinical trials do not ultimately indicate that our product candidates are safe and efficacious for their intended application, the FDA may not approve any NDA that we may file to market such product candidates, and our business would not be able to generate revenue from the sale of any such product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have limited experience in conducting clinical trials and have never obtained approval for any product candidates and may be unable to do so successfully.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company, we have limited experience in conducting clinical trials and have never progressed a product candidate through to regulatory approval. In part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain that the planned clinical trials will begin or conclude on time, if at all. Large-scale trials will require significant additional financial and management resources. In addition, due to the significant lack of drug development for non-muscle invasive urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, clinical research organizations, or CROs, and/or consultants are likely to have extensive experience conducting clinical trials for the indications we are targeting. Third-party clinical investigators do not operate under our control. Any performance failure on the part of such third parties could delay the clinical development of our product candidates or delay or prevent us from obtaining regulatory approval or commercializing our current or future product candidates, depriving us of potential product revenue and resulting in additional losses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have not applied for regulatory approvals to market any of our product candidates, and we may be delayed in obtaining or failing to obtain such regulatory approvals and to commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of developing, obtaining regulatory approval for and commercializing our product candidates is long, complex, costly and uncertain, and delays or failure can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs are subject to extensive and rigorous regulation by the FDA and foreign regulatory agencies, as applicable. These regulations are agency-specific and differ by jurisdiction. We are not permitted to market any product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from the respective regulatory agencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA or relevant foreign regulatory authority with preclinical and clinical data that demonstrates the safety and efficacy of the product for the intended indication.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we can submit an NDA to the FDA or comparable similar applications to foreign regulatory authorities, we must conduct Phase 3 clinical trials, or a pivotal/registration trial equivalent, for each product candidate. We commenced a single pivotal, open-label, single-arm Phase 3 clinical trial of MitoGel for the treatment of low-grade UTUC in the first quarter of 2017. This clinical trial is substantially broader than the previous Compassionate Use program for MitoGel for the treatment of patients with UTUC and requires us to enroll a considerably larger number of patients in multiple clinics and medical centers across multiple countries. Based on our discussions with the FDA, our current expectation is that our pivotal clinical trial for MitoGel will evaluate approximately 74 patients. We cannot assure you that we will be able to complete patient enrollment, generate top-line and final data or submit the NDA for MitoGel in timely fashion.&nbsp;&nbsp;Moreover, we are also planning to commence a Phase 2b clinical trial of VesiGel in 2018. Before commencing a clinical trial for VesiGel in the United States, we must first file an IND, which must be cleared by the FDA. We cannot assure you that the FDA will not decide to materially alter these parameters, including potentially requiring a pivotal study with a control arm, during the trial or require us to conduct more than one pivotal trial before submitting an NDA.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3 clinical trials often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials may be unsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign regulatory agencies may suspend one or all of our clinical trials or require that we conduct additional clinical, preclinical, manufacturing, validation or drug product quality studies and submit that data before considering or reconsidering any NDA or comparable foreign regulatory application that we may submit. Depending on the extent of these additional studies, approval of any applications that we submit may be significantly delayed or may cause the termination of such programs or may require us to expend more resources than we have available.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of these outcomes occur, we may not receive regulatory approval for the corresponding product candidates, and our business would not be able to generate revenue from the sale of any such product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to advance our preclinical product candidates into clinical development and through regulatory approval and commercialization.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain of our product candidates are currently in preclinical development and are therefore currently subject to the risks associated with preclinical development, including the risks associated with:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">generating adequate and sufficient preclinical safety and efficacy data in a timely fashion to support the initiation of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtaining regulatory approval to commence clinical trials in any jurisdiction, including the submission and acceptance of INDs; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">contracting with the necessary parties to conduct a clinical trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">enrolling sufficient numbers of patients in clinical trials in timely fashion, if at all; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">timely manufacture of sufficient quantities of the product candidate for use in clinical trials. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in advancing our preclinical product candidates into clinical trials in a timely fashion, our business may be harmed. Even if we are successful in advancing our preclinical product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in &#8220;Risk Factors.&#8221; Accordingly, we cannot assure you that we will be able to develop, obtain regulatory approval for, commercialize or generate significant revenue from our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. We do not know whether our ongoing and future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including failure to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain regulatory approval, or feedback on trial design, in order to commence a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identify, recruit and train suitable clinical investigators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reach agreement on acceptable terms with prospective CROs and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain and maintain institutional review board, or IRB, approval at each clinical trial site; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identify, recruit and enroll suitable patients to participate in a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">have a sufficient number of patients enrolled, complete a trial or return for post-treatment follow-up; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">address any patient safety concerns that arise during the course of a trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">address any conflicts with new or existing laws or regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add a sufficient number of clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">raise sufficient capital to fund a trial. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment is a significant factor in the timing and success of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians&#8217; and patients&#8217; or caregivers&#8217; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be developed or approved for the indications we are investigating.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the trial&#8217;s data safety monitoring board, by the FDA or by the applicable foreign regulatory authorities. Such authorities may suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>If we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market opportunities for our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed and may be small.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer therapies are sometimes characterized as first-line, second-line or third-line. When cancer is detected early enough, first-line therapy, often chemotherapy, hormone therapy, surgery, radiotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life. Second- and third-line therapies are administered to patients when prior therapy is not or is no longer effective. For urothelial cancers, the current first-line standard of care is surgery designed to remove one or more tumors. Chemotherapy is currently used in treating urothelial cancer only as an adjuvant, or supplemental therapy, after tumor resection. We are designing our lead product candidates with the goal of replacing surgery as the first-line standard of care for certain urothelial cancers. We intend to seek approval of MitoGel for the first-line treatment of low-grade UTUC and of VesiGel for the first-line treatment of low-grade NMIBC in both cases as a chemoablation agent to replace tumor resection surgeries. However, there is no guarantee that our product candidates, if approved, would be approved for first-line or even later lines of therapy, and, that prior to any such approvals, we will not have to conduct additional clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who have previously failed prior treatments, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or third-party market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we receive regulatory approval for our product candidates and obtain significant market share, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including the use of the products as first- or second-line therapy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">MitoGel or VesiGel or any of our other product candidates may produce undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials or that are not expected with MMC treatment or inconsistent with catheter administration procedures. This could prevent us from gaining marketing approval or market acceptance for these product candidates, or from maintaining such approval and acceptance, and could substantially increase commercialization costs and even force us to cease operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with most pharmaceutical products, use of MitoGel or VesiGel or our other product candidates may be associated with side effects or adverse events that can vary in severity and frequency. Our proprietary reverse thermal gelation hydrogel, or RTGel, which is used in the formulation of MitoGel and VesiGel, has not undergone extensive testing in humans. Side effects or adverse events associated with the use of MitoGel and VesiGel may be observed at any time, including in clinical trials or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval or market our product candidates. To date in our clinical trials, we have observed several adverse events and serious adverse events, consisting primarily of burning sensation, rash, flank pain, kidney swelling, kidney infection, urgency in urination and pain during urination. In addition, we have observed transient perturbation of laboratory measures of renal and hematopoietic function as well as renal stricture and stenosis. These adverse events are known MMC, or procedure-related adverse events and many are indicated as potential side effects of MMC usage on the MMC label. However, we cannot assure you that we will not observe additional drug or procedure-related serious adverse events in the future or that the FDA will not determine them as such. Side effects such as toxicity or other safety issues associated with the use of our product candidates could require us to perform additional studies or halt development or sale of these product candidates or expose us to product liability lawsuits, which will harm our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, the commenced single pivotal Phase 3 clinical trial for MitoGel and the planned Phase 2b clinical trial for VesiGel will involve a larger patient base than that previously studied, and the commercial marketing of MitoGel and VesiGel, if approved, will further expand the clinical exposure of the drugs to a wider and more diverse group of patients than those participating in the clinical trials, which may identify undesirable side effects caused by these products that were not previously observed or reported.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>The FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date upon which we become aware of the adverse event as well as the nature and severity of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including enforcing a hold on or cessation of clinical trials, withdrawal of approved drugs from the market, criminal prosecution, the imposition of civil monetary penalties or seizure of our products.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in the event we discover the existence of adverse medical events or side effects caused by one of our product candidates, a number of other potentially significant negative consequences could result, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to submit an NDA or similar application for our product candidates because of insufficient risk-reward, or the denial of such application by the FDA or foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or foreign regulatory authorities suspending or terminating our clinical trials or suspending or withdrawing their approval of the product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or foreign regulatory authorities requiring the addition of labeling statements, such as Box or other warnings or contraindications or distribution and use restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or foreign regulatory authorities requiring us to issue specific communications to healthcare professionals, such as letters alerting them to new safety information about our product, changes in dosage or other important information; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the FDA or foreign regulatory authorities issuing negative publicity regarding the affected product, including safety communications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our being limited with respect to the safety-related claims that we can make in our marketing or promotional materials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our being required to change the way the product is administered, conduct additional preclinical studies or clinical trials or restrict or cease the distribution or use of the product; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our being sued and held liable for harm caused to patients. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving approval or market acceptance of the affected product candidate and could substantially increase commercialization costs or even force us to cease operations. We cannot assure you that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if our product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA or applicable foreign regulatory agency may grant approval contingent on the performance of additional costly post-approval clinical trials, risk mitigation requirements and surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing expenses, and cause the approved product candidate not to be commercially viable. Absence of long-term safety data may further limit the approved uses of our products, if any.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or applicable foreign regulatory agency also may approve our product candidates for a more limited indication or a narrower patient population than we originally requested or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory agency refusal to approve pending applications or supplements to applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspension of any ongoing clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or withdrawal of marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an injunction or imposition of civil or criminal penalties or monetary fines; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">seizure or detention of products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">bans or restrictions on imports and exports; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issuance of warning letters or untitled letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal of regulatory authorities to approve pending applications or supplements to applications. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, various aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention and, consequently, could adversely affect our business, financial condition, cash flows and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain FDA or foreign regulatory approvals for our product candidates, the commercial success of such products will depend significantly on their broad adoption and use by physicians, for approved indications, including, in the case of MitoGel, for the first-line treatment of low-grade UTUC, and in the case of VesiGel, for the first-line treatment of low-grade NMIBC, and for other therapeutic indications that we may seek to pursue with any of our product candidates. Physicians treating low-grade UTUC and low-grade NMIBC have never had to consider first-line treatments other than surgery. The degree and rate of physician and patient adoption of our product candidates, if approved, will depend on a number of factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the clinical indications for which the product is approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of adverse side effects and the level of risk/reward observed in our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which physicians recommend our products to patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">physicians&#8217; and patients&#8217; willingness to adopt new therapies in lieu of other products or treatments, including willingness to adopt our lead product candidates as locally-administered drug replacements to current surgical standards of care; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of treatment, safety and efficacy in relation to alternative treatments, including the recurrence rate of our treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which the costs of our product candidates are reimbursed by third-party payors, and patients&#8217; willingness to pay for our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">whether treatment with our product candidates, including the treatment of low-grade UTUC with MitoGel and the treatment of low-grade NMIBC with VesiGel, will be deemed to be an elective procedure by third- party payors; if so, the cost of treatment would be borne by the patient and would be less likely to be broadly adopted; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">proper training of physicians or nurses for the skillful administration of our products, including MitoGel and VesiGel, and development of a broad experiential knowledge base of aggregated clinician feedback from which we can refine appropriate procedures for product administration, without which there could be a risk of adverse events; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the revenues and profitability that our products will offer physicians as compared to alternative therapies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effectiveness of our sales and marketing efforts, especially the success of any targeted marketing efforts directed toward physicians and clinics and any direct-to-consumer marketing efforts we may initiate. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If MitoGel, VesiGel or any of our other product candidates is approved for use but fails to achieve the broad degree of physician adoption and market acceptance necessary for commercial success, our operating results and financial condition would be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are not successful in developing, receiving regulatory approval for and commercializing our preclinical and clinical product candidates other than MitoGel or VesiGel, our ability to expand our business and achieve our strategic objectives could be impaired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>Although we will devote a substantial portion of our resources to the continued clinical testing and potential approval of MitoGel for the treatment of low-grade UTUC and VesiGel for the treatment of low-grade NMIBC, another key element of our strategy is to discover, develop and commercialize a portfolio of products based on our proprietary RTGel platforms to serve additional therapeutic markets. We are seeking to do so through our internal research programs, but our resources are limited, and those that we have are geared towards clinical testing and seeking regulatory approval of MitoGel, VesiGel and our other existing product candidates. We </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may also explore strategic collaborations for the development or acquisition of new products, but we may not be successful in entering into such relationships. While we have commenced a single pivotal Phase 3 clinical trial for MitoGel and plan to commence a Phase 2b clinical trial for VesiGel, all of our other potential product candidates remain in the preclinical and/or early clinical stages of development. Research programs to identify product candidates require substantial technical, financial and human resources, regardless of whether any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the research methodology used may not be successful in identifying potential product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">competitors may develop alternatives that render our product candidates obsolete or less attractive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a product candidate may in a subsequent trial be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">intellectual property or other proprietary rights of third parties for product candidates we develop may potentially block our entry into certain markets or make such entry economically impracticable. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed, and our business will be more vulnerable to any problems that we encounter in developing and commercializing our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates, if approved, will face significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target or seek to have existing drugs approved for use for the treatment of the indications that we target.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware that other companies, such as Roche, Vyriad, GSK, Celgene, Lipac Oncology, Samyang biopharma, Merck Sharp &amp; Dohme Corp., Eleven biotherapeutics, Viralytics Limited, AADi, LLC, Biocancell Ltd., Altor BioScience Corporation, FKD Therapies Oy, Spectrum Pharmaceuticals, Inc., Taris Biomedical LLC and Abnoba, are conducting or have recently conducted clinical trials for product candidates for the treatment of low-grade and high-grade NMIBC, including carcinoma in situ, or CIS. In addition, we are aware of several pharmaceutical companies that are developing drug candidates for muscle-invasive bladder cancer. The FDA approved 4 immunotherapy drugs known as checkpoint inhibitors; Tecentriq (atezolizumab), Bavenico (Avelumab), Imfinzi (durbalumab) and Keytruda (pembrolizumazb) for the treatment of locally advanced or metastic bladder cancer, a form of muscle invasive bladder cancer. We do not know whether these potential competitors are already developing, or plan to develop, low-grade UTUC or high-grade UTUC treatments or other indications that we are pursuing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective, easier to administer or less costly than our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we face competition from existing standards of treatment, including transurethral resection of bladder tumor, or TURBT, surgery for bladder cancer. If we are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates in replacement of the existing standard of care, which is first-line tumor surgical procedures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have no experience in marketing or distributing products and no internal capability to do so and are therefore subject to certain risks in relation to the commercialization of our product candidates once approved.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>We have not yet established a commercial organization for the marketing, sale and distribution of our product candidates. Therefore, even if we receive approval to market our product candidates in the United States or other markets, in order to successfully commercialize our product candidates, we will need to either build marketing, sales, distribution, managerial and other non-technical capabilities or contract with third parties to obtain these capabilities. This involves many challenges, such as recruiting and retaining talented personnel, training employees, setting the appropriate system of incentives, managing additional headcount and integrating new business units into an </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing corporate infrastructure. The development of our own sales infrastructure or contracting with third parties will involve substantial expense, much of which we will incur well in advance of any marketing or sales. Moreover, we do not have experience as a company in establishing a significant sales infrastructure, and we cannot be certain that we will successfully develop this capability or contract successfully with third parties for the necessary services. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain personnel for medical affairs, marketing and sales. If we fail to establish an effective sales and marketing infrastructure or contract with third parties to do so, we will be unable to successfully commercialize our product candidates, which in turn would have an adverse effect on our business, financial condition and results of operations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have entered into a licensing agreement and in the future may enter into collaborations with other third parties for the development or commercialization of our product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, we entered into the Allergan Agreement. Under the Allergan Agreement, we granted Allergan an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, which we refer to collectively as the Licensed Products. Either party may terminate the Allergan Agreement for uncured material breach by the other party and for the insolvency of the other party. We may terminate the Allergan Agreement if Allergan or its affiliates challenges any of our patents licensed to Allergan and such patent challenge is not required under a court order or subpoena and is not a defense against a claim, action or proceeding asserted by us, our affiliates or licensees against Allergan, its affiliates or sublicensees. In addition, Allergan may unilaterally terminate the Allergan Agreement for any reason upon advance notice. If Allergan has the right to terminate the Allergan Agreement due to our uncured material breach, Allergan may elect to continue the agreement and reduce all future milestone and royalty payment obligations to us by a specified percentage. In the event of any termination of the Allergan Agreement, Allergan will assign or grant a right of reference to any regulatory documentation related to RTGel to us, all rights and licenses to Allergan will terminate, and the license Allergan granted to us under their improvements to RTGel will continue. If any of these events occurs, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for the Licensed Products and will not be able to, or may be delayed in our efforts to, successfully commercialize the Licensed Products, and our business will be harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may utilize a variety of types of collaboration, distribution and other marketing arrangements with third parties to develop our product candidates and commercialize our approved product candidates, if any. We are not currently party to any such arrangement. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing collaboration with Allergan and any future collaborations that we enter into, may pose a number of risks, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not perform their obligations as expected; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product candidates developed by collaborators may not perform sufficiently in clinical trials to be determined to be safe and effective, thereby delaying or terminating the drug approval process and reducing or eliminating milestone payments to which we would otherwise be entitled if the product candidates had successfully met their endpoints and/or received FDA approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trials conducted by collaborators could give rise to new safety concerns; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trials, such as the ongoing Phase 2 trial being conducted by Allergan for overactive bladder with BotuGel, could fail to meet its efficacy objectives;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not pursue development and commercialization of our product candidates that receive marketing approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would divert management attention and resources, be time-consuming and expensive; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If the Allergan Agreement, and any future collaborations that we enter into, do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed, and we may need additional resources to develop our product candidates. All the risks relating to product development, regulatory approval and commercialization described in this annual report also apply to the activities of our collaborators.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, subject to its contractual obligations to us, if a collaborator of ours were to be involved in a business combination, it might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If in the future we acquire or in-license technologies or product candidates, we may incur various costs, may have integration difficulties and may experience other risks that could harm our business and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, we may acquire or in-license additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely require additional development efforts prior to commercial sale, including extensive preclinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by regulatory authorities. If intellectual property related to product candidates or technologies we in-license is not adequate, we may not be able to commercialize the affected products even after expending resources on their development. In addition, we may not be able to manufacture economically or successfully commercialize any product candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval, and such products may not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may be materially harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce MitoGel, VesiGel and Vesimune for preclinical studies and clinical trials, and expect to continue to do so to support commercial scale production of MitoGel, VesiGel and Vesimune, if approved. There are significant risks associated with the manufacture of pharmaceutical products and contracting with contract manufacturers and with single-source suppliers. Furthermore, our existing third-party subcontractors and single-source suppliers may not be able to meet the increased need for certain raw materials, compounds and components that may result from our potential commercialization efforts. This increases the risk that we will not have sufficient quantities of MitoGel, VesiGel or Vesimune or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>We currently rely on third party subcontractors and suppliers for certain compounds and components necessary to produce MitoGel, VesiGel and Vesimune for our preclinical studies, clinical trials and commercial use, should our drug candidates receive regulatory </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval. We currently depend on Teva Pharmaceuticals Industries Ltd., or Teva, as our single-source supplier of MMC active pharmaceutical ingredient, or API, for MitoGel and VesiGel. Teva is in the midst of a corporate restructuring. Although we are not aware of any impact of the restructuring as currently in effect on Teva&#8217;s ability or willingness to supply us with MMC API in the quantities and on the timeline required, it is possible that the restructuring could adversely affect our ability to obtain MMC in any given period and could require us to expend funds and effort to identify and engage one or more alternate suppliers of MMC. We also currently depend on single sources for the gel contained in MitoGel and VesiGel, and Imiquimod for Vesimune. Because there are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development and commercialization of our product candidates or any future product candidates, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to rely on these or other subcontractors and suppliers to support our commercial requirements if MitoGel, VesiGel or any of our other product candidates is approved for marketing by the FDA or foreign regulatory authorities. We also rely on a single third-party manufacturer to produce the MMC drug product, or final MMC formulation, necessary for our clinical trial and commercial requirements.&nbsp;&nbsp;We have yet to complete the MMC drug product validation process, and scale-up work at this manufacturer that would be required for approval and commercial purposes, and there is a risk that we will not be able to do so in a timely or satisfactory manner. Even if we establish ourselves as an approved commercial supplier of MMC through this drug product manufacturer, we plan to continue to rely on third parties for such production of MMC API, as well as for the raw materials, compounds and components necessary to produce our product candidates and for preclinical studies and clinical trials. We would expect that if we become a commercial supplier of MMC, through a third-party manufacturer of MMC, it would provide us with enhanced control of material supply for both clinical trials and the commercial market, enable the more rapid implementation of process changes, and allow for better long-term margins. However, we have no experience as a company in the commercial supply of drugs and may never be successful as a commercial supplier of MMC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are successful in being approved as a commercial supplier of MMC, cost-overruns, unexpected delays, equipment failures, labor shortages, natural disasters, power failures, production failures or product recalls, and numerous other factors could prevent us from realizing the intended benefits of our sales strategy and have a material adverse effect on our business. Further, establishing ourselves as a commercial supplier of MMC, if we choose to pursue this, will require additional investment, will be time-consuming and may be subject to delays, including because of shortage of labor, compliance with regulatory requirements or receipt of necessary regulatory approvals. In addition, building out our MMC commercial supply capabilities may cost more than we currently anticipate, and delays or problems may adversely impact our ability to provide supply for the development and commercialization of our product candidates as well as our financial condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, before we can begin to commercially manufacture our product candidates, whether in a third-party facility or in our own facility, once established, we must obtain regulatory approval from FDA for our manufacturing process and facility in order to sell such products in the United States. A manufacturing authorization would also have to be obtained from the appropriate European Union regulatory authorities in order sell such products in the European Union. In order to obtain approval, we will need to ensure that all of the processes, methods and equipment of such manufacturing facilities are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and suppliers. If any vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that we may develop.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our continuing reliance on third party subcontractors and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing or supply agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third party subcontractors and suppliers may not be able to comply with cGMP or quality system regulation, also called QSR, or similar regulatory requirements outside the United States. If any of these risks transpire, we may be unable to timely retain alternate subcontractors or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture and commercial sale of our product candidates, if approved.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>Our failure or the failure of our third-party subcontractors and suppliers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supplies of MitoGel, VesiGel or any of our other product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components for MitoGel, VesiGel or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to obtain marketing approval in international jurisdictions would prevent our product candidates from being marketed abroad.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market and sell our products in the European Union and other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. Regulatory approval processes outside the United States generally include all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to submit for marketing approvals and may not receive the necessary approvals to commercialize our product candidates in any particular market.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We intend to rely on third parties and consultants to assist us in conducting our single pivotal Phase 3 clinical trial for MitoGel, our Phase 2b clinical trial for VesiGel and certain clinical trials for our other product candidates. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize MitoGel, VesiGel or any of our other product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have the ability to independently conduct many of our preclinical studies or our clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs to conduct clinical trials on our product candidates. Third parties play a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. Due to the limited drug development for non-muscle invasive urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, CROs and/or consultants are likely to have extensive experience conducting clinical trials for the indications we are targeting. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they otherwise perform in a substandard manner, our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory approval for, or successfully commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and the third parties upon whom we rely are required to comply with Good Clinical Practice, or GCP, regulations, which are regulations and guidelines enforced by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or our third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed, or the regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, a regulatory authority will determine that any of our clinical trials comply or complied with applicable GCP regulations. In addition, our clinical trials must be conducted with material produced under current cGMP regulations, which are enforced by regulatory authorities. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>In order for our clinical trials to be carried out effectively and efficiently, it is imperative that our CROs and other third parties communicate and coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some of which may compete with us. Our CROs and other third parties may terminate their agreements with us upon as few as 30 days&#8217; notice under certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. Switching or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new CRO commences work. As a result, delays may occur, which can impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship with our CROs, clinical investigators and other third parties, there can be no assurance that we will not encounter such challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, prospects, financial condition or results of operations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to market our product candidates, if approved, will be limited to certain indications. If we want to expand the indications for which we may market our products, we will need to obtain additional regulatory approvals, which may not be granted.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently developing MitoGel for the treatment of low-grade UTUC, and VesiGel and Vesimune for the treatment of various forms of bladder cancer. The FDA and other applicable regulatory agencies will restrict our ability to market or advertise our products to the scope of the approved label for the applicable product and for no other indications, which could limit physician and patient adoption. We may attempt to develop and, if approved, promote and commercialize new treatment indications for our products in the future, but we cannot predict when or if we will receive the regulatory approvals required to do so. Failure to receive such approvals will prevent us from promoting or commercializing new treatment indications. In addition, we would be required to conduct additional clinical trials or studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business will be limited.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse our products, we may become subject to prohibitions on the sale or marketing of our products, significant sanctions, and product liability claims, and our image and reputation within the industry and marketplace could be harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. For example, if we receive marketing approval for MitoGel for the treatment of low-grade UTUC, the first indication we are pursuing, we cannot promote the use of our product in a manner that is inconsistent with the approved label. However, physicians are able, in their independent medical judgment, to use MitoGel on their patients in an off-label manner, such as for the treatment of other urology indications. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would harm our business. The federal government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation with physicians, patients and caregivers, and our position within the industry.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physicians may also misuse our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance covering our clinical trials with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Furthermore, the use of our products for conditions other than those approved by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to manage our growth effectively, our business could be disrupted.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, we had 42 full-time employees and four part-time employees, of whom all except 9 are based in Israel. We will need to continue to expand our development, quality, sales, managerial, operational, finance, marketing and other resources to manage our operations and clinical trials, continue our development activities and commercialize our product candidates, if approved. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our expansion strategy requires that we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manage our clinical trials effectively; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identify, recruit, retain, incentivize and integrate additional employees; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue to improve our operational, financial and management controls, reporting systems and procedures. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to our limited financial resources and our limited experience in managing a larger company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage expansion could delay the execution of our development and strategic objectives or disrupt our operations; and if we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our revenues will suffer and we would incur significant additional losses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any of our other products we develop.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for our product candidates or products we develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of clinical trial participants or cancellation of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">costs to defend the related litigation, which may be only partially recoverable even in the event of successful defenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a diversion of management&#8217;s time and our resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to trial participants or patients; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exhaustion of any available insurance and our capital resources; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to commercialize any product we develop. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop. We currently carry general clinical trial product liability insurance in an amount that we believe is adequate to cover the scope of our ongoing clinical programs. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing MitoGel, VesiGel or any other product candidate, we intend to expand our insurance coverage to include the commercialization of MitoGel, VesiGel or any other approved product that we may have; however, we may be unable to obtain this liability insurance on commercially reasonable terms.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize any of the products we develop.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of members of our senior management, as well as our senior scientists and other members of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we have not historically experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems in the future. For example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. Moreover, although we have established a U.S. subsidiary, we are domiciled in Israel and are predominantly based in Israel, which may make it difficult to hire necessary U.S.-based personnel.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug development programs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from cyber-security threats, including computer viruses, harmful code and unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If a disruption event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Under applicable employment laws, we may not be able to enforce covenants not to compete.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally enter into non-competition agreements as part of our employment agreements with our employees. These agreements generally prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work, and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working for us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, Israeli labor courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts as justification for the enforcement of non-compete undertakings, such as the protection of a company&#8217;s trade secrets or other intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, breach of contract or other unauthorized activities that violate: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws; or laws that require the reporting of financial information or data accurately.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>Specifically, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. Activities subject to these laws also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Corporate Code of Ethics and Conduct, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, even if we are successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such laws subject us to numerous penalties, including, but not limited to, the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities and our third-party subcontractors&#8217; and suppliers&#8217; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including Mitomycin C, or MMC, key components of our product candidates, and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Despite our efforts, we cannot eliminate the risk of contamination. This could cause an interruption of our commercialization efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our subcontractors and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exchange rate fluctuations between the U.S. Dollar and the New Israeli Shekel may negatively affect our earnings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in New Israeli Shekels, or NIS, which is the lawful currency of the State of Israel. As a result, we are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. For example, even though the level of devaluation of the dollar against the NIS in 2016 was 1.5% and the level of devaluation of the dollar against the NIS in 2017 was 9.8%, if the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not adequate, we may not be able to compete effectively, and we otherwise may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part upon our ability to obtain and maintain patent protection and utilize trade secret protection for our intellectual property and proprietary technologies, our products and their uses, as well as our ability to operate without infringing upon the proprietary rights of others. We rely upon a combination of patents, trade secret protection and confidentiality agreements, assignment of invention agreements and other contractual arrangements to protect the intellectual property related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating overactive bladder topically without the need for injections, an in-dwelling ureter catheter system for optimal delivery of a drug into the renal cavity, and pharmaceutical compositions comprising an imidazoquinolin (amine) and lactic acid for use in a method for the treatment of bladder diseases.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><a name="_AEIOULastRenderedPageBreakAEIOU27"></a>We seek patent protection for our product candidates, and we have established several patent families comprised of issued patents and pending patent applications covering our proprietary RTGel formulation technology and the formulations, methods of use and manufacturing aspects of our product candidates. In the United States, we currently have 13 granted patents that are directed to protect our lead product candidates, MitoGel, VesiGel, BotuGel, Vesimune and RTGel as well as to our future product candidates that are under company research. These patents claim methods, systems, and novel compositions for treating cancer in internal cavities, in particular urinary tract cancer. These issued patents are expected to expire between 2024 and 2035. Moreover, our IP portfolio includes more than 45 patent applications filed worldwide that are directed to various methods, systems and compositions for treating cancer locally, by intravesical means. We have four pending patent applications relating to the product candidate BotuGel in the European Union, China and Israel as well as one granted patent in Russia. In addition, we have two granted patents related to Vesimune in the United States as well as two granted patents in the European Union, two granted patents in Japan and one granted patent in each of Australia, Mexico, China, Russia, and Hong Kong, each of which is expected to remain in effect until 2030. In addition to the issued patents mentioned above, our portfolio includes pending patent applications relating to Vesimune in the European Union, Hong Kong, Canada, Brazil and Israel. Moreover, we hold five granted patents in the United States as well as patent applications filed worldwide that relate to novel formulations of phospholipid drug analogs (saturated lipid conjugate compositions) for the treatment of urinary tract cancer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limitations on the scope of our intellectual property rights may limit our ability to prevent third parties from designing around such rights and competing against us. For example, our patents do not claim a new compound. Rather, the active pharmaceutical ingredients of our products are existing compounds and our granted patents and pending patent applications are directed to, among other things, novel formulations of these existing compounds with our RTGel. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing topical formulations that design around our patent claims, but which may contain the same active ingredients, or by seeking to invalidate our patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in the market.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, the patent applications that we own, or license may fail to result in granted patents in the United States or foreign jurisdictions, or if granted may fail to prevent a potential infringer from marketing its product or be deemed invalid and unenforceable by a court. Competitors in the field of reverse thermal gel therapies have created a substantial amount of scientific publications, patents and patent applications and other materials relating to their technologies. Our ability to obtain and maintain valid and enforceable patents depends on various factors, including interpretation of our technology and the prior art and whether the differences between them allow our technology to be patentable. Patent applications and patents granted from them are complex, lengthy and highly technical documents that are often prepared under very limited time constraints and may not be free from errors that make their interpretation uncertain. The existence of errors in a patent may have an adverse effect on the patent, its scope and its enforceability. Our pending patent applications may not issue, and the scope of the claims of patent applications that do issue may be too narrow to adequately protect our competitive advantage. Also, our granted patents may be subject to challenges or narrowly construed and may not provide adequate protection.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that we infringe, misappropriate or otherwise violate the intellectual property rights of third parties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our patents do successfully issue, third parties may challenge the validity, enforceability or scope of such granted patents or any other granted patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant. Also, patents granted by the United States Patent and Trademark Office, or USPTO, may be subject to reexamination and other challenges.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, even if they are not challenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. To meet such challenges, which are part of the risks and uncertainties of developing and marketing product candidates, we may need to evaluate third party intellectual property rights and, if appropriate, to seek licenses for such third party intellectual property or to challenge such third party intellectual property, which may be costly and may or may not be successful, which could also have an adverse effect on the commercial potential for MitoGel, VesiGel and any of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may receive only limited protection, or no protection, from our issued patents and patent applications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we encounter delays in our clinical trials or regulatory approval of our product candidates, the period of time during which we could market any of our product candidates under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating overactive bladder topically without the need for injections, an in-dwelling ureter catheter system for optimal delivery of a drug into the renal cavity, and pharmaceutical compositions comprising an imidazoquinolin (amine) and lactic acid for use in a method for the treatment of bladder diseases or any of our product candidates or (ii) conceive and invent any of the inventions claimed in our patents or patent applications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>The patent application process, also known as patent prosecution, is expensive and time consuming, and we or any future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or any future licensors or licensees will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. If we or any future licensors or licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or in-license may fail to result in issued patents in the United States or foreign countries with claims that cover our product candidates. Even if patents do successfully issue from the patent applications that we own or in-license, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed, by any person within nine months from the publication of their grant. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our product candidates, provide exclusivity for our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop or threaten our ability to commercialize our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, if we encounter delays in our development efforts, including our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A considerable number of our patents and patent applications are entitled to effective filing dates prior to March 16, 2013. For U.S. patent applications in which patent claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by those patent claims. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our trade secrets may not have sufficient intellectual property protection.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product candidates, and our product development processes (such as manufacturing and formulation technologies) that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have an adverse effect on our business. Furthermore, trade secret protection does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties that have access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of our product candidates, and third parties involved in our clinical trials to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us is kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by third parties in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could harm our business, operating results and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, or the America Invents Act, or AIA, was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able to enter the market earlier than should otherwise have been the case, which could harm our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a claimed drug. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect our trademarks from infringement, our business prospects may be harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own trademarks that identify MitoGel, VesiGel and Vesimune and have registered these trademarks in the United States and Israel. Although we take steps to monitor the possible infringement or misuse of our trademarks, it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized use of our trademarks could harm our reputation or commercial interests. In addition, our enforcement against third-party infringers or violators may be unduly expensive and time-consuming, and the outcome may be an inadequate remedy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time consuming.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic drug manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us and/or our licensors to engage in complex, lengthy and costly litigation or other proceedings.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding patent and other intellectual property rights in the pharmaceutical industry. Recently, the AIA introduced new procedures including inter partes review and post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future, including challenges by competitors who perceive our patents as blocking entry into the market for their products, and the outcome of such challenges.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates. They may also put our pending patent applications at risk of not issuing or issuing with limited and potentially inadequate scope to cover our product candidates. The outcome following legal assertions of invalidity and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administration panel to affect the validity or enforceability of a claim. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a negative impact on our business.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcing our or our licensor&#8217;s intellectual property rights through litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our ordinary shares could be significantly harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A significant portion of our intellectual property has been developed by our employees during their employment. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company are regarded as &#8220;service inventions.&#8221; The Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, has previously held, in certain cases, that employees may be entitled to remuneration for service inventions that they develop during their service for a company despite their explicit waiver of such right. Therefore, although we enter into agreements with our employees pursuant to which they waive their right to special remuneration for service inventions created in the scope of their employment or engagement and agree that any such inventions are owned exclusively by us, we may face claims by employees demanding remuneration beyond their regular salary and benefits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-party claims alleging intellectual property infringement may adversely affect our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property rights of competitors. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product candidates may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by our product candidates. It is also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be found to be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a>Third parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial expenses and, and would be a substantial diversion of management time and employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to (i) pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed the third party&#8217;s patents; (ii) obtain one or more licenses from the third party; (iii) pay royalties to the third party; and/or (iv) redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our product candidates, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defending ourselves or our licensors in litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees&#8217; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a negative impact on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the FDA does not conclude that MitoGel, VesiGel, or our other product candidates satisfy the requirements under Section 505(b)(2) of the Federal Food Drug and Cosmetic Act, or Section 505(b)(2), or if the requirements for such product candidates are not as we expect, the approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced a single pivotal Phase 3 clinical trial for MitoGel and expect to commence a Phase 2b clinical trial of VesiGel under the FDA&#8217;s Section 505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant, and for which the applicant has not received a right of reference, which could expedite the development program for MitoGel, VesiGel and our other product candidates by potentially decreasing the amount of preclinical and clinical data that we would need to generate in order to obtain FDA approval. However, while we believe that our product candidates are reformulations of existing drugs or biologics and, therefore, will not be treated as new chemical entities, or NCEs, the submission of an NDA under the Section 505(b)(2) or similar regulatory pathway does not preclude the FDA from determining that the product candidate that is the subject of such submission is an NCE and therefore not eligible for review under such regulatory pathway.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>If the FDA does not allow us to pursue the Section 505(b)(2) or similar regulatory pathway as anticipated, we may need to conduct additional preclinical experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely increase significantly. Moreover, inability to pursue the Section 505(b)(2) or similar regulatory pathway could result in new competitive products reaching the market more quickly than our product candidates, which would likely harm our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) or similar regulatory pathway, our product candidates may not receive the requisite approvals for commercialization.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain competitors and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway for our product candidates, there is no guarantee this would ultimately lead to faster product development or earlier approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, even if these product candidates are approved under the Section 505(b)(2) pathway, as the case may be, the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other conditions of approval or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fast track designation for one or more of our product candidates may not actually lead to a faster development or regulatory review or approval process.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, we received fast track designation for MitoGel for the treatment of UTUC. If a product is intended for the treatment of a serious condition, and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA fast track designation. Even though we have received fast track designation for MitoGel for the treatment of UTUC, fast track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with fast track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We expect current and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products, if approved.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010, or collectively, the ACA, a law intended, among other things, to broaden access to health insurance, improve quality of care, and reduce or constrain the growth of healthcare spending.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions of the ACA relevant to the pharmaceutical industry include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, not including orphan drug sales; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-family:Times New Roman;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (70% commencing January 1, 2019) point-of-sale discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">new requirements to report annually certain financial arrangements with physicians and teaching hospitals; as defined in the ACA and its implementing regulations, including reporting any payment or &#8220;transfer of value&#8221; provided to physicians and teaching hospitals and any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been judicial and Congressional challenges to certain aspects of the ACA. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA. For example, since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. The recently enacted Tax Cuts and the Jobs Act also includes a provision that repeals, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact our business.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, which started in 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>Additionally, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. House of Representatives formed an Affordable Drug Pricing Task Force to advance legislation intended to control pharmaceutical drug costs and investigate pharmaceutical drug pricing, and the U.S. Senate requested information from certain pharmaceutical companies in connection with an investigation into pharmaceutical drug pricing practices<a name="_AEIOULastRenderedPageBreakAEIOU35"></a>. Further, the Trump Administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump Administration have both stated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. If healthcare policies or reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we obtain regulatory approval and commercialization of MitoGel, VesiGel or any of our other product candidates, these laws may result in additional reductions in healthcare funding, which could have an adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of MitoGel, VesiGel or our other product candidates may be.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely affect how much or under what circumstances healthcare providers will prescribe or administer our products. This could adversely affect our business by reducing our ability to generate revenues, raise capital, obtain additional licensees and market our products. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact product sales.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to obtain Orphan Drug Designation or exclusivity for future product candidates we may develop. If our competitors are able to obtain orphan drug exclusivity for their products that are for the same indication as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan drug if it is intended to treat an orphan disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug Designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the FDA has granted MitoGel orphan drug designation for the treatment of UTUC and to Vesimune for treatment of CIS, we may not receive orphan drug designation for any of our other product candidates. If our competitors are able to obtain orphan drug exclusivity for their products that are the same or similar to our product candidates before our drug candidates are approved, we may not be able to have competing product candidates approved by the FDA for a significant period of time. Any delay in our ability to bring our product candidates to market would negatively impact our business, revenue, cash flows and operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity for our product candidates, we may be subject to earlier competition and our potential revenue will be reduced.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages, user-fee waivers and market exclusivity for certain periods of time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>MitoGel and Vesimune have been granted Orphan Drug Designation for the treatment of UTUC and CIS, respectively, in the United States. Even if we obtain Orphan Drug Designation for our other product candidates, we may not be the first to obtain regulatory approval for any particular orphan indication due to the uncertainties associated with developing biopharmaceutical products. Further, even if we obtain Orphan Drug Designation for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked during the period of marketing exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved product. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for a different orphan indication, this may negatively impact the market opportunity for our product candidate. There have been legal challenges to aspects of the FDA&#8217;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates in ways that are difficult to predict.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If and when regulatory approval has been granted, our product candidates or any approved product will be subject to continual regulatory review by the FDA and/or non-U.S. regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, if the applicable regulatory agency approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical trials that we conduct post-approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers&#8217; processes, or failure to comply with regulatory requirements, may result in, among other things:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fines, warning letters or holds on clinical trials </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us, or suspension or revocation of product license approvals; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with healthcare professionals, independent contractors, clinical investigators, CROs, consultants and vendors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may currently be or may become subject to various U.S. federal and state health care laws, including those intended to prevent health care fraud and abuse.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program such as Medicare and Medicaid. Remuneration has been broadly defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced-price items and services.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><a name="_AEIOULastRenderedPageBreakAEIOU37"></a>Federal false claims laws, including the federal False Claims Act, or FCA, and civil monetary penalties law impose penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. The FCA has been used to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many states have similar fraud and abuse statutes and regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. State and federal authorities have aggressively targeted medical technology companies for, among other things, alleged violations of these anti-fraud statutes, based on unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices, including certain marketing arrangements that rely on volume-based pricing and off-label promotion of FDA-approved products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including public and private payors, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose, among other things, specified requirements on covered entities and their business associates relating to the privacy and, security and transmission of individually identifiable health information, including mandatory contractual terms and required implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations will also be subject to the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members. We may also be subject to state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and/or state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidelines promulgated by the federal government.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor, including commercial insurers. If any of our business activities, including but not limited to our relationships with healthcare providers, are found to violate any of the aforementioned laws, we may be subject to administrative, civil and/or criminal penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, diminished profits and future earnings and curtailment or restructuring of our operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents.Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or reinterpreted by the FDA or the applicable foreign regulatory agency in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes to manufacturing methods; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recall, replacement, or discontinuance of one or more of our products; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additional recordkeeping. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these would likely entail substantial time and cost and could harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could negatively impact our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of MitoGel, VesiGel and our other product candidates, if approved, will depend on the coverage and reimbursement policies of third-party payors, like government authorities, private health insurers, and managed care organizations. Third-party payors decide which medications they will cover and separately establish reimbursement levels.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government and other third-party payors are increasingly challenging the prices charged for health care products, examining the cost effectiveness of drugs in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement for prescription drugs. We cannot be sure that coverage will be available for MitoGel, VesiGel or our other product candidates, if approved, or, if coverage is available, the level of reimbursement will be adequate to make our products affordable for patients or profitable for us.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, decisions about reimbursement for new medicines under Medicare are made by CMS, as the administrator for the Medicare program. Private payors often use CMS as a model for their coverage and reimbursement decisions. It is difficult to predict what CMS as well as other payors will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement by a third-party payor may depend upon a number of factors including the third-party payor&#8217;s determination that use of a product is:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a covered benefit under its health plan; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">safe, effective and medically necessary; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">appropriate for the specific patient; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">cost-effective; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">neither experimental nor investigational. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may not be able to provide data sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels. We cannot be sure that coverage or adequate reimbursement will be available for MitoGel, VesiGel or any of our other product candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only to limited levels, we may not be able to commercialize MitoGel, VesiGel or our other product candidates, or achieve profitably at all, even if approved.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Legislative or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of MitoGel, VesiGel or any of our other product candidates and to produce, market, and distribute our products after clearance or approval is obtained.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of MitoGel, VesiGel or any of our other product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes to manufacturing methods; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">change in protocol design; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additional treatment arm (control); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recall, replacement, or discontinuance of one or more of our products; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additional recordkeeping. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of these would likely entail substantial time and cost and could harm our business and our financial results.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a>Risks Related to Ownership of Our Ordinary Shares</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market price of our ordinary shares has been and may continue to be subject to fluctuation and you could lose all or part of your investment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock market in general has been, and the market price of our ordinary shares in particular has been and may continue to be, subject to fluctuation, whether due to, or irrespective of, our operating results and financial condition. The market price of our ordinary shares on the Nasdaq Global Market may fluctuate as a result of a number of factors, some of which are beyond our control, including, but not limited to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">actual or anticipated variations in our and our competitors&#8217; results of operations and financial condition; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">physician and market acceptance of our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the mix of products that we sell; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our success or failure to obtain approval for and commercialize our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">development of technological innovations or new competitive products by others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcements of technological innovations or new products by us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">publication of the results of preclinical or clinical trials for MitoGel, VesiGel or our other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure by us to achieve a publicly announced milestone; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays between our expenditures to develop and market new or enhanced product candidates and the generation of sales from those products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">developments concerning intellectual property rights, including our involvement in litigation brought by or against us; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in our expenditures to promote our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares or other securities in the future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">success or failure of our research and development projects or those of our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the trading volume of our ordinary shares; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">general economic and market conditions and other factors, including factors unrelated to our operating performance. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors and any corresponding price fluctuations may negatively impact the market price of our ordinary shares and result in substantial losses being incurred by our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class action litigation. If we were to become involved in securities litigation, it could impose a substantial cost upon us and divert the resources and attention of our management from our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our ordinary shares relies in part on the research and reports that equity research analysts publish about us and our business, if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us. The price of our ordinary shares could decline if no research reports are published about us or our business, or if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a>Future sales of our ordinary shares could reduce the market price of our ordinary shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our existing shareholders, particularly our directors, their affiliates, or our executive officers, sell a substantial number of our ordinary shares in the public market, the market price of our ordinary shares could decrease significantly. The perception in the public market that our shareholders might sell our ordinary shares could also depress the market price of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of this annual report, the holders of approximately 4,515,674 ordinary shares are entitled to registration rights. In addition, our sale of additional ordinary shares or similar securities in order to raise capital might have a similar negative impact on the share price of our ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional ordinary shares or other equity securities and may cause you to lose part or all of your investment in our ordinary shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The significant share ownership position of our officers, directors and entities affiliated with certain of our directors may limit your ability to influence corporate matters.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our officers, directors and entities affiliated with certain of our directors beneficially own or control, directly or indirectly, approximately 24.4% of our outstanding ordinary shares. Accordingly, these persons are able to significantly influence, though not independently determine, the outcome of matters required to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors, and the outcome of any proposed merger or consolidation of our company. These interests may not be consistent with those of our other shareholders. In addition, these persons&#8217; significant interest in us may discourage third parties from seeking to acquire control of us, which may adversely affect the market price of our ordinary shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share capital in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be investors&#8217; sole source of gain for the foreseeable future. In addition, Israeli law limits our ability to declare and pay dividends and may subject our dividends to Israeli withholding taxes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. We do not believe that we were classified as a PFIC for the taxable year ended December 31, 2017. However, based upon the expected nature and composition of our income and assets, we anticipate that we will be classified as a PFIC for the taxable year ending December 31, 2018. For purposes of these tests, passive income includes dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares) and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders, and having interest charges apply to distributions by us and gains from the sales of our shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which may be determined based on the fair market value of each asset, with the value of goodwill and going concern value determined in large part by reference to the market value of our common shares, which may be volatile) from time to time. We cannot provide any assurances regarding our PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided any opinion regarding our PFIC status.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently intend to provide the information necessary for our U.S. shareholders to make QEF elections.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">As a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, and we will not be subject to certain U.S. securities laws including, but not limited to, U.S. proxy rules and the filing of certain Exchange Act reports.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><a name="_AEIOULastRenderedPageBreakAEIOU42"></a>As a foreign private issuer, we are permitted to and follow certain home country corporate governance practices instead of those otherwise required by the Nasdaq Stock Market for domestic U.S. issuers. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the Nasdaq Global Market may provide less protection to you than what is accorded to investors under the Nasdaq Rules applicable to domestic U.S. issuers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a foreign private issuer, we are exempt from the rules and regulations under the Securities Exchange Act of 1934, or the Exchange Act, related to the furnishing and content of proxy statements, including the requirement to disclose the compensation of our Chief Executive Officer, Chief Financial Officer, President of Israel Operations and the other two most highly compensated executive officers on an individual basis. Nevertheless, pursuant to regulations promulgated under the Israeli Companies Law, 5759-1999, or the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated office holders on an individual basis. Such disclosure is not as extensive as that required of a U.S. domestic issuer. Our officers, directors and principal shareholders are also exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act and we are exempt from filing quarterly reports with the SEC under the Exchange Act. Moreover, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information, although we have voluntarily adopted a corporate disclosure policy substantially similar to Regulation FD. These exemptions and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic issuer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Loss of foreign private issuer status in the future could result in significantly increased costs and divert management attention.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We would lose our foreign private issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S. citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. However, we cannot assure you that at June 30, 2018, the next determination date of our foreign private issuer status, we will qualify as a foreign private issuer. If we cease to qualify as a foreign private issuer at this determination date, we will be required to begin reporting as a domestic issuer on January 1, 2019. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. We may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other public companies that are not emerging growth companies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For as long as we remain an emerging growth company we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not &#8220;emerging growth companies.&#8221; These exemptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reduced disclosure obligations regarding executive compensation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenues of at least $1.07 billion; (ii) the last day of our fiscal year following the fifth anniversary of the closing of our initial public offering; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (iv) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange Act. We have opted out of the extended transition period made available to emerging growth companies to comply with newly adopted public company accounting requirements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>When we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to our Operations in Israel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our headquarters, research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our headquarters and research and development facilities are located in Ra&#8217;anana, Israel. In addition, the majority of our key employees are residents of Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility, earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our research and development is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are approved and we choose to manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likely expect, or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our prospective customers&#8217; expectations, our business, prospects, financial results and reputation could be harmed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Political, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, Hamas (an Islamist militia and political group that controls the Gaza Strip) and Hezbollah (an Islamist militia and political group based in Lebanon). In addition, several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely affect our operations and results of operations and adversely affect the market price of our ordinary shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and results of operations.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our operations could be disrupted by the obligations of our employees to perform military service. As of December 31, 2017, we had 36 employees based in Israel. Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36 days per year (and in some cases more) until they reach the age of 40 (and in some cases, up to the age of 45 or older). Additionally, they may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in the region, there have been, at times, call-ups of military reservists, and it is possible that there will be additional call-ups in the future. Our operations could be disrupted by the absence of these employees due to military service. Such disruption could harm our business and operating results.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Israeli government grants we have received for research and development activities restrict our ability to manufacture products and transfer technologies outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received and incur financial penalties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have received grants under the Israeli Law for the Encouragement of Industrial Research, Development and Technological Innovation, 5754-1984, or the R&amp;D Law, from the Israel Innovation Authority in Israel, or the IIA, formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, an independent and impartial public entity, for some of our development programs. Through December 31, 2017, we had received grants in the aggregate amount of $2.1 million. We may in the future apply to receive additional grants from the IIA. However, we cannot predict whether we will be entitled to any future grants, or the amounts of any such grants.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><a name="_AEIOULastRenderedPageBreakAEIOU44"></a>A recipient of a grant from the IIA is obligated to pay royalties generally at a rate of 3% to 5% on revenues from sales of products developed with IIA-funded technology, up to the amount of the grant related to any such products plus accrued interest. Under the R&amp;D Law, a company that received grants from the IIA may not transfer IIA-funded technology or manufacture products developed with IIA-funded technology outside of the State of Israel without first obtaining the approval of the IIA. For example, under the Allergan Agreement, Allergan has the option to manufacture products developed with IIA-funded technology outside of Israel and, although Allergan has not yet exercised this option, we have requested approval from the IIA for a possible transfer and are currently awaiting their response. We may not receive any such approval upon any request, which could prevent us, for example, from out-licensing our product candidates or complying with our existing agreements. Even if we do receive such approvals, we may be required to pay increased royalties of up to 300% of the amount of the original grant and other amounts. If we do not receive such approvals, we may be required to pay significant penalties.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, new rules published by the IIA for granting a right to use know- how developed from research and development that was conducted pursuant to a plan approved by the IIA outside of Israel, or Licensing Rules, came into effect. The Licensing Rules allow a recipient of a grant from the IIA to grant third parties outside of Israel the right to use know-how, or License, provided that the IIA authorized the grant of the License. In such case, the recipient of the grant has to pay the IIA for the License. The amount of payment is based on various factors, including the consideration received by the licensor and, in accordance with the formulas set forth in the Licensing Rules, may equal up to six times the IIA-funding amount plus interest. When the consideration for the grant includes nonmonetary compensation or monetary compensation that is not fixed, or when a &#8220;special relationship&#8221; exists between the licensor and licensee (e.g., when a party controls the other party or is the other party&#8217;s exclusive distributor) or when the agreed consideration does not reflect, in the IIA&#8217;s opinion, the market value, the IIA may base the value of the transaction on an economic assessment that it obtains for such purpose.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The IIA may also impose certain conditions on any arrangement under which it permits us to transfer IIA-funded technology outside of the State of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of the State of Israel of IIA-funded technology (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to IIA. The restrictions under the R&amp;D Law will continue to apply even after we have repaid the full amount of royalties due to the IIA. If we fail to satisfy the conditions of the R&amp;D Law, we may be required to refund the amounts of the grants previously received, together with interest and penalties, and may become subject to criminal charges.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Provisions of Israeli law and our articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a tender offer for all of a company&#8217;s issued and outstanding shares can only be completed if shareholders not accepting the tender offer hold less than 5% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless shareholders not accepting the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tender offer hold less than 2% of the company&#8217;s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">It may be difficult to enforce a judgment of a U.S. court against us, our officers and directors or the Israeli experts named in this annual report in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors and these experts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are incorporated in Israel. Several of our directors and executive officers listed in this annual report reside outside of the United States, and most of our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It may also be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The rights and responsibilities of the holders of our ordinary shares are governed by our articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. companies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Management and Employees </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on our executive officers and key clinical and technical personnel to operate our business effectively, and we must attract and retain highly skilled employees in order to succeed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends upon the continued service and performance of our executive officers who are essential to our growth and development. The loss of one or more of our executive officers could delay or prevent the continued successful implementation of our growth strategy, could affect our ability to manage our company effectively and to carry out our business plan, or could otherwise be detrimental to us. As of December 31, 2017, we had 42 full-time employees. Therefore, knowledge of our product candidates and clinical trials is concentrated among a small number of individuals. <font style="color:#000000;">Members</font> of our executive team as well as key clinical, scientific </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and technical personnel may resign at any time and there can be no assurance that we will be able to continue to retain such personnel. If we cannot recruit suitable replacements in a timely manner, our business will be adversely impacted. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our growth and continued success will also depend on our ability to attract and retain additional highly qualified and skilled research and development, operational, managerial and finance personnel. However, we face significant competition for experienced personnel in the pharmaceutical field. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to quality candidates than what we have to offer. If we cannot retain our existing skilled scientific and operational personnel and attract and retain sufficiently skilled additional scientific and operational personnel, as required, for our research and development and manufacturing operations on acceptable terms, we may not be able to continue to develop and commercialize our existing product candidates or new products. Further, any failure to effectively integrate new personnel could prevent us from successfully growing our company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_4"></a><a name="Item_4"></a>Item 4.&nbsp;&nbsp;Information on the Company </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_4A"></a>History and development of the company. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_271"></a>Our legal and commercial name is UroGen Pharma Ltd. We are a company organized under the laws of State of Israel. We were formed in 2004 with an indefinite duration. We are registered with the Israeli Registrar of Companies. Our principal executive offices are located at 9 Ha&#8217;Ta&#8217;asiya Street, Ra&#8217;anana 4365007, Israel. Our telephone number is +972 (9) 770-7601. Investors should contact us for any inquiries through the address and telephone number of our principal executive office. We maintain a web site at<a name="_cp_field_47_271"></a> <font style="text-decoration:none;color:#000000;">http://www.urogen.com</font>. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our web site is not a part of this annual report. Urogen Pharma, Inc., our wholly-owned subsidiary, was incorporated on October 25, 2015 under the laws of the State of Delaware. Urogen Pharma, Inc. has been appointed as our agent in the United States and is located at 499 Park Avenue, 12th Floor, New York, New York 10022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>We are an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act of 1933, or the Securities Act, as modified by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not &#8220;emerging growth companies&#8221; such as not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002. We could remain an &#8220;emerging growth company&#8221; for up to five years, or until the earliest of (a) the last day of the first fiscal year in which our annual gross revenue exceeds $1 billion, (b) the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (c) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For information regarding our capital expenditures, see &#8220;Item 5.B. Operating and Financial Review and Prospects &#8211; Liquidity and Capital Resources.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_4B"></a>Business overview. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. We are developing our product candidates as chemoablation agents, which means they are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, or UTUC, and low-grade non-muscle invasive bladder cancer or NMIBC. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#8217; quality of life by replacing costly, sub-optimal and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder and upper urinary tract surgeries, including removal of the kidney, which are major surgical procedures typically performed when local endoscopic tumor resection fails to control the disease progression. Additionally, we believe that our product candidates, which are based on novel formulations of previously approved drugs, may qualify for streamlined regulatory pathways to market approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates, MitoGel and VesiGel, are formulated using our proprietary reverse thermally triggered hydrogel, or RTGel, technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage of the active drug throughout the organ. Consequently, we believe that RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. No drugs have been approved by the U.S. Food and Drug Administration, or the FDA, for the treatment NMIBC, in more than 15 years and for the treatment of UTUC, there are no drugs approved.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently evaluating the safety and efficacy of MitoGel, our novel sustained-release formulation of MMC, in patients with low-grade UTUC in a Phase 3 pivotal, single-arm, open label clinical trial, which follows a recently completed &#8220;Compassionate Use&#8221; program for MitoGel for the treatment of the same indication. The Compassionate Use Program was conducted in the U.S. and Israel. &#8220;Compassionate Use&#8221; is the use outside of a clinical trial of an investigational, or not approved, medical product when patient enrollment in a clinical trial is not possible, typically due to patient ineligibility or a lack of ongoing clinical trials. In the Compassionate Use Program, 22 patients were enrolled, 18 of which had confirmed low-grade UTUC. Of the 18 patients, 13 patients had completed the six-weekly treatment regimen and were evaluated for tumor response. These 13 patients were evaluated for tumor response at the primary evaluation time either endoscopically or through the use of a nonsurgical viewing instrument. Complete response was also confirmed by a cytology (urine) confirmation. Of these 13 patients, eight, or approximately 62% (or 8/18, or 44%, on an Intent to Treat basis), achieved a complete response, with a median durability of response without recurrence of 12 months to date, based on investigator reports. Our analysis of the median recurrence-free durability of those patients who achieved a complete response is still ongoing, with, to our knowledge, only three of the eight patients recurring to date. To date, of the five patients still ongoing without recurrence, to our knowledge, four have durability of response of 12 months or greater. Recurrences were generally of small tumors, presenting with diameters of several millimeters in size that were consequently managed by endoscopic tumor resection. Importantly, of the eight patients that achieved a complete response, or a complete response following an initial partial response, four had a solitary kidney. As all the patients in the Compassionate Use program were candidates for a nephroureterectomy, these four patients otherwise may have had their solitary kidney removed and become dialysis patients.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a>Five out of the 13 evaluated patients achieved a partial response at the primary evaluation time. One patient who achieved a partial response received three additional monthly courses of MitoGel, and thereafter achieved a complete response. In this Compassionate Use program, MitoGel had been observed to be well-tolerated. We have obtained Orphan Drug Designation for MitoGel for the treatment of UTUC as well as Fast Track Designation for the treatment of patients with low-grade UTUC not amenable to endoscopic resection or contraindicated for nephroureterectomy, which is the removal of the kidney and upper tract, including impaired renal function. We believe that MitoGel has the potential to become the first FDA-approved drug for the treatment of low-grade UTUC serving as a first-line chemoablation agent, sparing patients from repeated tumor resection surgeries and potentially reducing the need for bladder and upper urinary tract surgeries, including upper urinary tract removals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we completed evaluating the safety and efficacy of VesiGel, our novel sustained-release high dose formulation of MMC, for the treatment of low-grade NMIBC in a Phase 2a study that was conducted in Europe and Israel. Of the 22 patients treated in the VesiGel high dose group (80mg MMC), 19, or approximately 86%, of the patients achieved a complete response at the primary evaluation time. Moreover, approximately 79% of the patients who achieved a complete response at the primary evaluation time with VesiGel in the study and who have been followed for 12 months thereafter, without receiving additional treatments, remained recurrence free. This compares to approximately 40% to 60% of patients who historically achieve a 12-month durable complete response with TURBT as first-line treatment, followed by adjuvant treatments of MMC instillations into the bladder. We plan to file an IND for VesiGel in the first half of 2018; and, if accepted, we expect to commence a U.S.-based Phase 2b clinical trial for VesiGel shortly thereafter. We also intend to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that VesiGel has the potential to replace tumor resection surgery and become the new first-line standard of care for the treatment of low-grade NMIBC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that urothelial cancer, which is comprised of bladder cancer and UTUC, affects a large and underserved patient population. Annual expenditures for Medicare alone in the United States for the treatment of urothelial cancer were estimated to have been at least $4.0 billion in 2010 and are projected to be at least $5.0 billion in 2020. The majority of the expenditures is spent on tumor resection surgeries such as TURBT and upper urinary tract removals. In 2012, the estimated prevalence of urothelial cancer in the United States was 625,000 with an annual incidence of approximately 80,000. The 2012 prevalence of each of low-grade NMIBC and low-grade UTUC in the United States was approximately 325,000 and 14,500, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC, which may include Carcinoma in Situ, or CIS. Vesimune is a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in initiating the innate immune response system. We believe that the combination of Vesimune with additional immunotherapy drugs, such as immune checkpoint inhibitors or sustain release </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chemotherapy drugs like VesiGel, could represent a valid alternative to the current standard of care for the post-TURBT adjuvant treatment of high-grade NMIBC.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded drug, that we believe can potentially serve as an effective treatment option for patients suffering from overactive bladder. In October 2016, we announced the licensing of the worldwide rights to RTGel in combination with neurotoxins, including BOTOX, to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, or the Allergan Agreement. In August 2017, we announced that Allergan had submitted an IND to the FDA in order to be able to commence clinical trials in the United States using the RTGel in combination with BOTOX. In October 2017, Allergan commenced a Phase 2 clinical trial of BotuGel for the treatment of overactive bladder.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Going forward, we will also refer to our product candidates, MitoGel, VesiGel and Vesimune, as UGN-101, UGN-102 and UGN-201, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a>Our Product Candidate Pipeline</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following chart summarizes the current status of our product candidate pipeline.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465606911252.jpg" title="" alt="" style="width:585px;height:287px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Uro-Oncological Indications Targeted by Our Product Candidates</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are administered locally using the standard practice of intravesical instillation directly into the bladder or upper urinary tract via a catheter. The instillation into the bladder is expected to take place in a physician&#8217;s office as a same-day treatment, in comparison with TURBT or similar tumor surgical procedures, which are operations conducted under general anesthesia in a hospital setting and may require at least an overnight stay. Tumor surgical procedures often have limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective chemoablation agent can potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery and hospital-acquired infections.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Bladder Cancer</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The bladder is a hollow organ in the pelvis with flexible muscular walls. Its main function is to store urine before it leaves the body. Urine is produced by the kidneys and is then carried to the bladder through the upper urinary tract tubes, called ureters. The bladder wall has four main layers. The innermost lining is comprised of cells called urothelial or transitional cells, and this inner layer is called the urothelium or transitional epithelium. Beneath the urothelium, there is a layer called the lamina propria. Next is a thick layer of muscle called the muscularis propria followed by a layer of perivesical fat.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465608511253.jpg" title="" alt="" style="width:386px;height:254px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0.25pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NMIBC tumor types are circled</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bladder cancer accounts for approximately 90% to 95% of all new cases of urothelial cancer in the United States, with a prevalence of approximately 580,000. Bladder cancer is nearly three to four times more common in men than women, and, with an average age at diagnosis of 73, mostly affects the elderly. Bladder cancers are described as non-muscle invasive or muscle-invasive based on how far into the wall of the bladder they have invaded. The magnitude and rate of the spreading of the cancer is called &#8220;staging,&#8221; which ranges from Ta to T1 for NMIBC, and T2 to T4 for muscle-invasive bladder cancers, as defined by the American Joint Committee on Cancer TNM System. In addition, Carcinoma in Situ, or CIS, a form of NMIBC, has a staging designation of Tis. Muscle-invasive bladder cancer, or MIBC, has an average five-year survival rate of 15% to 63%, depending on severity. MIBC represents a worse prognosis than NMIBC, which has a five-year survival rate of approximately 90%. NMIBC accounts for approximately 80% of all new cases of bladder cancer diagnosed in the United States each year, which corresponds to an estimated annual incidence and prevalence of approximately 60,000 and 465,000 cases, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-muscle invasive bladder cancers are divided into two grades, low and high, with high-grade tumors more likely to recur and progress into muscle-invasive tumors. CIS tumors are all high-grade. Overall, approximately 70% of patients with NMIBC present with low-grade disease at diagnosis.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chart below indicates the prevalence of stage and grade of bladder cancer in the United States.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465609311254.jpg" title="" alt="" style="width:351px;height:180px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Upper Tract Urothelial Carcinoma</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTUC refers to malignant changes of the transitional urothelial cells lining the upper urinary tract of the renal pelvis and ureter. UTUC typically exhibits high local recurrence and development of metastases. Similar to NMIBC, the prognosis of patients with UTUC correlates with the stage and grade of disease at the time of initial diagnosis. The key prognostic factor at the time of diagnosis of UTUC is whether the tumor is in the muscle-invasive or non-muscle invasive stage. The number, size and location of tumors presented also represent important prognostic factors for UTUC. Approximately 40% of the patients diagnosed annually with UTUC in the United States present with non-muscle invasive UTUC. Non-muscle invasive UTUC is also divided into two grades, low and high. In two studies conducted in 1997 and 2003 of 30 and 20 patients with non-muscle invasive UTUC, 87% and 75% of patients were diagnosed with low-grade non-muscle invasive UTUC, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chart below indicates the prevalence of stage and grade of UTUC in the United States.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465610411255.jpg" title="" alt="" style="width:373px;height:210px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTUC accounts for approximately 5% to 10% of all new cases of urothelial cancer, which corresponds to an estimated annual incidence in the United States of up to 7,500 cases. In 2012, the estimated prevalence of UTUC in the United States was approximately 45,000, of which approximately 14,500 had low-grade disease. UTUC is nearly three times more common in men than women and affects mostly the elderly.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. Moreover, the anatomical complexity of the upper urinary tract, particularly the renal pelvis, presents significant challenges to the proper identification and ability to reach and resect all tumors in tumor resection surgical procedures. Consequently, patients with high-grade disease or patients with low-grade disease that present with a large number of tumors typically undergo nephroureterectomy, which is kidney and upper urinary tract removal. In addition, the stage and grade of UTUC are often misdiagnosed, which we believe is due to the structural complexity of the upper urinary tract. Due to these factors, the current standard of care for the treatment of UTUC is nephroureterectomy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tumor resection, which aims to be a kidney sparing surgical procedure, is conducted only in patients with low-grade disease that present with a limited number of tumors. Such procedures are followed by adjuvant chemotherapy treatment, typically with MMC. However, the upper urinary tract&#8217;s anatomical constraints limit the effectiveness of surgical procedures and adjuvant chemotherapy treatments, leading to high rates of recurrence and risk for progression in this patient population. In a study published in 2009 in the Journal of Endourology evaluating 57 patients with low-grade UTUC who underwent tumor resections, 89.5% of patients recurred with a mean of 5.5 recurrences per patient over a four-year period. Moreover, approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper urinary tract removal.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We believe that because tumor resection procedures followed by adjuvant chemotherapy therapy are sub-optimal, nephroureterectomy is often used even in patients that may be otherwise candidates for organ-sparing treatments.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Non-Muscle Invasive Bladder Cancer</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to MIBC is between 20% and 30%. As a consequence, NMIBC patients often undergo multiple repeat TURBT procedures and adjuvant chemotherapy and immunotherapy treatments.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard of care for treating NMIBC patients is TURBT followed by adjuvant chemotherapy or immunotherapy treatment. TURBT is a surgical operation for tumor removal conducted under general anesthesia in a hospital setting and may require at least an overnight stay. Moreover, TURBT&#8217;s success is tied to the physician&#8217;s ability to overcome challenges in properly identifying, reaching and resecting all tumors. No drugs have been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved by the FDA for NMIBC, all used as adjuvant treatment, following TURBT. Efficacy of drug treatments has historically been limited due to challenges presented by bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the drug almost immediately and causing the excretion of the drug from the bladder at first urine voiding.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Competitive Strengths</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our lead product candidates for uro-oncology, which are being developed by leveraging our expertise in drug development and our proprietary formulation technology, have the ability to replace the costly, sub-optimal and burdensome tumor resection procedures that represent the current first-line standard of care. Furthermore, we believe our proprietary formulation technology has broad applications and may allow us to develop additional product candidates for indications within and beyond the urinary tract.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Potential ability to develop non-surgical, first-line drug therapies for uro-oncology<font style="font-style:normal;">. </font><font style="font-weight:normal;font-style:normal;">Leveraging our innovative formulation technology, we are developing two lead product candidates, MitoGel and VesiGel, as potential replacements to first-line treatment for low-grade UTUC and NMIBC, respectively. Both MitoGel and VesiGel are chemoablation agents designed to overcome the challenges posed by the anatomy of the urinary tract by increasing the dwell time and enhancing the tissue coverage of MMC. Clinical data generated to date supports our belief that our lead product candidates may be able to replace the current first-line tumor surgical procedures, providing a chemoablation treatment that has the potential to better eradicate tumors irrespective of their detectability and location within the urinary tract. Of the 13 low-grade UTUC patients treated with MitoGel in a recently-completed Compassionate Use program and evaluated endoscopically or through the use of a nonsurgical viewing instrument for efficacy, eight achieved a complete response and the remaining five achieved a partial response at the primary evaluation time. In the case of VesiGel, 19 of 22, or approximately 86%, of the patients treated with the high dose of VesiGel in a recently-completed Phase 2a trial conducted in Europe and Israel, evaluating the efficacy and safety of VesiGel&#8217;s chemoablation properties, achieved a complete response at the primary evaluation time.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expertise in developing proprietary formulations of drugs for clinical benefit.<font style="font-weight:normal;font-style:normal;"> We focus on developing proprietary RTGel formulations of previously approved drugs whose efficacy for a particular indication is limited by current formulations or routes of administration. While we have not yet brought a drug to market, our expertise has enabled us to develop proprietary RTGel-based formulations for several previously approved drugs to date, including clinical stage proprietary formulations of MMC and botulinum toxin. Our formulations are designed to significantly increase the dwell time and exposure of the drugs to the target sites and limit the need for urine retention, potentially providing enhanced clinical activity, reduced patient burden and increased patient compliance over existing formulations and modes of administration. With 13 Ph.Ds. and medical doctors on our staff, we have a strong research and development team to advance our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lower development risks and costs for our pipeline product candidates.<font style="font-weight:normal;font-style:normal;"> We expect the approval process for each of our current uro-oncology product candidates to be conducted according to the FDA&#8217;s 505(b)(2) regulatory pathway, a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug development. Furthermore, two of our product candidates, MitoGel and Vesimune, have received Orphan Drug Designation from the FDA for the treatment of UTUC and CIS, respectively, which we expect will provide seven years of marketing exclusivity following FDA approval, if received. We submitted an IND for MitoGel in November 2016, which was accepted by the FDA in December 2016. We commenced a single pivotal, open-label, single-arm Phase 3 clinical trial for the treatment of low-grade UTUC in the first quarter of 2017. The clinical trial is being conducted in the United States and Israel with anticipated enrollment of approximately 74 patients. Additionally, we expect that our product candidates are more likely to be safe and well-tolerated because they are novel formulations of previously approved drugs.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leverageable proprietary formulation technology.<font style="font-weight:normal;font-style:normal;"> We believe that RTGel has multiple potential applications beyond urology. Our formulation know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of targeted body cavities. We believe that our proprietary formulation technology can improve the efficacy of locally administered drugs in body cavities such as the stomach, uterus and rectum that present anatomical and physiological challenges related to frequent wash out, rapid excretion and bodily secretions. In October 2016, we announced that we licensed worldwide rights to a proprietary RTGel formulation with BOTOX to Allergan for the treatment of overactive bladder and related indications pursuant to the Allergan Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>Strong intellectual property position.<font style="font-weight:normal;font-style:normal;"> We have a robust intellectual property portfolio that includes 28 issued patents worldwide and more than 45 pending patent applications filed worldwide. In the United States, we have 13 granted patents that are directed to protect our lead product candidates MitoGel, VesiGel and Botugel as well as our RTGel technology and our other potential product candidates that are under preclinical review. These patents claim methods, systems, and novel compositions for treating cancer in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;">internal cavities, in particular treating a urinary tract cancer. These issued patents are expected to expire between 2024 and 2035. Additionally, the FDA has granted Orphan Drug Designation to MitoGel for the treatment of UTUC and Vesimune for the treatment of CIS bladder cancer, which potentially entitles us to marketing exclusivity for MitoGel and Vesimune for seven years following approval, if granted, by the FDA.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Experienced and accomplished leadership team with proven track record.<font style="font-weight:normal;font-style:normal;"> We have an experienced management team, with each member possessing more than 15 years of biopharmaceutical and related industry experience. Our Chief Executive Officer, Ron Bentsur, successfully navigated Auryxia (ferric citrate) through the 505(b)(2) streamlined regulatory pathway to FDA approval. In addition, our Chairman, Arie Belldegrun, M.D., is a seasoned biotech executive and was the founder, Chairman, Chief Executive Officer and President of Kite Pharma, which was recently sold to Gilead Sciences, Inc. for $11.8 billion. Dr. Belldegrun is also a urologist by training. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product candidates.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Growth Strategy</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to become the leading biopharmaceutical company focused on the development of novel therapies for local treatment of urological pathologies. The key elements of our strategy are as follows:</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Establish each of our lead product candidates, MitoGel and VesiGel, as the first-line treatment in its target indication.<font style="font-weight:normal;font-style:normal;"> We believe that data from treatments in our Compassionate Use program conducted in the United States, Europe and Israel provide preliminary evidence of the potential safety and efficacy of MitoGel for the treatment of low-grade UTUC. We submitted an IND for MitoGel with the FDA in November 2016, which was accepted by the FDA in December 2016, and we commenced a single pivotal Phase 3 clinical trial in the first quarter of 2017 pursuant to the FDA&#8217;s 505(b)(2) regulatory pathway. We recently completed a Phase 2a randomized, open-label, single-arm, active-controlled clinical trial of VesiGel for the treatment of low-grade NMIBC, conducted in Europe and Israel. We expect to submit an IND for VesiGel in the first half of 2018, and, if accepted, to commence a Phase 2b U.S.-based clinical trial shortly thereafter. We also expect to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that these local drug treatments have the potential to replace costly, sub-optimal and burdensome tumor resection and kidney removal surgeries to become the first-line standard of care.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:0.1pt;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expand our uro-oncology product pipeline.<font style="font-weight:normal;font-style:normal;"> A Phase 1 clinical trial of Vesimune was completed under an IND in 12 patients with CIS, an aggressive form of high-grade urinary bladder cancer. In the trial, 10 patients were evaluated for response, of which 40% achieved a complete response rate with Vesimune as a single-agent treatment. We believe that combining Vesimune with immune checkpoint inhibitors or chemotherapy has the potential to serve as a treatment option for high-grade urothelial tumors. We are also pursuing preclinical oncology programs that take advantage of our RTGel technology. We are conducting preclinical programs for high-grade bladder cancer and high-grade UTUC. We may also evaluate in-licensing or acquiring additional product candidates for the treatment of urological cancers.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Utilize our proprietary technology to expand our pipeline to other body cavities and indications.<font style="font-weight:normal;font-style:normal;"> We believe that RTGel may be suitable for multiple additional applications. Our know-how may enable us to develop different drug formulations to facilitate the delivery, retention, increased dwell time and sustained release of active drugs to a variety of targeted body cavities. Beyond the urinary tract, we may target the gastrointestinal tract and the female reproductive system. In the future, we may also choose to develop our RTGel technology in combination with other drugs to treat cancer and other indications endemic to such body cavities.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Evaluate and selectively pursue potential collaborations to develop improved formulations and product life-cycle management strategies. We entered into the Allergan Agreement to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients. This collaboration provides us with funding for our research and development efforts and may accelerate the development and commercialization of our approved products, if any. In addition, we may in-license or acquire additional product candidates for urological indications. Such collaborations would allow us to obtain financial support and to capitalize on the expertise and resources of our potential partners, which could allow for new and improved versions of approved or clinical stage drugs and could accelerate the development and commercialization of additional product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RTGel: Our Reverse Thermally Triggered Hydrogel Platform Technology</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have developed RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel, which, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when heated. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, by conforming to the anatomy of the target organ while preventing rapid excretion of the drug. The following images show the progression of five stages of RTGel at different temperatures.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465614011256.jpg" title="" alt="" style="width:602px;height:100px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0.25pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LT: Liquid at low temperature</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0.25pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BT: Converts into gel form at body temperature</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RTGel&#8217;s components are polymer-based and are inactive ingredients that have been approved by the FDA for use in other products such as Oraqix, a periodontal gel, Namenda, an oral solution for Alzheimer&#8217;s disease, and Xeloda, an oral chemotherapy. We formulate RTGel with an active drug: MMC in the case of MitoGel and VesiGel, and botulinum toxin in the case of BotuGel. The resulting formulations are instilled intravesically in liquid form directly into the bladder or upper urinary tract using standard instillation methodologies via catheters and thereafter convert into gel form at body temperature. Subsequently, upon contact with urine, RTGel gradually dissolves and releases the active drug over a period of several hours and is less affected by urine creation and voiding cycles as compared to water formulations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that RTGel, when formulated with an active drug, may allow for the improved efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. RTGel achieves this by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">increasing the exposure of active drugs in the bladder and upper urinary tract by significantly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urinary tract, which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard MMC water formulation, currently used as adjuvant treatment, in the upper urinary tract is approximately five minutes, compared to approximately six hours when MMC is formulated with RTGel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations. For instance, it is only possible to dissolve 0.5 mg of MMC in 1 ml of water while it is possible to formulate up to 8 mg of MMC with 1 ml of RTGel; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintaining the active drug&#8217;s molecular structure and mode of action. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These characteristics of RTGel enable sustained release of MMC in the urinary tract for both MitoGel and VesiGel, and of botulinum toxin in the case of BotuGel. Further, RTGel may be particularly effective in the bladder and upper urinary tract where tumor visibility and access are challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics of RTGel may prove useful for the local delivery of active drugs to other bodily cavities in addition to the bladder and upper urinary tract.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MMC&#8212;Our Target Active Drug for the Treatment of UTUC and NMIBC</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MMC is a generic drug currently utilized off-label as the standard adjuvant chemotherapy for the treatment of low-grade UTUC and NMIBC after tumor resection, such as TURBT. MMC, a chemotherapy agent, is typically administered using a water-based formulation, which has a relatively short dwell time in the bladder limited to first voiding. MMC often causes temporary irritation of the bladder, including the need to urinate frequently and urgently. This often results in first voiding occurring shortly after instillation. In the upper urinary tract, the dwell time is limited to approximately five minutes as urine flows continuously and no active retention by the patient is feasible. Numerous in vitro models, in vivo studies and computer simulations have shown that increased dwell time of MMC in the bladder results in more efficacious treatment of bladder cancer. In one such study, it was shown that MMC activity increased with exposure time. Specifically, the MIC90, or mean inhibitory concentration that causes 90% inhibition in cell growth, was 11-fold lower when exposure time was increased from 30 minutes to eight hours.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MMC&#8217;s main effect is on the cancer cell&#8217;s DNA and has been demonstrated to be most effective when the cancer cell is in its S-phase, or synthesis phase, during which the DNA is replicated. Each cancer cell goes through various phases during the cell cycle. However, the cell cycle is not synchronized in all cancer cells, which means that at any given point in time only a portion of the cancer cells are at their S-phase, or susceptible to the instilled MMC in the bladder. Thus, because our RTGel-based MMC sustained-release formulations, MitoGel and VesiGel, provide for a significantly longer dwell time of MMC in the upper urinary tract and in the bladder as compared to standard MMC water formulations, there is a greater chance that tumor cells will go through their S-phase while the instilled MMC is still present using MitoGel or VesiGel, potentially resulting in a higher percentage of tumor cells being affected by the instilled MMC.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MitoGel: Our Product Candidate for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing MitoGel, our novel sustained-release formulation of MMC, for the treatment of low-grade UTUC. We have observed preliminary evidence of the efficacy of MitoGel in an investigator-initiated Compassionate Use program for the treatment of unresectable UTUC. Additionally, the FDA granted MitoGel Orphan Drug Designation for the treatment of UTUC and Fast Track Designation. We plan to develop MitoGel through the FDA&#8217;s 505(b)(2) regulatory pathway. We commenced a pivotal, open-label, single-arm Phase 3 clinical trial for MitoGel in the first quarter of 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies for Upper Tract Urothelial Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. The current standard-of-care for the treatment of UTUC is nephroureterectomy, which is complete kidney and ureter removal. Recent advances in resection instrument technology have allowed physicians in some cases to treat patients with low-grade UTUC using endoscopic tumor resection, a kidney-sparing treatment, rather than nephroureterectomy followed by adjuvant chemotherapy, typically MMC, treatment. However, the specific anatomy and physiology of the upper urinary tract make the performance of organ-sparing endoscopic tumor resection and instillation of adjuvant chemotherapy challenging, leading to high recurrence rates. Patients often undergo multiple endoscopic resection procedures, which increases the probability of potential complications of resection, including perforation and ureteral stricture, or a narrowing of the ureter. A recent study published in 2009 in the Journal of Endourology, evaluating 57 patients with low-grade UTUC who underwent tumor resections showed that recurrence occurred in 89.5% of patients, with a mean of 5.5 recurrences per patient, over a four-year period. Moreover, approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper tract removal.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MMC is currently administered using a water-based formulation, which limits the dwell time in the bladder until first voiding. In the upper urinary tract, the dwell time of MMC is approximately five minutes as urine flows continuously and no active retention by the patient is feasible.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Solution: MitoGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MitoGel is our novel sustained-release RTGel-based formulation of MMC that we are developing for the treatment of low-grade UTUC. RTGel is liquid at lower temperatures and converts into gel form at body temperature. This temperature-dependent viscosity characteristic allows for simple and convenient instillation of the cooled MitoGel in its liquid form to the upper urinary tract via standard catheters. Once instilled, MitoGel converts into gel form in less than 10 minutes at body temperature. Subsequently, upon contact with urine, MitoGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus several minutes for MMC in its water-based formulation. We believe that this substantial increase in dwell time of MMC positions MitoGel as a potential first-line chemoablation treatment for low-grade UTUC, potentially sparing patients from repeated tumor resection surgeries and potentially reducing the need for bladder and upper urinary tract surgeries, including upper urinary tract removal.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Orphan Drug Designation granted to MitoGel for the treatment of UTUC potentially entitles us to marketing exclusivity for MitoGel for seven years following approval by the FDA, if granted, as well as priority review of our New Drug Application, or NDA. We believe Fast Track Designation may allow us to obtain priority or expedited review of our NDA filing as well as the possibility for a rolling NDA submission.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Initial Clinical Results for MitoGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a>MitoGel was evaluated in an investigator-initiated Compassionate Use program for the treatment of severe, non-resectable UTUC, which commenced in September 2014. The Compassionate Use program, which was conducted in the United States, Europe and Israel, included patients diagnosed with unilateral and bilateral low- and high-grade UTUC, as well as patients with a solitary kidney. Patients in the Compassionate Use program received six weekly instillations of MitoGel administered directly to the upper urinary tract. Consistent with the nature of Compassionate Use programs, which are investigator-initiated programs, a statistical plan or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">primary endpoint was not used as in a regular clinical trial. Approximately four weeks following the completion of the treatment course, the patients were evaluated for response. Patients were visually evaluated endoscopically or through the use of a nonsurgical viewing instrument, with additional confirmation through urine cytology, or examination of cells collected from a urine specimen. At the evaluation time, which was approximately four weeks following the completion of the treatment course, patients were deemed to have achieved a complete response if, in the judgment of the physician, no tumors initially diagnosed by the physician were detected and a partial response if, in the judgment of the physician, the size or number of tumors had decreased or if, following an initial complete response, there is tumor recurrence within three months after the evaluation time. Safety and feasibility of treatment with MitoGel were also evaluated. Twenty-two patients were treated in the study, with more than 130 instillations of MitoGel performed. Of the 22 patients treated, 18 were assessed as having low-grade UTUC. Of the 18 patients assessed as having low-grade disease, 14 completed six instillations of MitoGel. Of these 14 patients, 13 were evaluated for response and one could not be evaluated to confirm response. Of the 13 patients who were evaluated for response, eight, or approximately 62%, achieved a complete response and five, or approximately 38%, achieved a partial response at the primary evaluation time. One of the patients who received a partial response subsequently received an additional three courses of MitoGel and thereafter achieved a complete response.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the eight patients who have achieved a complete response at the primary evaluation time, we are aware of three patients who have subsequently experienced recurrences to date. Recurrences were generally of small tumors, a few millimeters in diameter, and were manageable by endoscopic tumor resection. To our knowledge, five of the eight patients have not recurred to date, with three of the five patients having achieved durability of 12 months or greater to date. The median durability for these eight patients is still ongoing and is now greater than nine months, based on investigator reports. The follow-up evaluation plan for patients in our Compassionate Use program is determined by each individual investigator and varies from patient to patient, and some patients have not undergone follow-up evaluation or have been lost to follow-up. As part of the ongoing single pivotal Phase 3 clinical trial, in order to potentially further extend durability, patients who achieve a complete response at the primary disease evaluation visit will be followed for durability of response and will receive monthly MitoGel maintenance instillations for up to 12 months.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MitoGel was observed to be well-tolerated in the Compassionate Use Program. The main observed adverse events, or AEs, related to MitoGel have been fatigue, allergic reaction, nausea, fever, and dysuria, which is pain or difficulty while urinating. All of the AEs that have been observed to date are known side effects associated with the use of MMC and appear on the MMC label as potential side effects. Various serious adverse events, or SAEs, were also reported most of which were determined to be unrelated to treatment with MitoGel. These SAEs include acute pyelonephritis, a kidney infection caused by bacteria; hydronephrosis, which is the swelling of the upper urinary tract due to a build-up of urine caused by some degree of obstruction; severe arrhythmia, which is a severe abnormal heart rhythm; cardiac asthma, which is a medical diagnosis of wheezing, coughing or shortness of breath due to congestive heart failure; aggravation of renal function; hyperkalemia, which is a condition of elevated levels of potassium in the blood; pancytopenia, which is a deficiency of red cells, white cells and platelets in the blood; scarring and narrowing of the calyceal infundibulum, which was most probably present at baseline; asymptomatic extravasation from the upper tract, which is leakage of fluids from the upper tract to the surrounding tissue; and death.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Compassionate Use program was allowed by the FDA to accumulate safety and efficacy data. In the first quarter of 2017, we commenced a pivotal, open-label, single-arm Phase 3 clinical trial of MitoGel for the treatment of low-grade UTUC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following images show pre-treatment and post-MitoGel treatment results from one low-grade UTUC patient in the Compassionate Use program.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465632111257.jpg" title="" alt="" style="width:259px;height:225px;"><img src="g2018031520465632411258.jpg" title="" alt="" style="width:211px;height:221px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Courtesy of Dr. J. Gregory Wirth, Geneva Hospital, Switzerland)</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The top left image is a pre-treatment ureteroscopic view of a tumor located in the ureter. The bottom left image is a pre-treatment x-ray revealing an obstruction within the ureter in which no contrast (black) can be visualized in the distal ureter (denoted by arrow). The top right image is a post-treatment ureteroscopic view of the same location following MitoGel chemoablation treatment. The bottom right image is a post-treatment x-ray of the ureter which reveals no obstruction within the ureter.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">IND-Enabling Studies for MitoGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our IND-enabling work for MitoGel, we have completed a large-scale good laboratory practices, or GLP, toxicity study in an upper urinary tract swine model in which more than 250 instillations of MitoGel were performed. This study evaluated the safety of the procedure and MitoGel administration, also utilizing higher dosage levels than those used in the clinical settings. In this GLP toxicology study, the instillation of MitoGel was found to be safe. We are also currently conducting chemistry, manufacturing and controls, or CMC, studies as part of our IND-enabling efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Next Steps in the Clinical Development of MitoGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on discussions with the FDA, we intend to develop MitoGel through the FDA&#8217;s 505(b)(2) regulatory pathway. We submitted an IND for MitoGel in November 2016, which was accepted by the FDA in December 2016. We commenced a pivotal, open-label, single-arm Phase 3 clinical trial of MitoGel for the treatment of low-grade UTUC in the first quarter of 2017.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465633811259.jpg" title="" alt="" style="width:578px;height:123px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(*) Only if clinical trial is successfully completed</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Phase 3 clinical trial is being conducted in the United States and Europe with anticipated enrollment of approximately 74 patients. We expect this clinical trial, if successfully completed, to support an NDA for low-grade UTUC for MitoGel. The patients will initially receive six weekly instillations of MitoGel. The primary efficacy endpoint is expected to be the complete response rate, defined as the percentage of patients with a complete response at the primary disease evaluation visit, which occurs approximately four weeks following the sixth weekly instillation. In addition, patients who achieve a complete response at the primary disease evaluation visit will be followed for durability of response. Such patients will also receive monthly MitoGel maintenance instillations for up to 12 months. If this clinical trial is successfully completed, we currently anticipate submitting an NDA for MitoGel in the first quarter of 2019. In the Phase 3 trial, to date, MitoGel therapy has been well tolerated. Adverse events encountered in treated subjects include the expected effects of Mitomycin C administration to the urinary tract (pain and urinary tract irritation). In addition, transient perturbation of laboratory measures of renal and hematopoietic function has been observed. No study participants have required medical intervention to address these changes.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">VesiGel: Our Product Candidate for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VesiGel is our novel sustained-release formulation of high dose MMC that we are developing for the treatment of low-grade NMIBC as a first-line non-surgical chemoablation alternative to TURBT. We recently completed a Phase 2a randomized, open-label, single-arm active-controlled clinical trial in Europe and Israel that evaluated the safety and efficacy of VesiGel (40mg and 80mg MMC) in low-grade NMIBC. We commenced the trial in September 2013 and the last patient was enrolled in March 2016. 19 of 22, or approximately 86%, of the patients with confirmed low-grade NMIBC treated in this trial achieved complete responses in the 80mg MMC dose group of VesiGel at the primary evaluation time, and therefore did not require surgical intervention. Approximately 79% of the patients who achieved a complete response at the primary evaluation time with VesiGel treatment and who had been followed for 12 months thereafter remained recurrence free and were able to sustain this durable complete response without receiving any additional treatment during this period. This compares to approximately 40% to 60% of patients who historically have been able to sustain a 12-month durable complete response following TURBT as first-line treatment followed by additional adjuvant treatments of MMC instillations into the bladder.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to submit an IND for VesiGel in the first half of 2018, and, if accepted, to commence a Phase 2b U.S. based clinical trial shortly thereafter.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies for Non-Muscle Invasive Bladder Cancer</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tumor grade and stage are the most important variables for determining the likelihood of progression from NMIBC to MIBC. The three stages of NMIBC are: Ta (70%), T1 (20%) and CIS or Tis (10%). Approximately 70% of NMIBC patients have a tumor that is classified as low-grade upon diagnosis. Ta and CIS are limited to the urothelial layer, and T1 is limited to the layer below, which is the lamina propria.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recurrence, which occurs in approximately 80% of patients, is the primary threat for NMIBC patients. Multiplicity, or number of tumors, tumor size and prior recurrence rate are the most important variables in determining the likelihood and potential severity of recurrence. In T1 and CIS NMIBC patients, progression, which occurs in approximately 45% of patients, is the main threat. Treatment ranges from one or more TURBT procedures followed by adjuvant chemotherapy or immunotherapy instillation(s) in NMIBC patients with a low risk of recurrence to cystectomy for the treatment of NMIBC patients with a high risk of recurrence.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TURBT is conducted in a hospital setting under general anesthesia and can often have side effects and complications. The most common complications, risks and limitations of TURBT include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">bleeding at the time of surgery that requires clot irrigation and mild burning; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">infection of the bladder; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injured urethra and bladder perforation with potential intra-abdominal leakage; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reimplantation and cell migration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">repeat TURBT procedures, which are necessary for approximately 10% of patients within three months; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">complete removal of tumor tissue often not being feasible; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential recurrence of up to 25% of the tumors at the original treatment site; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">some tumors not being detectable. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-operative adjuvant treatments for NMIBC, which are given to prevent reimplantation of the cancerous cells, consist primarily of chemotherapy in the case of low-grade tumors and immunotherapy in the case of high-grade tumors, and are administered intravesically via catheter. Adjuvant intravesical chemotherapy is used primarily in low-grade tumors following TURBT in order to try to delay tumor recurrence but is not used as a chemoablation agent. The rationale is to expose tumors to high local drug concentrations while minimizing the systemic exposure, thereby enhancing the treatment effect and reducing the drug toxicity. However, these traditional adjuvant treatments to treating bladder cancer have been limited because, after instillation, the drug concentration is reduced, and the drug is washed out due to urine voiding. As a result, the cancerous tissue is not exposed to the chemotherapy drug for the optimal length of time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No drugs have been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved for NMIBC, all used as adjuvant treatment: Thiotepa, which was approved in 1959; bacille Calmette-Guerin, or BCG, which was approved in 1989; and Valstar, which was approved in 1998. MMC is the drug used most often for intravesical chemotherapy. It is used off-label as an adjuvant treatment in the post-operative setting for low-grade tumors with high risk of recurrence. Other drugs that can be used include docetaxel and gemcitabine. BCG, an immunotherapy-based drug, is used as an adjuvant treatment for patients with high-grade NMIBC. Upon recurrence, which occurs in approximately 35% of patients, the patients undergo another round of BCG therapy with a response rate of 30% to 50%. Radical cystectomy, or surgical removal of the bladder, is also a common treatment option for patients who fail multiple intravesical BCG therapies. However, treatment with BCG is associated with severe side effects, as evidenced by a Black Box warning on the label, which is a warning placed on a prescription drug&#8217;s label by the FDA and is designed to call attention to serious or life-threatening risks.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not aware of any drugs currently in development for the treatment of NMIBC that take into consideration bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the active drug almost immediately.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Solution: VesiGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a>VesiGel, an RTGel-based formulation of high dose MMC, is our product candidate for the treatment of low-grade NMIBC. VesiGel is administered locally using standard catheters and is designed to conform to the bladder&#8217;s anatomy and persist in the bladder despite urine flow and bladder movement. Once instilled, VesiGel converts into gel form within approximately 10 minutes at body temperature. Subsequently, upon contact with urine, VesiGel gradually dissolves and releases the active drug, MMC, over a period of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">several hours versus the time until first voiding, often less than an hour, for MMC in its current water-based formulation, without compromising the safety of the patient or interfering with the natural flow of urine out of the bladder. We believe that the resulting significantly increased dwell time of MMC in the bladder prolongs exposure of MMC to the tissue and therefore has the potential to chemoablate visible and unseen tumors. As a result of these properties, our goal is to develop VesiGel as a first-line chemoablation non-surgical alternative to TURBT for the treatment of low-grade NMIBC.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Phase 2a Clinical Trial</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed a Phase 2a randomized, open-label, single-arm, active-controlled clinical trial in Europe and Israel that evaluated the safety and efficacy of VesiGel 0.06% (40 mg MMC in 64 ml gel) and VesiGel 0.12% (80 mg MMC in 64 ml gel) in low-grade NMIBC compared to the intravesical instillation of 40 mg of MMC in water (MMC 0.1%). We commenced the trial in September 2013 and the last patient was enrolled in March 2016. In this trial, patients underwent six weekly instillations according to their assigned treatment arm. The primary endpoint of the trial used for observational purposes only is the complete response rate at the primary disease endpoint, which is evaluated approximately four weeks after the sixth weekly installation. Safety, feasibility of local treatment with VesiGel and durability of response are also being evaluated. 81 patients were enrolled, 65 of whom have been evaluated for response. Of the 65 evaluable patients in the study, 20, 22 and 23 patients were in the VesiGel 40mg MMC, VesiGel 80mg MCC and the water-based 40mg MMC control arm, respectively. The results to date indicate complete response rates at the primary evaluation time of 45%, 86% and 70% for VesiGel 40mg MMC, VesiGel 80mg MMC and water-based 40mg MMC control arm, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In treating low-grade NMIBC, resection of small tumors is primarily conducted in the outpatient setting, typically without anesthesia using fulguration, a procedure that destroys the diseased area in the lining of the bladder by burning using electric current. The effectiveness of tumor resection in these cases is high and the one-year recurrence rate is estimated to be only 10%. However, in patients with larger tumors and multiple tumors, standard management includes surgical removal using TURBT, a procedure conducted in the operating room in a hospital setting under general anesthesia, which may require at least an overnight stay. TURBT is associated with increased risks and costs and higher recurrence rates that can reach up to 60%.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When evaluating the effect of chemoablation on large tumors that would typically be treated with TURBT, we observed a more profound difference in the complete response rate between the VesiGel 80mg MMC arm compared to the water-based 40mg MMC control arm. In tumors less than or equal to 1 cm2 in size, the complete response rate at the primary evaluation time was 78% (18 patients) and 88% (16 patients) in the water-based 40mg MMC control group and the VesiGel 80mg MMC group, respectively. However, in tumors greater than 1 cm2 in size, the complete response rate at the primary evaluation time was 40% (five patients) and 83% (six patients) in the control group and VesiGel 80mg MMC group, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph below illustrates the complete response rates by tumor size for the VesiGel 80mg MMC and water-based 40mg MMC control treatment arms.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465680711260.jpg" title="" alt="" style="width:433px;height:260px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a>We also observed a difference in the complete response rate between the VesiGel 80mg MMC arm compared to the water-based 40mg MMC control arm when evaluating the effect of chemoablation on the number of tumors. In cases of three or fewer tumors, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complete response rate at the primary evaluation time was 80% (15 patients) and 81% (16 patients) in the water-based 40mg MMC control group and the VesiGel 80mg MMC group, respectively. However, in cases of more than three tumors, cases that would typically be treated using TURBT, the complete response rate at the primary evaluation time was 50% (eight patients) and 100% (six patients) in the water-based 40mg MMC control group and the VesiGel 80mg MMC group, respectively.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph below illustrates the complete response rates by tumor volume for the VesiGel 80mg MMC and water-based 40mg MMC control treatment arms.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465681511261.jpg" title="" alt="" style="width:490px;height:299px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the incidence of AEs reported for both VesiGel groups in the study has been low and appears similar to that of the active control group, with the majority of the AEs having occurred in the VesiGel 80mg MMC group. The main observed AEs related to VesiGel have been dysuria, allergy, lower urinary tract symptoms, and hematuria, or the presence of blood in the urine. The AEs that have occurred were associated with the use of MMC, MMC intravesical instillation or the cystoscopy procedure itself. The MMC-related AEs were primarily burning sensation, rash, urgency, and dysuria, which is painful or difficult urination. These AEs appear on the MMC label as potential side effects. SAEs were also reported, including allergy, weakness, hematuria, difficult or labored breathing, lower urinary tract symptoms other than dysuria, and death. None were determined to be related to VesiGel, except for two allergy cases that were resolved.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following images show cytoscopic views of complete responses in a low-grade NMIBC patient treated with VesiGel.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465682211262.jpg" title="" alt="" style="width:603px;height:271px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The image to the left is a pre-treatment cystoscopic view of a tumor located in the bladder. The image to the right is a post-treatment cystoscopic view of the same location following VesiGel chemoablation treatment.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Dose Escalation Study for VesiGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In parallel to our Phase 2a clinical trial, in the first half of 2015, we initiated a dose escalation study for patients with NMIBC in Europe and Israel to evaluate the safety and efficacy of VesiGel at dose levels higher than 80 mg MMC. To date, we have enrolled 14 patients. All patients to date have been treated with the 120 mg MMC in 60 ml gel dose, or 0.2% concentration. Of the 12 low-grade NMIBC patients evaluated to date, 10 have achieved a complete response (83%). However, at the 120 mg MMC dose level, we also observed a higher rate of MMC-related AEs than in patients treated with the 80 mg MMC dose. Five of 12 patients did not complete six weekly instillations due to their non-compliance, although three of these five patients achieved a complete response. As a result, we have determined to focus our development efforts going forward on the 80 mg MMC dose level.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Phase 1 Clinical Trial for VesiGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In early 2014, we completed a Phase 1 clinical trial in India evaluating two earlier formulations of VesiGel. Patients underwent six weekly instillations according to their assigned treatment of RTGel (40 ml) formulated with either 40 mg MMC or 80 mg MMC. Following completion of the six instillations, patients were evaluated for safety and efficacy. We enrolled 19 patients, 15 of whom were evaluated for response to treatment. Of the 15 evaluable patients, seven achieved a complete response, with two out of five from the 40 mg MMC arm and five out of 10 from the 80 mg MMC arm. Patients were followed for one year after treatment. The results of this study led to the initiation of our Phase 2a clinical trial, in which we are using a higher volume of RTGel, 64 ml compared to 40 ml, in an attempt to further enhance the efficacy of the 40 mg and 80 mg MMC VesiGel dose groups, by increasing the dwell time of the drug.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Durability of Response</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Per protocol, the patients in our Phase 2a and Phase 1 clinical trials were followed for 12 months after the primary disease evaluation time point. To date, 41 patients treated with different VesiGel formulations completed the 12-month follow-up period, 28 of whom achieved a complete response at the primary disease evaluation time point and did not receive any additional treatments. Of these 28 patients, 28 (100%), 25 (89%), 24 (86%) and 22 (79%) had durable complete responses at three, six, nine and 12 months, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph below demonstrates the durability data for the patients treated with VesiGel who achieved a complete response at the primary disease evaluation time point and were followed for 12 months.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465684211263.jpg" title="" alt="" style="width:398px;height:208px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that these results support our belief that VesiGel, acting as a chemoablation agent, can replace TURBT, with the possibility of improving durability of response.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Next Steps in the Clinical Development of VesiGel</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed the Phase 2a clinical trial in the first half of 2017. We recently met with the FDA to discuss next steps in the clinical development program for VesiGel. We plan to submit an IND for VesiGel in the first half of 2018 and, if accepted, to commence a U.S. based Phase 2b clinical trial for VesiGel shortly thereafter.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesimune: Our Product Candidate for the Treatment of High-Grade NMIBC</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing Vesimune, our immune-modulation product candidate, for the treatment of high-grade NMIBC. A Phase 1 dose escalation study was conducted in 23 NMIBC patients and Vesimune appeared to be well-tolerated in the study. This was followed by a Phase 1 pilot study under an IND in 12 patients with CIS bladder cancer in the United States. 40% of the 10 evaluable patients achieved a complete response, and Vesimune was observed to be well-tolerated in the trial. We intend to further investigate the use of Vesimune for the treatment of high-grade NMIBC, as a single agent or possibly combining it with VesiGel, MitoGel or with immune checkpoint inhibitors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Limitations of Current Therapies for High-Grade NMIBC</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High-grade NMIBC is a highly aggressive form of bladder cancer. TURBT is the initial treatment of choice for high-grade NMIBC; however, the high rates of recurrence and significant risk of progression to muscle-invasive tumors are particularly dangerous. Bladder removal can be the first treatment of choice for young, otherwise healthy patients with high-grade disease or for patients who cannot tolerate BCG. BCG, an immunotherapy-based drug, is the current standard of care as an adjuvant therapy post-resection in high-grade tumors. However, treatment with BCG is associated with severe side effects, as evidenced by a Black Box warning on the label.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Solution: Vesimune</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that Vesimune, our immune-modulation product candidate, could represent a valid alternative to the current standard of care for the BCG adjuvant, post-TURBT treatment of high-grade NMIBC. Vesimune&#8217;s active ingredient is Imiquimod, an imidazoquinoline, synthetic immune modulator, which specifically targets TLR7, which is expressed in bladder cancer cells. Toll-like receptors are pattern recognition receptors whose importance in stimulating innate and adaptive immunity has been established by recent studies. Toll-like receptors are able to sense microbial components as well as host-derived endogenous molecules released by injured tissues and play a critical role in defending against invading pathogens.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Imiquimod, in its topical formulation, is FDA approved for several indications, including superficial basal cell carcinoma. Vesimune is a liquid formulation of Imiquimod for intravesical administration that has been optimized for delivery in the urinary tract. Vesimune does not use our RTGel technology. We believe that Vesimune may elicit an adaptive immune response in the presence of released bladder cancer antigens, which may translate into a long lasting acquired immune response. We also believe the combination of Vesimune with immune checkpoint inhibitors could further increase the adaptive immune response and potentially represent a viable alternative to BCG for the adjuvant treatment of high-grade NMIBC or UTUC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have obtained Orphan Drug Designation for Vesimune for the treatment of CIS in the bladder. We have an active IND for Vesimune, which has been effective since 2013.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We acquired Vesimune from Telormedix SA, a private Swiss-based biotechnology company, in the fourth quarter of 2015. Telormedix conducted all of the previous studies related to Vesimune, including the Phase 1 and Phase 1b studies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Vesimune Clinical Results and Post-Study Follow-Up</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesimune was evaluated in a Phase 1 dose escalation study that enrolled 23 patients diagnosed with NMIBC. Vesimune was well-tolerated at the doses used. Subsequently, a Phase 1b study of Vesimune was conducted under an IND in patients with CIS bladder cancer in the United States. The Phase 1b study was commenced in April 2013 and completed in February 2014. Patients were dosed with Vesimune 0.4% weekly for six weeks. The study was designed to evaluate the safety and preliminary efficacy of Vesimune in CIS patients. The primary efficacy endpoint for observational purposes only was the rate of complete response at five to seven weeks after the sixth weekly instillation. Twelve patients were enrolled into the pilot study, of which 10 patients were evaluable for response. Four of the 10 patients, or 40%, achieved a complete response. Vesimune was observed to be well tolerated in this trial. The most common AEs related to Vesimune were urination urgency, dysuria, fatigue, urinary tract infections and hematuria. One SAE, a urinary tract infection, was observed and was resolved. For observational purposes, patients were followed for an additional six-month period beyond the completion of the study, referred to as the Post-Study Follow Up. Of the four patients who had achieved a complete response with Vesimune in the study, two patients remained disease free at the end of the Post-Study Follow Up while receiving no additional therapy. The two other patients who had achieved a complete response with Vesimune in the study also remained disease free at the end of the Post-Study Follow Up while receiving BCG therapy during this period.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chart below represents the complete response rates for patients receiving only Vesimune:</font></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520465687011264.jpg" title="" alt="" style="width:429px;height:231px;"></p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;line-height:10pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Next Steps in the Clinical Development of Vesimune</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to further investigate the use of Vesimune for the treatment of high-grade NMIBC, as a single agent or possibly combined with MitoGel, VesiGel or other immunotherapy agents. Such a combination study would evaluate whether this multimodality approach, harnessing the power of the immune system together with the chemoablation properties of VesiGel or MitoGel, can provide a safe and effective approach for the treatment of high-grade urothelial tumors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preclinical Programs</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Using our proprietary RTGel formulation technology, we are pursuing additional preclinical programs to expand and enhance our uro-oncology product portfolio. In particular, we are pursuing preclinical programs for high-grade bladder cancer and high-grade UTUC using checkpoint inhibitors such as an anti PD-L1 or an anti CTLA-4.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">License Agreement with Allergan</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2016, we entered into the Allergan Agreement with Allergan and granted Allergan an exclusive worldwide license to research, develop, manufacture and commercialize pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, to which we refer as the Licensed Products, which are approved for the treatment of adults with overactive bladder who cannot use or do not adequately respond to anticholinergics. Additionally, we granted Allergan a non-exclusive, worldwide license to use certain of our trademarks as required for Allergan to practice its exclusive license with respect to the Licensed Products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Allergan Agreement, Allergan is solely responsible, at its expense, for developing the Licensed Products and obtaining all regulatory approvals for Licensed Products worldwide. Allergan is also solely responsible, at its expense, for commercializing the Licensed Products worldwide after receiving the regulatory approval to do so. Allergan is required to use commercially reasonable efforts to develop and commercialize the Licensed Products for overactive bladder in certain major market countries.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will supply Allergan with certain quantities of RTGel for development of Licensed Products through Phase 2 clinical trials using BOTOX together with RTGel in patients with overactive bladder, at Allergan&#8217;s request and expense. Allergan has the right to reduce the next milestone payment to us if there is a material supply failure from us. Prior to completion of the first Phase 2 clinical trial, Allergan has the right to request that we transfer to Allergan our manufacturing process for RTGel and Allergan will assume the responsibility to manufacture RTGel and Licensed Product for its own development and commercialization activities.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allergan paid us a nonrefundable upfront license fee of $17.5 million upon signing the agreement, and, in the third quarter of 2017, we received an additional $7.5 million milestone payment upon the submission by Allergan of an IND to the FDA for a Licensed Product. In October 2017, we announced that Allergan had begun a Phase 2 study of RTGel in combination with BOTOX for the treatment of overactive bladder.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>Further, we are eligible to receive additional material milestone payments of up to an aggregate of $200.0 million upon the successful completion of certain development, regulatory and commercial milestones, including $20.0 million upon initiation of a Phase 3 clinical trial for a Licensed Product for overactive bladder; $15.0 million upon initiation of a Phase 3 clinical trial for a Licensed Product for a specified second indication; $50.0 million and $25.0 million upon the first commercial sale of a Licensed Product for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">overactive bladder in the United States and the European Union, respectively; $25.0 million and $15.0 million upon the first commercial sale of a Licensed Product for a specified second indication in the United States and the European Union, respectively; and $50.0 million upon net sales of all Licensed Products of $500.0 million. Allergan will pay us a tiered royalty in the low single digits based on worldwide annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of our patent coverage of Licensed Products. We are responsible for payments to any third party for certain RTGel-related third party intellectual properties.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Allergan Agreement, Allergan granted us a non-exclusive, sublicensable, fully paid-up, perpetual, worldwide license under any improvements Allergan makes to the composition, formulation, or manufacture of RTGel for the research, development, manufacture and commercialization of any product containing RTGel and any active ingredient (other than a clostridial toxin) for all indications other than indications covered by the agreement and an exclusive, sublicensable, royalty-bearing (in low single digits), perpetual worldwide license under such improvements for use in the prevention or treatment of oncology indications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue to research, develop and commercialize other products combining RTGel with other active ingredients, except that there are certain restrictions with respect to the overactive bladder and neurogenic detrusor overactivity indications. Neurogenic detrusor overactivity is when a known neurologic abnormality impairs the signaling systems between the bladder and the central nervous system, and the brain is unable to inhibit the detrusor muscles controlling urination.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Either party may terminate the Allergan Agreement for uncured material breach by the other party and for the insolvency of the other party. We may terminate the Allergan Agreement if Allergan or its affiliates challenges any of our patents licensed to Allergan and such patent challenge is not required under a court order or subpoena and is not a defense against a claim, action or proceeding asserted by us, our affiliates or licensees against Allergan, its affiliates or sublicensees. In addition, Allergan may unilaterally terminate the Allergan Agreement for any reason upon advance notice. If Allergan has the right to terminate the Allergan Agreement due to our uncured material breach, Allergan may elect to continue the agreement and reduce all future milestone and royalty payment obligations to us by a specified percentage. In the event of any termination of the Allergan Agreement, Allergan will assign or grant a right of reference to any regulatory documentation related to RTGel to us, all rights and licenses to Allergan will terminate, and the license Allergan granted to us under their improvements to RTGel will continue.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent estate includes patents and applications with claims directed to our MitoGel, VesiGel, RTGel, BotuGel and Vesimune product candidates, as well as broader claims for potential future product candidates. On a worldwide basis, our patent estate includes more than 70 issued patents and pending patent applications for our product candidates as well as for new treatment methods, manufacturing process, novel intravesical devices and systems and future combination products that are mainly designed to treat internal cavity cancers. In the United States, we currently have <font style="Background-color:#FFFFFF;">13</font> issued patents and more than 45 patent applications filed worldwide that are directed to methods, systems and compositions for treating internal cavity cancers, and in particular, urinary tract cancer and bladder cancer.</p>
<p style="margin-bottom:0pt;margin-top:12pt;line-height:11pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These U.S.-issued patents are expected to remain in effect until between 2024 and 2035. Our worldwide intellectual property portfolio includes four pending patent applications relating to BotuGel in the European Union, China and Israel, as well as one granted patent in each of the United States and Russia. In addition, we have two granted patents related to Vesimune in the United States as well as two granted patents in the European Union, two granted patents in Japan, and one granted patent in each of Hong Kong and Brazil, each of which are expected to remain in effect until 2030. In addition to the issued patents mentioned above, our portfolio includes pending patent applications relating to Vesimune in the European Union, Canada, Brazil, Hong Kong and Israel. Moreover, we hold five granted patents in the United States, four in Europe, one in each of Israel, Japan, New Zealand and Australia, as well as pending patent applications filed worldwide that relate to novel formulations of phospholipid drug analogs (saturated lipid conjugate compositions) for the treatment of urinary tract cancer. Our patents and patent applications mainly relate to hydrogel-based pharmaceutical compositions for optimal delivery of any drug to the internal cavity such as a bladder and/or urinary tract; the method for treating urothelial cancer using hydrogel based composition; the method for treating overactive bladder topically without a need for injections; special catheters and in-dwelling ureter-catheter systems for optimal delivery of a drug into the renal cavity; pharmaceutical compositions comprising an imidazoquinolin-amine (specifically imiquimod) and lactic acid for treating bladder cancer diseases, and novel phospholipid drug analogs for treating cancer or infections. In addition to patents, we have filed for trademark registration with the United States Patent and Trademark Office, or the USPTO, for &#8220;MitoGel,&#8221; &#8220;VesiGel,&#8221; &#8220;RTGel&#8221; and &#8220;BotuGel.&#8221; Furthermore, we rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. Preparing and filing patent applications is a joint endeavor of our research and development team and our in-house and external patent attorneys. Our patent attorneys conduct patent prior-art searches and then analyze the data in order to provide our research and development team with recommendations on a routine basis. This results in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">protecting our product candidates that are under development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">encouraging pharmaceutical companies to negotiate development agreements with us; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;line-height:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">preventing competitors from attempting to design-around our inventions. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We submit patent applications directly with the USPTO as provisional patent applications. We would then continue filing under the Patent Cooperation Treaty, or PCT, which is an international patent law treaty that provides a unified procedure for filing a single initial patent application to seek patent protection for an invention simultaneously in any one of the designated member states. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The standard of care for treating NMIBC patients is the TURBT procedure for tumor resection, followed by post-operative adjuvant chemotherapy or immunotherapy instillations, administered to prevent reimplantation of the cancerous cells. The adjuvant agents used are predominately generic treatments and regimens. Only three drugs have been approved for the treatment of non-muscle invasive bladder cancer (NMIBC: Thiotepa, which was approved by the FDA in 1959; BCG, which was approved by the FDA in 1989; Valstar, which was approved by the FDA in 1998. Despite the approval of these drugs, there remain high unmet needs in the bladder cancer market. BCG has been used to treat patients with CIS and high-grade T1 since 1990. Valstar is indicated for patients with CIS (High Grade NMIBC) that do not respond to BCG treatment and Thiotepa is an over 50-year-old drug, rarely used, indicated for superficial papillary carcinoma of the bladder. MMC is used off-label as the standard adjuvant treatment in the post-TURBT setting for low-grade NMIBC patients. Off-label means that while the FDA has not approved MMC as adjuvant treatment in the post-TURBT setting for low-grade NMIBC patients, physicians are permitted to utilize it as standard of care for this indication as part of medical practice. However, off-label usage as a standard of care does not change the FDA&#8217;s approval criteria and does not suggest that FDA approval is more likely than for other investigational drugs. In the UTUC space, there are no approved drugs used to treat the disease. Tumor resection surgeries are conducted in some cases of low-grade UTUC; however, complete kidney and upper urinary tract removal is the standard of care for frequently recurring UTUC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several products in the development pipeline, most of which are second- or third line-treatments mainly targeted for high-grade NMIBC patients who have failed BCG treatment. All are targeted to reduce recurrence, but none are developed to reduce the need for TURBT and other tumor resection therapies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware that other companies, such as Roche, Vyriad, GSK, Celgene, Lipac Oncology, Samyang biopharma, Merck Sharp &amp; Dohme Corp., Eleven biotherapeutics, Viralytics Limited, AADi, LLC, Biocancell Ltd., Altor BioScience Corporation, FKD Therapies Oy, Spectrum Pharmaceuticals, Inc., Taris Biomedical LLC and Abnoba, are conducting or have recently conducted clinical trials for product candidates for the treatment of low-grade and high-grade NMIBC, including CIS. In addition, we are aware of several pharmaceutical companies that are developing drug candidates for muscle-invasive bladder cancer. The FDA approved 4 immunotherapy drugs known as checkpoint inhibitors; Tecentriq (atezolizumab), Bavenico (Avelumab), Imfinzi (durbalumab) and Keytruda (pembrolizumazb) for the treatment of locally advanced or metastic baldder cancer, a form muscle invasive bladder cancer. We do not know whether these potential competitors are already developing, or plan to develop, low-grade UTUC or high-grade UTUC treatments or other indications that we are pursuing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we face competition from existing standards of treatment, including TURBT, which is surgery for bladder cancer. If we are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates to replace the existing standard of care, which is a first-line tumor surgical procedure for both bladder cancer and UTUC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target, or seek to have existing drugs approved for use for the treatment of the indications that we target.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These potential competitors may therefore introduce competing products without our prior knowledge and without our ability to take preemptive measures in anticipation of their commercial launch. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective, easier to administer or less costly than our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">nonclinical laboratory and animal tests that must be conducted in accordance with good laboratory practices, or GLPs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submission of an IND, which must become effective before clinical trials may begin; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submission to the FDA of an NDA; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">satisfactory completion of an FDA advisory committee review, if applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and GCPs; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">FDA approval of an NDA to permit commercial marketing for particular indications for use. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the commencement of marketing of controlled substances, the U.S. Drug Enforcement Agency, or DEA, must also determine the controlled substance schedule, taking into account the recommendation of the FDA.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The testing and approval process requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess potential safety and efficacy. Prior to commencing the first clinical trial with a product candidate, we must submit the results of the preclinical tests and preclinical literature, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the conduct of the clinical trial by imposing a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each study site proposing to conduct the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including any changes to the study plans. Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&#8217;s or the IRB&#8217;s requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business objectives or competitive climate. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise us to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, for purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 1&#8212;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase 1 trials may also be used to gain an initial indication of product effectiveness. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Phase 2&#8212;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-family:Times New Roman;">Phase 3&#8212;These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. Evidence is considered to be statistically significant when the probability of the result occurring by random chance, rather than from the efficacy of the treatment, is sufficiently low. These clinical trials are intended to establish the overall risk/benefit ratio of the </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product and provide an adequate basis for product labeling. These trials may be done globally to support global registrations so long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may be made a condition to be satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can provide important safety information.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials must be conducted under the supervision of qualified investigators in accordance with GCP requirements, which includes the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the Federal Food, Drug and Cosmetic Act, or the FDCA. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if SAEs occur.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">505(b)(2) Regulatory Approval Process</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 505(b)(2) of the FDCA, or 505(b)(2), provides an alternate regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The applicant may rely upon the FDA&#8217;s prior findings of safety and efficacy for an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orange Book Listing</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 505 of the FFDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#8220;abbreviated&#8221; because they are generally not required to include preclinical and clinical data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo or other testing. The generic version must deliver the same amount of active ingredients into a subject&#8217;s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any applicant who submits an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a Paragraph IV certification. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through a Paragraph IV certification. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the competitor has provided a Paragraph IV certification to the FDA, the competitor must also send notice of the Paragraph IV certification to the holder of the NDA for the reference listed drug and the patent owner once the application has been accepted for filing by the FDA. The NDA holder or patent owner may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification prevents the FDA from approving the application until the earlier of 30 months from the date of the lawsuit, expiration of the patent, settlement of the lawsuit, a decision in the infringement case that is favorable to the applicant or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a Paragraph IV certification, the NDA holder or patent owner regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s decision to initiate patent litigation. The applicant may also elect to submit a statement certifying that its proposed label does not contain, or carves out, any language regarding the patented method-of-use rather than certify to a listed method-of-use patent.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Exclusivity</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA provides periods of regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&#8217;s approval of the NDA. Five years of exclusivity are available to NCEs. An NCE is a drug that contains no active moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent, or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (i.e., formed by the chemical interaction of two compounds), chelate (i.e., a chemical compound), or clathrate (i.e., a polymer framework that traps molecules), of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept for review or approve an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials, other than bioavailability or bioequivalence trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the condition of the new drug&#8217;s approval. As a general matter, three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Orphan Drug Act</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan Drug Designation must be requested before submitting an NDA. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application user fee.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fast Track Designation</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA is required to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment, and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track program, the sponsor of a new product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the submission of the IND for the product candidate. The FDA must determine if the product candidate qualifies for Fast Track designation within 60 days after receipt of the sponsor&#8217;s request.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Fast Track products, the sponsor may have more frequent interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the NDA is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. A Fast Track designated product candidate would ordinarily meet the FDA&#8217;s criteria for priority review.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NDA Submission and Review by the FDA</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product development, including chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be paid at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the manufacturing controls are adequate to assure and preserve the product&#8217;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. The FDA&#8217;s NDA review times may differ based on whether the application is a standard review or priority review </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application. The FDA may give a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a standard NDA for an NME and make a decision on the application. For non-NME standard applications, the FDA has set the review goal of 10 months from the submission date to complete its initial review and to make a decision on the application. For priority review applications, the FDA has set the review goal of reviewing NME NDAs within six months of the 60-day filing date and non-NME applications within six months of the submission date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the FDA&#8217;s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the review cycle of the application is complete, and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing, or other information or analyses in order for the FDA to reconsider the application. The FDA has the goal of reviewing 90% of application resubmissions in either two or six months of the resubmission date, depending on the kind of resubmission. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a risk evaluation and mitigation strategy, or REMS, as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product, or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning. The FDA also may not approve the inclusion of labeling claims necessary for successful marketing. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4 post-marketing studies to monitor the effect of approved products and may limit further marketing of the product based on the results of these post-marketing studies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-approval Requirements</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program user fee requirements for any approved products, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other requirements, which impose procedural and documentation requirements upon us and our third-party manufacturers. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP regulations and other FDA regulatory requirements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented, or FDA notification. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations on manufacturers of pharmaceutical products related to product and tracking and tracing.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with any of the FDA&#8217;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. Any of these sanctions could result in adverse publicity, among other adverse consequences.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Regulations</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education and other activities following product approval will be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services and its various divisions, including the CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense and state and local governments. Our business activities must comply with numerous healthcare laws and regulations, including those described below.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable, in whole or in part, by Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value, including unlawful financial inducements paid to prescribers and beneficiaries, as well as impermissible promotional practices. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent requirement of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal civil and criminal false claims laws, including the federal False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or for approval by, the federal government, including the Medicare and Medicaid programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their Average Manufacturer Price, or AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part B, to also calculate and report their average sales price, which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program, effective April 1, 2016, that, among other things, revises the manner in which the AMP is to be calculated by manufacturers participating in the program and implements certain amendments to the Medicaid rebate statute created under the ACA. Drugs that are approved under a biologics license application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the manufacturer&#8217;s best price for the drug and inflation penalties which can substantially increase rebate payments. For BLA and NDA drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans Affairs a different price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires manufacturers to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false pricing information to the government creates potential federal False Claims Act liability.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including public and private payors, or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. The ACA amended the federal health care fraud criminal statute implemented under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have violated the statute.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the ACA and its implementing regulations, require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with specified exceptions) to report annually information related to specified payments or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually specified ownership and investment interests held by physicians and their immediate family members.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information on HIPAA covered entities and their business associates, including mandatory contractual terms and the implementation of certain safeguards of such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways, may not have the same effect and may not be preempted by HIPAA, thus complicating compliance efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and/or state laws that require drug manufacturers to report information related to marketing expenditures or payments and other transfers of value to physicians and other healthcare providers.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcement actions can be brought by federal or state governments or, in some cases, as &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government. Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal, civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion from government programs, refusal to allow us to enter into supply contracts, including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for our products, once approved, and related treatments will be available from third-party payors, such as government health administration authorities, private health insurers and managed care organizations. Third-party payors determine which medications they will cover and separately establish reimbursement levels. Even if we obtain coverage for a given product by a third-party payor, the third-party payor&#8217;s reimbursement rates may not be adequate to make the product affordable to patients or profitable to us, or the third-party payors may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage, are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes and are challenging the prices charged for medical products. Further, no uniform policy for determining coverage and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available, or if reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Reform Measures</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2010, the ACA was passed, which is changing health care financing by both governmental and private insurers and significantly affecting the U.S. pharmaceutical industry. The ACA, among other things, subjected manufacturers to new annual fees and taxes for specified branded prescription drugs, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, expanded health care fraud and abuse laws, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, imposed an additional rebate similar to an inflation penalty on new formulations of drugs, extended the Medicaid Drug Rebate Program to Medicaid managed care organizations, expanded the 340B program, which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics and community health centers, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a>However, some provisions of the ACA have yet to be fully implemented and certain provisions have been subject to judicial and Congressional challenges, as well as efforts by the Trump Administration to repeal or replace certain aspects of the ACA. For example, since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. The recently enacted Tax Cuts and Jobs Act also includes a provision that repeals, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called &#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221; </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact our business. We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact our business.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2027 unless additional U.S. Congressional action is taken. In addition, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted legislation at the federal and state levels designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump Administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. While any proposed measures will require authorization through additional legislation to become effective, Congress and the Trump Administration have both stated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have been increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Additional health reform measures may continue and affect our business in unknown ways.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books and records that accurately and fairly reflect all transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign Regulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to develop or sell any products outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing, Supply and Production</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate manufacturing facilities for the production of our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw materials, active ingredients and finished products for our preclinical research and clinical trials, including the single pivotal Phase 3 clinical trial for MitoGel. We do not have long-term agreements with any of these third parties. We also do not have any current contractual relationships for the manufacture of commercial supplies of our product candidates if they are approved. If product candidates are approved by any regulatory agency, we intend to enter into agreements with a third-party contract manufacturer and one or more back-up manufacturers for the commercial production of those products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development and commercial quantities of any products that we develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal resources to manage our manufacturing contractors. The relevant manufacturers of our drug products for our current preclinical and clinical trials have advised us that they are compliant with both current good laboratory practice, or cGLP, and cGMP.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates, if approved, may not be producible in sufficient commercial quantities, in compliance with regulatory requirements or at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the processes, methods and equipment are compliant with cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and foreign regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Marketing, Sales and Distribution</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given our stage of development, we do not have any internal sales, marketing or distribution infrastructure or capabilities, and our marketing department currently consists only of a marketing director, whose main responsibility is to produce marketing and communication materials, exhibitions, website content and to identify unmet needs in the urology market, assess their commercial potential and advise on the prioritization of the development of our future product candidates accordingly. We have recently formed a U.S. subsidiary, Urogen Pharma, Inc., to support our U.S. development and potential commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that we receive regulatory approvals for our products in markets outside of the United States, we intend, where appropriate, to pursue commercialization relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are equipped to market or sell our products through their well-developed sales, marketing and distribution organizations in such countries.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may out-license some or all of our worldwide patent rights to more than one party to achieve the fullest development, marketing and distribution of any products we develop.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_4C"></a>Organizational structure.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Urogen Pharma, Inc., our wholly owned subsidiary, was incorporated under the laws of the State of Delaware in October 2015.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_4D"></a>Property, plants and equipment.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are located at 9 HaTa&#8217;asiya St., Ra&#8217;anana 4365007, Israel, where we lease an approximately 11,495 square foot facility. This Israeli facility houses our administrative headquarters and our research and development laboratories. We also maintain an office at 499 Park Avenue, New York, New York, where we lease approximately 9,336 square feet of space, which serves as the headquarters for our U.S. subsidiary. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional or alternative spaces will be available in the future on commercially reasonable terms. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_4_A"></a><a name="Item_4_A"></a>Item 4A. Unresolved Staff Comments </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_5"></a><a name="Item_5"></a>Item 5. Operating and Financial Review and Prospects </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_5A"></a><font style="color:#000000;">Operating results. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is currently used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. We are developing our product candidates as chemoablation agents, which means they are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, or UTUC, and low-grade bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#8217; quality of life by replacing costly, sub-optimal and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder and upper urinary tract surgeries, including removal of the upper urinary tract, which are major surgical procedures typically performed when local endoscopic tumor resection fails to control the disease progression. Additionally, we believe that our product candidates, which are based on formulations of previously approved drugs, may qualify for streamlined regulatory pathways to market approval.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates, MitoGel and VesiGel, are formulated using our proprietary reverse thermally triggered hydrogel, or RTGel, technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage of the active drug throughout the organ. Consequently, we believe that RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. No drugs have been approved by the U.S. Food and Drug Administration, or the FDA, for the treatment of non-muscle invasive bladder cancer, or NMIBC, in more than 15 years.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC, which may include Carcinoma in Situ, or CIS. Vesimune is a novel, liquid formulation of Imiquimod, a generic toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in initiating the innate immune response system. We believe that the combination of Vesimune with additional immunotherapy drugs, such as immune checkpoint inhibitors or chemotherapy drugs like VesiGel, could represent a valid alternative to the current standard of care for the post-TURBT adjuvant treatment of high-grade NMIBC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BotuGel is our proprietary novel RTGel-based formulation of BOTOX, a branded drug, that we believe can potentially serve as an effective treatment option for patients suffering from overactive bladder. In October 2016, we announced the licensing of the worldwide rights to RTGel in combination with neurotoxins, including BOTOX, to Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, or the Allergan Agreement. In August 2017, we announced that Allergan had submitted an IND to the FDA in order to be able to commence clinical trials in the United States using the RTGel in combination with BOTOX. In October 2017, Allergan commenced a Phase 2 clinical trial of BotuGel for the treatment of overactive bladder.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses in each period since our formation in 2004. We incurred net losses of $20.0 million, $1.9 million and $12.7 million for the years ended December 31, 2017, 2016 and 2015, respectively. As of December 31, 2017 our accumulated deficit was $47.2 million. We expect to continue to incur losses for the foreseeable future, and our losses may fluctuate significantly from year to year. We expect that our expenses will increase substantially in connection with our ongoing activities as we:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">conduct the single pivotal Phase 3 clinical trial for MitoGel, and plan to initiate a Phase 2b clinical trial for VesiGel, each pursuant to the FDA&#8217;s 505(b)(2) regulatory pathway;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">initiate an additional clinical trial for Vesimune in combination with another agent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">continue the preclinical development of our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">submit an NDA seeking regulatory approval for any product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maintain, expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add equipment and physical infrastructure to support our research and development;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">hire additional clinical development, regulatory, commercial, quality control and manufacturing personnel; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need substantial additional funding to support our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for and, if any of our product candidates are approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allergan License Agreement</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a>We entered into an exclusive license agreement with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc in October 2016, which we refer to as the Allergan Agreement. Allergan paid us a nonrefundable upfront license fee of $17.5 million, and we are eligible to receive additional milestone payments upon the successful completion of certain development, regulatory and commercial milestones. Under the Allergan Agreement, Allergan is solely responsible, at its expense, for developing, obtaining regulatory approvals for and commercializing, on a worldwide basis, pharmaceutical products that contain RTGel and clostridial toxins (including BOTOX), alone or in combination with certain other active ingredients, which we refer to collectively as the Licensed Products. Allergan is obligated to pay us a tiered royalty in the low single digits based on worldwide </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">annual net sales of Licensed Products, subject to certain reductions for the market entry of competing products and/or loss of our patent coverage of Licensed Products. We are responsible for payments to any third party for certain RTGel-related third party intellectual properties. In July 2017, Allergan notified us that they had submitted their Investigational New Drug, or IND, application for BotuGel, our proprietary novel RTGel-based formulation of BOTOX for the treatment of overactive bladder, to the FDA. The submission of the IND triggered the second milestone under the Allergan Agreement, pursuant to which we received a payment of $7.5 million in August 2017. Allergan commenced a Phase 2 clinical trial of BotuGel in October 2017, pursuant to Allergan Agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;letter-spacing:0.25pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have any products approved for sale and, to date, we have not recognized any revenues from sales of MitoGel, VesiGel or Vesimune. During the year ended December 31, 2016, we recognized revenues of $17.5 million from a payment received under the Allergan Agreement. For the year ended December 31, 2017, we recognized revenues of $7.5 million under the Allergan Agreement upon the achievement of a milestone in August 2017. The remaining revenues we recognized during the year ended December 31, 2017 are related to sales of RTGel to Allergan, per the Allergan Agreement. In the future, we may generate revenue from a combination of product sales, reimbursements, up-front payments, milestone payments and royalties in connection with the Allergan Agreement and future collaborations. If we fail to achieve clinical success and/or to obtain regulatory approval of any of our product candidates in a timely manner, our ability to generate future revenue will be impaired.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses, net</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The largest component of our total operating expenses has historically been, and we expect will continue to be, research and development. Research and development expenses consist primarily of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">salaries and related costs, including share-based compensation expense, for our personnel in research and development functions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred under agreements with third parties, including CROs, subcontractors, suppliers and consultants, preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expenses incurred to acquire, develop and manufacture preclinical study and clinical trial materials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">facility and equipment costs, including depreciation expense, maintenance and allocated direct and indirect overhead costs. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense all research and development costs as incurred. In light of the fact that our employees and internal resources may be engaged in projects for multiple programs at any time, our focus is on total research and development expenditures, and we do not allocate our internal research and development expenses by project.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through December 31, 2017, we had received grants of <font style="color:#000000;">$2.1 </font>million in the aggregate from the Israeli Innovation Authority, or the IIA, for research and development funding. Pursuant to the terms of the grants, we are obligated to pay the IIA royalties of 3.0% to 4.5% on revenues from sales of products developed from a project financed in whole or in part by IIA grants, up to a limit of 100% of the amount of the grant received, plus annual interest calculated at a rate based on 12-month LIBOR.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to paying any royalties due, we must abide by other restrictions associated with receiving such grants under the R&amp;D Law, which will continue to apply to us following full repayment to the IIA. For example, under the Allergan Agreement, Allergan has the option to manufacture products developed with IIA-funded technology outside of Israel, which would require approval from the IIA. Although Allergan has not yet exercised this option, we have requested approval from the IIA for a possible transfer. We may not receive such approval. Even if we do receive such approval, we may be required to pay increased royalties of up to 300% of the amount of the original grant received and other amounts. If the IIA deems the license to Allergan a technology transfer, we may be required to pay up to 600% of the amount of the original grant and other amounts. The Israeli government grants we have received for research and development activities restrict our ability to manufacture products and transfer technologies outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received and incur financial penalties.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, new rules published by the IIA for granting a right to use know- how developed from research and development that was conducted pursuant to a plan approved by the IIA outside of Israel, or Licensing Rules, came into effect. The Licensing Rules allow a recipient of a grant from the IIA to grant third parties outside of Israel the right to use know-how, or License, provided that the IIA authorized the grant of the License. In such case, the recipient of the grant has to pay the IIA for the License. The amount of payment is based on various factors, including the consideration received by the licensor and, in accordance with the formulas set forth in the Licensing Rules, may equal up to six times the IIA-funding amount plus interest. When the consideration for the grant includes nonmonetary compensation or monetary compensation that is not fixed, or when a &#8220;special relationship&#8221; exists between the licensor and licensee (e.g., when a party controls the other party or is the other party&#8217;s exclusive distributor) or when the agreed consideration does not reflect, in the IIA&#8217;s opinion, the market value, the IIA may base the value of the transaction on an economic assessment that it obtains for such purpose.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently focused on advancing our product candidates, and our future research and development expenses will depend on their clinical success. Research and development expenses will continue to be significant and will increase over at least the next several years as we continue to develop our product candidates and conduct preclinical studies and clinical trials of our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our product candidates. Due to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with certainty the costs we will incur and the timelines that will be required in the continued development and approval of our product candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, if and when such arrangements will be entered into, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under applicable accounting rules, we deduct the IIA grants from research and development expenses as the applicable costs are incurred. We also had a preclinical collaboration for BotuGel with Allergan into which we initially entered into in February 2014. We deduct amounts received from the preclinical collaboration with Allergan from our research and development expenses as the applicable costs are incurred. As a result, our research and development expenses are shown on our financial statements net of the IIA grants and amounts received from the preclinical collaboration.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive, finance, and human resource functions, facility costs and external professional service costs, including legal, accounting and audit services and other consulting fees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase in the future as we increase our administrative headcount and infrastructure to support our continued research and development programs and the potential approval and commercialization of our product candidates. We also anticipate that we will incur increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer insurance premiums, executive compensation, and other costs associated with being a public company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if any of our product candidates receives regulatory approval and if we invest in building a commercial infrastructure to support the marketing of our products, we expect to incur greater expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Finance expenses, net</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses, net, consisted primarily of finance expenses on warrants offset by interest income.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income taxes</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have yet to generate taxable income in Israel. We have historically incurred operating losses resulting in carry forward tax losses totaling approximately $24.8 million as of December 31, 2017. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax assets related to these carry forward losses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Analysis of Results of Operations</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Comparison of the years ended December 31, 2017, 2016 and 2015</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2017, 2016 and 2015:</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653230"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross profit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,558</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,502</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses, net<sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,697</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,287</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,515</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses<sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,811</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,417</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,895</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating (loss) income</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,410</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,739</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,981</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Includes share-based compensation expense as follows: </p></td></tr></table></div>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,923</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,967</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508367544"></a>Total share-based compensation expense increased $4.3 million in 2017 over 2016 due to an increase in the fair market value of our share price for 2017 grants and modifications associated with our IPO.</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31, 2017 and 2016</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our total revenues decreased by $9.3 million to $8.2 million in the year ended December 31, 2017 from $17.5 million in the year ended December 31, 2016. This decrease is mainly due to the difference in proceeds of $7.5 million and $17.5 million received from Allergan upon the achievement of certain milestones under the Allergan Agreement in each of the years ended December 31, 2017 and 2016, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased by $8.4 million to $18.7 million in the year ended December 31, 2017 from $10.3 million in the year ended December 31, 2016. The increase was attributable mainly to an increase in direct costs associated with the MitoGel Phase 3 clinical trial of approximately $3.1 million, an increase of approximately $2.8 million of share-based compensation expenses related to an increase in personnel and the grant date fair value of common stock, and an increase of approximately $2.5 million in headcount, consulting and related costs to support increased clinical trial activities. Total non-cash research and development share-based compensation expense for the year ended December 31, 2017 was $3.9 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a>General and administrative expenses increased by approximately $2.4 to $8.8 million in the year ended December 31, 2017 from $6.4 million in the year ended December 31, 2016. The increase in general and administrative expenses resulted primarily from an increase in share-based compensation expense of approximately $1.6 million related to an increase in personnel and the grant date fair value of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">common stock, an increase of $1.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in payroll and recruitment costs due to headcount and related costs to support our growing business, an increase of $0.9 million in professional service expenses, commercial services, director and officer insurance premiums, and other costs associated with being a public company,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and an increase of $0.3 million in rent and office maintenance related to our new office in New York</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. These increases were offset by $1.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of IPO expenses in the statement of operations in 2016.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Total non-cash general and administrative share-based compensation expense for the year ended December 31, 2017 was $2.4 million.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Finance expenses, net</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses, net, decreased by approximately $2.7 million to less than $1,000 in the year ended December 31, 2017 from $2.7 million in the year ended December 31, 2016.&nbsp;&nbsp; The change in finance expenses, net, was primarily due to the recording of the increased fair value of the warrants to the income statement in 2016.&nbsp;&nbsp;The warrants converted to Preferred A-1 shares upon the close of the IPO in May 2017.&nbsp;&nbsp;There was minimal change in the fair value of the warrants in 2017 prior to conversion.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31, 2016 and 2015</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenues</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our total revenues increased by $17.5&#160;million from $0 in the year ended December&#160;31, 2015 to $17.5&#160;million in the year ended December&#160;31, 2016, due to the nonrefundable upfront license fee received under the Allergan Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and development expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses decreased by $228,000, or 2%, to $10.3&#160;million in the year ended December&#160;31, 2016 from $10.5&#160;million in the year ended December&#160;31, 2015. Approximately $4.1&#160;million of the decrease relates to&#160;in-process&#160;research and development costs in connection with intellectual property related to Vesimune that we purchased from Telormedix SA in 2015. This decrease is partly offset by an increase of $3.9&#160;million primarily attributable to an increase in share-based compensation to consultants and employees of $997,000, an increase of $546,000 in payroll mainly due to increased headcount and a $1.2&#160;million increase relating to research and development expense offsets in 2015 from IIA grants and from our prior preclinical collaboration with Allergan for BotuGel.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General and administrative expenses</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased by $4.5&#160;million, or 237%, to $6.4&#160;million in the year ended December&#160;31, 2016 from $1.9&#160;million in the year ended December&#160;31, 2015. The increase in general and administrative expenses resulted primarily from an increase in share-based compensation expenses to employees and directors of $521,000, an increase of $773,000 in payroll and an increase in professional services expenses of $2.8&#160;million of which $1.7 million relates to this offering. The increase was primarily related to our strengthening of our senior management team and payments to professional services consultants hired by us in preparation for this offering.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Finance expenses, net</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance expenses, net, increased by $2.4&#160;million to $2.7&#160;million in the year ended December&#160;31, 2016 from $0.3 million in the year ended December&#160;31, 2015. The change in finance expense was primarily due to the increased fair value of the warrants converted to Series&#160;A-1 preferred shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of Foreign currency exchange risk, see &#8220;Item 11&#8212; Quantitative and Qualitative Disclosures About Market Risk.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_5B"></a><font style="color:#000000;">Liquidity and capital resources. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a>Since our inception, we have incurred losses and negative cash flows from our operations. For the year ended December 31, 2017, we incurred a net loss of $20.0 million while net cash of $9.6 million was used in our operating activities and $61.6 million was provided by our financing activities. As of December 31, 2017, we had working capital of $67.4 million, and an accumulated deficit of $47.2 million. Our principal source of liquidity as of December 31, 2017 consisted of cash and cash equivalents of $37 million and short-</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term investments of $36.0 million, all of which is held in U. S. dollars We believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating and capital expenditure requirements for at least the next </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2 months.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital resources</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through December 31, 2017, we financed our operations primarily through public equity offerings, private placements of equity securities and through the upfront payment received under the Allergan Agreement. In May 2017, we raised $60.8 million, net of issuance costs and underwriting discounts and commissions, in our IPO on the Nasdaq Stock Market. In August 2017, we received $7.5 million from Allergan upon the achievement of a milestone under the Allergan Agreement. In addition, during the year ended December 31, 2016, we recorded $1.7 million in general and administrative expenses related to IPO costs, in accordance with SEC staff Bulletin Topic 5A.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the company completed a secondary public offering on the Nasdaq Stock Market of 1,463,414 ordinary shares, at a public offering price of $41.00 per share, in consideration for approximately $64 million net of issuance costs. In addition, the underwriters exercised their option to purchase an additional 219,512 ordinary shares at the public offering price.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;color:#auto;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our statement of cash flows for the years ended December 31, 2017, 2016 and 2015:</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,571</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,189</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,175</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(793</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(301</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.64%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,581</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cash used in operating activities during the aforementioned periods resulted primarily from our net losses incurred during such periods, as adjusted for non-cash charges and measurements and changes in components of working capital. Adjustments to net losses for non-cash items mainly included depreciation and amortization, fair value adjustment of the Preferred A-1 warrants and share-based compensation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $9.6 million during the year ended December 31, 2017, compared to $4.2 million provided by operating activities during the year ended December 31, 2016. The increase in cash used in operating activities was attributable primarily to the receipt of the different milestone payments from Allergan of $7.5 million in 2017 and $17.5 million in 2016 and an increase in expenditures related to the MitoGel Phase 3 clinical trial of approximately $3.1 million, as well as an increase in personnel related costs to support our growing business and service provider costs related to becoming a public company. These increases were offset by the recording of $1.7 million of IPO expenses in 2016. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by operating activities was $4.2&#160;million in the year ended December&#160;31, 2016, compared to $7.2&#160;million used in operating activities in the year ended December&#160;31, 2015. The $11.4&#160;million increase was attributable primarily to the decrease of $10.8&#160;million in the loss for the year which mainly related to the $17.5&#160;million revenue from Allergan, partly offset by an increase of $4.5&#160;million in general and administrative expenses as a result of strengthening our senior management team and payments to professional services consultants hired by us in preparation for this offering.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net cash used in investing activities</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of cash in investing activities relates primarily to short term investments in mutual funds, the purchase of property and equipment and changes in restricted deposits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities was $36.4 million during the year ended December 31, 2017, compared to $0.8 million during the year ended December 31, 2016. The increase of $35.6 million is primarily related to the Company&#8217;s investment in highly liquid, short term mutual funds.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities was $793,000 in the year ended December&#160;31, 2016, compared to $301,000 in the year ended December&#160;31, 2015. The use of cash in investing activities mainly related to leasehold improvements in the Israel and the U.S. offices.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $61.6 million during the year ended December 31, 2017, compared to cash used in financing activities of $0.1 million during the year ended December 31, 2016. The difference is primarily related to the net proceeds received from our IPO in May 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in financing activities was $9,000 in the year ended December&#160;31, 2016, compared to $21.6&#160;million provided by financing activities in the year ended December&#160;31, 2015, the difference of which mainly related to funds raised pursuant to the 2015 and 2014 Share Purchase Agreements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2015, we entered into a share purchase agreement, to which we refer as the 2015 Share Purchase Agreement. In September 2014, we entered into a share purchase agreement, to which we refer as the 2014 Share Purchase Agreement. During 2015, we raised $18.1&#160;million from the 2015 Share Purchase Agreement and $3.6&#160;million from the 2014 Share Purchase Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Funding Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the company completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for approximately $64 million net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&#8217; option to purchase an additional 219,512 ordinary shares at the public offering price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our present and future funding requirements will depend on many factors, including, among other things:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the progress, timing and completion of clinical trials for MitoGel and VesiGel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">preclinical studies and clinical trials for Vesimune or any of our other product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs related to obtaining regulatory approval for MitoGel, VesiGel and Vesimune and any of our other product candidates, and any delays we may encounter as a result of regulatory requirements or adverse clinical trial results with respect to any of these product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">selling, marketing and patent-related activities undertaken in connection with the commercialization of MitoGel and VesiGel and any of our other product candidates, and costs involved in the development of an effective sales and marketing organization;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other amounts we may be required to pay to obtain rights to third party intellectual property rights;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">potential new product candidates we identify and attempt to develop; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">revenues we may derive either directly or in the form of royalty payments from future sales of MitoGel, VesiGel, Vesimune, BotuGel and any other product candidates. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we may finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of any additional securities may include liquidation or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information as to the risks associated with our future funding needs, see &#8220;Item 3.D &#8211; Risk Factors.&#8221; We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_5C"></a>Research and development, patents and licenses, etc.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of our research and development activities, see &#8220;Item 4.B&#8212;Business Overview&#8221; and &#8220;Item 5.A&#8212;Operating Results.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_5D"></a>Trend information.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of trends, see &#8220;Item 5.A&#8212;Operating Results&#8221; and &#8220;Item 5.B&#8212;Liquidity and Capital Resources.&#8221;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">E.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_5E"></a>Off-balance sheet arrangements. </p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the U.S. Securities and Exchange Commission.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_5F"></a>Tabular disclosure of contractual obligations. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our known contractual obligations as of December 31, 2017 are summarized in the following table. The obligations detailed below do not include grants received from the IIA pursuant to which we will owe royalties or reimbursement upon commercialization of our product candidates. As of December 31, 2017, the maximum royalty amount payable by us under these funding arrangements is $2.1 million, excluding interest.</p>
<p style="margin-bottom:0pt;margin-top:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual obligations as of December 31, 2017 are as follows:</p>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653234"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due By Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 To 3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3 To 5</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Greater Than</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations<sup style="font-size:85%; vertical-align:top"> (1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,927</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,620</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Operating lease obligations consist of payments pursuant to lease agreements for our Israeli offices and laboratory facility and our New York offices. In November 2014, we entered into a lease agreement for our Israeli offices effective from February 1, 2015 for a period of three years, with an option to extend the lease agreement by an additional three years. In April 2016, we signed an addendum to the November 2014 lease agreement in order to increase the office space rented and extend the rental period. In November 2017, we signed an additional addendum to the November 2014 lease agreement in order to increase the office space rented. The<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:0.15pt;">lease</font><font style="letter-spacing:0.45pt;"> </font>agr<font style="letter-spacing:-0.1pt;">e</font>ement<font style="letter-spacing:0.85pt;"> is </font>effective<font style="letter-spacing:0.7pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>2019.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:10pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2015, Urogen Pharma, Inc. entered into a lease agreement for its previous New York office for a period of seven years, which period commenced on May 1, 2016. In September 2017, Urogen Pharma, Inc. entered into a new lease agreement for its current New York office for a period of approximately 41 months, which period commenced in October 2017. The new lease agreement will terminate on February 1, 2021, unless earlier terminated in accordance with its terms. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">G.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:10pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_5G"></a>Safe harbor. </p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act and as defined in the Private Securities Litigation Reform Act of 1995. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><a name="Item_6"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_6"></a>I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">tem 6. Directors, Senior Management and Employees </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_6A"></a><font style="color:#000000;">Directors and senior management. </font></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information relating to our executive officers and directors as of December 31, 2017. Unless otherwise stated, the address for our executive officers and directors is c/o UroGen Pharma Ltd., 9 Ha&#8217;Ta&#8217;asiya Street, Ra&#8217;anana 4365007, Israel. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NAME</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AGE</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">POSITION</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%; border-top:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Executive Officers</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ron Bentsur </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gil Hakim </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Israeli Operation</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary Titus </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Schoenberg, M.D. </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Medical Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Non-Employee Directors</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arie Belldegrun, M.D. </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cynthia Butitta </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fred Cohen, M.D. </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kathryn Falberg </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stuart Holden, M.D. </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ran Nussbaum </p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pini Orbach, Ph.D.*</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* Effective as of March 12, 2018, Dr. Orbach has resigned as a member of our board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Executive Officers </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ron Bentsur <font style="font-style:normal;">has served as our Chief Executive Officer since August 2015, and as a member of our board of directors since October 2015. Mr. Bentsur has more than 15 years of experience in the biotech industry. Until 2015, Mr. Bentsur served for more than five years as the Chief Executive Officer of Keryx Biopharmaceuticals, Inc., and during his tenure, Keryx received FDA approval pursuant to the FDA&#8217;s 505(b)(2) regulatory pathway for Auryxia (ferric citrate) and launched it commercially in the United States. Prior to that Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals Ltd., a position he held from January 2006 until April 2009. From October 2000 Mr. Bentsur was with Keryx and served as its Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr. Bentsur worked as an investment banker in New York City, spending most of this period at ING Barings Furman Selz. Mr. Bentsur also serves as a member of the board of directors of Stemline Therapeutics, Inc. since 2009, and of Advanced Inhalation Technologies, Ltd. since August 2015. Mr. Bentsur holds a B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an M.B.A. (Magna Cum Laude), from New York University&#8217;s Stern School of Business. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Gil Hakim<font style="font-style:normal;"> has served as our President, Israeli Operation, since August 2015 and, prior to that, served as our Chief Executive Officer since August 2010. Mr. Hakim has more than 20 years of experience in the biotech industry. Prior to joining us, Mr. Hakim served as Director of New Product Development at Medispec Ltd. from 2004 to 2010 and was in charge of product development in fields such as cardiology, urology and dermatology. Prior to Medispec, from 2002 to 2004, Mr. Hakim was Director of Marketing and Clinical Research at MTRE Advanced Technologies Ltd., a wholly owned subsidiary of Mennen Medical Ltd. that develops thermoregulation devices. Prior to that, from 2000 to 2002, he was Business Development Manager at Omrix Biopharmaceuticals, Inc. (acquired by Johnson &amp;Johnson in 2008), which develops biological glue and blood derivative products. Before that, from 1998 to 2000, he served as European Product Manager at Biosense-Webster (Johnson &amp; Johnson) in Belgium, following Johnson &amp;Johnson&#8217;s acquisition of Biosense Israel, where he was also part of the Research and Development team. Mr. Hakim holds a B.Sc. in Life Sciences from Ben-Gurion University, Israel. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Gary Titus<font style="font-style:normal;"> has served as our Chief Financial Officer since July 2015. Mr. Titus has been a member of the board of directors of ImmunoCellular Therapeutics, Ltd. since January 2013. Mr. Titus has more than 20 years of business experience in the healthcare and biopharmaceutical industries, primarily in senior management roles. Prior to his appointment as our Chief Financial Officer, from 2014 to 2015, Mr. Titus held the position of Chief Financial Officer of BioCardia, Inc. Prior to that, from 2008 to 2013, Mr. Titus was Senior Vice President and Chief Financial Officer at SciClone Pharmaceuticals, Inc. From 2006 to 2008, Mr. Titus was Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, Inc. From 2003 to 2006, he was Chief Financial Officer and Vice President at Nuvelo, Inc. Earlier in his career, Mr. Titus held a variety of positions at other companies, including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc. and Johnson &amp; Johnson&#8217;s healthcare division, LifeScan, Inc. Mr. Titus holds a B.Sc. in Accounting from the University of South Florida and a B.Sc. in Finance from the University of Florida. Mr. Titus also completed the Global BioExecutive Program at the University of California Berkeley&#8217;s Haas School of Business. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Mark Schoenberg, M.D.</font><font style="font-style:normal;"> has served as our Chief Medical Officer since December 2017 and, prior to that, served as our Medical Director since February 2016. Dr. Schoenberg has over 20 years of experience in clinical practice and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr. Schoenberg has been University Professor and Chairman of the Urology Department at The Montefiore Medical Center for The Albert Einstein College of Medicine of Yeshiva University. Prior to joining Montefiore, from 2005 to 2014, Dr. Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins Hospital. Dr. Schoenberg is also the past chair of the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell&#8217;s Urology and a past Senior Editor of the journal Seminars in Urologic Oncology. Dr. Schoenberg received his M.D. (Alpha Omega Alpha) from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The University of Pennsylvania, where he served as chief resident and urology instructor, before completing basic research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr. Schoenberg is a fellow of the American College of Surgeons, as well as a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Directors </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Arie Belldegrun, M.D.<font style="font-style:normal;"> has served as our Chairman since December 2012. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was a research fellow at the National Cancer Institute/National Institute of Health in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. Dr. Belldegrun has more than 20 years of experience in the life science and biotech industry. In 1996 he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman of the board of directors and as a board member until 2007, when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also a founder and the Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009, when it was acquired by Johnson &amp; Johnson. He served as Chairman and Chief Executive Officer of Kite Pharma, Inc., until October 2017, when it was acquired by Gilead Sciences, Inc. He currently also serves as the Chairman of Arno Therapeutics, Inc., and Two River Group, and until January 2017 served as a board member of Teva Pharmaceutical Industries Ltd. Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, Israel, his post graduate studies in Immunology at the Weizmann Institute of Science, Israel, and his residency in Urologic Surgery at Harvard Medical School. Dr. Belldegrun has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. Dr. Belldegrun is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cynthia Butitta<font style="font-style:normal;"> has served as our director since October 2017. Ms. Butitta served as Chief Financial Officer of Kite Pharma Inc. from January 2014 to May 2016 and as Chief Operating Officer from March 2014 to September 2017. From May 2011 to December 2012, she was Senior Vice President and Chief Financial Officer at NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company. Prior to that, Ms. Butitta served as Chief Operating Officer of Telik, Inc., a biopharmaceutical company, from March 2001 to December 2010 and as its Chief Financial Officer from August 1998 to December 2010. Ms. Butitta also served as Principal Accounting Officer of Telik, Inc. until December 2010. She served as a Director of Catalyst Semiconductor Inc., a semiconductor products company, from June 2000 to February 2003. Ms. Butitta received her B.S. degree with honors in Business and Accounting from Edgewood College in Madison, Wisconsin, and an M.B.A. degree in Finance from the University of Wisconsin, Madison. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fred Cohen, M.D.<font style="font-style:normal;"> has served as our director since May 2017. Dr. Cohen is a Senior Advisor to TPG Capital, where he served for over 15 years as a Partner, and founder of TPG Biotechnology, a life science focused venture capital fund. Beginning in 2017, Dr. Cohen has served as a co-founder and managing partner of Vida Ventures, a biotechnology venture capital fund. In addition, for over two decades throughout his career, Dr. Cohen has been affiliated with University of California, San Francisco where he held various clinical responsibilities, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism. Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, and his M.D. from Stanford. Dr. Cohen currently serves on the Board of Directors of several other biotechnology and pharmaceutical companies. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Kathryn Falberg<font style="font-style:normal;"> has served as our director since April 2017. She previously served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a multi-national specialty biopharmaceutical company, from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. Her responsibilities at Jazz Pharmaceuticals included strategy, corporate development, corporate communications and information technology. From 2001 through 2009, Ms. Falberg served as a corporate director and audit committee chair for several companies. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Strategy and Chief Financial Officer and prior to that as Vice President, Corporate Controller and Chief Accounting Officer, and Vice President, Treasurer. Ms. Falberg also serves as a member of the board of directors for the public biopharmaceutical companies Aimmune Therapeutics, Inc., Axovant Sciences Ltd. and The Trade Desk, Inc., a publicly held technology company. Ms. Falberg also served on the board of directors of Medivation, Inc. from 2013 to 2016 and Halozyme Therapeutics, Inc. from 2007 to 2016. Ms. Falberg received an M.B.A. in Finance and B.A., in Economics from the University of California, Los Angeles and is a certified public accountant (inactive). </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stuart Holden, M.D.</font><font style="font-style:normal;"> has served as our director since December 2015. Dr. Holden has been the Chairman of ProQuest Investments&#8217; Scientific Advisory Board since it was founded in 1998. Since May 2014, Dr. Holden has served as a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked in the field of prostate cancer for more than 36 years. Dr. Holden also serves as Medical Director of the Prostate Cancer Foundation since the foundation&#8217;s inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. Dr. Holden has served as a member of the board of directors of Telormedix SA from 2008 to 2017 and served as a member of the board of directors of Acurian, Inc. from 1999 through 2014. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.A. degree from the University of Wisconsin-Madison and completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital&#8212;Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society. Dr. Holden was appointed to serve on our board by ProQuest Investments IV, L.P., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association as in effect prior to our initial public offering. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Ran Nussbaum<font style="font-style:normal;"> has served as our director since May 2013. Mr. Nussbaum is a managing partner and the co-founder of The Pontifax Group, a group of Israeli-based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies and a shareholder of our company. He also serves as a board member on many of Pontifax&#8217;s portfolio companies, including BioBlast Pharma Ltd., Eloxx Pharmaceuticals Ltd., and Quiet Therapeutics Ltd. Mr. Nussbaum was appointed to serve on our board by Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited, two of our shareholders, pursuant to rights granted to such shareholders under our articles of association as in effect prior to our initial public offering. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pini Orbach, Ph.D.<font style="font-style:normal;"> has served as our director since October 2014. Dr. Orbach has served as a director of Quiet Therapeutics Ltd. since January 2013. Dr. Orbach has 10 years of experience in executive positions. Since February 2010, Dr. Orbach has been the head of Pharma and Life Science at Arkin Holdings. Dr. Orbach was the Chief Executive Officer of NanoDoc Technology, Inc. from 2010 to 2015, Chairman of the board of directors of cCAM Biotherapeutics Ltd. from 2014 to 2015 and served as a Director of Quiet Therapeutics Ltd. since January 2013, FusiMab Ltd. from 2011 to 2014, HealOr Ltd. from 2010 to 2013, Metallo-Therapy Ltd. from 2011 to 2015, Insuline Medical Ltd. from December 2013 to January 2015, and CollPlant Holdings Ltd. from May 2013 to August 2014. Prior to joining Arkin Holdings, Dr. Orbach served as Chief Executive Officer of several healthcare companies in Israel. Dr. Orbach received his Ph.D. from the Department of Physiology and Functional Genomics at the University of Florida and was a postdoctoral fellow at the Cardiovascular Research Center at Harvard Medical School. Dr. Orbach was appointed to serve on our board by Arkin Communications Ltd., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association as in effect prior to our initial public offering. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrangements Concerning Election of Directors; Family Relationships </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors consists of eight directors. Currently serving directors will continue to serve pursuant to their appointment until the first annual general meeting of shareholders held after our initial public offering. We are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family relationships among our executive officers and directors. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_6B"></a><a name="_Hlk508365605"></a><font style="color:#000000;">Compensation. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate compensation paid, and equity-based compensation and other payments expensed by us to our directors and executive officers with respect to the year ended December 31, 2017 was $4.3 million. This amount does not include business travel, relocation, professional and business association dues and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2017, our directors and executive officers were granted options to purchase 355,000 ordinary shares, at a weighted-average exercise price of $20.71 per share under our 2017 Equity Incentive Plan. As of December 31, 2017, options to purchase 1,141,106 ordinary shares and restricted share units covering 194,560 ordinary shares, granted to our directors and executive officers, remained outstanding. Since our initial public offering, our board of directors has approved certain modifications and new terms of compensation for our directors and office holders (as such term is used under Israeli law). Under Israeli law, modifications or new compensation to directors and other office holders that was approved by the board prior to adoption of a compensation policy, or which is inconsistent with the company&#8217;s stated compensation policy, would generally be subject to shareholder approval. These matters were approved by our shareholders&#8217; on February 14, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a compensation policy in accordance with the Israeli Companies Law, which our shareholders&#8217; approved on February 14, 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any written agreements with any director providing for benefits upon the termination of such director&#8217;s relationship with our company, other than our employment agreement with our Chief Executive Officer.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Executive Officers; Consulting and Directorship Services Provided by Directors</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into written employment agreements with all of our executive officers. These agreements contain standard provisions for a company in our industry regarding non-solicitation, confidentiality of information, non-competition and assignment of inventions. Our executive officers will not receive benefits upon the termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment, which varies for each individual. In addition, we previously entered into an agreement with the chairman of our board of directors for management services pertaining to the development of our business, including serving as chairman of the board of directors, assisting us in our financing activities and overseeing our clinical development activities; however, such agreement was terminated by our board of directors on March 29, 2017.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2017 Equity Incentive Plan</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors adopted our 2017 Equity Incentive Plan, or our 2017 Plan, in March 2017 and our shareholders approved our 2017 Plan in April 2017. Our 2017 Plan provides for the grant of incentive stock options to our employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to our employees, directors and consultants.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Authorized Shares<font style="font-style:normal;">. The maximum number of ordinary shares that may be issued under our 2017 Plan as of the date of this annual report is 1,400,000. In addition, the number of ordinary shares reserved for issuance under our 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of ordinary shares that may be issued upon the exercise of incentive stock options under our 2017 Plan is 5,600,000.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary Shares subject to stock awards granted under our 2017 Plan that expire or terminate without being exercised in full, do not reduce the number of shares available for issuance under our 2017 Plan. Additionally, shares issued pursuant to stock awards under our 2017 Plan that we repurchase or that are forfeited, as well as shares used to pay the exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award, become available for future grant under our 2017 Plan.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Administration<font style="font-style:normal;">. Our board of directors, or a duly authorized committee of our board of directors, administers our 2017 Plan. Our board of directors may also delegate to one or more of our officers the authority to (1) designate employees (other than officers) to receive specified stock awards and (2) determine the number of shares subject to such stock awards. Under the 2017 Plan, our board of directors has the authority to determine the terms of awards, including recipients, the exercise, purchase or strike price of stock awards, if any, the number of shares subject to each stock award, the fair market value of an Ordinary Share, the vesting schedule applicable to the awards, together with any vesting acceleration, the form of consideration, if any, payable upon exercise or settlement of the award and the terms of the award agreements.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Section 162(m) Limits<font style="font-style:normal;">. At such time as necessary for compliance with Section 162(m) of the Code, no participant may be granted stock awards covering more than 230,000 of our ordinary shares under the 2017 Plan during any calendar year pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by reference to an increase over an exercise price or strike price of at least 100% of the fair market value of our ordinary shares on the date of grant. Additionally, no participant may be granted in a calendar year a performance stock award covering more than 230,000 of our ordinary shares or a performance cash award having a maximum value in excess of $3.0 million under our 2017 Plan. The limitations are designed to allow us to grant compensation that will not be subject to the $1,000,000 annual limitation on the income tax deductibility of compensation paid to a covered executive officer imposed by Section 162(m) of the Code.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<font style="font-style:normal;">. Incentive stock options and nonstatutory stock options are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Unit Awards</font><font style="font-style:normal;">. Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors, or a duly authorized committee of our board of directors, and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#8217;s cessation of continuous service for any reason.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Awards<font style="font-style:normal;">. Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan administrator. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any other form of legal consideration that may be acceptable to our board of directors, or a duly authorized committee of our board of directors, and permissible under applicable law. The plan administrator determines the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ceases for any reason, we may receive through a forfeiture condition or a repurchase right any or all of the Ordinary Shares held by the participant that have not vested as of the date the participant terminates service with us.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Appreciation Rights<font style="font-style:normal;">. Stock appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the plan administrator. The plan administrator determines the purchase price or strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. A stock appreciation right granted under the 2017 Plan vests at the rate specified in the stock appreciation right agreement as determined by the plan administrator.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Awards<font style="font-style:normal;">. The 2017 Plan permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation that is not subject to the $1,000,000 limitation on the income tax deductibility imposed by Section 162(m) of the Code. Our compensation committee may structure awards so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a designated performance period.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Other Stock Awards<font style="font-style:normal;">. The plan administrator may grant other awards based in whole or in part by reference to our Ordinary Shares. The plan administrator will set the number of shares under the stock award and all other terms and conditions of such awards.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Changes to Capital Structure<font style="font-style:normal;">. In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split or recapitalization, appropriate adjustments will be made to (1) the class and maximum number of shares reserved for issuance under the 2017 Plan, (2) the class and maximum number of shares by which the share reserve may increase automatically each year, (3) the class and maximum number of shares that may be issued upon the exercise of incentive stock options, (4) the class and maximum number of shares subject to stock awards that can be granted in a calendar year (as established under the 2017 Plan pursuant to Section 162(m) of the Code) and (5) the class and number of shares and exercise price, strike price or purchase price, if applicable, of all outstanding stock awards.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transactions<font style="font-style:normal;">. Our 2017 Plan provides that in the event of certain specified significant transactions, including: (1) a sale of all or substantially all of our assets, (2) the sale or disposition of more than 50% of our outstanding securities, (3) the consummation of a merger or consolidation where we do not survive the transaction and (4) the consummation of a merger or consolidation where we do survive the transaction but our Ordinary Shares outstanding prior to such transaction are converted or exchanged into other property by virtue of the transaction, unless otherwise provided in an award agreement or other written agreement between us and the award holder, the administrator may take one or more of the following actions with respect to such stock awards: (1) arrange for the assumption, continuation or substitution of a stock award by a successor corporation, (2) arrange for the assignment of any reacquisition or repurchase rights held by us to a successor corporation, (3) accelerate the vesting, in whole or in part, of the stock award and provide for its termination prior to the transaction, (4) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us, (5) cancel or arrange for the cancellation of the stock award prior to the transaction in exchange for a cash payment, if any, determined by the board or (6) make a payment, in the form determined by the board, equal to the excess, if any, of the value of the property the participant would have received upon exercise of the awards prior to the transaction over any exercise price payable by the participant in connection with the exercise.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of a change in control, awards granted under the 2017 Plan will not receive automatic acceleration of vesting and exercisability, although this treatment may be provided for in an award agreement. Under the 2017 Plan, a change in control is defined to include (1) the acquisition by any person or company of more than 50% of the combined voting power of our then outstanding stock, (2) a merger, consolidation or similar transaction in which our stockholders immediately prior to the transaction do not own, directly or indirectly, more than 50% of the combined voting power of the surviving entity (or the parent of the surviving entity), (3) a sale, lease, exclusive license or other disposition of all or substantially all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders, (4) our stockholders approve and the board approves a plan of complete dissolution or liquidation or a complete dissolution or liquidation of the Company otherwise occurs except for a liquidation into a parent corporation and (5) a circumstance in which the members of the Incumbent Board (as defined in the 2017 Plan) no longer constitute a majority of the members of the board.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Transferability</font><font style="font-style:normal;">. A participant may not transfer stock awards under our 2017 Plan other than by will, the laws of descent and distribution or as otherwise provided under our 2017 Plan.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Amendment or Termination<font style="font-style:normal;">. Our board of directors has the authority to amend, suspend or terminate our 2017 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require the approval of our stockholders. No incentive stock options may be granted after the tenth anniversary of the date our board of directors adopted our 2017 Plan. No stock awards may be granted under our 2017 Plan while it is suspended or after it is terminated.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Acceleration Upon Death<font style="font-style:normal;">. Our 2017 Plan provides that if a participant dies while in a service relationship with us, all vested options and stock appreciation rights held by the participant as of the date of death shall be exercisable by the participant&#8217;s estate, by a person who acquired the right to exercise the option or stock appreciation right by bequest or inheritance, or by a person designated to exercise the option or stock appreciation right upon the participant&#8217;s death, but only within the period ending on the earlier of (i) the date 18 months following the date of death (or such longer or shorter period specified in the participant&#8217;s award agreement), and (ii) the expiration of the term of such option or stock appreciation right as set forth in the award agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2017 Israeli Equity Incentive Sub Plan</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our 2017 Israeli Equity Incentive Sub Plan governs equity awards granted to our Israeli employees, directors and service providers. The 2017 Israeli Equity Incentive Sub Plan was adopted under our 2017 Equity Incentive Plan. The 2017 Israeli Equity Incentive Sub Plan provides for the grant by us of awards pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance New Version, 5721&#8212;1961, or the Ordinance, and the rules and regulations promulgated thereunder. in June 2017, we submitted the 2017 Israeli Equity Incentive Sub Plan to the Israeli Tax Authority, or the ITA, and it is effective with respect to awards granted from 30 days thereafter. The 2017 Israeli Equity Incentive Sub Plan provides for awards to be granted to those of our or our affiliates&#8217; employees, directors and officers who are not Controlling Shareholders, as defined in the Ordinance, and who are considered Israeli residents, to the extent that such awards either are (i) intended to qualify for special tax treatment under the &#8220;capital gains track&#8221; provisions of Section 102(b)(2) of the Ordinance or (ii) not intended to qualify for such special tax treatment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2017 Israeli Equity Incentive Sub Plan also provides for the grant of awards under Section 3(i) of the Ordinance to our Israeli non-employee service providers and Controlling Shareholders, who are not eligible for such special tax treatment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">2010 Israeli Share Option Plan</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2010, we adopted our 2010 Israeli Share Option Plan, or the 2010 Plan. The 2010 Plan provides for the grant of share options and restricted share units to our company&#8217;s employees, non-employee directors and consultants. The reserved pool of shares under the 2010 Plan is 2,701,579 shares. On March 29, 2017, our board resolved that as of the consummation of our initial public offering, shares that are forfeited, cancelled, terminated or expire unexercised under the 2010 Plan shall not be available for issuance under new awards.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2010 Plan provides for the grant by us of awards pursuant to Sections 102 and 3(i) of the Ordinance and the rules and regulations promulgated thereunder. Section 102 of the Ordinance allows employees, directors and officers who are not controlling shareholders and who are Israeli residents, to receive favorable tax treatment for compensation in the form of shares or options. Section 102 of the Ordinance includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee. Section 102(b)(2) of the Ordinance, which provides the most favorable tax treatment for grantees, permits the issuance to a trustee under the &#8220;capital gains track.&#8221; In order to comply with the terms of the capital gains track, all options granted under a specific plan and subject to the provisions of Section 102 of the Ordinance, as well as the shares issued upon exercise of such options and other shares received following any realization of rights with respect to such options, such as share dividends and share splits, must be registered in the name of a trustee selected by the board of directors and held in trust for the benefit of the relevant employee, director or officer. The trustee may not release these options or shares to the relevant grantee before the second anniversary of the registration of the options in the name of the trustee. However, under this track, we are not allowed to deduct an expense with respect to the issuance of the options or shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2010 Plan provides for awards to be granted to our employees or those of our affiliates, directors and officers who are not controlling shareholders, as defined in the Ordinance, and who are considered Israeli residents, to the extent that such awards either are (i) intended to qualify for special tax treatment under the &#8220;capital gains track&#8221; provisions of Section 102(b)(2) of the Ordinance or (ii) not intended to qualify for such special tax treatment. The 2010 Plan also provides for the grant of awards under Section 3(i) of the Ordinance to our Israeli non-employee service providers and controlling shareholders, who are not eligible for such special tax treatment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2010 Plan is administered by our board of directors. Although awards under the 2010 Plan may be granted until 10 years after the effective date of the 2010 Plan, as of the consummation of our initial public offering, we stopped granting additional awards under the 2010 Plan.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of options granted under the 2010 Plan, including the exercise price, vesting provisions and the duration are determined by our board of directors and set forth in an award agreement. Except as provided in the applicable award agreement, or in the discretion of the compensation committee, an option may be exercised only to the extent that it is then exercisable and, generally, shall expire for employees 90 days following termination of the service of the grantee, and in the case of retiring directors, not later than nine months following our listing on the Nasdaq Global Market.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted share units are awards covering a number of hypothetical units with respect to shares that are granted subject to such vesting and transfer restrictions and conditions of payment as our board of directors may determine in an award agreement. Restricted share units are payable in cash, ordinary shares of equivalent value or a combination thereof.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of any dividend (excluding any ordinary dividend) or other distribution, recapitalization, share split, reverse share split, reorganization, merger, consolidation, split-up, split-off, combination, repurchase or exchange of shares or similar event (including a change in control) that affects the ordinary shares, the board of directors will make any such adjustments in such manner as it may deem equitable, including any or all of the following: (i) adjusting the number of shares available for grant under the 2010 Plan, and (ii) providing for a substitution or assumption of awards.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All unvested options shall vest in their entirety upon (i) the sale of all or substantially all of the shares of the Company, (ii) a merger, consolidation or reorganization in which the Company is not the surviving entity, or (iii) the sale, transfer or disposition of all or substantially all of the assets of the Company. Further, in such event the optionholders may elect to exchange the options for ordinary shares on a cashless exercise basis.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C</font><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_6C"></a><font style="color:#000000;">Board Practices. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Board of Directors</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, our board of directors is responsible for setting our general policies and supervising the performance of management. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the terms of the employment agreement that we have entered into with him. All other executive officers are also appointed by our board of directors and are subject to the terms of any applicable employment agreements that we may enter into with them.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under our amended and restated articles of association, our board of directors must consist of at least five directors and not more than nine directors. Our board of directors currently consists of eight directors. Other than vacancies to be filled through selection by the remaining members of our board, the Israeli Companies Law and our amended and restated articles of association provide that directors are elected annually at the general meeting of our shareholders by a vote of the holders of a majority of the voting power represented present and voting in person, by proxy or by other voting instrument at that meeting. We have only one class of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, our board of directors is required to employ independent judgment and discretion when voting and is prohibited from entering into any voting arrangements with respect to actions taken at meetings of the board. Further, the Israeli Companies Law provides that in the event a director learns about an alleged breach of law or improper conduct of business relating to a company matter, said director must promptly take action to summon a meeting of the board of directors to address any such breach.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the exemptions available to foreign private issuers under Nasdaq rules, we do not follow the requirements of the Nasdaq rules with regard to the process of nominating directors. Instead, we follow Israeli law and practice, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on our board of directors, including filling empty board seats up to the maximum number of directors permitted under our articles of association, for a term of office equal to the remaining period of the term of office of each director whose office has been vacated. Vacancies on our board of directors may be filled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until the next annual general meeting of our shareholders in which the other directors then in office are proposed to be replaced or reappointed.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Directors may be removed from office by a resolution at a general meeting of shareholders adopted by a majority of the voting power of our company or under other circumstances set forth in our amended and restated articles of association.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, we would be required to include on our board of directors at least two members, each of whom qualifies as an external director, and as to whom special qualifications, voting requirements and other provisions would be applicable. We would also be required to include one such external director on each of our board committees.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under regulations promulgated under the Israeli Companies Law, Israeli companies whose shares are traded on stock exchanges such as the Nasdaq Stock Market that do not have a controlling shareholder (as defined therein) and which comply with the requirements of the jurisdiction where the company&#8217;s shares are traded with respect to the appointment of independent directors and the composition of an audit committee and compensation committee, may elect not to follow the Israeli Companies Law requirements with respect to the composition of its audit committee and compensation committee and the appointment of external directors. As we do not have a controlling shareholder, we have elected to comply with the requirements of the Nasdaq Stock Market with respect to the composition of our board and such committees, and therefore we are exempt from the Israeli Companies Law requirements with respect thereto, including the appointment of external directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leadership Structure of the Board</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Israeli Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its members to serve as chairman of the board of directors. Our board of directors has appointed Arie Belldegrun, M.D. to serve as chairman of the board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Board Committees</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law and our amended and restated articles of association, our board of directors is permitted to form committees, and to delegate to any such committee powers allotted to the board of directors, subject to certain exceptions. In general, the board of directors may overturn a resolution adopted by a committee it has formed; provided, however, that the board&#8217;s decision shall not affect the ability of third parties, who were not aware of such decision, to rely on the committee&#8217;s resolution prior to the time it is overturned. Only members of the board of directors can be members of a board committee, unless the committee is solely advisory.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee consists of Kathryn Falberg, Pini Orbach and Stuart Holden. Kathryn Falberg serves as chairperson of the audit committee.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Israeli Companies Law Requirements</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, we are required to maintain an audit committee.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Listing Requirements</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Nasdaq Rules, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq Stock Market. Our board of directors has determined that Kathryn E. Falberg is an audit committee financial expert as such term is defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq Rules. Each of the members of our audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and satisfies the independent director requirements under the Nasdaq Rules.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit Committee Role</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee charter sets forth the responsibilities of the audit committee consistent with the rules and regulations of the SEC and the Nasdaq Rules, as well as the requirements for such committee under the Israeli Companies Law, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recommending the engagement or termination of the person filling the office of our internal auditor; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the auditors are independent of management.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, our audit committee is responsible for:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli Companies Law); </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">examining our internal audit controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his or her responsibilities; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation, Nominating and Corporate Governance Committee and Compensation Policy</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a compensation, nominating and corporate governance committee. The members of this committee are Arie Belldegrun, Ran Nussbaum, Fred Cohen and Cynthia Butitta. Cynthia Butitta serves as chairperson of the committee.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Israeli Companies Law Requirements</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, the board of directors of a public company must maintain a compensation committee.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duties of the compensation, nominating and corporate governance committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office holders, to which we refer as a compensation policy. Such policy must be adopted by the company&#8217;s board of directors, after considering the recommendations of the compensation, nominating and corporate governance committee, and will need to be approved by the company&#8217;s shareholders, which we refer to as a Special Majority Approval for Compensation. A Special Majority Approval for Compensation requires shareholder approval by a majority vote of the shares present and voting at a meeting of shareholders called for such purpose, provided that either: (i) such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement, excluding abstentions; or (ii) the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the company&#8217;s aggregate voting rights. We have adopted a compensation policy, which remains subject to shareholder approval. Even if the company&#8217;s shareholders do not approve the compensation policy, the board of directors may resolve to approve the compensation policy if and to the extent the board determines, in its judgment following internal discussions, that approval of the compensation policy is in the best interests of the company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation policy serves as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy relates to certain factors, including advancement of the company&#8217;s long-term objectives, business plan and policies, and creation of appropriate incentives for office holders. It also considers, among other things, the company&#8217;s risk management, size and the nature of its operations. The compensation policy furthermore considers the following additional factors:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the education, skills, expertise and accomplishments of the relevant office holder; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the office holder&#8217;s roles and responsibilities and prior compensation agreements with him or her; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the relationship between the terms offered and the average compensation of the company&#8217;s personnel; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the impact of disparities in salary upon work relationships in the company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possibility of reducing variable compensation at the discretion of the board of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of service, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation policy also includes the following principles:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the link between variable compensation and long-term performance and measurable criteria; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the company&#8217;s financial statements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the minimum holding or vesting period for variable, equity-based compensation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">maximum limits for severance compensation. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compensation, Nominating and Corporate Governance Committee Roles</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation, nominating and corporate governance committee is responsible for (i) recommending the compensation policy to our board of directors for its approval (and subsequent approval by our shareholders) and (ii) duties related to the compensation policy and to the compensation of our office holders, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than five years from a company&#8217;s initial public offering, or otherwise three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur five years from a company&#8217;s initial public offering, or otherwise every three years); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recommending to the board of directors&#8217; periodic updates to the compensation policy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">assessing implementation of the compensation policy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">determining whether to approve the terms of compensation of certain office holders which, according to the Israeli Companies Law, require the committee&#8217;s approval; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">determining whether the compensation terms of a candidate for the position of the chief executive officer of the company needs to be brought to approval of the shareholders. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our compensation, nominating and corporate governance charter sets forth the responsibilities of the compensation, nominating and corporate committee, which include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the responsibilities set forth in the compensation policy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our compensation, nominating and corporate governance committee is responsible for:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">overseeing our corporate governance functions on behalf of the board; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">making recommendations to the board regarding corporate governance issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identifying and evaluating candidates to serve as our directors consistent with the criteria approved by the board; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reviewing and evaluating the performance of the board; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">serving as a focal point for communication between director candidates, non-committee directors and our management; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">selecting or recommending to the board for selection candidates to the board; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">making other recommendations to the board regarding affairs relating to our directors. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disclosure of Compensation of Executive Officers</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, President, Israeli Operation and other two most highly compensated executive officers on an individual, rather than on an aggregate, basis. Nevertheless, under regulations promulgated under the Israeli Companies Law, we are required to disclose the annual compensation of our five most highly compensated office holders (as defined under the Israeli Companies Law) on an individual basis, rather than on an aggregate basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing such disclosure, at the latest, in the notice (which is generally part of the proxy statement) for our 2018 annual general meeting of shareholders, which will be filed under cover of a Report of Foreign Private Issuer on Form 6-K and we may elect to provide such information at an earlier date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Internal Auditor</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal auditor may not be:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a person (or a relative of a person) who holds more than 5% of the company&#8217;s outstanding shares or voting rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an office holder (including a director) of the company (or a relative thereof); or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a member of the company&#8217;s independent accounting firm, or anyone on its behalf. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;letter-spacing:-0.1pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive officer, the chairman of the board and the chairman of the audit committee. The internal auditor is entitled to receive notice of audit committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee convene a meeting within a reasonable time to discuss an issue raised by the internal auditor. The internal auditor is responsible for preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee for their approval. We intend to appoint an internal auditor in compliance with Israeli law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Approval of Related Party Transactions under Israeli Law</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fiduciary Duties of Directors and Executive Officers</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Israeli Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#8220;Executive Officers and Directors&#8221; is an office holder under the Israeli Companies Law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An office holder&#8217;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty includes an obligation that an office holder act in good faith and in the best interests of the company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duty of care includes a duty to use reasonable means to obtain:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">all other important information pertaining to any such action. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The duty of loyalty includes a duty to:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refrain from any activity that is competitive with the company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Israeli Companies Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may be aware of and all related material information or documents concerning any existing or proposed transaction with the company. An interested office holder&#8217;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. A personal interest includes an interest of any person in an action or transaction of a company, including a personal interest of such person&#8217;s relative or of a corporate body in which such person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one&#8217;s ownership of shares in the company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A personal interest also includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such person has no personal interest in the matter. An office holder is not, however, required to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. Under the Israeli Companies Law, an &#8220;extraordinary transaction&#8221; is defined as any of the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a transaction other than in the ordinary course of business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a transaction that is not on market terms; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a transaction that may have a material impact on a company&#8217;s profitability, assets or liabilities. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If it is determined that an office holder has a personal interest in a transaction, which is not an extraordinary transaction, approval by the board of directors is required for the transaction, unless the company&#8217;s articles of association provide for a different method of approval. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of his or her duty of loyalty. However, a company may not approve a transaction or action that is not in the company&#8217;s interest or that is not performed by the office holder in good faith.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An extraordinary transaction in which an office holder has a personal interest requires approval first by the company&#8217;s audit committee and subsequently by the board of directors.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director generally requires approval first by the company&#8217;s compensation committee, then by the company&#8217;s board of directors. If such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company&#8217;s stated compensation policy, or if the office holder is the chief executive officer (apart from a number of specific exceptions), then such arrangement is further subject to a Special Majority Approval for Compensation. If the shareholders of a company do not approve the compensation terms of office holders at a meeting of the shareholders, other than directors, the compensation committee and board of directors may override the shareholders&#8217; decision, subject to certain conditions. Arrangements regarding the compensation, indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by simple majority, in that order, and under certain circumstances, a Special Majority Approval for Compensation.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting or vote on that matter unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the transaction that is subject to approval. If a majority of the members of the audit committee or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a>The approval of the audit committee, the board of directors and the shareholders of the company, in that order, is required for (i) extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, (ii) the engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company, (iii) the terms of engagement and compensation of a controlling shareholder or his or her relative who is not an office holder or (iv) </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the employment of a controlling shareholder or his or her relative by the company, other than as an office holder. In addition, the shareholder approval requires one of the following, which we refer to as a Special Majority:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">at least a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting at the meeting approves the transaction, excluding abstentions; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meeting do not exceed 2% of the aggregate voting rights in the company. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years and under certain conditions, five years from a company&#8217;s initial public offering, approval is required at the end of such period unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an office holder require the approval of the compensation committee, board of directors and shareholders by a Special Majority.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to regulations promulgated under the Israeli Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors or other office holders, that would otherwise require approval of a company&#8217;s shareholders may be exempt from shareholder approval under certain conditions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shareholder Duties</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at a general meeting and at shareholder class meetings with respect to the following matters:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an amendment to the company&#8217;s articles of association; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an increase of the company&#8217;s authorized share capital; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a merger; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the approval of related party transactions and acts of office holders that require shareholder approval. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A shareholder also has a general duty to refrain from discriminating against other shareholders.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, certain shareholders have a duty of fairness toward the company. These shareholders include a controlling shareholder, a shareholder who knows that he or she has the power to determine the outcome of a shareholder vote and a shareholder who has the power to appoint or to prevent the appointment of an office holder of the company or other power towards the company. The Israeli Companies Law does not define the substance of the duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exculpation, Insurance and Indemnification of Directors and Officers</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. A company may not exculpate in advance a director from liability arising out of a breach of the duty of care with respect to a distribution.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding, and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder, if and to the extent provided in the company&#8217;s articles of association:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a financial liability imposed on the office holder in favor of a third party. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an act or omission committed with intent to derive illegal personal benefit; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders. See &#8220;Approval of Related Party Transactions under Israeli Law&#8212;Fiduciary Duties of Directors and Executive Officers.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Israeli Companies Law.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain directors and officers liability insurance for the benefit of our office holders to the fullest extent permitted by the Israeli Companies Law. In addition, we have entered into agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and restated articles of association and Israeli law. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_6D"></a><font style="color:#000000;">Employees. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653235"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.22%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Full Time Employees:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:69.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, we had 42 full-time employees and four part-time employees, 33 based in Israel and 9 based in the United States. Of these employees, 34 are primarily engaged in research and development activities and 12 are primarily engaged in general and administrative matters. A total of 13 employees have an M.D. or Ph.D. degree. None of our employees is represented by a labor union. We have never experienced any employment-related work stoppages and believe our relationships with our employees are good.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU97"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israeli labor laws govern the length of the workday and workweek, minimum wages for employees, procedures for hiring and dismissing employees, determination of severance pay, annual leave, sick days, advance notice of termination, payments to the National Insurance Institute, and other conditions of employment and include equal opportunity and anti-discrimination laws. While none of our employees is party to any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialists&#8217; Associations) are applicable to our employees in Israel by order of the Israeli Ministry of Economy and Industry. These provisions primarily concern pension fund benefits for all employees, insurance for work-related accidents, recuperation pay and travel expenses. We generally provide our employees with benefits and working conditions beyond the required minimums.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">E.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="Item_6E"></a><font style="color:#000000;">Share ownership. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For information regarding the share ownership of our directors and executive officers, see &#8220;Item 6.B&#8212;Compensation&#8221; and &#8220;Item 7.A&#8212;Major Shareholders.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MAJOR_SHAREHOLDERS_RELATED_PARTY_"></a><a name="ITEM_7_MAJOR_SHAREHOLDERS_RELATED_PARTY_"></a>Item 7. Major Shareholders and Related Party Transactions </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="A_MAJOR_SHAREHOLDERS"></a><a name="A_MAJOR_SHAREHOLDERS"></a>Major shareholders.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of December&#160;31, 2017 by:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">each person or entity known by us to own beneficially 5% or more of our outstanding ordinary shares;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">each of our directors and executive officers individually; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">all of our executive officers and directors as a group.</font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The beneficial ownership of our ordinary shares is determined in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table below, we deem ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days of December 31, 2017 to be outstanding and to be beneficially owned by the person holding the options for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The percentage of shares beneficially owned has been computed on the basis of 13,751,390&#160;ordinary shares outstanding as of December 31, 2017.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, and based on their reported registered office, there are 11 record holders in the United States, holding in aggregate approximately 1.2% of our outstanding ordinary shares. These do not include outstanding ordinary shares held in street name. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and voting power with respect to such shares.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our shareholders, including the shareholders listed below, have the same voting rights attached to their ordinary shares, and neither our principal shareholders nor our directors and executive officers have different or special voting rights with respect to their ordinary shares.&nbsp;&nbsp;A description of any material relationship that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is included under &#8220;Item 7.B&#8212;Related Party Transactions.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless otherwise noted below, the address of each shareholder, director and executive officer is c/o UroGen Pharma Ltd., 9 Ha&#8217;Ta&#8217;asiya St., Ra&#8217;anana 4365007, Israel.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name Of Beneficial Owner</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Percent</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5% or Greater Shareholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arkin Communication Ltd. <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,643,658</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities affiliated with Consonance Capman GP LLC <sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">916,450</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Menora Mivtachim Holdings Ltd. <sup style="font-size:85%; vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,338,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pontifax (Israel) III Limited Partnership <sup style="font-size:85%; vertical-align:top">(4)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">998,171</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pontifax Cayman III Limited Partnership <sup style="font-size:85%; vertical-align:top">(5)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">465,998</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ProQuest Investments IV, L.P. <sup style="font-size:85%; vertical-align:top">(6)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,451,329</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directors and Executive Officers</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arie Belldegrun, M.D.<sup style="font-size:85%; vertical-align:top"> (7)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303,693</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ron Bentsur <sup style="font-size:85%; vertical-align:top">(8)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fred Cohen, M.D. <sup style="font-size:85%; vertical-align:top">(9)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kathryn Falberg <sup style="font-size:85%; vertical-align:top">(10)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cynthia Butitta <sup style="font-size:85%; vertical-align:top">(11)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pini Orbach, Ph.D. <sup style="font-size:85%; vertical-align:top">(12)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stuart Holden, M.D. <sup style="font-size:85%; vertical-align:top">(13)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gil Hakim <sup style="font-size:85%; vertical-align:top">(14)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,602</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary Titus<sup style="font-size:85%; vertical-align:top"> (15)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,467</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ran Nussbaum <sup style="font-size:85%; vertical-align:top">(16)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,464,169</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark Schoenberg, M.D.<sup style="font-size:85%; vertical-align:top"> (17)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,600</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All directors and executive officers as a group (11 persons)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,269,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td colspan="9" valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;"><font style="font-size:10pt;">Indicates beneficial ownership of less than 1% of the total ordinary shares outstanding.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 1,643,658 ordinary shares. Mr. Moshe Arkin is the sole beneficial owner of Arkin Communication Ltd. The percentage ownership of Arkin Communication Ltd. decreased from 21.0% as of March 31, 2017. The address of Arkin Communication Ltd. is 6 HaChoshlim St., Bldg. C, Herzliya 46724, Israel.</p></td></tr></table></div>
<p style="margin-bottom:0pt;Background-color:#FFFFFF;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 916,450 ordinary shares. Consonance Capital Master Account LP directly holds 877,886 ordinary shares. Consonance Capital Management LP is the investment adviser of Consonance Capital Master Account LP, and pursuant to an investment advisory agreement, Consonance Capital Management LP exercises voting and investment power over the shares held by Consonance Capital Master Account LP. A managed account managed by Consonance Capital Opportunity Fund Management LP directly holds 38,564 ordinary shares. Consonance Capman GP LLC is the general partner of Consonance Capital Opportunity Fund Management LP and is the general partner of Consonance Capital Master Account LP. Mitchell Blutt is the Manager and Member of Consonance Capman GP LLC and Chief Executive Officer of Consonance Capital Master Account LP. The address of Consonance Capman GP LLC is 1370 Avenue of the Americas, Floor 33, New York, NY 10019.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Represents ordinary shares beneficially owned as of December 31, 2017, based on a Schedule 13G/A filed on December 11, 2017, by Menora Mivtachim Holdings Ltd. In such filing, Menora Mivtachim Holdings Ltd. lists its address as Menora House, 115 Allenby St., Tel Aviv 61008, Israel, and indicates that it has shared voting power with respect to 1,338,762 ordinary shares and shared dispositive power with respect to 1,338,762 ordinary shares.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 968,525 ordinary shares and 29,646 ordinary shares issuable upon exercise of outstanding options. Does not include 14,316 ordinary shares issuable upon exercise of outstanding options which have not vested. Pontifax Management Fund III L.P. is the general partner of Pontifax (Israel) III Limited Partnership, and Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax (Israel) III Limited Partnership. The percentage ownership of Pontifax (Israel) III Limited Partnership decreased from 11.4% as of March 31, 2017. The address of Pontifax (Israel) III Limited Partnership is 14 Shenkar St., Herzliya 4672514, Israel.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a>Consists of 452,162 ordinary shares and 13,836 ordinary shares issuable upon exercise of outstanding options. Does not include 6,683 ordinary shares issuable upon exercise of outstanding options which have not vested. Pontifax Management Fund III L.P. is the general partner of Pontifax Cayman III Limited Partnership, and Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are directors of Pontifax Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax Cayman III Limited Partnership. The percentage </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership of Pontifax (Israel) III Limited Partnership decreased from 5.3% as of March 31, 2017. The address of Pontifax Cayman III Limited Partnership is 14 Shenkar St., Herzliya 4672514, Israel.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 1,451,329 ordinary shares. ProQuest Associates IV LLC is the managing member and sole general partner of ProQuest Investments VI, L.P. Jay Moorin and Alain Schreiber are the managing members of ProQuest Associates IV LLC and, as such, hold voting and/or dispositive power over the shares held by ProQuest Investments IV, L.P. The percentage ownership of ProQuest Investments IV, L.P. increased from 10.2% as of March 31, 2017. The address of ProQuest Investments IV, L.P. is 2430 Vanderbilt Beach Road, 108-190, Naples, FL 34109, USA.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 84,211 ordinary shares and 219,482 ordinary shares issuable upon exercise of outstanding options. Does not include 85,000 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8) </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 33,683 ordinary shares and 102,993 ordinary shares issuable upon exercise of outstanding options. Does not include 159,067 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9) </font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 7,500 ordinary shares issuable upon exercise of outstanding options. Does not include 32,500 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10) Consists of 10,000 ordinary shares issuable upon exercise of outstanding options. Does not include 30,000 ordinary shares issuable upon exercise of outstanding options which have not vested.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 4,167 ordinary shares issuable upon exercise of outstanding options. Does not include 45,833 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 40,241 ordinary shares issuable upon exercise of outstanding options. Does not include 21,000 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 37,000 ordinary shares issuable upon exercise of outstanding options. Does not include 21,000 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 23,033 ordinary shares and 136,569 ordinary shares issuable upon exercise of outstanding options. Does not include 74,333 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 17,467 ordinary shares issuable upon exercise of outstanding options. Does not include 67,733 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of beneficial ownership of securities held by Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership described in notes 3 and 4 above.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;Background-color:#FFFFFF;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Consists of 88,600 ordinary shares issuable upon exercise of outstanding options. Does not include 43,200 ordinary shares issuable upon exercise of outstanding options which have not vested.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="RELATED_PARTY_TRANSACTIONS"></a><a name="RELATED_PARTY_TRANSACTIONS"></a>Related party transactions. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Shareholders</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Registration rights agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into an investors&#8217; rights agreement dated September 18, 2014, as amended on October 1, 2015 and on April 12, 2016, or the Registration Rights Agreement, with certain of our shareholders. The Registration Rights Agreement provides that certain holders of our ordinary shares have the right to demand that we file a registration statement or request that their ordinary shares be covered by a registration statement that we are otherwise filing. The registration rights are described in more detail under &#8220;Description of Share Capital&#8212;Registration Rights.&#8221; All rights under the Registration Rights Agreement, other than the registration rights, terminated upon the closing of our initial public offering.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Telormedix SA agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a>We have entered into an asset purchase agreement, or the agreement, dated as of October 1, 2015, with Telormedix SA. Also on October 1, 2015, we entered into the 2015 Share Purchase Agreement, as further described below, pursuant to which ProQuest, which beneficially owns 62.6% of Telormedix, became a 10% beneficial owner of the company. Pursuant to the 2015 Share Purchase Agreement, ProQuest appointed Stuart Holden, M.D., who was a member of the board of directors of Telormedix, to our board of directors. Pursuant to the agreement, we purchased all of the intellectual property assets of Telormedix in consideration for an aggregate amount of 691,200 Series A preferred shares, which converted to ordinary shares in connection with our initial public offering. Upon the occurrence of each of three specified regulatory milestones, we are required to issue an additional 92,800 ordinary </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares to Telormedix, for an aggregate potential maximum amount of 278,400 ordinary shares. In April 2017, Telormedix transferred 135,200 Series A preferred shares and the right to receive an additional aggregate of 54,462 Series A preferred shares upon the occurrence of the milestones to ProQuest, and 80,800 Series A preferred shares and the right to receive an additional 32,538 Series A preferred shares upon the occurrence of the milestones to Aravis Venture I L.P.&nbsp;&nbsp;As of the date of this filing, the Company has deemed the probability of occurrence of the three specified regulatory milestones to be remote.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Agreements and Arrangements with, and Compensation of, Directors and Executive Officers</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employment agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into written employment agreements with each of our executive officers. These agreements contain customary provisions and representations, including confidentiality, non-competition, non-solicitation and inventions assignment undertakings by the executive officers. However, the enforceability of the non-competition provisions may be limited under applicable law. The agreements are terminable by us at will, subject to prior notice, which varies for each individual. Our executive officers will not receive benefits upon termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment. However, Ron Bentsur, our Chief Executive Officer, Gary Titus, our Chief Financial Officer, and Mark Schoenberg, our Chief Medical Officer will be entitled to accelerated vesting of their restricted stock units and stock options, respectively, in the event of termination without cause.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Consulting and option agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into an agreement with our chairman of the board of directors, Arie Belldegrun, M.D., for management services pertaining to the development of our business. These services included serving as chairman of the board of directors, assisting us in our financing activities and overseeing our clinical development activities. In consideration of these services, as of December 31, 2016, we had issued Dr. Belldegrun options under our 2010 Israeli Share Option Plan to purchase 128,000 ordinary shares at $4.02 per share and 166,482 ordinary shares at $5.00 per share. The agreement had no fixed term and was terminable at will (i) by Dr. Belldegrun upon 30 days&#8217; prior written notice and (ii) by us at any time pursuant to the directions of our board of directors or shareholders. The agreement contained customary provisions and representations, including confidentiality and inventions assignment undertakings by Dr. Belldegrun. On March 29, 2017, our board resolved to terminate the agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also entered into an option agreement with our non-executive directors Pini Orbach and Stuart Holden and option agreements with Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership, which are represented by our non-executive director Ran Nussbaum, according to which each was granted options under our 2010 Israeli Share Option Plan in the number and on the terms set out in the section above titled &#8220;Principal Shareholders.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also entered into an option agreement with our non-executive directors Pini Orbach, Kathryn E. Falberg, Fred Cohen, Cynthia Butitta and Stuart Holden and option agreements with Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership, which are represented by our non-executive director Ran Nussbaum, pursuant to which each was granted options under our 2017 Equity Incentive Plan in the amount and on the terms set out in the &#8220;Principal Shareholders&#8221; table above.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing agreements</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Between 2012 and 2015, Arkin Communications Ltd. or Arkin, which appointed Pini Orbach, Ph.D., to our board of directors, Pontifax (Israel) III Limited Partnership, or Pontifax IL, and Pontifax Cayman III Limited Partnership, or Pontifax CM, which appointed Ran Nussbaum to our board of directors, Shirat HaChaim Ltd., or Shirat HaChaim, a company controlled by Chaim Hurvitz, who served as our director until December 2017, Bellco Capital LLC, or Bellco, through several entities controlled by it (the beneficial owners of Bellco Capital are Rebecka Belldegrun, M.D. and our chairman Arie Belldegrun, M.D.) and ProQuest Investments IV, L.P., or ProQuest, which appointed Stuart Holden, M.D. to our board of directors, invested in the company an aggregate amount of approximately $22.4 million in consideration of the securities described below:</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From January 2012 through July 2013, we entered into share purchase agreements with Pontifax IL, Pontifax CM, Shirat HaChaim and other investors, pursuant to which the company issued to the investors 1,375,233 ordinary shares at $5.00 per share, of which 272,691, 127,308 and 100,000 ordinary shares were issued to Pontifax IL, Pontifax CM and Shirat HaChaim, respectively.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 18, 2014, we entered into the 2014 Share Purchase Agreement with Arkin, Pontifax IL, Pontifax CM, Shirat HaChaim and other investors, pursuant to which the company issued to the investors 1,456,573 Series A preferred shares at $5.94 per share and 728,312 warrants exercisable into shares of Series A-1 preferred shares at $7.81 per share, of which 757,894, 172,224, 80,402 and 84,210 shares and 378,950, 86,112, 40,204 and 42,105 warrants were issued to Arkin, Pontifax IL, Pontifax CM and Shirat HaChaim, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 1, 2015, we entered into the 2015 Share Purchase Agreement with ProQuest, Arkin, Pontifax IL, Pontifax CM, Shirat HaChaim, Bellco and other investors, pursuant to which the company issued to the investors 3,045,654 Series A preferred shares at $5.94 per share, of which 842,105, 589,475, 390,380, 182,252, 168,422 and 84,211 shares were issued to ProQuest, Arkin, Pontifax IL, Pontifax CM, Shirat HaChaim and Bellco, respectively.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lease agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our U.S. subsidiary, UroGen Pharma, Inc., entered into a lease agreement, dated as of September 15, 2017 and commencing as of October 2017, for office space in New York, which serves as the headquarters for our U.S. subsidiary. Prior to that, our U.S. subsidiary entered into a lease agreement, dated as of November 2015 and commencing as of May 2016, for office space in New York, which served as the headquarters for our U.S. subsidiary. Our U.S. subsidiary shared the office space equitably with Kite Pharma, Inc., a Delaware corporation, who was a co-signatory to such lease agreement. Arie Belldegrun, M.D., our chairman, served until November 2017 as the Chairman and Chief Executive Officer of Kite Pharma until its acquisition in November 2017 by Gilead Sciences, Inc.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indemnification agreements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our articles of association permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extent permitted by the Israeli Companies Law. We have entered into indemnification agreements with each of our directors and executive officers, undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect to liabilities resulting from a public offering of our shares, to the extent that these liabilities are not covered by insurance. We have also obtained Directors and Officers insurance for each of our executive officers and directors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Relationships</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Family members of Chaim Hurvitz, our former director, beneficially own more than 10% of Pontifax IL and Pontifax CM.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="C_INTERESTS_EXPERTS_COUNSEL"></a><a name="C_INTERESTS_EXPERTS_COUNSEL"></a>Interests of experts and counsel. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of this annual report, Hamburger Evron &amp; Co. beneficially owns an aggregate of 83,928 of our ordinary shares issuable upon the exercise of options.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Item_8._Financial"></a><a name="ITEM_8_FINANCIAL_INFORMATION"></a><a name="ITEM_8_FINANCIAL_INFORMATION"></a>Item 8. Financial Information </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="A_CONSOLIDATED_STATEMENTS_OR_FINANCIAL_I"></a><a name="A_CONSOLIDATED_STATEMENTS_OR_FINANCIAL_I"></a>Consolidated Statements and Other Financial Information.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See &#8220;Item 18 &#8211; Financial Statements.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Legal proceedings</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in any legal proceedings. We may become involved in material legal proceedings in the future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends to our shareholders and we do not intend to pay cash dividends in the foreseeable future. We intend to reinvest any earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our board of directors and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other factors that our board of directors may deem relevant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Israeli Companies Law imposes further restrictions on our ability to declare and pay dividends. See final prospectus as filed under the Securities Act with the SEC on January 22, 2018, under "Description of Share Capital&#8212;Dividend and Liquidation Rights" for additional information.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of dividends may be subject to Israeli withholding taxes. See "Item 10.E. Taxation" for additional information.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><a name="B_SIGNIFICANT_CHANGES"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="B_SIGNIFICANT_CHANGES"></a>Significan</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">t Changes. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as disclosed elsewhere in this annual report, there have been no other significant changes since December 31, 2016.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_FER_LISTING"></a><a name="ITEM_9_FER_LISTING"></a>Item 9. The Offer and Listing. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="A_FER_LISTING_DETAILS"></a><a name="A_FER_LISTING_DETAILS"></a>Offer and listing details. </p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ordinary shares have been listed on the Nasdaq Global Market under the symbol &#8220;URGN&#8221; since May 4, 2017. Prior to that date, there was no public trading market for our ordinary shares. Our initial public offering was priced at $13.00 per share. The following table sets forth for the periods indicated the high and low sales prices per ordinary share as reported on the Nasdaq Global Market:</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Select Market</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="3" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Common Share</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653237"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">High</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Low</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yearly:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44.63</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.01</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$56.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$37.53</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Quarter 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.02</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.01</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Quarter 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33.77</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.07</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth Quarter 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44.63</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.56</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Quarter 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$56.56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$37.53</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Month Ended:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33.77</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.37</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33.17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.56</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44.63</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.72</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$41.25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$36.66</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$56.56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$37.53</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$53.78</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$44.15</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$58.66</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.84%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$51.16</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 12, 2018, the closing price of our Ordinary Shares on the Nasdaq Global Market was $56.00 per Ordinary Share.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="B_PLAN_DISTRIBUTION"></a><a name="B_PLAN_DISTRIBUTION"></a>Plan of distribution. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="C_MARKETS"></a><a name="C_MARKETS"></a>Markets. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Ordinary Shares have been listed on the Nasdaq Global Market under the symbol &#8220;URGN&#8221; since May 4, 2017.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="D_SELLING_SHAREHOLDERS"></a><a name="D_SELLING_SHAREHOLDERS"></a>Selling shareholders </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">E.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="E_DILUTION"></a><a name="E_DILUTION"></a>Dilution. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="F_EXPENSES__ISSUE"></a><a name="F_EXPENSES__ISSUE"></a>Expenses of the issue. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_ADDITIONAL_INFORMATION"></a><a name="ITEM_10_ADDITIONAL_INFORMATION"></a>Item 10. Additional Information. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><a name="A_SHARE_CAPITAL"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="A_SHARE_CAPITAL"></a>Share c</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">apital. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="B_MEMORUM_ARTICLES_ASSOCIATION"></a><a name="B_MEMORUM_ARTICLES_ASSOCIATION"></a>Memorandum and articles of association.&nbsp;&nbsp;</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this item has been reported previously in our Registration Statement on Form F-1 as filed under the Securities Act with the SEC on April 24, 2017 and has not changed since, and therefore is incorporated by reference to that Registration Statement.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="C_MATERIAL_CONTRACTS"></a><a name="C_MATERIAL_CONTRACTS"></a>Material contracts. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For information on our material contracts, please see &#8220;Item 4. Information on the Company,&#8221; Item 6. Directors, Senior Management and Employees,&#8221; and &#8220;Item 7.B. Related Party Transactions&#8221; of this annual report.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="D_EXCHANGE_CONTROLS"></a><a name="D_EXCHANGE_CONTROLS"></a>Exchange controls. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are currently no Israeli currency control restrictions on the import or export of capital or the remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of war with Israel.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">E.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="E_TAXATION"></a><a name="E_TAXATION"></a>Taxation. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our ordinary shares. You should consult your own tax advisor concerning the tax consequences in your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Israeli Tax Considerations and Government Programs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a brief summary of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our ordinary shares. This summary does not discuss certain tax benefits, including under the Law for Encouragement of Capital Investments, 5719-1959, to which we may become eligible in the future if we establish a manufacturing facility for our products in Israel. This summary also does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. Because parts of this discussion are based on new tax legislation that has not yet been subject to judicial or administrative interpretation, the appropriate tax authorities or the courts may not accept the views expressed in this discussion. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described below.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General Corporate Tax Structure in Israel</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of 2018, Israeli companies are generally subject to corporate tax at the rate of 23% of a company&#8217;s taxable income (reduced from 24% in 2017). In addition, capital gains realized by Israeli companies are subject to tax at the regular corporate tax rate.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Taxation of our Shareholders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Capital gains taxes applicable to non-Israeli resident shareholders. <font style="font-style:normal;">As of 2018, capital gain is generally subject to tax at the corporate tax rate of 23% (reduced from 24% in 2017) if generated by a company, or at the rate of 25% if generated by an individual, or 30% in the case of sale of shares by a substantial shareholder at the time of sale or at any time during the preceding 12-month period. A person is considered to be a substantial shareholder if it holds, directly or indirectly, alone or together with another affiliated party, 10% or more of a company&#8217;s means of control, which include, among other things, voting rights, the right to receive profits of the company, the right to receive proceeds upon liquidation and the right to appoint a director.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a>Notwithstanding the foregoing, a non-Israeli resident who derives capital gains from the sale of our shares that were purchased after the shares were listed for trading on the Nasdaq is exempt from Israeli tax on such capital gains so long as they were not attributable to a permanent establishment that the non-resident maintains in Israel. In the case of a shareholder that is a corporation, in order for it to qualify as a non-Israeli resident for these purposes, it must be incorporated in, as well as managed and controlled from, a jurisdiction other than the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State of Israel, and persons who are Israeli residents may not either: (i) have a controlling interest (directly or indirectly, alone or together with another, or together with another Israeli resident) exceeding 25% in one or more of the means of control in such corporation or (ii) be the beneficiaries of, or entitled to, 25% or more of the revenues or profits of such corporation, whether directly or indirectly. Such exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business income.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, a sale of shares by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. In transactions involving a sale of all of the shares of an Israeli resident company, such as a merger or other transaction, the Israel Tax Authority may, among other things, require from shareholders who are not liable for Israeli tax the execution of a declaration in the form specified by that authority or a specific exemption from the Israeli Tax Authority to confirm their status as non-Israeli residents may be required to be presented, and, in the absence of such declaration or exemption, may require the purchaser of the shares to withhold taxes.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, with respect to mergers involving an exchange of shares, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions in which the sellers receive shares in the acquiring entity that are publicly traded on a stock exchange, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of such shares has occurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Taxation of non-Israeli shareholders on receipt of dividends.<font style="font-style:normal;"> Non-Israeli residents are generally subject to Israeli withholding tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt of a valid certificate from the Israel Tax Authority, allowing for such reduced withholding tax rate). With respect to a person who is considered a substantial shareholder at the time of receiving the dividend or at any time during the preceding 12 months, subject to the terms of an applicable tax treaty, the applicable withholding tax rate is 30%.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Convention between the Government of the United States of America and the Government of the State of Israel with respect to Taxes on Income, or the U.S.-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident (for the purposes of the U.S.-Israel Tax Treaty) is 25%. However, with regard to dividends paid to a U.S. resident corporation which held 10% or more of our outstanding voting rights throughout the taxable year in which the dividend was distributed and which maintained its shareholdings at or above such threshold during the entire previous taxable year, the maximum rate of withholding tax is generally 12.5%, provided that no more than 25% of our gross income for such preceding year consists of certain types of dividends and interest.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. residents who are subject to Israeli withholding tax on a dividend may be entitled to a credit or deduction for U.S. federal income tax purposes in the amount of the taxes withheld, subject to detailed limitations under U.S. laws applicable to foreign tax credits.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Excess Tax<font style="font-style:normal;">. Individuals who are subject to tax in Israel, whether an Israeli resident or a non-Israeli resident, are also subject to an additional tax on annual income exceeding NIS 640,000 in 2017 and thereafter (linked to the Israeli consumer price index) at a rate of 3%, including, but not limited to, dividends, interest and capital gain, subject to the provisions of an applicable tax treaty.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Material U.S. Federal Income Tax Consequences to U.S. Holders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following discussion describes the material U.S. federal income tax consequences to U.S. Holders (as defined below) under present law of an investment in our ordinary shares. The effects of any applicable state or local laws, or other U.S. federal tax laws such as estate and gift tax laws are not discussed. This summary applies only to investors who hold the ordinary shares as capital assets (generally, property held for investment) and who have the U.S. dollar as their functional currency. This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, U.S. Treasury regulations promulgated thereunder, judicial decisions, published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, and the U.S.-Israel Tax Treaty, all as in effect as of the date of annual report. All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following discussion does not address all U.S. federal income tax consequences relevant to a holder&#8217;s particular circumstances or to holders subject to particular rules, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">U.S. expatriates and certain former citizens or long-term residents of the United States;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">persons subject to the alternative minimum tax;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU105"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">persons holding our ordinary shares as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment for U.S. federal income tax purposes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">banks, insurance companies, and other financial institutions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">real estate investment trusts and regulated investment companies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">brokers, dealers, and traders in securities, commodities or currencies;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">partnerships, S corporations, and other entities or arrangements treated as partnerships for U.S. federal income tax purposes;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">tax-exempt organizations and governmental organizations;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">persons who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">persons that own, directly, indirectly or constructively 10% or more of our stock;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">persons that hold their shares through a permanent establishment or fixed base outside the United States; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">persons deemed to sell our ordinary shares under the constructive sale provisions of the Code.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE U.S. STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE ORDINARY SHARES.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of our ordinary shares that, for U.S. federal income tax purposes, is or is treated as any of the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an individual who is a citizen or resident of the United States;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a corporation, or entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state thereof, or the District of Columbia;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">a trust that (1) is subject to the supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you are a partner in a partnership (or other entity taxable as a partnership for U.S. federal income tax purposes) that holds our ordinary shares, your tax treatment generally will depend on your status and the activities of the partnership. Partnerships holding our ordinary shares and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences applicable to them.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated below, this entire discussion is subject to the discussion of the U.S. federal income tax rules applicable to a &#8220;passive foreign investment company,&#8221; or a PFIC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Passive Foreign Investment Company Considerations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are classified as a PFIC in any taxable year, a U.S. Holder will be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a non-U.S. company that does not distribute all of its earnings on a current basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must determine our PFIC status annually based on tests (described below) which are factual in nature, and our status will depend on our income, assets and activities each year. We do not believe that we were classified as a PFIC for the taxable year ended December 31, 2017. However, based upon the expected nature and composition of our income and assets, we presently anticipate that we will be classified as a PFIC for the taxable year ending December 31, 2018. We cannot provide any assurances regarding our PFIC status for the current or future taxable years, and our U.S. tax counsel has not provided any opinion regarding our PFIC status.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU106"></a><a name="_AEIOULastRenderedPageBreakAEIOU106"></a>A non-U.S. corporation is classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect to the income and assets of subsidiaries, either (i) at least 75% of its gross income is &#8220;passive income&#8221; or (ii) at least 50% of the average quarterly value of its total gross assets (which, assuming we are not a CFC for the year being tested, would be measured by fair market value of the assets, and for which purpose the total value of our assets may be </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined in part by the market value of our ordinary shares, which is subject to change) is attributable to assets that produce &#8220;passive income&#8221; or are held for the production of passive income.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income, and generally includes amounts derived by reason of the temporary investment of funds raised in offerings of our ordinary shares. However, rents and royalties received from unrelated parties in connection with the active conduct of a trade or business are not considered passive income for purposes of the PFIC test. If a non-U.S. corporation owns directly or indirectly at least 25% by value of the stock of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation&#8217;s income. If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our ordinary shares, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns our ordinary shares, regardless of whether we continue to meet the tests described above unless the holder makes a so-called &#8220;purging election&#8221; with respect to our ordinary shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S.<font style="font-style:normal;"> </font>Holders should consult with their tax advisors regarding the availability and consequences of any PFIC purging elections.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are a PFIC, and you are a U.S. Holder, then unless you make one of the elections described below, a special tax regime will apply to both (a) any &#8220;excess distribution&#8221; by us to you (generally, your ratable portion of aggregate distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of the three preceding years or your holding period for our ordinary shares) and (b) any gain realized on the sale or other disposition of the ordinary shares. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a) the excess distribution or gain had been realized ratably over your holding period, (b) the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#8217;s regular ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (c) the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the lower rates of taxation applicable to long-term capital gains discussed under &#8220;Taxation of Dividends and Other Distributions on our Ordinary Shares.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment (such as mark-to-market treatment) of our ordinary shares. If a U.S. Holder makes the mark-to-market election, then in lieu of being subject to the tax and interest change rules disclosed above, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ordinary shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in the ordinary shares will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ordinary shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and our ordinary shares are &#8220;regularly traded&#8221; on a &#8220;qualified exchange.&#8221; Our ordinary shares will be treated as &#8220;regularly traded&#8221; in any calendar year in which more than a de minimis quantity of the ordinary shares are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principle purposes the meeting of the trading requirement are disregarded). The Nasdaq Global Market is a qualified exchange for this purpose and, consequently, if the ordinary shares are regularly traded, the mark-to-market election will be available to a U.S. Holder.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not currently intend to provide the information necessary for U.S. Holders to make QEF elections. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are determined to be a PFIC, the general tax treatment for U.S. Holders described in this section will apply to indirect distributions and gains deemed to be realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs. A mark-to-market election cannot be made with respect to the stock of any of our subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each U.S. Holder that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax. U.S. Holders should consult their tax advisors regarding whether we are a PFIC and the potential application of the PFIC rules.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU107"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Taxation of Dividends and Other Distributions on our Ordinary Shares</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company Considerations,&#8221; above, the gross amount of any distribution to you with respect to our ordinary shares will be included in your gross income as dividend income when actually or constructively received to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent the amount of the distribution exceeds our current and accumulated earnings and profits, it will be treated first as a return of your tax basis in our ordinary shares, and to the extent the amount of the distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that the entire amount of any distribution will generally be reported as dividend income. Any dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not a PFIC for a given year in which a dividend is paid and the taxable year preceding the dividend, non-corporate U.S. Holders may qualify for the preferential rates of taxation with respect to dividends on ordinary shares applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) applicable to qualified dividend income (as discussed below). We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the U.S.-Israel Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Israel Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an exchange-of-information program. Therefore, subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company Considerations&#8221; above, if the U.S.-Israel Tax Treaty is applicable, such dividends will generally be &#8220;qualified dividend income&#8221; in the hands of individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk reduction transaction requirements. The dividends will not be eligible for the dividends received deduction generally allowed to corporate U.S. Holders. As discussed in &#8220;Taxation&#8212;Israeli Tax Considerations and Government Programs,&#8221; payments of dividends by us may be subject to Israeli withholding tax. For U.S. federal income tax purposes, U.S. Holders will be treated as having received the amount of Israeli taxes withheld by us, and as then having paid over the withheld taxes to the Israeli taxing authorities. As a result of this rule, the amount of dividend income included in gross income for U.S. federal income tax purposes by a U.S. Holder with respect to a payment of dividends may be greater than the amount of cash actually received (or receivable) by the U.S. Holder from us with respect to the payment. Dividends will generally constitute foreign source income for foreign tax credit limitation purposes. Any tax withheld with respect to distributions on our ordinary shares at the rate applicable to a U.S. Holder may, subject to a number of complex limitations, be claimed as a foreign tax credit against such U.S. Holder&#8217;s U.S. federal income tax liability or may be claimed as a deduction for U.S. federal income tax purposes. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed by us with respect to our ordinary shares generally will constitute &#8220;passive category income&#8221; or &#8220;general category income.&#8221; The rules with respect to the foreign tax credit are complex and involve the application of rules that depend upon a U.S. Holder&#8217;s particular circumstances. You are urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular circumstances.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Taxation of Disposition of the Ordinary Shares</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the discussion above under &#8220;&#8212;Passive Foreign Investment Company Considerations,&#8221; you will recognize gain or loss on any sale, exchange or other taxable disposition of an ordinary share equal to the difference between the amount realized on the disposition of the ordinary share and your adjusted tax basis in the ordinary share. The tax basis in an ordinary share generally will be the cost of such ordinary share. Any such gain or loss will be capital gain or loss and will be long-term capital gain or loss if you have held the ordinary share for more than one year at the time of sale, exchange or other taxable disposition. Otherwise, such gain or loss will be short-term capital gain or loss. Long-term capital gains recognized by certain non-corporate U.S. Holders, including individuals, generally will be taxable at a reduced rate. The deductibility of capital losses is subject to limitations. Any such gain or loss you recognize generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional Medicare Tax</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain U.S. Holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their &#8220;net investment income,&#8221; which may include all or a portion of their dividend income and net gains from the disposition of ordinary shares. Each U.S. Holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its income and gains in respect of its investment in our ordinary shares.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Information Reporting and Backup Withholding</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU108"></a>U.S. backup withholding tax and information reporting requirements may apply to certain payments to certain holders of our ordinary shares. Information reporting will generally apply to payments of dividends on, and to proceeds from the sale or redemption of, our ordinary shares made within the United States, or by a U.S. payer or U.S. middleman, to a holder of our shares, other than an exempt </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recipient (including a payee that is not a U.S. person that provides an appropriate certification and certain other persons). Certain U.S. Holders are exempt from backup withholding, including corporations and certain tax-exempt organizations. A U.S. Holder will be subject to backup withholding if such holder is not otherwise exempt and such holder:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fails to furnish the holder&#8217;s taxpayer identification number, which for an individual is ordinarily his or her social security number;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">furnishes an incorrect taxpayer identification number;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against the U.S. Holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Additional Reporting Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain U.S. Holders who are individuals (and under proposed regulations, certain entities) are required to report information relating to an interest in our ordinary shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return. U.S. Holders should consult their tax advisors regarding the possible implications of these tax return disclosure obligations.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">F.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="F_DIVIDENDS_PAYING_AGENTS"></a><a name="F_DIVIDENDS_PAYING_AGENTS"></a>Dividends and paying agents. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Not applicable.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">G.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="G_STATEMENT_BY_EXPERTS"></a><a name="G_STATEMENT_BY_EXPERTS"></a>Statement by experts. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.&nbsp;&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="H_DOCUMENTS_ON_DISPLAY"></a><a name="H_DOCUMENTS_ON_DISPLAY"></a>Documents on display. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to certain of the information reporting requirements of the Exchange Act, or the Exchange Act. As a foreign private issuer, we are exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the Exchange Act, with respect to their purchase and sale of our shares. In addition, we are not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC, within four months after the end of each fiscal year, an annual report on Form 20-F containing financial statements audited by an independent accounting firm. We publish unaudited interim financial information after the end of each quarter. We furnish this quarterly financial information to the SEC under cover of a Form 6-K. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_350"></a>You may read and copy any document we file with the SEC at its public reference facilities at 100 F Street, NE, Washington, D.C. 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, NE, Washington, D.C. 20549. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of this <a name="_cp_field_47_350"></a>website is <font style="text-decoration:none;color:#000000;">http://www.sec.gov</font>. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference facilities.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">I.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="I_SUBSIDIARY_INFORMATION"></a><a name="I_SUBSIDIARY_INFORMATION"></a>Subsidiary Information. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 11. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Market risk is the risk of loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely impact our financial position, results of operations or cash flows.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU109"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Foreign currency exchange risk</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in NIS. As a result, we are exposed to the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the NIS against the dollar. For example, although the dollar appreciated against the NIS in 2015 by 0.3%, the level of devaluation of the dollar against the NIS in 2016 was 1.5%. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. Our operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently engage in currency hedging activities in order to reduce this currency exposure, but we may begin to do so in the future. Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Liquidity risk</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We monitor forecasts of our liquidity reserve (comprising cash and cash equivalents and deposits). We generally carry this out based on our expected cash flows in accordance with practice and limits set by our management. We are in the research and development stage and we are therefore exposed to liquidity risk. However, we believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inflation risk</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not believe that the rate of inflation in Israel has had a material impact on our business to date, however, our costs in Israel will increase if inflation in Israel exceeds the devaluation of the shekel against the U.S. dollar or if the timing of such devaluation lags behind inflation in Israel.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_DESCRIPTION_SECURITIES_OR_THAN_E"></a><a name="ITEM_12_DESCRIPTION_SECURITIES_OR_THAN_E"></a>Item 12. Description of Securities Other than Equity Securities. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="DEBT_SECURITIES"></a><a name="DEBT_SECURITIES"></a>Debt Securities. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="B_WARRANTS_RIGHTS"></a><a name="B_WARRANTS_RIGHTS"></a>Warrants and Rights. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="C_OR_SECURITIES"></a><a name="C_OR_SECURITIES"></a>Other Securities.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="D_AMERICAN_DEPOSITARY_SHARES"></a><a name="D_AMERICAN_DEPOSITARY_SHARES"></a>American Depositary Shares. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU110"></a><a name="PART_II"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> II </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_DEFAULTS_DIVIDEND_ARREARAGES_DEL"></a><a name="ITEM_13_DEFAULTS_DIVIDEND_ARREARAGES_DEL"></a>Item 13. Defaults, Dividend Arrearages and Delinquencies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_MATERIAL_MODIFICATIONS_TO_RIGHTS"></a><a name="ITEM_14_MATERIAL_MODIFICATIONS_TO_RIGHTS"></a>Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, we sold 5,144,378 of our ordinary shares, in our initial public offering, IPO, at a price of $13.00 per ordinary share, for aggregate gross proceeds to us of approximately $66.9 million. The net offering proceeds to us, after deducting underwriting discounts and commissions and offering expenses, were approximately $60.8 million. The offering commenced on May 1, 2017 and did not terminate before all of the securities registered in the registration statement were sold. The effective date of the registration statement, File No. 333-217201, for our ordinary shares was May 3, 2017. Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the IPO, Raymond James &amp; Associates, Inc. and Oppenheimer &amp; Co. Inc acted as co-managers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the net proceeds of our offering were paid directly or indirectly to any of our directors or executive officers, to their associates, persons owning ten percent or more of any class of our equity securities, or to any of our affiliates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, we sold 1,682,926 of our ordinary shares in a secondary public offering at a price of $41.00 per share, for aggregate gross proceeds to us of approximately $69.0 million. The net offering proceeds to us, after deducting underwriting discounts and commissions and offering expenses, were approximately $64.0 million. The offering commenced on January 16, 2018 and did not terminate before all of the securities registered in the registration statement were sold. The effective date of the registration statement, File No. 333-222558, for our ordinary shares was January 18, 2018. Jefferies LLC and Cowen and Company acted as joint book-running managers for the offering, Oppenheimer &amp; Co. Inc., Ladenburg Thalmann &amp; Co. Inc. and National Securities Corporation acted as co-managers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None of the net proceeds of our offering were paid directly or indirectly to any of our directors or executive officers, to their associates, persons owning ten percent or more of any class of our equity securities, or to any of our affiliates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_CONTROLS_PROCEDURES"></a><a name="ITEM_15_CONTROLS_PROCEDURES"></a>Item 15. Controls and Procedures. </p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disclosure Controls and Procedures</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chief Executive Officer (<font style="font-style:italic;">principal executive officer</font>) and Chief Financial Officer (<font style="font-style:italic;">principal financial officer</font>), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;of the Exchange Act) as of December&#160;31, 2017, have concluded that, as of such date, our disclosure controls and procedures were effective and ensured that information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (<font style="font-style:italic;">principal executive officer</font>) and Chief Financial Officer (<font style="font-style:italic;">principal financial officer</font>), to allow timely decisions regarding required disclosure and is recorded, processed, summarized and reported within the time periods specified by the SEC&#8217;s rules and forms.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report does not include a report of management&#8217;s assessment regarding internal control over financial reporting due to a transition period established by rules of the SEC for newly public companies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Attestation Report of the Registered Public Accounting Firm</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This annual report does not include an attestation report of our registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the period covered by this annual report that has materially affected, or is reasonably likely to materially affect, internal control over financial reporting.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU111"></a><a name="ITEM_16_RESERVED"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_RESERVED"></a>Item 16. [</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Reserved] </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16A_AUDIT_COMMITTEE_FINANCIAL_EXPER"></a><a name="ITEM_16A_AUDIT_COMMITTEE_FINANCIAL_EXPER"></a>Item 16A. Audit committee financial expert. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has determined that Kathryn E. Falberg is an &#8220;audit committee financial expert&#8221; as defined by SEC rules and has the requisite financial sophistication under the applicable rules and regulations of the Nasdaq Stock Market. Ms. Falberg is independent as such term is defined in Rule 10A-3 under the Exchange Act and under the listing standards of the Nasdaq Stock Market.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16B_CODE_ETHICS"></a><a name="ITEM_16B_CODE_ETHICS"></a>Item 16B. Code of Ethics. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_field_47_356"></a>We have adopted a Corporate Code of Ethics and Conduct, or the Code of Conduct, that is applicable to all of our employees, executive officers and directors. A copy of the Code of Conduct is available on our website <a name="_cp_field_47_356"></a>at <font style="text-decoration:none;color:#000000;">www.urogen.com</font>. Information contained on, or that can be accessed through, our website does not constitute a part of this report and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Under Item 16B of Form 20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of Form 20-F, we are required to disclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item 16B.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16C_PRINCIPAL_ACCOUNTANT_FEES_SERVI"></a><a name="ITEM_16C_PRINCIPAL_ACCOUNTANT_FEES_SERVI"></a>Item 16C. Principal Accountant Fees and Services.<sup style="font-size:85%; vertical-align:top">4</sup></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kesselman &amp; Kesselman (a member firm of Pricewaterhouse Coopers International Limited, or PwC), has served as our principal independent registered public accounting firm for each of the two years ended December 31, 2017 and 2016.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides information regarding fees paid by us to PwC for all services, for the years ended December 31, 2017 and 2016:</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653238"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit fees <sup style="font-size:85%; vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">294,864</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172,200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Audit-related fees <sup style="font-size:85%; vertical-align:top">(2)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,408</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,050</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax fees <sup style="font-size:85%; vertical-align:top">(3)</sup></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,544</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fees</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404,272</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306,794</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><sup style="font-size:85%; vertical-align:top"></sup>Includes professional services rendered in connection with the audit of our annual financial statements, as well as the review of our interim financial statements.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fees for registration statements. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Tax consulting services.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audit and Non-Audit Services Pre-Approval Policies and Procedures</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To ensure the independence and objectivity of our external auditors, the provision of all non-audit services by the external auditors is pre-approved by our audit committee.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16D_EXEMPTIONS_FROM_LISTING_STARDS_"></a><a name="ITEM_16D_EXEMPTIONS_FROM_LISTING_STARDS_"></a>Item 16D. Exemptions from the Listing Standards for Audit Committees. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16E_PURCHASES_EQUITY_SECURITIES_BY_"></a><a name="ITEM_16E_PURCHASES_EQUITY_SECURITIES_BY_"></a>Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.<font style="font-weight:bold;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU112"></a><a name="ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFYIN"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16F_CHANGE_IN_REGISTRANTS_CERTIFYIN"></a>Item 16F. Change in Registra</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">nt&#8217;s Certifying Accountant.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16G_CORPORATE_GOVERNANCE"></a><a name="ITEM_16G_CORPORATE_GOVERNANCE"></a>Item 16G. Corporate Governance.</p>
<p style="margin-bottom:0pt;margin-top:12pt;Background-color:#FFFFFF;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Home Country Practice Exemptions</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:0.25pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the Nasdaq Global Market, are considered public companies under Israeli law and are required to comply with various corporate governance requirements under Israeli law relating to such matters as the composition and responsibilities of the audit committee and the compensation committee (subject to certain exceptions that we intend to continue to utilize), and a requirement to have an internal auditor. This is the case even if our shares are not listed on the Tel Aviv Stock Exchange, or TASE, which our shares are not expected to be. These requirements are in addition to the corporate governance requirements imposed by the Nasdaq Rules and other applicable provisions of U.S. securities laws to which we are subject (as a foreign private issuer). Under the Nasdaq Rules, a foreign private issuer may generally follow its home country rules of corporate governance in lieu of the comparable requirements of the Nasdaq Rules, except for certain matters including the composition and responsibilities of the audit committee and the independence of its members within the meaning of the rules and regulations of the SEC.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have elected to rely on this &#8220;home country practice exemption&#8221; with respect to the following Nasdaq requirements:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Quorum</font><font style="font-family:Times New Roman;">. As permitted under the Israeli Companies Law and pursuant to our articles of association, the quorum required for an ordinary meeting of shareholders consists of at least two shareholders present in person, by proxy or by other voting instrument in accordance with the Israeli Companies Law, who hold at least 33<sup style="font-size:85%; vertical-align:top">1</sup>/<sub style="font-size:85%; vertical-align:bottom">3</sub>% of the voting power of our shares (and in an adjourned meeting, with some exceptions, at least two shareholders), instead of 33<sup style="font-size:85%; vertical-align:top">1</sup>/<sub style="font-size:85%; vertical-align:bottom">3</sub>% of the issued share capital required under the Nasdaq Rules.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Nomination of Directors</font><font style="font-family:Times New Roman;">. With the exception of directors elected by our board of directors due to a vacancy, our directors are elected at an annual general meeting of our shareholders and hold office until the next annual general meeting following his or her election. The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of directors itself or a duly authorized committee thereof, in accordance with the provisions of our articles of association and the Israeli Companies Law.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Proxy Statements.</font><font style="font-family:Times New Roman;">&#160;We are not required to and, in reliance on home country practice, we do not comply with certain Nasdaq Rules regarding the provision of proxy statements for general meetings of shareholders. Israeli corporate law does not have a regulatory regime for the solicitation of proxies. We intend to provide notice convening an annual general meeting, including an agenda and other relevant documents.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Shareholder Approval.</font><font style="font-family:Times New Roman;">&#160;We are not required to and, in reliance on home country practice, we do not comply with certain Nasdaq Rules regarding shareholder approval for certain issuances of securities under Nasdaq Rule 5635. In accordance with the provisions of our articles of association and the Israeli Companies Law, our board of directors is authorized to issue securities, including shares, warrants and convertible notes.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Executive Sessions</font><font style="font-family:Times New Roman;">. We are not required to and, in reliance on home country practice, we do not comply with certain Nasdaq Rules regarding regularly scheduled meetings at which only independent directors are present. In accordance with the provisions of our articles and the Israeli Companies Law, such regularly scheduled meetings at which only independent directors are present are not required.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than as stated above, we currently take all actions necessary to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and the Nasdaq Rules. We may in the future elect to use the home country practice exemption with respect to some or all of the other Nasdaq Rules.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16H_MINE_SAFETY_DISCLOSURE"></a><a name="ITEM_16H_MINE_SAFETY_DISCLOSURE"></a>Item 16H. Mine Safety Disclosure </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU113"></a><a name="PART_III"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">III</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_17_FINANCIAL_STATEMENTS"></a><a name="ITEM_17_FINANCIAL_STATEMENTS"></a>Item 17. Financial Statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See pages F-1 through F-21 of this annual report.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_18_FINANCIAL_STATEMENTS"></a><a name="ITEM_18_FINANCIAL_STATEMENTS"></a>Item 18. Financial Statements. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following consolidated financial statements, and the related notes thereto, and the Report of Independent Registered Public Accounting Firm are filed as a part of this annual report.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:89.91%;"></td>
<td style="width:10.09%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><font style="text-decoration:underline;">Consolidated Statements of Operations</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CHANGES_IN_SHARE"><font style="text-decoration:underline;">Statements of Changes in Shareholders&#8217; Equity</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU114"></a><a name="Item_19"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Item_19"></a>I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">tem 19. Exhibits. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT NUMBER</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT DESCRIPTION</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;1.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517175069/d401998dex31.htm"><font style="text-decoration:underline;">Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Form 6-K filed on May 18, 2017)</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex101.htm"><font style="text-decoration:underline;">Form of Officer Indemnity and Exculpation Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-217201))</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex42_984.htm"><font style="text-decoration:underline;">Amended and Restated 2010 Israeli Share Option Plan </font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex103.htm"><font style="text-decoration:underline;">Investors&#8217; Rights Agreement, dated September 18, 2014, as amended on October 1, 2015 and April&nbsp;&nbsp;12, 2016, among the Registrant and the Registrant&#8217;s shareholders (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-217201))</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.4</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex104.htm"><font style="text-decoration:underline;">Asset Purchase Agreement, dated October 1, 2015, between the Registrant and Telormedix SA (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form F-1 (File No.&nbsp;&nbsp;333-217201))</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.5&#8224;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex105.htm"><font style="text-decoration:underline;">License Agreement, dated as of October 7, 2016, by and between the Registrant and Allergan Pharmaceuticals International Limited (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-217201))</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.6</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex106.htm"><font style="text-decoration:underline;">2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form F-1(File No. 333-217201))</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.7</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex107.htm"><font style="text-decoration:underline;">2017 Israeli Equity Incentive Sub Plan to the 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-217201))</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;8.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex211.htm"><font style="text-decoration:underline;">Subsidiary of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Registration Statement on Form F-1(File No. 333-217201))</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex121_51.htm"><font style="text-decoration:underline;">Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex122_50.htm"><font style="text-decoration:underline;">Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.1*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex131_49.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.2*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex132_48.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.1*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="urgn-ex151_1183.htm"><font style="text-decoration:underline;">Consent of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1668243/000119312517116003/d142578dex991.htm"><font style="text-decoration:underline;">Consent of Dr. J. Gregory Wirth (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Registration Statement on Form F-1 (File No. 333-217201))</font></a></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Interactive data files pursuant to Rule&#160;405 of Regulation S-T: (i)&#160;Consolidated Balance Sheets, (ii)&#160;Consolidated Statements of Operations, (iii)&#160;Consolidated Statements of Changes in Shareholders Equity, (iv) Consolidated Statements of Cash Flows, and (v)&#160;the Notes to Consolidated Financial Statements</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Registrant has been granted confidential treatment for certain portions of this exhibit. This exhibit omits the information subject to this confidentiality treatment. Omitted portions have been filed separately with the SEC.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU115"></a><a name="SIGNATURES"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNA</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TURES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd. </p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="color:#000000;"> March </font>15, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ron Bentsur</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ron Bentsur</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer </p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8.5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU116"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:0.05pt;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE<font style="letter-spacing:0.6pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:94%; border-bottom:solid 0.75pt transparent;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PAGE</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited<font style="letter-spacing:0.7pt;"> </font>Financial<font style="letter-spacing:0.8pt;"> </font>Statements</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>independent<font style="letter-spacing:1pt;"> </font>registered<font style="letter-spacing:0.8pt;"> </font>pu<font style="letter-spacing:-0.1pt;">b</font>lic<font style="letter-spacing:0.5pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>firm</a><font style="letter-spacing:-2.1pt;"> </font><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS">Consolidated<font style="letter-spacing:1.05pt;"> </font>Balan<font style="letter-spacing:-0.1pt;">c</font>e<font style="letter-spacing:0.65pt;"> </font>sheets<font style="letter-spacing:0.55pt;"> </font>as<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2016</a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS">Consolidated Statements of operations for the years ended December 31, 2017, 2016 and 2015</a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CHANGES_IN_SHARE">Consolidated Statements of changes in shareholders&#8217; equity for the years ended December 31, 2017, 2016 and 2015</a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of cash flows for the years ended December 31, 2017, 2016 and 2015</a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements</a><font style="text-decoration:none;color:#auto;"></font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%;">
<p style="text-align:right;margin-top:1pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:48.79%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520470937611265.jpg" title="" alt="" style="width:78px;height:59px;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>REPORT<font style="letter-spacing:0.75pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>INDEPENDENT<font style="letter-spacing:1.25pt;"> </font><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>REGISTERED<font style="letter-spacing:1.15pt;"> </font>P<font style="letter-spacing:-0.1pt;">U</font>BLIC<font style="letter-spacing:0.7pt;"> </font>ACCOUNTING<font style="letter-spacing:1.2pt;"> </font>FIRM</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>shareholders<font style="letter-spacing:1.05pt;"> </font>of</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Georgia;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying <font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#FF0000;"> </font>balance sheets of UroGen Pharma Ltd. and its subsidiary as of December 31, 2017 and 2016, and the related consolidated statements of operations, changes in shareholders equity and cash flows for each of the three years in the period ended <font style="color:#000000;">December 31, 2017</font>, including the related notes (collectively referred to as the &#8220;<font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#FF0000;"> </font>financial statements&#8221;).&nbsp;&nbsp;In our opinion, the <font style="color:#000000;">consolidated</font> financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended<font style="color:#FF0000;"> </font><font style="color:#000000;">December 31,</font><font style="font-weight:bold;color:#000000;"> </font><font style="color:#000000;">2017</font><font style="font-weight:bold;color:#FF0000;"> </font>in conformity with <font style="color:#000000;">accounting principles generally accepted</font> in the United States of America.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Georgia;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These <font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#FF0000;"> </font>financial statements are the responsibility of the Company&#8217;s management and board of directors.&nbsp;&nbsp;Our responsibility is to express an opinion on the Company&#8217;s <font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#000000;"> </font>financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits of these <font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#FF0000;"> </font>financial statements in accordance with the standards of the PCAOB.&nbsp;&nbsp;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the <font style="color:#000000;">consolidated</font> financial statements are free of material misstatement, whether due to error or fraud.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the <font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#FF0000;"> </font>financial statements, whether due to error or fraud, and performing procedures that respond to those risks.&nbsp;&nbsp;Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the <font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#FF0000;"> </font>financial statements.&nbsp;&nbsp;Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the <font style="color:#000000;">consolidated</font><font style="font-weight:bold;color:#FF0000;"> </font>financial statements.&nbsp;&nbsp;We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel Aviv, Israel <font style="margin-left:36pt;color:#000000;">/s/Kesselman &amp; Kesselman</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2018<font style="margin-left:36pt;">Certified Public Accountants (Isr.)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40%;text-indent:0%;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A member of PricewaterhouseCoopers International Limited</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company's auditor since 2010.</p>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Kesselman<font style="letter-spacing:0.95pt;"> </font>&amp;<font style="letter-spacing:0.15pt;"> </font>Kesselman,<font style="letter-spacing:1pt;"> </font>Trade<font style="letter-spacing:0.5pt;"> </font>Tower,<font style="letter-spacing:0.6pt;"> </font>25<font style="letter-spacing:0.25pt;"> </font>Hamered<font style="letter-spacing:0.8pt;"> </font>Street,<font style="letter-spacing:0.6pt;"> </font>Tel-Aviv<font style="letter-spacing:0.7pt;"> </font>6812508,<font style="letter-spacing:0.75pt;"> </font>Israel,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">P.O<font style="letter-spacing:0.35pt;"> </font>Box<font style="letter-spacing:0.35pt;"> </font>50005<font style="letter-spacing:0.5pt;"> </font>Tel-Aviv<font style="letter-spacing:0.7pt;"> </font>6150001<font style="letter-spacing:0.7pt;"> </font>Telephone:<font style="letter-spacing:0.95pt;"> </font>+972-3-7954555,<font style="letter-spacing:1.35pt;"> </font>Fax:<font style="letter-spacing:0.4pt;"> </font>+972-3-7954<font style="letter-spacing:-0.1pt;">5</font>56,<font style="letter-spacing:1.4pt;"> </font>www.pwc.com/il</p>
<p style="margin-top:0pt;line-height:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU117"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMA</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LTD.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font><a name="CONSOLIDATED_BALANCE_SHEETS"></a>BALANCE<font style="letter-spacing:0.9pt;"> </font>SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.35pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT ASSETS:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,999</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted deposit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">198</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inventory</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">958</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,472</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,041</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NON-CURRENT ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted deposit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL ASSETS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,056</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Shareholder's equity</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT LIABILITIES:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,435</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee related accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">687</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of warrants for preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,035</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,137</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NON-CURRENT LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants for preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMITMENTS AND CONTINGENCIES (Note 6)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LIABILITIES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,035</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,749</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SHAREHOLDERS&#8217; EQUITY:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares, NIS 0.01 par value; 100,000,000 and 17,600,000 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorized at December 31, 2017 and 2016, respectively; 13,751,390 and 2,305,743 shares issued and outstanding as of December 31, 2017 and 2016, respectively</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A and A-1 preferred shares, NIS 0.01 par value: 0 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 14,400,000 shares authorized at December 31, 2017 and 2016, respectively; 0 and 5,193,427 shares issued and outstanding at December 31, 2017 and 2016, respectively</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,502</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,214</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,214</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL SHAREHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,515</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,307</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,550</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,056</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU118"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMA</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LTD.</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font><a name="CONSOLIDATED_STATEMENTS_OPERATIONS"></a>STATEMENTS<font style="letter-spacing:1.2pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.5pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>ata)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653241"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REVENUES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,530</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COST OF REVENUES</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GROSS PROFIT</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,558</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,502</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OPERATING EXPENSES:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RESEARCH AND DEVELOPMENT EXPENSES, NET</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,697</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,287</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,515</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GENERAL AND ADMINISTRATIVE EXPENSES</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,811</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,895</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OPERATING (LOSS) INCOME</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,950</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,410</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FINANCE EXPENSES, NET</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,739</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LOSS BEFORE INCOME TAXES</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INCOME TAX EXPENSE</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NET LOSS</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LOSS PER ORDINARY SHARE BASIC AND DILUTED</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,716,790</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300,959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>accompanying<font style="letter-spacing:1.15pt;"> </font>notes<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>integral<font style="letter-spacing:0.6pt;"> </font><font style="letter-spacing:-0.1pt;">p</font>art<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMA</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LTD.</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CHANGES_IN_SHARE"></a>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>STATEMENTS<font style="letter-spacing:1.2pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font><a name="CONSOLIDATED_STATEMENTS_CHANGES_IN_SHARE"></a>CHANGES<font style="letter-spacing:0.9pt;"> </font>IN<font style="letter-spacing:0.2pt;"> </font>SHAR<font style="letter-spacing:-0.1pt;">E</font>HOLDERS<font style="letter-spacing:1.5pt;"> </font>EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ordinary Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preferred Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">paid-in capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amounts</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE AS OF JANUARY 1, 2015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300,959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">867,103</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,739</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,584</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,163</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CHANGES DURING 2015:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of preferred shares, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,635,124</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,246</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,255</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of IP R&amp;D in consideration for Preferred A Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">691,200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,101</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,103</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE AS OF JANUARY 1, 2016</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300,959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,193,427</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,535</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,273</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,281</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CHANGES DURING 2016:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options into ordinary shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,967</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,967</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE AS OF JANUARY 1, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,743</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,193,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,502</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,214</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,307</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CHANGES DURING 2017:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of options into ordinary shares, net of 68,416 shares withheld to pay option price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">743,806</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">402</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants into preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364,036</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,731</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,732</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of preferred shares into ordinary shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,557,463</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,557,463</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IPO, net of issuance expense and underwriters discounts of $6,105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,144,378</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,772</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE AS OF DECEMBER&#160;31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,751,390</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,692</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,214</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,515</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>accompanying<font style="letter-spacing:1.15pt;"> </font>notes<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>integral<font style="letter-spacing:0.6pt;"> </font><font style="letter-spacing:-0.1pt;">p</font>art<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(*)<font style="letter-spacing:0.25pt;"> </font>Represents<font style="letter-spacing:0.9pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>less<font style="letter-spacing:0.35pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>thousand</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU119"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMA</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LTD.</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>STATEMENTS<font style="letter-spacing:1.2pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>CASH<font style="letter-spacing:0.55pt;"> </font>FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.5pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments required to reconcile net loss to net cash (used in) provided by operating activities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">213</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In process R&amp;D</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,103</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Share based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,300</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,967</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exchange rates differences</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value adjustment of warrants for preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating asset and liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in inventory</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(211</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Decrease (increase) in accounts receivable</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Increase) decrease in prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(562</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(737</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in accounts payable and accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,534</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">481</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,155</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in deferred revenues</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase in employee related accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,263</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,571</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,189</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,175</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,001</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in restricted deposit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(271</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(695</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(301</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,377</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(793</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(301</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of options into ordinary shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of warrants for preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">382</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of deferred equity offering cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(579</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of ordinary shares, net of issuance expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,841</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of preferred shares from 2014 Share Purchase Agreement net of issuance cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,581</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance cost for secondary offering</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,585</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,581</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INCREASE IN CASH AND CASH EQUIVALENTS</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,637</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,387</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,105</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,362</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,975</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,870</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE YEAR</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,999</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,362</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,975</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of IP R&amp;D in consideration for Preferred A Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,103</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non cash issuance cost</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants to preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,732</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>accompanying<font style="letter-spacing:1.15pt;"> </font>notes<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>integral<font style="letter-spacing:0.6pt;"> </font><font style="letter-spacing:-0.1pt;">p</font>art<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU120"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PHARMA</font><font style="letter-spacing:0.8pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LTD.</font></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>1&#8212;NATURE<font style="letter-spacing:1pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>OPERATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<font style="letter-spacing:0.65pt;"> </font>Pharma<font style="letter-spacing:0.65pt;"> </font>Ltd.<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>company<font style="letter-spacing:0.75pt;"> </font>incorporated<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>April<font style="letter-spacing:0.4pt;"> </font>20<font style="letter-spacing:-0.1pt;">0</font>4<font style="letter-spacing:0.45pt;"> </font>(&#8220;UPL&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<font style="letter-spacing:0.65pt;"> </font>Pharma<font style="letter-spacing:0.65pt;"> </font>Inc.,<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>subsidiary<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>UPL,<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>incorporated<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>Del<font style="letter-spacing:-0.1pt;">a</font>ware<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>October<font style="letter-spacing:0.65pt;"> </font>2015<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>began<font style="letter-spacing:0.5pt;"> </font>operati<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>February<font style="letter-spacing:0.75pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>(&#8220;UPI&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>UPI<font style="letter-spacing:0.35pt;"> </font>(together<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>&#8220;Company&#8221;)<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>clinical<font style="letter-spacing:0.55pt;"> </font>stage<font style="letter-spacing:0.45pt;"> </font>bi<font style="letter-spacing:-0.1pt;">o</font>pharmaceutical<font style="letter-spacing:1.45pt;"> </font>company<font style="letter-spacing:0.75pt;"> </font>focused<font style="letter-spacing:0.65pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>oping<font style="letter-spacing:0.85pt;"> </font>novel<font style="letter-spacing:0.45pt;"> </font>therapies<font style="letter-spacing:0.75pt;"> </font>desi<font style="letter-spacing:-0.1pt;">g</font>ned<font style="letter-spacing:0.75pt;"> </font>to change<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>standard<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>care<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>urological<font style="letter-spacing:0.8pt;"> </font>pathologies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2015 the Company entered into an agreement with Allergen Pharmaceuticals International Limited (&#8220;Allergen&#8221;), a wholly owned subsidiary of Allergan plc, pursuant to which the Company undertook to supply its gel product and supporting services to Allergan for consideration of $750, to allow Allergan to conduct certain scientific investigations aimed at testing utility of the Company&#8217;s gel product for the delivery of a certain proprietary product of Allergan. Further, the Company granted Allergan a time limited option to negotiate an exclusive, worldwide right to research, develop, make and have made, use, sell, offer to sell and import the Company&#8217;s product in combination with Allergan&#8217;s product. &#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the agreement from 2015, on October 7, 2016, the Company entered into an exclusive license agreement with Allergan to license worldwide rights to some of its products indicated for use with neurotoxins. As stipulated in the agreement, Allergan paid a non-refundable upfront fee of $17.5 million in accordance with the terms of the license agreement. Allergan shall pay the Company additional milestone payments of up to $207.5 million and tiered royalty payments as a percentage of net sales of the licensed product all as stated in the agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>described<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>Note<font style="letter-spacing:0.4pt;"> </font>8a,<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>April<font style="letter-spacing:0.4pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any&#8217;s<font style="letter-spacing:0.9pt;"> </font>board<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>shareholders<font style="letter-spacing:1.05pt;"> </font>approv<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.75pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>aggregate<font style="letter-spacing:0.8pt;"> </font>3.2-for-1<font style="letter-spacing:0.7pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>split<font style="letter-spacing:0.35pt;"> </font>of the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>ordinary,<font style="letter-spacing:0.7pt;"> </font>Preferred<font style="letter-spacing:0.75pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>Preferred<font style="letter-spacing:0.75pt;"> </font>A-1<font style="letter-spacing:0.3pt;"> </font>shares.<font style="letter-spacing:0.6pt;"> </font>All<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>reflected<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>financial statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>notes<font style="letter-spacing:0.45pt;"> </font>thereto<font style="letter-spacing:0.6pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>adjusted,<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>retroactive<font style="letter-spacing:0.85pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>is,<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>reflect this<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>split.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the Company raised $60.8 million, net of issuance costs and underwriting discounts, in an Initial Public Offering ("IPO") on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) (see Note 8a).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&#8217;s submission of an Investigational New Drug (&#8220;IND&#8221;) application for the Company&#8217;s RTGel in combination with Allergan&#8217;s BOTOX for the treatment of overactive bladder to the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company received the milestone payment in August 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market in consideration for approximately $64 million net of issuance costs. Also, see Note 12.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company&#8217;s product candidates may never achieve commercialization and it will continue to incur losses for the foreseeable future. Therefore, in order to fund the Company&#8217;s research and development expenses, general and administrative expenses and capital expenditures until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>2&#8212;SIGNIFICANT<font style="letter-spacing:1.4pt;"> </font>ACCOUNTING<font style="letter-spacing:1.2pt;"> </font>POLICIES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Basis<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>presentation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>b<font style="letter-spacing:-0.1pt;">e</font>en<font style="letter-spacing:0.45pt;"> </font>prepared<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>account<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.85pt;"> </font>principles<font style="letter-spacing:0.75pt;"> </font>generally<font style="letter-spacing:0.75pt;"> </font>accept<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>United<font style="letter-spacing:0.55pt;"> </font>States<font style="letter-spacing:0.55pt;"> </font>of America<font style="letter-spacing:0.7pt;"> </font>(&#8220;U.S.<font style="letter-spacing:0.55pt;"> </font>GAAP&#8221;).</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU121"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b. Principles of consolidation</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The consolidated financial statements include the financial statements of UPL and its wholly owned subsidiary, UPI. Intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c.<font style="letter-spacing:0.2pt;"> </font>Use<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>estimates<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preparation<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>financial<font style="letter-spacing:0.75pt;"> </font>statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>preparation<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>conformity<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>U.S.<font style="letter-spacing:0.4pt;"> </font>GAAP<font style="letter-spacing:0.5pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>man<font style="letter-spacing:-0.1pt;">a</font>gement<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>make<font style="letter-spacing:0.45pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>affect the<font style="letter-spacing:0.05pt;"> </font>reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>assets<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities,<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>disclosure<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cont<font style="letter-spacing:-0.1pt;">i</font>ngent<font style="letter-spacing:0.85pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>financ<font style="letter-spacing:-0.1pt;">i</font>al<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenues<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>duri<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>Actual<font style="letter-spacing:0.5pt;"> </font>results<font style="letter-spacing:0.55pt;"> </font>may<font style="letter-spacing:0.35pt;"> </font>differ<font style="letter-spacing:0.45pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>estimates.<font style="letter-spacing:0.8pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>applicable<font style="letter-spacing:0.9pt;"> </font>to these<font style="letter-spacing:0.45pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financi<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.65pt;"> </font>statements,<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>most<font style="letter-spacing:0.4pt;"> </font>significant<font style="letter-spacing:0.8pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>relate<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>compensat<font style="letter-spacing:-0.1pt;">i</font>on, the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>timing<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>recognition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d.<font style="letter-spacing:0.2pt;"> </font>Functional<font style="letter-spacing:0.9pt;"> </font>currency</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>U.S.<font style="letter-spacing:0.4pt;"> </font>dollar<font style="letter-spacing:0.45pt;"> </font>(&#8220;Dollar&#8221;)<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>primary<font style="letter-spacing:0.6pt;"> </font>economic<font style="letter-spacing:0.8pt;"> </font>environment<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>subsidiary<font style="letter-spacing:0.8pt;"> </font>are conducted.<font style="letter-spacing:0.9pt;"> </font>Therefore,<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>functional<font style="letter-spacing:0.8pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Dol<font style="letter-spacing:-0.1pt;">l</font>ar.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<font style="letter-spacing:1pt;"> </font>transactions<font style="letter-spacing:0.95pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>currencies<font style="letter-spacing:0.85pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Do<font style="letter-spacing:-0.1pt;">l</font>lar<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>functional<font style="letter-spacing:0.8pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>usi<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exchange<font style="letter-spacing:0.8pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>in effect<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>transaction.<font style="letter-spacing:0.95pt;"> </font>At<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>date,<font style="letter-spacing:0.45pt;"> </font>monetary<font style="letter-spacing:0.75pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liab<font style="letter-spacing:-0.1pt;">i</font>lities<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>denominated<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>currencies<font style="letter-spacing:0.85pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>than the<font style="letter-spacing:0.05pt;"> </font>Dollar<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>official<font style="letter-spacing:0.55pt;"> </font>exch<font style="letter-spacing:-0.1pt;">a</font>nge<font style="letter-spacing:0.8pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>effects<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>foreign<font style="letter-spacing:0.55pt;"> </font>currency<font style="letter-spacing:0.8pt;"> </font>re-measurements<font style="letter-spacing:1.45pt;"> </font>are recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>&#8220;fin<font style="letter-spacing:-0.1pt;">a</font>ncial<font style="letter-spacing:0.75pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>(expenses).&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e.<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.45pt;"> </font>equivalents</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equiv<font style="letter-spacing:-0.1pt;">a</font>lents<font style="letter-spacing:0.9pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>short-term,<font style="letter-spacing:0.85pt;"> </font>highly<font style="letter-spacing:0.5pt;"> </font>liquid<font style="letter-spacing:0.45pt;"> </font>investments,<font style="letter-spacing:1pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>incl<font style="letter-spacing:-0.1pt;">u</font>de<font style="letter-spacing:0.6pt;"> </font>short-term<font style="letter-spacing:0.8pt;"> </font>bank<font style="letter-spacing:0.4pt;"> </font>deposits<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>original maturities<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>three<font style="letter-spacing:0.45pt;"> </font>months<font style="letter-spacing:0.6pt;"> </font>or<font style="letter-spacing:0.25pt;"> </font>less<font style="letter-spacing:0.35pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>withdrawal<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>readily<font style="letter-spacing:0.55pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>to known<font style="letter-spacing:0.55pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">f.&nbsp;&nbsp;Short-term investments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in short-term investments that consist of mutual and bond funds.&nbsp;&nbsp;While these investments are considered highly liquid and available to fund current operations, there is more than an insignificant risk of change in value due to interest rate, quoted price, or penalty on withdrawal and are therefore classified as short-term investments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508805153"></a><a name="jump_exp_1"></a><a name="jump_exp_2"></a><a name="jump_exp_1"></a><a name="jump_exp_2"></a>We classify our short-term investments as available-for-sale in accordance with FASB ASC Topic 320, &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within stockholders&#8217; equity.&nbsp;&nbsp;There was no change in value for the period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="jump_exp_6"></a>Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">g.<font style="letter-spacing:0.2pt;"> </font>Property<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>stated<font style="letter-spacing:0.5pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>cost,<font style="letter-spacing:0.4pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accumulated<font style="letter-spacing:1pt;"> </font>depreciation.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>d<font style="letter-spacing:-0.1pt;">e</font>preciated<font style="letter-spacing:0.95pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>basis<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">s</font>eful<font style="letter-spacing:0.5pt;"> </font>lives.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU122"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rates</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depreciation</font><font style="letter-spacing:1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">follows:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653246"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15-30</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-15</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold<font style="letter-spacing:0.85pt;"> </font>improvements<font style="letter-spacing:1.1pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>amortized<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>strai<font style="letter-spacing:-0.1pt;">g</font>ht-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>shorter<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>term<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>useful life<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">h.<font style="letter-spacing:0.15pt;"> </font>Impairment<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>long-lived<font style="letter-spacing:0.85pt;"> </font>assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>tests<font style="letter-spacing:0.4pt;"> </font>long-lived<font style="letter-spacing:0.8pt;"> </font>assets,<font style="letter-spacing:0.6pt;"> </font>comprised<font style="letter-spacing:0.85pt;"> </font>solely<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment,<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>whenever<font style="letter-spacing:0.8pt;"> </font>ev<font style="letter-spacing:-0.1pt;">e</font>nts<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>circumstances<font style="letter-spacing:1.15pt;"> </font>present an<font style="letter-spacing:0.25pt;"> </font>indication<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>impairment.<font style="letter-spacing:0.95pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sum<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>undiscounted<font style="letter-spacing:1.05pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>less<font style="letter-spacing:0.35pt;"> </font>th<font style="letter-spacing:-0.1pt;">a</font>n<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>carrying<font style="letter-spacing:0.65pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>such assets, an<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>recognized.<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:-0.1pt;">s</font>ets<font style="letter-spacing:0.55pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>written<font style="letter-spacing:0.55pt;"> </font>down<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>values,<font style="letter-spacing:0.6pt;"> </font>calculated<font style="letter-spacing:0.8pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>ased<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the present<font style="letter-spacing:0.6pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>discounted<font style="letter-spacing:0.85pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>some<font style="letter-spacing:0.45pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>e<font style="letter-spacing:0.45pt;"> </font>measure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017 and<font style="letter-spacing:0.35pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>d<font style="letter-spacing:-0.1pt;">i</font>d<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>long-lived<font style="letter-spacing:0.8pt;"> </font>assets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i.<font style="letter-spacing:0.2pt;"> </font>Financial<font style="letter-spacing:0.8pt;"> </font>instruments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issues<font style="letter-spacing:0.55pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>A<font style="letter-spacing:-0.1pt;">S</font>C<font style="letter-spacing:0.4pt;"> </font>480<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine<font style="letter-spacing:0.8pt;"> </font>whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>should be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liability.<font style="letter-spacing:0.6pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company further<font style="letter-spacing:0.55pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument&#8217;s<font style="letter-spacing:0.95pt;"> </font>characteristics<font style="letter-spacing:1.15pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine<font style="letter-spacing:0.8pt;"> </font>whether<font style="letter-spacing:0.65pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>c<font style="letter-spacing:-0.1pt;">l</font>assified<font style="letter-spacing:0.75pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>temporary<font style="letter-spacing:0.8pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>(mezzanine)<font style="letter-spacing:1pt;"> </font>or within<font style="letter-spacing:0.5pt;"> </font>permanent<font style="letter-spacing:0.85pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ith<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.55pt;"> </font>480-10-S99.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issues<font style="letter-spacing:0.55pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>freestanding<font style="letter-spacing:1pt;"> </font>instruments,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>first<font style="letter-spacing:0.3pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>l<font style="letter-spacing:-0.1pt;">i</font>ability,<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>subsequent<font style="letter-spacing:0.95pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>va<font style="letter-spacing:-0.1pt;">l</font>ue<font style="letter-spacing:0.45pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>earnings<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>ea<font style="letter-spacing:-0.1pt;">c</font>h<font style="letter-spacing:0.4pt;"> </font>period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>further<font style="letter-spacing:0.55pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>815-40<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.3pt;"> </font>determine whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>wit<font style="letter-spacing:-0.1pt;">h</font>in<font style="letter-spacing:0.5pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>rather<font style="letter-spacing:0.5pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>liability,<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>subse<font style="letter-spacing:-0.1pt;">q</font>uent<font style="letter-spacing:0.95pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value recognized<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>earnings<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>ea<font style="letter-spacing:-0.1pt;">c</font>h<font style="letter-spacing:0.4pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>See<font style="letter-spacing:0.35pt;"> </font>note<font style="letter-spacing:0.4pt;"> </font>7<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>note<font style="letter-spacing:0.4pt;"> </font>8.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j.<font style="letter-spacing:0.15pt;"> </font>Share-based<font style="letter-spacing:1.05pt;"> </font>compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>employees&#8217;<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors&#8217;<font style="letter-spacing:0.75pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>payment<font style="letter-spacing:0.7pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>classif<font style="letter-spacing:-0.1pt;">i</font>ed<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant-date<font style="letter-spacing:0.8pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value method.<font style="letter-spacing:0.65pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>payment<font style="letter-spacing:0.7pt;"> </font>transactions<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recogni<font style="letter-spacing:-0.1pt;">z</font>ed<font style="letter-spacing:0.9pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>expense<font style="letter-spacing:0.7pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requisite<font style="letter-spacing:0.7pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>of December<font style="letter-spacing:0.65pt;"> </font>31,<font style="letter-spacing:0.1pt;"> </font>2016,<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>Company<font style="letter-spacing:0.6pt;"> </font>has<font style="letter-spacing:0.15pt;"> </font>early<font style="letter-spacing:0.25pt;"> </font>ad<font style="letter-spacing:-0.1pt;">o</font>pted<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>policy<font style="letter-spacing:0.3pt;"> </font>to account<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>forfeitures<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.2pt;"> </font>occur<font style="letter-spacing:0.25pt;"> </font>according<font style="letter-spacing:0.6pt;"> </font>to the<font style="letter-spacing:0.1pt;"> </font>FASB&#8217;s<font style="letter-spacing:0.4pt;"> </font>Accounting Standards<font style="letter-spacing:0.65pt;"> </font>Update<font style="letter-spacing:0.5pt;"> </font>(ASU)<font style="letter-spacing:0.3pt;"> </font>2016-09,<font style="letter-spacing:0.65pt;"> </font>Improvements<font style="letter-spacing:0.95pt;"> </font>to Employee<font style="letter-spacing:0.65pt;"> </font>Share-Based<font style="letter-spacing:0.85pt;"> </font>Payment<font style="letter-spacing:0.55pt;"> </font>Accounting.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:-0.1pt;">d</font>justment<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>beginning<font style="letter-spacing:0.6pt;"> </font>of the period<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>material<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>reflected<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>conso<font style="letter-spacing:-0.1pt;">l</font>idated<font style="letter-spacing:1pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>shareholders&#8217;<font style="letter-spacing:1.05pt;"> </font>e<font style="letter-spacing:-0.1pt;">q</font>uity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>elected<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>compen<font style="letter-spacing:-0.1pt;">s</font>ation<font style="letter-spacing:1.1pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>conditioned<font style="letter-spacing:0.9pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>conti<font style="letter-spacing:-0.1pt;">n</font>ued<font style="letter-spacing:0.8pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>graded<font style="letter-spacing:0.6pt;"> </font>vesting<font style="letter-spacing:0.6pt;"> </font>schedule<font style="letter-spacing:0.05pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sin<font style="letter-spacing:-0.1pt;">g</font>le-option<font style="letter-spacing:1pt;"> </font>award<font style="letter-spacing:0.5pt;"> </font>approach.<font style="letter-spacing:0.8pt;"> </font>Performance<font style="letter-spacing:1pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>wards<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>expensed<font style="letter-spacing:0.05pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requisite<font style="letter-spacing:0.7pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>hen<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>achievement<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>criteria<font style="letter-spacing:0.55pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>probable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>non-employees<font style="letter-spacing:1.3pt;"> </font>are<font style="letter-spacing:0.35pt;"> </font>re-measured<font style="letter-spacing:1.1pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>commitment<font style="letter-spacing:0.95pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>reached which<font style="letter-spacing:0.5pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>usually<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>completed.<font style="letter-spacing:0.9pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>va<font style="letter-spacing:-0.1pt;">l</font>ue<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>charged<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>service period<font style="letter-spacing:0.5pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU123"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">k.</font><font style="letter-spacing:0.15pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue</font><font style="letter-spacing:0.75pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">recognition</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Virtually<font style="letter-spacing:0.65pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>revenues<font style="letter-spacing:0.75pt;"> </font>are<font style="letter-spacing:0.25pt;"> </font>derived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>Allergan,<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>lic<font style="letter-spacing:-0.1pt;">e</font>nse<font style="letter-spacing:0.6pt;"> </font>worldwide<font style="letter-spacing:0.8pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>some<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>products. See also Note 1. Revenue<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>hen<font style="letter-spacing:0.45pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>conditi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.8pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>met:<font style="letter-spacing:0.4pt;"> </font>(i)<font style="letter-spacing:0.2pt;"> </font>there<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>persuasive<font style="letter-spacing:0.85pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>arrangement; (ii)<font style="letter-spacing:0.25pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>occurred:<font style="letter-spacing:0.75pt;"> </font>(iii)<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable:<font style="letter-spacing:1.1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(iv)<font style="letter-spacing:0.3pt;"> </font>collectab<font style="letter-spacing:-0.1pt;">i</font>lity<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonably<font style="letter-spacing:0.9pt;"> </font>assured.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:1pt;"> </font>contains<font style="letter-spacing:0.7pt;"> </font>two<font style="letter-spacing:0.3pt;"> </font>deliverables:<font style="letter-spacing:1pt;"> </font>(a)<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>comp<font style="letter-spacing:-0.1pt;">o</font>nent<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(b)<font style="letter-spacing:0.25pt;"> </font>Allergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>require<font style="letter-spacing:0.6pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>RTGel<font style="letter-spacing:0.55pt;"> </font>vi<font style="letter-spacing:-0.1pt;">a</font>ls from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.3pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>multiple<font style="letter-spacing:0.65pt;"> </font>deliverab<font style="letter-spacing:-0.1pt;">l</font>es,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>shall<font style="letter-spacing:0.4pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>u<font style="letter-spacing:-0.1pt;">n</font>it<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the following<font style="letter-spacing:0.7pt;"> </font>criteria<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>met:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="letter-spacing:0.25pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>customer<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>is.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>sold<font style="letter-spacing:0.05pt;"> </font>separately<font style="letter-spacing:0.85pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>vendor<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>customer<font style="letter-spacing:0.75pt;"> </font>could<font style="letter-spacing:0.45pt;"> </font>resell<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s)<font style="letter-spacing:0.55pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standal<font style="letter-spacing:-0.1pt;">o</font>ne<font style="letter-spacing:0.9pt;"> </font>basis.<font style="letter-spacing:0.5pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>context<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>customer&#8217;s<font style="letter-spacing:0.85pt;"> </font>ability<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>resell<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s),<font style="letter-spacing:0.6pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>criterion<font style="letter-spacing:0.65pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>require<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>existence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>ob<font style="letter-spacing:-0.1pt;">s</font>ervable<font style="letter-spacing:0.9pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>deliverable(s),<font style="letter-spacing:1.1pt;"> </font>and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="letter-spacing:0.25pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>includes<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>general<font style="letter-spacing:0.6pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>return<font style="letter-spacing:0.5pt;"> </font>relative<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s),<font style="letter-spacing:0.6pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>unde<font style="letter-spacing:-0.1pt;">l</font>ivered<font style="letter-spacing:1.1pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or items<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>probable<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>subst<font style="letter-spacing:-0.1pt;">a</font>ntially<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>control<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>vendor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>deliverables<font style="letter-spacing:0.95pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>separab<font style="letter-spacing:-0.1pt;">l</font>e,<font style="letter-spacing:0.85pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>allocated<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>units<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>relati<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.6pt;"> </font>selling<font style="letter-spacing:0.55pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>deliverable<font style="letter-spacing:0.85pt;"> </font>(where<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>locable<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>element<font style="letter-spacing:0.65pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>limited<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amo<font style="letter-spacing:-0.1pt;">u</font>nt<font style="letter-spacing:0.6pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>contingent<font style="letter-spacing:0.85pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>future products<font style="letter-spacing:0.7pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>services)<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>appropriate<font style="letter-spacing:0.9pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>recognition<font style="letter-spacing:0.9pt;"> </font>princip<font style="letter-spacing:-0.1pt;">l</font>es<font style="letter-spacing:0.75pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>applied<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>unit. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>component<font style="letter-spacing:0.9pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>standa<font style="letter-spacing:-0.1pt;">l</font>one<font style="letter-spacing:0.9pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>(and<font style="letter-spacing:0.4pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>accounted<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>separately<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services)<font style="letter-spacing:0.75pt;"> </font>since<font style="letter-spacing:0.5pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>can<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>the license<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intended<font style="letter-spacing:0.7pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>without<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any&#8217;s<font style="letter-spacing:0.9pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services.<font style="letter-spacing:0.7pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>four<font style="letter-spacing:0.35pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>605<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ere<font style="letter-spacing:0.4pt;"> </font>met<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> 2017 and </font>2016: (1)<font style="letter-spacing:0.25pt;"> </font>persuasive<font style="letter-spacing:0.85pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>exists<font style="letter-spacing:0.5pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.45pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>engaged<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>inding<font style="letter-spacing:0.6pt;"> </font>agreement;<font style="letter-spacing:0.9pt;"> </font>(2)<font style="letter-spacing:0.25pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>has occurred<font style="letter-spacing:0.7pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>rendered<font style="letter-spacing:0.75pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>l<font style="letter-spacing:0.2pt;"> </font>documents<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>request<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.8pt;"> </font>relating<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>know-how<font style="letter-spacing:0.8pt;"> </font>were provided<font style="letter-spacing:0.7pt;"> </font>before<font style="letter-spacing:0.55pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.3pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>can<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intend<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.7pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>without<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>(except<font style="letter-spacing:0.6pt;"> </font>for immaterial<font style="letter-spacing:0.85pt;"> </font>support<font style="letter-spacing:0.6pt;"> </font>services);<font style="letter-spacing:0.8pt;"> </font>(3)<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable,<font style="letter-spacing:1.1pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>indicated<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>licen<font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:0.6pt;"> </font>agreement;<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(4)<font style="letter-spacing:0.25pt;"> </font>collectability<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonably assured.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>milestone<font style="letter-spacing:0.8pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>royalties<font style="letter-spacing:0.7pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>Allergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>reve<font style="letter-spacing:-0.1pt;">n</font>ue<font style="letter-spacing:0.65pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>product,<font style="letter-spacing:0.65pt;"> </font>which are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable<font style="letter-spacing:1.05pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>th<font style="letter-spacing:-0.1pt;">e</font>ir<font style="letter-spacing:0.4pt;"> </font>occurrence.<font style="letter-spacing:0.95pt;"> </font>Therefore,<font style="letter-spacing:0.85pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>recogniz<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.9pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>for payment<font style="letter-spacing:0.7pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>met,<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>become<font style="letter-spacing:0.65pt;"> </font>due<font style="letter-spacing:0.35pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>payable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During October<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>n<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$17.5<font style="letter-spacing:0.45pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>represented<font style="letter-spacing:0.85pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>consi<font style="letter-spacing:-0.1pt;">d</font>eration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>both the<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intellectual<font style="letter-spacing:0.85pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>well<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font><font style="letter-spacing:-0.1pt;">A</font>llergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>(which<font style="letter-spacing:0.55pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>e<font style="letter-spacing:0.25pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>future payments<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>according<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>pricing<font style="letter-spacing:0.55pt;"> </font>stipulat<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>agreement).<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.85pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>pricing<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the supply<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>represents<font style="letter-spacing:0.85pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>se<font style="letter-spacing:-0.1pt;">l</font>ling<font style="letter-spacing:0.55pt;"> </font>price.<font style="letter-spacing:0.45pt;"> </font>Accordingly,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>allo<font style="letter-spacing:-0.1pt;">c</font>ated<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>entire<font style="letter-spacing:0.45pt;"> </font>upfront<font style="letter-spacing:0.6pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>of $17.5<font style="letter-spacing:0.45pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the license<font style="letter-spacing:0.6pt;"> </font>component.<font style="letter-spacing:0.95pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>addition,<font style="letter-spacing:0.7pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>servi<font style="letter-spacing:-0.1pt;">c</font>es<font style="letter-spacing:0.65pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.3pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>equal<font style="letter-spacing:0.45pt;"> to </font>the<font style="letter-spacing:0.3pt;"> </font>consi<font style="letter-spacing:-0.1pt;">d</font>eration<font style="letter-spacing:1.05pt;"> </font>stipulated<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the agreement<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>services,<font style="letter-spacing:0.7pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>provided.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&#8217;s submission of an IND application for the Company&#8217;s RTGel in combination with Allergan&#8217;s BOTOX for the treatment of overactive bladder to the U.S. FDA. The Company received the milestone payment in August 2017. This milestone was recognized as revenue during the year ended December 31, 2017, as conditions for payment were met and the milestone payment was considered fixed or determinable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">l.<font style="letter-spacing:0.2pt;"> </font>Research<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1.1pt;"> </font>costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU124"></a>Research<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>expen<font style="letter-spacing:-0.1pt;">s</font>ed<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>incurred<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>consist<font style="letter-spacing:0.6pt;"> </font>primarily<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>cost<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>salaries,<font style="letter-spacing:0.7pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>compensat<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:1.1pt;"> </font>expenses,<font style="letter-spacing:0.05pt;"> </font>payroll<font style="letter-spacing:0.55pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>employee<font style="letter-spacing:0.8pt;"> </font>benefits,<font style="letter-spacing:0.7pt;"> </font>subcontractors<font style="letter-spacing:1.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>materials<font style="letter-spacing:0.75pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>evelopment<font style="letter-spacing:1pt;"> </font>activities, including preclinical studies, clinical trials, manufacturing costs<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>professional<font style="letter-spacing:0.05pt;"> </font>services. The<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>performed<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>others<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>connection<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>nd<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>activities of an<font style="letter-spacing:0.05pt;"> </font>entity,<font style="letter-spacing:0.3pt;"> </font>including<font style="letter-spacing:0.55pt;"> </font>research<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.15pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment<font style="letter-spacing:0.85pt;"> </font>conducted<font style="letter-spacing:0.65pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>others<font style="letter-spacing:0.35pt;"> </font>on </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">behalf</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</font><font style="letter-spacing:0.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entity,</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inc</font><font style="letter-spacing:-0.1pt;">l</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uded</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in research</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs.</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grants</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Innovation</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authority,</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f/k/a</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Office</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientist</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel&#8217;s</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ministry</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Industry,</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trade</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Labor</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(the</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;IIA&#8221;)</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognized</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">when</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grant</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">becomes</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">receiva</font><font style="letter-spacing:-0.1pt;">b</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">le,</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assurance</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Com</font><font style="letter-spacing:-0.1pt;">p</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditions</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attached</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grant</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reaso</font><font style="letter-spacing:-0.1pt;">n</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assurance</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grant</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received.</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grant</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deducted</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</font><font style="letter-spacing:1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="letter-spacing:-0.1pt;">a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pplicable</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incurred.</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016,</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompany</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had</font><font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$175</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</font><font style="letter-spacing:1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decis</font><font style="letter-spacing:-0.1pt;">i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financing</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunities.</font><font style="letter-spacing:1.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended</font><font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">D</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ecember</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$126</font><font style="font-size:12pt;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was received from Allergan, in connection with the pre-clinical collaboration agreement signed in August 2015 and deducted from the research and development expenses. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>intangibles<font style="letter-spacing:0.85pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>purchased<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>others<font style="letter-spacing:0.5pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>particular<font style="letter-spacing:0.75pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment<font style="letter-spacing:1pt;"> </font>project<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>alternative<font style="letter-spacing:0.85pt;"> </font>future uses<font style="letter-spacing:0.4pt;"> </font>(in<font style="letter-spacing:0.25pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>research<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>projects<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>otherwise)<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>s<font style="letter-spacing:-0.1pt;">e</font>parate<font style="letter-spacing:0.7pt;"> </font>economic<font style="letter-spacing:0.8pt;"> </font>values<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment costs<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>time<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>incurred. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">m.<font style="letter-spacing:0.15pt;"> </font>Income tax</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">1)<font style="letter-spacing:0.2pt;"> </font>Deferred<font style="letter-spacing:0.7pt;"> </font>taxes</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred<font style="letter-spacing:0.6pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabi<font style="letter-spacing:-0.1pt;">l</font>ity<font style="letter-spacing:0.65pt;"> </font>method.<font style="letter-spacing:0.65pt;"> </font>Under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>method,<font style="letter-spacing:0.65pt;"> </font>deferred<font style="letter-spacing:0.7pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and liabilities<font style="letter-spacing:0.7pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>bas<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>differences<font style="letter-spacing:0.9pt;"> </font>between<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>reporti<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>tax bases<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>mea<font style="letter-spacing:-0.1pt;">s</font>ured<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>enacted<font style="letter-spacing:0.65pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>laws.<font style="letter-spacing:0.45pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>llowance<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the extent<font style="letter-spacing:0.5pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>deferred<font style="letter-spacing:0.7pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>realized<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>foresee<font style="letter-spacing:-0.1pt;">a</font>ble<font style="letter-spacing:0.95pt;"> </font>future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2)<font style="letter-spacing:0.2pt;"> </font>Uncertain<font style="letter-spacing:0.8pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>positions</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>follows<font style="letter-spacing:0.55pt;"> </font>a<font style="letter-spacing:0.3pt;"> </font>two-step<font style="letter-spacing:0.8pt;"> </font>approach<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>recognizing<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>measuring<font style="letter-spacing:0.85pt;"> </font>uncertain<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>positions.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>first<font style="letter-spacing:0.3pt;"> </font>step<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>evaluate<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>position for<font style="letter-spacing:0.25pt;"> </font>recognition<font style="letter-spacing:0.9pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>determining<font style="letter-spacing:0.95pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>availab<font style="letter-spacing:-0.1pt;">l</font>e<font style="letter-spacing:0.7pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>indicates<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>position<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ill<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>sustained<font style="letter-spacing:0.8pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on technical<font style="letter-spacing:0.7pt;"> </font>merits.<font style="letter-spacing:0.55pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>threshold<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>met,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>second<font style="letter-spacing:0.6pt;"> </font>step<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>measure<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>benefit<font style="letter-spacing:0.55pt;"> </font>as<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>largest<font style="letter-spacing:0.55pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>of being<font style="letter-spacing:0.45pt;"> </font>realized<font style="letter-spacing:0.65pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>ultim<font style="letter-spacing:0.1pt;">a</font>te<font style="letter-spacing:0.65pt;"> </font>settlement. As of December 31, 2017 and 2016, the Company had not accrued a provision for uncertain tax positions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">n.<font style="letter-spacing:0.25pt;"> </font>Loss<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic<font style="letter-spacing:0.45pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>(&#8220;LPS&#8221;)<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>dividing<font style="letter-spacing:0.65pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year,<font style="letter-spacing:0.45pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>reducing<font style="letter-spacing:0.7pt;"> </font>cumulati<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.85pt;"> </font>dividends<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;">, </font>by<font style="letter-spacing:0.25pt;"> </font>the weighted<font style="letter-spacing:0.75pt;"> </font>average<font style="letter-spacing:0.75pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>peri<font style="letter-spacing:-0.1pt;">o</font>d.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>calculation<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>ex<font style="letter-spacing:-0.1pt;">c</font>ludes<font style="letter-spacing:0.7pt;"> </font>potential<font style="letter-spacing:0.7pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>issuances<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordi<font style="letter-spacing:-0.1pt;">n</font>ary<font style="letter-spacing:0.8pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>options, warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>anti-dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o.<font style="letter-spacing:0.2pt;"> </font>Fair<font style="letter-spacing:0.45pt;"> </font>value<font style="letter-spacing:0.5pt;"> </font>measurement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair<font style="letter-spacing:0.35pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>rec<font style="letter-spacing:-0.1pt;">e</font>ived<font style="letter-spacing:0.7pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sale<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>paid<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>transfer<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.3pt;"> </font>orderly transaction<font style="letter-spacing:0.9pt;"> </font>between<font style="letter-spacing:0.7pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>participants<font style="letter-spacing:0.9pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>measurement<font style="letter-spacing:1.1pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>increase<font style="letter-spacing:0.7pt;"> </font>consistency<font style="letter-spacing:0.95pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>comparability<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value measurements,<font style="letter-spacing:1.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>guidance<font style="letter-spacing:0.75pt;"> </font>establishes<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>e<font style="letter-spacing:0.45pt;"> </font>hierarchy<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>prioritizes<font style="letter-spacing:0.8pt;"> </font>observable<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>unob<font style="letter-spacing:-0.1pt;">s</font>ervable<font style="letter-spacing:1.2pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>measure<font style="letter-spacing:0.7pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value into<font style="letter-spacing:0.3pt;"> </font>three<font style="letter-spacing:0.45pt;"> </font>broad<font style="letter-spacing:0.5pt;"> </font>levels,<font style="letter-spacing:0.55pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>described<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>fo<font style="letter-spacing:-0.1pt;">l</font>lows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>1:<font style="letter-spacing:0.2pt;"> </font>Quoted<font style="letter-spacing:0.6pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>(unadjusted)<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>active<font style="letter-spacing:0.5pt;"> </font>markets<font style="letter-spacing:0.65pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>accessible<font style="letter-spacing:0.85pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>measurement<font style="letter-spacing:1.1pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>liabilities.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value hierarchy<font style="letter-spacing:0.75pt;"> </font>gives<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>highest<font style="letter-spacing:0.6pt;"> </font>priority<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Level<font style="letter-spacing:0.45pt;"> </font>1<font style="letter-spacing:0.15pt;"> </font>inputs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>2:<font style="letter-spacing:0.2pt;"> </font>Observable<font style="letter-spacing:1.05pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>quoted<font style="letter-spacing:0.55pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>active<font style="letter-spacing:0.5pt;"> </font>markets but<font style="letter-spacing:0.3pt;"> </font>corroborated<font style="letter-spacing:1pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>3:<font style="letter-spacing:0.2pt;"> </font>Unobservable<font style="letter-spacing:1.1pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>us<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.4pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>little<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>market<font style="letter-spacing:0.65pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>available.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>hierarchy<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">g</font>ives<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>lowest<font style="letter-spacing:0.55pt;"> </font>priority<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Level<font style="letter-spacing:0.45pt;"> </font>3 inputs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>determining<font style="letter-spacing:0.95pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>utilizes<font style="letter-spacing:0.55pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>ation<font style="letter-spacing:0.75pt;"> </font>techniques<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>maximize<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>observable<font style="letter-spacing:0.9pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>minimize<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>of unobservable<font style="letter-spacing:1.05pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>extent<font style="letter-spacing:0.5pt;"> </font>possib<font style="letter-spacing:-0.1pt;">l</font>e<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>counterparty<font style="letter-spacing:1pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>assessment<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU125"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">p.</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration</font><font style="letter-spacing:1.2pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">credit</font><font style="letter-spacing:0.5pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">risks</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial<font style="letter-spacing:0.75pt;"> </font>instruments<font style="letter-spacing:0.95pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>potentially<font style="letter-spacing:0.8pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>concentrati<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>consist<font style="letter-spacing:0.6pt;"> </font>principally<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equiva<font style="letter-spacing:-0.1pt;">l</font>ents and short-term investments.<font style="letter-spacing:0.95pt;"> </font>The Company<font style="letter-spacing:0.8pt;"> </font>deposits<font style="letter-spacing:0.7pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>eq<font style="letter-spacing:-0.1pt;">u</font>ivalents<font style="letter-spacing:0.9pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>highly<font style="letter-spacing:0.5pt;"> </font>rated<font style="letter-spacing:0.45pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nstitutions,<font style="letter-spacing:0.9pt;"> </font>and,<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>matter<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>policy,<font style="letter-spacing:0.55pt;"> </font>limits<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amounts<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit exposure<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>single<font style="letter-spacing:0.5pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nstitution.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>experienced<font style="letter-spacing:1pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>cre<font style="letter-spacing:-0.1pt;">d</font>it<font style="letter-spacing:0.45pt;"> </font>losses<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>belie<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.6pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is exposed<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>significant<font style="letter-spacing:0.8pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>instruments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">q.<font style="letter-spacing:0.2pt;"> </font>Segment<font style="letter-spacing:0.75pt;"> </font>reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating<font style="letter-spacing:0.8pt;"> </font>segments<font style="letter-spacing:0.8pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>reported<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>manner<font style="letter-spacing:0.65pt;"> </font>consistent<font style="letter-spacing:0.8pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>internal<font style="letter-spacing:0.6pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>ch<font style="letter-spacing:-0.1pt;">i</font>ef<font style="letter-spacing:0.4pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>decision-maker,<font style="letter-spacing:1.25pt;"> </font>who<font style="letter-spacing:0.35pt;"> </font>is responsible<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>allocating<font style="letter-spacing:0.75pt;"> </font>resources<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>assessing<font style="letter-spacing:0.8pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>segments.<font style="letter-spacing:0.85pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>o<font style="letter-spacing:-0.1pt;">p</font>erates<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>operating segment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r.<font style="letter-spacing:0.2pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>Costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>SEC<font style="letter-spacing:0.4pt;"> </font>Staff<font style="letter-spacing:0.4pt;"> </font>Accounting<font style="letter-spacing:0.9pt;"> </font>Bulletin<font style="letter-spacing:0.6pt;"> </font>Topic<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">5</font>A.<font style="letter-spacing:0.3pt;"> Costs directly attributable to a proposed or actual offering of securities are deferred and recorded against the gross proceeds of the offering upon completion. </font>During<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.4pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016, the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>$1.7<font style="letter-spacing:0.4pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>g<font style="letter-spacing:-0.1pt;">e</font>neral<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>administrative<font style="letter-spacing:1.1pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">s.<font style="letter-spacing:0.15pt;"> </font>Newly<font style="letter-spacing:0.55pt;"> </font>issued<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>recently<font style="letter-spacing:0.7pt;"> </font>adopted<font style="letter-spacing:0.7pt;"> </font>accounting<font style="letter-spacing:0.95pt;"> </font>pronouncements</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>August<font style="letter-spacing:0.6pt;"> </font>2014,<font style="letter-spacing:0.45pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> Accounting Standards Update (&#8220;</font>ASU&#8221;)<font style="letter-spacing:0.35pt;"> No. </font>2014-15&#8212;Presentation<font style="letter-spacing:1.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Financial<font style="letter-spacing:0.75pt;"> </font>Statements&#8212;Going<font style="letter-spacing:1.55pt;"> </font>Concern<font style="letter-spacing:0.7pt;"> </font>(ASC<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">S</font>ubtopic<font style="letter-spacing:0.75pt;"> </font>205-40):<font style="letter-spacing:0.8pt;"> </font>&#8220;Disclosure of<font style="letter-spacing:0.2pt;"> </font>Uncertainties<font style="letter-spacing:1.05pt;"> </font>about<font style="letter-spacing:0.45pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>Entity&#8217;s<font style="letter-spacing:0.6pt;"> </font>Ability<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Conti<font style="letter-spacing:-0.1pt;">n</font>ue<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>Going<font style="letter-spacing:0.5pt;"> </font>Concern&#8221;.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>update<font style="letter-spacing:0.55pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>managem<font style="letter-spacing:-0.1pt;">e</font>nt<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>assess<font style="letter-spacing:0.6pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>company&#8217;s ability<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>continue<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>going<font style="letter-spacing:0.45pt;"> </font>concern<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>nd<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>provide<font style="letter-spacing:0.6pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>footnote<font style="letter-spacing:0.65pt;"> </font>disclosures<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>certain<font style="letter-spacing:0.55pt;"> </font>circumstances.<font style="letter-spacing:1.2pt;"> </font>All<font style="letter-spacing:0.25pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>new<font style="letter-spacing:0.35pt;"> </font>requirements<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>annu<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.55pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>ending<font style="letter-spacing:0.55pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>per<font style="letter-spacing:-0.1pt;">i</font>ods<font style="letter-spacing:0.6pt;"> </font>thereafter.<font style="letter-spacing:0.8pt;"> </font>The adoption of the guidance did not have a material impact on the Company&#8217;s financial statements.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;, &#8220;ASU 2014-09&#8221;, or &#8220;the New Revenue Standard&#8221;). ASU 2014-09 requires entities to recognize revenue that represents the transfer of promised goods or services to customers in an amount equivalent to the consideration to which the entity expects to be entitled to in exchange for those goods or services. The following steps should be applied to determine this amount: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in ASU 605, &#8220;Revenue Recognition,&#8221; and most industry-specific guidance in the Accounting Standards Codification. The New Revenue Standard is effective for the Company for annual reporting periods, including interim periods therein, beginning January 1, 2018. The New Revenue Standard may be applied retrospectively with the cumulative effect recognized as of the date of adoption (modified retrospective method). The Company will adopt the New Revenue Standard using modified retrospective method. The Company has substantially completed its assessment of the New Revenue Standard and identified two revenue streams (1) licensing revenue and (2) revenue from clinical supply of RTGel per the license agreement with Allergan. The implementation of the New Revenue Standard will not have a material impact on the amount or timing of the Company&#8217;s current revenue recognition related to these revenue streams. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>February<font style="letter-spacing:0.75pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> No. </font>2016-02,<font style="letter-spacing:0.75pt;"> </font>Leases<font style="letter-spacing:0.6pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>842 or &#8220;ASU<font style="letter-spacing:0.5pt;"> </font>2016-02&#8221;).<font style="letter-spacing:0.95pt;"> </font>ASU<font style="letter-spacing:0.4pt;"> </font>2016-02<font style="letter-spacing:0.7pt;"> </font>supersedes<font style="letter-spacing:0.95pt;"> </font>existing<font style="letter-spacing:0.65pt;"> </font>guida<font style="letter-spacing:0.1pt;">n</font>ce<font style="letter-spacing:0.75pt;"> </font>in Leases<font style="letter-spacing:0.6pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>840).<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>revised<font style="letter-spacing:0.6pt;"> </font>standard<font style="letter-spacing:0.7pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>les<font style="letter-spacing:-0.1pt;">s</font>ees<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>ari<font style="letter-spacing:-0.1pt;">s</font>ing<font style="letter-spacing:0.55pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>leases<font style="letter-spacing:0.55pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>terms greater<font style="letter-spacing:0.6pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>twelve<font style="letter-spacing:0.55pt;"> </font>months<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet,<font style="letter-spacing:0.5pt;"> </font>including<font style="letter-spacing:0.7pt;"> </font>tho<font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:0.45pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>leases,<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>disc<font style="letter-spacing:-0.1pt;">l</font>ose<font style="letter-spacing:0.65pt;"> </font>key<font style="letter-spacing:0.3pt;"> </font>information about<font style="letter-spacing:0.45pt;"> </font>leasing<font style="letter-spacing:0.6pt;"> </font>arrangements.<font style="letter-spacing:1.15pt;"> </font>Lessees<font style="letter-spacing:0.7pt;"> </font>w<font style="letter-spacing:-0.1pt;">i</font>ll<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>li<font style="letter-spacing:-0.1pt;">a</font>bility<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.25pt;"> </font>right-of-use<font style="letter-spacing:1.05pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheets,<font style="letter-spacing:0.6pt;"> </font>while lessor<font style="letter-spacing:0.5pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>remain<font style="letter-spacing:0.55pt;"> </font>larg<font style="letter-spacing:-0.1pt;">e</font>ly<font style="letter-spacing:0.55pt;"> </font>unchanged.<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>guidance<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:-0.1pt;">n</font>ual<font style="letter-spacing:0.55pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>beginning<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>Decem<font style="letter-spacing:-0.1pt;">b</font>er<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2018,<font style="letter-spacing:0.45pt;"> </font>with early<font style="letter-spacing:0.4pt;"> </font>adoption<font style="letter-spacing:0.8pt;"> </font>permitted.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>evaluating<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>impact<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>adopt<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASU<font style="letter-spacing:0.5pt;"> </font>2016-02<font style="letter-spacing:0.7pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>consolidated financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>disclosures.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU126"></a>In<font style="letter-spacing:0.2pt;"> </font>August<font style="letter-spacing:0.6pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> No. </font>2016-15,<font style="letter-spacing:0.75pt;"> </font>&#8220;Statement<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows:<font style="letter-spacing:0.55pt;"> </font>Classification<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Certain<font style="letter-spacing:0.6pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Rec<font style="letter-spacing:-0.1pt;">e</font>ipts<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Payments,&#8221; which<font style="letter-spacing:0.5pt;"> </font>addresses<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>presentation<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>(or<font style="letter-spacing:0.25pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>generally<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>escribed<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>such)<font style="letter-spacing:0.45pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>230,<font style="letter-spacing:0.4pt;"> </font>Statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows,<font style="letter-spacing:0.55pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intent<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>reduce<font style="letter-spacing:0.55pt;"> </font>diversity<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>practi<font style="letter-spacing:-0.1pt;">c</font>e.<font style="letter-spacing:0.7pt;"> </font>Among<font style="letter-spacing:0.6pt;"> </font>others,<font style="letter-spacing:0.55pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>ASU addresses<font style="letter-spacing:0.95pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flow<font style="letter-spacing:0.35pt;"> </font>treatment<font style="letter-spacing:0.75pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>debt<font style="letter-spacing:0.4pt;"> </font>prepayment<font style="letter-spacing:0.95pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>debt<font style="letter-spacing:0.4pt;"> </font>extinguishment<font style="letter-spacing:1.2pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>proce<font style="letter-spacing:-0.1pt;">e</font>ds<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>settlement<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>insurance claims.<font style="letter-spacing:0.6pt;"> </font>Entities<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>disclose<font style="letter-spacing:0.65pt;"> </font>how<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reconc</font><font style="letter-spacing:-0.1pt;">i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">les</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">balance</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sheet</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restricted</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shown </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">separately</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cash</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equivalents</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="letter-spacing:-0.1pt;">a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lance</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sheet.</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Entities</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">must</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disclose</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ab</font><font style="letter-spacing:-0.1pt;">o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ut</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nature</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the restrictions.</font><font style="letter-spacing:0.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amendments</font><font style="letter-spacing:1.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">public</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entities</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fiscal</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beg</font><font style="letter-spacing:-0.1pt;">i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nning</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017,</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interim </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periods</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fiscal</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years.</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Early</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adopti</font><font style="letter-spacing:-0.1pt;">o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permitted.</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">retrospective</font><font style="letter-spacing:1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adoption</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required.</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes the</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adoption</font><font style="letter-spacing:0.7pt;"> of the guidance will be immaterial to its financial statements</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>November<font style="letter-spacing:0.85pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> </font>No.<font style="letter-spacing:0.3pt;"> </font>2016-18,<font style="letter-spacing:0.8pt;"> </font>&#8220;Statement<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows<font style="letter-spacing:0.5pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>230):<font style="letter-spacing:0.45pt;"> </font>Restricted<font style="letter-spacing:0.8pt;"> </font>Cash&#8221;<font style="letter-spacing:0.5pt;"> </font>(&#8220;ASU<font style="letter-spacing:0.5pt;"> </font>2016-18&#8221;).<font style="letter-spacing:0.95pt;"> </font>ASU 2016-18<font style="letter-spacing:0.7pt;"> </font>amends<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>classification<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>presentati<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash flows.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.45pt;"> </font>ASU<font style="letter-spacing:0.4pt;"> </font>2016-18<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>public<font style="letter-spacing:0.5pt;"> </font>business<font style="letter-spacing:0.7pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>begin<font style="letter-spacing:-0.1pt;">n</font>ing<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>periods within<font style="letter-spacing:0.5pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years.<font style="letter-spacing:0.5pt;"> </font>Early<font style="letter-spacing:0.45pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>permitted,<font style="letter-spacing:0.8pt;"> </font>inclu<font style="letter-spacing:-0.1pt;">d</font>ing<font style="letter-spacing:0.7pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>period. The<font style="letter-spacing:0.05pt;"> Company believes</font><font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> of the guidance </font>will be immaterial to its<font style="letter-spacing:0.7pt;"> financial statements</font>.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.55pt;"> </font>3&#8212;PROPERTY<font style="letter-spacing:1.25pt;"> </font>AND<font style="letter-spacing:0.4pt;"> </font>EQUIPMENT</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653247"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DECEMBER&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Manufacturing equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,382</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,111</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less&#8212;Accumulated depreciation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(370</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Property and equipment, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation<font style="letter-spacing:1pt;"> </font>expense<font style="letter-spacing:0.7pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>$<font style="letter-spacing:-0.1pt;">207</font><font style="letter-spacing:0.45pt;">, </font>$213 and $113<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;">, </font>2016 and 2015<font style="letter-spacing:0.45pt;"> </font>respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>4&#8212;EMPLOYEE<font style="letter-spacing:1.25pt;"> </font>RIGHTS<font style="letter-spacing:0.7pt;"> </font>UPON<font style="letter-spacing:0.55pt;"> </font>RETIREMENT</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>law<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>make<font style="letter-spacing:0.45pt;"> </font>severance<font style="letter-spacing:0.85pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>dismissal<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>employ<font style="letter-spacing:-0.1pt;">e</font>e<font style="letter-spacing:0.8pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>termination<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>employment<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>certain other<font style="letter-spacing:0.45pt;"> </font>circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>operates<font style="letter-spacing:0.7pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>post-employment<font style="letter-spacing:1.35pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>contribution<font style="letter-spacing:0.95pt;"> </font>pl<font style="letter-spacing:-0.1pt;">a</font>ns.<font style="letter-spacing:0.5pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>contribution<font style="letter-spacing:0.95pt;"> </font>plan<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>program<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>benefits<font style="letter-spacing:0.65pt;"> </font>an employee<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>termination<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>employment,<font style="letter-spacing:1pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>re<font style="letter-spacing:-0.1pt;">g</font>ularly<font style="letter-spacing:0.7pt;"> </font>makes<font style="letter-spacing:0.55pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>indepe<font style="letter-spacing:-0.1pt;">n</font>dent<font style="letter-spacing:1pt;"> </font>entity<font style="letter-spacing:0.45pt;"> </font>so<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>legal<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>constructive<font style="letter-spacing:0.95pt;"> </font>obl<font style="letter-spacing:-0.1pt;">i</font>gation<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>additional<font style="letter-spacing:0.8pt;"> </font>contributi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:1pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fund<font style="letter-spacing:0.4pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>hold<font style="letter-spacing:0.35pt;"> </font>sufficient<font style="letter-spacing:0.7pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>all employees<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>benefits<font style="letter-spacing:0.65pt;"> </font>relating<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employee<font style="letter-spacing:0.8pt;"> </font>servi<font style="letter-spacing:-0.1pt;">c</font>e<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>current<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>prior<font style="letter-spacing:0.4pt;"> </font>periods.<font style="letter-spacing:0.65pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fund<font style="letter-spacing:0.4pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.4pt;"> </font>included<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s financial<font style="letter-spacing:0.65pt;"> </font>position.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>operates<font style="letter-spacing:0.7pt;"> </font>pension<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>severance<font style="letter-spacing:0.85pt;"> </font>compensation<font style="letter-spacing:1.1pt;"> </font>plans<font style="letter-spacing:0.45pt;"> </font>sub<font style="letter-spacing:-0.1pt;">j</font>ect<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>14<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israeli<font style="letter-spacing:0.6pt;"> </font>Severance<font style="letter-spacing:0.85pt;"> </font>Pay<font style="letter-spacing:0.35pt;"> </font>Law.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>plans<font style="letter-spacing:0.45pt;"> </font>are funded<font style="letter-spacing:0.55pt;"> </font>through<font style="letter-spacing:0.65pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>insurance<font style="letter-spacing:0.8pt;"> </font>compan<font style="letter-spacing:-0.1pt;">i</font>es<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>pension<font style="letter-spacing:0.65pt;"> </font>funds<font style="letter-spacing:0.45pt;"> </font>administered<font style="letter-spacing:1pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>trustees.<font style="letter-spacing:0.7pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>terms,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>plans<font style="letter-spacing:0.45pt;"> </font>meet<font style="letter-spacing:0.45pt;"> </font>the definition<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>contribution<font style="letter-spacing:0.95pt;"> </font><font style="letter-spacing:-0.1pt;">p</font>lan,<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>above.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>5&#8212;PROCEEDS<font style="letter-spacing:1.25pt;"> </font>FROM<font style="letter-spacing:0.55pt;"> </font>EXERCISE<font style="letter-spacing:0.9pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>WARRANTS<font style="letter-spacing:1.05pt;"> </font>FOR<font style="letter-spacing:0.4pt;"> </font>PRE<font style="letter-spacing:-0.1pt;">F</font>ERRED<font style="letter-spacing:1.1pt;"> A-1 </font>SHARES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s warrants outstanding prior to the IPO were exercisable for Series A-1 preferred shares at an exercise price of $7.81 per share. Prior to the IPO, such warrants were exercisable for 728,312 Preferred A-1 shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017 and 2016, the Company notified holders of these warrants that it was ready to accept an exercise notice that was conditioned on the price per share at which the Company&#8217;s shares would be sold in an anticipated IPO. Prior to the IPO, the Company received a total amount of $952 as consideration for the conditional cash exercise of these warrants. The cash received was recorded among current liabilities as proceeds from exercise of warrants for preferred shares. As of December 31, 2017, following the exercise of the warrants, the cash received was re-classified to additional paid in capital. See also Note 8.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU127"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE</font><font style="letter-spacing:0.5pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6&#8212;COMMITMENT</font><font style="letter-spacing:1.5pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND</font><font style="letter-spacing:0.4pt;"> </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONTINGENCIES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Lease<font style="letter-spacing:0.55pt;"> </font>agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>April<font style="letter-spacing:0.4pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>UPL<font style="letter-spacing:0.8pt;"> </font>signed<font style="letter-spacing:0.55pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:-0.1pt;">d</font>dendum<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>November<font style="letter-spacing:0.85pt;"> </font>2014<font style="letter-spacing:0.45pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>increase<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>s<font style="letter-spacing:-0.1pt;">p</font>ace<font style="letter-spacing:0.5pt;"> </font>rented<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to extend<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>rent<font style="letter-spacing:0.35pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:0.15pt;">lease</font><font style="letter-spacing:0.45pt;"> </font>agr<font style="letter-spacing:-0.1pt;">e</font>ement<font style="letter-spacing:0.85pt;"> is </font>effective<font style="letter-spacing:0.7pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>rent<font style="letter-spacing:0.35pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ending<font style="letter-spacing:0.55pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;">,</font><font style="letter-spacing:0.35pt;"> </font>2016 and 2015,<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>approximately<font style="letter-spacing:1.1pt;"> </font>$276<font style="letter-spacing:0.45pt;">,</font><font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">$</font>218 and $121,<font style="letter-spacing:0.45pt;"> </font>respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPI<font style="letter-spacing:0.35pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>7<font style="letter-spacing:0.15pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>commencing<font style="letter-spacing:1pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>May<font style="letter-spacing:0.35pt;"> </font>1,<font style="letter-spacing:0.2pt;"> </font>2016.<font style="letter-spacing:0.45pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>part<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>UPI<font style="letter-spacing:0.35pt;"> </font>provided the<font style="letter-spacing:0.05pt;"> </font>lessor<font style="letter-spacing:0.5pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>letter<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>renews on an annual basis.<font style="letter-spacing:0.25pt;"> </font><font style="font-size:12pt;">&#160;</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:12pt;">&#160;</font><font style="letter-spacing:0.4pt;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter, UPI entered into a new lease agreement for its New York headquarters. The lease agreement commenced in October 2017 and shall terminate in February 2021. The rent expense<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.3pt;"> </font>a<font style="letter-spacing:-0.1pt;">p</font>proximately<font style="letter-spacing:1.1pt;"> </font>$342 and rent expense for the eight months ended December 31, 2016 was $102.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>minimum<font style="letter-spacing:0.75pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>next<font style="letter-spacing:0.35pt;"> </font>seven<font style="letter-spacing:0.5pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>u<font style="letter-spacing:-0.1pt;">n</font>der<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreements<font style="letter-spacing:0.95pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>$1,115<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year 2018,<font style="letter-spacing:0.45pt;"> </font>$1,054<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2019,<font style="letter-spacing:0.55pt;"> </font>$873 in 2020, $305 in<font style="letter-spacing:0.45pt;"> </font>2021, $192 in<font style="letter-spacing:0.35pt;"> </font>2022,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>$80<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b.<font style="letter-spacing:0.2pt;"> </font>Grants<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israel<font style="letter-spacing:0.5pt;"> </font>Innovation<font style="letter-spacing:0.9pt;"> </font>Authority<font style="letter-spacing:0.8pt;"> </font>(&#8220;IIA&#8221;<font style="letter-spacing:0.1pt;">)</font>,<font style="letter-spacing:0.6pt;"> </font>formerly<font style="letter-spacing:0.75pt;"> </font>known<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Office<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Chief<font style="letter-spacing:0.45pt;"> </font>Scientist<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>State<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA<font style="letter-spacing:0.25pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>fundi<font style="letter-spacing:-0.1pt;">n</font>g.<font style="letter-spacing:0.65pt;"> </font>Up<font style="letter-spacing:0.25pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>2007,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA<font style="letter-spacing:0.35pt;"> </font>participation<font style="letter-spacing:0.95pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>funding<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>part<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Director<font style="letter-spacing:0.65pt;"> </font>General<font style="letter-spacing:0.65pt;"> </font>Directive<font style="letter-spacing:0.7pt;"> </font>8.2<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel<font style="letter-spacing:0.45pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>provi<font style="letter-spacing:-0.1pt;">d</font>ed<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Granot<font style="letter-spacing:0.55pt;"> </font>Ventures.<font style="letter-spacing:0.8pt;"> </font>Since<font style="letter-spacing:0.45pt;"> </font>2008,<font style="letter-spacing:0.45pt;"> </font>the funding<font style="letter-spacing:0.6pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>directly<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>committed<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>royalties<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Government<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>proceeds<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>sales<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>products<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>dev<font style="letter-spacing:-0.1pt;">e</font>lopment of<font style="letter-spacing:0.2pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA<font style="letter-spacing:0.25pt;"> </font>participates<font style="letter-spacing:0.9pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>way<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>grants.<font style="letter-spacing:0.55pt;"> </font>At<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>time<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>were<font style="letter-spacing:0.4pt;"> </font>received,<font style="letter-spacing:0.75pt;"> </font>successful<font style="letter-spacing:0.85pt;"> </font>development<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>projects<font style="letter-spacing:0.65pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not assured.<font style="letter-spacing:0.7pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>case<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>failure<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>project<font style="letter-spacing:0.55pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>partly<font style="letter-spacing:0.45pt;"> </font>financed<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>above,<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>o<font style="letter-spacing:-0.1pt;">b</font>ligated<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>royalties.<font style="letter-spacing:0.85pt;"> </font>Under the<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>funding<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA,<font style="letter-spacing:0.3pt;"> </font>royalties<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>3%-4.5%<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>payable<font style="letter-spacing:0.65pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>sales<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>products<font style="letter-spacing:0.7pt;"> </font>devel<font style="letter-spacing:-0.1pt;">o</font>ped<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>project<font style="letter-spacing:0.55pt;"> </font>so<font style="letter-spacing:0.25pt;"> </font>funded,<font style="letter-spacing:0.6pt;"> </font>up<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>100% of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>(dollar<font style="letter-spacing:0.5pt;"> </font>linked);<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>addition<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>annual<font style="letter-spacing:0.55pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nterest<font style="letter-spacing:0.6pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.35pt;"> </font>12-month<font style="letter-spacing:0.85pt;"> </font>LIBOR. The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>several<font style="letter-spacing:0.6pt;"> </font>conditions,<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:-0.1pt;">c</font>luding<font style="letter-spacing:0.7pt;"> </font>restrictions<font style="letter-spacing:0.85pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intellectual<font style="letter-spacing:0.85pt;"> </font>property.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>maximum<font style="letter-spacing:0.8pt;"> </font>royalty<font style="letter-spacing:0.55pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>payable<font style="letter-spacing:0.65pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">n</font>der<font style="letter-spacing:0.5pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>funding<font style="letter-spacing:0.6pt;"> </font>arrangements<font style="letter-spacing:1.1pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>$2,105<font style="letter-spacing:0.55pt;"> </font>(exclud<font style="letter-spacing:-0.1pt;">i</font>ng interest).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c.<font style="letter-spacing:0.2pt;"> </font>Financing<font style="letter-spacing:0.85pt;"> </font>success<font style="letter-spacing:0.7pt;"> </font>fees</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>agreements<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>third<font style="letter-spacing:0.4pt;"> </font>parties<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>shareholders<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>connect<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>fundraising<font style="letter-spacing:0.9pt;"> </font>efforts.<font style="letter-spacing:0.55pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the services<font style="letter-spacing:0.65pt;"> </font>rendered,<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>undertook<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>third<font style="letter-spacing:0.4pt;"> </font>parties<font style="letter-spacing:0.55pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>shareholders<font style="letter-spacing:1.05pt;"> </font>certain<font style="letter-spacing:0.55pt;"> </font>success<font style="letter-spacing:0.65pt;"> </font>fees<font style="letter-spacing:0.35pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>funds<font style="letter-spacing:0.45pt;"> </font>actually<font style="letter-spacing:0.65pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>by the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.9pt;"> </font>and/or<font style="letter-spacing:0.55pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company,<font style="letter-spacing:0.8pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>agreed<font style="letter-spacing:0.6pt;"> </font>betw<font style="letter-spacing:-0.1pt;">e</font>en<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total<font style="letter-spacing:0.25pt;"> </font>success<font style="letter-spacing:0.45pt;"> </font>fees<font style="letter-spacing:0.2pt;"> </font>to third<font style="letter-spacing:0.2pt;"> </font>parties for the year ended December 31, 2017 were $28 and payable in cash and<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.2pt;"> </font>ended<font style="letter-spacing:0.35pt;"> </font>December<font style="letter-spacing:0.65pt;"> </font>31,<font style="letter-spacing:0.1pt;"> </font>2016<font style="letter-spacing:0.25pt;"> </font>consisted<font style="letter-spacing:0.6pt;"> </font>of 5,726<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.4pt;"> </font>to third<font style="letter-spacing:0.2pt;"> </font>parties<font style="letter-spacing:0.35pt;"> </font>to purchase<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:-0.1pt;">d</font>inary shares<font style="letter-spacing:0.4pt;"> </font>with<font style="letter-spacing:0.2pt;"> </font>a fair<font style="letter-spacing:0.15pt;"> </font>value<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>$9.<font style="letter-spacing:0.15pt;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>7&#8212;FINANCIAL<font style="letter-spacing:1.25pt;"> </font>INSTRUMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Warrants<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.8pt;"> </font>shares</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>2014,<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>part<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>(the &#8220;2014<font style="letter-spacing:0.8pt;"> </font>SPA&#8221;),<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>arrants<font style="letter-spacing:0.7pt;"> </font>(the<font style="letter-spacing:0.5pt;"> </font>&#8220;A-1<font style="letter-spacing:0.4pt;"> </font>warrants&#8221;)<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares.<font style="margin-left:36pt;"></font><font style="font-size:12pt;">&#160;</font><font style="letter-spacing:0.4pt;"> </font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:12pt;">&#160;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU128"></a>The<font style="letter-spacing:0.35pt;"> </font>warrants<font style="letter-spacing:0.8pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>exercisable<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>representing<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>pri<font style="letter-spacing:-0.1pt;">c</font>e.<font style="letter-spacing:0.45pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>event<font style="letter-spacing:0.45pt;"> </font>that the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.6pt;"> </font>were<font style="letter-spacing:0.15pt;"> </font>exercised<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>connection<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>M&amp;A<font style="letter-spacing:0.4pt;"> </font>event,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>holder<font style="letter-spacing:0.5pt;"> </font>could<font style="letter-spacing:0.35pt;"> </font>elect<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>convert<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrant<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrants</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">classified</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liabilities</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accordance</font><font style="letter-spacing:0.95pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASC</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480,</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">freestanding</font><font style="letter-spacing:1pt;"> </font><font style="letter-spacing:-0.1pt;">i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nstruments,</font><font style="letter-spacing:1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercisable</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preferred</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares,</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redeemable</font><font style="letter-spacing:0.95pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="letter-spacing:-0.1pt;">v</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">represent</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Deemed</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liquidation&#8221;</font><font style="letter-spacing:0.95pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">events</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,</font><font style="letter-spacing:1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrants</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">measured</font><font style="letter-spacing:0.8pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fair</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">every</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reporting</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period,</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cha</font><font style="letter-spacing:-0.1pt;">n</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ges</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fair</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognized</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earnings</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">finan</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ce expenses, net.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accor<font style="letter-spacing:-0.1pt;">d</font>ance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Hybrid<font style="letter-spacing:0.55pt;"> </font>Method.<font style="letter-spacing:0.65pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Hybrid Method<font style="letter-spacing:0.65pt;"> </font>combines<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>probabilities<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>scenario<font style="letter-spacing:0.7pt;"> </font>w<font style="letter-spacing:-0.1pt;">h</font>ich<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>20%<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liquidation<font style="letter-spacing:0.8pt;"> </font>e<font style="letter-spacing:-0.1pt;">v</font>ent<font style="letter-spacing:0.45pt;"> </font>scenario<font style="letter-spacing:0.7pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>estimated at<font style="letter-spacing:0.05pt;"> </font>80%.<font style="letter-spacing:0.45pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>mainly<font style="letter-spacing:0.55pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:0.4pt;"> </font>estimation<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the Company&#8217;s<font style="letter-spacing:0.85pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>derived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>DCF<font style="letter-spacing:0.4pt;"> </font>calcu<font style="letter-spacing:-0.1pt;">l</font>ation<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>assumption<font style="letter-spacing:0.9pt;"> </font>relating<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>forecast,<font style="letter-spacing:0.7pt;"> </font>clini<font style="letter-spacing:-0.1pt;">c</font>al<font style="letter-spacing:0.55pt;"> </font>success probabilities,<font style="letter-spacing:1pt;"> </font>relevant<font style="letter-spacing:0.65pt;"> </font>discount<font style="letter-spacing:0.7pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>betw<font style="letter-spacing:-0.1pt;">e</font>en<font style="letter-spacing:0.75pt;"> </font>10.5%-19%<font style="letter-spacing:1.05pt;"> </font>(10.5%<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flow<font style="letter-spacing:0.35pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>derived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>19%<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>erived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.85pt;"> </font>internal<font style="letter-spacing:0.6pt;"> </font>development)<font style="letter-spacing:1.1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expect<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.75pt;"> </font>volatility<font style="letter-spacing:0.65pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>73.93%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the IPO, the Company converted all outstanding warrants into 364,036 Preferred A-1 shares of the Company and subsequently converted all of its preferred shares, including the Preferred A-1 shares, into ordinary shares. See also Note 5 and Note 8.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b.<font style="letter-spacing:0.2pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>financial<font style="letter-spacing:0.75pt;"> </font>instruments<font style="letter-spacing:1pt;"> </font>measured<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>classified<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>Level<font style="letter-spacing:0.5pt;"> </font>3.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>below<font style="letter-spacing:0.5pt;"> </font>sets<font style="letter-spacing:0.35pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>summary<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>Lev<font style="letter-spacing:-0.1pt;">e</font>l<font style="letter-spacing:0.45pt;"> </font>3:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value of warrants for preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrants for preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,780</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>fi<font style="letter-spacing:-0.1pt;">n</font>ancial<font style="letter-spacing:0.65pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.75pt;"> </font>a<font style="letter-spacing:-0.1pt;">p</font>proximate<font style="letter-spacing:1pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>carrying<font style="letter-spacing:0.65pt;"> </font>amounts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>8&#8212;SHARE<font style="letter-spacing:0.9pt;"> </font>CAPITAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Share<font style="letter-spacing:0.5pt;"> </font>capital</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>capit<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued and Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares of NIS 0.01 par value</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,600,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,751,390</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,743</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A and A-1 preferred shares of NIS 0.01 par value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,400,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,193,427</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Terms<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.95pt;"> </font>ordinary<font style="letter-spacing:0.75pt;"> </font>shares<font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each<font style="letter-spacing:0.45pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>vote.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>hol<font style="letter-spacing:-0.1pt;">d</font>ers<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>receive<font style="letter-spacing:0.6pt;"> </font>dividends<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>henever<font style="letter-spacing:0.8pt;"> </font>funds<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>legally available,<font style="letter-spacing:0.75pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>if<font style="letter-spacing:0.3pt;"> </font>declared<font style="letter-spacing:0.7pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Board<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Directors.<font style="letter-spacing:0.8pt;"> </font>Since<font style="letter-spacing:0.45pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>inception,<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Comp<font style="letter-spacing:-0.1pt;">a</font>ny<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>declared<font style="letter-spacing:0.7pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>dividends.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU129"></a>In<font style="letter-spacing:0.2pt;"> </font>October<font style="letter-spacing:0.65pt;"> </font>2015<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>agr<font style="letter-spacing:-0.1pt;">e</font>ement<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>Telormedix<font style="letter-spacing:0.9pt;"> </font>SA<font style="letter-spacing:0.3pt;"> </font>(&#8220;TMX&#8221;)<font style="letter-spacing:0.65pt;"> </font>pursuant<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company purchased<font style="letter-spacing:0.85pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intellectual<font style="letter-spacing:0.85pt;"> </font>pro<font style="letter-spacing:-0.1pt;">p</font>erty<font style="letter-spacing:0.65pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>TMX<font style="letter-spacing:0.4pt;"> </font>(in<font style="letter-spacing:0.25pt;"> </font>process<font style="letter-spacing:0.65pt;"> </font>R&amp;D)<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.3pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>691,200<font style="letter-spacing:0.65pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the Company<font style="letter-spacing:0.8pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$5.94, which were subsequently converted into ordinary shares on the date of the IPO.<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:0.2pt;"> </font><font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>issue<font style="letter-spacing:0.25pt;"> </font>ad<font style="letter-spacing:-0.1pt;">d</font>itional<font style="letter-spacing:0.8pt;"> </font>shares upon the occurrence of each of three milestones as set in the agreement. The Company has deemed the probability of achieving these milestones to be remote<font style="letter-spacing:0.8pt;">. </font><font style="color:#000000;">The acquired intellectual property costs totaling $4.1&#160;million were expensed as incurred to research and development costs in accordance with ASC&#160;730, as </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">the intellectual property is purchased from others for a particular research and development project and has no alternative future uses and therefore no separate economic value. </font><font style="font-size:11pt;letter-spacing:0.55pt;"> </font><font style="font-size:11pt;letter-spacing:0.65pt;"> </font><font style="font-size:11pt;letter-spacing:0.6pt;"> </font><font style="font-size:14pt;">&#160;</font><font style="font-size:11pt;letter-spacing:0.55pt;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On April 19, 2017, the Company&#8217;s board of directors and shareholders approved an aggregate 3.2 for-1 share split of the Company&#8217;s ordinary, Preferred A and Preferred A-1 shares. The share split was effected on April 19, 2017 by the issuance of 2.2 ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 share held immediately prior to the share split.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_390"></a>In May 2017, the Company completed an IPO on the Nasdaq Stock Market, in which it issued 5,144,378 ordinary shares, at a public offering price of $13.00 per share, in consideration for $60.8 million, net of underwriting discounts<a name="_cp_text_1_390"></a> and commissions and issuance costs, including exercise of the underwriters&#8217; option to purchase additional 671,005 ordinary shares at the IPO price. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO, the Company converted all outstanding warrants for Preferred A 1 shares into 364,036 Preferred A-1 shares of the Company. Subsequently, the Company converted all outstanding Preferred A and Preferred A-1 shares into ordinary shares at a ratio of 1:1. As of December 31, 2017, the Company&#8217;s share capital was composed entirely of ordinary shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, during the years ended December 31, 2017 and 2016, the Company recorded $0.0 and $1.7 million, respectively, in general and administrative expenses related to IPO costs, in accordance with SEC staff Bulletin Topic 5A.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company&#8217;s convertible preferred shares included Series A and A-1 preferred shares.  The<font style="letter-spacing:0.35pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>$5.94<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the exercise<font style="letter-spacing:0.7pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>$7.81.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>holder<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>was:<font style="letter-spacing:0.45pt;"> </font>(i)<font style="letter-spacing:0.25pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>votes<font style="letter-spacing:0.45pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font><font style="letter-spacing:-0.1pt;">e</font>qual<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>which such<font style="letter-spacing:0.4pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>then<font style="letter-spacing:0.4pt;"> </font>convertible,<font style="letter-spacing:0.9pt;"> </font>(ii)<font style="letter-spacing:0.25pt;"> </font>had<font style="letter-spacing:0.4pt;"> </font>voting<font style="letter-spacing:0.5pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>powers<font style="letter-spacing:0.6pt;"> </font>equal<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>voting<font style="letter-spacing:0.5pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>powers<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>h<font style="letter-spacing:-0.1pt;">o</font>lder<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.4pt;"> </font>vote<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>single<font style="letter-spacing:0.5pt;"> </font>class<font style="letter-spacing:0.45pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font><font style="letter-spacing:-0.1pt;">h</font>olders<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(iii)<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>notice<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>meeting<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the shareholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>issuance<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>dividends<font style="letter-spacing:0.75pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>annum<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>8%<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>original<font style="letter-spacing:0.65pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>pri<font style="letter-spacing:-0.1pt;">c</font>e<font style="letter-spacing:0.45pt;"> </font>(as defined)<font style="letter-spacing:0.5pt;"> </font>per<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.2pt;"> </font>accrued<font style="letter-spacing:0.4pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>such<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.55pt;"> </font>shares<font style="letter-spacing:0.4pt;"> </font>(sub<font style="letter-spacing:-0.1pt;">j</font>ect<font style="letter-spacing:0.45pt;"> </font>to appropriate<font style="letter-spacing:0.85pt;"> </font>adjustment<font style="letter-spacing:0.7pt;"> </font>in the<font style="letter-spacing:0.1pt;"> </font>event<font style="letter-spacing:0.3pt;"> </font>of any<font style="letter-spacing:0.15pt;"> </font>stock<font style="letter-spacing:0.25pt;"> </font>dividend,<font style="letter-spacing:0.55pt;"> </font>stock<font style="letter-spacing:0.25pt;"> </font>split, combination<font style="letter-spacing:0.95pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>similar<font style="letter-spacing:0.55pt;"> </font>recapitalization<font style="letter-spacing:1.2pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ith<font style="letter-spacing:0.35pt;"> </font>respect<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>holders<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>had<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>follo<font style="letter-spacing:-0.1pt;">w</font>ing<font style="letter-spacing:0.7pt;"> </font>conversion<font style="letter-spacing:0.85pt;"> </font>rights:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optional conversion - each preferred share was convertible, at the option of the holder thereof, at any time after the date of issuance of such share into such number of fully paid shares of ordinary shares as was determined by dividing the original purchase price by the conversion price applicable to such share, in effect on the date that the certificate was surrendered for conversion. The initial conversion price of the preferred shares was the original purchase price; provided, however, that the conversion price for the preferred shares was subject to certain adjustments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automatic<font style="letter-spacing:0.8pt;"> </font>conversion<font style="letter-spacing:0.85pt;"> </font>-<font style="letter-spacing:0.1pt;"> </font>Each<font style="letter-spacing:0.45pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>was to be automatica<font style="letter-spacing:-0.1pt;">l</font>ly<font style="letter-spacing:0.25pt;"> </font>converted<font style="letter-spacing:0.8pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>conversion<font style="letter-spacing:0.9pt;"> </font>price<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the time<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share,<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consummation<font style="letter-spacing:1.15pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>events:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Upon<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>closing<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>IPO,<font style="letter-spacing:0.4pt;"> </font>where<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.85pt;"> </font>pre-money<font style="letter-spacing:0.95pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>$75,000<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>proceeds<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Comp<font style="letter-spacing:-0.1pt;">a</font>ny of<font style="letter-spacing:0.2pt;"> </font>$25,000<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>(a<font style="letter-spacing:0.2pt;"> </font>&#8220;Qualified<font style="letter-spacing:0.8pt;"> </font>Public<font style="letter-spacing:0.5pt;"> </font>Offering&#8221;);<font style="letter-spacing:0.85pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>event<font style="letter-spacing:0.45pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>holders<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>majority<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>sixty<font style="letter-spacing:0.4pt;"> </font>percent<font style="letter-spacing:0.6pt;"> </font>(60%)<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>then<font style="letter-spacing:0.4pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>voting<font style="letter-spacing:0.5pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>single<font style="letter-spacing:0.5pt;"> </font>class, consent<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>such.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted in 8a4, in May 2017, upon completion of the IPO, all of the convertible preferred shares were converted into ordinary shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the<font style="letter-spacing:0.35pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>perma<font style="letter-spacing:-0.1pt;">n</font>ent<font style="letter-spacing:0.85pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.3pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>classification<font style="letter-spacing:1.15pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>meet<font style="letter-spacing:0.45pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requirements<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>classificat<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:1pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>ASC<font style="letter-spacing:0.45pt;"> </font>480-10-S99.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During 2017, the Company received $404 from a portion of the exercise of 812,222 options into 743,806 ordinary shares, which were net of 68,416 shares surrendered to pay the exercise price on the balance.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><a name="_cp_text_1_404"></a>In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for $64 million net of underwriting discounts and commissions and issuance costs, including exercise of<a name="_cp_text_1_404"></a> the underwriters&#8217; option to purchase additional 219,512 ordinary shares at the public offering price. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;letter-spacing:0.2pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU130"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;letter-spacing:0.2pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b. </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Share-based</font><font style="letter-spacing:1.05pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">compensation</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>October<font style="letter-spacing:0.65pt;"> </font>2010,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>board<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>approved<font style="letter-spacing:0.75pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>option<font style="letter-spacing:0.5pt;"> </font>plan<font style="letter-spacing:0.35pt;"> </font>(the<font style="letter-spacing:0.35pt;"> </font>&#8220;Pl<font style="letter-spacing:-0.1pt;">a</font>n&#8221;)<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>employees,<font style="letter-spacing:0.9pt;"> </font>consultants, directors,<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>providers.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.4pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>su<font style="letter-spacing:-0.1pt;">b</font>ject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>terms<font style="letter-spacing:0.45pt;"> </font>stipulated<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>102<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>Income<font style="letter-spacing:0.6pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>Ordinance (&#8220;Section<font style="letter-spacing:0.75pt;"> </font>102&#8221;).<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>option<font style="letter-spacing:0.5pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>track<font style="letter-spacing:0.4pt;"> </font>chosen<font style="letter-spacing:0.6pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company,<font style="letter-spacing:0.8pt;"> </font>either<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>&#8220;regular<font style="letter-spacing:0.65pt;"> </font>income&#8221;<font style="letter-spacing:0.65pt;"> </font>track<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>&#8220;capital<font style="letter-spacing:0.6pt;"> </font>gains&#8221;<font style="letter-spacing:0.5pt;"> </font>track,<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>set<font style="letter-spacing:0.3pt;"> </font>out<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>102.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>registered<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>un<font style="letter-spacing:-0.1pt;">d</font>er<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>capital<font style="letter-spacing:0.55pt;"> </font>gains<font style="letter-spacing:0.45pt;"> </font>track,<font style="letter-spacing:0.45pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>offers<font style="letter-spacing:0.45pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>favorable<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the employees.<font style="letter-spacing:0.9pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result,<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>pursuant<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>terms<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>102,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>allowed<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>claim<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>ex<font style="letter-spacing:-0.1pt;">p</font>ense<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>the amounts<font style="letter-spacing:0.7pt;"> </font>credited<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>respect<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>them<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>P<font style="letter-spacing:-0.1pt;">l</font>an,<font style="letter-spacing:0.45pt;"> </font>including<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>salary<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:-0.1pt;">n</font>efits<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>accounts,<font style="letter-spacing:0.8pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exception<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>work-income<font style="letter-spacing:1pt;"> </font>b<font style="letter-spacing:-0.1pt;">e</font>nefit<font style="letter-spacing:0.55pt;"> </font>component,<font style="letter-spacing:0.95pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>any,<font style="letter-spacing:0.35pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>For<font style="letter-spacing:0.4pt;"> </font>non-employees<font style="letter-spacing:1.3pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>for non-Israeli<font style="letter-spacing:0.95pt;"> </font>employees,<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>3(i)<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>Income<font style="letter-spacing:0.6pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>Ordinance.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>volatility<font style="letter-spacing:0.65pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>histori<font style="letter-spacing:-0.1pt;">c</font>al<font style="letter-spacing:0.7pt;"> </font>volatility<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>comparable<font style="letter-spacing:1pt;"> </font>companies.<font style="letter-spacing:0.9pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>risk-free<font style="letter-spacing:0.65pt;"> </font>interest<font style="letter-spacing:0.6pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>assumption<font style="letter-spacing:0.9pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on observed<font style="letter-spacing:0.75pt;"> </font>interest<font style="letter-spacing:0.6pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>appropriate<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>term<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>dol<font style="letter-spacing:-0.1pt;">l</font>ar<font style="letter-spacing:0.45pt;"> </font>terms.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>term<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>length<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>time<font style="letter-spacing:0.35pt;"> </font>until the<font style="letter-spacing:0.05pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>dates<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>exercising<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options and<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>(except<font style="letter-spacing:0.6pt;"> </font>senior<font style="letter-spacing:0.5pt;"> </font>managem<font style="letter-spacing:-0.1pt;">e</font>nt)<font style="letter-spacing:1.1pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>simplified<font style="letter-spacing:0.75pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>due<font style="letter-spacing:0.35pt;"> </font>to insufficient<font style="letter-spacing:0.85pt;"> </font>specific<font style="letter-spacing:0.6pt;"> </font>historical<font style="letter-spacing:0.7pt;"> </font>information<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>employ<font style="letter-spacing:-0.1pt;">e</font>es&#8217;<font style="letter-spacing:0.9pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>behavior,<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.3pt;"> </font>non-employees,<font style="letter-spacing:1.35pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>senior<font style="letter-spacing:0.5pt;"> </font>management<font style="letter-spacing:1.05pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>contractual<font style="letter-spacing:0.9pt;"> </font>term.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Company&#8217;s board of directors adopted the 2017 Equity Incentive Plan ("2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to the Company's employees, directors and consultants.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of ordinary shares that may be issued upon the exercise of incentive stock options under the 2017 Plan is 5,600,000.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, the Company&#8217;s board of directors approved modifications of performance conditions for 67,200 restricted stock units and contingent options for executive management. The Company recorded an expense of $527 under general and administrative expenses with respect to these modifications.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2017 and 2016, the Company granted options to certain employees and non-employees as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Options</font><font style="font-weight:bold;letter-spacing:0.65pt;"> </font><font style="font-weight:bold;">granted</font><font style="font-weight:bold;letter-spacing:0.65pt;"> </font><font style="font-weight:bold;">to</font><font style="font-weight:bold;letter-spacing:0.2pt;"> </font><font style="font-weight:bold;">employees</font><font style="font-weight:bold;letter-spacing:0.85pt;"> </font><font style="font-weight:bold;">and</font><font style="font-weight:bold;letter-spacing:0.35pt;"> </font><font style="font-weight:bold;">directors:</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set<font style="letter-spacing:0.3pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>below<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>made<font style="letter-spacing:0.45pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> and directors </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>20<font style="letter-spacing:-0.1pt;">1</font>7.<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>majority<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>vest<font style="letter-spacing:0.35pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>of four<font style="letter-spacing:0.35pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expire<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>seventh<font style="letter-spacing:0.65pt;"> </font>anniversary<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>grant.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) </font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During<font style="letter-spacing:0.55pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>712,900<font style="letter-spacing:0.65pt;"> </font>options and restricted stock units<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>ra<font style="letter-spacing:-0.1pt;">n</font>ging<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>$0<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>$39.26<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share. <font style="font-size:12pt;">&#160;&#160;</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During<font style="letter-spacing:0.55pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>404,813<font style="letter-spacing:0.8pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>ra<font style="letter-spacing:-0.1pt;">n</font>ging<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>$5<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>$5.94<font style="letter-spacing:0.45pt;"> </font>per share. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="letter-spacing:-0.2pt;">During 2015, the Company granted 1,098,777 options to employees and directors with prices ranging from $0 to $5.94 per share.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of options granted to employees and directors during 2017, 2016 and 2015 was $14,249, $906 and $2,334, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU131"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">total</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unrecognized</font><font style="letter-spacing:1.05pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compensati</font><font style="letter-spacing:-0.1pt;">o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</font><font style="letter-spacing:1.1pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">employee</font><font style="letter-spacing:0.8pt;"> and director </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">options</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$14,131,</font><font style="letter-spacing:0.6pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whi</font><font style="letter-spacing:-0.1pt;">c</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expected</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognized</font><font style="letter-spacing:0.9pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weighted</font><font style="letter-spacing:0.75pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">average</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.15pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.31</font><font style="letter-spacing:0.4pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>irectors<font style="letter-spacing:0.7pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Black-Scholes<font style="letter-spacing:1.15pt;"> </font>mod<font style="letter-spacing:-0.1pt;">e</font>l.<font style="letter-spacing:0.55pt;"> </font>The underlying<font style="letter-spacing:0.85pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>used<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>computing<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of ordinary shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.00-39.26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98-5.54</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98-3.01</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.53%-76.32%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.8%-80%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.78%-76.68%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.85%-2.47%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4%&#8211;2.13%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38%&#8211;2.08%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5-10 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1-7 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;">Options</font><font style="font-weight:bold;letter-spacing:0.65pt;"> </font><font style="font-weight:bold;">granted</font><font style="font-weight:bold;letter-spacing:0.65pt;"> </font><font style="font-weight:bold;">to</font><font style="font-weight:bold;letter-spacing:0.2pt;"> </font><font style="font-weight:bold;">consultants</font><font style="font-weight:bold;letter-spacing:0.9pt;"> </font><font style="font-weight:bold;">and</font><font style="font-weight:bold;letter-spacing:0.35pt;"> </font><font style="font-weight:bold;">other</font><font style="font-weight:bold;letter-spacing:0.45pt;"> </font><font style="font-weight:bold;">service</font><font style="font-weight:bold;letter-spacing:0.6pt;"> </font><font style="font-weight:bold;">providers:</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no new grants issued to consultants and service providers in 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During<font style="letter-spacing:0.55pt;"> </font>2016 and 2015,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>132,0<font style="letter-spacing:-0.1pt;">3</font>2<font style="letter-spacing:0.65pt;"> and 203,820 </font>options,<font style="letter-spacing:0.65pt;"> </font>respectively,<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>providers<font style="letter-spacing:0.75pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>an exercise<font style="letter-spacing:0.7pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>ranging<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>$0<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>$5.94<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016 and 2015<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>opt<font style="letter-spacing:-0.1pt;">i</font>ons<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>providers<font style="letter-spacing:0.75pt;"> </font>during<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">2</font>016 and 2015<font style="letter-spacing:0.45pt;"> </font>was $671 and $57, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>pro<font style="letter-spacing:-0.1pt;">v</font>iders<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">s</font>ing<font style="letter-spacing:0.45pt;"> </font>the Black-Scholes<font style="letter-spacing:1.15pt;"> </font>model.<font style="letter-spacing:0.55pt;"> </font>The<font style="letter-spacing:0.3pt;"> </font>underlying<font style="letter-spacing:0.85pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>computing<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>opt<font style="letter-spacing:-0.1pt;">i</font>ons<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of ordinary shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.58-37.21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.58-7.96</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.45%-74.50%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.72%-80%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.31%-76.3%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38%-2.26%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.56%-2.27%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88%-2.07%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9-5.9 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8-8.5 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.8-7 years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>summarizes<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font><font style="letter-spacing:-0.1pt;">o</font>utstanding<font style="letter-spacing:0.95pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>Decem<font style="letter-spacing:-0.1pt;">b</font>er<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017, 2016<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2015,<font style="letter-spacing:0.45pt;"> </font>and related<font style="letter-spacing:0.55pt;"> </font>inform<font style="letter-spacing:0.1pt;">a</font>tion:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directors</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consultants and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service providers</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of January 1, 2015</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,823</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098,777</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.99</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,826</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.98</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,088</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,686,600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,238</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.48</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404,813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,032</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.15</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.03</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,784</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,030,613</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634,486</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.62</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,686</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.93</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(682,184</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,038</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,021,829</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.70</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498,762</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Including 38,400 ordinary shares issuable upon the vesting of options granted in 2016, which were contingent upon the closing of the IPO.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.5pt;"> </font>summarizes<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>outstand<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.95pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>exercisable<font style="letter-spacing:0.9pt;"> </font>options and restricted stock units<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2<font style="letter-spacing:-0.1pt;">0</font>17:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="8" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">share</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding at end</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual life</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercisable at end of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00 - 10.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,948,091</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.62</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142,310</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.98</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.01 - 20.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292,500</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.49</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,501</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.01 - 30.00</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.01 - 40.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.81</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,520,591</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,194,811</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>aggregate<font style="letter-spacing:0.8pt;"> </font>intrinsic<font style="letter-spacing:0.65pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>total<font style="letter-spacing:0.35pt;"> </font>vested<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>e<font style="letter-spacing:-0.1pt;">x</font>ercisable<font style="letter-spacing:0.9pt;"> </font>options and restricted stock units<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>$38,308.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>illustrates<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>com<font style="letter-spacing:-0.1pt;">p</font>ensation<font style="letter-spacing:1.1pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653256"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,923</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,967</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>9&#8212;TAXES<font style="letter-spacing:0.9pt;"> </font>ON<font style="letter-spacing:0.3pt;"> </font>INCOME</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>taxed<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>laws:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>rates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>taxed<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>regular<font style="letter-spacing:0.6pt;"> </font>rate.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>24%<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">2</font>5%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Economic<font style="letter-spacing:0.8pt;"> </font>Efficiency<font style="letter-spacing:0.8pt;"> </font>Law<font style="letter-spacing:0.35pt;"> </font>(Legi<font style="letter-spacing:-0.1pt;">s</font>lative<font style="letter-spacing:0.9pt;"> </font>Amendments<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>Implementing<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Economic<font style="letter-spacing:0.8pt;"> </font>Policy<font style="letter-spacing:0.5pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>2018 Budget<font style="letter-spacing:0.6pt;"> </font>Year),<font style="letter-spacing:0.5pt;"> </font>2016<font style="letter-spacing:0.6pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>published,<font style="letter-spacing:0.9pt;"> </font>introducing<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>gradual<font style="letter-spacing:0.6pt;"> </font>reduction<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>n<font style="letter-spacing:0.2pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>25%<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>23%.<font style="letter-spacing:0.45pt;"> </font>However,<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>law<font style="letter-spacing:0.3pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>included<font style="letter-spacing:0.7pt;"> </font>a temporary<font style="letter-spacing:0.8pt;"> </font>provision<font style="letter-spacing:0.75pt;"> </font>setting<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>24%.<font style="letter-spacing:0.45pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>was<font style="letter-spacing:0.25pt;"> </font>24%<font style="letter-spacing:0.4pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>20<font style="letter-spacing:-0.1pt;">1</font>7<font style="letter-spacing:0.45pt;"> </font>and would be<font style="letter-spacing:0.35pt;"> </font>23%<font style="letter-spacing:0.4pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2018<font style="letter-spacing:0.45pt;"> </font>and thereafter.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>change<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>mentioned<font style="letter-spacing:0.85pt;"> </font>above<font style="letter-spacing:0.5pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font><font style="letter-spacing:-0.1pt;">n</font>ot<font style="letter-spacing:0.3pt;"> </font>affected<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>date in Israel.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b.<font style="letter-spacing:0.2pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>assessments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>assessments<font style="letter-spacing:1.05pt;"> </font>filed<font style="letter-spacing:0.35pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>2013<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>final.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c.<font style="letter-spacing:0.2pt;"> </font>Losses<font style="letter-spacing:0.65pt;"> </font>for<font style="letter-spacing:0.3pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>purposes<font style="letter-spacing:0.8pt;"> </font>carried<font style="letter-spacing:0.6pt;"> </font>forward<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>future<font style="letter-spacing:0.55pt;"> </font>years</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font>approximately<font style="letter-spacing:1.1pt;"> </font><font style="letter-spacing:-0.1pt;">$</font>24.8<font style="letter-spacing:0.65pt;"> million </font>of<font style="letter-spacing:0.2pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>carry<font style="letter-spacing:0.45pt;"> </font>forward<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>losses<font style="letter-spacing:0.55pt;"> </font>available<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>reduce<font style="letter-spacing:0.55pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>taxable<font style="letter-spacing:0.6pt;"> </font>income without<font style="letter-spacing:0.6pt;"> </font>limitation<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>use.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU132"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d.</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Deferred</font><font style="letter-spacing:0.75pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">income</font><font style="letter-spacing:0.65pt;"> </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">taxes:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653257"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In respect of:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forward</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,844</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,280</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,691</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Rent</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance Costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-Process R&amp;D</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less&#8212;valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,725</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>change<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>lowance<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>were<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653259"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,551</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes during the year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,567</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,948</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the end of the year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,725</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main reconciling item between the statutory tax rates of the Company (not UPI) and the effective rate is the share-based compensation and provision for full valuation allowance in respect of tax benefits from carryforward tax losses due to the uncertainty of the realization of such tax benefits.<font style="font-size:12pt;"><br /></font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regarding the Company&#8217;s US operations, as of December 31, 2017, UPI had federal tax net operating losses of $0.4 million and state tax net operating losses of $0.7 million in several jurisdictions available to carry forward and reduce future income tax liabilities. The federal and state net operating losses begin to expire after 2036.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Internal Revenue Code contains provisions that may limit the use of the net operating tax loss carryforward available if significant changes occur in the stock ownership of UPI. In the event UPI has had a change in ownership, utilization of the carry&#8209;forwards could be restricted due to the &#8220;change in ownership provisions&#8221; under Section&#160;382 of the Internal Revenue Code and similar state provisions. Such limitations could result in the expiration of the net operating carry&#8209;forwards before their utilization.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.55pt;"> </font>10&#8212;LOSS<font style="letter-spacing:0.85pt;"> </font>PER<font style="letter-spacing:0.4pt;"> </font>ORDINARY<font style="letter-spacing:0.95pt;"> </font>SHARE</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>sets<font style="letter-spacing:0.35pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>calculation<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>ic<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>indicat<font style="letter-spacing:-0.1pt;">e</font>d:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk508653260"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss attributable to equity holders of the Company</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,941</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,689</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend accumulated for preferred shares during the period</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,467</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss attributable to equity holders of the Company, after deducting dividend</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accumulated for preferred shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,825</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,408</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,541</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,716,790</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,503</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300,959</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss per ordinary share (LPS)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU133"></a>For<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.35pt;"> </font>20<font style="letter-spacing:-0.1pt;">16</font> and 2015,<font style="letter-spacing:0.45pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>underlying<font style="letter-spacing:0.85pt;"> </font>outstand<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.95pt;"> </font>options,<font style="letter-spacing:0.75pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.45pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>preferred shares<font style="letter-spacing:0.55pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>excluded<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>calculat<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>anti-dilutive.<font style="letter-spacing:0.95pt;"> </font>Di<font style="letter-spacing:-0.1pt;">l</font>uted<font style="letter-spacing:0.6pt;"> </font>LPS<font style="letter-spacing:0.35pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>include 2,415,545,<font style="letter-spacing:0.35pt;"> </font>2,665,099<font style="letter-spacing:0.8pt;"> and 2,199,838 </font>ordi<font style="letter-spacing:-0.1pt;">n</font>ary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>underlying<font style="letter-spacing:0.85pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>opti<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UROGEN<font style="letter-spacing:0.8pt;"> </font>PHARMA<font style="letter-spacing:0.8pt;"> </font>LTD.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES<font style="letter-spacing:0.65pt;"> </font>TO<font style="letter-spacing:0.3pt;"> </font>THE<font style="letter-spacing:0.4pt;"> </font>CONSOLIDATED<font style="letter-spacing:1.4pt;"> </font>FINANCIAL<font style="letter-spacing:0.95pt;"> </font>STATEMENTS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(U.S.<font style="letter-spacing:0.45pt;"> </font>dollars<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>thousands,<font style="letter-spacing:0.9pt;"> </font>except<font style="letter-spacing:0.55pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017, 2016</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="letter-spacing:-0.1pt;">0</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respectively,</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">728,312</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shares</font><font style="letter-spacing:0.55pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issuable</font><font style="letter-spacing:0.65pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">up</font><font style="letter-spacing:-0.1pt;">o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise</font><font style="letter-spacing:0.7pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="letter-spacing:0.2pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.35pt;"> Preferred </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</font><font style="letter-spacing:0.35pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrants, which were converted to ordinary shares upon the IPO, for</font><font style="letter-spacing:0.25pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">years</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ended</font><font style="letter-spacing:0.5pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="letter-spacing:0.85pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,</font><font style="letter-spacing:0.3pt;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2016 and 2015, and 5,193,427 shares issuable upon conversion of preferred shares for the years ended December 31, 2016 and 2015</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.55pt;"> </font>11&#8212;RELATED<font style="letter-spacing:1.2pt;"> </font>PARTIES-TRANSAC<font style="letter-spacing:0.1pt;">T</font>IONS<font style="letter-spacing:2.2pt;"> </font>AND<font style="letter-spacing:0.4pt;"> </font>BALANCES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPI<font style="letter-spacing:0.35pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement,<font style="letter-spacing:0.9pt;"> </font>dated<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>November<font style="letter-spacing:0.85pt;"> </font>20<font style="letter-spacing:-0.1pt;">1</font>5<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>commencing<font style="letter-spacing:1pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>May<font style="letter-spacing:0.35pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>space<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>New<font style="letter-spacing:0.4pt;"> </font>York.<font style="letter-spacing:0.25pt;"> </font>UPI<font style="letter-spacing:0.35pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>space<font style="letter-spacing:0.5pt;"> </font>equitably<font style="letter-spacing:0.75pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>Kite<font style="letter-spacing:0.35pt;"> </font>P<font style="letter-spacing:-0.1pt;">h</font>arma,<font style="letter-spacing:0.7pt;"> </font>Inc.,<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>Delaware<font style="letter-spacing:0.75pt;"> </font>corporation,<font style="letter-spacing:0.95pt;"> </font>which<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>cosignatory<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement.<font style="letter-spacing:0.9pt;"> </font>Arie<font style="letter-spacing:0.35pt;"> </font>Bell<font style="letter-spacing:-0.1pt;">d</font>egrun,<font style="letter-spacing:0.9pt;"> </font>M.D.,<font style="letter-spacing:0.45pt;"> </font>UPL&#8217;s<font style="letter-spacing:0.5pt;"> </font>chairman,<font style="letter-spacing:0.8pt;"> </font>served<font style="letter-spacing:0.55pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Chairman<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>Chief<font style="letter-spacing:0.5pt;"> </font>Executive<font style="letter-spacing:0.8pt;"> </font>Officer<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Kite Pharma,<font style="letter-spacing:0.7pt;"> </font>Inc. until his resignation effective as of October 3, 2017, in connection with the acquisition of Kite Pharma, Inc. by Gilead Sciences, Inc.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>12&#8212;SUBSEQUENT<font style="letter-spacing:1.6pt;"> </font>EVENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_418"></a><a name="_cp_text_1_419"></a><a name="_cp_text_1_421"></a>In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for approximately<a name="_cp_text_2_418"></a><a name="_cp_text_1_419"></a> $64 million net of underwriting discounts and commissions and issuance costs, including exercise of <a name="_cp_text_1_421"></a>the underwriters&nbsp;&nbsp;option to purchase an additional 219,512 ordinary shares at the public offering price. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>urgn-ex42_984.htm
<DESCRIPTION>EX-4.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex42_984.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE AMENDED AND RESTATED 2010 ISRAELI SHARE OPTION PLAN</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(*<font style="font-family:Times New Roman Bold;font-variant: small-caps;">In compliance with Amendment No. 132 of the Israeli Tax Ordinance, 2002</font>)</p>
<p style="margin-top:12pt; clear:both;text-align:right;margin-bottom:0pt;text-indent:0%;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 2 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF </font><font style="font-size:11pt;">CONTENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PURPOSE OF THE ISOP</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEFINITIONS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADMINISTRATION OF THE ISOP</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DESIGNATION OF PARTICIPANTS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DESIGNATION OF OPTIONS PURSUANT TO SECTION 102</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TRUSTEE</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SHARES RESERVED FOR THE ISOP; RESTRICTION THEREON</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PURCHASE PRICE</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADJUSTMENTS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERM AND EXERCISE OF OPTIONS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VESTING OF OPTIONS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DIVIDENDS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONDITIONS UPON ISSUANCE OF SHARES</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RESTRICTIONS ON ASSIGNABILITY AND SALE OF OPTIONS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EFFECTIVE DATE AND DURATION OF THE ISOP</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PURCHASE FOR INVESTMENT, REPRESENTATIONS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INABILITY TO OBTAIN AUTHORITY</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AMENDMENTS OR TERMINATION</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GOVERNMENT REGULATIONS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CONTINUANCE OF EMPLOYMENT OR HIRED SERVICES</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GOVERNING LAW &amp; JURISDICTION</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INTEGRATION OF SECTION 102 AND TAX COMMISSIONER'S PERMIT</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TAX CONSEQUENCES</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-EXCLUSIVITY OF THE ISOP</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8.2%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.</p></td>
<td valign="top"  style="width:81.8%;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MULTIPLE AGREEMENTS</p></td>
<td valign="top"  style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289520"></a><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;"><br /><a name="_Toc509289520"></a></font></p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 3 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">This plan, as amended from time to time, shall be known as </font><font style="font-weight:normal;">UroGen Pharma (formerly </font><font style="font-weight:normal;">TheraCoat</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Ltd.</font><font style="font-weight:normal;">)</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">20</font><font style="font-weight:normal;">10</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">Israeli Share Option Plan (the &#8220;</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ISOP</font><font style="font-weight:normal;">&#8221;). </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888244"></a>PURPOSE OF THE ISOP</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ISOP is intended to provide an incentive to retain, in the employ of the<font style="font-weight:bold;"> </font>Company (as defined below) and its Affiliates (as defined below), persons of training, experience, and ability, to attract new employees, directors, consultants, service providers and any other entity which the Board shall decide their services are considered valuable to the Company (as defined below), to encourage the sense of proprietorship of such persons, and to stimulate the active interest of such persons in the development and financial success of the Company (as defined below) by providing them with opportunities to purchase shares in the Company (as defined below), pursuant to the ISOP. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509227722"></a><a name="_Toc508888245"></a>DEFINITIONS</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of the ISOP and related documents, including the Option Agreement, the following definitions shall apply:</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Affiliate</font>&#8221; means any &#8220;employing company&#8221; within the meaning of Section 102(a) of the Ordinance.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2.<font style="margin-left:36pt;"></font>"<font style="font-weight:bold;">Applicable Laws</font>" means the requirements relating to the administration of share option plans under applicable corporate laws, securities laws, any stock exchange or quotation system on which the Shares (as defined below) are listed or quoted and the applicable laws of any other country or jurisdiction where Options are granted under the ISOP.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Approved 102 Option</font>&#8221; means an Option granted pursuant to Section 102(b) of the Ordinance and held in trust by a Trustee for the benefit of the Optionee. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.4.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Board</font>&#8221; means the Board of Directors of the Company.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Capital Gain Option</font>&#8221; or &#8220;<font style="font-weight:bold;">CGO</font>&#8221; as defined in Section 5.4 below.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Cause</font>&#8221; means any of the following: (a)&#160;the Optionee's theft, dishonesty, or falsification of any Company documents or records; (b)&#160;the Optionee's improper use or disclosure of the Company's confidential or proprietary information; (c)&#160;any deliberate action by the Optionee which has a detrimental effect on the Company's reputation or business; (d)&#160;the Optionee's failure or inability to perform any reasonable assigned duties after written notice from the Company of, and a reasonable opportunity to cure, such failure or inability; (e)&#160;any material breach of the Optionee of any employment agreement between the Optionee and the Company, which breach is not cured pursuant to the terms of such agreement; or (f)&#160;the Optionee's conviction (including any plea of guilty or nolo contendere) of any criminal act which impairs the Optionee's ability to perform his, her or its duties with the Company. For purposes of the definition of Cause, with respect to an Optionee employed by or providing services to an Affiliate of the Company, "Company" shall include Affiliate employing or engaging the services of the Optionee.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.7.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Chairman</font>&#8221; means the chairman of the Committee.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.8.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Committee</font>&#8221; means a share option compensation committee appointed by the Board, which shall consist of no fewer than two members of the Board.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Company</font>&#8221; means TheraCoat Ltd., an Israeli company.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.10.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Companies Law</font>&#8221; means the Israeli Companies Law 5759-1999.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.11.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Controlling Shareholder</font>&#8221; shall have the meaning ascribed to it in Section 32(9) of the Ordinance.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.12.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Date of Grant</font>&#8221; means, the date of grant of an Option, as determined by the Board and set forth in the Optionee&#8217;s Option Agreement. </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 4 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.13.</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">"</font><font style="font-weight:bold;">Director</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">" means a member of the Board of Directors of the Company, or any Affiliate.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.14.<font style="margin-left:36pt;"></font>"<font style="font-weight:bold;">Disability</font>" means physical or mental infirmity which impairs Optionee's ability to substantially perform his duties, which continues for a period of at least sixty (60) consecutive days.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.15.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Employee</font>&#8221; means a person who is employed by the Company or its Affiliates, including an individual who is serving as a director or an office holder, but excluding Controlling Shareholder. An Employee&#8217;s employment shall not be deemed to have been terminated in the case of (i) any leave of absence approved by the Company (or by the Affiliate that employs the person) or (ii) transfers between locations of the Company (or Affiliate that employs the person) or between the Company, any of its Affiliates, or any successor. No such leave may exceed ninety days, unless reemployment upon expiration of such leave is guaranteed by statute or contract. Neither service as a Director nor payment of a director's fee shall be sufficient to constitute "employment". </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.16.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Expiration date</font>&#8221; means the date upon which an Option shall expire, as set forth in Section 10.2 of the ISOP. <font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Fair Market Value</font>&#8221; means as of any date, the value of a Share determined as follows: </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17.1.<font style="margin-left:36pt;"></font>If the Shares are listed on any established stock exchange or a national market system, the Fair Market Value shall be the closing sales price for such Shares (or the closing bid, if no sales were reported), as quoted on such exchange or system for the last market trading day prior to time of determination, as reported, or such other source as the Board deems reliable. Without derogating from the above, solely for the purpose of determining the tax liability pursuant to Section 102(b)(3) of the Ordinance, if at the Date of Grant the Company&#8217;s shares are listed on any established stock exchange or a national market system or if the Company&#8217;s shares will be registered for trading within ninety (90) days following the Date of Grant, the Fair Market Value of a Share at the Date of Grant shall be determined in accordance with the average value of the Company&#8217;s shares on the thirty (30) trading days preceding the Date of Grant or on the thirty (30) trading days following the date of registration for trading, as the case may be;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17.2.<font style="margin-left:36pt;"></font>If the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value shall be the mean between the high bid and low asked prices for the Shares on the last market trading day prior to the day of determination, or; </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.17.3.<font style="margin-left:36pt;"></font>In the absence of an established market for the Shares, the Fair Market Value thereof shall be determined in good faith by the Board. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.18.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">IPO</font>&#8221; means the initial public offering of the Company&#8217;s shares.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.19.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">ISOP</font>&#8221; means this 2008 Israeli Share Option Plan.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.20.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">ITA</font>&#8221; means the Israeli Tax Authorities.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.21.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Non-Employee</font>&#8221; means a consultant, adviser, service provider, Controlling Shareholder or any other person who is not an Employee.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.22.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Ordinary Income Option</font>&#8221; or &#8220;<font style="font-weight:bold;">OIO</font>&#8221; as defined in Section 5.5 below.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.23.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Option</font>&#8221; means an option to purchase one or more Shares of the Company pursuant to the ISOP, including restricted stock/share unit.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.24.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">102 Option</font>&#8221; means any Option granted to Employees pursuant to Section 102 of the Ordinance.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.25.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">3(i) Option</font>&#8221; means an Option granted pursuant to Section 3(i) of the Ordinance to any person who is Non- Employee. </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 5 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.26.</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;">Optionee</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means a person who receives or holds an Option under the ISOP.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.27.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Option Agreement</font>&#8221;<font style="margin-left:36pt;">means the share option agreement between the Company and an Optionee that sets out the terms and conditions of an Option.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.28.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Ordinance</font>&#8221; means the Israeli Income Tax Ordinance [New Version] 1961 as now in effect or as hereafter amended. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.29.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Purchase Price</font>&#8221; means the price for each Share subject to an Option. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.30.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Section 102</font>&#8221; means Section 102 of the Ordinance as now in effect or as hereafter amended.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.31.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Share</font>&#8221; means the ordinary shares, NIS 0.01 par value each, of the Company.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.32.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Successor Company</font>&#8221; means any entity the Company is merged to or is acquired by, in which the Company is not the surviving entity.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Transaction</font>&#8221; means (i) merger, acquisition or reorganization of the Company with one or more other entities in which the Company is not the surviving entity, (ii) a sale of all or substantially all of the assets of the Company. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.34.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Trustee</font>&#8221; means any individual appointed by the Company to serve as a trustee and approved by the ITA, all in accordance with the provisions of Section 102(a) of the Ordinance.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.35.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Unapproved 102 Option</font>&#8221; means an Option granted pursuant to Section 102(c) of the Ordinance and not held in trust by a Trustee. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.36.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Vested Option</font>&#8221; means any Option, which has already been vested according to the Vesting Dates.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.37.<font style="margin-left:36pt;"></font>&#8220;<font style="font-weight:bold;">Vesting Dates</font>&#8221; means, as determined by the Board or by the Committee, the date as of which the Optionee shall be entitled to exercise the Options or part of the Options, as set forth in Section 11 of the ISOP.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289521"></a><a name="_Toc508888246"></a>ADMINISTRATION OF THE ISOP</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1.<font style="margin-left:36pt;"></font>The Board shall have the power to administer the ISOP either directly or upon the recommendation of the Committee, all as provided by applicable law and in the Company&#8217;s Articles of Association. Notwithstanding the above, the Board shall automatically have residual authority if no Committee shall be constituted or if such Committee shall cease to operate for any reason.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2.<font style="margin-left:36pt;"></font>The Committee shall select one of its members as its Chairman and shall hold its meetings at such times and places as the Chairman shall determine. The Committee shall make such rules and regulations for the conduct of its business as it shall deem advisable.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>3.3.<font style="margin-left:36pt;"></font>The Committee shall have the power to recommend to the Board and the Board shall have the full power and authority to: (i) designate participants; (ii) determine the terms and provisions of the respective Option Agreements, including, but not limited to, the number of Options to be granted to each Optionee, the number of Shares to be covered by each Option, provisions concerning the time and the extent to which the Options may be exercised and the nature and duration of restrictions as to the transferability or restrictions constituting substantial risk of forfeiture and to cancel or suspend awards, as necessary; (iii) determine the Fair Market Value of the Shares covered by each Option; (iv) make an election as to the type of Approved 102 Option; and (v) designate the type of Options; (vi) alter any restrictions and conditions of any Options or Shares subject to any Option; (vii) interpret the provisions and supervise the administrations of the ISOP; (viii) accelerate the right of an Optionee to exercise in whole or in part, any previously granted Option; (ix) determine the Purchase Price of the Option; (x) prescribe, amend and rescind rules and regulations relating to the </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 6 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ISOP; and (xi) make all other determinations deemed necessary or advisable for the administration of the ISOP.</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:0pt;margin-left:14.38%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4.<font style="margin-left:36pt;"></font>Notwithstanding the above, the Committee shall not be entitled to grant Options to the Optionees, however, it will be authorized to issue Shares underlying Options which have been granted by the Board and duly exercised pursuant to the provisions herein in accordance with Section 112(a)(5) of the Companies Law.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5.<font style="margin-left:36pt;"></font>The Board shall have the authority to grant, at its discretion, to the holder of an outstanding Option, in exchange for the surrender and cancellation of such Option, a new Option having a purchase price equal to, lower than or higher than the Purchase Price of the original Option so surrendered and canceled and containing such other terms and conditions as the Committee may prescribe in accordance with the provisions of the ISOP.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6.<font style="margin-left:36pt;"></font>The interpretation and construction by the Committee of any provision of the ISOP or of any Option Agreement thereunder shall be final and conclusive unless otherwise determined by the Board.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289522"></a><a name="_Toc508888247"></a>DESIGNATION OF PARTICIPANTS</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1.<font style="margin-left:36pt;"></font>The persons eligible for participation in the ISOP as Optionees shall include any Employees and/or Non-Employees of the Company or of any Affiliate; provided, however, that (i) Employees may only be granted 102 Options; (ii) Non-Employees may only be granted 3(i) Options; and (iii) Controlling Shareholders may only be granted 3(i) Options. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2.<font style="margin-left:36pt;"></font>The grant of an Option hereunder shall neither entitle the Optionee to participate nor disqualify the Optionee from participating in, any other grant of Options pursuant to the ISOP or any other option or share plan of the Company or any of its Affiliates.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289524"></a>4.3.<font style="margin-left:36pt;"></font>Anything in the ISOP to the contrary notwithstanding, all grants of Options to directors and office holders shall be authorized and implemented in accordance with the provisions of the Companies Law or any successor act or regulation, as in effect from time to time.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888248"></a>DESIGNATION OF OPTIONS PURSUANT TO SECTION 102</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.1.<font style="margin-left:36pt;"></font>The Company may designate Options granted to Employees pursuant to Section 102 as Unapproved 102 Options or Approved 102 Options.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2.<font style="margin-left:36pt;"></font>The grant of Approved 102 Options shall be made under this ISOP adopted by the Board as described in Section 16 below, and shall be conditioned upon the approval of this ISOP by the ITA.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.3.<font style="margin-left:36pt;"></font>Approved 102 Option may either be classified as Capital Gain Option or Ordinary Income Option.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref113940204"></a>5.4.<font style="margin-left:36pt;"></font>Approved 102 Option elected and designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) shall be referred to herein as CGO. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref113940253"></a>5.5.<font style="margin-left:36pt;"></font>Approved 102 Option elected and designated by the Company to qualify under the ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) shall be referred to herein as OIO. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>5.6.<font style="margin-left:36pt;"></font>The Company&#8217;s election of the type of Approved 102 Options as CGO or OIO granted to Employees (the &#8220;Election&#8221;), shall be appropriately filed with the ITA before the Date of Grant of an Approved 102 Option. Such Election shall become effective beginning the first Date of Grant of an Approved 102 Option under this ISOP and shall remain in effect until the end of the year following the </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 7 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year during which the Company first granted Approved 102 Options. The Election shall obligate the Company to grant only the type of Approved 102 Option it has elected, and shall apply to all Optionees who were granted Approved 102 Options during the period indicated herein, all in accordance with the provisions of Section 102(g) of the Ordinance. For the avoidance of doubt, such Election shall not prevent the Company from granting Unapproved 102 Options simultaneously.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7.<font style="margin-left:36pt;"></font>All Approved 102 Options must be held in trust by a Trustee, as described in Section 6 below.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8.<font style="margin-left:36pt;"></font>For the avoidance of doubt, the designation of Unapproved 102 Options and Approved 102 Options shall be subject to the terms and conditions set forth in Section 102 of the Ordinance and the regulations promulgated thereunder.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.9.<font style="margin-left:36pt;"></font>With regards to Approved 102 Options, the provisions of the ISOP and/or the Option Agreement shall be subject to the provisions of Section 102 and the Tax Assessing Officer&#8217;s permit, and the said provisions and permit shall be deemed an integral part of the ISOP and of the Option Agreement. Any provision of Section 102 and/or the said permit which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in the ISOP or the Option Agreement, shall be considered binding upon the Company and the Optionees.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref113940451"></a><a name="_Ref113940690"></a><a name="_Toc508888249"></a>TRUSTEE</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1.<font style="margin-left:36pt;"></font>Approved 102 Options which shall be granted under the ISOP and/or any Shares allocated or issued upon exercise of such Approved 102 Options and/or other shares received subsequently following any realization of rights, including without limitation bonus shares, shall be allocated or issued to the Trustee and held for the benefit of the Optionees for such period of time as required by Section 102 or any regulations, rules or orders or procedures promulgated thereunder (the &#8220;<font style="font-weight:bold;">Holding Period</font>&#8221;). In the case the requirements for Approved 102 Options are not met, then the Approved 102 Options may be treated as Unapproved 102 Options, all in accordance with the provisions of Section 102 and regulations promulgated thereunder. <font style="margin-left:36pt;"> </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2.<font style="margin-left:36pt;"></font>Notwithstanding anything to the contrary, the Trustee shall not release any Shares allocated or issued upon exercise of Approved 102 Options prior to the full payment of the Optionee&#8217;s tax liabilities arising from Approved 102 Options which were granted to him and/or any Shares allocated or issued upon exercise of such Options. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3.<font style="margin-left:36pt;"></font>With respect to any Approved 102 Option, subject to the provisions of Section 102 and any rules or regulation or orders or procedures promulgated thereunder, an Optionee shall not sell or release from trust any Share received upon the exercise of an Approved 102 Option and/or any share received subsequently following any realization of rights, including without limitation, bonus shares, until the lapse of the Holding Period required under Section 102 of the Ordinance. Notwithstanding the above, if any such sale or release occurs during the Holding Period, the sanctions under Section 102 of the Ordinance and under any rules or regulation or orders or procedures promulgated thereunder shall apply to and shall be borne by such Optionee.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.4.<font style="margin-left:36pt;"></font>Upon receipt of Approved 102 Option, the Optionee will sign an undertaking to release the Trustee from any liability in respect of any action or decision duly taken and bona fide executed in relation with the ISOP, or any Approved 102 Option or Share granted to him thereunder. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289525"></a><a name="_Ref113940595"></a><a name="_Toc508888250"></a>SHARES RESERVED FOR THE ISOP; RESTRICTION THEREON</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>7.1.<font style="margin-left:36pt;"></font>The Company shall from time to time reserve, out of its authorized but unissued share capital, such number of Shares as the Board deems appropriate (subject to the Articles of Association) for the purposes of this ISOP and/or for the purposes of any other share option plans which have previously been, or may in the future be, adopted by the Company, subject to adjustment as set forth in Section 9 below. Any Shares which remain unissued and which are not subject to then outstanding </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 8 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options at the termination or expiration of this ISOP shall cease to be reserved for the purpose of this ISOP, but may continue to be reserved for other share option plans then in effect, and in any event, until termination of this ISOP the Company shall at all times reserve sufficient number of Shares to</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> meet the requirements of any then outstanding Options. Should any Option for any reason expire or be canceled prior to its exercise or relinquishment in full, the Shares subject to such Option may again be subjected to a new Option under this ISOP or under the Company's other share option plans, provided, however, that Shares that have actually been issued under this ISOP shall not be returned to the pool under this ISOP and shall not become available for future distribution under this ISOP.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.2.<font style="margin-left:36pt;"></font>Each Option granted pursuant to the ISOP, shall be evidenced by a written Option Agreement between the Company and the Optionee, in such form as the Board or the Committee shall from time to time approve. Each Option Agreement shall state, among other matters, the number of Shares to which the Option relates, the type of Option granted thereunder (whether a CGO, OIO, Unapproved 102 Option or a 3(i) Option), the Vesting Dates, the Purchase Price per share, the Expiration Date and such other terms and conditions as the Committee or the Board in its discretion may prescribe, provided that they are consistent with this ISOP. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289526"></a>7.3.<font style="margin-left:36pt;"></font>Until the consummation of an IPO, such Shares shall be voted by an irrevocable proxy (the &#8220;<font style="font-weight:bold;">Proxy</font>&#8221;) pursuant to the directions of the Board, such Proxy to be assigned to the Trustee, who will abstain from any and all votes. The Trustee shall be indemnified and held harmless by the Company against any cost or expense <a name="_Toc509289526"></a>(including counsel fees) reasonably incurred by him/her, or any liability (including any sum paid in settlement of a claim with the approval of the Company) arising out of any act or omission to act in connection with the voting of such Proxy unless arising out of such member's own fraud or bad faith, to the extent permitted by applicable law. Such indemnification shall be in addition to any rights of indemnification the person(s) may have as a director or otherwise under the Company's Articles of Association, any agreement, any vote of shareholders or disinterested directors, insurance policy or otherwise. Without derogating from the above, with respect to Approved 102 Options, such shares shall be voted in accordance with the provisions of Section 102 and any rules, regulations or orders promulgated thereunder.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888251"></a>PURCHASE PRICE</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289527"></a><a name="_Toc509289528"></a>8.1.<font style="margin-left:36pt;"></font>The Purchase Price of each Share subject to an Option shall be <a name="_Toc509289528"></a>equal to the Share's Fair Market Value or as otherwise determined by the Board in its sole and absolute discretion in accordance with applicable law, subject to any guidelines as may be determined by the Board from time to time. Each Option Agreement will contain the Purchase Price determined for each Option covered thereby (but in any event, not less than the nominal value of the Share issuable upon exercise thereof).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289529"></a>8.2.<font style="margin-left:36pt;"></font>The Purchase Price shall be payable upon the exercise of the Option in a form satisfactory to the Committee, including <a name="_Toc509289529"></a>without limitation, by cash, check or wire transfer. The Committee shall have the authority to postpone the date of payment on such terms as it may determine.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.3.<font style="margin-left:36pt;"></font>The Purchase Price shall be denominated in the currency of the primary economic environment of, either the Company or the Optionee (that is the functional currency of the Company or the currency in which the Optionee is paid) as determined by the Company.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref113940495"></a><a name="_Toc508888252"></a>ADJUSTMENTS</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the occurrence of any of the following described events, Optionee's rights to purchase Shares under the ISOP shall be adjusted as hereafter provided:</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289533"></a><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>9.1.<font style="margin-left:36pt;"></font>In the event of a Transaction or an IPO, or if the Company is voluntarily liquidated or dissolved while unexercised Options remain outstanding under the ISOP, the Company shall immediately notify all unexercised Option holders of such event, and the Option holders shall then </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 9 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wenty</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0) days to exercise any unexercised Vested Option held by them at that time, in accordance with the exercise procedure set forth herein</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or in the case of a merger or acquisition &#8211; to </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">convert such Options into options in the acquiring or merging entity, all pursuant to the Board's determination and full discretion</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the above and subject to any applicable law, the Board shall have full power and authority </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">different</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> mechanisms with respect to unexercised Options outstanding under the ISOP.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.2.<font style="margin-left:36pt;"></font>If the outstanding shares of the Company shall at any time be changed or exchanged by declaration of a share dividend (bonus shares), share split, combination or exchange of shares, recapitalization, or any other like event by or of the Company, and as often as the same shall occur, then the number, class and kind of the Shares subject to the ISOP or subject to any Options therefore granted, and the Purchase Prices, shall be appropriately and equitably adjusted so as to maintain the proportionate number of Shares without changing the aggregate Purchase Price, provided, however, that no adjustment shall be made by reason of the distribution of subscription rights (rights offering) on outstanding shares. Upon happening of any of the foregoing, the class and aggregate number of Shares issuable pursuant to the ISOP (as set forth in Section 7 hereof), in respect of which Options have not yet been exercised, shall be appropriately adjusted, all as will be determined by the Board whose determination shall be final.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289534"></a>9.3.<font style="margin-left:36pt;"></font>Anything herein to the contrary notwithstanding, if prior to the completion of the IPO all or substantially all of the shares of the Company are to be sold, or in case of a Transaction, all or substantially all of the shares of the Company are to be exchanged for securities of another Company, then each Optionee shall be obliged to sell or exchange, as the case may be, any Shares such Optionee purchased under the ISOP, in accordance with the instructions issued by the Board in connection with the Transaction, whose determination shall be final.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289535"></a><a name="_Toc508888253"></a>TERM AND EXERCISE OF OPTIONS</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289536"></a>10.1.<font style="margin-left:36pt;"></font>Options shall be exercised by the Optionee by giving written notice to the Company, in such form and method as may be determined by the Company and when applicable, by the Trustee in accordance with the requirements of Section 102, which exercise shall be effective upon receipt of such notice by the Company and the payment of the Purchase Price at the Company&#8217;s principal office. The notice shall specify the number of Shares with respect to which the Option is being exercised.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2.<font style="margin-left:36pt;"></font>Options, to the extent not previously exercised, shall terminate forthwith upon (a) the later of: (i) the date set forth in the Option Agreement; (ii) the expiration of seven (7) years from the Date of Grant, or (iii) the expiration of nine (9) month period as or the effective date of the Company&#8217;s initial registration statement under the Securities Act of 1933; or to the extent applicable (b) the expiration of any extended period in any of the events set forth in Section 10.5 below.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289540"></a>10.3.<font style="margin-left:36pt;"></font>The Options may be exercised by the Optionee in whole at any time or in part from time to time, to the extent that the Options become vested and exercisable, prior to the Expiration Date, and provided that, subject to the provisions of section 10.5 below, the Optionee is employed by or providing services to the Company or any of its Affiliates, at all times during the period beginning with the granting of the Option and ending upon the date of exercise.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289541"></a>10.4.<font style="margin-left:36pt;"></font>Subject to the provisions of Section 10.5 below, in the event of termination of Optionee&#8217;s employment or services, with the Company or any of its Affiliates, all Options granted to such Optionee will immediately expire. A notice of termination of employment or service shall be deemed to constitute termination of employment or service. For the avoidance of doubt, in case of such termination of employment or service, the unvested portion of the Optionee&#8217;s Option shall not vest and shall not become exercisable.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289542"></a><a name="_Ref113940624"></a><a name="_Ref113940637"></a><a name="_Ref113940659"></a><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>10.5.<font style="margin-left:36pt;"></font>Notwithstanding anything to the contrary hereinabove and unless otherwise determined in the Optionee&#8217;s Option Agreement, an Option may be exercised after the date of </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 10 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">termination of Optionee's employment or service with the Company or any Affiliates during an additional period of time beyond the date of such termination, but only with respect to the number of Vested Options at the time of such termination according to the Vesting Dates, if</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289543"></a>10.5.1.<font style="margin-left:36pt;"></font>termination is without Cause, in which event any Vested Option still in force and unexpired may be exercised within a period of ninety (90) days after the date of such termination, and in case of retiring members of the board of directors, subject to Section 10.2 above, the later of (i) the closing of a Transaction, (ii) 3<sup style="font-size:85%; vertical-align:top">rd</sup> (third) anniversary of the retirement date, and (iii) the expiration of nine (9) month period as or the effective date of the Company&#8217;s initial registration statement under the Securities Act of 1933; or</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289544"></a>10.5.2.<font style="margin-left:36pt;"></font>termination is the result of death or Disability of the Optionee, in which event any Vested Option still in force and unexpired may be exercised within a period of twelve (12) months after the date of such termination; or -</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289545"></a>10.5.3.<font style="margin-left:36pt;"></font>prior to the date of such termination, the Committee shall authorize an extension of the terms of all or part of the Vested Options beyond the date of such termination for a period not to exceed the period during which the Options by their terms would otherwise have been exercisable.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5.4.<font style="margin-left:36pt;"></font>For avoidance of any doubt, if termination of employment or service is for Cause, any outstanding unexercised Option (whether vested or non-vested), will immediately expire and terminate, and the Optionee shall not have any right in connection to such outstanding Options.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289547"></a>10.6.<font style="margin-left:36pt;"></font>To avoid doubt, the Optionees shall not have any of the rights or privileges of shareholders of the Company in respect of any Shares purchasable upon the exercise of any Option, nor shall they be deemed to be a class of shareholders or creditors of the Company for purpose of the operation of Sections 350 and 351 of the Companies Law or any successor to such section, until registration of the Optionee as holder of such Shares in the Company&#8217;s register of shareholders upon exercise of the Option in accordance with the provisions of the ISOP, but in case of Options and Shares held by the Trustee, subject to the provisions of Section 6 above<a name="_Toc509289547"></a>.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7.<font style="margin-left:36pt;"></font>Any form of Option Agreement authorized by the ISOP may contain such other provisions as the Committee may, from time to time, deem advisable. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8.<font style="margin-left:36pt;"></font>With respect to Unapproved 102 Option, if the Optionee ceases to be employed by the Company or any Affiliate, the Optionee shall extend to the Company and/or its Affiliate a security or guarantee for the payment of tax due at the time of sale of Shares, all in accordance with the provisions of Section 102 and the rules, regulation or orders promulgated thereunder.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289548"></a><a name="_Ref113940340"></a><a name="_Toc508888254"></a>VESTING OF OPTIONS</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289549"></a>11.1.<font style="margin-left:36pt;"></font>Subject to the provisions of the ISOP, each Option shall vest following the Vesting Dates and for the number of Shares as shall be provided in the Option Agreement. However, no Option shall be exercisable after the Expiration Date. Unless the Committee provides otherwise, vesting of Options granted hereunder shall be tolled during any unpaid leave of absence. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.2.<font style="margin-left:36pt;"></font>Unless otherwise stated in the Optionee's Option Agreement, all Options granted pursuant to this ISOP, shall vest annually, in four (4) equal portions, over a 4-year period from its Date of Grant, with twenty five percent (25%) of such Options becoming vested at the end of each twelve (12) month period following the Date of Grant.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.3.<font style="margin-left:36pt;"></font>An Option may be subject to such other terms and conditions on the time or times when it may be exercised, as the Board may deem appropriate. The vesting provisions of individual Options may vary.</p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 11 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.4.</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of Change of Control all unvested options shall immediately become fully vested in their entirety. </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:italic;">Change of Control&#8221;</font> means any of the following events: (a) sale of all or substantially all of the shares of the Company; or (b) a merger, consolidation, reorganization of the Company or a similar business combination, in which the Company is not the surviving entity; or (c) the sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets or, all or substantially all of the shares of the Company are to be exchanged for securities of another Company.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.5.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cashless (Net) Exercise</font>.&nbsp;&nbsp;In the event of Change of Control, in lieu of cash payment method, the Optionee may elect, at any time, to exchange the Options for a number of Shares equal to the increase in value of the Shares otherwise purchasable hereunder on the date of exchange (&#8220;Cashless (Net) Exercise&#8221;).&nbsp;&nbsp;If the Optionee elects to exchange the Options as provided in this Section 11.5, the Optionee shall tender to the Company the Options along with the notice of exercise, and the Company shall issue to the Optionee the number of Shares computed using the following formula:</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X = <font style="text-decoration:underline;">Y (A-B)</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.87%;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-family:Times New Roman;">A</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:16.76%;width:76.24%;">
<tr>
<td style="width:15.13%;"></td>
<td style="width:7.67%;"></td>
<td style="width:53.45%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X =</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the number of Shares to be issued to the Optionee.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Y =</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of Shares purchasable under the Options (as adjusted to the date of such calculation, but excluding those shares already issued under the Options).</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A =</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Fair Market Value (as defined below) of one share of the Company&#8217;s Shares.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B =</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price (as adjusted to the date of such calculation).</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">Fair Market Value</font>&#8221; of a Share shall mean:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as set forth in paragraph 0 (below), if the exercise of this Options is immediately prior to a Transaction, then the price per share paid by purchaser of the Company&#8217;s securities (or deemed price per share paid for the Company&#8217;s assets).</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Exercise Date is the closing of the IPO then the IPO price per share in such offering.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:7.94%;text-indent:0%;font-family:Times New Roman;font-size:6pt;"><a name="_Ref56763598"></a>&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289550"></a>SHARES SUBJECT TO RIGHT OF FIRST REFUSAL</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289551"></a>12.1.<font style="margin-left:36pt;"></font>Notwithstanding anything to the contrary in the Articles of Association of the Company, none of the Optionees shall have a right of first refusal in relation with any sale of shares in the Company.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.2.<font style="margin-left:36pt;"></font>Unless otherwise determined by the Committee, until such time as the Company shall complete an IPO, an Optionee shall not have the right to sell Shares issued upon the exercise of an Option within six (6) months and one day of the date of exercise of such Option or issuance of such Shares. Unless otherwise determined by the Committee, until such time as the Company shall complete an IPO, the sale of Shares issuable upon the exercise of an Option shall be subject to a right of first refusal on the part of the Repurchaser(s), in accordance with the applicable provision set forth in the Company Articles of Association, in effect at the pertinent time and as amended from time to time.</p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 12 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509227756"></a><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.3.</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchaser(s) means (i) the Company, if permitted by applicable law, (ii) if the Company is not permitted by applicable law, then any affiliate of</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company designated by the Committee; or (iii) if no decision is reached by the Committee, then the Company&#8217;s existing shareholders (save, for avoidance of doubt, for other Optionees who already exercised their Options), pro rata in accordance with their shareholding.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4.<font style="margin-left:36pt;"></font>Any sale of Shares issued under the ISOP by the Optionee that is not made in accordance with the ISOP or the Option Agreement or the Articles of Association of the Company, shall be null and void.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.5.<font style="margin-left:36pt;"></font>Prior to the IPO, and in addition to the right refusal, any transfer of Shares by an Optionee shall require the approval of the Board as to the identity of the transferee and as may be required under the Article of Association. The Board may refuse to approve the transfer of Shares by an Optionee to any other person or entity the Board determines, in its discretion, may be detrimental to the Company, including without limitation to a competitor of the Company. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.6.<font style="margin-left:36pt;"></font>Notwithstanding anything herein to the contrary, the Optionee shall be bound by the "bring along" provisions of the Articles of Association and/or any agreement among the Company and all or substantially all of its shareholders, as in effect from time to time, to the effect that if, prior to the completion of the IPO, shareholders holding a certain percentage of the Company's share capital (as set forth in such agreement) (<font style="font-weight:bold;">"Proposing Holders"</font>), elect to sell all of their equity securities in the Company to a third party, or agree to merge or consolidate the Company with or into another entity, and such sale or merger is conditioned upon the sale of all remaining stock of the Company to such third party, or to agreement of all of the shareholders, the Optionees shall be required, if so demanded by the Proposing Holders, to sell or transfer all of their equity securities in the Company to such third party as stipulated in the Articles of Association or such other shareholders agreement referred to herein. If no specific percentage of Proposing Holders is stipulated in the Article of Association or such a shareholders agreement, then the percentage for the purposes of this Section and for the purpose of Section 341 of the Companies Law shall be seventy percent (70%). </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289553"></a><a name="_Toc508888255"></a>DIVIDENDS</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to all Shares (but excluding, for avoidance of any doubt, any unexercised Options) allocated or issued upon the exercise of Options purchased by the Optionee and held by the Optionee or by the Trustee, as the case may be, the Optionee shall be entitled to receive dividends in accordance with the quantity of such Shares, subject to the provisions of the Company&#8217;s Articles of Association (and all amendments thereto) and subject to any applicable taxation on distribution of dividends, and when applicable subject to the provisions of Section 102 and the rules, regulations or orders promulgated thereunder.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc34530398"></a><a name="_Toc508888256"></a><a name="_Toc509289554"></a>CONDITIONS UPON ISSUANCE OF SHARES </p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Legal Compliance</font>. Shares shall not be issued pursuant to the exercise of an Option unless the exercise of such Option and the issuance and delivery of such Shares shall comply with Applicable Laws and shall be further subject to the approval of counsel for the Company with respect to such compliance.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Investment Representations</font>. As a condition to the exercise of an Option, the Committee may require the person exercising such Option to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>14.3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Lock Up</font>. As a condition to the exercise of an Option the Optionee will sign and execute a lock up agreement, prohibiting the Optionee from, pledging, selling, contracting to sell, or </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 13 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otherwise dispose of or</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> transfer any with respect to the Shares for such </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a period, and on such terms and conditions, as determined by the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Board</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at it</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> sole and absolute discretion.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888257"></a>RESTRICTIONS ON ASSIGNABILITY AND SALE OF OPTIONS</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc34529539"></a>15.1.<font style="margin-left:36pt;"></font>Options may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Optionee, only by the Optionee, or by his guardian or legal representative to the extent provided for herein. An Optionee may file with the Board a written designation of the beneficiary on such form as may be prescribed by the Board and may from time to time amend or revoke such designation. If no designated beneficiary survives the Optionee, then the executor or administrator of the Optionee estate shall be deemed to be the Optionee&#8217;s beneficiary.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289555"></a>15.2.<font style="margin-left:36pt;"></font>As long as Options and/or Shares are held by the Trustee on behalf of the Optionee, all rights of the Optionee over the Shares are personal, cannot<a name="_Toc509289555"></a> be transferred, assigned, pledged or mortgaged, other than by will or pursuant to the laws of descent and distribution. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Ref113940408"></a><a name="_Toc508888258"></a>EFFECTIVE DATE AND DURATION OF THE ISOP</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289556"></a><a name="_Toc509289556"></a>The ISOP shall be effective as of the day it was adopted by the Board and shall terminate at the end of ten (10) years from such day of adoption.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company shall obtain the approval of the Company&#8217;s shareholders for the adoption of this ISOP or for any amendment to this ISOP, if shareholders&#8217; approval is necessary or desirable to comply with any applicable law, or if shareholders' approval is required by any authority or by any governmental agencies or national securities exchanges.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888192"></a><a name="_Toc508888259"></a><a name="_Toc34530399"></a>PURCHASE FOR INVESTMENT, REPRESENTATIONS</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.1.<font style="margin-left:36pt;"></font>Upon the grant of Options to an Optionee or the issuance of Shares upon the exercise thereof, the Company shall obtain from the Optionee the representations and undertakings as follows, and any other representations and warranties that the Committee may deem advisable, and the giving of such representations and warranties by the Optionee shall be condition precedent to Optionee's right to receive the Option and/or be issued the Shares upon exercise thereof: </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>That the Optionee knows that there is no certainly that the exercise of the Options will be financially worthwhile. The Optionee thereby undertakes not to have any claim against the Company or any of its directors, employees, stockholders or advisors if it emerges, at the time of exercising the Options, that the Optionee's investment in the Company's Shares was not worthwhile, for any reason whatsoever. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>That the Optionee knows and understands that his rights regarding the Options and the Shares are subject for all intents and purposes to the instructions of the Company's documents of incorporation and to the agreements of the shareholders in the Company.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>That the Optionee knows that neither this ISOP nor the grant of Option or Shares thereunder shall impose any obligation on the Company to continue the engagement of the Optionee, and nothing in this ISOP or in any Option or Shares granted pursuant thereto shall confer upon any Optionee any right to continue being engaged by the Company, or restrict the right of the Company to terminate such engagement at any time.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.2.<font style="margin-left:36pt;"></font>That the Optionee knows and agrees that it is possible that in the next future issuances by the Company of any additional share capital or other rights or securities convertible into or exchangeable foe share capital of the Company, without consideration or for consideration, the price per share will be less than the price determined herein, and that in such event the Optionee will in no event be entitled to any right to full ratchet anti-dilution protection.  </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 14 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888260"></a><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INABILITY TO OBTAIN AUTHORITY</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The inability of the Company to obtain authority from any regulatory body having jurisdiction, or corporate organ which authority is deemed by the Company's counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888261"></a>AMENDMENTS OR TERMINATION</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board may at any time, but when applicable, after consultation with the Trustee, amend, alter, suspend or terminate the ISOP. No amendment, alteration, suspension or termination of the ISOP shall impair the rights of any Optionee, unless mutually agreed otherwise between the Optionee and the Company, which agreement must be in writing and signed by the Optionee and the Company. Termination of the ISOP shall not affect the Committee&#8217;s ability to exercise the powers granted to it hereunder with respect to Options granted under the ISOP prior to the date of such termination.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289557"></a><a name="_Toc508888262"></a>GOVERNMENT REGULATIONS</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ISOP, and the granting and exercise of Options hereunder, and the obligation of the Company to sell and deliver Shares under such Options, shall be subject to all applicable laws, rules, and regulations, whether of the State of Israel or any other state having jurisdiction over the Company and the Optionee, and the Ordinance and to such approvals by any governmental agencies or national securities exchanges as may be required. Nothing herein shall be deemed to require the Company to register the Shares under the securities laws of any jurisdiction.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">21.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289558"></a><a name="_Toc508888263"></a>CONTINUANCE OF EMPLOYMENT OR HIRED SERVICES</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neither the ISOP nor the Option Agreement with the Optionee shall impose any obligation on the Company or an Affiliate thereof, to continue any Optionee in its employ or service, and nothing in the ISOP or in any Option granted pursuant thereto shall confer upon any Optionee any right to continue in the employ or service of the Company or an Affiliate thereof or restrict the right of the Company or an Affiliate thereof to terminate such employment or service at any time.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">22.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289559"></a><a name="_Toc508888264"></a>GOVERNING LAW &amp; JURISDICTION</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ISOP shall be governed by and construed and enforced in accordance with the laws of the State of Israel applicable to contracts made and to be performed therein, without giving effect to the principles of conflict of laws. The competent courts of Tel-Aviv, Israel shall have sole jurisdiction in any matters pertaining to the ISOP.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">23.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888265"></a><a name="_Toc509289560"></a>INTEGRATION OF SECTION 102 AND TAX COMMISSIONER'S PERMIT</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1.<font style="margin-left:36pt;"></font>With regards to Approved 102 Options, the provisions of this ISOP and the Option Agreement shall be subject to the provisions of Section 102 and the ITA's permit, and the said provisions and permit shall be deemed an integral part of this ISOP and of the individual Option Agreement with each Optionee.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.2.<font style="margin-left:36pt;"></font>Any provision of Section 102 and/or the said permit which is necessary in order to receive and/or to keep any tax benefit pursuant to Section 102, which is not expressly specified in this ISOP or the individual Option Agreement of the Optionees, shall be considered binding upon the Company and the Optionees. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">24.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc508888266"></a>TAX CONSEQUENCES</p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>24.1.<font style="margin-left:36pt;"></font>Any tax consequences arising from the grant or exercise of any Option, from the payment for Shares covered thereby or from any other event or act (of the Company and/or its Affiliates, the Trustee or the Optionee), hereunder, shall be borne solely by the Optionee. The Company and/or its Affiliates and/or the Trustee shall withhold taxes according to the requirements </p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:100%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">UroGen Pharma Ltd.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-variant: small-caps;font-style:normal;text-transform:none;">(formerly TheraCoat Ltd.)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Garamond;font-style:normal;text-transform:none;font-variant: normal;">AMENDED AND RESTATED ISRAELI 2010 SHARE OPTION PLAN </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-variant: small-caps;font-weight:normal;font-style:normal;text-transform:none;">Page 15 of 15</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under the applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Optionee shall agree to indemnify the Company and/or its Affiliates and/or the Trustee and hold them harmless against and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Optionee.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.2.<font style="margin-left:36pt;"></font>The Company and/or, when applicable, the Trustee shall not be required to release any Share certificate to an Optionee until all required payments have been fully made.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">25.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289561"></a><a name="_Ref113940749"></a><a name="_Toc508888267"></a>NON-EXCLUSIVITY OF THE ISOP</p></td></tr></table></div>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The adoption of the ISOP by the Board shall not be construed as amending, modifying or rescinding any previously approved incentive arrangements or as creating any limitations on the power of the Board to adopt such other incentive arrangements as it may deem desirable, including, without limitation, the granting of Options otherwise than under the ISOP, and such arrangements may be either applicable generally or only in specific cases. </p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, prior grant of options to Optionees of the Company under their employment agreements, and not in the framework of any previous option plan, shall not be deemed an approved incentive arrangement for the purpose of this Section 25.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">26.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;text-align:justify;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_Toc509289562"></a><a name="_Toc508888268"></a>MULTIPLE AGREEMENTS</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.94%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc509289563"></a>The terms of each Option may differ from other Options granted under the ISOP at the same time, or at any other time. The Board may also grant more than one Option to a given Optionee during the term of the ISOP, either in addition to, or in substitution for, one or more Options previously granted to that Optionee.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:right;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>urgn-ex121_51.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex121_51.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 12.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Ron Bentsur, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">I have reviewed this annual report on Form 20-F of UroGen Pharma Ltd.; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions): </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="color:#000000;"> March 15, 2018</font></p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ron Bentsur</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ron Bentsur</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>urgn-ex122_50.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex122_50.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 12.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Gary Titus, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this annual report on Form 20-F of UroGen Pharma Ltd.; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="color:#000000;"> March 15, 2018</font></p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Gary Titus</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary Titus</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>urgn-ex131_49.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex131_49.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 13.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2017 (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Ron Bentsur, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="color:#000000;"> March 15, 2018</font></p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Ron Bentsur</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ron Bentsur</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>urgn-ex132_48.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex132_48.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 13.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2017 (the &#8220;Report&#8221;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Gary Titus, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.44%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="color:#000000;"> March 15, 2018</font></p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By</p></td>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Gary Titus</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gary Titus</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>urgn-ex151_1183.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
urgn-ex151_1183.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:14pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018031520425006510840.jpg" title="" alt="" style="width:148px;height:125px;"></p></td>
<td valign="top"  style="width:50%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 15.1</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Georgia;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-222955, 333-221212 and 333-218992) of Urogen Pharma Ltd. of our report dated March 15, 2018 relating to the financial statements, which appears in this Form 20-F.<font style="color:#000000;"> </font></p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:423pt;;">
<tr>
<td style="width:170.2pt;"></td>
<td style="width:252.8pt;"></td>
</tr>
<tr style="height:14pt;">
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel-Aviv, Israel</p></td>
<td valign="bottom" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/Kesselman &amp; Kesselman</font></p></td>
</tr>
<tr style="height:14pt;">
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 15, 2018</p></td>
<td valign="bottom" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certified Public Accountants (lsr.)</p></td>
</tr>
<tr style="height:14pt;">
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Georgia;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A member firm of PricewaterhouseCoopers International Limited</p></td>
</tr>
</table></div>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Georgia;font-weight:normal;text-transform:none;font-variant: normal;"><img src="g2018031520425009210840.jpg" title="" alt="" style="width:604px;height:34px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#FFFFFF;font-size:1pt;font-family:Georgia;font-weight:normal;text-transform:none;font-variant: normal;">Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel, P.O Box 50005 Tel-Aviv 6150001&nbsp;&nbsp;Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g2018031520425009210840.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520425009210840.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M1F16"?( /4U=HH4:G\W;I]_7K^ ^:';OU^[[OQ,^'6;:=M0"I./L)(ES'][
M)^7UZ5"_B&TCT>WU,Q7'D3L$51'EP22.1^%:U%+EJ6^+\/\ @AS4[_#^/_ *
M4FIP1:M#IK)*9IHS(K!/D 'J:9#K-M.VH!4G'V$D2YC^]@$_+Z]*T**?+.^_
MX"O"VWXF2_B&TCT>WU,Q7'D3L$51'EP22.1^%69-3@BU:'3624S31F16"?(
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MI./L)(ES'][ )^7UZ5"_B&TCT>WU,Q7'D3L$51'EP22.1^%:U%+EJ6^+\/\
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M1F16"?( /4U=HH4:G\W;I]_7K^ ^:';OU^[[OQ,^'6;:=M0"I./L)(ES'][
M)^7UZ5"_B&TCT>WU,Q7'D3L$51'EP22.1^%:U%+EJ6^+\/\ @AS4[_#^/_ *
M4FIP1:M#IK)*9IHS(K!/D 'J:9#K-M.VH!4G'V$D2YC^]@$_+Z]*T**?+.^_
MX"O"VWXF2_B&TCT>WU,Q7'D3L$51'EP22.1^%69-3@BU:'3624S31F16"?(
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MI./L)(ES'][ )^7UZ5"_B&TCT>WU,Q7'D3L$51'EP22.1^%:U%+EJ6^+\/\
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M,V[8N-7U)$ '<+@?^A2)^5>L6T$5G:0VT("PPQB-!Z*!@?I7B>OZE>:W\9M
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M%; B.->>Q VDYY X&!R:[JN;\=ZWK'A[PE=:EH6F?VC?1%=L.QG !/+%5Y(
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MYCD#TQFKOCBWN_B)H:>'M)L;R"VN)XVNK^^M7MEAC5@QVI(%=G)   7'7)%
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M+DG?!W,N,$_,_)YRHKU.RGO[W4A*D+6FDQ1%426/;).YQAMIY15 P <$D\@
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MN#[$UB_%S2]<UWP_X?U+3='N;E;&]2[NM,(4RD8X!"D@D<@A<_>]JU3?ZO\
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M[A$CQKG:.2,C/.#C(]C6[0 4444 %%%% !1110 4444 %%%% !1110 4444
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MT5M<6*UGO)(]-(;[5:QK@W(.,*S]0G7(&,YQG&0=1$2*-8XU5$4!551@ #H
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M25#;-V"%8<G(]: /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$W6M7:)I]K$K-NG^9F5,=  68DXST'I6%\ [*&U^&D4Z2(\UY<RSS88$J<[
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MC=M?Y0S*R\EL<<_..>:]"M-+T72/%,0L[.2_UJ9?])O;B9II;>'!Y9VSM!.
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MDBO-_!^K>*-=^-&KQ:O?-'::79@-8VLK>1'(^W"D='8 MEB.J\<8J/0_&/\
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MOZQ#K=JD3><VH.R22%E!4Q9\L@Y/ 4=/2O2[>UAL[**TME\J&&,11JO\"@8
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M/X55/O.=S.,*#2_#SQ/I%CX^\>:AXCOX-+OY[M1'%?.(F$*E\ ;NIQMX'H*
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M-Q]MTMF6<R1X1BK;6VG/.&XY ]LBN%^"D@TW4O%VB:BPBUA-1::1)#AI$/\
M$!W&<G(_O"@#4\.^.KZU\2>,M/UN>>XTG05$BW\\*))P.58(%5B>2N ,@>]:
M'AJ\\2>.-&&NMJDN@V=R6-C:VL$4C^6#@/*TJMG.,X4+QCGFJ/Q0N+OQ+\-O
M$EOH]M)-#;^41,AR+C;(&D"#'(4 9(ZD$=JU?#OB?1-'^$VCZLUU&+*WTV)0
M PW,ZH 8P.[[AC'K0!1\#>+-;\7Z+KFFR7-K:Z[I5V;1KP6Q>)\,0'\O<.2%
M88SC.#[5B^ _$/CWQ'<>)=+?4[&9;"^-M%J\MJ/EP6!"PIM#$X4C)XSSNZ5/
M\.M-O?!O@'Q!XJUN$P7U^9M2D@;@HJJ652/4DDXZ\@=:N?!2Q&E?"^+4;H[9
M+^6:^G=NN,[03_P% ?QH S?"/B/QY>>*?$GA2>_L=0FT]E"ZK+;A%A!S_P L
MTQO)[+D8(.6/0W?!/B#Q2/BEK_A+7=4BU6WL;99TNDM4AVLWED+A?9SU)^[U
MIGP.B>]T77/$\ZD3ZUJ<DW/]P'@?@S.*S/@[KVE:KXE\6:K<:A;)JFJZB5M[
M:655E:% 2NU2<G@X.!_#0!ZGXAURT\-Z!>ZQ>G$%K&7('5CT"CW)( ^M<YX,
M\/ZI:>';[5+J6.W\2ZX_VNYFEA\P0$C]W'MRI(1<#&>N:JZG_P 5M\0H-'4;
MM%\/.EU?'^&:[/,47H0H^8CU(!KN+^\33].NKV0$QV\+RL!U(4$G^5 'GGPR
M\0^)=5\2>+=+US4(]1@TJZ6"&X2W6'YLN& "_P"Z.#DCUJIX>_XG_P"T#XDU
M/AX-&LH[&,^CM@G]1**A^!>J:8WA*\EDU&UDUF]NY[ZZMA*OG 9 SLSG'&<_
M[50? K6=,O+36KF;4+4:UJVJ2W#6K2J)2N V0N<D9+G(H ]CHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>"&ZMY;>XBCF@E0I)'(H97
M4C!!!X(([5)10!@#P+X0!!'A70P1T(T^+_XFM^BB@"M<:=8WEQ;W%S9V\\]L
MVZ"26)6:(^JDC*GZ5895=2K*&5A@@C((I:* ,FV\+>'K.[^UVN@Z7!<YSYT5
MG&KY_P!X#-:U%% $-W:6U_:R6MY;Q7%O*-LD4R!T<>A!X-8O_"">#_\ H5-#
M_P#!=#_\37044 4=.T72M'1DTO3+.Q1OO+:P+$#]=H%6;FUM[RW>WNH(IX7&
M&CE0,K#W!X-2T4 4--T32=&5ETO2[*Q5_O"UMTB!^NT"I%TO3TU*34DL;5;^
M10CW0A42LHZ OC)' XS5NB@#.O\ P_HNJW,=SJ.D:?>3QC:DMQ;)(RCT!8$B
MM!55%"JH55&  , "EHH \S\)>'M=\#:YXCEETV\UJ/5;O[1%<VUS$-H^; =)
M74@_-R5W9P/2M/2?"%_?^-?^$Q\3-"+R&(PZ?I\+%TM$.<EFXW.<G) P,]^,
M=S10!5O]-L-4M_L^H65M>0$Y\NXB61?R8$4S3M(TS2(C%IFG6EE&QR4MH%C!
M_!0*NT4 (RJZ,CJ&5A@J1D$5EVGAG0+"[-W9:'IMM<DY,T-I&CY_W@,UJT4
M%9=[X9T'4;L75]HFFW5R.DT]I&[_ )D9K4HH @FM@]C):PMY :,QHT8QLR,
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+ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g2018031520465609311254.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465609311254.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "U 6 # 2(  A$! Q$!_\0
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M;IFOMX]CQ"G1R20R+)$[1R*<JZ'!!]B*]M_X5-X;_O7W_?\ '^%'_"IO#?\
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MT>QXN][=R2-(]U.TC+L+&0DE?3Z>U05[?_PJ;PW_ 'K[_O\ C_"C_A4WAO\
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MO/\ H$P?]_C_ (4?\+7O/^@3!_W^/^%'MJ?</:Q/4JK_ /,1/_7$?S->:_\
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MND6HW2 'Y.W-3?\ "'^'?^@/:_\ ?%:=UU@_Z[#^M6*;V$HJ^QB?\(?X=_Z
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M_P \T_[[_P#K5+11<+$6Z;_GFG_??_UJ19F^T>4Z $KN!#9[XJ:JY_Y"*_\
M7(_S%"!EBBBBD,**** "BBB@ IDLBPQ-(V=JC)Q3ZKWW_'E-_NTUN)[#_-/_
M #QD_3_&CS3_ ,\9/T_QJ6B@"+S3_P \9/T_QH\T_P#/&3]/\:EHH B\T_\
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M'V+17R%9^)-<L)UGM=7O8Y%.0?.8C\03S7TYX'UJY\0>#[#4KL+]HE0B0J,
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MQEJ^A26>FZ7<&U\]"\DR??ZXP#VK-T6I\H^?2YZQ17R"WB3768LVM:B2>O\
MI+_XTG_"1:Y_T&=0_P# E_\ &M/JK[BYSZXN?O6__74?R-3U\@?\)#K9ZZQJ
M!QT_TE_\:/\ A(M<_P"@SJ'_ ($O_C3^K/N'.?7]%?('_"1:Y_T&=0_\"7_Q
MK=\,?$#Q'H^K6Y_M*XNK=G D@N)"ZL#]>E)X9]&'M#KK;_CUB_W!4M16_P#Q
M[1?[HJ6O4/'-70D@N=1BM9[6&5&#DE@=W"D]0?:G6M@FH+%-)%]G263RD,6
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M>358LYX8)MT]G'=*>-CNR@<]<J0:KT5L!V&NZ':R>+G\.Z1806S H1<2W#G
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MUOJ8OXHV216+*@;"*2H7('T&,=/:DO/#MG>75S<>9<P/=1B*Y$$I43*,@9_
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g2018031520470937611265.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520470937611265.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ $\# 2(  A$! Q$!_\0
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6+]Y"[RHFU5!Z*H]!6W10 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g2018031520465608511253.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465608511253.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ 8,# 2(  A$! Q$!_\0
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MGMM&U.6%_NNL0PP_.@#I**P/^$EF_P"@#JO_ 'Z'^-'_  DLW_0!U7_OT/\
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MDLW_ $ =5_[]#_&C_A)9O^@#JO\ WZ'^- &_16!_PDLW_0!U7_OT/\:#XFE
M).@ZI@<G]T/\: -^BN9M/&*WULMQ;:+J<D+$@,(ASC@]ZG_X26;_ * .J_\
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M\*Z:-+C2TCD9TC#'<1C.3FNIK)T9/DED[$XS6M6U%>XC*J_>"BBBM3,****
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MR8Q6B.>1Y]X3=M)\976G/PLFY1^'(KTFO-O% _LOQO9WR\+(58X^N#7I .X
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MZXUS5],AU*"34&G^RSP$7#Q ,$?[P..,>].U'Q;>&]U-=-O(WM8W@C6=4WK
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MF@#G/A]_R(FD_P#7-O\ T)J*3X??\B)I/_7)O_0FHH&:.@?\A?Q!_P!?H_\
M1:UO5@Z#_P A?Q!_U^C_ -%K6]0(**** "BBB@ HHHH **** "BBB@ HHHH
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)YB>HXHH&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g2018031520465684211263.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465684211263.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #1 8\# 2(  A$! Q$!_\0
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M/-3W_P"^31YJ>_\ WR:?10 SS4]_^^31YJ>__?)I]% #/-3W_P"^31YJ>_\
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MWT/X:(_)7U;\Z/)7U;\ZDHKG-B/R5]6_.O+_ (FH$U2TQG_5GK7JE>6_$_\
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M "UXKXY_Y&R[^HKVC>O]X5XMXX(/BR[QZBNO!_&<^)^$YVBBBO1.(]!^%O\
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M-NR[14?G1_WOTH\Z/^]^E<!UDE5M0_Y!UQ_US;^52^='_>_2J]_,AT^X&?\
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M!=I_UQ3_ -!%?/G>OH/3?^07:?\ 7%/_ $$5Q8W9'5AMV6J***X#K"JVH?\
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MK \:?\BG>_[H_G6_6!XT_P"13O?]T?SJZ?QHF?PL\1HHHKV3S ]/K7T'IO\
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MZ(L<#S RC>2H=@HSZ8 YH [VE[5@Z'J5[=7DT%XT;?N(YT*+C ?/R_ABMZ@
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/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g2018031520425006510840.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520425006510840.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +J W(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **KWUY'86<ES*K%$QD(.>2!_6L?\
MX3#3_P#GC=?]\K_\56%7$TJ3Y9RLS6%"I45XJYT%%<__ ,)AI_\ SQNO^^5_
M^*H_X3#3_P#GC=?]\K_\56?U[#?SHOZI6_E.@HKG_P#A,-/_ .>-U_WRO_Q5
M'_"8:?\ \\;K_OE?_BJ/KV&_G0?5*W\IT%%<_P#\)AI__/&Z_P"^5_\ BJ/^
M$PT__GC=?]\K_P#%4?7L-_.@^J5OY3H**Y__ (3#3_\ GC=?]\K_ /%4?\)A
MI_\ SQNO^^5_^*H^O8;^=!]4K?RG045S_P#PF&G_ //&Z_[Y7_XJC_A,-/\
M^>-U_P!\K_\ %4?7L-_.@^J5OY3H**Y__A,-/_YXW7_?*_\ Q5'_  F&G_\
M/&Z_[Y7_ .*H^O8;^=!]4K?RG04445UG.%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 97B7_D7[K_@
M'_H8KSZO0?$O_(OW7_ /_0Q7GU?-9S_'7I^K/;RW^$_7]$%%%%>2>B%%%% !
M1110 4444 %%%% !1110!ZM1117W9\F%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^>G_ (Z*/MMQ_P ]/_'14%%%@Y8]CTG^V+__ )[_ /CB_P"%']L7_P#SW_\
M'%_PJC17N>VJ?S/[SPO94_Y4;VCW]S=7;I-+N41D@;0.<CTK;KF_#_\ Q_R?
M]<C_ #%=)7IX63E3NV>=B8I5+(****Z3G"BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-/\ E7W&C_;FH_\ /S_XXO\ A72Z5/)<Z;#-,VZ1LY.,=R*XFNQT/_D#P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_0C7N\/_ .\R_P +_-'%C_X:]?\ ,T:***^O/)"BBB@ HHHH **** "BBB@
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MG_HN2HJSY(.78WPU)5JT:;ZG7_\ "5^'/^@_I7_@9'_C1_PE?AS_ *#^E?\
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M^'?^@!I?_@''_A6O11R1[![:I_,_O,C_ (17P[_T -+_ / ./_"C_A%?#O\
MT -+_P# ./\ PK7HHY(]@]M4_F?WF1_PBOAW_H :7_X!Q_X4?\(KX=_Z &E_
M^ <?^%:]%')'L'MJG\S^\R/^$5\._P#0 TO_ , X_P#"C_A%?#O_ $ -+_\
M ./_  K7HHY(]@]M4_F?WF1_PBOAW_H :7_X!Q_X4?\ "*^'?^@!I?\ X!Q_
MX5KT4<D>P>VJ?S/[S.M?#^BV5PEQ::186\Z9VRQ6R(RY&#@@9Z$BM&BBFDEL
M3*4I.\G<****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN(V_]FK@YHI+>>2&52DD;%'4]00<$5]^5\(:[_R,.I_]?<O_ *&: ,^BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX'\(V]@RJ;Z;]]>2#^*0CIGT4<#Z$]Z\X_:7_P"09X=_Z[3_ ,DH ^=Z***
M"O;/V;/^1IUG_KR7_P!#%>)U[9^S9_R-.L_]>2_^AB@#Z3HHKRSXS?$@>$M&
M_LC3)@-:OD.&4\V\1X+_ %/('XGM0!Y_\=/B3_:MX_A32)\V-N_^FRH>)9!_
M!_NJ>OJ?I7B=!))))R3U)K6\->'=0\5Z_;:/IL>^>=N6/W8U[LWH * .B^&/
MP^N/'GB$1N'CTJV(>\G'''9%/]YOT&37V#:6EO86<-G:0I#;P((XXT& J@8
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MMQX[\2O<@LFFV^8[. _PKW8C^\W4_@.U<70!)!!+<W$<$$;232L$1$&2S$X
M ]:^NOA1\.HO N@>9=*CZS>*&NI!SY8ZB-3Z#OZGZ"N+^!?PT^QPQ^+M9@_T
MB5<Z?"X^XI_Y:D>I[>W/<8]UH **** "OG3]I33&36-$U4+\LL#V[-[HVX?^
MAG\J^BZ\Z^-GAQO$'PYNWACWW.G,+R, <D+D./\ ODD_A0!\BT444 %%%% '
MM7[.?B%;/Q)J&A3/A;^(2P@_\](\Y ^JDG_@-?2M?!NCZK=:'K%IJED^RYM9
M5EC/;(/0^QZ'ZU]K^$_$]CXO\.6NL6##9,N)(\\Q./O(?<'\Q@]Z -NBBB@
MHHHH **** "BH8;NVN9)HX+B*5X&V2JCABC8SAL=#CM4U !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.I_]?<O_ *&: ,^BBB@ HHKT+X0^!3XS\6H]U$6TJP(FNB1PY_AC_$CGV!H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH'^LE(Y_ =!["N&^&GP4E\'^(FUG6;NUO)H4Q:)"&PC'@L=P'(' ^I]J]BH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-?$+_DG/B/
M_L'3_P#H!KI:YKXA?\DY\1_]@Z?_ - - 'Q+1110 4444 ?5'[/7_)-7_P"O
M^7_T%*]7KRC]GK_DFK_]?\O_ *"E>KT %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
3!1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g2018031520465681511261.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465681511261.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L >L# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^H_M$/\
MSVC_ .^A4E16P_T:+_<% "_:(?\ GM'_ -]"C[1#_P ]H_\ OH5)@>E&!Z4
M1_:(?^>T?_?0H^T0_P#/:/\ [Z%28'I1@>E $?VB'_GM'_WT*/M$/_/:/_OH
M5)@>E&!Z4 1_:(?^>T?_ 'T*/M$/_/:/_OH5)@>E&!Z4 1_:(?\ GM'_ -]"
MC[1#_P ]H_\ OH5)@>E&!Z4 1_:(?^>T?_?0H^T0_P#/:/\ [Z%28'I1@>E
M$?VB'_GM'_WT*/M$/_/:/_OH5)@>E&!Z4 1_:(?^>T?_ 'T*/M$/_/:/_OH5
M)@>E&!Z4 1_:(?\ GM'_ -]"C[1#_P ]H_\ OH5)@>E&!Z4 1_:(?^>T?_?0
MH^T0_P#/:/\ [Z%28'I1@>E $?VB'_GM'_WT*/M$/_/:/_OH5)@>E&!Z4 1_
M:(?^>T?_ 'T*/M$/_/:/_OH5)@>E&!Z4 1_:(?\ GM'_ -]"C[1#_P ]H_\
MOH5)@>E&!Z4 1_:(?^>T?_?0H^T0_P#/:/\ [Z%28'I1@>E $?VB'_GM'_WT
M*/M$/_/:/_OH5)@>E&!Z4 1_:(?^>T?_ 'T*/M$/_/:/_OH5)@>E&!Z4 1_:
M(?\ GM'_ -]"C[1#_P ]H_\ OH5)@>E&!Z4 1_:(?^>T?_?0H^T0_P#/:/\
M[Z%28'I1@>E $?VB'_GM'_WT*/M$/_/:/_OH5)@>E&!Z4 1_:(?^>T?_ 'T*
M/M$/_/:/_OH5)@>E&!Z4 1_:(?\ GM'_ -]"C[1#_P ]H_\ OH5)@>E&!Z4
M1_:(?^>T?_?0H^T0_P#/:/\ [Z%28'I1@>E $?VB'_GM'_WT*/M$/_/:/_OH
M5)@>E&!Z4 1_:(?^>T?_ 'T*/M$/_/:/_OH5)@>E&!Z4 1_:(?\ GM'_ -]"
MC[1#_P ]H_\ OH5)@>E&!Z4 1_:(?^>T?_?0H^T0_P#/:/\ [Z%28'I1@>E
M$?VB'_GM'_WT*/M$/_/:/_OH5)@>E&!Z4 1_:(?^>T?_ 'T*/M$/_/:/_OH5
M)@>E&!Z4 1_:(?\ GM'_ -]"C[1#_P ]H_\ OH5)@>E&!Z4 ,66-SA'5CZ Y
MI]1'_CZ3_<;^8J6@ J*V_P"/6+_<'\JEJ*V_X]8O]P?RH EHHHH *9-N\B3:
MQ1MIPPQD?G3Z;(@DC9"2 PP2.M &7'<7$\=C#Y[(\J,[RA5W';@8&1CG/IVJ
M&&[O+L2H+CRFMXR2P48D;L3D=/I6@--@6WCA#2#RCE'#?,OXTC:5:M&B!655
M0H0K8W*>H- %!K^]0I<,0L,J94-C:,C@^O!ZUKV\J30*\<AD7&-Q&"2/44V6
MS@G!$B;EV;-O8"G00);Q[(\XR223DDGJ30 YI-IQM8_04WSA_P \W_*I:* (
MO.'_ #S?\J/.'_/-_P JEHH B\X?\\W_ "H\X?\ /-_RJ6B@"+SA_P \W_*C
MSA_SS?\ *I:* (O.'_/-_P J/.'_ #S?\JEHH B\X?\ /-_RH\X?\\W_ "J6
MB@"+SA_SS?\ *CSA_P \W_*I:* (O.'_ #S?\J/.'_/-_P JEHH B\X?\\W_
M "H\X?\ /-_RJ6B@"+SA_P \W_*CSA_SS?\ *I:* (O.'_/-_P J/.'_ #S?
M\JEHH B\X?\ /-_RH\X?\\W_ "J6B@"+SA_SS?\ *CSA_P \W_*I:* (O.'_
M #S?\J/.'_/-_P JEHH B\X?\\W_ "H\X?\ /-_RJ6B@#.OM<L=-*"\D,1?[
MN5ZU3_X2_1?^?O\ \=-8/Q!_UUE_NM7%UW4<+"<%)LXJN)E";BCU+_A+]%_Y
M^_\ QTT?\)?HO_/W_P".FO+:*U^I0[LS^N3[(]2_X2_1?^?O_P =-.C\6:/+
M(L:7668A0-IY)KRNK.G?\A.T_P"NR?S%)X."5[L:Q<V]CV'SO^F;_E1YP_YY
MO^52T5YIZ!%YP_YYO^5'G#_GF_Y5+10!%YP_YYO^5'G#_GF_Y5+10!%YP_YY
MO^5'G#_GF_Y5+10!%YP_YYO^5'G#_GF_Y5+10!%YP_YYO^5'G#_GF_Y5+10!
M&LNYL;''N14E%% $1_X^D_W&_F*EJ(_\?2?[C?S%2T %16W_ !ZQ?[@_E4M1
M6W_'K%_N#^5 $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"?$'_
M %UE_NM7%UVGQ!_UUE_NM7%UZ^&_A(\K$?Q&%%%%;F 59T[_ )"=I_UV3^8J
MM5G3O^0G:?\ 79/YBE+9E1W1[-1117A'M!1110 4444 %%%% !1110 4444
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MG2/6;_OV:?L*G\HO;4^YTM%<U_PG.D>LW_?LU:T_Q5IVI7BVL!D\Q@2-RX'
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MXOY4^B@!GE1_W%_*CRH_[B_E3Z* &>5'_<7\J/*C_N+^5/HH \O\9 +XDG
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MHH B/_'TG^XW\Q4M1'_CZ3_<;^8J6@ J*V_X]8O]P?RJ6HK;_CUB_P!P?RH
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M7FG_ )Y/^E'FG_GD_P"E=QP$M%1>:?\ GD_Z4>:?^>3_ *4 2T5%YI_YY/\
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M%% $1_X^D_W&_F*EJ(_\?2?[C?S%2T %16W_ !ZQ?[@_E4M16W_'K%_N#^5
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ME@BA03U.!0 XNJG!8 TGFQ_WQ^=.*J>J@_44FQ/[B_E0 GFQ_P!\?G1YL?\
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M^XW\Q4M !45M_P >L7^X/Y5+45M_QZQ?[@_E0!+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !156^U&TTV%9;N811LVT$@GG\*@AUNPNK2
M>YMIO.C@&9-JD8'XT^5VO;07,KVOJ:-%53?VZRRH\@01!=SN0%&>@R:>;NWW
M;!/$TA7>$#C)'K]*0R>BJ+ZFJN52WFE"JKR-'M(0'IWY_#-3O>6Z;QYJ%T3>
M8PPW8^G6@">BJT]['#:QSE6;S"JHHQDD]!SQ4 U5&.Q+>9I]S*81MW#: 3SG
M'\0[]Z -"BJB:E9O$CFXB3>,@.X4_D?H:>;ZT6-9&NH!&QPK&08)]C0!8HI
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M* (C_P ?2?[C?S%2U$?^/I/]QOYBI: "H(Q/'$J;(SM&,[S_ (5/10!%F?\
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M^%2T4 19G_YYQ_\ ?9_PHS/_ ,\X_P#OL_X5+10!%F?_ )YQ_P#?9_PHS/\
M\\X_^^S_ (5+10!%F?\ YYQ_]]G_  HS/_SSC_[[/^%2T4 19G_YYQ_]]G_"
MC,__ #SC_P"^S_A4M% $69_^><?_ 'V?\*,S_P#/./\ [[/^%2T4 19G_P">
M<?\ WV?\*,S_ //./_OL_P"%2T4 19G_ .><?_?9_P *,S_\\X_^^S_A4M%
5$2K(9@[A0 I'#9ZX]O:I:** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g2018031520465614011256.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465614011256.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !E EL# 2(  A$! Q$!_\0
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M.UP(A%&VU>"68^@YZUQ%Q\8=3,I^S:=:+'V\W<Q/Y$5C_$N\>;Q?<VV3Y<&
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M'X=/PJCH?@[2]'F6>-'GN%^[+*<[?H.@KIXQ4RE?0<8VU9*..:E4\55FF6$
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M^FVDA#/!:Q1L1T)5 /Z5FK;E3YMF]C%OQ_Q,I_\ ?I$'%27H_P")C/\ [U-
M[5L]B"10:L)TJ$5,G2I&5I7AFNO*DD,6P?>([U2D4@\N&&:J:OG[6PS[BJ2N
M^W!8_G0%BY?N[&! <H"<<]*@?& ,C-*[J4 '6H)$*D<]* -^POR8DBG!##@'
MUJ2]NC#;M(N"PZ9JAITH:2;'/RJ,_G1J<ZI:-D]Q2&/6^W@;F /UQ37G#?Q
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M,5212XZ@'I4$BY'2J$;>7-)[@4Q'91G.E69]G_G2CI4=D=^B6)]G_P#0JDI
M**@-R8G/\7.*L"J,^/-88IE$QG5QG !]A2[LC&*J)P:G5SMX% 6$ VR,3WI_
M!!)I#R*9OQGOD4 78EV)VYYJO=-M=#5E?NK]*S=1F*SQ(!U&:0(E,YQ@8_&L
MB^L8[NY6:1$W*NWC(XJ^@W8R:20Q?\]%!]ZI*Y,YJ"U.:U'PQ;:D$C<!0K;@
M<GCBMRSA73K&*U@6-(HEP%5:>K1E\;L_0&II+9RORD4W%)W"-7GC9/0@M9)I
M9'+294'IBNLT[_D'Q_C_ #KDH8VMV<,PRV.E=7I1SIL1^O\ ,U,@.<5?G;ZU
M.HYIN,,WUJ6-:H":,5,HYIBCBI4%2!"\L33>1*"!P<YJ%TA4%HI2R^A%5M54
M?:1D]0.*I1%E.PG@T#-8[60_-C( (SUJ"(D2/W 8\TD4BA.>O2E;U!H > ^=
MR<8Y%;$3,T2EOO8YXK$BE_TB)<_QC^=;[4@,QKYA<21M@*IP*4W*'G>*RI;F
M-[Z=%<$JY!&>E2B,O%OP=O<T 6VG'9U_.JTUPJC)(_"FBWR/EJ"Y@=5SC Z9
MIB*5QK$:2B/RI6SQE5KN[0[K. ^L:GGZ5YK.I2ZC?!X:O2;,_P"@V_\ UR7^
M5*0&)>#_ $Z8_P"U3$'-4-5U^TMM4N(9%EW(^#A1C^=5E\4Z>.J3_P#?(_QK
M=4IM;&;K4UHV;JKZU,,"L$>+=-'\%Q_WP/\ &@^+--/&RX_[Y'^-+V-3L'MZ
M?<KZPP^WN/I_*JJHQP%4\TEUJVEW$YDQ<@G_ &1_C2)J]@A!$EUQ_L#_ !I>
MQJ=@]O3[EIE*1<KS3"A>$MMI#KNFL/F6<GUV#_&F-K&EMP?M6/0*!_6CV-3L
M'MZ?<L:<Y#3*>#@?UJMK]TEKIWF2MM4R*N?J:L6VNZ/;[L17'/\ LC_&ENO$
M&DW$#1^3,<_WD&/YT>PJ=@]O3[F9;[77(!_*K2QOC(R*A6_T=/NI<+[ <?SJ
M8:QIR]!<?]\C_&CV-3L'MZ?<DVOWS4,X(C.>*5M;LR?E:=1_US!_K4$^IV4R
MX:2Y;VV@#]#35&IV%[:GW-[PW B:RC#KL;^56<8=OK5#PO>VTVM)'%YF_8WW
M@,=*J/XGMED8>1+P3Z4U2G=JP.M!*]S=45( <5SZ^*K4?\N\WZ5*/%UF/^7:
M;]/\:/85.P?6*?<W<D"N3U>4C490">H_E5YO%EFP_P"/:<?B*Q[S4K"XN#,8
MYU)]Q1["IV!XBGW(BLAZ*<]>E1KO#?,34Z:E;C!5I_R%,-Y9LV6$Y^@'^-5&
ME470QJ5(2M:0;&<' )JWI9DWR+CH!4/V[3\8*7('M@5<LM;TRSW8M9SNZG(_
MQI.C4?0N%:G'=D.O3_9=)DEG.V,%0Q/;) J&TP\>5_#BM*Y\1Z=<0-$;.4AN
MS $5074=-3[EM.OL",?SJ?J]3L:?6*7<MJD@Y&X4_$O<M^=5QK=F/^6,_P"8
MIW]OVN,+!,#ZY%"H5>Q/UBGW$F#[#P>E=!X3B":9?'.=RC/Y&N8FU>&9=I$^
M#V&!71^%;N#^R]3<;DCB0%BW88-*5*:5VBHUH2=DS0 XJ9!64-=TS/-VO_?)
M_P *F37])'6\3_OD_P"%'LY]A^TAW1JCI22?ZI_]TUG?\)#I/_/ZG_?)_P *
M9+KVEO&RK?(,C'W3_A2]G/LQ^TAW1F;@7('0FK"'-4DO;!'W"]B;ZJW^%6H]
M6T[&'NH@/93_ (4O9S[,7M(=T3=*KW!P><G(IW]HZ7GB]3VR#_A4;WFFR'Y]
M23;Z!#_A2]G/LP]I#NC:!.Q?H*Y>X=O[8NL,00X'!]JZ!=8T4*!]O3@?W6_P
MK#F71/[2N+NWO%228AG.&(8@8I^SGV8_:0[HG2:7^]GZ@&I?/D_V?^^!_A4*
M:A8(,&\C/T4T[^U;'_GO&?P/^%'LY]F'M8=T2-(2.0/R JC+!YDC;1CCG%63
MJMD1@2P#W.[_  JLEY9B1F:[CY]%.*:IS["]I#NCJ;%#'H=BI[!__0JE%4)=
M6M+'0;"=RS12%U4H,]ZH_P#"5Z;Z3_\ ? _QH5*;V0G5@MV;V16=</\ OVQZ
MU2_X2O33VG_[X'^-0/XBTMGW;9\_[H_QJO8U.P>WI]S556(Z5* 0O-8P\2:8
M/^?C_O@?XU(/%.F@=)_^^!_C2]C4[![>GW--<[N:9)QZ5G_\)/IGI/\ ]\#_
M !IH\2:0#GRYL^Z#_&CV-3L'MJ?\QT2<QK]*P=:G\K5+6,HYWHV"%XX]33QX
MMTP#[L__ 'P/\:AG\3Z7-@,DQ'N@_P :/8U.P_;T^Y:B9MN<&JLL<C.VU2>:
M@_MW2?X1<+]!_P#7I!KVFCHUS^*BJC2J+H8UY4ZBMS%J*&8'E"*O%F"\J:R1
MXBTX'.;@_P# !_C1)XBTZ1<$W 'LN/ZTY4ZC^R31=.FK<Q/*Y>5L9XZUUFC?
M\@F'Z'^9KADUS3$!PLW)_N__ %Z[?0[B.YT:":+=L8'&X<]36=2$HJ[1TQJQ
MEHF9!'SGZU8C K ;Q+8I*P(FX)'W1_C4J>*].4<K/_WP/\:OV,^Q/MJ?<Z =
M:E4@=:YT>+=-S]V?_O@?XT'Q;IA[7'_? _QI>QJ=A>WI]RQK,BBZ7'/RBJ<:
MD\A3S5:ZUS2KB0/_ *0#C^Z/\:1==TU!@/<\?[ _QI>QJ=A^VI]S60%4Y&*1
M6W$C'2J0\2:7MPPG/_ /_KTT^(-((P?M ^B#_&E[&IV%[:GW+<)V7\6< ;Q_
M.NJX(KBH==T**4.%N693G)7./UK3_P"$TTC&-MS_ -^Q_C1[&IV'[>GW.=2Z
MMWUS4$20,R7#*P'8UMPR8 "R']:RY]5T*>ZDG\J9'<Y+*@!/UYI$UC2T/$MU
MCT*#_&CV%3L#KT^YN"1_[Q/XT&3'7-9B^(M)'47)_P" BB3Q)I9'[M;A3[J#
M_6G[&IV%[:GW$U296C5<@$GI7;V./[/MO^N2_P A7FL^HV$T@<O.V/517I5B
M5;3[9E^Z8E(S]!45(2C\2*C.,OA9X_X]&=2U(><8OWP^8*Q'4<';S@]*X^.^
MO(WW>9-!&\<6$,9<1KDAF&1D]NOKSTKM_&5VEEK6H3NC.!,%VKC))( ZD#J:
MPH=8LIECW2B)W8J(W(SD';V)'7WKTHI-+6VAYK;3>E]3--]J)M_.,CJJ1EOE
M@&9/G*JW/3C#'_(JN-8U!C:H9-A/+MY?!'F%1G(XR!QP.36\VJ6"F0-=Q#R_
MO_-TYQ_/BHDFTK49O,0V\\D:AMV 2HS_ $/Y4VNTA<W>)!H=Y>78E-VRY 4[
M=I!0\Y'0?UK8JA'K%A)#%*+E%67[F[@_YY%*=8TX2F(WD(D#;2N[G.<?SJXM
M)6N1)-O8O45375+%A(5NHB(OO_-TYQ_/B@ZK8J$S=1_.NY>>HZ?SJN9=R>67
M8N451_MBQ\U(_M"Y=-ZGL1G'7ZU)+J5G"P62YC0EBHR>XZ_ED4<R[AROL6J*
MAM[J&ZC+P2+(H."1V-34Q;!1110!T/@K_D9(_P#KF_\ *N,UZTEO+BWCCC1Q
MYS[MZDJ!M;DX]\5V?@K_ )&2/_KF_P#*N:N[D0WL414DSR,H/I@$_P!*Q:3F
MT_(V3:@FO/\ 0P98M4MK=UCN+AU25(A\G/EA!EA\I));Z]ZFN1?-:V,J^8]P
MD4A9E0CYO+.,C'KCC%7AJ]D9&3SN0<9*, ?F"\'&#R0#CI3TU*UD5C%+YFU6
M8A%).%.#^M.T>XN:78R9FU.!=@ENI=LPP1&-SJ5&1D*0 "3U'XU'';W1CM%8
M7,K(^)&E3D8FB/7'3 )_/TK5CUBSE2 EW0S %0\3#&3@9XXR>F>O:D37-/>0
M1K,VYB ,Q.!R<#G&,9XSTSQ1:-]QWEV,5O[4'^C1)=1H4=3A>.0Q!'R\'.._
MX59)O$560W8C<1"67R?WN/GSQM]=HZ=#6DFLV$D32),Q V\>6V3NZ8&,G.#T
M]*7^U[(D!9'<E ^$A=N"<#H/8\>U)1C_ # Y2_E*%HVK-+;RSO, &16C,8 *
ME3DGC.>G?@UO5GQ:U9S2,JM)M4)AS$P4[\ 8./4C_(-.;6+%)&0S'<H+-\C$
M  D')QZ@BKBXI;D24F]B]14-O<Q74?F1,2H)4AE*D$=B#R*FJR&K!1110 5U
M?AG_ )%OQ!_UQ_\ 96KE*ZOPS_R+?B#_ *X_^RM65?X/N_,UH?']_P"1YQJ]
MT\-TX%^ULJ6QD0#;AF![@CGZ"FC7I!&59(A.HE+1YY&Q-W2M=C;O=K&RJ9E3
M>,KR!G'6E MG)<>4Q;@MP<XI\KOHQ<RMJC(_M"_21H\0M,\NWYB=BCR]W'?M
M2Z;KDNHWXA6.-8]FYN3N'RJ1]?O'\JU99+:%#+(T:JN,L<<9X%5XK&PBN_/3
M EP7QYAP,C!(&<"BTKZ,+QML5?[0N4E*1A& DE+&0G(57 P,?6JT>L74]VL9
M>")<2!U'7( (P>A.#6X'MCR'B/!/!'X_K2!;0*A A"LV4QCD^WO1RR[@I+L8
M::E+#,TKRDHL);#$D9V1'M[D_G4?]LW<Z[BT4:[&RJGYB5DVY!Y[=N>]= 3:
MYVEH<GY<$CGV_2F1-8RQJT7D,BYQ@# QUI<KON/F5MC*;7+CS=J1V[%W9$3<
M=R$2!/F^N<_XUJZ?<R7-L7E51(DCQMLZ$JQ&1^5/S:JSN3"#D;SD?AFIE 4?
M* .<\544T]63)IK1"T4459 4444 =)JG_(D:-_UTD_FU>: W\#75\CE8UFD0
MEG9\@R8!V] %&>E>EZI_R)&C?]=)/YM7%Q:Q;27,D)#Q[-_SO@*=APW.?YUA
M!)K?J_S.B3:>W1?D9*:I?23I")PR/O5'2+YGZX;![?2K N)WTK2Y!.\LAF7>
MP&,_*<@CZU>GUFP@M#<?:8F7!VA7&6([#WJREW;N%VRH2V<#/IU_*K2\R&_(
MYY]5U&"%#+,I+K'(2(L'# Y4#H3P*2::Y=;V-YWD95N!MVD%!@;:VXM7T^=(
MV2[B_>':H+ $FG?VKI_F^7]L@W[MNWS!G/I2Y5_,/F?\IBR:C=6LL,$3,N^X
MDR&3((,S#K[#FHX[^[BMK9S<&1]A265HS^[^9021WQ70?VC8[I%^U0[HO]8-
MX^7G'/XT?VE8X0_:H?G4LOSCD#J?THY?[PN;^Z8K:EJ1MUE1UPB,Y/E?ZT!\
M#Z9'-=&.E4AJ^GF58UNXB60N"&XP.O-3/?6D;A'N(E8D* 6')/0?K5QLNI,K
MOH6**A@N[>ZW>1-'+M.&V,#BIJHC8**** "O5/"7_(KVGT;_ -"->5UZIX2_
MY%>T^C?^A&N3&? O4ZL'\;]#Q[6I)([B%HRP/GMG'?Y&Z_CBJ5K<7\UE=K++
MF80+(CK'C!92<8]B*U-3O4L7W.CN7E*JJ 9SR>Y'I4,6J64JVY%PBM.@>-&.
M&(/3BM[*^YC=VV,2TNKU94G2X\^-VB1P8\;LJ<GVQBI["_O+VQO3<%"1%D*H
MPR-@Y%:4&K6=Q<O!%.C;<88,""3G@>_%/?4K.-X4:X0&;)C.>&Q227<;?D8%
MOJ%R41S(TR0(2KK$1SY>2N.^#4$^K7UQ82QO.$!5PK"+)E/&%XZ=3R*Z4ZI8
M"+S3>0",MMW;QC/I1_:E@(C+]L@\L-M+;QC/I2<?[PU+^Z8%WJ5ZM\SHVZ2#
MS0L'EGY0!PQ/?/6KEKJ%VZQ237$?DHLDDCJF=RJ1@>QY/Y5K?;[/S-GVF+=L
MWXWC.W&<_E4,FI:8\162Y@='4G:6!W =?KT-/EL[\PN:ZMRF4DS6+1SW+.@N
M()'. 2/,8@@?7''X4R#5+U)A 90S1KM:(Q\J!$&W%OKQ6[%J%G-"LL<\90@$
M'/8G _7BHA>Z9M?%S;XE<JWSCYFP ?TQ1R]F'-W1@_VWJ!B4QS(\;8S.8MH4
ME<[?SK:LFN;PW'VF0>5P@C12.J@D[NO<UHHJH@50 H& !VIU4H-;LF4T]D<V
MC7%G$I@DD4$W#R%@9"0CX4#)XX-,@UB\DAC\VX6)3*R^?Y6[. I P..<G\JZ
M>BER/HQ\ZZHS=%EEDM)!/<&:1)65LIM*\]*]VTW_ )!5G_UP3_T$5XW7LFF_
M\@JS_P"N"?\ H(KEQBM&*.G".\I,\G\9VB7VLZA;N<*9U8\9S@@X_2N970%C
M9ECN66!R T>P?=#%@H/;&2/I7?7D4,WC6\254?YG*(YPK.%^4'\:L'1H+DB2
M[5UD\M28H8/+<99@254'.,>W45KS027,NAGRS;=GU//%T,"5&:X9EB;,2[1\
MH\Q7()[\J!5BUTU;699%D+8#C&/[S[JZ^V2WBUNTW1AT6T+ <#+!&.3D'GBI
MCHMDV)9!.$(5_,#KB;*,Q"\<8(QWJN:$7L3RSDMSS\Z"&\G=<;O*4QX:/@IG
M('7K[_I4SZ,CJP\TC<DB_=_OOOKM(=.TM[=)6CN<LB.0)A_%(4Q]WMUK$N8A
M!=S0@Y$<C*#ZX.*J/(]$B9<Z5VSG4T%Y;<K<W!W8Q&%483Y]_P"/05/_ &-B
M!T2X,;,@4M&N.C%CWSSG!YK6HJO9Q)=21C?V%BW2);IAA'4G8.<OO!_ T_\
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MH_"FCP-&J[1JET%  P/0'('Y\T44_;U.X>PI]AK> ;9V+-?SLQ.22HR33?\
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M Z5_S\7G_?:__$T?\(#I7_/Q>?\ ?:__ !-%%'MZG</84^P?\(#I7_/Q>?\
M?:__ !-'_" Z5_S\7G_?:_\ Q-%%'MZG</84^P?\(#I7_/Q>?]]K_P#$T?\
M" Z5_P _%Y_WVO\ \3111[>IW#V%/L'_  @.E?\ /Q>?]]K_ /$UTL$*P6\<
7*DE8U" GK@#%%%1.I*?Q,J-.,/A1_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g2018031520465682211262.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465682211262.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $0 EP# 2(  A$! Q$!_\0
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M *[Q?^B4K9H Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
MY+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&
MD_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H
M_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^
M"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
MY+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&
MD_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H
M_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^
M"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
MY+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&
MD_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H
M_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^
M"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
MY+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&
MD_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H
M_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^
M"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
MY+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&
MD_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H
M_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^
M"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
MY+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&
MD_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H
M_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^
M"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
MY+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&
MD_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H
M_L[QU_T,&D_^"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^
M"]O_ (NNMHH Y+^SO'7_ $,&D_\ @O;_ .+H_L[QU_T,&D_^"]O_ (NNMHH
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MG6X<Q[L$?,,9_G6G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM69(06^\/Q/_ -?_ #BI)9/5/T_^M5*1QU!/T_R:WIK4I(TK>3]V0&(]E_\
MU4%2&+#=CW'_ -:JEI+D$Y!]\U>#AEVYS[8S_2O1C>PG=,KMN)Z_I2YVCE>?
M<_\ UZ5XLD'@'UV__6IOELO&&_.FV4M1K.I/X=,UF7^CV%\N98PKG^)>#_*M
M(D\Y//I_DU&77@<9]\5-O(JW<X+5/#]S8EI(P9H!_$HY'UK'KU)@K @XP?;_
M .M7.:QX:60-/:KL?J4[-_A_]:BZ1FX=CCZ6E=&1RK@JPZ@TE49A1110!]@^
M"O\ D2-$_P"O./\ ]!J[KW_(OZA_U[O_ "JEX*_Y$C1/^O./_P!!J[KW_(OZ
MA_U[O_*D!\8M]X_6DI6^\?K24 %&,G%* 2< 9-='I&C ;9KA<L>BFANQ48MO
M0@TO0'GVRW/RQ]E[FNMM[>*",)&@50.PI&&T+@8]JE'W:ANYT1@HC2,$#UJ0
M8QBE3!XS2'@XI%$;(-N>])%'N;_&I&]!4T2*#\W!QQ3*19M"J+RO7H<5KHRQ
MQ8(R3TJG:P;(QG#<]#3K@9R1D#L*"B&XRY)!P3[TQ#R$!P:>(P4)/45#'$S2
MD_RHN5T)@N>M5;@?-BM 0LP] !5*9=IQUH,UN/MH\L /QJX;?/1L+WJ&V4\8
M!)]JT! S+ELJ":+@UJ<YK?A:VU-"\8$4P'#@?>^M>=:CIESIEP8;E"#V;L:]
MJDB9HSCZ5C:GI$.HVQANDSZ-W%4F83@GL>1 45I:OH\^DW)CE4F(GY'[,*S:
M9@--=S\(?^2CZ=]&_P#0:XBNW^$7_)2-.^C_ /H)H ^IJ**1C@4 4[Z^6T5,
MGYF; %5;O68K4+N89([U@:E>?;O$ZP*2(K1/WGH2:Y/Q#K$EUJ(CC8[-V.*X
MYXA\_+'T.N%!./-+U/3[358[D @CFM)3D9K@_#2RLBDG/%=U&,(,UV'(/HHH
MH **** "BBB@ IKMM4FG5#<[O*.* *-IJBW$DD>1N0]*9!K44ER\!8!E[5R+
M74FE>+<.V(9QD?7O46O>;IVM0WD?RQ2$ GZUQ_6'&?++O8ZO8IQNNUST=)%=
M<@T^L;1KOSX5YSD5LUV'*%%%% $-W_QY3_\ 7-OY5SWPZ_Y)YH?_ %ZK_6NA
MN_\ CRG_ .N;?RKGOAU_R3S0_P#KU7^M %_2O^0]KW_7>+_T2E;%8^E?\A[7
MO^N\7_HE*V* "BBB@#P/]H/_ )#&B_\ 7O)_Z$*\<KV/]H/_ )#&B_\ 7O)_
MZ$*\<H *M6%C-J%TL,0/)^9NRBH(8GGF2*,99S@5Z#I.G#3;-8E&7/+-ZFF!
M9TVRATRW6&#@_P 39Y)_.M>&X8#']:J)DD#<?I5E0!C!S]2?\?\ /-1."D!:
M^T;AT)_#_P"M_G%-+D#.-N.^.GZ>WZ&H"2%_A]O_ *_^?6H_,^480+[X'^'^
M<&N25*PTR9Y\<>9CL5)_^O[?^.^]599&]!] ^<?K_G IK.1G#,!Z8_SZ#_OG
MWJI+<*F0/F]LG _7_.!2IX>=1V@K^@I5(05Y.P^23<3E<_A_];_/%02'@G&/
MI_G_ #FHVN7(P JCV&?Y_P">*A/)KU*65U;7E*WXG++,*:?NJYJ6C.L>"1SZ
MMC^O^<U8$F#\W4_W7!_K6,(96Z1N?HII"DB]4<?@:ZU@8?S?U]Y'U^5[\GX_
M\ VMBOT7KZI_]:G8P.!_X[C^E8PN)E/^M?CL34JWS?QHA]U4 _RJ)X*HOA=S
M2&84Y.TM#09G!QT^M1M(.,G/X_\ U_\ .:A2Y$@PN=WIQ_A2^8Q.#D5PS@XN
MTD=\)1FN:.J L#SQ_P "Y_S_ /KIA'H/S'_UO;]#4F4Z\$_[1_\ K_YR:80O
MM]<?Y_SFH>A5S$UO1?MD331KB=!P/[P'8^_^%<8RLC%6!5AU!'->F'<.F0/<
M?_6_SBN;\1:9YJ?;(A\R##KZCU_"J3(G'JCEJ*2EJC(^P?!7_(D:)_UYQ_\
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MNK_(]!\/VGEP)QVKI!TJEIL0C@7Z5>KTSS@HHHH **** "BBB@ I&&5Q2T4
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MW#KP3\M6V,;?=8<]JK2VQQN0' ZUV0Q%.LN2LC@GA:E!\]%_(E,BMSC=^/\
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M^B4K8H **** / _V@_\ D,:+_P!>\G_H0KBO!]CE);PCK\BUVW[07.LZ(/\
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M"5[C'TIK!0O7'-)YN3C./3BHV.7QFGKT 5AD<,?SJL^X'''Y58VJ6P3^51R
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M@D553?&H(J1-Y?<QSVH'8O1MMCYYJ9<+\S]ZJY"XR<#/>KEM:^?-NW;E'Z4
MD."M/@@?(.?K5ZV CYSS5H6V8QQT%4G?9)MH!FJC[UZCZ5>A3=CM6/;298&M
M2&8;,#ENXH$:"A-O/!!Q56Y;:< ]:B><J">^:@N+D 9[T#9FWK9?)/&:DMXE
M9.>]0[/.EP>]6(XWMYE0M^[//- C2@C 3:!V[U6N%V,589]"*G2X0C"D>_-5
M[MUVY)&:9-C-=,=:A=@@/>GW$Q4$YS67-=CIFA@)<R_*:=X+FW>/--7U=O\
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MPN/I3,1ORW6F/M"X JM#))]Q\L<,:9$I8UE:CK,6C6+2I;?:K@_<CS5LG?\
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MDXI8QM7<:9&=TG'K4FB+T2[0":F)&:@9_E QTJ5>3G\Z10_/'%21KE@!^-1
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MO/\ OPW^% %*BKO]C:I_T#;S_OPW^%']C:I_T#;S_OPW^% %*BKO]C:I_P!
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M?_/-?RH\J/\ YYK^5/HH 9Y4?_/-?RH\J/\ YYK^5/HH 9Y4?_/-?RH\J/\
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M6AZ7ITS2V=C!"Y79E$ P/0>U ''6MY,/#>C6EI+=>>MBTS1PR")0H( 9W/0
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M_P"N;?RKGOAU_P D\T/_ *]5_K70W?\ QY3_ /7-OY5SWPZ_Y)YH?_7JO]:
M+^E?\A[7O^N\7_HE*V*YQI-4TW6]3DAT2XO8+EXW22*>)1Q&JD$,P/45-_;6
ML?\ 0JWW_@5;_P#QR@#=HK"_MK6/^A5OO_ JW_\ CE']M:Q_T*M]_P"!5O\
M_'* -VBL+^VM8_Z%6^_\"K?_ ..4?VUK'_0JWW_@5;__ !R@#=HK"_MK6/\
MH5;[_P "K?\ ^.4?VUK'_0JWW_@5;_\ QR@#=HK"_MK6/^A5OO\ P*M__CE'
M]M:Q_P!"K??^!5O_ /'* -VBL+^VM8_Z%6^_\"K?_P".4?VUK'_0JWW_ (%6
M_P#\<H W:*PO[:UC_H5;[_P*M_\ XY1_;6L?]"K??^!5O_\ '* -VBL+^VM8
M_P"A5OO_  *M_P#XY1_;6L?]"K??^!5O_P#'* -VBL+^VM8_Z%6^_P# JW_^
M.4?VUK'_ $*M]_X%6_\ \<H W:*PO[:UC_H5;[_P*M__ (Y1_;6L?]"K??\
M@5;_ /QR@#=HK"_MK6/^A5OO_ JW_P#CE']M:Q_T*M]_X%6__P <H W:*PO[
M:UC_ *%6^_\  JW_ /CE']M:Q_T*M]_X%6__ ,<H W:*PO[:UC_H5;[_ ,"K
M?_XY1_;6L?\ 0JWW_@5;_P#QR@#=HK"_MK6/^A5OO_ JW_\ CE']M:Q_T*M]
M_P"!5O\ _'* -VBL+^VM8_Z%6^_\"K?_ ..4?VUK'_0JWW_@5;__ !R@#=HK
M"_MK6/\ H5;[_P "K?\ ^.4?VUK'_0JWW_@5;_\ QR@#=HK"_MK6/^A5OO\
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..N;> )(H8-@_4<4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g2018031520465687011264.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465687011264.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H :X# 2(  A$! Q$!_\0
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M)".01'DCZ<XSR*Z"@ HIK GHQ7\*;L?_ )Z'\J )**CV/_ST/Y4;'_YZ'\J
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MVL?E>49#%(SG#;@,\"HTUF]>.UE2&&3[6K&.,$AEQZGO[T ;U%8D.ML95CN
MD6UB'<J<'G  ]#DBMN@ HIK-M[$_04GF_P"P_P#WS0 ^BF>;_L/_ -\T>;_L
M/_WS0 ^BF>;_ +#_ /?-'F_[#_\ ?- #Z*9YO^P__?-,EN4AB>60,J("S$KT
M% $U%8G_  ENA_\ /\O_ 'R?\*/^$MT3_G^7_OD_X5?LI]F1[2'=&W16)_PE
MNB?\_P O_?)_PH_X2W1/^?Y?^^3_ (4>RGV8>TAW1MT5B?\ "6Z)_P _R_\
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MA2V9XXOW1]*6D7[H^E+7N'B!1110 4444 =1X$_Y#LG_ %Q/\Q7H]><>!/\
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M^\__ 'T:DHH C\H?WG_[Z-'E#^\__?1J2B@"/RA_>?\ [Z-4]6C TB\.Y_\
M4O\ Q>U:%4M7_P"0/>?]<7_E51^)"ELSQP?='TI:1?NCZ4M>X>(%%%% !111
M0!TW@9=VN2#)'[D]#]*]%\H?WG_[Z->>>!/^0[)_UQ/\Q7H]>7B_XAZ>%_AD
M?E#^\_\ WT:/*']Y_P#OHU)17*=)'Y0_O/\ ]]&CRA_>?_OHU)10!'Y0_O/_
M -]&CRA_>?\ [Z-244 1^4/[S_\ ?1H\H?WG_P"^C4E% $?E#^\__?1H\H?W
MG_[Z-244 1^4/[S_ /?1H\H?WG_[Z-244 1^4/[S_P#?1H\H?WG_ .^C4E%
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M>_\ SS/YBC>__/,_F*?10 S>_P#SS/YBC>__ #S/YBGT4 ,WO_SS/YBC>_\
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MW#*_VMF!VH>V,\?3% '2T5SL4VH020F2.::'<2@&03R!S^>0#714 %%-;?\
MP;?QIO[[T3\S0!)14?[[T3\S1^^]$_,T 245'^^]$_,T?OO1/S- $E4M7_Y
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MDXX!QGZ5T5%% #6#'[K8_"DVR?\ /3_QVGT4 ,VR?\]/_':-LG_/3_QVGT4
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MYZ/^='EG_GH_YUB:DE%1^6?^>C_G1Y9_YZ/^= $E%1^6?^>C_G1Y9_YZ/^=
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M@&V ]@2,C':M*&(00)$K,P10H+')./4T /HHHH **** "BBB@ HHHH ****
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M,I /0X(Y!IDNBQ2K>1F:0173;G3CAN.0?PJ673(Y+B2<2,KR1"(Y (P#GH:
M+,$Z7$0D0.%/]Y2I_(U+533[!-/@:)'=@S%SNZ GL!V'M5N@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M/?V]M=
MP6TKE9)\^7D<,0,D9^E00ZWITR1,MU&HESY>\XW#U'MQ3-6LK#6+86=U(PW-
MN5HGVL"/1ATJO+X>TF2[2]P%*JJ<%=AV\#@CM[4 7?[8L"5VW,94[OG#?*-O
M7FDBUO2YG5([^W9F)  <=N:RX= T65IT6XDD*.R.IEP$+@9 &,#C'2K<GA_3
M-^9 P+2*^"^,D#:/TH NR:G8PQF22[A5  <EQT/3\Z:=6T\)$YO( LOW#O'/
M:L^+PUIL;!6GGE92A DE!*A#E1TZ4V3POH\DXNFSN8MDEP0VY]Q'((QNH WZ
M*CCGAD=XHY8V>,X=58$K]1VJ2@ HHHH **** "BBB@ HHHH **** "JNH:A!
MIEHUS<%O+!"_*N223@<5:JIJ6FVVK69M+M2T+,K$ XS@Y% %*+Q1I,EREN;G
MRY&#?ZP;<%6"D'/?)%79-4L(H_,>\A5"2 2XY(Z_E5>YT&PN6<M$4W6YMB(S
MM 0L&.!ZY YJBWAFPAGU&ZGE(BN(PN. (E'4C.1D]2: --M7L8]YDN$15 RS
M' .>F*/[7L0&9[A$59/+W,>"< _U%95OHFCW,4=S;W=QE"NRX\T[LCIRPYJ.
MXT;0[NZEM9+R;SI96,D8E^\Y5<Y&,9PHH W4U.QENS:QW<+3C(\L.,\#)_2J
MA\0V N&B8RJ%E\DRF,[-_INI+70].@EAFA+$Q3M.I\S(WE-A_2FGP[9-.[M+
M</&\OGM 9/W>_P!<=?UH LIK.GO@&[B5BN_:S $+ZFG?VOIVQ'^V0X=MJ_-R
M2.HQ5$^&-)-G<6SJYBN(A')E_P"$'(_6E@\.6,,D5Q;S3)*F[][&R@N&QD-@
M8/W1^5 %F+7M*FMS.E]%Y0<QEB<?,.HYI9=;T^*\AM/M*//,P540Y//K5.7P
MIITP0.TY\N1G3+@[=W4#(Z&I(O#5C#=1S1M,JQRB980^$#XQG&* -BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;(N^-D_
MO CFBB@#FAX/4VAMVOW\O#A56, *&[=<_F:JZMX/FE>,6,D?D;RS0,-JCY%7
MH.WRY/?FBB@"Q-X.6XP[W91BQ9XD4^7R@4@#(/&.#VJYJ_ATZI;V\ O&ABBC
MV8";B>F#DG((HHH R(_!]X]]>-<7"".?>!,I/F*#TQ_7-:$?@^V$422RA]BR
M#&SY26 &[!)P1C-%% %W2="32;JYF242?: N_,8#9 QG=WK7HHH **** "BB
MB@ HHHH **** "BBB@ HHHH *@O;87EE-;,Q42H4+ =,T44 8MQX4ADMK2&"
MXV+;QM'MD3S%;(P3@G@^AJ,^#XL8%]..,;L#=]P+U_"BB@!A\&JUO(IOFCE<
MJ-\$80*H4JP"YZLK')^A[5=TWPW'I\+QF]N926&UMY4A ,*IQU 'YT44 9UU
MX1NGM3&FHB0JBQ1B2+ "AL\\_,?RK=TG31I=M)%YN\R2-(<+M52>RKV''3ZT
944 7Z*** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g2018031520465606911252.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465606911252.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $@ DH# 2(  A$! Q$!_\0
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MX33Q+_T&KO\ [^4?\)IXE_Z#5W_W\KIVO]#M)II(HM,DN#/:+*?*5DSM/FE
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MK!I+8&%%%%, HP/2BB@ P/2BBB@ HP/2BB@ P/2C ]*** #%&!Z444 %%%%
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M_P#" >*?^@1+_P!]"C_A /%/_0(E_P"^A7O7VJ7U'Y4?:I?4?E1S2"R/!?\
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M]0TO4+:W-W]DWI)"K!6(9<;EW'&1[GI60D=].-96;2M1BEO+C?Y=O*B%4V
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M>:- U-BBL%?$AN###96+37<K2XB+A0J1MM+%O3. ..]7;34I)]2ELI[<P2+
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M)@_Z^7_I7C]XS/?7#.06,C$D9]??FO8OA@VWP;]T'_27ZCZ42V!'745)YO\
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M3\J?%)EC\B#Y3T%)C1!13_-_Z9I^5+YO_3-/RIB(Z*D\W_IFGY4>;_TS3\J
M(Z*D\W_IFGY4>;_TS3\J (Z*D\W_ *9I^5'F_P#3-/RH CK43[B_2L_S?^F:
M?E6BOW%^E1(J)\X^-?\ D=-6_P"OAJO>#4M[E;FVG(8[TDCC<%5W#/.\<#Z'
MK5'QK_R.FK?]?#5H^#?/>UOHH+NZ@)*EQ" 0PY^\#6OV2.IS%\[2:A<NYR[2
M,2>.3GVKU_X9?\B8/^OE_P"E>07VW^T+C9G;YC8W=>M>O_#'_D3!_P!?+_TH
MEL".PHJ#[9:^09_M,7DAMN_>-N[.,9]<\5/BI&%%1-<P)=+:M,BW#H76,GYB
MHZGZ5%;:E87DKQ6M[;SR1_?2.4,5_ 4 6J*AGNK>VD@CGF2-YW\N)6/+MZ#W
MJ:@ HHHH *D/_'N/]XU'4A_X]Q_O&A@1T4U9$<L$=6*':P!Z'T-.H ***KSW
MUI;2+'<74,4C_=5W )H L444C,$1G<X502Q/8"@!:*;%(DT2RQ,'C<95AT(I
M#-$)EA,B"5P65"WS,!U(% #Z*A6ZMW>-%N(F>0%D4.,L!U(]<4K75NCNC3Q!
MH\;U+C*YZ9],T 2T5 EY:R7+6Z7,+3KPT8<;A^%$=[:37#V\5S"\R?>C5P6'
MX4 3USVO^-],T/6'L+J.=IE17.Q<C!%=#7BWQ3<)X\9F;:!!'D_G36X=#M?^
M%FZ+_P \;O\ [X%'_"S=%_YXW?\ WP*\>^V6W_/=/SH^V6W_ #W3\ZJR)NSV
M'_A9NB_\\;O_ +X%'_"S=%_YXW?_ 'P*\>^V6W_/=/SH^V6W_/=/SHL@NSV'
M_A9NB_\ /&[_ .^!3S\3]$,:KY%WD9_@%>-_;+;_ )[I^='VRV_Y[I^=%D%V
M>P_\+-T7_GC=_P#? I5^)6D2,%2VO78]%6/)->._;+;_ )[I^=:_AO6M.T[6
M!<W5P!$(I%^4\Y*X&/3ZT-(-3TUOB1I*+N>UO57.W)CQSZ?6HYOB+I4EE*1:
MWNQT9 _E?+DC'6N1;QAH^I:<T5^MLK2&0[2I8I\@"$-ZD]3572M:TJ#PTUI/
MK$>^XF7S8'C+".,'/RCH6/\ *IT'J-\%^-YO#=U]@ORTFF2-]3"3W'MZBO;[
M>:*YL?/@D62*3#(ZG(85\^>,+_0I;B.73&B9!"%?R4VAI,GD#Z8KM?@_)K\N
MG7#2J%T3/[OS,[B_^Q[>M#&CTZBBBD 4444 %%%% #YB!&A)P G)]*\\L;[^
MPDN+>V:VG9#"\FHQ$L)(VDVGS0?NN/6O1)/NQ_[M9JW>DB&?RYK+REYF";<<
MG'S 4AG*76K/?:O9RC5([2&.]NX8KKRP5"!5QUX/U-,;7]>FTPWB7$<#0V<,
MQC-N")&>38<YY QS@5W!@@,6QH83'C[I0;<?2J_]H::T,LHN;9HHR$D8,"%Y
MP ?QQ18+G-3WFHM>&RFG6::&YDCCN?( 8 Q;A@#C(/%.$TTOPQDDDOFNYO(^
M:4 !@=P^7Y>X_.NLD\J%6DEV(%Y9V &/?-5[6ZT^Y#Q6<MM*!\S)$5(Y[D"B
MP7//]9>ZT\>(;Y'F:VN9EM9D!)\ML+L<>G<''K5O45LQ-KTP<C64N4%D8V/F
M[MJX 'IU]J[Q3#*9$7RW*G$BX!P?>F(;5KR14$)NHP"^%&]0>F3UYP:+!<;:
M2M(]RKW$4S1R[2L8QY7 ^0^IYS^-6:@M(;:*)FM0NR1V=F4YW,>I)]>,?A4B
MS1N[(LBEE;:P!Y!ZX^M,0^BF121S)OB<.N2,J<\@X/ZT/-%&,O(J@L$Y/\1Z
M#ZT /HHHH **** "I(?O-_NFHZDB^\W^Z:&"(Z*** "BH_M$.POYR;0VPMNX
M#>GUJ3% !145Q<V]I%YES-'"F<;G8 9I\4L<\:R0NLD;#*LAR#^- #J*** "
MM1/N+]*RZU$^XOTJ)E1/G+QK_P CIJW_ %\-2^'+B&"*<&ZM()F903=)D-%S
MN /KTXI/&O\ R.FK?]?#5@ULE=$=2:[,37DQ@.8BYV<8X[<5[#\,?^1,'_7R
M_P#2O&*]G^&7_(F#_KY?^E$M@1E_V1=_\)BV@?97_L>6_&K&7;B, +DQ_P#?
M9S^%4;"?Q/.=2:\U.YM+CR9A*GDR.4;<-C*,;0 /0G@UZE2Y/K6=BKGE;IX@
MU;38XK>WNXII-+N8P96R7<.,$.0" PS@'UH2\U)5NH_#FD^0(=,.S_B7>3-!
M*, IO_C)&37J>32Y/K18+GF>G1:I<SZ)+//-=PQZLCIN1\PKY9W99P"1G\J]
M+I<GUI*:0FPHHHH *D_Y=U_WC4=2'_CW'^\:&!Q3WEQ:+XBMK6.X6^EN3+"4
MB)ROEIEE/3. <>XJ%[O4[6WN;_37O[NRM98VCCF&7FRI5U'&2 2I^H-=QDXQ
MFDR?6E8=SDM";Q$9)X+B022V*>4'NLK'.S,3N^49.$V_CFJ=\US8SZL9K57U
M*:99(&:T\])TV@"-2?NX/^-=S1D^M%@N<E.;Z*'5[R9[YB)DBBA1]J1H0N6&
M!G .<GTK+,^IRZ6D5_-J"VY^UI&UNK;G8'$0.1G!'3/6O0:7)]:+!<X&T.M)
M>6=NUP]HD<5N+=65\,-O[P8 P3G(.2,5IZ_IMS<^*;6^LXV%Q969E@?'!829
M*$_[2Y&/I759/K118+GF=I97RVNCZI'I\ZW5AI[W"PE<-G[02T7U*G]*L/IE
MX6U&[EMI#<7T<$\GR]S("%_!<<=N:]$R:*+!<\]CL[L^))6@5FF&HSL(_LVW
M8KIM\PR]Q[5N^%GLX[*SLC8/#J,$.VX9K?!#_P 1+]]QR??-=+DT9-%@N%<Q
MXG^'^D>)=7:^OI+H2[%3$<F!@5T]23?ZT_A_*GU%T/._^%/>&O\ GK??]_O_
M *U'_"GO#7_/6^_[_?\ UJ] HH"YY_\ \*>\-?\ /6^_[_?_ %J/^%/>&O\
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M':F_\(]J,EM++-"[7D=G:);L9N5D0MOQSUZ<]Z[?SX?[K_F*/.A_NO\ F*+
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MZBO:4GBN=.MIX)%DBD!974Y!%)C0VBBBF 4444 %3)_QZR_[PJ&ID_X]9?\
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M_4_SI,"&BBBF 4444 %3)_QZR_[PJ&ID_P"/67_>%)@B&BBBF 4444 %%%%
M$TWW(?\ <_K6#;^&K"VMYK=&N&@FSOC>4D$DY)^N>];TWW(?]S^M0TD! MG
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ME$[CRX0P7Z\DUXE>H8[^XC)4E9&!*DD=>V:]C^%W_(F_]O+TI+0([G9;(O\
MGBGZT;(O^>*?K2T5!0FR+_GBGZT;(O\ GBGZTM% ";(O^>*?K1LB_P">*?K2
MT4 )LB_YXI^M&R+_ )XI^M+10 FR+_GBGZT_;'Y('E+C=TYIM/\ ^6(_WJ!D
M>R+_ )XI^M&R+_GBGZTM% A-D7_/%/UHV1?\\4_6EHH 39%_SQ3]:-D7_/%/
MUI:* $V1?\\4_6C9%_SQ3]:6B@!-D7_/%/UHV1?\\4_6EHH 39%_SQ3]:-D7
M_/%/UI:* $V1?\\5_6GRI&9#F)2?7FFT^7_6&@9'LB_YXI^M&R+_ )XI^M+1
M0(39%_SQ3]:-D7_/%/UI:* $V1?\\4_6GLL?E(#$N.<"FT]O]4GU- R/9%_S
MQ3]:-D7_ #Q3]:6J5MJMG=ZA=V$4H^U6I EC/4 ]"/44Q%S9%_SQ3]:-D7_/
M%/UI:*0";(O^>*?K3PL?E,/*7&1QS3:>/]4WU% R/9%_SQ3]:-D7_/%/UI:*
M!";(O^>*?K1LB_YXI^M+10 FR+_GBGZT;(O^>*?K2T4 .=(]J9B4_+QUIFR+
M_GBGZU(_1/\ =IE"&)LB_P">*?K1LB_YXI^M+10(39%_SQ3]:-D7_/%/UI:*
M $V1?\\4_6C9%_SQ3]:6B@!-D7_/%/UHV1?\\4_6EHH 39%_SQ3]:-D7_/%/
MUI:* $V1?\\4_6C9%_SQ3]:6B@!-D7_/%/UHV1?\\4_6EHH 39%_SQ3]:?&L
M88XB4?*?6FT^/J?]TT#(]D7_ #Q3]:-D7_/%/UI:*!";(O\ GBGZT;(O^>*?
MK2T4 )LB_P">*?K1LB_YXI^M+10 FR+_ )XI^M&R+_GBGZTM% ";(O\ GBGZ
MUH+]T8]*H5?7[H^E3(I'SCXU_P"1TU;_ *^&JQX7=%M[A8R_VIW4*J6(N25P
M<\'&!5?QK_R.FK?]?#5:\(&_#3_9+F..'<OFQO%OW]>GH>M;_9,NISET"+N8
M'LY_A"]_0=/I7LOPN_Y$W_MY>O'+T1B_N!""(_,;;D<XS7L?PN_Y$W_MY>E+
M8<=SLZ***S*"BBB@ HHHH **** "G_\ +$?[U,I__+$?[U QE%%% @HHHH *
M*** "BBB@ HHHH **** "N*\5_$!O#WB%]-6Q6;$:N'+XSFNUKQ#XL2K#X[9
MW. ((_ZTX[Z@]CHO^%KS?] I/^_M'_"UYO\ H%)_W]KRS^U+;U?_ +YH_M2V
M]7_[YK2T2+R/4_\ A:\W_0*3_O[1_P +7F_Z!2?]_:\L_M2V]7_[YH_M2V]7
M_P"^:+1"\CU+_A:\W_0*3_O[6F/'>M/# R^'#LE!:-O-X88+?AP">:\9_M.V
M]7_[YKK(OB+!#<6(C1TM[>W1)-J#>\BQLH.?0$TFET&FSKK3XEWU_<+!:Z*L
MDK=%$O\ C7":WKNIP>,9M;@1[*[5P&CSG;CJK>HI1XLTBX\1V^I7T=R\<<"!
MP@ +RJ.I]L\UDZEKEM>:A=W9EED$CER\BX+9]:%8-3W7PCXNL_%6G[X\17D8
M_?P$\@^H]1715\_?#?1=;UKQ$FHV$K6-E;/F2X ZC^X/7/Z5] U#*04\?ZIO
MJ*93Q_JF^HI#&4444""BBB@ HHHH >_1/]VF4]^B?2N?3Q=I<D+R*9P AD0-
M%CS%#!25]<$B@9NT5''/%+#YL<BO'C.Y#N_E5/3]8M=1N9K:)9HYHE#M'-&4
M)4\!A[4"-"BJD&IV=Q#)*LZ*B2M$QD(7YE.#UIMQJUE9RLEU,( &1 \APK,W
M0 T 7:*JQ:C:RQO)YR)&LIB#NX"L1_=.>:5+^TEO)[1+F)KBW"F6,-R@(R,_
M@* +-%0FZMQ;^?\ :(O)[2;QM/X]*I_VY:?V3#J6)/L\LBQKE><E]G/MF@#2
MHIB312@&.6-PP)!5@<@=ZAOM0MM/T^6^N'Q;QKN+*-V1[8ZYH LT5DW7B*PM
M;6.Y)DDAEM'O$9%SF- "?Q^85I">(R"/S4\PKOV;ANQZXZT 245";NU5-[7,
M 4-M+&08SZ=>M.%Q T@C6:,R%=P0.,D>N/2@"2GQ]3_NFH4FBE9ECEC<K]X*
MP./K4T?4_P"Z:!C****!!1110 4444 %%%% !5]?NCZ50J^OW1]*F12/G'QK
M_P CIJW_ %\-5GPG;QR)/-)$)-LB*@&,J3GYN2.!5;QK_P CIJW_ %\-5_P;
M$\EO>M'*(-CH7E&TEEYRF&SP?45M]DRZG-7_ )G]HW/FNKR>:VYEZ$YZBO8O
MA=_R)O\ V\O7CEZ4-]<&- B&1MJ@Y &>E>Q_"[_D3?\ MY>B6PX[FA!XSL)]
M<_LK[->(QNGLTG:/]V\JC)4'.>GM5^X\1Z-;6]Y.^I6S+9J7G"2!F0#VKD%\
M!Z@?$T]^'M+=7U&2[%Y&S&;RV!'E[?NCKUIEKX U!K=;:Z.GQ);6$]G%+"I+
M7!DZ/)]/YUEJ7H=O;ZWIEW:"ZAOH&A,0F+;Q\J'N?3GBL^?Q7 NI3V-EI]_J
M+6Q47,EI$&2(GD DGDXYP*YF\\&:]<6ICA73(3<Z8EA<J"<)L;(9<=<T[4_!
M.L,E]:V$EHUO>S)<B5Y7CDM90H#$;?O XXS1=CT.VEU:PBE> W4/VI8C+]GW
M@.0!GIZTFC:G'K6BVFIQ1M''<Q^8J,<E?K^5<@G@:\7Q'<7DKK<0R3FYCD,[
M*8V\O;@ICYOSQ74>&]-ET;PUI^FSLK2VT6QF3H3D]*>HC5HHHH$%/_Y9#_>I
ME/\ ^60_WJ!F#=^)K:UDNC]ENI;:T;;<W,:92(X!/N< C..E:HN[9E5A<1%6
M8HIWCEAG(^O!_*N=N-$U46^J:;:M:FRU&1V,[D[X0XPXV]SUQ]:BN?"$TUY>
MQQW*1V$L$GD*,[HYW01E_H "?JQHU Z(:KI[0-.+ZW\E#M9_,& ?3-.CU&RF
MG$$=W"\I7<$5P217,V_A64PH)XD$@F@:3S)O,#K'GH, #K3KWPWJ5[K9G:>.
M.W61S&T9V[4:,J % Z@GKGF@#:G\0Z1;^29-0@Q+-Y"E7!&_!//H..M36FJ6
MMW"\JRQJJ[F.7!^13C?].*PO[#OWT[3HGLM-673[F.0*G2955E.3CC.[/X5!
M/X1NVAC6"6"%FN9A/@<-;R.&*CW&,?\  C1J!U*7UG)<_9TNH6F*[A&'&['T
MK.O/$=M8ZA+:RV]R5A,8EG1,I&9/NYK/L?#,EIKSW#@R6XNGN87\XC9N& NS
M'..G7%0ZUX6NM2URYNXH[8&80^5<N[![<IU(4<&C4#=AUNS=)FGE2V\NY>V'
MFN!N*XR1[<T:AK=GI\]O TJ/<33QPB%7&X;S@-CTK U'PSJMQ!<6\,T)BN)I
MY"-VT@OC:2<<CCD"E/AB_P#M4:@6C1?;(+IKAL^:NQ0"@_+CZT:@;QURQ.K1
MZ='-')(RNSLD@(CV]<U,-5TXVYN/MUOY(;:9/,&,^E<H/"&H2V_V5S:0)';3
MVZW$6?,DWMD,?ZU;MO"\FZ"2>",.MS%+*LDOFA@@(&.,#K1J!U:L'564@J1D
M$=Q63K'A/0=9OS=:CIL-Q/M"[W'.!6N      .@%/E_UAH Y;_A7OA+_ * =
MM^1H_P"%>^$O^@';?D:Z:BF(YG_A7OA+_H!VWY&C_A7OA+_H!VWY&NFHH YG
M_A7OA+_H!VWY&G'X>>$O+4_V';9.>QKI*>W^J3\:0SEO^%>^$O\ H!VWY&O/
M+KX<_P!M^/;RQLX/L6B6KJ99$&!T^ZOJ?Y5[30 !T &>3Q3$5=/TZTTFPAL;
M&!8;>)=J(H_7ZU:HHI %/'^J;ZBF4\?ZIOJ*!C****!!1110 4444 /;_EG]
M*XJ'P?(OAAH)B\VH&$PJLDV8XU9P6"^F0/TKM7Z)]*Q8_$FF"&V:ZNX+>6X0
M.D?F;^"< Y QC/&:!B:1IDFEWFJM'"B6\S1/!&C8&5B"M],L#_.H= AU+[;=
MWNKV0ANY\#>LX=50'Y448R .N3U)JQK7B"VT.XL([F*1DO)3&9$Z18Q\S>V2
M!^- \1:<D-Q-=3"V2&ZDM<R'.]D/) ':@#%_X1BXFE_TF"&2,/>N SY&9!\A
M_P ]*AF\-:B]I^]MXKEX_L;+&TGWO*!#C)Z5U0U73S')(+R$I'LWL&X&_P"[
M^?:F?VYI>ZX'V^'_ $<%I<DX4 X)SWY]*- .8O?#^K?8[NWM+2W\F>[N)53<
MN45T 3&X8'(.<<TDGAC4C;ZA%'#$)KNPM8_M D&?,C7#J>_S>M=);^(=&NKB
M*"'4H'DE?RT49R6].G7^=0:1XFT_58,^?%%<*)#)"6Y0(Y4G/3MG\:6@:F+_
M ,(_>(+>X&G^>HN)));.:=0#NCVAA@8&#V_&K+Z#>?\ ""VND_9H7N(I$9H#
M)A"HDW%=WTK9_P"$@TC[(UV=0A$"L$+G(^8]!C&>:=J.HS6=D+JUL7O8]AD;
M;*L>U,9S\W7Z4: <C?Z1J5I;?:K6%;.ZN[YHHK='W"**5%0\CC@C?^%=%JNC
MW%U;Z9I]E(MO:6\BO(Y 8@(/D 4]?F _*HI/%D VS164TMFJ0O/<;@ODB097
MY3R< Y..E78M8:?4K^PCL9A-:Q+*OF,%$V[<!CTY4\FF!S;^&-7_ +.DL28I
MEBM+RV@D+!=XDVE,CMCD?@*LP^'KY=?DN)U=T,YGCG251@>7M"D8SQTQT[UM
M:5J\^H7E[:SZ<UI):; Q\Y9%)89QE>X&#^(K5H"YYIK&E'2]-T;3VMU3;83+
M=A<89B$#8)!!?@X/6ME=*U2[US3[U+5(;.*9)5.55A%Y)7#<;BV2.,XXKLB
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@/\I_[IH\I_[IHN RKZ_='TJGY3_W35Q?NCZ5,AH__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g2018031520465632411258.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465632411258.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #> -0# 2(  A$! Q$!_\0
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M;O.QZ<8N,%;J9KZ)I%J&2.1C(G!.>]%L]I;R%7"2HIPV.H^M6_/*@)"VR->
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MQG..I7L:O4 %%%% "$9%8&N>%X]:U&RO_M;03V894_=)(I#=<A@16_2$X[T
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M4[ /_':TA"[.>K4Y8-+J=1$BQH$10JJ, #M3Z04M=)YP4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g2018031520465680711260.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465680711260.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% ;(# 2(  A$! Q$!_\0
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M7'_'S+_OG^=%,1M6_P#Q[1?[@_E4E1V__'M%_N#^524AA1110 4444 %%%%
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M+2+B9(8KZ-I'8*J@'DG\*U*EQ<=T4I)[,****0PHHHH **** "BBB@ HHHH
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MY#^G_P#7PG\Q7K]>=C?B1Z&#^%A1117$=@4444 %%%% !1110 4444 %%%%
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M/_/63\Q1Y1_YZR?F* )*KW__ "#KG_KDW\C4GE'_ )ZR?F*KWT1_L^Y_>/\
MZINX]#3CN)['CE%%%>Z>(%%%% &AH7_(?T__ *^$_F*]?KQ_0QG7K 9(_P!(
M3D?45ZYY1_YZR?F*\[&_$CT,'\+)**C\H_\ /63\Q1Y1_P">LGYBN(["2BH_
M*/\ SUD_,4>4?^>LGYB@"2BH_*/_ #UD_,4>4?\ GK)^8H DHJ/RC_SUD_,4
M>4?^>LGYB@"2BH_*/_/63\Q1Y1_YZR?F* )**:J;<_.S?6G4 8-Q_P ?,O\
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M^(?^1@OO^NIK,K3\0_\ (P7W_74UF5\56_B2]6?<4?X<?1!11169H%>N:/\
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M)49/RBO)Z];T7_D!V'_7O'_Z"*]/+&W.7H>7FB2A'U+7D0_\\H_^^11Y$/\
MSRC_ .^14E%>P>(1^1#_ ,\H_P#OD4>1#_SRC_[Y%244 -6-$^XBKGK@8IU%
M% &#<?\ 'S+_ +Y_G11<?\?,O^^?YT4Q&U;_ /'M%_N#^525';_\>T7^X/Y5
M)2&%%%% !1110 4444 %%%% !1110 56U'_D&7?_ %Q?_P!!-6:K:C_R#+O_
M *XO_P"@FG'="EL>,T445[IX@4444 :.@?\ (P6'_7=?YUZ]7D.@?\C!8?\
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M_A7DN@?\C!8?]=U_G7KU>=C?B1Z&#^%GE&OD-K]Z1WE/:LVM/Q#_ ,C!??\
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MQ&U;_P#'M%_N#^525';_ /'M%_N#^524AA1110 4444 %%%% !1110 4444
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M[\!0J4Y-S5CS\PQ%.K!*#N7**CWR?\\O_'J-\G_/+_QZO4/*)**CWR?\\O\
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M^M110 ?VI_TQ_P#'O_K4?VI_TQ_\>_\ K444 ']J?],?_'O_ *U']J?],?\
MQ[_ZU%% !_:G_3'_ ,>_^M1_:G_3'_Q[_P"M110 ?VI_TQ_\>_\ K4?VI_TQ
M_P#'O_K444 ']J?],?\ Q[_ZU']J?],?_'O_ *U%% !_:G_3'_Q[_P"M1_:G
M_3'_ ,>_^M110 ?VI_TQ_P#'O_K4?VI_TQ_\>_\ K444 ']J?],?_'O_ *U'
M]J?],?\ Q[_ZU%% !_:G_3'_ ,>_^M1_:G_3'_Q[_P"M110 ?VI_TQ_\>_\
MK4?VI_TQ_P#'O_K444 ']J?],?\ Q[_ZU']J?],?_'O_ *U%% !_:G_3'_Q[
M_P"M1_:G_3'_ ,>_^M110 ?VI_TQ_P#'O_K4?VI_TQ_\>_\ K444 ']J?],?
M_'O_ *U']J?],?\ Q[_ZU%% !_:G_3'_ ,>_^M1_:G_3'_Q[_P"M110 ?VI_
MTQ_\>_\ K4?VI_TQ_P#'O_K444 ']J?],?\ Q[_ZU']J?],?_'O_ *U%% !_
M:G_3'_Q[_P"M1_:G_3'_ ,>_^M110 ?VI_TQ_P#'O_K4?VI_TQ_\>_\ K444
M ']J?],?_'O_ *U']J?],?\ Q[_ZU%% !_:G_3'_ ,>_^M1_:G_3'_Q[_P"M
M110 ?VI_TQ_\>_\ K4?VI_TQ_P#'O_K444 ']J?],?\ Q[_ZU']J?],?_'O_
M *U%% !_:G_3'_Q[_P"M1_:G_3'_ ,>_^M110 ?VI_TQ_P#'O_K4?VI_TQ_\
M>_\ K444 ']J?],?_'O_ *U']J?],?\ Q[_ZU%% %%SYDC/TW$G%%%%(9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g2018031520465633811259.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465633811259.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ D,# 2(  A$! Q$!_\0
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MTW6;?4Y;B%8IX)[<CS89TVLN>AZGBKT<L4JEHY$=0<$JP-/E787,RY]ONO\
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M+MA>RBOHWPW_ ,BMI'_7E#_Z *^;+F/RKATX(!X(KZ3\-_\ (K:1_P!>4/\
MZ *]R<5&*C'8\&,G)N4MS4HHHK(L**** "BBB@ HHHH **** "BBB@ HHHH
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M4/\ Z *^9J^F?#?_ "*VD?\ 7E#_ .@"LJI<#4HHHK$T"BBB@ HHHH ****
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M1W)EL5J***U("J&KZB=+LUG6#SF:18PF_;R??!J_6/XELYKW2UB@A,S"9&9
M0,@=>M)[#6Y:BOWC@,FI11V67"+F8,#^.!BGQ:G8S6TES'=Q-#']]PW"_6L2
M?3WN-.M[>#2GMD2]CD>)W5LKW/4\5'?Z/=ROK'DVX*2R021)D 2!1\P__72N
MRK(TK?7[>XU"Y1983:0PB7S@WO@YJ];ZE974KQ6]U%)(@RRJV<"N9O;>Y*:Q
M?2V)M8I;,*H+*22#WQWIT&G7FH/&ZV8LT2P: /N'SLRX&,=N]*["R.BM]5L+
MN9H;:[AEE7^%6J"VUFW_ +/AN+V>VA:4,1MDRI"G'![]JR[*RO);G2%DL#:K
M8(1)(67YSMQA<=<]:CTS2+N+^P1<6WRVPG\T,0=A8G;1=A9&O=^(-/M(K64S
MJ\=R^Q60C '=C[#O6DCK(BNC!E89!'<5RATJ]BTR';:%V@U(S^4",F/)Z=OP
MKJXR6B0E"A*@E3_#[4TV)I=!U%%%42%>:>,_^1CE_P!Q/Y5Z77FGC/\ Y&.7
M_<3^51/8TI[G/T445D;!6Z/$)C\'PZ+")HYDO#<&57P"I7&..:PJ*5@.OT?Q
MC;Z:OAT/:RO_ &4]PTF&'[SS,XQ],T[2O&=OIS>'"]I*_P#9371?##]YYN<8
M^F:XZBERH=V=OX/UVS5]&TJY*P"#4FNVN)6PF/+( ]CGOTJ;QI.#9V%\-0FA
MU&*X81VJW<4OEIU\P&( *2V.O)_"N"HHY=;A?2Q)%-+#.L\4KI,C;ED5B&!]
M0?6HR23DG)-%%4(**** "OIGPW_R*VD?]>4/_H KYFKZ9\-_\BMI'_7E#_Z
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MDVSF:*Z;[-!_SQC_ .^!1]F@_P">,?\ WP*?M5V%[)]SF:*Z;[-!_P \8_\
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M9_X"1_X4?\(OX?\ ^@%IG_@)'_A1[5!R'S17TSX;_P"16TC_ *\H?_0!3?\
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M)6G_ '^7_&O(**/J4>X?7)=CU_\ MS2?^@E:?]_E_P :/[<TG_H)6G_?Y?\
M&O(**/J4>X?7)=CU_P#MS2?^@E:?]_E_QH_MS2?^@E:?]_E_QKR"BCZE'N'U
MR78]?_MS2?\ H)6G_?Y?\:/[<TG_ *"5I_W^7_&O(**/J4>X?7)=CU_^W-)_
MZ"5I_P!_E_QH_MS2?^@E:?\ ?Y?\:\@HH^I1[A]<EV/7_P"W-)_Z"5I_W^7_
M !H_MS2?^@E:?]_E_P :\@HH^I1[A]<EV-GP_P"&H](\:KK<VN:2]N))7V)/
M\V'# =1COZUZ-_;FD_\ 02M/^_R_XUY!13>#B]V"Q<ET/7_[<TG_ *"5I_W^
M7_&C^W-)_P"@E:?]_E_QKR"BE]2CW#ZY+L>O_P!N:3_T$K3_ +_+_C1_;FD_
M]!*T_P"_R_XUY!11]2CW#ZY+L>RPZE8W*R-!>02",;G*2 [1ZFH?[<TG_H)6
MG_?Y?\:\HL;ZXTZ[2YMG*2+^1'H?:MB^L;?5[1]4TM DB\W5H.J'^\O^S4/"
M1B]7H6L5*2T6IW_]N:3_ -!*T_[_ "_XT?VYI/\ T$K3_O\ +_C7D%%7]2CW
M(^N2['<^.H+/Q1H<5C::QIT4B7"REI9@!@*P[9Y^:I_!HL?#GAV/3KK5]/DE
M61V+13#;R<]\5Y_13^IQM:X?6Y7O8]?_ +<TG_H)6G_?Y?\ &C^W-)_Z"5I_
MW^7_ !KR"BE]2CW#ZY+L>O\ ]N:3_P!!*T_[_+_C1_;FD_\ 02M/^_R_XUY!
M11]2CW#ZY+L>O_VYI/\ T$K3_O\ +_C1_;FD_P#02M/^_P O^->044?4H]P^
MN2['K_\ ;FD_]!*T_P"_R_XT?VYI/_02M/\ O\O^->044?4H]P^N2['K_P#;
MFD_]!*T_[_+_ (T?VYI/_02M/^_R_P"->044?4H]P^N2['K_ /;FD_\ 02M/
M^_R_XT?VYI/_ $$K3_O\O^->044?4H]P^N2['K_]N:3_ -!*T_[_ "_XT?VY
MI/\ T$K3_O\ +_C7D%%'U*/</KDNQZ__ &YI/_02M/\ O\O^-']N:3_T$K3_
M +_+_C7D%%'U*/</KDNQZ_\ VYI/_02M/^_R_P"-.36=+D=434+5F8X $JY)
MKQZBCZE'N'UR78]OHKB_"OBKS-FGZA)\_P!V*9C][_9/O[UVE<52G*G*S.VG
M44U=!1116984R:&.XA>&9%>-QAE8<$4^D9E12S$*H&22> * /,/$GAN31IO.
MA#/9N?E;NA]#_C6!74^*?$YU)FLK-B+13\S=Y3_A7+5[-%S<%S[GD5N3G?)L
M%%%%:F04444 %%%% $MM)'#=12RQ":-&!:,G 8>E=C#/:ZOX7U*YNM-M;98
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MA'"-.MM'BM-*ANHKI%:XE:'>3G&>>W4]:JZFFFS>'+6SCU>W:2S#-P#^\//
MJ+2'2VMK>23Q)Y5JN'DME+;AW*@?X5.\/F^Y6T_DNQD^([*+3]>NK>!=L0(9
M5],@''ZUE5>UF_\ [4U>XO "JR-\H/7 &!^@JC77"_*K[G-.W,[;!1115$!1
M110 4444 %=WX5\5>9LT_4)/G^[%,Q^]_LGW]ZX2NO\ "WA8W12_OTQ .8HC
M_'[GV_G].N&(4.3WS?#N?/[AZ!1117D'JB,RHI9B%4#))/ %>=>*/%#:BS65
MDQ6T!PSCK*?\*[^\LX+^V:WN59XF^\H<KG\B*RO^$0T+_GQ_\C/_ /%5O0G3
M@^:6YA6A4FK1/+**]3_X1#0O^?'_ ,C/_P#%4?\ "(:%_P ^/_D9_P#XJNSZ
M[3[,Y?J<^Z/+**]3_P"$0T+_ )\?_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[
M,/J<^Z/+**]3_P"$0T+_ )\?_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<
M^Z/+**]3_P"$0T+_ )\?_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<^Z/+
M**]3_P"$0T+_ )\?_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<^Z/+**]3
M_P"$0T+_ )\?_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<^Z/+**]3_P"$
M0T+_ )\?_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<^Z/+**]3_P"$0T+_
M )\?_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<^Z/+**]3_P"$0T+_ )\?
M_(S_ /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<^Z/+**]3_P"$0T+_ )\?_(S_
M /Q5'_"(:%_SX_\ D9__ (JCZ[3[,/J<^Z/+*L6-C<:C=I;6R%Y&_(#U/M7I
M?_"(:%_SX_\ D9__ (JK5MH.F6EO-!;VWEI,,2;9&RP]-V<X_&E+&PMHAK!R
MOJS@KZ^M])M'TO2WWNW%U=CJY_NK_LUS]>I_\(AH7_/C_P"1G_\ BJ/^$0T+
M_GQ_\C/_ /%4HXJG%;,<L-4D^AY917J?_"(:%_SX_P#D9_\ XJC_ (1#0O\
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7T&!17!5JRJ2NSMITU35D%%%%9FA__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g2018031520465632111257.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465632111257.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B 00# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#I[RX\0:CX
MA\36^G2ZW+/;7"QVGV6Y1((24! <,>1GGITKIX=>U_\ X22'0O)L6>VL(;J]
MG<MEB20X0#C/'':KJZ?K]K?7D]C%H47VF3>[F.4/)C@%B#R<4Q;#Q(M^]\L?
MA\73QB-IA%+N*@Y SGIFMG)/L9I-&7X>\;ZGK5_8,VF*+"_>14*(X:';G!9C
M\K9QSMZ&K_B/4M6MO&'AJRL9X4M;MY?.1P<OM7//MCI[]:AMO#FK66H-?VUA
MX:BNVR3*D$H//7'/&>^*GOM)U_4WMWO8/#\[6[^9"SQRY1O4'/%#Y>:Z#6QE
MMXYU:+1]:UJ6PLS8:?<26L2*[>9)('"J3V"\\]ZE7QKJ5OI^I/J%K;PRVZQ&
M"=XY4CE,AQMV$%]P[8Z^U7TTG7TM;BU6V\.BWN&9YHO)EVR,WWB1GG-5(O"N
MHPV$]C'IOAD6UP098_(E(?'3//;MZ4_<#WC%U+QMKL_AC73&D-G?:==00F4(
MRDI(1_"V2IY[]O>M76O%^MZ;=ZK;0VNGN=+L([R9W9_G)SE5'X<$U.OAC4TL
M[BT73O#(M[D*)HQ!+B3'3=SR1ZU(/#^LB.6/[%X<VRP"WD!AE.^,=%//(%%X
M!:11;QYJ%@-1;4;&V<0:4FIQ+;NV<,<!&)^HY'Y4P^.M8M=(U2ZN],B9K6R2
M[AD5'CC;) *$-SGGAAP:U1H^O"5I1:^'-[0"V8F&7F(=$//W?:JL'A74;6UN
M+:'3?#*0W*A9D$$N' Z \]/:CW ]X@N/%>NJ-7LI(K&*YBTC^T;>6(L0G8JP
M/4CJ#T]JV_#]YJUQHN@RW,EG(;BW#W+,S!V!0%2H[GU[>E5CI.OF9YC;>'3(
M\'V=F,,N3%_<//3VJ.S\/ZO9FR6*S\/1QV;$P;(I<Q!N&VY/&12?+8:O<Z^B
MBBL2PHHHH **** /,M=NM7N?'>L6-I)K<J0VD+0Q:?<K&L;L#RVXXP36M;ZU
MXDMI=(\/3"Q;6I+!KFZN+@GR_E.-H"XRWJ>G>M6:PUR/6+J]L8M$1I@$\V2.
M3S60= Q!YQ5/4M#US6%1=1M?#MR(SE#)%*2N>N#G-;<R=DS.S,N3Q]JEQHVF
M7MCI:?Z1YPN&"M/Y9C./E1<,RDY^8=!4H\3:IJ>N>$FL+FT^QZA%,\Z)N*N4
M'S<D \=NG/6K5UX;U6]MK>WN+#PT\5N,0KY$H\L>BX/ I\GA_6)4LT>R\-[;
M)MUL!#*/*/\ LX/%.\ ]X?XRU+5['4O#L.F3PQK=WXBE$@/S_*3@X[<=N>E4
M)/&VJPP>(M1>QM#IVCS2P;5=O-E<8VGT YYK1U'2=?U:%(M0@\/7$<;B1!)'
M*=K#H1SP:6/2O$$45S$EOX=6.Z8O.ODRXE8]2PSSFDN6UF-WN4+7QKJ,=EJ4
MNIVEO"MM:I<17+))'$2QQL((+=2,$#FL?4O'&O/H'B&-8X;2]L(H)4G$3(=D
MAP?D;)!]"?R%;EOX7U*UM+BU@TWPRD%RNV9/(E(D'8'GH*2+PMJ4%O/!'IOA
ME8IXQ%,OD2_O%'0-SS33@F+WB/4/%>N6=W<6,-OI[2V>DC4)I)&?#')RH ]<
M=33(/'6H0F274+&V,+:-_:T*V[MN _N,3U//45=CT#684*I9^' &M_LQ_=2\
MQ?W#ST]JD31]>CDCD2U\.!HX/LR'R9>(O[G7[OM2]P/>,^P\:ZM)9WD]WIT6
MV/36OXI$1T3(&?+.[D_[PX/-,'B_77"12V]A%)>Z.^H6S1ECY14 X;/7KVJW
M:>&-3L8[B.UT[PU$MPGERA8)?G7^Z>>GMTJP-'UX20N+;P[NAA-O&?)E^6,]
M4'/3@<4_<#WAWA34-9O/#&@W-S-9RO<H&G>1F#LA7(*CH6SU[5U5<=:^'=6L
MTM8X+'PY&EK(98 L4O[MCP2O/!Q78#..>O>LYVOH5&]M1:***@H^-/\ A,?$
M_P#T,6J_^!;_ .-'_"8>)_\ H8M5_P# M_\ &L6E[T%&U_PF'BC_ *&+5?\
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M  I >8_\*\\9?]"UJ/\ WZI?^%>^,?\ H6M1_P"_5>F_\-&V7_0M77_@4O\
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MUBI#X"\8'_F6]1_[]5Z+_P -'61_YEJY_P# I?\ "C_AHVR_Z%JZ_P# I?\
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M4\L<BL=H8C^5/FM61U8=1Z5JV\:M%DD D=S3LPNC,MY,J"$R1W-7U_>QLDC
MHP*LOJ#UJ9[$ ?NV3Z;A42Q-&VUE*_6D.]SYEUVP.E:[?6!X$$S(OTSQ^F**
MV_BD@MO'MYM_Y:)&Y^I4#^E% SN?AU<B7PE'%N_U4CJ1^.?ZUT<*_:+AE')4
M5Y?\/[Z4376GQO@N/-4>N.#_ $KUOPU&B-)')S))SD]2?2@1I:69(HIH&Y!&
MX5LVUP#$=PY_E3! JHS@ 8&/K7-/<W&L:D=-LW*P(?WKCOZT ;,^KXD-O81F
M>8\9'W5J73;%[<O-,_F7,I^=O3VJ[:Z9!9VPBA3 QR3U/UJ98@I^Z* *.J6K
MW.GRP+O=F'"J<?J*Y2/3?$5I!%!;PL1Y4>YVD!PX!WYSR<G;^M=XT96-I#P.
MY)XHM2DZ!TD#K_>'2M(U'%:'/5H1J2NV<&UAXIB1B96?L-VP<84\<=<[P,\=
M*V?#-CK:ZA+-J>\6_EXB4[3W/WL=\8Z<5T5Z@$:J#R35J/\ =H%%-U6U84<+
M&+30-;KC.*JR@J<+S6HV/*!R,U2F4LN0,&LCI*+L<<C%0N ZX(_^M5[[*9%R
M&&:GL[ L"TJXH Q 2H/!XZUD^ ;H77Q0\7;3D16UI'^(#Y_4UU6J106=O+<R
M%4CAC,CMV  R:\Q^ ]^VJ>*O%M^^<W/E2<]@6?'Z4 >WW'_'K-_N'^5>-?#&
M_P >"+?)!2*XFB;Z;R?ZU[+<?\>LW^X?Y5\[?![44G77- D/SL3=P#UQ\K@?
MA@T >HVDALKB2U)_<D[HCZ ]J=<3<]>E-C7S[5&_B48S5.X+ <]J +&\%L^M
M074*NI'3-0139_\ UU._S+O!P* ,^.11-Y>[]X#Q_M>U7%D8D?*5'H:8MI%)
MN/\ &3D&KD?,9$B?.HZGOZ&@"&^MA/8Y'8@@U>@40Q(H'0#-4XW:63:/]2A_
M,U>QNP<@<T 8NO:;?:A>P7-C)L:""15!8[69B.&'<$ \]15+3M/U>WFC6ZD#
M0JA4@."#P-H QD$'.3GFNQAA$B$@GBJ=R(X9/GD5 ?[QK6-1K1'-5PT*C;DS
ME#I%[8R3RV,<:-),S ;L?(4P!T.,-SBC^SM=X<WK9/(7(V]5QVZ8WY^HKIY2
M'A8H&!'0LI&?IFA)0X0'' I^VDB/J<._Y'.VEAK0O8'N+DBW5]TNUP2W7IQP
MOW>/;K72MD@KU'N:CB'F2L!T'04VZEBL[::YN#MA@1I'/H ,FHE-RW-Z5&--
M.Q\]_$R07/CS4/\ IELB_)116!J=Z^HZI=7TF=]Q*TAS[G-%0;$FDZC+I.JV
M]_$,M"^2O]X=Q^(KW_3Y(=0M8-0L9=T4JAXV'\C[CI7SI79^ _&7_"/W)L;Y
MR=-F;.[KY+?WOH>_YT >_P!K="YA$;??3AA[^M86AK)H_B6\@EC_ '$OS>8>
MW<?A4T<^UX[N%E8%<@J<AUK626&\"2!%<'@Y'3VH$:":I;3(&MBUSNZ>2,C\
M^@_.FM]LE?(V6Z^WSM_@/UIUNT,06%0B+V1<#]*NJ%8[157705GU(/(M-FZ8
MO-)CAICNQ]!T'Y5'YZQL=OW0,5/+$$&2<BL^X*$C!XI-M@DD$MP789/TJXD^
M2ISGBLQ8RT@P,XJ8/M;!X-(9JLS2+\F:4X50K'I3+:YC\M5SR.QI+N4;<A3T
MZT .$H5O:K$=UL'M6(9FSUQ^%8GBOQI9>$=(-U<%9;N0$6UL#S(WJ?11W- '
M/_&OQDEGHZ^'K23_ $J^&ZXQU2'/3_@1'Y UF_LY?\A/Q#_UQ@_F]>.ZGJ=W
MK.IW&HW\QENKA][L?Y#T Z 5[%^SE_R$_$/_ %Q@_F] SWNX_P"/6;_</\J^
M,?#^NW'AKQ1:ZQ;<O;3EF3/WT)PRGZC-?9UQ_P >LW^X?Y5\.2?ZZ3_?/\Z!
M'U'I>HVM_;M<V,F^SG/FPG_9;D ^XZ?A4D\9D!.*\.^'GC4>';PV&H.?[,N&
M^_U\AO[W^Z>_YU[JMQ"8U9'1T8;E93D$>M &1) R-GI5:Y:4QE5D9"?:M6:1
M')Q6?./QH WK*R064>TEQM'/7FHK^-H[-R 15?3;XVD@5F_</Z_PUKWD?VBS
MD53D]1[T 9ZQQ66GB1V/R+N<@9I(KSSTCD@MV=2,AG^4?KS^E78&#PQNG(V_
M-[&DD8)S330M1G^DR#YKCRU_NQ#;^IY_E4)@ABD\Q5!;NW4_F>:F\T$9/3TJ
M*XE10&'XT7860R2=2,!:@^4<YQGUI9&!7*#!]1597\U2>012&7X@0<@\GL*\
M\^+?B9;335T"W?\ TBZ >XP?N1=A_P "/Z"MKQ#XQMO"U@\DN);MP1;P9Y8^
MI]%'<UX-?WUSJ=_/?7DIEN)W+NY[G_"@"H_7\**'ZT4 %%%% SKO"/CJ[\.,
MMK<JUUII/^KS\T7NA_I7KV@ZW97R_:],NEG@;EE'5#Z,.H-?.=3V=[=:?<K<
M6=Q)!,O1XVP?_KT ?0OBI[R.V%_92$P\;P.&C/K]*=X>^($?DB'558R+P)E'
M7ZBO--&^+.H6BB+5+2.[C(PSIA6(]QT/Z5U6GZQ\.]?;=)J$FE7+]4E&Q,_R
M_6@1ZM%=)JEOYMJX>,_Q#I5F/3X_+!D&<^O>L?PU!9Z-IDK6^LV-[:X+'RI0
M<#UZUK6VK6-]%-)87"W1B7+K'R0#0!!Y<4<QA"Y)/!J.ZL@A#H>>^:P+[Q5!
M;7A8(0=W()QBJ5U\0=-B*M<7UK"H/.Z09'X"@#IXAMG4..,UHR_-'@<_2O,]
M2^-/ARQMFCL[:XU*X_V5\N/_ +Z;G\A7F/B/XF>(_$2/ ;@6-DW!M[4E<CT9
MNIH ]+\9?$K3M ,EGI[)?:D."%;,<1_VB.I]A7AVIZI>ZS?R7VH7#3W$G5F[
M#T [#VJITHH&%>V_LY?\A/Q#_P!<8/YO7B5>V_LY?\A/Q#_UQ@_F] 'O=Q_Q
MZS?[A_E7PY)_KI/]\_SK[CN/^/6;_</\J^')/]=)_OG^= AM=1X9\:7>A!;2
MX,EQI_:,-\T7NOM[5R]% SWS2M5L=4M1<65R98^^&Y4^XZBM'YF7.[>/UKYY
MM+RYL+@3VD\D$HZ-&V#_ /7KM-)^)E[;;5U&V6<#_EI%\K?B.A_2@1ZI;R"1
M6B;J.F>XK6TV]: ^1,<H/N/Z5P">/-!OE26.Z-O.#DI,NW/X]*ZFPU.SOE1X
M;F&4,/X9 : .F*%"[6Q4;CD@]#_A67<ZA) ["Y@PO9E/%.@N9;9B-I=/2J^H
MW*-&7W #^Z_% #O[0B:/?&WR]\UGW>K1B,X>L*Z\1Z;8EC<75O&P["0<^V!7
M$WGCJW?S#';,S$_*%.!^)- '>/X@*D!2>*YO5OB"FF+)%9%;BZ;C_83ZGO\
M2N OM>OK_*M)Y41_@CXS]3U-9E %B^OKK4KR2[O)FFGD/S.Q_0>@]JKT44#&
M/U_"BA^OX44""BBB@84444 %%%% #"2ARA*YZXXIWVV[A_U5U-'G@[9"***
M$-Q/*<R32.3U+,32@#THHH 6BBB@ HHHH *]M_9R_P"0GXA_ZXP?S>BB@#WN
MX_X]9O\ </\ *OAR3_72?[Y_G110(;1110,**** "FEBG*$J?4<444 *+Z[
LP+J<#_KH:0W,\A^>>1O]YR:** % 'I2T44 %%%% !1110!&_7\**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g2018031520465610411255.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018031520465610411255.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #3 78# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH *\<^)GB?4QKLFDV]S);VL*C<(VVER1GDCMSTKV.O
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M_P (_K7_ $"+[_P';_"CFCW#VD.YFT5I?\(_K7_0(OO_  ';_"C_ (1_6O\
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M:,0O;*;VV4+-RT8(/4X'UH]O+LA\\ST'_A97AW_GI<_]^#1_PLKP[_STN?\
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M?!_B6YG:7^QW3/\ "L@('XEB:3HRMHF)K38YJNN^&W_(WI_UQ>J/_"$>)/\
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M9(?'VKB1"I:8L,CJ/6N8KZT\0>#M"\3A3JE@DLBC"RJ2K@?45S?_  ICP?\
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M/:SP-,VU&;!&?0XZ5YQD5=T7GQ!IH')^T+Q^=.>%IJ+:%#$U'))GL)(52S$
M 9)/:A6#*&4@J1D$'@U3UB"2YT2_@A7?)+;R(BYZDJ0!7,HVM?\ "):?86EA
M?VL]LMNES]Q7>-<"01MN(W8''2O,/2.SHKBA:^(FAU*6P>^BAC,,ME#>2@R2
M.I)D0G)PC# P3U]*AMH?&$U\D=P9XK;495N97\Q,V"J>81CD[ACD9YW4 =R[
MK&A=V"JHR68X J."[MKI2;>XBF ZF-PV/RK!\5:==WL^E3QVWVVSM9S)<V6X
M#S05PIP>&VGG!ZUD&#7FMM<.G6+6V^T46DGV>*"8R[CE?E)R ,8)]Z .[I"0
MJEB0 !DD]JX_6++5K>."UL5U&=#"[-<_:F9A+QA2 R_7/0>E59(/$<L-H-2C
MU&16TM$*V4J(1=8^<R<CVP>1UH [B*6.>)989%DC<95T.01[&G]J\[@TWQ)9
MZ?I%HPNHK.+3Q&Z6IRZ3YZMM89&.G)%='J-MJ;^ KNV$TD^I&Q=?,*!'=MI[
M D G^= &[!/#<PK-!*DL3C*NC9!'L123W5O:A3<3Q1!C@&1PN?SK"L-(TO5=
M)T^\C$R8M8UA>*5HS$ .P!X/KZ]ZQ/$'A^[_ +4@%G#="W2R:$7*(ET\C,Q)
M5ED/'8[AR<XR,4 =O-=VUNJM/<11*YPI=PH/TS3FN(5D2-I8Q(XRBEAEOH.]
M<'9Z1>V,T$NH:";F$Z3':1V\3+,+=U)W+\Q_B!7GGI2VWA&]BL-)B;S!J(2/
MSIBRM% (R2O)&XD!L84@''/ H [U9$9V174LF-R@\KGIFD$L;2-&'4R* 64'
MD9]17,^%8=7M+B:WO+)8H2&>29L;WEW'G=D[\K@YP,=*HW'AW4?^$KUG7;&,
M17RF$VKLP"7*",!XF]B1P3T/- '9_:(?D_?1_.<)\P^8^@]:5Y8XMOF2*FX[
M5W'&3Z"O.8O"-_J6D>'+:\LY+5X&NI)&#J6M9&R8V!!Y(;'2IK[1O$&OPVU]
MJMBJW=E=VZ00)(I7"R*99^N/F X'4 'UH [V2[MHL>9/$F7$8W.!\QZ+]3Z5
M-7GNLZ?<VVC^+/-MV$E_?1FQVX)D<J@4C'3Y@?RKOX@XA02$%PHW$=SWH ?1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &-KUQX=M5CDUV2QCSQ&UR5!/TSS6'_ &Q\.O\ G\T;_OI:\]^._P#R'--_
MZ]S_ .A&O)<#TKLITKQ3NS%O78^G/[8^'7_/YHW_ 'TM7M)U;P9)?K'I5WI1
MNVX41,NX_2OE7 ]*U_"O'BS2<?\ /U'_ #JG0TW8KVUL?75%<]XRO+VQT>WE
ML'99VOK9,!L;@TB@J3@X!'!K+O\ 5=9BU^[CN8E@ACT6>=(H9RP9PZ@'.T$'
M!(XKA-SM:*\]N?&NHP,EI:K:+.MG;2)]I!(D:0?-N<NNT#'4YS4]QJVLV&I>
M*+NWGAF@LDMY!%,KL&^3+!,'Y0>N>: .[HKGO$VIWUMX92\L \;2/%YLBIO:
M")B-[A>Y ]O?M678ZO!!X@@M;6\N+Y)H)9$E%^)U.P Y=,?)G/&#ZT =K17&
M0>)]2'AW3-0O9+.&?4]AACC@8JF5+$,6=1GCJ2/3FHK7QG?7=EIC.MG:-=7$
M\,EU,"84\LG& &ZMCCYL=>30!W%%><:=XJU.TTQ"62Y:[U6XB-TYS%$JC*XW
M,O!Z#+#\:[+0-0O-1TQI[R*!91(Z#R)%=74'@\$@$^F3B@#5QCI17(^&AJFK
M>&;2]CU5H+BX>6:<M$)#O+'"#=]U5QC _,5-K5Y_9>EB37-5D6227$$=AF$N
M<8" Y)]3DD 9]!0!U%%<!#?W\=OX?M-3UG_1IVG^U7<$X^\.8XFE'&0#R1C)
M6H5N]7GTB>YCU:7[)!>306DA)$EP./+8;1^\P=PQT/>@#T6BN.T?7;J3Q ;;
M4A.+ASY"PHPV184-DJ.3GN_3/ HUZ?6QXP@32;EL06)N#9MCR[D[\%2>QQT/
M8^U '8T5YJ^NZAK.C7DEE?WEIY^NQ6L;[=LD",$!7!'&"3FI-5\1ZQJ&A7EE
M;M+9:EID+OJ4\:XVLGW%0D?\M/O>RY[T >C45QBW5W>:MJ%G/=S+;_V-%*,-
MMV.<Y8'L>*W/"][<:CX7TV\NLF>6!6<G^(^OX]?QH UZ*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \P^,6E65S865W
M- &N%<H'W$';UQP:\>_LNS_YX_\ C[?XT45Z.'_AHXZS:GH']EV?_/'_ ,?;
M_&NI^'VB:=<>,;/S;8/Y9WKEVX8=#UHHJZGP,B$FY(^AB >H!^M!4$Y(!XQT
MHHKRSO,J[\.Z7=W$SS6Q)N@!.%E=5E &!N4$ \>HK32*..,1I&JH %"@<8'0
M444 /IB11QEBD:J6ZX&,T44 *8T9-C(I7^Z1Q08T9-K(I7T(XHHH "B,I5D4
MJ>H(X-*JJBA54*HZ "BB@""TL;:Q65;6%8EED:5PO0LQR3[9-3,B.,.JL/<9
MHHH 3RHO+,?EIL/5=HQ^5.V+\ORCY?N\=*** #:N_?M&[&,XYQ1@9S@9]:**
M #:O]T=<].]&T'.0.>O'6BB@"&ZM(+RVEM[B,/%*NQUR1N7TXJ6.-(8DBC4)
M&BA551@ #H*** '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>24
<FILENAME>urgn-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-15T19:01:19.6472015+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : f94fb2f9093b4031a25f038a50ff9384 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:urgn="http://www.urogen.com/20171231" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="urgn-20171231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217ILS_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:ILS</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <unit id="U_urgnLicenseAgreement">
    <measure>urgn:LicenseAgreement</measure>
  </unit>
  <unit id="U_urgnSegment">
    <measure>urgn:Segment</measure>
  </unit>
  <context id="C_0001668243_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">urgn:SeriesAAndAOnePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">urgn:SeriesAAndAOnePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20150801_20150831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">urgn:AllerganPharmaceuticalsInternationalLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-08-01</startDate>
      <endDate>2015-08-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20161006_20161007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">urgn:AllerganPharmaceuticalsInternationalLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-10-06</startDate>
      <endDate>2016-10-07</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_us-gaapRangeAxis_us-gaapMaximumMember_20161007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">urgn:AllerganPharmaceuticalsInternationalLimitedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-10-07</instant>
    </period>
  </context>
  <context id="C_0001668243_20170419_20170419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
    </entity>
    <period>
      <startDate>2017-04-19</startDate>
      <endDate>2017-04-19</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNCM</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-01</startDate>
      <endDate>2017-05-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20170701_20170731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">urgn:AllerganPharmaceuticalsInternationalLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-07-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_urgnSecondaryPublicOfferingMember_20180101_20180131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNCM</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">urgn:SecondaryPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">urgn:AllerganPharmaceuticalsInternationalLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20170701_20170731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">urgn:AllerganPharmaceuticalsInternationalLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-07-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:ComputersAndSoftwareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">urgn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">urgn:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">urgn:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_20160401_20160430">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20160501_20160501">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-05-01</startDate>
      <endDate>2016-05-01</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20171001_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-10-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20160502_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-05-02</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiLegalEntityAxis_urgnIsraelInnovationAuthorityMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiLegalEntityAxis_urgnIsraelInnovationAuthorityMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiLegalEntityAxis_urgnIsraelInnovationAuthorityMember_us-gaapRangeAxis_us-gaapMaximumMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:IsraelInnovationAuthorityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_us-gaapValuationTechniqueAxis_urgnHybridMethodValuationTechniqueMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">urgn:HybridMethodValuationTechniqueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_urgnLiquidationEventMember_us-gaapValuationTechniqueAxis_urgnHybridMethodValuationTechniqueMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">urgn:HybridMethodValuationTechniqueMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">urgn:LiquidationEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">urgn:AllerganPharmaceuticalsInternationalLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_urgnInternalDevelopmentMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis">urgn:InternalDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">urgn:AOneWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">urgn:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-01</startDate>
      <endDate>2017-05-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiLegalEntityAxis_urgnTelormedixSAMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20151001_20151031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:TelormedixSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiLegalEntityAxis_urgnTelormedixSAMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20151001_20151031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">urgn:TelormedixSAMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNCM</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">urgn:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-01</startDate>
      <endDate>2017-05-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-01</startDate>
      <endDate>2017-05-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_urgnSecondaryPublicOfferingMember_20180131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">urgn:SecondaryPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNCM</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170301_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-03-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">urgn:TwoThousandSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170401_20170430">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-04-30</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170401_20170430">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-04-30</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">urgn:ConsultantsAndOtherServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeThreeMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeFourMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeThreeMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeFourMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">urgn:ExercisePricePerShareRangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementScenarioAxis_us-gaapScenarioForecastMember_20180101_20181231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20151101_20151130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-11-01</startDate>
      <endDate>2015-11-30</endDate>
    </period>
  </context>
  <context id="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20160502_20160531">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConsolidatedEntitiesAxis">us-gaap:SubsidiariesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-05-02</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001668243_20170101_20171231">20-F</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001668243_20170101_20171231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001668243_20170101_20171231">2017-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001668243_20170101_20171231">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001668243_20170101_20171231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001668243_20170101_20171231">URGN</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001668243_20170101_20171231">UroGen Pharma Ltd.</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001668243_20170101_20171231">0001668243</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001668243_20170101_20171231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer id="F_000009" contextRef="C_0001668243_20170101_20171231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCurrentReportingStatus id="F_000010" contextRef="C_0001668243_20170101_20171231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="F_000011" contextRef="C_0001668243_20170101_20171231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000012" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_shares">13751390</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000013" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">36999000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000014" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">21362000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:ShortTermInvestments id="F_000015" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">36001000</us-gaap:ShortTermInvestments>
  <us-gaap:RestrictedInvestmentsCurrent id="F_000016" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">198000</us-gaap:RestrictedInvestmentsCurrent>
  <us-gaap:RestrictedInvestmentsCurrent id="F_000017" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">95000</us-gaap:RestrictedInvestmentsCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000018" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">83000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet id="F_000019" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">316000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="F_000020" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000021" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">958000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000022" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">396000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000023" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">74472000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000024" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">22041000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000025" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000026" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">741000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RestrictedInvestmentsNoncurrent id="F_000027" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">29000</us-gaap:RestrictedInvestmentsNoncurrent>
  <us-gaap:RestrictedInvestmentsNoncurrent id="F_000028" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">24000</us-gaap:RestrictedInvestmentsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000029" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">244000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000030" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">250000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000031" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">75550000</us-gaap:Assets>
  <us-gaap:Assets id="F_000032" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">23056000</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000033" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">4435000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000034" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">1880000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000035" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">1950000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000036" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">687000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000037" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">650000</us-gaap:DeferredRevenueCurrent>
  <urgn:ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent id="F_000038" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">570000</urgn:ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000039" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">7035000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000040" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">3137000</us-gaap:LiabilitiesCurrent>
  <urgn:WarrantsForPreferredSharesNoncurrent id="F_000041" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">3612000</urgn:WarrantsForPreferredSharesNoncurrent>
  <us-gaap:CommitmentsAndContingencies id="F_000042" xsi:nil="true" contextRef="C_0001668243_20171231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000043" xsi:nil="true" contextRef="C_0001668243_20161231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:Liabilities id="F_000044" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">7035000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000045" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">6749000</us-gaap:Liabilities>
  <us-gaap:CommonStockValue id="F_000046" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">37000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000047" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:CommonStockValue>
  <us-gaap:PreferredStockValue id="F_000048" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20161231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:PreferredStockValue>
  <us-gaap:AdditionalPaidInCapital id="F_000049" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">115692000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="F_000050" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">43502000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000051" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">-47214000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000052" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">-27214000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000053" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">68515000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000054" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">16307000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000055" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">75550000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000056" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">23056000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000057" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_iso4217ILS_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000058" contextRef="C_0001668243_20161231" decimals="INF" unitRef="U_iso4217ILS_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000059" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_shares">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000060" contextRef="C_0001668243_20161231" decimals="INF" unitRef="U_shares">17600000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000061" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_shares">13751390</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000062" contextRef="C_0001668243_20161231" decimals="INF" unitRef="U_shares">2305743</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000063" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_shares">13751390</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000064" contextRef="C_0001668243_20161231" decimals="INF" unitRef="U_shares">2305743</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000065" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20171231" decimals="INF" unitRef="U_iso4217ILS_shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000066" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20161231" decimals="INF" unitRef="U_iso4217ILS_shares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000067" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20171231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000068" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20161231" decimals="INF" unitRef="U_shares">14400000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000069" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20171231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000070" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20161231" decimals="INF" unitRef="U_shares">5193427</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000071" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20171231" decimals="INF" unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000072" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAAndAOnePreferredStockMember_20161231" decimals="INF" unitRef="U_shares">5193427</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:Revenues id="F_000073" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">8158000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000074" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">17530000</us-gaap:Revenues>
  <us-gaap:CostOfRevenue id="F_000075" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">600000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="F_000076" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">28000</us-gaap:CostOfRevenue>
  <us-gaap:GrossProfit id="F_000077" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">7558000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="F_000078" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">17502000</us-gaap:GrossProfit>
  <urgn:ResearchAndDevelopmentExpenseNet id="F_000079" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">18697000</urgn:ResearchAndDevelopmentExpenseNet>
  <urgn:ResearchAndDevelopmentExpenseNet id="F_000080" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">10287000</urgn:ResearchAndDevelopmentExpenseNet>
  <urgn:ResearchAndDevelopmentExpenseNet id="F_000081" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">10515000</urgn:ResearchAndDevelopmentExpenseNet>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000082" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">8811000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000083" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">6417000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000084" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1895000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingIncomeLoss id="F_000085" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-19950000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000086" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">798000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000087" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-12410000</us-gaap:OperatingIncomeLoss>
  <urgn:FinanceIncomeExpenseNet id="F_000088" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-31000</urgn:FinanceIncomeExpenseNet>
  <urgn:FinanceIncomeExpenseNet id="F_000089" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-2739000</urgn:FinanceIncomeExpenseNet>
  <urgn:FinanceIncomeExpenseNet id="F_000090" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-279000</urgn:FinanceIncomeExpenseNet>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000091" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-19981000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000092" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-1941000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000093" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-12689000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000094" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">19000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000095" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20000000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000096" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-1941000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000097" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-12689000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000098" contextRef="C_0001668243_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">-2.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000099" contextRef="C_0001668243_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">-1.91</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000100" contextRef="C_0001668243_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">-5.88</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000101" contextRef="C_0001668243_20170101_20171231" decimals="0" unitRef="U_shares">9716790</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000102" contextRef="C_0001668243_20160101_20161231" decimals="0" unitRef="U_shares">2305503</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000103" contextRef="C_0001668243_20150101_20151231" decimals="0" unitRef="U_shares">2300959</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesIssued id="F_000104" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231" decimals="INF" unitRef="U_shares">2300959</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000105" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="F_000106" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20141231" decimals="INF" unitRef="U_shares">867103</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000107" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20141231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000108" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20141231" decimals="-3" unitRef="U_iso4217USD">15739000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000109" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20141231" decimals="-3" unitRef="U_iso4217USD">-12584000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000110" contextRef="C_0001668243_20141231" decimals="-3" unitRef="U_iso4217USD">3163000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000111" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20150101_20151231" decimals="INF" unitRef="U_shares">3635124</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000112" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000113" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">21246000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000114" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">21255000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets id="F_000115" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20150101_20151231" decimals="INF" unitRef="U_shares">691200</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets id="F_000116" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets id="F_000117" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4101000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets id="F_000118" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4103000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000119" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">449000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000120" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">449000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000121" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-12689000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued id="F_000122" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20151231" decimals="INF" unitRef="U_shares">2300959</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000123" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20151231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="F_000124" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20151231" decimals="INF" unitRef="U_shares">5193427</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000125" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20151231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000126" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20151231" decimals="-3" unitRef="U_iso4217USD">41535000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000127" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20151231" decimals="-3" unitRef="U_iso4217USD">-25273000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000128" contextRef="C_0001668243_20151231" decimals="-3" unitRef="U_iso4217USD">16281000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000129" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231" decimals="INF" unitRef="U_shares">4784</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000130" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000131" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000132" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-1941000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued id="F_000133" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF" unitRef="U_shares">2305743</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000134" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:StockholdersEquity>
  <us-gaap:SharesIssued id="F_000135" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20161231" decimals="INF" unitRef="U_shares">5193427</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000136" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20161231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000137" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231" decimals="-3" unitRef="U_iso4217USD">43502000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000138" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231" decimals="-3" unitRef="U_iso4217USD">-27214000</us-gaap:StockholdersEquity>
  <urgn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice id="F_000139" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">743806</urgn:StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice>
  <urgn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice id="F_000140" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2000</urgn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice>
  <urgn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice id="F_000141" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">402000</urgn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice>
  <urgn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice id="F_000142" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">404000</urgn:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000143" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">6300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000144" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">6300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <urgn:StockIssuedDuringPeriodSharesWarrantsExercised id="F_000145" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">364036</urgn:StockIssuedDuringPeriodSharesWarrantsExercised>
  <urgn:StockIssuedDuringPeriodValueWarrantsExercised id="F_000146" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1000</urgn:StockIssuedDuringPeriodValueWarrantsExercised>
  <urgn:StockIssuedDuringPeriodValueWarrantsExercised id="F_000147" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4731000</urgn:StockIssuedDuringPeriodValueWarrantsExercised>
  <urgn:StockIssuedDuringPeriodValueWarrantsExercised id="F_000148" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4732000</urgn:StockIssuedDuringPeriodValueWarrantsExercised>
  <urgn:StockIssuedDuringPeriodSharesPreferredSharesExercised id="F_000149" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">5557463</urgn:StockIssuedDuringPeriodSharesPreferredSharesExercised>
  <urgn:StockIssuedDuringPeriodValuePreferredSharesExercised id="F_000150" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">14000</urgn:StockIssuedDuringPeriodValuePreferredSharesExercised>
  <urgn:StockIssuedDuringPeriodSharesPreferredSharesExercised id="F_000151" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">-5557463</urgn:StockIssuedDuringPeriodSharesPreferredSharesExercised>
  <urgn:StockIssuedDuringPeriodValuePreferredSharesExercised id="F_000152" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapPreferredStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-14000</urgn:StockIssuedDuringPeriodValuePreferredSharesExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000153" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231" decimals="INF" unitRef="U_shares">5144378</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000154" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000155" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">60757000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000156" contextRef="C_0001668243_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">60772000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss id="F_000157" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20000000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued id="F_000158" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" unitRef="U_shares">13751390</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity id="F_000159" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">37000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000160" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" unitRef="U_iso4217USD">115692000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000161" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" unitRef="U_iso4217USD">-47214000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000162" contextRef="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231" decimals="INF" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000163" contextRef="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231" decimals="INF" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="F_000164" contextRef="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231" decimals="INF" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000165" contextRef="C_0001668243_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">6105000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000166" contextRef="C_0001668243_20170101_20171231" decimals="INF" unitRef="U_shares">68416</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:Depreciation id="F_000167" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">207000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000168" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">213000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="F_000169" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">113000</us-gaap:Depreciation>
  <us-gaap:ResearchAndDevelopmentInProcess id="F_000170" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4103000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ShareBasedCompensation id="F_000171" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">6300000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000172" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1967000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000173" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">449000</us-gaap:ShareBasedCompensation>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="F_000174" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="F_000175" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000176" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">168000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000177" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">2740000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="F_000178" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">241000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:IncreaseDecreaseInInventories id="F_000179" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">211000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="F_000180" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000181" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-83000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000182" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">83000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000183" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">562000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000184" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-739000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000185" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">737000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000186" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2534000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000187" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">481000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000188" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1155000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000189" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">650000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000190" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1263000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000191" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">178000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000192" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">191000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000193" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-9571000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000194" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">4189000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000195" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-7175000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquireShortTermInvestments id="F_000196" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">36001000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="F_000197" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:IncreaseDecreaseInRestrictedCash id="F_000198" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">98000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000199" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">271000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000200" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">695000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000201" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">301000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000202" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-36377000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000203" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-793000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000204" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-301000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000205" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">404000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises id="F_000206" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">382000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="F_000207" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">570000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000208" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">579000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000209" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">60841000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000210" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">21581000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfFinancingCosts id="F_000211" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">42000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000212" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">61585000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000213" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-9000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000214" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">21581000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000215" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15637000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000216" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">3387000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000217" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">14105000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000218" contextRef="C_0001668243_20151231" decimals="-3" unitRef="U_iso4217USD">17975000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000219" contextRef="C_0001668243_20141231" decimals="-3" unitRef="U_iso4217USD">3870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 id="F_000220" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4103000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
  <urgn:NoncashIssuanceCost id="F_000221" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">202000</urgn:NoncashIssuanceCost>
  <urgn:NoncashIssuanceCost id="F_000222" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">181000</urgn:NoncashIssuanceCost>
  <urgn:NoncashExerciseOfWarrantsToPreferredShares id="F_000223" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4732000</urgn:NoncashExerciseOfWarrantsToPreferredShares>
  <us-gaap:NatureOfOperations id="F_000224" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;1&amp;#8212;NATURE&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;OF&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;OPERATIONS&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UroGen&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Pharma&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Ltd.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Israeli&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;company&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;incorporated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;April&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;20&lt;font style="letter-spacing:-0.1pt;"&gt;0&lt;/font&gt;4&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(&amp;#8220;UPL&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UroGen&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Pharma&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Inc.,&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;subsidiary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;UPL,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;incorporated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Del&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ware&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;October&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;2015&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;began&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;operati&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;February&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(&amp;#8220;UPI&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UPL&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;UPI&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(together&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;&amp;#8220;Company&amp;#8221;)&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;clinical&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;stage&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;bi&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;pharmaceutical&lt;font style="letter-spacing:1.45pt;"&gt; &lt;/font&gt;company&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;focused&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;deve&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;oping&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;novel&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;therapies&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;desi&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;ned&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to change&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;standard&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;care&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;urological&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;pathologies.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2015 the Company entered into an agreement with Allergen Pharmaceuticals International Limited (&amp;#8220;Allergen&amp;#8221;), a wholly owned subsidiary of Allergan plc, pursuant to which the Company undertook to supply its gel product and supporting services to Allergan for consideration of $750, to allow Allergan to conduct certain scientific investigations aimed at testing utility of the Company&amp;#8217;s gel product for the delivery of a certain proprietary product of Allergan. Further, the Company granted Allergan a time limited option to negotiate an exclusive, worldwide right to research, develop, make and have made, use, sell, offer to sell and import the Company&amp;#8217;s product in combination with Allergan&amp;#8217;s product. &amp;#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the terms of the agreement from 2015, on October 7, 2016, the Company entered into an exclusive license agreement with Allergan to license worldwide rights to some of its products indicated for use with neurotoxins. As stipulated in the agreement, Allergan paid a non-refundable upfront fee of $17.5 million in accordance with the terms of the license agreement. Allergan shall pay the Company additional milestone payments of up to $207.5 million and tiered royalty payments as a percentage of net sales of the licensed product all as stated in the agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;described&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Note&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;8a,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;April&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;board&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;directors&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;shareholders&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;approv&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;aggregate&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;3.2-for-1&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;split&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;ordinary,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;Preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;A-1&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;shares.&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;All&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;reflected&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;financial statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;notes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;thereto&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;adjusted,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;retroactive&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;ba&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;is,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;reflect this&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;split.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2017, the Company raised $60.8 million, net of issuance costs and underwriting discounts, in an Initial Public Offering ("IPO") on the Nasdaq Stock Market (&amp;#8220;Nasdaq&amp;#8221;) (see Note 8a).&lt;/p&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&amp;#8217;s submission of an Investigational New Drug (&amp;#8220;IND&amp;#8221;) application for the Company&amp;#8217;s RTGel in combination with Allergan&amp;#8217;s BOTOX for the treatment of overactive bladder to the U.S. Food and Drug Administration (&amp;#8220;FDA&amp;#8221;). The Company received the milestone payment in August 2017.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market in consideration for approximately $64 million net of issuance costs. Also, see Note 12.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company&amp;#8217;s product candidates may never achieve commercialization and it will continue to incur losses for the foreseeable future. Therefore, in order to fund the Company&amp;#8217;s research and development expenses, general and administrative expenses and capital expenditures until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000225" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2&amp;#8212;SIGNIFICANT&lt;font style="letter-spacing:1.4pt;"&gt; &lt;/font&gt;ACCOUNTING&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;POLICIES&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;a.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Basis&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;presentation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;b&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;en&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;prepared&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;account&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ng&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;principles&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;generally&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;accept&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;United&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;States&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of America&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;(&amp;#8220;U.S.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;GAAP&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;b. Principles of consolidation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The consolidated financial statements include the financial statements of UPL and its wholly owned subsidiary, UPI. Intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;c.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Use&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;estimates&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preparation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;statements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;preparation&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;conformity&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;U.S.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;GAAP&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;man&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;gement&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;make&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;estimates&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assumptions&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;affect the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;reported&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;disclosure&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cont&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ngent&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;financ&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;al&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the reported&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;revenues&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;duri&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;period.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Actual&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;results&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;may&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;differ&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;those&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;estimates.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;applicable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;to these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;consolidated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;financi&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;l&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements,&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;most&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;significant&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;estimates&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assumptions&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;relate&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;compensat&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on, the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;timing&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;revenue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;recognition.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;d.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Functional&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;currency&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;U.S.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;dollar&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(&amp;#8220;Dollar&amp;#8221;)&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;primary&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;economic&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;environment&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;operations&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subsidiary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;are conducted.&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;Therefore,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;functional&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Dol&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ar.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accordingly,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;transactions&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;currencies&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Do&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;lar&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;functional&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;usi&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;exchange&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;transaction.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;At&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;date,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;monetary&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liab&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;lities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;denominated&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;currencies&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Dollar&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;official&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;exch&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;nge&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;date.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;effects&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;foreign&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;re-measurements&lt;font style="letter-spacing:1.45pt;"&gt; &lt;/font&gt;are recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consolidated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;operations&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;&amp;#8220;fin&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ncial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;(expenses).&amp;#8221;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;e.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;equivalents&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;considers&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equiv&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;lents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;short-term,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;highly&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;liquid&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;investments,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;incl&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;de&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;short-term&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;bank&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;original maturities&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;three&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;months&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;less&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;purchase&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;withdrawal&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;readily&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;convertible&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;to known&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;f.  Short-term investments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests in short-term investments that consist of mutual and bond funds.&amp;nbsp;&amp;nbsp;While these investments are considered highly liquid and available to fund current operations, there is more than an insignificant risk of change in value due to interest rate, quoted price, or penalty on withdrawal and are therefore classified as short-term investments. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We classify our short-term investments as available-for-sale in accordance with FASB ASC Topic 320, &amp;#8220;Investments &amp;#8212; Debt and Equity Securities&amp;#8221;. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within stockholders&amp;#8217; equity.&amp;nbsp;&amp;nbsp;There was no change in value for the period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;g.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Property&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Property&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;stated&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cost,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accumulated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;depreciation.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;d&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;preciated&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;straight-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;eful&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;lives.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Annual&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;depreciation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15-30&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6-15&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;improvements&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amortized&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;strai&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;ht-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;shorter&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;term&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;useful life&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;improvements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;h.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Impairment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;assets&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;tests&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;assets,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;comprised&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;solely&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;impairment&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;whenever&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;ev&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nts&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;circumstances&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;present an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;indication&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;impairment.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sum&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;undiscounted&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;less&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;th&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;n&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;carrying&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;such assets, an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;impairment&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;recognized.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;written&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;down&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;values,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;calculated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;ased&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the present&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;discounted&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;some&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;val&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;e&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;measure.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017 and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;d&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;d&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;impairment&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;assets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;i.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Financial&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;instruments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;issues&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;considers&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provisions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:-0.1pt;"&gt;S&lt;/font&gt;C&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determine&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;should be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;liability.&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;scope&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company further&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;analyzes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&amp;#8217;s&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;characteristics&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determine&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;should&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;c&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;assified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;temporary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(mezzanine)&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;or within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;permanent&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ith&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;provisions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;480-10-S99.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;issues&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;freestanding&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;instruments,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;first&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;analyzes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provisions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determine whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;should&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;l&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ability,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subsequent&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;va&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ue&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;earnings&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ea&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;h&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;scope&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;further&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;analyzes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provisi&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ns&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;815-40&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;determine whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;should&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;wit&lt;font style="letter-spacing:-0.1pt;"&gt;h&lt;/font&gt;in&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;rather&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;liability,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subse&lt;font style="letter-spacing:-0.1pt;"&gt;q&lt;/font&gt;uent&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;earnings&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ea&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;h&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;period.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;See&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;note&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;7&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;note&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;8.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;j.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Share-based&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;accounts&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;employees&amp;#8217;&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;directors&amp;#8217;&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;classif&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ed&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grant-date&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value method.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;transactions&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;recogni&lt;font style="letter-spacing:-0.1pt;"&gt;z&lt;/font&gt;ed&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;expense&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;requisite&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;period.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of December&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;early&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;ad&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;pted&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;policy&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;to account&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;forfeitures&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;occur&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;according&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;FASB&amp;#8217;s&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Accounting Standards&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Update&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(ASU)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016-09,&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Improvements&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;to Employee&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Share-Based&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;Payment&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Accounting.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;justment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;beginning&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of the period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;material&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;therefore&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;reflected&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;conso&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;idated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;shareholders&amp;#8217;&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;e&lt;font style="letter-spacing:-0.1pt;"&gt;q&lt;/font&gt;uity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;elected&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;compen&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ation&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;conditioned&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;only&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;conti&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ued&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;graded&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;vesting&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;schedule&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;straight-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sin&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;le-option&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;award&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;approach.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;wards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;expensed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;requisite&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;hen&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;achievement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;criteria&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;probable.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;non-employees&lt;font style="letter-spacing:1.3pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;re-measured&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;until&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;commitment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;reached which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;usually&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;completed.&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;va&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ue&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;charged&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;operations&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;service period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;straight-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;k.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Revenue&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;recognition&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Virtually&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;revenues&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;derived&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Allergan,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;lic&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nse&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;worldwide&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;rights&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;some&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;products. See also Note 1. Revenue&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;only&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;hen&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;conditi&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ns&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;met:&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;(i)&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;there&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;persuasive&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;evidence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;arrangement; (ii)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;occurred:&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;(iii)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;fixed&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determinable:&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(iv)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;collectab&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;lity&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reasonably&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;assured.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;contains&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;two&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;deliverables:&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;(a)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;comp&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;nent&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(b)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Allergan&amp;#8217;s&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;right&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;require&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;RTGel&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;vi&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ls from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;multiple&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;deliverab&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;es,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;shall&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;considered&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;separate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;it&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;criteria&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;met:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;customer&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;standalone&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;ba&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;is.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;standalone&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sold&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;separately&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;vendor&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;customer&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;could&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;resell&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item(s)&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;standal&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ne&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;basis.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;context&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;customer&amp;#8217;s&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;ability&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;resell&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item(s),&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;this&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;criterion&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;does&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;require&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;existence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;ob&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ervable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;deliverable(s),&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;and&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(b)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;includes&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;general&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;right&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;return&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;relative&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item(s),&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;unde&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ivered&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;considered&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;probable&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subst&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ntially&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;control&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;vendor.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;deliverables&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;separab&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;e,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;allocated&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;separate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;units&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;relati&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;e&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;selling&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;deliverable&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;(where&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;locable&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;element&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;limited&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amo&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;nt&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;contingent&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;future products&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;services)&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;appropriate&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;revenue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;recognition&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;princip&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;es&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;applied&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;unit. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;component&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;standa&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;one&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(and&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;therefore&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;accounted&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;separately&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services)&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;can&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;intended&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;purposes&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;without&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;four&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;conditions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;605&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ere&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;met&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; 2017 and &lt;/font&gt;2016: (1)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;persuasive&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;evidence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;exists&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;engaged&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;inding&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement;&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;(2)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;has occurred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;rendered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;l&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;documents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;request&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;relating&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;know-how&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;were provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;before&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;can&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;intend&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;purposes&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;without&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;(except&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for immaterial&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;support&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;services);&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;(3)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;fixed&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determinable,&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;indicated&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;licen&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;e&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement;&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(4)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;collectability&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reasonably assured.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;also&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;entitled&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;milestone&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;royalties&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Allergan&amp;#8217;s&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;reve&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;product,&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;which are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;considered&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;fixed&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determinable&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;until&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;th&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ir&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;occurrence.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;Therefore,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;only&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;recogniz&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;conditions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for payment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;met,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;become&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;due&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;payable.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During October&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;received&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;n&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$17.5&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;million&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;represented&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;consi&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;eration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;both the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;intellectual&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;well&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;A&lt;/font&gt;llergan&amp;#8217;s&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;right&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;(which&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;e&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;future payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;according&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;pricing&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;stipulat&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;agreement).&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;determined&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;pricing&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the supply&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;represents&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;standalone&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;se&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ling&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;price.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Accordingly,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;allo&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;ated&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;entire&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;upfront&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of $17.5&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;million&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;component.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;addition,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;revenue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;servi&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;es&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;equal&lt;font style="letter-spacing:0.45pt;"&gt; to &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consi&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;eration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;stipulated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;services,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provided.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&amp;#8217;s submission of an IND application for the Company&amp;#8217;s RTGel in combination with Allergan&amp;#8217;s BOTOX for the treatment of overactive bladder to the U.S. FDA. The Company received the milestone payment in August 2017. This milestone was recognized as revenue during the year ended December 31, 2017, as conditions for payment were met and the milestone payment was considered fixed or determinable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;l.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Research&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;costs&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;expen&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;incurred&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;primarily&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;cost&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;salaries,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;compensat&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;expenses,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;payroll&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;employee&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;benefits,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;subcontractors&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;materials&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;evelopment&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;activities, including preclinical studies, clinical trials, manufacturing costs&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;professional&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services. The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;performed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;others&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;connection&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;nd&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;activities of an&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;entity,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;including&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;deve&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;opment&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;conducted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;others&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;on behalf&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;entity,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;shall&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;inc&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;uded&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;in research&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;development costs.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Grants&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;received&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Israel&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Innovation&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;Authority,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;f/k/a&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Office&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Chief&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Scientist&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Israel&amp;#8217;s&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Ministry&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Industry,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;Trade&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Labor&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&amp;#8220;IIA&amp;#8221;)&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;becomes&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;receiva&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;le,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;there&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reasonable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;assurance&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;comply&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;conditions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;attached&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;there&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reaso&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;able&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;assurance&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;received.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;deducted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;pplicable&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;incurred.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;n&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;increase&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$175&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;result&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;decis&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pursue&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;one&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;programs&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;approved&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;result&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;financing&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;opportunities.&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;For&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;D&lt;/font&gt;ecember&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$126&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;was received from Allergan, in connection with the pre-clinical collaboration agreement signed in August 2015 and deducted from the research and development expenses. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;intangibles&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;purchased&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;others&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;particular&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;deve&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;opment&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;project&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;no&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;alternative&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;future uses&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;(in&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;projects&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;otherwise)&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;therefore&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;no&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;s&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;parate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;economic&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;values&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;deve&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;opment costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;time&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;m.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Income tax&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;1)&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Deferred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;taxes&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabi&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ity&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;method.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liability&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;method,&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;determined&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;bas&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;differences&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;between&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;reporti&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;tax bases&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;mea&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;currently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;enacted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;laws.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;valuation&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;llowance&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the extent&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;likely&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;realized&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;foresee&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ble&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;future.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2)&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Uncertain&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;positions&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;follows&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;two-step&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;approach&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognizing&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;measuring&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;uncertain&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;positions.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;first&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;step&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;evaluate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;position for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;recognition&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;determining&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;availab&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;e&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;evidence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;indicates&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;likely&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;position&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ill&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;sustained&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on technical&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;merits.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;this&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;threshold&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;met,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;second&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;step&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;measure&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;benefit&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;largest&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;likely&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of being&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;realized&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ultim&lt;font style="letter-spacing:0.1pt;"&gt;a&lt;/font&gt;te&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;settlement. As of December 31, 2017 and 2016, the Company had not accrued a provision for uncertain tax positions.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;n.&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Loss&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(&amp;#8220;LPS&amp;#8221;)&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;dividing&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;reducing&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;cumulati&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;e&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;dividends&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt;, &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the weighted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;average&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;peri&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;d.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;calculation&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;diluted&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ex&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;ludes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;potential&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;issuances&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordi&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;options, warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;convertible&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;anti-dilutive.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;o.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Fair&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;measurement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;rec&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ived&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sale&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;paid&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;transfer&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;liability&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;orderly transaction&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;between&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;participants&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measurement&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;date.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;increase&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;consistency&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;comparability&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value measurements,&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;guidance&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;establishes&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;val&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;e&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;hierarchy&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;prioritizes&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;observable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;unob&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ervable&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;measure&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;three&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;broad&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;levels,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;described&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;fo&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;lows:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;1:&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Quoted&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;prices&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(unadjusted)&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;active&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;markets&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;accessible&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measurement&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;liabilities.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value hierarchy&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;gives&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;highest&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;priority&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;1&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;inputs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;2:&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Observable&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;prices&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;quoted&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;active&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;markets but&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;corroborated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;data.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;3:&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Unobservable&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;us&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;little&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;no&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;available.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;hierarchy&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;ives&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;lowest&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;priority&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;3 inputs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determining&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;utilizes&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;val&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;ation&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;techniques&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;maximize&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;observable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;minimize&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of unobservable&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;extent&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;possib&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;e&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;considers&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;counterparty&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assessment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;p.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Concentration&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;risks&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;instruments&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;potentially&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;concentrati&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;principally&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equiva&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ents and short-term investments.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;eq&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;ivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;highly&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;rated&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nstitutions,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;matter&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;policy,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;limits&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;credit exposure&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;single&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nstitution.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;experienced&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;cre&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;it&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;losses&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;accounts&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;does&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;belie&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;e&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;is exposed&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;significant&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;instruments.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;q.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Segment&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;reporting&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;segments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;reported&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;manner&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;consistent&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;internal&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;ch&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ef&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;decision-maker,&lt;font style="letter-spacing:1.25pt;"&gt; &lt;/font&gt;who&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is responsible&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;allocating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;resources&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assessing&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;segments.&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;o&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;erates&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;one&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;operating segment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;r.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Costs&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;accounts&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;SEC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Staff&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Accounting&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;Bulletin&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Topic&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;5&lt;/font&gt;A.&lt;font style="letter-spacing:0.3pt;"&gt; Costs directly attributable to a proposed or actual offering of securities are deferred and recorded against the gross proceeds of the offering upon completion. &lt;/font&gt;During&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016, the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;$1.7&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;million&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;g&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;neral&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;administrative&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;s.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Newly&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;recently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;adopted&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;pronouncements&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;August&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;2014,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; Accounting Standards Update (&amp;#8220;&lt;/font&gt;ASU&amp;#8221;)&lt;font style="letter-spacing:0.35pt;"&gt; No. &lt;/font&gt;2014-15&amp;#8212;Presentation&lt;font style="letter-spacing:1.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Financial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;Statements&amp;#8212;Going&lt;font style="letter-spacing:1.55pt;"&gt; &lt;/font&gt;Concern&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;(ASC&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;S&lt;/font&gt;ubtopic&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;205-40):&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;&amp;#8220;Disclosure of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Uncertainties&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;about&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Entity&amp;#8217;s&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Ability&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Conti&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ue&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Going&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Concern&amp;#8221;.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;update&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;managem&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nt&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assess&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;company&amp;#8217;s ability&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;continue&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;going&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;concern&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;nd&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;provide&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;footnote&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;disclosures&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;certain&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;circumstances.&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;All&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;apply&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;new&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;requirements&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;annu&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;l&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;ending&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;interim&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;thereafter.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The adoption of the guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &amp;#8220;Revenue from Contracts with Customers&amp;#8221; (&amp;#8220;Topic 606&amp;#8221;, &amp;#8220;ASU 2014-09&amp;#8221;, or &amp;#8220;the New Revenue Standard&amp;#8221;). ASU 2014-09 requires entities to recognize revenue that represents the transfer of promised goods or services to customers in an amount equivalent to the consideration to which the entity expects to be entitled to in exchange for those goods or services. The following steps should be applied to determine this amount: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in ASU 605, &amp;#8220;Revenue Recognition,&amp;#8221; and most industry-specific guidance in the Accounting Standards Codification. The New Revenue Standard is effective for the Company for annual reporting periods, including interim periods therein, beginning January 1, 2018. The New Revenue Standard may be applied retrospectively with the cumulative effect recognized as of the date of adoption (modified retrospective method). The Company will adopt the New Revenue Standard using modified retrospective method. The Company has substantially completed its assessment of the New Revenue Standard and identified two revenue streams (1) licensing revenue and (2) revenue from clinical supply of RTGel per the license agreement with Allergan. The implementation of the New Revenue Standard will not have a material impact on the amount or timing of the Company&amp;#8217;s current revenue recognition related to these revenue streams. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;February&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.35pt;"&gt; No. &lt;/font&gt;2016-02,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;Leases&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;(Topic&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;842 or &amp;#8220;ASU&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2016-02&amp;#8221;).&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;2016-02&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;supersedes&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;existing&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;guida&lt;font style="letter-spacing:0.1pt;"&gt;n&lt;/font&gt;ce&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in Leases&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;(Topic&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;840).&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;revised&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;standard&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;les&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ees&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;ari&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ing&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;leases&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;terms greater&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;twelve&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;months&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;including&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;tho&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;e&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;currently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;leases,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;disc&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ose&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;key&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;information about&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;leasing&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;arrangements.&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;Lessees&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;w&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ll&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;li&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;bility&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;right-of-use&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheets,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;while lessor&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;remain&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;larg&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ly&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;unchanged.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;guidance&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;effective&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ual&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;beginning&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Decem&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;er&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2018,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;with early&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;permitted.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;currently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;evaluating&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;impact&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;adopt&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2016-02&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consolidated financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;disclosures.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;August&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.35pt;"&gt; No. &lt;/font&gt;2016-15,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&amp;#8220;Statement&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Flows:&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Classification&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Certain&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Rec&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ipts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Payments,&amp;#8221; which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;addresses&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;presentation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;(or&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;generally&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;escribed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;such)&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;230,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Flows,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;intent&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;reduce&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;diversity&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;practi&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;e.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;Among&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;others,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;this&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;ASU addresses&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flow&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;treatment&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;such&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;debt&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;prepayment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;debt&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;extinguishment&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;proce&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ds&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;settlement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;insurance claims.&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;disclose&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;how&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;reconc&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;les&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;shown separately&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;b&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;lance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;must&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;also&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;disclose&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;information&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;ab&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ut&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;nature&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the restrictions.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;amendments&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;effective&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;public&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;business&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;beg&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nning&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;interim periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;those&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Early&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;adopti&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;permitted.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;retrospective&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;required.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;The Company believes the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; of the guidance will be immaterial to its financial statements&lt;/font&gt;.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;November&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;No.&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016-18,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;&amp;#8220;Statement&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Flows&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(Topic&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;230):&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Restricted&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Cash&amp;#8221;&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(&amp;#8220;ASU&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2016-18&amp;#8221;).&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;ASU 2016-18&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;amends&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;classification&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;presentati&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash flows.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;2016-18&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;effective&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;public&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;business&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;begin&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ing&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;interim&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;periods within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;those&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Early&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;permitted,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;inclu&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;ing&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;interim&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;period. The&lt;font style="letter-spacing:0.05pt;"&gt; Company believes&lt;/font&gt;&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; of the guidance &lt;/font&gt;will be immaterial to its&lt;font style="letter-spacing:0.7pt;"&gt; financial statements&lt;/font&gt;.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000226" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;3&amp;#8212;PROPERTY&lt;font style="letter-spacing:1.25pt;"&gt; &lt;/font&gt;AND&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;EQUIPMENT&lt;/p&gt;
&lt;p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DECEMBER&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;531&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less&amp;#8212;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;expense&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;$&lt;font style="letter-spacing:-0.1pt;"&gt;207&lt;/font&gt;&lt;font style="letter-spacing:0.45pt;"&gt;, &lt;/font&gt;$213 and $113&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt;, &lt;/font&gt;2016 and 2015&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;respectively.&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <urgn:EmployeeRightsUponRetirementTextBlock id="F_000227" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;4&amp;#8212;EMPLOYEE&lt;font style="letter-spacing:1.25pt;"&gt; &lt;/font&gt;RIGHTS&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;UPON&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;RETIREMENT&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;law&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;make&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;severance&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;dismissal&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;employ&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;e&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;termination&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employment&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;certain other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;circumstances.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;operates&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;post-employment&lt;font style="letter-spacing:1.35pt;"&gt; &lt;/font&gt;defined&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;contribution&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;pl&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ns.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;defined&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;contribution&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;plan&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;program&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;benefits&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;an employee&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;termination&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employment,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;re&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;ularly&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;makes&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;fixed&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;separate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;indepe&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;dent&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;entity&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;so&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;no&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;legal&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;constructive&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;obl&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;gation&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pay&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;additional&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;contributi&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ns&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fund&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;does&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;hold&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;sufficient&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pay&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;all employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;benefits&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;relating&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employee&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;servi&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;e&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;current&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;prior&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;periods.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fund&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;included&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;position.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;operates&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;pension&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;severance&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;compensation&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;plans&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;sub&lt;font style="letter-spacing:-0.1pt;"&gt;j&lt;/font&gt;ect&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Section&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;14&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Israeli&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Severance&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;Pay&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Law.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;plans&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are funded&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;through&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;insurance&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;compan&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;es&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pension&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;funds&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;administered&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;trustees.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;terms,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;plans&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;meet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the definition&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;defined&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;contribution&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;lan,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;defined&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;above.&lt;/p&gt;&lt;/div&gt;</urgn:EmployeeRightsUponRetirementTextBlock>
  <urgn:ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock id="F_000228" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;5&amp;#8212;PROCEEDS&lt;font style="letter-spacing:1.25pt;"&gt; &lt;/font&gt;FROM&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;EXERCISE&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;OF&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;WARRANTS&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;FOR&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;PRE&lt;font style="letter-spacing:-0.1pt;"&gt;F&lt;/font&gt;ERRED&lt;font style="letter-spacing:1.1pt;"&gt; A-1 &lt;/font&gt;SHARES&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s warrants outstanding prior to the IPO were exercisable for Series A-1 preferred shares at an exercise price of $7.81 per share. Prior to the IPO, such warrants were exercisable for 728,312 Preferred A-1 shares. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2017 and 2016, the Company notified holders of these warrants that it was ready to accept an exercise notice that was conditioned on the price per share at which the Company&amp;#8217;s shares would be sold in an anticipated IPO. Prior to the IPO, the Company received a total amount of $952 as consideration for the conditional cash exercise of these warrants. The cash received was recorded among current liabilities as proceeds from exercise of warrants for preferred shares. As of December 31, 2017, following the exercise of the warrants, the cash received was re-classified to additional paid in capital. See also Note 8.&lt;/p&gt;&lt;/div&gt;</urgn:ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000229" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;6&amp;#8212;COMMITMENT&lt;font style="letter-spacing:1.5pt;"&gt; &lt;/font&gt;AND&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;CONTINGENCIES&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;a.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Lease&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;agreement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;April&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;UPL&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;signed&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;dendum&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;November&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;2014&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;increase&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;office&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;s&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;ace&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;rented&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to extend&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rent&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;period.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:0.15pt;"&gt;lease&lt;/font&gt;&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;agr&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ement&lt;font style="letter-spacing:0.85pt;"&gt; is &lt;/font&gt;effective&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;until&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;rent&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ending&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt;,&lt;/font&gt;&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016 and 2015,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;approximately&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;$276&lt;font style="letter-spacing:0.45pt;"&gt;,&lt;/font&gt;&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;$&lt;/font&gt;218 and $121,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UPI&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;entered&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;office&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;7&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;commencing&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;May&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;1,&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;2016.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;part&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;UPI&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;provided the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;lessor&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;letter&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;renews on an annual basis.&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the fourth quarter, UPI entered into a new lease agreement for its New York headquarters. The lease agreement commenced in October 2017 and shall terminate in February 2021. The rent expense&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;proximately&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;$342 and rent expense for the eight months ended December 31, 2016 was $102.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;minimum&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;next&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;seven&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;der&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;agreements&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;$1,115&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year 2018,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;$1,054&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;2019,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;$873 in 2020, $305 in&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;2021, $192 in&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2022,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;$80&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;2023.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;b.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Grants&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Israel&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Innovation&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;Authority&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;(&amp;#8220;IIA&amp;#8221;&lt;font style="letter-spacing:0.1pt;"&gt;)&lt;/font&gt;,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;formerly&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;known&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Office&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Chief&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Scientist&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;State&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Israel&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;received&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;grants&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;IIA&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;fundi&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Up&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;until&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2007,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;IIA&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;participation&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;funding&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;operations&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;part&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Director&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;General&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Directive&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;8.2&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Israel&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;grants&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;provi&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;ed&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Granot&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Ventures.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;2008,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the funding&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;directly&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;committed&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pay&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;royalties&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Government&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Israel&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;proceeds&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;sales&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;products&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;dev&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;lopment of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;IIA&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;participates&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;way&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;grants.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;At&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;time&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grants&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;received,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;successful&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;projects&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;not assured.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;case&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;failure&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;project&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;partly&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;financed&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;above,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;o&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;ligated&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pay&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;such&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;royalties.&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;Under the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;terms&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;funding&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;IIA,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;royalties&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;3%-4.5%&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;payable&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;sales&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;products&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;devel&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ped&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;project&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;so&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;funded,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;up&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;100% of&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;received&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;(dollar&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;linked);&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;addition&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;annual&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nterest&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;12-month&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;LIBOR. The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;several&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;conditions,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;luding&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;restrictions&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;intellectual&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;property.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;maximum&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;royalty&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;payable&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;der&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;funding&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;arrangements&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;$2,105&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;(exclud&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ng interest).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;c.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Financing&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;success&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;fees&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;entered&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;agreements&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;third&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;parties&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;shareholders&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;connect&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fundraising&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;efforts.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;rendered,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;undertook&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pay&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;those&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;third&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;parties&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;shareholders&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;certain&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;success&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;fees&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;funds&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;actually&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;received&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;by the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and/or&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;purchase&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;agreed&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;betw&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;en&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;parties.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;success&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;fees&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;to third&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;parties for the year ended December 31, 2017 were $28 and payable in cash and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;consisted&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of 5,726&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to third&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;parties&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to purchase&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;inary shares&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a fair&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;$9.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:FinancialInstrumentsDisclosureTextBlock id="F_000230" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;7&amp;#8212;FINANCIAL&lt;font style="letter-spacing:1.25pt;"&gt; &lt;/font&gt;INSTRUMENTS&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;a.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Warrants&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;shares&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;2014,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;part&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;purchase&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;(the &amp;#8220;2014&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;SPA&amp;#8221;),&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;arrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;(the&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&amp;#8220;A-1&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;warrants&amp;#8221;)&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares.&lt;font style="margin-left:36pt;"&gt;&lt;/font&gt;&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;exercisable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Series&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;A-1&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;representing&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;pri&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;e.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;event&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;that the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;exercised&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;connection&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;M&amp;amp;A&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;event,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;holder&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;could&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;elect&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;convert&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;warrant&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;basis. The&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;A-1&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;freestanding&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nstruments,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;exercisable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Series A-1&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;redeemable&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;certain&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;e&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;ents&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;represent&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&amp;#8220;Deemed&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;Liquidation&amp;#8221;&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;events. Accordingly,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;A-1&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;every&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;period,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cha&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ges&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in earnings&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;finance expenses, net.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;measured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accor&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;ance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Hybrid&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Method.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Hybrid Method&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;combines&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;probabilities&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;scenario&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;w&lt;font style="letter-spacing:-0.1pt;"&gt;h&lt;/font&gt;ich&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;20%&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;liquidation&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;e&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;ent&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;scenario&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;estimated at&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;80%.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;determined&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;mainly&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;estimation&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;derived&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;DCF&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;calcu&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ation&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;assumption&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;relating&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;revenue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;forecast,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;clini&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;al&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;success probabilities,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;relevant&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;discount&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;betw&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;en&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;10.5%-19%&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;(10.5%&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flow&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;derived&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;19%&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;erived&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;internal&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;development)&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expect&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;volatility&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;73.93%.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the completion of the IPO, the Company converted all outstanding warrants into 364,036 Preferred A-1 shares of the Company and subsequently converted all of its preferred shares, including the Preferred A-1 shares, into ordinary shares. See also Note 5 and Note 8.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;b.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;instruments&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;measured&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Level&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;3.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;below&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;sets&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;forth&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;summary&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Lev&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;l&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;3:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in fair value of warrants for preferred shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of warrants for preferred shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fi&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ancial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;proximate&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;carrying&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;amounts.&lt;/p&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
  <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock id="F_000231" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;8&amp;#8212;SHARE&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;CAPITAL&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;a.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Share&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;capital&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;capit&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;l&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ordinary shares of NIS 0.01 par value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,600,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,751,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,305,743&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A and A-1 preferred shares of NIS 0.01 par value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,400,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,193,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Terms&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="font-weight:normal;font-style:normal;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Each&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;entitled&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;one&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;vote.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;hol&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;ers&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;also&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;entitled&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;receive&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;dividends&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;henever&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;funds&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;legally available,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;declared&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Board&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Directors.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;inception,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Comp&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ny&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;declared&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;dividends.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;October&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;2015&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;entered&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;purchase&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;agr&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Telormedix&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;SA&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;(&amp;#8220;TMX&amp;#8221;)&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;pursuant&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company purchased&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;intellectual&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;pro&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;erty&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;TMX&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;(in&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;process&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;R&amp;amp;D)&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;691,200&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Series&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$5.94, which were subsequently converted into ordinary shares on the date of the IPO.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;issue&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;ad&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;itional&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;shares upon the occurrence of each of three milestones as set in the agreement. The Company has deemed the probability of achieving these milestones to be remote&lt;font style="letter-spacing:0.8pt;"&gt;. &lt;/font&gt;&lt;font style="color:#000000;"&gt;The acquired intellectual property costs totaling $4.1&amp;#160;million were expensed as incurred to research and development costs in accordance with ASC&amp;#160;730, as the intellectual property is purchased from others for a particular research and development project and has no alternative future uses and therefore no separate economic value. &lt;/font&gt;&lt;font style="font-size:11pt;letter-spacing:0.55pt;"&gt; &lt;/font&gt;&lt;font style="font-size:11pt;letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="font-size:11pt;letter-spacing:0.6pt;"&gt; &lt;/font&gt;&lt;font style="font-size:14pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-size:11pt;letter-spacing:0.55pt;"&gt; &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;On April 19, 2017, the Company&amp;#8217;s board of directors and shareholders approved an aggregate 3.2 for-1 share split of the Company&amp;#8217;s ordinary, Preferred A and Preferred A-1 shares. The share split was effected on April 19, 2017 by the issuance of 2.2 ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 share held immediately prior to the share split.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In May 2017, the Company completed an IPO on the Nasdaq Stock Market, in which it issued 5,144,378 ordinary shares, at a public offering price of $13.00 per share, in consideration for $60.8 million, net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&amp;#8217; option to purchase additional 671,005 ordinary shares at the IPO price. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Upon the completion of the IPO, the Company converted all outstanding warrants for Preferred A 1 shares into 364,036 Preferred A-1 shares of the Company. Subsequently, the Company converted all outstanding Preferred A and Preferred A-1 shares into ordinary shares at a ratio of 1:1. As of December 31, 2017, the Company&amp;#8217;s share capital was composed entirely of ordinary shares.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, during the years ended December 31, 2017 and 2016, the Company recorded $0.0 and $1.7 million, respectively, in general and administrative expenses related to IPO costs, in accordance with SEC staff Bulletin Topic 5A.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;The Company&amp;#8217;s convertible preferred shares included Series A and A-1 preferred shares.  The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Series&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;$5.94&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Series&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;A-1&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;$7.81.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;holder&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was:&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(i)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;entitled&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;votes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;qual&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;which such&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;then&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;convertible,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;(ii)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;voting&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;rights&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;powers&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;equal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;voting&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;rights&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;powers&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;h&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;lder&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordinary shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;vote&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;single&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;class&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;h&lt;/font&gt;olders&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(iii)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;entitled&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;notice&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;meeting&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the shareholders.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;issuance&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;dividends&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;annum&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;8%&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;original&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;purchase&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;pri&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;e&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(as defined)&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accrued&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;such&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;(sub&lt;font style="letter-spacing:-0.1pt;"&gt;j&lt;/font&gt;ect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to appropriate&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;adjustment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;event&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of any&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;stock&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;dividend,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;stock&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;split, combination&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;similar&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;recapitalization&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ith&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;respect&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;holders&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;follo&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ing&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;conversion&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;rights:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Optional conversion - each preferred share was convertible, at the option of the holder thereof, at any time after the date of issuance of such share into such number of fully paid shares of ordinary shares as was determined by dividing the original purchase price by the conversion price applicable to such share, in effect on the date that the certificate was surrendered for conversion. The initial conversion price of the preferred shares was the original purchase price; provided, however, that the conversion price for the preferred shares was subject to certain adjustments.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Automatic&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;conversion&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;-&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Each&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was to be automatica&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ly&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;converted&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;conversion&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the time&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;such&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consummation&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;one&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;events:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;i)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;closing&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;IPO,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;where&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;pre-money&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;valuation&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;$75,000&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;proceeds&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Comp&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ny of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$25,000&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(a&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;&amp;#8220;Qualified&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Public&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Offering&amp;#8221;);&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;or&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ii)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;event&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;holders&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;majority&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;sixty&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;percent&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;(60%)&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;then&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;voting&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;single&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;class, consent&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;such.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As noted in 8a4, in May 2017, upon completion of the IPO, all of the convertible preferred shares were converted into ordinary shares.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the IPO, the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Series&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;perma&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ent&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;liability&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;classification&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;scope&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;meet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;requirements&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;classificat&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;480-10-S99.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;During 2017, the Company received $404 from a portion of the exercise of 812,222 options into 743,806 ordinary shares, which were net of 68,416 shares surrendered to pay the exercise price on the balance.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for $64 million net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&amp;#8217; option to purchase additional 219,512 ordinary shares at the public offering price. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;letter-spacing:0.2pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;b. Share-based&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;October&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;2010,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;board&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;directors&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;approved&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;option&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;plan&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&amp;#8220;Pl&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;n&amp;#8221;)&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;grants&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;employees,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;consultants, directors,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;providers.&lt;/p&gt;
&lt;p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Israeli&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Plan&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;su&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;ject&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;terms&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;stipulated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Section&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;102&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Israeli&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Tax&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Ordinance (&amp;#8220;Section&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;102&amp;#8221;).&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;option&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;grants&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;track&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;chosen&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;either&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;&amp;#8220;regular&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;income&amp;#8221;&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;track&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;&amp;#8220;capital&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;gains&amp;#8221;&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;track,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;set&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;out&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Section&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;102.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;registered&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Plan&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;un&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;er&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;capital&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;gains&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;track,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;offers&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;favorable&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the employees.&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;result,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;pursuant&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;terms&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Section&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;102,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;allowed&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;claim&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;ex&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;ense&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;purposes&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;credited&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;respect&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;them&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;P&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;an,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;including&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;salary&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;efits&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;accounts,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;exception&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;work-income&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;b&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nefit&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;component,&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;any,&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;determined&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;date.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;For&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;non-employees&lt;font style="letter-spacing:1.3pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for non-Israeli&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;employees,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Plan&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Section&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;3(i)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Israeli&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Tax&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Ordinance.&lt;/p&gt;
&lt;p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;volatility&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;histori&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;al&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;volatility&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;comparable&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;companies.&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;risk-free&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;interest&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assumption&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on observed&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;interest&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;appropriate&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;term&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;dol&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ar&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;terms.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;term&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;length&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;time&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;until the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;dates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;exercising&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;options and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;(except&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;senior&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;managem&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nt)&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;simplified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;due&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to insufficient&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;specific&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;historical&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;information&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employ&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;es&amp;#8217;&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;behavior,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;non-employees,&lt;font style="letter-spacing:1.35pt;"&gt; &lt;/font&gt;directors&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;senior&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;management&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;contractual&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;term.&lt;/p&gt;
&lt;p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2017, the Company&amp;#8217;s board of directors adopted the 2017 Equity Incentive Plan ("2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company&apos;s employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to the Company&apos;s employees, directors and consultants.&lt;/p&gt;
&lt;p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of ordinary shares that may be issued upon the exercise of incentive stock options under the 2017 Plan is 5,600,000.&lt;/p&gt;
&lt;p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.&lt;/p&gt;
&lt;p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2017, the Company&amp;#8217;s board of directors approved modifications of performance conditions for 67,200 restricted stock units and contingent options for executive management. The Company recorded an expense of $527 under general and administrative expenses with respect to these modifications.&lt;/p&gt;
&lt;p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2017 and 2016, the Company granted options to certain employees and non-employees as follows:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-style:italic;"&gt;1)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Options&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;directors:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Set&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;forth&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;below&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grants&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;made&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; and directors &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;20&lt;font style="letter-spacing:-0.1pt;"&gt;1&lt;/font&gt;7.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;majority&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;vest&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of four&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expire&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;seventh&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;anniversary&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;grant.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;a) &lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;During&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;712,900&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;options and restricted stock units&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;directors&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;prices&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;ra&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ging&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;$0&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$39.26&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share. &lt;font style="font-size:12pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;b)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;During&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;404,813&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;directors&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;prices&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;ra&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ging&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;$5&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$5.94&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;per share. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;c)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;font style="letter-spacing:-0.2pt;"&gt;During 2015, the Company granted 1,098,777 options to employees and directors with prices ranging from $0 to $5.94 per share.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of options granted to employees and directors during 2017, 2016 and 2015 was $14,249, $906 and $2,334, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;total&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;unrecognized&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;compensati&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;cost&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employee&lt;font style="letter-spacing:0.8pt;"&gt; and director &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;$14,131,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;whi&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;h&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;a weighted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;average&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;3.31&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;irectors&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Black-Scholes&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;mod&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;l.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;The underlying&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;computing&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value of ordinary shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$13.00-39.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.98-5.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.98-3.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71.53%-76.32%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74.8%-80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69.78%-76.68%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.85%-2.47%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4%&amp;#8211;2.13%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.38%&amp;#8211;2.08%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5-10 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1-7 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-style:italic;"&gt;2)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Options&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consultants&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;providers:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no new grants issued to consultants and service providers in 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;2016 and 2015,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;132,0&lt;font style="letter-spacing:-0.1pt;"&gt;3&lt;/font&gt;2&lt;font style="letter-spacing:0.65pt;"&gt; and 203,820 &lt;/font&gt;options,&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;respectively,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consultants&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;providers&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;an exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;ranging&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;$0&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$5.94&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016 and 2015&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;opt&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ons&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consultants&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;providers&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;during&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;2&lt;/font&gt;016 and 2015&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was $671 and $57, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consultants&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;pro&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;iders&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ing&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the Black-Scholes&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;model.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;underlying&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;computing&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;opt&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ons&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value of ordinary shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.58-37.21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.58-7.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.45%-74.50%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.72%-80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73.31%-76.3%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38%-2.26%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.56%-2.27%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.88%-2.07%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.9-5.9 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8-8.5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.8-7 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;summarizes&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;utstanding&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Plan&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Decem&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;er&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017, 2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2015,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;inform&lt;font style="letter-spacing:0.1pt;"&gt;a&lt;/font&gt;tion:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Directors&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consultants and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Service providers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of January 1, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;332,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,098,777&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,686,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;404,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,032&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(60,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,030,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;634,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;712,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(682,184&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(130,038&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,021,829&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Including 38,400 ordinary shares issuable upon the vesting of options granted in 2016, which were contingent upon the closing of the IPO.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;summarizes&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;outstand&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ng&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;exercisable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;options and restricted stock units&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2&lt;font style="letter-spacing:-0.1pt;"&gt;0&lt;/font&gt;17:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding at end&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercisable at end of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.00 - 10.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,948,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,142,310&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$10.01 - 20.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;292,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$20.01 - 30.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$30.01 - 40.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,520,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,194,811&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;aggregate&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;intrinsic&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;total&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;vested&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;e&lt;font style="letter-spacing:-0.1pt;"&gt;x&lt;/font&gt;ercisable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;options and restricted stock units&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;$38,308.&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;illustrates&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;ensation&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;operations:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000232" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;9&amp;#8212;TAXES&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;ON&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;INCOME&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;taxed&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Israeli&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;laws:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;a.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Tax&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;rates&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;taxed&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;regular&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;rate.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;corporate&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;24%&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;2&lt;/font&gt;5%.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Economic&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Efficiency&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Law&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(Legi&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;lative&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;Amendments&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Implementing&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Economic&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Policy&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2018 Budget&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Year),&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;published,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;introducing&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;gradual&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;reduction&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;n&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;corporate&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;25%&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;23%.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;However,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;law&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;also&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;included&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;a temporary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;provision&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;setting&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;corporate&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;24%.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;result,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;corporate&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;24%&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;20&lt;font style="letter-spacing:-0.1pt;"&gt;1&lt;/font&gt;7&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and would be&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;23%&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;2018&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and thereafter.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;change&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;mentioned&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;above&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ot&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;affected&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;date in Israel.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;b.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Tax&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assessments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;assessments&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;filed&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;2013&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;considered&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;final.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;c.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Losses&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;purposes&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;carried&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;forward&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;years&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;approximately&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;$&lt;/font&gt;24.8&lt;font style="letter-spacing:0.65pt;"&gt; million &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;carry&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;forward&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;losses&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;available&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;reduce&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;taxable&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;income without&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;limitation&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;use.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;d.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Deferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;taxes:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,887&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;742&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance Costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-Process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;761&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;806&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less&amp;#8212;valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;change&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;valuation&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;lowance&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at the beginning of the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes during the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at the end of the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The main reconciling item between the statutory tax rates of the Company (not UPI) and the effective rate is the share-based compensation and provision for full valuation allowance in respect of tax benefits from carryforward tax losses due to the uncertainty of the realization of such tax benefits.&lt;font style="font-size:12pt;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Regarding the Company&amp;#8217;s US operations, as of December 31, 2017, UPI had federal tax net operating losses of $0.4 million and state tax net operating losses of $0.7 million in several jurisdictions available to carry forward and reduce future income tax liabilities. The federal and state net operating losses begin to expire after 2036.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Internal Revenue Code contains provisions that may limit the use of the net operating tax loss carryforward available if significant changes occur in the stock ownership of UPI. In the event UPI has had a change in ownership, utilization of the carry&amp;#8209;forwards could be restricted due to the &amp;#8220;change in ownership provisions&amp;#8221; under Section&amp;#160;382 of the Internal Revenue Code and similar state provisions. Such limitations could result in the expiration of the net operating carry&amp;#8209;forwards before their utilization.&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000233" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;10&amp;#8212;LOSS&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;PER&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;ORDINARY&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;SHARE&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;sets&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;forth&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;calculation&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ba&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ic&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;diluted&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;indicat&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss attributable to equity holders of the Company&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,689&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend accumulated for preferred shares during the period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,467&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss attributable to equity holders of the Company, after deducting dividend&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; accumulated for preferred shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,408&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,541&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of ordinary shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,716,790&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,305,503&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,300,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss per ordinary share (LPS)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;20&lt;font style="letter-spacing:-0.1pt;"&gt;16&lt;/font&gt; and 2015,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;underlying&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;outstand&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ng&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;options,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;A-1&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;convertible&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;preferred shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;excluded&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;calculat&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;diluted&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;anti-dilutive.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;Di&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;uted&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;LPS&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;does&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;include 2,415,545,&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2,665,099&lt;font style="letter-spacing:0.8pt;"&gt; and 2,199,838 &lt;/font&gt;ordi&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;underlying&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;opti&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ns&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017, 2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2&lt;font style="letter-spacing:-0.1pt;"&gt;0&lt;/font&gt;15,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;respectively, 728,312&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;issuable&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;up&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; Preferred &lt;/font&gt;A-1&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;warrants, which were converted to ordinary shares upon the IPO, for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016 and 2015, and 5,193,427 shares issuable upon conversion of preferred shares for the years ended December 31, 2016 and 2015.&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000234" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;11&amp;#8212;RELATED&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;PARTIES-TRANSAC&lt;font style="letter-spacing:0.1pt;"&gt;T&lt;/font&gt;IONS&lt;font style="letter-spacing:2.2pt;"&gt; &lt;/font&gt;AND&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;BALANCES&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;UPI&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;entered&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;agreement,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;dated&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;November&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;20&lt;font style="letter-spacing:-0.1pt;"&gt;1&lt;/font&gt;5&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;commencing&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;May&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;office&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;space&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;New&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;York.&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;UPI&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;office&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;space&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;equitably&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Kite&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;P&lt;font style="letter-spacing:-0.1pt;"&gt;h&lt;/font&gt;arma,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;Inc.,&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Delaware&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;corporation,&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;cosignatory&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;such&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;agreement.&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;Arie&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Bell&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;egrun,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;M.D.,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;UPL&amp;#8217;s&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;chairman,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;served&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Chairman&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Chief&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Executive&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Officer&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Kite Pharma,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;Inc. until his resignation effective as of October 3, 2017, in connection with the acquisition of Kite Pharma, Inc. by Gilead Sciences, Inc.&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000235" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;12&amp;#8212;SUBSEQUENT&lt;font style="letter-spacing:1.6pt;"&gt; &lt;/font&gt;EVENTS&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for approximately $64 million net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&amp;nbsp;&amp;nbsp;option to purchase an additional 219,512 ordinary shares at the public offering price. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000236" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;a.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Basis&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;presentation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;b&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;en&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;prepared&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;account&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ng&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;principles&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;generally&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;accept&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;United&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;States&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of America&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;(&amp;#8220;U.S.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;GAAP&amp;#8221;).&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000237" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;b. Principles of consolidation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;The consolidated financial statements include the financial statements of UPL and its wholly owned subsidiary, UPI. Intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000238" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;c.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Use&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;estimates&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preparation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;statements&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;preparation&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;conformity&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;U.S.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;GAAP&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;man&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;gement&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;make&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;estimates&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assumptions&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;affect the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;reported&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;disclosure&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cont&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ngent&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;financ&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;al&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the reported&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;revenues&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;duri&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;period.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Actual&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;results&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;may&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;differ&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;those&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;estimates.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;applicable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;to these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;consolidated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;financi&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;l&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements,&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;most&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;significant&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;estimates&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assumptions&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;relate&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;compensat&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on, the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;timing&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;revenue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;recognition.&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="F_000239" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;d.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Functional&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;currency&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;U.S.&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;dollar&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(&amp;#8220;Dollar&amp;#8221;)&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;primary&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;economic&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;environment&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;operations&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subsidiary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;are conducted.&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;Therefore,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;functional&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Dol&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ar.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accordingly,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;transactions&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;currencies&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Do&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;lar&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;functional&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;usi&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;exchange&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;transaction.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;At&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;date,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;monetary&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liab&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;lities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;denominated&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;currencies&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than the&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Dollar&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;official&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;exch&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;nge&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;rate&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;date.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;effects&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;foreign&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;currency&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;re-measurements&lt;font style="letter-spacing:1.45pt;"&gt; &lt;/font&gt;are recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consolidated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;operations&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;&amp;#8220;fin&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ncial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;(expenses).&amp;#8221;&lt;/p&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000240" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;e.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;equivalents&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;considers&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equiv&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;lents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;short-term,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;highly&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;liquid&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;investments,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;incl&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;de&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;short-term&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;bank&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;original maturities&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;three&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;months&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;less&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;purchase&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;withdrawal&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;readily&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;convertible&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;to known&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash.&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:MarketableSecuritiesPolicy id="F_000241" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;f.  Short-term investments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests in short-term investments that consist of mutual and bond funds.&amp;nbsp;&amp;nbsp;While these investments are considered highly liquid and available to fund current operations, there is more than an insignificant risk of change in value due to interest rate, quoted price, or penalty on withdrawal and are therefore classified as short-term investments. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We classify our short-term investments as available-for-sale in accordance with FASB ASC Topic 320, &amp;#8220;Investments &amp;#8212; Debt and Equity Securities&amp;#8221;. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within stockholders&amp;#8217; equity.&amp;nbsp;&amp;nbsp;There was no change in value for the period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&amp;#160;&lt;/p&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000242" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;g.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Property&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Property&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;stated&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cost,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accumulated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;depreciation.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;d&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;preciated&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;straight-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;eful&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;lives.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Annual&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;depreciation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15-30&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6-15&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;improvements&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amortized&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;strai&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;ht-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;shorter&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;term&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;useful life&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;improvements.&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000243" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;h.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Impairment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;assets&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;tests&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;assets,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;comprised&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;solely&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;equipment,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;impairment&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;whenever&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;ev&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nts&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;circumstances&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;present an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;indication&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;impairment.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sum&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;undiscounted&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;less&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;th&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;n&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;carrying&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;such assets, an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;impairment&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;recognized.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;written&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;down&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;estimated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;values,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;calculated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;ased&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the present&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;expected&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;discounted&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;some&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;val&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;e&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;measure.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017 and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;d&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;d&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;impairment&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;long-lived&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;assets.&lt;/p&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000244" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;i.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Financial&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;instruments&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;issues&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;considers&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provisions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:-0.1pt;"&gt;S&lt;/font&gt;C&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determine&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;should be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;liability.&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;scope&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company further&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;analyzes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&amp;#8217;s&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;characteristics&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determine&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;should&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;c&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;assified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;temporary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(mezzanine)&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;or within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;permanent&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ith&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;provisions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;480-10-S99.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;issues&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;freestanding&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;instruments,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;first&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;analyzes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provisions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determine whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;should&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;l&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ability,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subsequent&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;va&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ue&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;earnings&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ea&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;h&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;scope&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;480,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;further&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;analyzes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provisi&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ns&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;815-40&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;determine whether&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;instrument&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;should&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;wit&lt;font style="letter-spacing:-0.1pt;"&gt;h&lt;/font&gt;in&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;rather&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;liability,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subse&lt;font style="letter-spacing:-0.1pt;"&gt;q&lt;/font&gt;uent&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;earnings&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ea&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;h&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;period.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;See&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;note&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;7&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;note&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;8.&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy id="F_000245" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;j.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Share-based&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;compensation&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;accounts&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;employees&amp;#8217;&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;directors&amp;#8217;&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;classif&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ed&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grant-date&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value method.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;payment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;transactions&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;recogni&lt;font style="letter-spacing:-0.1pt;"&gt;z&lt;/font&gt;ed&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;expense&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;requisite&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;period.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of December&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;early&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;ad&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;pted&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;policy&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;to account&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;forfeitures&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;occur&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;according&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;FASB&amp;#8217;s&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Accounting Standards&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Update&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(ASU)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016-09,&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Improvements&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;to Employee&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Share-Based&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;Payment&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Accounting.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;justment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;beginning&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of the period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;material&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;therefore&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;reflected&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;conso&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;idated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;shareholders&amp;#8217;&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;e&lt;font style="letter-spacing:-0.1pt;"&gt;q&lt;/font&gt;uity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;elected&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;compen&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ation&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;conditioned&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;only&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;conti&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ued&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;graded&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;vesting&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;schedule&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;straight-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sin&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;le-option&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;award&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;approach.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;wards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;expensed&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;requisite&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;hen&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;achievement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;criteria&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;probable.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;non-employees&lt;font style="letter-spacing:1.3pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;re-measured&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;until&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;commitment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;reached which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;usually&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;completed.&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;va&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ue&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;equity&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;awards&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;charged&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;operations&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;over&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;service period&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;straight-line&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;method.&lt;/p&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000246" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;k.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Revenue&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;recognition&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Virtually&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;revenues&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;derived&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Allergan,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;lic&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nse&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;worldwide&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;rights&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;some&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;products. See also Note 1. Revenue&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;only&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;hen&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;conditi&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ns&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;met:&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;(i)&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;there&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;persuasive&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;evidence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;arrangement; (ii)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;occurred:&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;(iii)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;fixed&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determinable:&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(iv)&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;collectab&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;lity&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reasonably&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;assured.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;contains&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;two&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;deliverables:&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;(a)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;comp&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;nent&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(b)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Allergan&amp;#8217;s&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;right&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;require&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;RTGel&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;vi&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ls from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;multiple&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;deliverab&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;es,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;shall&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;considered&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;separate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;it&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;all&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;criteria&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;met:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(a)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;customer&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;standalone&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;ba&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;is.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;standalone&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sold&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;separately&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;vendor&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;customer&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;could&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;resell&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item(s)&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;standal&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ne&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;basis.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;context&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;customer&amp;#8217;s&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;ability&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;resell&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item(s),&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;this&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;criterion&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;does&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;require&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;existence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;ob&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ervable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;deliverable(s),&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;and&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(b)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;includes&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;general&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;right&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;return&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;relative&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;item(s),&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;unde&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ivered&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;item&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or items&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;considered&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;probable&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;subst&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ntially&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;control&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;vendor.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;When&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;deliverables&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;separab&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;e,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;allocated&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;separate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;units&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;relati&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;e&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;selling&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;deliverable&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;(where&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;locable&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;element&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;limited&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amo&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;nt&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;contingent&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;future products&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;services)&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;appropriate&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;revenue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;recognition&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;princip&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;es&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;applied&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;unit. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;component&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;standa&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;one&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(and&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;therefore&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;accounted&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;separately&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services)&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;can&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;intended&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;purposes&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;without&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;four&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;conditions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;605&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ere&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;met&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; 2017 and &lt;/font&gt;2016: (1)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;persuasive&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;evidence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;exists&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;engaged&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;inding&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement;&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;(2)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;delivery&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;has occurred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;rendered&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;since&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;l&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;documents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;request&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;relating&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&amp;#8217;s&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;know-how&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;were provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;before&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Allergan&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;can&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;intend&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;purposes&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;without&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;(except&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for immaterial&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;support&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;services);&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;(3)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;fixed&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determinable,&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;indicated&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;licen&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;e&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;agreement;&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;(4)&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;collectability&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reasonably assured.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;also&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;entitled&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;milestone&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;royalties&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Allergan&amp;#8217;s&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;reve&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;product,&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;which are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;considered&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;fixed&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determinable&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;until&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;th&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ir&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;occurrence.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;Therefore,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;only&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;recogniz&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;conditions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for payment&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;met,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;they&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;become&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;due&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;payable.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During October&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;received&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;n&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$17.5&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;million&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;represented&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;arrangement&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;consi&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;eration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;both the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;intellectual&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;property&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;well&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;A&lt;/font&gt;llergan&amp;#8217;s&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;right&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;future&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;(which&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;e&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consideration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;future payments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;according&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;pricing&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;stipulat&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;agreement).&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;determined&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;pricing&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the supply&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;represents&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;standalone&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;se&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ling&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;price.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Accordingly,&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;allo&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;ated&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;entire&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;upfront&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;fee&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of $17.5&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;million&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the license&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;component.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;addition,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;revenue&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;supply&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;servi&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;es&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;equal&lt;font style="letter-spacing:0.45pt;"&gt; to &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consi&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;eration&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;stipulated&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the agreement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;services,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;provided.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&amp;#8217;s submission of an IND application for the Company&amp;#8217;s RTGel in combination with Allergan&amp;#8217;s BOTOX for the treatment of overactive bladder to the U.S. FDA. The Company received the milestone payment in August 2017. This milestone was recognized as revenue during the year ended December 31, 2017, as conditions for payment were met and the milestone payment was considered fixed or determinable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000247" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;l.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Research&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;costs&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;expen&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;incurred&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;primarily&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;cost&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;salaries,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;compensat&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;expenses,&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;payroll&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;employee&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;benefits,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;subcontractors&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;materials&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;evelopment&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;activities, including preclinical studies, clinical trials, manufacturing costs&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;professional&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;services. The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;services&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;performed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;others&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;connection&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;nd&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;activities of an&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;entity,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;including&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;deve&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;opment&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;conducted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;others&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;on behalf&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of the&lt;font style="letter-spacing:0.1pt;"&gt; &lt;/font&gt;entity,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;shall&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;inc&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;uded&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;in research&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;development costs.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Grants&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;received&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Israel&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Innovation&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;Authority,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;f/k/a&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Office&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Chief&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Scientist&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Israel&amp;#8217;s&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Ministry&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Industry,&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;Trade&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;Labor&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&amp;#8220;IIA&amp;#8221;)&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;becomes&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;receiva&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;le,&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;there&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reasonable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;assurance&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;any&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;comply&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;conditions&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;attached&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;there&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;reaso&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;able&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;assurance&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;received.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;deducted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;pplicable&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;incurred.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;n&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;increase&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$175&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;result&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;decis&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;pursue&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;one&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;programs&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;had&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;been&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;approved&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;result&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;financing&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;opportunities.&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;For&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;D&lt;/font&gt;ecember&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;$126&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;was received from Allergan, in connection with the pre-clinical collaboration agreement signed in August 2015 and deducted from the research and development expenses. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;intangibles&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;purchased&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;others&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;particular&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;deve&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;opment&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;project&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;no&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;alternative&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;future uses&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;(in&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;development&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;projects&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;otherwise)&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;therefore&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;no&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;s&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;parate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;economic&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;values&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;research&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;deve&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;opment costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;time&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <urgn:DeferredTaxesPolicyTextBlock id="F_000248" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;m.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Income tax&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;1)&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Deferred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;taxes&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabi&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ity&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;method.&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;Under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liability&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;method,&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;determined&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;bas&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;differences&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;between&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;reporti&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;g&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;tax bases&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;mea&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ured&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;currently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;enacted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;laws.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;valuation&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;llowance&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;recognized&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the extent&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;likely&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;deferred&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;taxes&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;realized&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;foresee&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;ble&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;future.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2)&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Uncertain&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;income&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;positions&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;follows&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;two-step&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;approach&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognizing&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;measuring&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;uncertain&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;positions.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;first&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;step&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;evaluate&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;position for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;recognition&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;determining&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;availab&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;e&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;evidence&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;indicates&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;likely&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;position&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;w&lt;/font&gt;ill&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;sustained&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on technical&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;merits.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;If&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;this&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;threshold&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;met,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;second&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;step&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;measure&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;tax&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;benefit&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;largest&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;amount&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;more&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;likely&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of being&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;realized&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ultim&lt;font style="letter-spacing:0.1pt;"&gt;a&lt;/font&gt;te&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;settlement. As of December 31, 2017 and 2016, the Company had not accrued a provision for uncertain tax positions.&lt;/p&gt;&lt;/div&gt;</urgn:DeferredTaxesPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000249" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;n.&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Loss&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;(&amp;#8220;LPS&amp;#8221;)&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;dividing&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;reducing&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;cumulati&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;e&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;dividends&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt;, &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the weighted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;average&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordinary&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;outstanding&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;peri&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;d.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;calculation&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;diluted&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;net&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ex&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;ludes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;potential&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;issuances&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ordi&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ary&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;upon&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;exercise&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;options, warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;convertible&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;each&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;anti-dilutive.&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000250" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;o.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Fair&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;measurement&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;price&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;rec&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ived&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;sale&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;would&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;paid&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;transfer&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;liability&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;orderly transaction&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;between&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;participants&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measurement&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;date.&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;order&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;increase&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;consistency&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;comparability&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value measurements,&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;guidance&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;establishes&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;val&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;e&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;hierarchy&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;prioritizes&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;observable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;unob&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ervable&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;measure&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value into&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;three&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;broad&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;levels,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;described&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;fo&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;lows:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;1:&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Quoted&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;prices&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(unadjusted)&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;active&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;markets&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;accessible&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;at&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;measurement&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;liabilities.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value hierarchy&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;gives&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;highest&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;priority&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;1&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;inputs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;2:&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Observable&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;prices&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;based&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;quoted&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;active&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;markets but&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;corroborated&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;by&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;data.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;3:&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Unobservable&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;us&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;when&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;little&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;no&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;market&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;available.&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;hierarchy&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;g&lt;/font&gt;ives&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;lowest&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;priority&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Level&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;3 inputs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;determining&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;utilizes&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;val&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;ation&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;techniques&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;maximize&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;observable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;minimize&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;use&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;of unobservable&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;inputs&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;extent&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;possib&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;e&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;considers&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;counterparty&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assessment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value.&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk id="F_000251" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;p.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Concentration&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;risks&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;instruments&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;that&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;potentially&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;subject&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;concentrati&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;consist&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;principally&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equiva&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ents and short-term investments.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;deposits&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;eq&lt;font style="letter-spacing:-0.1pt;"&gt;u&lt;/font&gt;ivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;highly&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;rated&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nstitutions,&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;matter&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;policy,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;limits&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;credit exposure&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;single&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nstitution.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;has&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;experienced&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;any&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;cre&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;it&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;losses&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;accounts&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;does&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;not&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;belie&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;e&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;it&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;is exposed&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;significant&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;credit&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;risk&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;these&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;instruments.&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000252" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;q.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Segment&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;reporting&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;segments&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;reported&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;manner&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;consistent&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;internal&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;reporting&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;provided&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;ch&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ef&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;decision-maker,&lt;font style="letter-spacing:1.25pt;"&gt; &lt;/font&gt;who&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;is responsible&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;allocating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;resources&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;assessing&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;performance&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;segments.&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;o&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;erates&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;one&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;operating segment.&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <urgn:InitialPublicOfferingCostsPolicyTextBlock id="F_000253" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;r.&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Costs&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;accounts&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;accordance&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;SEC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Staff&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Accounting&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;Bulletin&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Topic&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;5&lt;/font&gt;A.&lt;font style="letter-spacing:0.3pt;"&gt; Costs directly attributable to a proposed or actual offering of securities are deferred and recorded against the gross proceeds of the offering upon completion. &lt;/font&gt;During&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;year&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016, the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;recorded&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;$1.7&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;million&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;g&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;neral&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;administrative&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;expenses&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;IPO&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;costs.&lt;/p&gt;&lt;/div&gt;</urgn:InitialPublicOfferingCostsPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000254" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;s.&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Newly&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;recently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;adopted&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;pronouncements&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;August&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;2014,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; Accounting Standards Update (&amp;#8220;&lt;/font&gt;ASU&amp;#8221;)&lt;font style="letter-spacing:0.35pt;"&gt; No. &lt;/font&gt;2014-15&amp;#8212;Presentation&lt;font style="letter-spacing:1.95pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Financial&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;Statements&amp;#8212;Going&lt;font style="letter-spacing:1.55pt;"&gt; &lt;/font&gt;Concern&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;(ASC&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;S&lt;/font&gt;ubtopic&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;205-40):&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;&amp;#8220;Disclosure of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Uncertainties&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;about&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Entity&amp;#8217;s&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Ability&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Conti&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ue&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;Going&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Concern&amp;#8221;.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;update&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;managem&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;nt&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;assess&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;company&amp;#8217;s ability&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;continue&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;going&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;concern&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;nd&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;provide&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;footnote&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;disclosures&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;certain&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;circumstances.&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;All&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;apply&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;new&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;requirements&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;annu&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;l&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;ending&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;interim&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;thereafter.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The adoption of the guidance did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09, &amp;#8220;Revenue from Contracts with Customers&amp;#8221; (&amp;#8220;Topic 606&amp;#8221;, &amp;#8220;ASU 2014-09&amp;#8221;, or &amp;#8220;the New Revenue Standard&amp;#8221;). ASU 2014-09 requires entities to recognize revenue that represents the transfer of promised goods or services to customers in an amount equivalent to the consideration to which the entity expects to be entitled to in exchange for those goods or services. The following steps should be applied to determine this amount: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in ASU 605, &amp;#8220;Revenue Recognition,&amp;#8221; and most industry-specific guidance in the Accounting Standards Codification. The New Revenue Standard is effective for the Company for annual reporting periods, including interim periods therein, beginning January 1, 2018. The New Revenue Standard may be applied retrospectively with the cumulative effect recognized as of the date of adoption (modified retrospective method). The Company will adopt the New Revenue Standard using modified retrospective method. The Company has substantially completed its assessment of the New Revenue Standard and identified two revenue streams (1) licensing revenue and (2) revenue from clinical supply of RTGel per the license agreement with Allergan. The implementation of the New Revenue Standard will not have a material impact on the amount or timing of the Company&amp;#8217;s current revenue recognition related to these revenue streams. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;February&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.35pt;"&gt; No. &lt;/font&gt;2016-02,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;Leases&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;(Topic&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;842 or &amp;#8220;ASU&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2016-02&amp;#8221;).&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;2016-02&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;supersedes&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;existing&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;guida&lt;font style="letter-spacing:0.1pt;"&gt;n&lt;/font&gt;ce&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;in Leases&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;(Topic&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;840).&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;revised&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;standard&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;requires&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;les&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ees&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;assets&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;liabilities&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;ari&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ing&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;leases&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;terms greater&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;than&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;twelve&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;months&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet,&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;including&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;tho&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;e&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;currently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;operating&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;leases,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;disc&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;ose&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;key&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;information about&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;leasing&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;arrangements.&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;Lessees&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;w&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ll&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;be&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;recognize&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;lease&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;li&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;bility&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;right-of-use&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;asset&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;their&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheets,&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;while lessor&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;accounting&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;remain&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;larg&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ly&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;unchanged.&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;guidance&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;effective&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ual&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;beginning&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Decem&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;er&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2018,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;with early&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;permitted.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;currently&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;evaluating&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;impact&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;adopt&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;on&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2016-02&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;will&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;have&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;its&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consolidated financial&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;disclosures.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;August&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.35pt;"&gt; No. &lt;/font&gt;2016-15,&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&amp;#8220;Statement&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Flows:&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;Classification&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Certain&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Rec&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ipts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Payments,&amp;#8221; which&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;addresses&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;presentation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;(or&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;amounts&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;generally&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;escribed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;such)&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;ASC&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;230,&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;Statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Flows,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;with&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;intent&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;reduce&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;diversity&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;practi&lt;font style="letter-spacing:-0.1pt;"&gt;c&lt;/font&gt;e.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;Among&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;others,&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;this&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;ASU addresses&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flow&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;treatment&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;such&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;debt&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;prepayment&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;debt&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;extinguishment&lt;font style="letter-spacing:1.2pt;"&gt; &lt;/font&gt;costs&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;proce&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;ds&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;settlement&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;insurance claims.&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;Entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;required&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;disclose&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;how&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;flows&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;reconc&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;les&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;balance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;if&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;shown separately&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;from&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;b&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;lance&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;sheet.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;must&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;also&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;disclose&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;information&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;ab&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;ut&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;nature&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the restrictions.&lt;font style="letter-spacing:0.05pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;amendments&lt;font style="letter-spacing:1.05pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;effective&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;public&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;business&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;beg&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;nning&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;interim periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;those&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Early&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;adopti&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;permitted.&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;A&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;retrospective&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;basis&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;required.&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;The Company believes the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; of the guidance will be immaterial to its financial statements&lt;/font&gt;.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.33%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/font&gt;&lt;font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;November&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;2016,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;FASB&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;issued&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;No.&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2016-18,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;&amp;#8220;Statement&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;Cash&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Flows&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(Topic&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;230):&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;Restricted&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;Cash&amp;#8221;&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;(&amp;#8220;ASU&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;2016-18&amp;#8221;).&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;ASU 2016-18&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;amends&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;classification&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;presentati&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;n&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;or&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;restricted&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;cash&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;equivalents&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statement&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;cash flows.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ASU&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;2016-18&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;effective&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;public&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;business&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;entities&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;begin&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;ing&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;after&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;15,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;interim&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;periods within&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;those&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;fiscal&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;years.&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Early&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;is&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;permitted,&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;inclu&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;ing&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;an&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;interim&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;period. The&lt;font style="letter-spacing:0.05pt;"&gt; Company believes&lt;/font&gt;&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;adoption&lt;font style="letter-spacing:0.7pt;"&gt; of the guidance &lt;/font&gt;will be immaterial to its&lt;font style="letter-spacing:0.7pt;"&gt; financial statements&lt;/font&gt;.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <urgn:ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock id="F_000255" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Annual&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;rates&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;depreciation&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15-30&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6-15&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</urgn:ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000256" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DECEMBER&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;531&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;441&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;106&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Manufacturing equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;201&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,382&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less&amp;#8212;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(577&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;805&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;741&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000257" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;below&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;sets&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;forth&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:0.15pt;"&gt; &lt;/font&gt;summary&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;changes&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;warrants&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;preferred&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;shares&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;classified&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;Lev&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;l&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;3:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;872&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in fair value of warrants for preferred shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance of warrants for preferred shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,780&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,612&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:ScheduleOfCapitalUnitsTextBlock id="F_000258" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;capit&lt;font style="letter-spacing:-0.1pt;"&gt;a&lt;/font&gt;l&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Company&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.62%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued and Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ordinary shares of NIS 0.01 par value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,600,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,751,390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,305,743&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A and A-1 preferred shares of NIS 0.01 par value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,400,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,193,427&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCapitalUnitsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000259" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;employees&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;d&lt;/font&gt;irectors&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;date&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;grant&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;using&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Black-Scholes&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;mod&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;l.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;The underlying&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;computing&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value of ordinary shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$13.00-39.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.98-5.54&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.98-3.01&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71.53%-76.32%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;74.8%-80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69.78%-76.68%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.85%-2.47%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4%&amp;#8211;2.13%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.38%&amp;#8211;2.08%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5-10 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1-7 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000260" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;granted&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;to&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;consultants&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;other&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;service&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;pro&lt;font style="letter-spacing:-0.1pt;"&gt;v&lt;/font&gt;iders&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;was&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;computed&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;u&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ing&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;the Black-Scholes&lt;font style="letter-spacing:1.15pt;"&gt; &lt;/font&gt;model.&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;The&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;underlying&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;data&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;used&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;computing&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;fair&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;value&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;opt&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ons&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;are&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value of ordinary shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.58-37.21&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$1.58-7.96&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68.45%-74.50%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72.72%-80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73.31%-76.3%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.38%-2.26%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.56%-2.27%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.88%-2.07%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.9-5.9 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8-8.5 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;"&gt;
&lt;p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.8-7 years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000261" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;summarizes&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;number&lt;font style="letter-spacing:0.65pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;options&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;&lt;font style="letter-spacing:-0.1pt;"&gt;o&lt;/font&gt;utstanding&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;under&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;Plan&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;Decem&lt;font style="letter-spacing:-0.1pt;"&gt;b&lt;/font&gt;er&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017, 2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2015,&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and related&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;inform&lt;font style="letter-spacing:0.1pt;"&gt;a&lt;/font&gt;tion:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.32%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Directors&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Consultants and&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Service providers&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of January 1, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;332,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,098,777&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203,826&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23,088&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,686,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;513,238&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;404,813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,032&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(60,800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.03&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,784&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,030,613&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;634,486&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;712,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.93&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(682,184&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(130,038&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,021,829&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498,762&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;*Including 38,400 ordinary shares issuable upon the vesting of options granted in 2016, which were contingent upon the closing of the IPO.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock id="F_000262" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;summarizes&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;outstand&lt;font style="letter-spacing:-0.1pt;"&gt;i&lt;/font&gt;ng&lt;font style="letter-spacing:0.95pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;exercisable&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;options and restricted stock units&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2&lt;font style="letter-spacing:-0.1pt;"&gt;0&lt;/font&gt;17:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.14%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;price per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;outstanding at end&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;contractual life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;exercisable at end of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;remaining contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$0.00 - 10.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,948,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.62&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,142,310&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.98&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$10.01 - 20.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;292,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.49&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,501&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$20.01 - 30.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$30.01 - 40.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.81&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,520,591&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,194,811&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000263" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;illustrates&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;effect&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;share-based&lt;font style="letter-spacing:1pt;"&gt; &lt;/font&gt;com&lt;font style="letter-spacing:-0.1pt;"&gt;p&lt;/font&gt;ensation&lt;font style="letter-spacing:1.1pt;"&gt; &lt;/font&gt;on&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;statements&lt;font style="letter-spacing:0.9pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;operations:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,923&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,377&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,967&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000264" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In respect of:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,844&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,280&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,691&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,887&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;742&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issuance Costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-Process R&amp;amp;D&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;761&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;806&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less&amp;#8212;valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:SummaryOfValuationAllowanceTextBlock id="F_000265" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;change&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;in&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;valuation&lt;font style="letter-spacing:0.75pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;l&lt;/font&gt;lowance&lt;font style="letter-spacing:0.8pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;years&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;ended&lt;font style="letter-spacing:0.5pt;"&gt; &lt;/font&gt;December&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;31,&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;2017&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;a&lt;font style="letter-spacing:-0.1pt;"&gt;n&lt;/font&gt;d&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;2016&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;were&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;as&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at the beginning of the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes during the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;341&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,948&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at the end of the year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,725&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,158&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000266" contextRef="C_0001668243_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;following&lt;font style="letter-spacing:0.7pt;"&gt; &lt;/font&gt;table&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;sets&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;forth&lt;font style="letter-spacing:0.4pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;calculation&lt;font style="letter-spacing:0.85pt;"&gt; &lt;/font&gt;of&lt;font style="letter-spacing:0.2pt;"&gt; &lt;/font&gt;ba&lt;font style="letter-spacing:-0.1pt;"&gt;s&lt;/font&gt;ic&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;and&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;diluted&lt;font style="letter-spacing:0.55pt;"&gt; &lt;/font&gt;loss&lt;font style="letter-spacing:0.35pt;"&gt; &lt;/font&gt;per&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;share&lt;font style="letter-spacing:0.45pt;"&gt; &lt;/font&gt;for&lt;font style="letter-spacing:0.25pt;"&gt; &lt;/font&gt;the&lt;font style="letter-spacing:0.3pt;"&gt; &lt;/font&gt;periods&lt;font style="letter-spacing:0.6pt;"&gt; &lt;/font&gt;indicat&lt;font style="letter-spacing:-0.1pt;"&gt;e&lt;/font&gt;d:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic and diluted:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss attributable to equity holders of the Company&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,941&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,689&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend accumulated for preferred shares during the period&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,467&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss attributable to equity holders of the Company, after deducting dividend&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; accumulated for preferred shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,408&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,541&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average number of ordinary shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,716,790&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,305,503&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,300,959&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss per ordinary share (LPS)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.88&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <dei:EntityIncorporationDateOfIncorporation id="F_000267" contextRef="C_0001668243_20170101_20171231">2004-04-30</dei:EntityIncorporationDateOfIncorporation>
  <us-gaap:OperationsCommencedDate1 id="F_000268" contextRef="C_0001668243_20170101_20171231">2016-02-29</us-gaap:OperationsCommencedDate1>
  <us-gaap:OperationsCommencedDate1 id="F_000269" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20170101_20171231">2016-02-29</us-gaap:OperationsCommencedDate1>
  <urgn:ConsiderationForSalesAndSupportingServices id="F_000270" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20150801_20150831" decimals="-3" unitRef="U_iso4217USD">750000</urgn:ConsiderationForSalesAndSupportingServices>
  <urgn:ConsiderationFeeReceivedForLicenseAndFutureSupplyServices id="F_000271" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20161006_20161007" decimals="-5" unitRef="U_iso4217USD">17500000</urgn:ConsiderationFeeReceivedForLicenseAndFutureSupplyServices>
  <urgn:AdditionalMilestonePaymentForLicensingAgreement id="F_000272" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_us-gaapRangeAxis_us-gaapMaximumMember_20161007" decimals="-5" unitRef="U_iso4217USD">207500000</urgn:AdditionalMilestonePaymentForLicensingAgreement>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000273" contextRef="C_0001668243_20170419_20170419" decimals="1" unitRef="U_pure">3.2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000274" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531" decimals="-5" unitRef="U_iso4217USD">60800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <urgn:MilestonePaymentForLicensingAgreement id="F_000275" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20170701_20170731" decimals="-5" unitRef="U_iso4217USD">7500000</urgn:MilestonePaymentForLicensingAgreement>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000276" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_urgnSecondaryPublicOfferingMember_20180101_20180131" decimals="-6" unitRef="U_iso4217USD">64000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:UnrealizedGainLossOnInvestments id="F_000277" contextRef="C_0001668243_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrealizedGainLossOnInvestments>
  <urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation id="F_000278" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.33</urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation>
  <urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation id="F_000279" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.50</urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation>
  <urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation id="F_000280" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.15</urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation>
  <urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation id="F_000281" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.06</urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation>
  <urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation id="F_000282" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.30</urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation>
  <urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation id="F_000283" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.15</urgn:PropertyPlantAndEquipmentAnnualRateOfDepreciation>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000284" contextRef="C_0001668243_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="F_000285" contextRef="C_0001668243_20160101_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <urgn:NumberOfDeliverableLicenseAgreements id="F_000286" contextRef="C_0001668243_20170101_20171231" decimals="INF" unitRef="U_urgnLicenseAgreement">2</urgn:NumberOfDeliverableLicenseAgreements>
  <urgn:DescriptionOfLicenseAgreementComponents id="F_000287" contextRef="C_0001668243_20170101_20171231">The license component has standalone value (and therefore is accounted for separately from the supply services) since Allergan can use the license for its intended purposes without the Company&#8217;s supply services. The four conditions of ASC 605 were met as of December 31, 2017 and 2016: (1) persuasive evidence of an arrangement exists since the Company and Allergan engaged with a binding agreement; (2) delivery has occurred or services have been rendered since all documents and data Allergan has requested relating to the Company&#8217;s know-how were provided before December 31, 2016 and Allergan can use the license for its intended purposes without the supply services (except for immaterial support services); (3) the fee is fixed or determinable, as indicated in the license agreement; and (4) collectability is reasonably assured.</urgn:DescriptionOfLicenseAgreementComponents>
  <urgn:ConsiderationFeeReceivedForLicenseAndFutureSupplyServices id="F_000288" contextRef="C_0001668243_us-gaapCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">17500000</urgn:ConsiderationFeeReceivedForLicenseAndFutureSupplyServices>
  <urgn:UpfrontFeeAllocatedToLicenseComponent id="F_000289" contextRef="C_0001668243_20171231" decimals="-5" unitRef="U_iso4217USD">17500000</urgn:UpfrontFeeAllocatedToLicenseComponent>
  <urgn:MilestonePaymentForLicensingAgreement id="F_000290" contextRef="C_0001668243_us-gaapCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20170701_20170731" decimals="-5" unitRef="U_iso4217USD">7500000</urgn:MilestonePaymentForLicensingAgreement>
  <urgn:IncreaseDecreaseInResearchAndDevelopmentExpense id="F_000291" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">175000</urgn:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <urgn:IncreaseDecreaseInResearchAndDevelopmentExpense id="F_000292" contextRef="C_0001668243_us-gaapCounterpartyNameAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-126000</urgn:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <us-gaap:UnrecognizedTaxBenefits id="F_000293" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000294" contextRef="C_0001668243_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:NumberOfOperatingSegments id="F_000295" contextRef="C_0001668243_20170101_20171231" decimals="INF" unitRef="U_urgnSegment">1</us-gaap:NumberOfOperatingSegments>
  <urgn:InitialPublicOfferingCost id="F_000296" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">1700000</urgn:InitialPublicOfferingCost>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000297" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20171231" decimals="-3" unitRef="U_iso4217USD">531000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000298" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20161231" decimals="-3" unitRef="U_iso4217USD">441000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000299" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20171231" decimals="-3" unitRef="U_iso4217USD">167000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000300" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnComputersAndSoftwareMember_20161231" decimals="-3" unitRef="U_iso4217USD">106000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000301" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20171231" decimals="-3" unitRef="U_iso4217USD">223000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000302" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_urgnLaboratoryEquipmentMember_20161231" decimals="-3" unitRef="U_iso4217USD">136000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000303" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20171231" decimals="-3" unitRef="U_iso4217USD">227000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000304" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapManufacturingFacilityMember_20161231" decimals="-3" unitRef="U_iso4217USD">227000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000305" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20171231" decimals="-3" unitRef="U_iso4217USD">234000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000306" contextRef="C_0001668243_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20161231" decimals="-3" unitRef="U_iso4217USD">201000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000307" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">1382000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000308" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">1111000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000309" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">577000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000310" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">370000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000311" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_20171231" decimals="INF" unitRef="U_iso4217USD_shares">7.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000312" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_20171231" decimals="INF" unitRef="U_shares">728312</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ProceedsFromWarrantExercises id="F_000313" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">952000</us-gaap:ProceedsFromWarrantExercises>
  <urgn:LeaseExpirationYear id="F_000314" contextRef="C_0001668243_us-gaapRangeAxis_us-gaapMaximumMember_20160401_20160430">2019</urgn:LeaseExpirationYear>
  <us-gaap:LeaseAndRentalExpense id="F_000315" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">276000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000316" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">218000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000317" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">121000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="F_000318" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20160501_20160501">P7Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <urgn:LeaseAgreementCommencementPeriod id="F_000319" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20171001_20171231">2017-10</urgn:LeaseAgreementCommencementPeriod>
  <urgn:LeaseAgreementTerminationPeriod id="F_000320" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20171001_20171231">2021-02</urgn:LeaseAgreementTerminationPeriod>
  <us-gaap:LeaseAndRentalExpense id="F_000321" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">342000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000322" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20160502_20161231" decimals="-3" unitRef="U_iso4217USD">102000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000323" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">1115000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000324" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">1054000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="F_000325" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">873000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="F_000326" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">305000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="F_000327" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">192000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <urgn:OperatingLeasesFutureMinimumPaymentsDueInSixYears id="F_000328" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">80000</urgn:OperatingLeasesFutureMinimumPaymentsDueInSixYears>
  <urgn:RoyaltyFeesPercentage id="F_000329" contextRef="C_0001668243_deiLegalEntityAxis_urgnIsraelInnovationAuthorityMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.03</urgn:RoyaltyFeesPercentage>
  <urgn:RoyaltyFeesPercentage id="F_000330" contextRef="C_0001668243_deiLegalEntityAxis_urgnIsraelInnovationAuthorityMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.045</urgn:RoyaltyFeesPercentage>
  <urgn:PercentageOfRoyaltyPayableOnGrantReceived id="F_000331" contextRef="C_0001668243_deiLegalEntityAxis_urgnIsraelInnovationAuthorityMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="INF" unitRef="U_pure">1.00</urgn:PercentageOfRoyaltyPayableOnGrantReceived>
  <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent id="F_000332" contextRef="C_0001668243_deiLegalEntityAxis_urgnIsraelInnovationAuthorityMember_us-gaapRangeAxis_us-gaapMaximumMember_20171231" decimals="-3" unitRef="U_iso4217USD">2105000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
  <urgn:SuccessFeesToThirdPartiesInStockOptions id="F_000333" contextRef="C_0001668243_20160101_20161231" decimals="INF" unitRef="U_shares">5726</urgn:SuccessFeesToThirdPartiesInStockOptions>
  <urgn:FairValueOfStockOptionsIssuedToThirdParties id="F_000334" contextRef="C_0001668243_20160101_20161231" decimals="0" unitRef="U_iso4217USD_shares">9</urgn:FairValueOfStockOptionsIssuedToThirdParties>
  <urgn:SuccessFeesToThirdPartiesInCash id="F_000335" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">28000</urgn:SuccessFeesToThirdPartiesInCash>
  <us-gaap:FairValueInputsProbabilityOfDefault id="F_000336" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_us-gaapValuationTechniqueAxis_urgnHybridMethodValuationTechniqueMember_20160101_20161231" decimals="2" unitRef="U_pure">0.20</us-gaap:FairValueInputsProbabilityOfDefault>
  <us-gaap:FairValueInputsProbabilityOfDefault id="F_000337" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_urgnLiquidationEventMember_us-gaapValuationTechniqueAxis_urgnHybridMethodValuationTechniqueMember_20160101_20161231" decimals="2" unitRef="U_pure">0.80</us-gaap:FairValueInputsProbabilityOfDefault>
  <us-gaap:FairValueInputsDiscountRate id="F_000338" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.105</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate id="F_000339" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.19</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate id="F_000340" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_urgnAllerganPharmaceuticalsInternationalLimitedMember_20160101_20161231" decimals="3" unitRef="U_pure">0.105</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueInputsDiscountRate id="F_000341" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_urgnInternalDevelopmentMember_20160101_20161231" decimals="2" unitRef="U_pure">0.19</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate id="F_000342" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_20160101_20161231" decimals="4" unitRef="U_pure">0.7393</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000343" contextRef="C_0001668243_us-gaapClassOfWarrantOrRightAxis_urgnAOneWarrantsMember_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531" decimals="INF" unitRef="U_shares">364036</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000344" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">3612000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000345" contextRef="C_0001668243_20151231" decimals="-3" unitRef="U_iso4217USD">872000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="F_000346" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">168000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="F_000347" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">2740000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <urgn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock id="F_000348" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">3780000</urgn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets id="F_000349" contextRef="C_0001668243_deiLegalEntityAxis_urgnTelormedixSAMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20151001_20151031" decimals="INF" unitRef="U_shares">691200</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <urgn:PreferredStockIssuedPricePerShare id="F_000350" contextRef="C_0001668243_deiLegalEntityAxis_urgnTelormedixSAMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20151001_20151031" decimals="INF" unitRef="U_iso4217USD_shares">5.94</urgn:PreferredStockIssuedPricePerShare>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000351" contextRef="C_0001668243_deiLegalEntityAxis_urgnTelormedixSAMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20151001_20151031" decimals="-5" unitRef="U_iso4217USD">4100000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ConversionOfStockSharesIssued1 id="F_000352" contextRef="C_0001668243_20170419_20170419" decimals="INF" unitRef="U_shares">2.2</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:StockholdersEquityNoteStockSplit id="F_000353" contextRef="C_0001668243_20170101_20171231">On April 19, 2017, the Company&#8217;s board of directors and shareholders approved an aggregate 3.2 for-1 share split of the Company&#8217;s ordinary, Preferred A and Preferred A-1 shares. The share split was effected on April 19, 2017 by the issuance of 2.2 ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 share held immediately prior to the share split.</us-gaap:StockholdersEquityNoteStockSplit>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000354" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531" decimals="INF" unitRef="U_shares">5144378</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000355" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170531" decimals="INF" unitRef="U_iso4217USD_shares">13.00</us-gaap:SharesIssuedPricePerShare>
  <urgn:NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice id="F_000356" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531" decimals="INF" unitRef="U_shares">671005</urgn:NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000357" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531" decimals="INF" unitRef="U_shares">364036</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <urgn:PreferredSharesIntoOrdinarySharesConversionRatio id="F_000358" contextRef="C_0001668243_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20170501_20170531" decimals="0" unitRef="U_pure">1</urgn:PreferredSharesIntoOrdinarySharesConversionRatio>
  <urgn:InitialPublicOfferingCost id="F_000359" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">0</urgn:InitialPublicOfferingCost>
  <urgn:PreferredStockIssuedPricePerShare id="F_000360" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapSeriesAPreferredStockMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">5.94</urgn:PreferredStockIssuedPricePerShare>
  <urgn:PreferredStockIssuedPricePerShare id="F_000361" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_urgnSeriesAOnePreferredStockMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">7.81</urgn:PreferredStockIssuedPricePerShare>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000362" contextRef="C_0001668243_20170101_20171231" decimals="2" unitRef="U_pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <urgn:PreMoneyValuation id="F_000363" contextRef="C_0001668243_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">75000000</urgn:PreMoneyValuation>
  <urgn:NetProceedsRequiredForConversion id="F_000364" contextRef="C_0001668243_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">25000000</urgn:NetProceedsRequiredForConversion>
  <urgn:PercentageOfOutstandingPreferredStockShares id="F_000365" contextRef="C_0001668243_20171231" decimals="2" unitRef="U_pure">0.60</urgn:PercentageOfOutstandingPreferredStockShares>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000366" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">812222</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="F_000367" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">743806</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000368" contextRef="C_0001668243_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">68416</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000369" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_urgnSecondaryPublicOfferingMember_20180101_20180131" decimals="INF" unitRef="U_shares">1682926</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000370" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_urgnSecondaryPublicOfferingMember_20180131" decimals="INF" unitRef="U_iso4217USD_shares">41.00</us-gaap:SharesIssuedPricePerShare>
  <urgn:NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice id="F_000371" contextRef="C_0001668243_deiEntityListingsExchangeAxis_exchXNCM_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_urgnSecondaryPublicOfferingMember_20180101_20180131" decimals="INF" unitRef="U_shares">219512</urgn:NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance id="F_000372" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170301_20170331" decimals="INF" unitRef="U_shares">1400000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum id="F_000373" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance id="F_000374" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_20170101_20171231" decimals="INF" unitRef="U_shares">5600000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="F_000375" contextRef="C_0001668243_us-gaapAwardTypeAxis_urgnTwoThousandSeventeenEquityIncentivePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="INF" unitRef="U_pure">1.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <urgn:ModificationsOfPerformanceConditionsInShares id="F_000376" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170401_20170430" decimals="INF" unitRef="U_shares">67200</urgn:ModificationsOfPerformanceConditionsInShares>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000377" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170401_20170430" decimals="-3" unitRef="U_iso4217USD">527000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000378" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_shares">712900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000379" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_shares">404813</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000380" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_shares">1098777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000381" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000382" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_iso4217USD_shares">5</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000383" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_iso4217USD_shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000384" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">39.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000385" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_iso4217USD_shares">5.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000386" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_iso4217USD_shares">5.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted id="F_000387" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">14249000</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted>
  <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted id="F_000388" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">906000</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted>
  <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted id="F_000389" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">2334000</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000390" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231" decimals="-3" unitRef="U_iso4217USD">14131000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000391" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">P3Y3M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharePrice id="F_000392" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231" decimals="INF" unitRef="U_iso4217USD_shares">13.00</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000393" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231" decimals="INF" unitRef="U_iso4217USD_shares">39.26</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000394" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20161231" decimals="INF" unitRef="U_iso4217USD_shares">2.98</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000395" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20161231" decimals="INF" unitRef="U_iso4217USD_shares">5.54</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000396" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20151231" decimals="INF" unitRef="U_iso4217USD_shares">2.98</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000397" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20151231" decimals="INF" unitRef="U_iso4217USD_shares">3.01</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000398" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000399" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000400" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000401" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.7153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000402" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000403" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.6978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000404" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.7632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000405" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000406" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.7668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000407" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.0185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000408" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000409" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000410" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.0247</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000411" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.0213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000412" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.0208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000413" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000414" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000415" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000416" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000417" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000418" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000419" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_shares">132032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000420" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_shares">203820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000421" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_iso4217USD_shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000422" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_iso4217USD_shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000423" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_iso4217USD_shares">5.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000424" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_iso4217USD_shares">5.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted id="F_000425" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">671000</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted>
  <urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted id="F_000426" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndServiceProvidersMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">57000</urgn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted>
  <us-gaap:SharePrice id="F_000427" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20171231" decimals="INF" unitRef="U_iso4217USD_shares">1.58</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000428" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20171231" decimals="INF" unitRef="U_iso4217USD_shares">37.21</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000429" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20161231" decimals="INF" unitRef="U_iso4217USD_shares">1.58</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000430" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20161231" decimals="INF" unitRef="U_iso4217USD_shares">7.96</us-gaap:SharePrice>
  <us-gaap:SharePrice id="F_000431" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20151231" decimals="INF" unitRef="U_iso4217USD_shares">2.98</us-gaap:SharePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000432" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000433" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000434" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000435" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.6845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000436" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.7272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000437" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.7331</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000438" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.7450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000439" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000440" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.763</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000441" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.0138</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000442" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.0156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000443" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000444" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.0226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000445" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_pure">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000446" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_pure">0.0207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000447" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000448" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000449" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000450" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000451" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000452" contextRef="C_0001668243_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000453" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20141231" decimals="INF" unitRef="U_shares">595823</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000454" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20141231" decimals="INF" unitRef="U_shares">332500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000455" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_shares">203826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000456" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="INF" unitRef="U_shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000457" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="INF" unitRef="U_shares">23088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000458" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20151231" decimals="INF" unitRef="U_shares">1686600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000459" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20151231" decimals="INF" unitRef="U_shares">513238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000460" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_shares">132032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000461" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="INF" unitRef="U_shares">60800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000462" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_shares">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000463" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="INF" unitRef="U_shares">4784</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000464" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20161231" decimals="INF" unitRef="U_shares">2030613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000465" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20161231" decimals="INF" unitRef="U_shares">634486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000466" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_shares">39500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000467" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_shares">5686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000468" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="INF" unitRef="U_shares">682184</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000469" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="INF" unitRef="U_shares">130038</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000470" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231" decimals="INF" unitRef="U_shares">2021829</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000471" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20171231" decimals="INF" unitRef="U_shares">498762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000472" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20141231" decimals="2" unitRef="U_iso4217USD_shares">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000473" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20141231" decimals="2" unitRef="U_iso4217USD_shares">3.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000474" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000475" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">2.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000476" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">5.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000477" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">2.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000478" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20151231" decimals="2" unitRef="U_iso4217USD_shares">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000479" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20151231" decimals="2" unitRef="U_iso4217USD_shares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000480" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">3.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000481" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">7.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000482" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">3.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000483" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">1.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000484" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">2.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000485" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20161231" decimals="2" unitRef="U_iso4217USD_shares">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000486" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20161231" decimals="2" unitRef="U_iso4217USD_shares">4.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000487" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">24.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000488" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">5.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000489" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">2.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000490" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">3.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000491" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000492" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnEmployeesAndDirectorsMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">10.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000493" contextRef="C_0001668243_us-gaapTitleOfIndividualAxis_urgnConsultantsAndOtherServiceProvidersMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000494" contextRef="C_0001668243_20161231" decimals="INF" unitRef="U_shares">38400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000495" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">0.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000496" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">10.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000497" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeThreeMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">20.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000498" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeFourMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">30.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000499" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">10.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000500" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">20.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000501" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeThreeMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">30.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000502" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeFourMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">40.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000503" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20171231" decimals="INF" unitRef="U_shares">1948091</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000504" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20171231" decimals="INF" unitRef="U_shares">292500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000505" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeThreeMember_20171231" decimals="INF" unitRef="U_shares">100000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000506" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeFourMember_20171231" decimals="INF" unitRef="U_shares">180000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000507" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_shares">2520591</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000508" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20170101_20171231">P4Y7M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000509" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20170101_20171231">P9Y5M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000510" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeThreeMember_20170101_20171231">P9Y9M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000511" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeFourMember_20170101_20171231">P9Y9M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000512" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20171231" decimals="INF" unitRef="U_shares">1142310</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000513" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20171231" decimals="INF" unitRef="U_shares">52501</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000514" contextRef="C_0001668243_20171231" decimals="INF" unitRef="U_shares">1194811</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000515" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeOneMember_20170101_20171231">P3Y11M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 id="F_000516" contextRef="C_0001668243_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_urgnExercisePricePerShareRangeTwoMember_20170101_20171231">P9Y6M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000517" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">38308000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000518" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">3923000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000519" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1167000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000520" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">170000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000521" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2377000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000522" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000523" contextRef="C_0001668243_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">279000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000524" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">6300000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000525" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1967000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000526" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">449000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000527" contextRef="C_0001668243_20170101_20171231" decimals="2" unitRef="U_pure">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000528" contextRef="C_0001668243_20160101_20161231" decimals="INF" unitRef="U_pure">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000529" contextRef="C_0001668243_20170101_20171231" decimals="2" unitRef="U_pure">0.24</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations id="F_000530" contextRef="C_0001668243_us-gaapStatementScenarioAxis_us-gaapScenarioForecastMember_20180101_20181231" decimals="2" unitRef="U_pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:OperatingLossCarryforwards id="F_000531" contextRef="C_0001668243_20171231" decimals="-5" unitRef="U_iso4217USD">24800000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000532" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">5844000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000533" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">3280000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000534" contextRef="C_0001668243_20151231" decimals="-3" unitRef="U_iso4217USD">3691000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent id="F_000535" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">46000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000536" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">2887000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000537" contextRef="C_0001668243_20151231" decimals="-3" unitRef="U_iso4217USD">742000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000538" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">897000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <urgn:DeferredTaxAssetsIssuanceCosts id="F_000539" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">1261000</urgn:DeferredTaxAssetsIssuanceCosts>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000540" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">761000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000541" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">806000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities id="F_000542" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:DeferredTaxAssetsOther id="F_000543" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">24000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000544" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">72000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000545" contextRef="C_0001668243_20151231" decimals="-3" unitRef="U_iso4217USD">66000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000546" contextRef="C_0001668243_20171231" decimals="-3" unitRef="U_iso4217USD">11725000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000547" contextRef="C_0001668243_20161231" decimals="-3" unitRef="U_iso4217USD">4158000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000548" contextRef="C_0001668243_20151231" decimals="-3" unitRef="U_iso4217USD">4499000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet id="F_000549" xsi:nil="true" contextRef="C_0001668243_20171231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredTaxAssetsNet id="F_000550" xsi:nil="true" contextRef="C_0001668243_20161231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredTaxAssetsNet id="F_000551" xsi:nil="true" contextRef="C_0001668243_20151231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000552" contextRef="C_0001668243_20141231" decimals="-3" unitRef="U_iso4217USD">2551000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000553" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-7567000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000554" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">341000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000555" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-1948000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic id="F_000556" contextRef="C_0001668243_20171231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000557" contextRef="C_0001668243_20171231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <urgn:FederalAndStateNetOperatingLossesExpirationYear id="F_000558" contextRef="C_0001668243_20170101_20171231">2036</urgn:FederalAndStateNetOperatingLossesExpirationYear>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000559" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">825000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000560" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">2467000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000561" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">852000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000562" contextRef="C_0001668243_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-20825000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000563" contextRef="C_0001668243_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-4408000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000564" contextRef="C_0001668243_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-13541000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000565" contextRef="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="INF" unitRef="U_shares">2415545</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000566" contextRef="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20160101_20161231" decimals="INF" unitRef="U_shares">2665099</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000567" contextRef="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20150101_20151231" decimals="INF" unitRef="U_shares">2199838</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000568" contextRef="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20160101_20161231" decimals="INF" unitRef="U_shares">728312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000569" contextRef="C_0001668243_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20150101_20151231" decimals="INF" unitRef="U_shares">728312</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000570" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20160101_20161231" decimals="INF" unitRef="U_shares">5193427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000571" contextRef="C_0001668243_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20150101_20151231" decimals="INF" unitRef="U_shares">5193427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <urgn:LeaseAgreementDate id="F_000572" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20151101_20151130">2015-11-30</urgn:LeaseAgreementDate>
  <urgn:LeaseCommencementDate id="F_000573" contextRef="C_0001668243_us-gaapConsolidatedEntitiesAxis_us-gaapSubsidiariesMember_20160502_20160531">2016-05-31</urgn:LeaseCommencementDate>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>urgn-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Schema Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-15T19:01:19.6472015+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : f94fb2f9093b4031a25f038a50ff9384 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:urgn="http://www.urogen.com/20171231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.urogen.com/20171231" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" namespace="http://fasb.org/us-gaap/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" namespace="http://fasb.org/us-types/2017-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.urogen.com/20171231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="urgn-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperations" id="Role_DisclosureNatureOfOperations">
        <link:definition>100070 - Disclosure - Nature Of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100090 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureEmployeeRightsUponRetirement" id="Role_DisclosureEmployeeRightsUponRetirement">
        <link:definition>100100 - Disclosure - Employee Rights Upon Retirement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1Shares" id="Role_DisclosureProceedsFromExerciseOfWarrantsForPreferredA1Shares">
        <link:definition>100110 - Disclosure - Proceeds from Exercise of Warrants for Preferred A-1 Shares</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingencies" id="Role_DisclosureCommitmentAndContingencies">
        <link:definition>100120 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100130 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapital" id="Role_DisclosureShareCapital">
        <link:definition>100140 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncome" id="Role_DisclosureTaxesOnIncome">
        <link:definition>100150 - Disclosure -  Taxes on Income</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShare" id="Role_DisclosureLossPerOrdinaryShare">
        <link:definition>100160 - Disclosure - Loss Per Ordinary Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalances" id="Role_DisclosureRelatedPartiesTransactionsAndBalances">
        <link:definition>100170 - Disclosure - Related Parties-Transactions and Balances</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" id="Role_DisclosureSignificantAccountingPoliciesTables">
        <link:definition>100200 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100210 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsTables" id="Role_DisclosureFinancialInstrumentsTables">
        <link:definition>100220 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalTables" id="Role_DisclosureShareCapitalTables">
        <link:definition>100230 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeTables" id="Role_DisclosureTaxesOnIncomeTables">
        <link:definition>100240 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareTables" id="Role_DisclosureLossPerOrdinaryShareTables">
        <link:definition>100250 - Disclosure - Loss Per Ordinary Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetails" id="Role_DisclosureNatureOfOperationsAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Nature of Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" id="Role_DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
        <link:definition>100280 - Disclosure - Significant Accounting Policies - Schedule of Annual Rates of Depreciation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails">
        <link:definition>100290 - Disclosure - Property and Equipment - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails" id="Role_DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Proceeds from Exercise of Warrants for Preferred A-1 Shares - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Commitment and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfWarrantsForPreferredSharesDetails" id="Role_DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfWarrantsForPreferredSharesDetails">
        <link:definition>100340 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Warrants for Preferred Shares (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalDetails" id="Role_DisclosureShareCapitalSummaryOfShareCapitalDetails">
        <link:definition>100350 - Disclosure - Share Capital - Summary of Share Capital (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails" id="Role_DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails">
        <link:definition>100360 - Disclosure - Share Capital - Summary of Share Capital (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails" id="Role_DisclosureShareCapitalAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Share Capital - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails" id="Role_DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails">
        <link:definition>100380 - Disclosure - Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Employees and Directors (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails" id="Role_DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails">
        <link:definition>100390 - Disclosure - Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Consultants and Other Service Providers (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails" id="Role_DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails">
        <link:definition>100400 - Disclosure - Share Capital - Summary of Number of Options Outstanding Under the Plan (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails" id="Role_DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails">
        <link:definition>100410 - Disclosure - Share Capital - Summary of Number of Options Outstanding and Exercisable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails" id="Role_DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails">
        <link:definition>100420 - Disclosure - Share Capital - Schedule of Effect of Share-Based Compensation on Statements of Operations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" id="Role_DisclosureTaxesOnIncomeAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Taxes on Income - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" id="Role_DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails">
        <link:definition>100440 - Disclosure - Taxes on Income - Schedule of Deferred Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfChangeInValuationAllowanceDetails" id="Role_DisclosureTaxesOnIncomeScheduleOfChangeInValuationAllowanceDetails">
        <link:definition>100450 - Disclosure - Taxes on Income - Schedule of Change in Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails" id="Role_DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails">
        <link:definition>100460 - Disclosure - Loss Per Ordinary Share - Schedule of Calculation of Basic and Diluted Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareAdditionalInformationDetails" id="Role_DisclosureLossPerOrdinaryShareAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Loss Per Ordinary Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails" id="Role_DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Related Parties-Transactions and Balances - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="urgn_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" name="ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_WarrantsForPreferredSharesNoncurrent" name="WarrantsForPreferredSharesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_SeriesAAndAOnePreferredStockMember" name="SeriesAAndAOnePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ResearchAndDevelopmentExpenseNet" name="ResearchAndDevelopmentExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_FinanceIncomeExpenseNet" name="FinanceIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" name="StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" name="StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" name="StockIssuedDuringPeriodSharesPreferredSharesExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" name="StockIssuedDuringPeriodValuePreferredSharesExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_NoncashIssuanceCost" name="NoncashIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_NoncashExerciseOfWarrantsToPreferredShares" name="NoncashExerciseOfWarrantsToPreferredShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_EmployeeRightsUponRetirementTextBlock" name="EmployeeRightsUponRetirementTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_EmployeeRightsUponRetirementAbstract" name="EmployeeRightsUponRetirementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" name="ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" name="ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_DeferredTaxesPolicyTextBlock" name="DeferredTaxesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_InitialPublicOfferingCostsPolicyTextBlock" name="InitialPublicOfferingCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" name="ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ConsultantsAndOtherServiceProvidersMember" name="ConsultantsAndOtherServiceProvidersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_AllerganPharmaceuticalsInternationalLimitedMember" name="AllerganPharmaceuticalsInternationalLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_SecondaryPublicOfferingMember" name="SecondaryPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ConsiderationForSalesAndSupportingServices" name="ConsiderationForSalesAndSupportingServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" name="ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_AdditionalMilestonePaymentForLicensingAgreement" name="AdditionalMilestonePaymentForLicensingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_MilestonePaymentForLicensingAgreement" name="MilestonePaymentForLicensingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_SummaryOfSignificantAccountingPolicyLineItems" name="SummaryOfSignificantAccountingPolicyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" name="PropertyPlantAndEquipmentAnnualRateOfDepreciation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_ComputersAndSoftwareMember" name="ComputersAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_NumberOfDeliverableLicenseAgreements" name="NumberOfDeliverableLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_DescriptionOfLicenseAgreementComponents" name="DescriptionOfLicenseAgreementComponents" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_UpfrontFeeAllocatedToLicenseComponent" name="UpfrontFeeAllocatedToLicenseComponent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_InitialPublicOfferingCost" name="InitialPublicOfferingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" name="ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" name="ProceedsFromExerciseOfWarrantsForPreferredSharesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_SeriesAOnePreferredStockMember" name="SeriesAOnePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_LeaseExpirationYear" name="LeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_IsraelInnovationAuthorityMember" name="IsraelInnovationAuthorityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_LeaseAgreementCommencementPeriod" name="LeaseAgreementCommencementPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_LeaseAgreementTerminationPeriod" name="LeaseAgreementTerminationPeriod" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" name="OperatingLeasesFutureMinimumPaymentsDueInSixYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_RoyaltyFeesPercentage" name="RoyaltyFeesPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_PercentageOfRoyaltyPayableOnGrantReceived" name="PercentageOfRoyaltyPayableOnGrantReceived" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_SuccessFeesToThirdPartiesInStockOptions" name="SuccessFeesToThirdPartiesInStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_FairValueOfStockOptionsIssuedToThirdParties" name="FairValueOfStockOptionsIssuedToThirdParties" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_SuccessFeesToThirdPartiesInCash" name="SuccessFeesToThirdPartiesInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_AOneWarrantsMember" name="AOneWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_HybridMethodValuationTechniqueMember" name="HybridMethodValuationTechniqueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_LiquidationEventMember" name="LiquidationEventMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_InternalDevelopmentMember" name="InternalDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_PreferredStockIssuedPricePerShare" name="PreferredStockIssuedPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_TelormedixSAMember" name="TelormedixSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_TwoThousandSeventeenEquityIncentivePlanMember" name="TwoThousandSeventeenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ConsultantsAndServiceProvidersMember" name="ConsultantsAndServiceProvidersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" name="NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_PreferredSharesIntoOrdinarySharesConversionRatio" name="PreferredSharesIntoOrdinarySharesConversionRatio" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_PreMoneyValuation" name="PreMoneyValuation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_NetProceedsRequiredForConversion" name="NetProceedsRequiredForConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_PercentageOfOutstandingPreferredStockShares" name="PercentageOfOutstandingPreferredStockShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="urgn_ModificationsOfPerformanceConditionsInShares" name="ModificationsOfPerformanceConditionsInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="urgn_ExercisePricePerShareRangeOneMember" name="ExercisePricePerShareRangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ExercisePricePerShareRangeTwoMember" name="ExercisePricePerShareRangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ExercisePricePerShareRangeThreeMember" name="ExercisePricePerShareRangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_ExercisePricePerShareRangeFourMember" name="ExercisePricePerShareRangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="urgn_DeferredTaxAssetsIssuanceCosts" name="DeferredTaxAssetsIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="urgn_FederalAndStateNetOperatingLossesExpirationYear" name="FederalAndStateNetOperatingLossesExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_LeaseAgreementDate" name="LeaseAgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="urgn_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>urgn-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-15T19:01:19.6472015+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : f94fb2f9093b4031a25f038a50ff9384 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="urgn-20171231.xsd#TemplateLink" roleURI="http://www.urogen.com/20171231/role/TemplateLink" />
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_WarrantsForPreferredSharesNoncurrent" xlink:type="locator" xlink:label="urgn_WarrantsForPreferredSharesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="urgn_WarrantsForPreferredSharesNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedInvestmentsCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ResearchAndDevelopmentExpenseNet" xlink:type="locator" xlink:label="urgn_ResearchAndDevelopmentExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <loc xlink:href="urgn-20171231.xsd#urgn_FinanceIncomeExpenseNet" xlink:type="locator" xlink:label="urgn_FinanceIncomeExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="urgn_FinanceIncomeExpenseNet" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="urgn_ResearchAndDevelopmentExpenseNet" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="10090.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10240.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails" xlink:href="urgn-20171231.xsd#Role_DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <loc xlink:href="urgn-20171231.xsd#urgn_DeferredTaxAssetsIssuanceCosts" xlink:type="locator" xlink:label="urgn_DeferredTaxAssetsIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="urgn_DeferredTaxAssetsIssuanceCosts" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10090.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>urgn-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-15T19:01:19.6472015+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : f94fb2f9093b4031a25f038a50ff9384 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="urgn-20171231.xsd#TemplateLink" roleURI="http://www.urogen.com/20171231/role/TemplateLink" />
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="urgn-20171231.xsd#urgn_WarrantsForPreferredSharesNoncurrent" xlink:type="locator" xlink:label="urgn_WarrantsForPreferredSharesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10240.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsCurrent" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="11190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" order="11310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="urgn_WarrantsForPreferredSharesNoncurrent" order="11470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="11550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11790.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11870.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10460.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10840.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" order="11000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodValueWarrantsExercised" order="11300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodSharesWarrantsExercised" order="11320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" order="11460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" order="11480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11620.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="10520.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalTables" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndOtherServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndOtherServiceProvidersMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCapitalUnitsTextBlock" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10430.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureNatureOfOperationsAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_MilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentForLicensingAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AdditionalMilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_AdditionalMilestonePaymentForLicensingAgreement" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" xlink:type="locator" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationForSalesAndSupportingServices" xlink:type="locator" xlink:label="urgn_ConsiderationForSalesAndSupportingServices" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:type="locator" xlink:label="us-gaap_OperationsCommencedDate1" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="urgn_SecondaryPublicOfferingMember" />
    <loc xlink:href="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd#exch_XNCM" xlink:type="locator" xlink:label="exch_XNCM" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain_2" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:type="locator" xlink:label="dei_EntityListingsExchangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" xlink:label="us-gaap_SubsidiariesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:href="urgn-20171231.xsd#urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_ConsolidatedEntitiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="us-gaap_SubsidiariesMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_RangeAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="dei_EntityListingsExchangeAxis" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain_2" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_ExchangeDomain" xlink:to="exch_XNCM" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_SecondaryPublicOfferingMember" order="10590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_OperationsCommencedDate1" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_ConsiderationForSalesAndSupportingServices" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_AdditionalMilestonePaymentForLicensingAgreement" order="10840.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_MilestonePaymentForLicensingAgreement" order="10990.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_InitialPublicOfferingCost" xlink:type="locator" xlink:label="urgn_InitialPublicOfferingCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_MilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentForLicensingAgreement" />
    <loc xlink:href="urgn-20171231.xsd#urgn_UpfrontFeeAllocatedToLicenseComponent" xlink:type="locator" xlink:label="urgn_UpfrontFeeAllocatedToLicenseComponent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" xlink:type="locator" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" />
    <loc xlink:href="urgn-20171231.xsd#urgn_DescriptionOfLicenseAgreementComponents" xlink:type="locator" xlink:label="urgn_DescriptionOfLicenseAgreementComponents" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfDeliverableLicenseAgreements" xlink:type="locator" xlink:label="urgn_NumberOfDeliverableLicenseAgreements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="urgn_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="locator" xlink:label="urgn_SummaryOfSignificantAccountingPolicyLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_NumberOfDeliverableLicenseAgreements" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_DescriptionOfLicenseAgreementComponents" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_UpfrontFeeAllocatedToLicenseComponent" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_MilestonePaymentForLicensingAgreement" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_InitialPublicOfferingCost" order="10870.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" xlink:type="locator" xlink:label="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" order="10260.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails" xlink:href="urgn-20171231.xsd#Role_DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10500.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAOnePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10200.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_SuccessFeesToThirdPartiesInCash" xlink:type="locator" xlink:label="urgn_SuccessFeesToThirdPartiesInCash" />
    <loc xlink:href="urgn-20171231.xsd#urgn_FairValueOfStockOptionsIssuedToThirdParties" xlink:type="locator" xlink:label="urgn_FairValueOfStockOptionsIssuedToThirdParties" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SuccessFeesToThirdPartiesInStockOptions" xlink:type="locator" xlink:label="urgn_SuccessFeesToThirdPartiesInStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PercentageOfRoyaltyPayableOnGrantReceived" xlink:type="locator" xlink:label="urgn_PercentageOfRoyaltyPayableOnGrantReceived" />
    <loc xlink:href="urgn-20171231.xsd#urgn_RoyaltyFeesPercentage" xlink:type="locator" xlink:label="urgn_RoyaltyFeesPercentage" />
    <loc xlink:href="urgn-20171231.xsd#urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" xlink:type="locator" xlink:label="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementTerminationPeriod" xlink:type="locator" xlink:label="urgn_LeaseAgreementTerminationPeriod" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementCommencementPeriod" xlink:type="locator" xlink:label="urgn_LeaseAgreementCommencementPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseExpirationYear" xlink:type="locator" xlink:label="urgn_LeaseExpirationYear" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IsraelInnovationAuthorityMember" xlink:type="locator" xlink:label="urgn_IsraelInnovationAuthorityMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" xlink:label="us-gaap_SubsidiariesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ConsolidatedEntitiesAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="us-gaap_SubsidiariesMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="urgn_IsraelInnovationAuthorityMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_LeaseExpirationYear" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_LeaseAgreementCommencementPeriod" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_LeaseAgreementTerminationPeriod" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_RoyaltyFeesPercentage" order="11020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_PercentageOfRoyaltyPayableOnGrantReceived" order="11060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_SuccessFeesToThirdPartiesInStockOptions" order="11160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_FairValueOfStockOptionsIssuedToThirdParties" order="11180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_SuccessFeesToThirdPartiesInCash" order="11200.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:type="locator" xlink:label="us-gaap_FairValueInputsDiscountRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:type="locator" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_InternalDevelopmentMember" xlink:type="locator" xlink:label="urgn_InternalDevelopmentMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LiquidationEventMember" xlink:type="locator" xlink:label="urgn_LiquidationEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_HybridMethodValuationTechniqueMember" xlink:type="locator" xlink:label="urgn_HybridMethodValuationTechniqueMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AOneWarrantsMember" xlink:type="locator" xlink:label="urgn_AOneWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="urgn_AOneWarrantsMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_2" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="urgn_HybridMethodValuationTechniqueMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_LiquidationEventMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:to="us-gaap_ResearchAndDevelopmentAssetTransactionDomain_2" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:to="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:to="urgn_InternalDevelopmentMember" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAOnePreferredStockMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInputsProbabilityOfDefault" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10880.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfShareCapitalDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10580.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10160.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ModificationsOfPerformanceConditionsInShares" xlink:type="locator" xlink:label="urgn_ModificationsOfPerformanceConditionsInShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PercentageOfOutstandingPreferredStockShares" xlink:type="locator" xlink:label="urgn_PercentageOfOutstandingPreferredStockShares" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NetProceedsRequiredForConversion" xlink:type="locator" xlink:label="urgn_NetProceedsRequiredForConversion" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PreMoneyValuation" xlink:type="locator" xlink:label="urgn_PreMoneyValuation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <loc xlink:href="urgn-20171231.xsd#urgn_InitialPublicOfferingCost" xlink:type="locator" xlink:label="urgn_InitialPublicOfferingCost" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PreferredSharesIntoOrdinarySharesConversionRatio" xlink:type="locator" xlink:label="urgn_PreferredSharesIntoOrdinarySharesConversionRatio" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" xlink:type="locator" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PreferredStockIssuedPricePerShare" xlink:type="locator" xlink:label="urgn_PreferredStockIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndServiceProvidersMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="urgn_SecondaryPublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd#exch_XNCM" xlink:type="locator" xlink:label="exch_XNCM" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:type="locator" xlink:label="dei_EntityListingsExchangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_TelormedixSAMember" xlink:type="locator" xlink:label="urgn_TelormedixSAMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="urgn_TelormedixSAMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_EntityListingsExchangeAxis" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_ExchangeDomain" xlink:to="exch_XNCM" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAOnePreferredStockMember" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_SecondaryPublicOfferingMember" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="11360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="11370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="11660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndServiceProvidersMember" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="12080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PreferredStockIssuedPricePerShare" order="12100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="12210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="12250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" order="12380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PreferredSharesIntoOrdinarySharesConversionRatio" order="12450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_InitialPublicOfferingCost" order="12500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="12640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PreMoneyValuation" order="12690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_NetProceedsRequiredForConversion" order="12710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PercentageOfOutstandingPreferredStockShares" order="12760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="12850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="12870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" order="13030.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="13050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="13120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_ModificationsOfPerformanceConditionsInShares" order="13140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="13270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="13330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" order="13420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="13850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13900.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10680.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10860.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="11040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="11220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="11400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="11760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11940.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndOtherServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndOtherServiceProvidersMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="11000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="11180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="11360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11540.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndOtherServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndOtherServiceProvidersMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12410.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeFourMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeFourMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeThreeMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeThreeMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeTwoMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeTwoMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeOneMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeOneMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeTwoMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeThreeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeFourMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="10880.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_FederalAndStateNetOperatingLossesExpirationYear" xlink:type="locator" xlink:label="urgn_FederalAndStateNetOperatingLossesExpirationYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IncomeTaxTable" xlink:type="locator" xlink:label="urgn_IncomeTaxTable" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IncomeTaxLineItems" xlink:type="locator" xlink:label="urgn_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="urgn_IncomeTaxLineItems" xlink:to="urgn_IncomeTaxTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="urgn_IncomeTaxTable" xlink:to="us-gaap_StatementScenarioAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="urgn_IncomeTaxLineItems" xlink:to="urgn_FederalAndStateNetOperatingLossesExpirationYear" order="10490.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureLossPerOrdinaryShareAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10200.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseCommencementDate" xlink:type="locator" xlink:label="urgn_LeaseCommencementDate" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementDate" xlink:type="locator" xlink:label="urgn_LeaseAgreementDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" xlink:label="us-gaap_SubsidiariesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ConsolidatedEntitiesAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="us-gaap_SubsidiariesMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="urgn_LeaseAgreementDate" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="urgn_LeaseCommencementDate" order="10160.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" xlink:type="locator" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd#exch_XNCM" xlink:type="locator" xlink:label="exch_XNCM" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:type="locator" xlink:label="dei_EntityListingsExchangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="urgn_SecondaryPublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_SecondaryPublicOfferingMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_EntityListingsExchangeAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_ExchangeDomain" xlink:to="exch_XNCM" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" order="10480.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>urgn-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-15T19:01:19.6472015+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : f94fb2f9093b4031a25f038a50ff9384 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="urgn_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="urgn_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="urgn_DocumentAndEntityInformationAbstract_lbl" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" />
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of warrants for preferred shares current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_WarrantsForPreferredSharesNoncurrent" xlink:type="locator" xlink:label="urgn_WarrantsForPreferredSharesNoncurrent" />
    <label xml:lang="en-US" xlink:label="urgn_WarrantsForPreferredSharesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants for preferred shares noncurrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_WarrantsForPreferredSharesNoncurrent" xlink:to="urgn_WarrantsForPreferredSharesNoncurrent_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="urgn_SeriesAAndAOnePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A and A one preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SeriesAAndAOnePreferredStockMember" xlink:to="urgn_SeriesAAndAOnePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_SeriesAAndAOnePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A and A-1 Preferred Shares</label>
    <label xml:lang="en-US" xlink:label="urgn_SeriesAAndAOnePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A And A One Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedInvestmentsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsCurrent" xlink:to="us-gaap_RestrictedInvestmentsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedInvestmentsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Investments Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InventoryNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NON-CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Investments Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Shareholder&apos;s equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee related accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</label>
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants for preferred shares</label>
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Warrants For Preferred Shares Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NON-CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</label>
    <label xml:lang="en-US" xlink:label="urgn_WarrantsForPreferredSharesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants for preferred shares</label>
    <label xml:lang="en-US" xlink:label="urgn_WarrantsForPreferredSharesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants For Preferred Shares Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES (Note 6)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SHAREHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, NIS 0.01 par value; 100,000,000 and 17,600,000 shares authorized at December 31, 2017 and 2016, respectively; 13,751,390 and 2,305,743 shares issued and outstanding as of December 31, 2017 and 2016, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A and A-1 preferred shares, NIS 0.01 par value: 0 and 14,400,000 shares authorized at December 31, 2017 and 2016, respectively; 0 and 5,193,427 shares issued and outstanding at December 31, 2017 and 2016, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary shares, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ResearchAndDevelopmentExpenseNet" xlink:type="locator" xlink:label="urgn_ResearchAndDevelopmentExpenseNet" />
    <label xml:lang="en-US" xlink:label="urgn_ResearchAndDevelopmentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ResearchAndDevelopmentExpenseNet" xlink:to="urgn_ResearchAndDevelopmentExpenseNet_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_FinanceIncomeExpenseNet" xlink:type="locator" xlink:label="urgn_FinanceIncomeExpenseNet" />
    <label xml:lang="en-US" xlink:label="urgn_FinanceIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Finance income expense net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_FinanceIncomeExpenseNet" xlink:to="urgn_FinanceIncomeExpenseNet_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COST OF REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">GROSS PROFIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GrossProfit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <label xml:lang="en-US" xlink:label="urgn_ResearchAndDevelopmentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RESEARCH AND DEVELOPMENT EXPENSES, NET</label>
    <label xml:lang="en-US" xlink:label="urgn_ResearchAndDevelopmentExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OPERATING (LOSS) INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <label xml:lang="en-US" xlink:label="urgn_FinanceIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">FINANCE EXPENSES, NET</label>
    <label xml:lang="en-US" xlink:label="urgn_FinanceIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finance Income Expense Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INCOME TAX EXPENSE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LOSS PER ORDINARY SHARE BASIC AND DILUTED</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" />
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares stock options exercised net of shares withheld to pay option price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:to="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" />
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value stock options exercised net of shares withheld to pay option price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:to="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="urgn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value warrants exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="urgn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" />
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares preferred shares exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" xlink:to="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" />
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value preferred shares exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" xlink:to="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred A Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of shares, net of issuance costs, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of IP R&amp;D in consideration, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Purchase Of Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of IP R&amp;D in consideration, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Purchase Of Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options into ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options into ordinary shares, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options into ordinary shares, net of 68,416 shares withheld to pay option price</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised Net Of Shares Withheld To Pay Option Price</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of options into ordinary shares, net of 68,416 shares withheld to pay option price, shares</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised Net Of Shares Withheld To Pay Option Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants into preferred shares</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Warrants Exercised</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants into preferred shares, shares</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrants Exercised</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of preferred shares into ordinary shares</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Preferred Shares Exercised</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of preferred shares into ordinary shares, shares</label>
    <label xml:lang="en-US" xlink:label="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Preferred Shares Exercised</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</label>
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issuance expense and underwriters discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares withheld to pay option price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Paid For Tax Withholding For Share Based Compensation</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_NoncashIssuanceCost" xlink:type="locator" xlink:label="urgn_NoncashIssuanceCost" />
    <label xml:lang="en-US" xlink:label="urgn_NoncashIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-cash issuance cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NoncashIssuanceCost" xlink:to="urgn_NoncashIssuanceCost_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NoncashExerciseOfWarrantsToPreferredShares" xlink:type="locator" xlink:label="urgn_NoncashExerciseOfWarrantsToPreferredShares" />
    <label xml:lang="en-US" xlink:label="urgn_NoncashExerciseOfWarrantsToPreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash exercise of warrants to preferred shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NoncashExerciseOfWarrantsToPreferredShares" xlink:to="urgn_NoncashExerciseOfWarrantsToPreferredShares_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments required to reconcile net loss to net cash (used in) provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In process R&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development In Process</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exchange rates differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value adjustment of warrants for preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating asset and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Increase in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Inventories</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease (increase) in accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Increase) decrease in prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in employee related accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Short Term Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in restricted deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Restricted Cash</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of options into ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants for preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred equity offering cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preferred shares from 2014 Share Purchase Agreement net of issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance cost for secondary offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Financing Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">INCREASE IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE YEAR</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of IP R&amp;D in consideration for Preferred A Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Intangible Assets Acquired1</label>
    <label xml:lang="en-US" xlink:label="urgn_NoncashIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non cash issuance cost</label>
    <label xml:lang="en-US" xlink:label="urgn_NoncashIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Issuance Cost</label>
    <label xml:lang="en-US" xlink:label="urgn_NoncashExerciseOfWarrantsToPreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants to preferred shares</label>
    <label xml:lang="en-US" xlink:label="urgn_NoncashExerciseOfWarrantsToPreferredShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Exercise Of Warrants To Preferred Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeeRightsUponRetirementTextBlock" xlink:type="locator" xlink:label="urgn_EmployeeRightsUponRetirementTextBlock" />
    <label xml:lang="en-US" xlink:label="urgn_EmployeeRightsUponRetirementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee rights upon retirement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_EmployeeRightsUponRetirementTextBlock" xlink:to="urgn_EmployeeRightsUponRetirementTextBlock_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeeRightsUponRetirementAbstract" xlink:type="locator" xlink:label="urgn_EmployeeRightsUponRetirementAbstract" />
    <label xml:lang="en-US" xlink:label="urgn_EmployeeRightsUponRetirementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee rights upon retirement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_EmployeeRightsUponRetirementAbstract" xlink:to="urgn_EmployeeRightsUponRetirementAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_EmployeeRightsUponRetirementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Rights Upon Retirement [Abstract]</label>
    <label xml:lang="en-US" xlink:label="urgn_EmployeeRightsUponRetirementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Rights Upon Retirement</label>
    <label xml:lang="en-US" xlink:label="urgn_EmployeeRightsUponRetirementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Rights Upon Retirement [Text Block]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" />
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of warrants for preferred shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" />
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Exercise of Warrants for Preferred Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Warrants For Preferred Shares [Abstract]</label>
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Exercise of Warrants for Preferred A-1 Shares</label>
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Warrants For Preferred Shares [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shareholders Equity And Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Taxes on Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Per Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties-Transactions and Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates in the Preparation of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Director Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_DeferredTaxesPolicyTextBlock" xlink:type="locator" xlink:label="urgn_DeferredTaxesPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="urgn_DeferredTaxesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DeferredTaxesPolicyTextBlock" xlink:to="urgn_DeferredTaxesPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_DeferredTaxesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Taxes</label>
    <label xml:lang="en-US" xlink:label="urgn_DeferredTaxesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Taxes Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_InitialPublicOfferingCostsPolicyTextBlock" xlink:type="locator" xlink:label="urgn_InitialPublicOfferingCostsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="urgn_InitialPublicOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_InitialPublicOfferingCostsPolicyTextBlock" xlink:to="urgn_InitialPublicOfferingCostsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_InitialPublicOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO Costs</label>
    <label xml:lang="en-US" xlink:label="urgn_InitialPublicOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Newly Issued and Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" />
    <label xml:lang="en-US" xlink:label="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of annual rates of depreciation of property plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Annual Rates of Depreciation</label>
    <label xml:lang="en-US" xlink:label="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Annual Rates Of Depreciation Of Property Plant And Equipment Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Fair Value of Warrants for Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <label xml:lang="en-US" xlink:label="urgn_EmployeesAndDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_EmployeesAndDirectorsMember" xlink:to="urgn_EmployeesAndDirectorsMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_EmployeesAndDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and Directors</label>
    <label xml:lang="en-US" xlink:label="urgn_EmployeesAndDirectorsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employees And Directors [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndOtherServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember" />
    <label xml:lang="en-US" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consultants and other service providers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ConsultantsAndOtherServiceProvidersMember" xlink:to="urgn_ConsultantsAndOtherServiceProvidersMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants and Other Service Providers</label>
    <label xml:lang="en-US" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consultants And Other Service Providers [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:to="us-gaap_ScheduleOfCapitalUnitsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capital Units [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Computing Fair Value of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Number of Options Outstanding Under the Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Number of Options Outstanding and Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effect of Share-Based Compensation on Statements of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Change in Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Valuation Allowance [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Calculation of Basic and Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <label xml:lang="en-US" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <label xml:lang="en-US" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</label>
    <label xml:lang="en-US" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="us-gaap_ConsolidatedEntitiesDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" xlink:label="us-gaap_SubsidiariesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UroGen Pharma Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiariesMember" xlink:to="us-gaap_SubsidiariesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiariesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiaries [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember" />
    <label xml:lang="en-US" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Allergan Pharmaceuticals International Limited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allergan</label>
    <label xml:lang="en-US" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allergan Pharmaceuticals International Limited [Member]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:type="locator" xlink:label="dei_EntityListingsExchangeAxis" />
    <label xml:lang="en-US" xlink:label="dei_EntityListingsExchangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Listings, Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_EntityListingsExchangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityListingsExchangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Listings Exchange [Axis]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain" />
    <label xml:lang="en-US" xlink:label="dei_ExchangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ExchangeDomain" xlink:to="dei_ExchangeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="dei_ExchangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exchange [Domain]</label>
    <loc xlink:href="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd#exch_XNCM" xlink:type="locator" xlink:label="exch_XNCM" />
    <label xml:lang="en-US" xlink:label="exch_XNCM_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nasdaq</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="exch_XNCM" xlink:to="exch_XNCM_lbl" />
    <label xml:lang="en-US" xlink:label="exch_XNCM_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">X N C M</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="urgn_SecondaryPublicOfferingMember" />
    <label xml:lang="en-US" xlink:label="urgn_SecondaryPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Secondary public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SecondaryPublicOfferingMember" xlink:to="urgn_SecondaryPublicOfferingMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_SecondaryPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secondary Public Offering</label>
    <label xml:lang="en-US" xlink:label="urgn_SecondaryPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Secondary Public Offering [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</label>
    <label xml:lang="en-US" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
    <label xml:lang="en-US" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation Date Of Incorporation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:type="locator" xlink:label="us-gaap_OperationsCommencedDate1" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of operating commencement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperationsCommencedDate1" xlink:to="us-gaap_OperationsCommencedDate1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperationsCommencedDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operations Commenced Date1</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationForSalesAndSupportingServices" xlink:type="locator" xlink:label="urgn_ConsiderationForSalesAndSupportingServices" />
    <label xml:lang="en-US" xlink:label="urgn_ConsiderationForSalesAndSupportingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration for sales and supporting services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ConsiderationForSalesAndSupportingServices" xlink:to="urgn_ConsiderationForSalesAndSupportingServices_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ConsiderationForSalesAndSupportingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration for sales and supporting services</label>
    <label xml:lang="en-US" xlink:label="urgn_ConsiderationForSalesAndSupportingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consideration For Sales And Supporting Services</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" xlink:type="locator" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" />
    <label xml:lang="en-US" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration fee received for license and future supply services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" xlink:to="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AdditionalMilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_AdditionalMilestonePaymentForLicensingAgreement" />
    <label xml:lang="en-US" xlink:label="urgn_AdditionalMilestonePaymentForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payment for licensing agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AdditionalMilestonePaymentForLicensingAgreement" xlink:to="urgn_AdditionalMilestonePaymentForLicensingAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration received for license and future supply services</label>
    <label xml:lang="en-US" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consideration Fee Received For License And Future Supply Services</label>
    <label xml:lang="en-US" xlink:label="urgn_AdditionalMilestonePaymentForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional milestone payment to be paid</label>
    <label xml:lang="en-US" xlink:label="urgn_AdditionalMilestonePaymentForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payment For Licensing Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share split, conversion ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Shares issued, net of issuance costs</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_MilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentForLicensingAgreement" />
    <label xml:lang="en-US" xlink:label="urgn_MilestonePaymentForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment for licensing agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_MilestonePaymentForLicensingAgreement" xlink:to="urgn_MilestonePaymentForLicensingAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_MilestonePaymentForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment for licensing agreement</label>
    <label xml:lang="en-US" xlink:label="urgn_MilestonePaymentForLicensingAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment For Licensing Agreement</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="locator" xlink:label="urgn_SummaryOfSignificantAccountingPolicyLineItems" />
    <label xml:lang="en-US" xlink:label="urgn_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_SummaryOfSignificantAccountingPolicyLineItems_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="urgn_SummaryOfSignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="urgn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies table.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="urgn_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="urgn_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <label xml:lang="en-US" xlink:label="urgn_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policy [Line Items]</label>
    <label xml:lang="en-US" xlink:label="urgn_SummaryOfSignificantAccountingPolicyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policy [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in value of short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Investments</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" xlink:type="locator" xlink:label="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" />
    <label xml:lang="en-US" xlink:label="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property plant and equipment annual rate of depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" xlink:to="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <label xml:lang="en-US" xlink:label="urgn_ComputersAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computers and software.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ComputersAndSoftwareMember" xlink:to="urgn_ComputersAndSoftwareMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ComputersAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers and Software</label>
    <label xml:lang="en-US" xlink:label="urgn_ComputersAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computers And Software [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <label xml:lang="en-US" xlink:label="urgn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LaboratoryEquipmentMember" xlink:to="urgn_LaboratoryEquipmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</label>
    <label xml:lang="en-US" xlink:label="urgn_LaboratoryEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Facility [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</label>
    <label xml:lang="en-US" xlink:label="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, annual rates of depreciation</label>
    <label xml:lang="en-US" xlink:label="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Annual Rate Of Depreciation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment loss for long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfDeliverableLicenseAgreements" xlink:type="locator" xlink:label="urgn_NumberOfDeliverableLicenseAgreements" />
    <label xml:lang="en-US" xlink:label="urgn_NumberOfDeliverableLicenseAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of deliverable license agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NumberOfDeliverableLicenseAgreements" xlink:to="urgn_NumberOfDeliverableLicenseAgreements_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_NumberOfDeliverableLicenseAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of deliverable license agreements</label>
    <label xml:lang="en-US" xlink:label="urgn_NumberOfDeliverableLicenseAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Deliverable License Agreements</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_DescriptionOfLicenseAgreementComponents" xlink:type="locator" xlink:label="urgn_DescriptionOfLicenseAgreementComponents" />
    <label xml:lang="en-US" xlink:label="urgn_DescriptionOfLicenseAgreementComponents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of license agreement components.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DescriptionOfLicenseAgreementComponents" xlink:to="urgn_DescriptionOfLicenseAgreementComponents_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_DescriptionOfLicenseAgreementComponents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License component, description</label>
    <label xml:lang="en-US" xlink:label="urgn_DescriptionOfLicenseAgreementComponents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Description Of License Agreement Components</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_UpfrontFeeAllocatedToLicenseComponent" xlink:type="locator" xlink:label="urgn_UpfrontFeeAllocatedToLicenseComponent" />
    <label xml:lang="en-US" xlink:label="urgn_UpfrontFeeAllocatedToLicenseComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee allocated to license component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_UpfrontFeeAllocatedToLicenseComponent" xlink:to="urgn_UpfrontFeeAllocatedToLicenseComponent_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_UpfrontFeeAllocatedToLicenseComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee allocated to license component</label>
    <label xml:lang="en-US" xlink:label="urgn_UpfrontFeeAllocatedToLicenseComponent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Allocated To License Component</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in research and development expenses</label>
    <label xml:lang="en-US" xlink:label="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued provision for uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_InitialPublicOfferingCost" xlink:type="locator" xlink:label="urgn_InitialPublicOfferingCost" />
    <label xml:lang="en-US" xlink:label="urgn_InitialPublicOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_InitialPublicOfferingCost" xlink:to="urgn_InitialPublicOfferingCost_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_InitialPublicOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO costs</label>
    <label xml:lang="en-US" xlink:label="urgn_InitialPublicOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less&#8212;Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" />
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of warrants for preferred shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" />
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of warrants for preferred shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Exercise Of Warrants For Preferred Shares [Table]</label>
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Warrants For Preferred Shares [Table]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="urgn_SeriesAOnePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A one preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SeriesAOnePreferredStockMember" xlink:to="urgn_SeriesAOnePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_SeriesAOnePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Preferred Shares</label>
    <label xml:lang="en-US" xlink:label="urgn_SeriesAOnePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A One Preferred Stock [Member]</label>
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Exercise of Warrants for Preferred Shares [Line Items]</label>
    <label xml:lang="en-US" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Warrants For Preferred Shares [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable number of warrants for preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseExpirationYear" xlink:type="locator" xlink:label="urgn_LeaseExpirationYear" />
    <label xml:lang="en-US" xlink:label="urgn_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseExpirationYear" xlink:to="urgn_LeaseExpirationYear_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_IsraelInnovationAuthorityMember" xlink:type="locator" xlink:label="urgn_IsraelInnovationAuthorityMember" />
    <label xml:lang="en-US" xlink:label="urgn_IsraelInnovationAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Israel Innovation Authority.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_IsraelInnovationAuthorityMember" xlink:to="urgn_IsraelInnovationAuthorityMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_IsraelInnovationAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IIA</label>
    <label xml:lang="en-US" xlink:label="urgn_IsraelInnovationAuthorityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Israel Innovation Authority [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration year</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementCommencementPeriod" xlink:type="locator" xlink:label="urgn_LeaseAgreementCommencementPeriod" />
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementCommencementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement commencement period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseAgreementCommencementPeriod" xlink:to="urgn_LeaseAgreementCommencementPeriod_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementTerminationPeriod" xlink:type="locator" xlink:label="urgn_LeaseAgreementTerminationPeriod" />
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement termination period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseAgreementTerminationPeriod" xlink:to="urgn_LeaseAgreementTerminationPeriod_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementCommencementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement, commencement period</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementCommencementPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Commencement Period</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement, termination period</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Termination Period</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" xlink:type="locator" xlink:label="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" />
    <label xml:lang="en-US" xlink:label="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum payments due in six years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" xlink:to="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</label>
    <label xml:lang="en-US" xlink:label="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum lease payments, 2023</label>
    <label xml:lang="en-US" xlink:label="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Six Years</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_RoyaltyFeesPercentage" xlink:type="locator" xlink:label="urgn_RoyaltyFeesPercentage" />
    <label xml:lang="en-US" xlink:label="urgn_RoyaltyFeesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty fees percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_RoyaltyFeesPercentage" xlink:to="urgn_RoyaltyFeesPercentage_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PercentageOfRoyaltyPayableOnGrantReceived" xlink:type="locator" xlink:label="urgn_PercentageOfRoyaltyPayableOnGrantReceived" />
    <label xml:lang="en-US" xlink:label="urgn_PercentageOfRoyaltyPayableOnGrantReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payable on grant received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PercentageOfRoyaltyPayableOnGrantReceived" xlink:to="urgn_PercentageOfRoyaltyPayableOnGrantReceived_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_RoyaltyFeesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty fees payable on product sales, percentage</label>
    <label xml:lang="en-US" xlink:label="urgn_RoyaltyFeesPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Fees Percentage</label>
    <label xml:lang="en-US" xlink:label="urgn_PercentageOfRoyaltyPayableOnGrantReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of royalty payable on grant received</label>
    <label xml:lang="en-US" xlink:label="urgn_PercentageOfRoyaltyPayableOnGrantReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payable On Grant Received</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty amount payable excluding interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties Current And Noncurrent</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_SuccessFeesToThirdPartiesInStockOptions" xlink:type="locator" xlink:label="urgn_SuccessFeesToThirdPartiesInStockOptions" />
    <label xml:lang="en-US" xlink:label="urgn_SuccessFeesToThirdPartiesInStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Success fees to third parties in stock options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SuccessFeesToThirdPartiesInStockOptions" xlink:to="urgn_SuccessFeesToThirdPartiesInStockOptions_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_FairValueOfStockOptionsIssuedToThirdParties" xlink:type="locator" xlink:label="urgn_FairValueOfStockOptionsIssuedToThirdParties" />
    <label xml:lang="en-US" xlink:label="urgn_FairValueOfStockOptionsIssuedToThirdParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of stock options issued to third parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_FairValueOfStockOptionsIssuedToThirdParties" xlink:to="urgn_FairValueOfStockOptionsIssuedToThirdParties_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SuccessFeesToThirdPartiesInCash" xlink:type="locator" xlink:label="urgn_SuccessFeesToThirdPartiesInCash" />
    <label xml:lang="en-US" xlink:label="urgn_SuccessFeesToThirdPartiesInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Success fees to third parties in cash.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_SuccessFeesToThirdPartiesInCash" xlink:to="urgn_SuccessFeesToThirdPartiesInCash_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_SuccessFeesToThirdPartiesInStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success fees to third parties in stock options</label>
    <label xml:lang="en-US" xlink:label="urgn_SuccessFeesToThirdPartiesInStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Success Fees To Third Parties In Stock Options</label>
    <label xml:lang="en-US" xlink:label="urgn_FairValueOfStockOptionsIssuedToThirdParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of stock options issued to third parties</label>
    <label xml:lang="en-US" xlink:label="urgn_FairValueOfStockOptionsIssuedToThirdParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Stock Options Issued To Third Parties</label>
    <label xml:lang="en-US" xlink:label="urgn_SuccessFeesToThirdPartiesInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success fees to third parties in cash</label>
    <label xml:lang="en-US" xlink:label="urgn_SuccessFeesToThirdPartiesInCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Success Fees To Third Parties In Cash</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_AOneWarrantsMember" xlink:type="locator" xlink:label="urgn_AOneWarrantsMember" />
    <label xml:lang="en-US" xlink:label="urgn_AOneWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">A-1 warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_AOneWarrantsMember" xlink:to="urgn_AOneWarrantsMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_AOneWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A-1 Warrants</label>
    <label xml:lang="en-US" xlink:label="urgn_AOneWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A One Warrants [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Technique</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Technique</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_HybridMethodValuationTechniqueMember" xlink:type="locator" xlink:label="urgn_HybridMethodValuationTechniqueMember" />
    <label xml:lang="en-US" xlink:label="urgn_HybridMethodValuationTechniqueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Hybrid method valuation technique.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_HybridMethodValuationTechniqueMember" xlink:to="urgn_HybridMethodValuationTechniqueMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_HybridMethodValuationTechniqueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hybrid Method Valuation Technique</label>
    <label xml:lang="en-US" xlink:label="urgn_HybridMethodValuationTechniqueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Hybrid Method Valuation Technique [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_LiquidationEventMember" xlink:type="locator" xlink:label="urgn_LiquidationEventMember" />
    <label xml:lang="en-US" xlink:label="urgn_LiquidationEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidation event.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LiquidationEventMember" xlink:to="urgn_LiquidationEventMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_LiquidationEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidation Event</label>
    <label xml:lang="en-US" xlink:label="urgn_LiquidationEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidation Event [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Assets Acquired Other than Through Business Combination by Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:to="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Assets Acquired Other Than Through Business Combination By Transaction [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAssetTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Asset, Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:to="us-gaap_ResearchAndDevelopmentAssetTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAssetTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Asset Transaction [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_InternalDevelopmentMember" xlink:type="locator" xlink:label="urgn_InternalDevelopmentMember" />
    <label xml:lang="en-US" xlink:label="urgn_InternalDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Internal development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_InternalDevelopmentMember" xlink:to="urgn_InternalDevelopmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_InternalDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal Development</label>
    <label xml:lang="en-US" xlink:label="urgn_InternalDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Internal Development [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:type="locator" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value inputs, probability of estimated rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsProbabilityOfDefault" xlink:to="us-gaap_FairValueInputsProbabilityOfDefault_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Probability Of Default</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:type="locator" xlink:label="us-gaap_FairValueInputsDiscountRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value inputs discount rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="us-gaap_FairValueInputsDiscountRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Discount Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assumptions, expected volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during period upon conversion of warrants, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" xlink:type="locator" xlink:label="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" />
    <label xml:lang="en-US" xlink:label="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs reconciliation recurring basis liability issuance of warrants for preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" xlink:to="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of warrants for preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of warrants for preferred shares</label>
    <label xml:lang="en-US" xlink:label="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issuance Of Warrants For Preferred Stock</label>
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_PreferredStockIssuedPricePerShare" xlink:type="locator" xlink:label="urgn_PreferredStockIssuedPricePerShare" />
    <label xml:lang="en-US" xlink:label="urgn_PreferredStockIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock issued price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PreferredStockIssuedPricePerShare" xlink:to="urgn_PreferredStockIssuedPricePerShare_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_TelormedixSAMember" xlink:type="locator" xlink:label="urgn_TelormedixSAMember" />
    <label xml:lang="en-US" xlink:label="urgn_TelormedixSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Telormedix SA.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_TelormedixSAMember" xlink:to="urgn_TelormedixSAMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_TelormedixSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TMX</label>
    <label xml:lang="en-US" xlink:label="urgn_TelormedixSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Telormedix S A [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</label>
    <label xml:lang="en-US" xlink:label="urgn_SeriesAOnePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred A-1 Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2017 equity incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Equity Incentive Plan</label>
    <label xml:lang="en-US" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Equity Incentive Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndServiceProvidersMember" />
    <label xml:lang="en-US" xlink:label="urgn_ConsultantsAndServiceProvidersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Consultants and service providers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ConsultantsAndServiceProvidersMember" xlink:to="urgn_ConsultantsAndServiceProvidersMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ConsultantsAndServiceProvidersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consultants and Service Providers</label>
    <label xml:lang="en-US" xlink:label="urgn_ConsultantsAndServiceProvidersMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consultants And Service Providers [Member]</label>
    <label xml:lang="en-US" xlink:label="urgn_PreferredStockIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock price per share</label>
    <label xml:lang="en-US" xlink:label="urgn_PreferredStockIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Issued Price Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses incurred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 shares held immediately prior to share split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Issued1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" xlink:type="locator" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" />
    <label xml:lang="en-US" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional shares exercised under underwriters option to purchase at the public offering price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" xlink:to="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of ordinary shares, shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of ordinary shares, price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs</label>
    <label xml:lang="en-US" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional ordinary shares exercised under underwriters option to purchase at the public offering price</label>
    <label xml:lang="en-US" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Shares Exercised Under Underwriters Option To Purchase At Public Offering Price</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_PreferredSharesIntoOrdinarySharesConversionRatio" xlink:type="locator" xlink:label="urgn_PreferredSharesIntoOrdinarySharesConversionRatio" />
    <label xml:lang="en-US" xlink:label="urgn_PreferredSharesIntoOrdinarySharesConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred shares into ordinary shares conversion ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PreferredSharesIntoOrdinarySharesConversionRatio" xlink:to="urgn_PreferredSharesIntoOrdinarySharesConversionRatio_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_PreferredSharesIntoOrdinarySharesConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred A and Preferred A-1 shares into ordinary shares conversion ratio</label>
    <label xml:lang="en-US" xlink:label="urgn_PreferredSharesIntoOrdinarySharesConversionRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Shares Into Ordinary Shares Conversion Ratio</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends at the rate per annum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Percentage</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_PreMoneyValuation" xlink:type="locator" xlink:label="urgn_PreMoneyValuation" />
    <label xml:lang="en-US" xlink:label="urgn_PreMoneyValuation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-money valuation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PreMoneyValuation" xlink:to="urgn_PreMoneyValuation_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NetProceedsRequiredForConversion" xlink:type="locator" xlink:label="urgn_NetProceedsRequiredForConversion" />
    <label xml:lang="en-US" xlink:label="urgn_NetProceedsRequiredForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds required for conversion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_NetProceedsRequiredForConversion" xlink:to="urgn_NetProceedsRequiredForConversion_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_PreMoneyValuation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-money valuation to convert automatically each preferred shares into ordinary shares upon the closing of an IPO</label>
    <label xml:lang="en-US" xlink:label="urgn_PreMoneyValuation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Money Valuation</label>
    <label xml:lang="en-US" xlink:label="urgn_NetProceedsRequiredForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds required to automatically convert preferred shares to ordinary shares upon the closing of an IPO</label>
    <label xml:lang="en-US" xlink:label="urgn_NetProceedsRequiredForConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Required For Conversion</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_PercentageOfOutstandingPreferredStockShares" xlink:type="locator" xlink:label="urgn_PercentageOfOutstandingPreferredStockShares" />
    <label xml:lang="en-US" xlink:label="urgn_PercentageOfOutstandingPreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of outstanding preferred stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_PercentageOfOutstandingPreferredStockShares" xlink:to="urgn_PercentageOfOutstandingPreferredStockShares_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_PercentageOfOutstandingPreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding preferred stock shares</label>
    <label xml:lang="en-US" xlink:label="urgn_PercentageOfOutstandingPreferredStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Outstanding Preferred Stock Shares</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of options into ordinary shares, amount received</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued upon exercise of options, net of shares surrendered</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</label>
    <label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares surrendered to pay the exercise price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of ordinary share isuable under the 2017 incentive plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Goods And Nonemployee Services Transaction Shares Approved For Issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares reserved for issuance, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ModificationsOfPerformanceConditionsInShares" xlink:type="locator" xlink:label="urgn_ModificationsOfPerformanceConditionsInShares" />
    <label xml:lang="en-US" xlink:label="urgn_ModificationsOfPerformanceConditionsInShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Modifications of performance conditions in shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ModificationsOfPerformanceConditionsInShares" xlink:to="urgn_ModificationsOfPerformanceConditionsInShares_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of stock option as percentage of fair market value on the date of grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <label xml:lang="en-US" xlink:label="urgn_ModificationsOfPerformanceConditionsInShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modifications of performance conditions in shares</label>
    <label xml:lang="en-US" xlink:label="urgn_ModificationsOfPerformanceConditionsInShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Modifications Of Performance Conditions In Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option exercise prices ranging lower limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option exercise prices ranging upper limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" />
    <label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value of options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of option granted</label>
    <label xml:lang="en-US" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Granted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost of employee options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected to be recognized over a weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options, Granted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Canceled/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Outstanding beginning balance</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Price Per Share, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Price Per Share, Canceled/Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Price Per Share, Outstanding beginning balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary shares issuable upon vesting of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeOneMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeOneMember" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price per share range one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ExercisePricePerShareRangeOneMember" xlink:to="urgn_ExercisePricePerShareRangeOneMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">0.00 - 10.00</label>
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Per Share Range One [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeTwoMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeTwoMember" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price per share range two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ExercisePricePerShareRangeTwoMember" xlink:to="urgn_ExercisePricePerShareRangeTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">10.01 - 20.00</label>
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Per Share Range Two [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeThreeMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeThreeMember" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price per share range three.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ExercisePricePerShareRangeThreeMember" xlink:to="urgn_ExercisePricePerShareRangeThreeMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">20.01 - 30.00</label>
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Per Share Range Three [Member]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeFourMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeFourMember" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price per share range four.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_ExercisePricePerShareRangeFourMember" xlink:to="urgn_ExercisePricePerShareRangeFourMember_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">30.01 - 40.00</label>
    <label xml:lang="en-US" xlink:label="urgn_ExercisePricePerShareRangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Per Share Range Four [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, number of options outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, number of options outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of the total vested and exercisable options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_IncomeTaxLineItems" xlink:type="locator" xlink:label="urgn_IncomeTaxLineItems" />
    <label xml:lang="en-US" xlink:label="urgn_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_IncomeTaxLineItems" xlink:to="urgn_IncomeTaxLineItems_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IncomeTaxTable" xlink:type="locator" xlink:label="urgn_IncomeTaxTable" />
    <label xml:lang="en-US" xlink:label="urgn_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_IncomeTaxTable" xlink:to="urgn_IncomeTaxTable_lbl" />
    <label xml:lang="en-US" xlink:label="urgn_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</label>
    <label xml:lang="en-US" xlink:label="urgn_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario, Unspecified</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Forecast</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</label>
    <label xml:lang="en-US" xlink:label="urgn_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</label>
    <label xml:lang="en-US" xlink:label="urgn_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate tax rate including temporary provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net carry forward tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_DeferredTaxAssetsIssuanceCosts" xlink:type="locator" xlink:label="urgn_DeferredTaxAssetsIssuanceCosts" />
    <label xml:lang="en-US" xlink:label="urgn_DeferredTaxAssetsIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_DeferredTaxAssetsIssuanceCosts" xlink:to="urgn_DeferredTaxAssetsIssuanceCosts_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In respect of:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
    <label xml:lang="en-US" xlink:label="urgn_DeferredTaxAssetsIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Costs</label>
    <label xml:lang="en-US" xlink:label="urgn_DeferredTaxAssetsIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Issuance Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process R&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less&#8212;valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Balance at the beginning of the year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</label>
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Balance at the end of the year</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_FederalAndStateNetOperatingLossesExpirationYear" xlink:type="locator" xlink:label="urgn_FederalAndStateNetOperatingLossesExpirationYear" />
    <label xml:lang="en-US" xlink:label="urgn_FederalAndStateNetOperatingLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and state net operating losses expiratiuon year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_FederalAndStateNetOperatingLossesExpirationYear" xlink:to="urgn_FederalAndStateNetOperatingLossesExpirationYear_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax net operating losses carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Domestic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax net operating losses carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</label>
    <label xml:lang="en-US" xlink:label="urgn_FederalAndStateNetOperatingLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state net operating losses expiration year</label>
    <label xml:lang="en-US" xlink:label="urgn_FederalAndStateNetOperatingLossesExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal And State Net Operating Losses Expiration Year</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted [Abstract]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss attributable to equity holders of the Company</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend accumulated for preferred shares during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends Income Statement Impact</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</label>
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of ordinary shares</label>
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss per ordinary share (LPS)</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred A-1 Warrants Converted to Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issuable Upon Conversion of Preferred Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from calculation of diluted loss per share, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementDate" xlink:type="locator" xlink:label="urgn_LeaseAgreementDate" />
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseAgreementDate" xlink:to="urgn_LeaseAgreementDate_lbl" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseCommencementDate" xlink:type="locator" xlink:label="urgn_LeaseCommencementDate" />
    <label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="urgn_LeaseCommencementDate" xlink:to="urgn_LeaseCommencementDate_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement date</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseAgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Date</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</label>
    <label xml:lang="en-US" xlink:label="urgn_LeaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>urgn-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-15T19:01:19.6472015+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : f94fb2f9093b4031a25f038a50ff9384 -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.urogen.com/20171231/role/TemplateLink" xlink:href="urgn-20171231.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="urgn-20171231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="urgn-20171231.xsd#urgn_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="urgn_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="urgn-20171231.xsd#urgn_WarrantsForPreferredSharesNoncurrent" xlink:type="locator" xlink:label="urgn_WarrantsForPreferredSharesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" xlink:label="us-gaap_InventoryNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsCurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="urgn_WarrantsForPreferredSharesNoncurrent" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="urgn-20171231.xsd#urgn_FinanceIncomeExpenseNet" xlink:type="locator" xlink:label="urgn_FinanceIncomeExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ResearchAndDevelopmentExpenseNet" xlink:type="locator" xlink:label="urgn_ResearchAndDevelopmentExpenseNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" xlink:label="us-gaap_GrossProfit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="urgn_ResearchAndDevelopmentExpenseNet" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="urgn_FinanceIncomeExpenseNet" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" />
    <loc xlink:href="urgn-20171231.xsd#urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" xlink:type="locator" xlink:label="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodValueWarrantsExercised" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodSharesWarrantsExercised" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodValuePreferredSharesExercised" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_li0l2" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="urgn-20171231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <loc xlink:href="urgn-20171231.xsd#urgn_NoncashExerciseOfWarrantsToPreferredShares" xlink:type="locator" xlink:label="urgn_NoncashExerciseOfWarrantsToPreferredShares" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NoncashIssuanceCost" xlink:type="locator" xlink:label="urgn_NoncashIssuanceCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="urgn_NoncashIssuanceCost" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="urgn_NoncashExerciseOfWarrantsToPreferredShares" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperations" xlink:href="urgn-20171231.xsd#Role_DisclosureNatureOfOperations" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="urgn-20171231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="urgn-20171231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureEmployeeRightsUponRetirement" xlink:href="urgn-20171231.xsd#Role_DisclosureEmployeeRightsUponRetirement" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureEmployeeRightsUponRetirement">
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeeRightsUponRetirementTextBlock" xlink:type="locator" xlink:label="urgn_EmployeeRightsUponRetirementTextBlock" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeeRightsUponRetirementAbstract" xlink:type="locator" xlink:label="urgn_EmployeeRightsUponRetirementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_EmployeeRightsUponRetirementAbstract" xlink:to="urgn_EmployeeRightsUponRetirementTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1Shares" xlink:href="urgn-20171231.xsd#Role_DisclosureProceedsFromExerciseOfWarrantsForPreferredA1Shares" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1Shares">
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingencies" xlink:href="urgn-20171231.xsd#Role_DisclosureCommitmentAndContingencies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingencies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstruments" xlink:href="urgn-20171231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstruments">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapital" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapital" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapital">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncome" xlink:href="urgn-20171231.xsd#Role_DisclosureTaxesOnIncome" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncome">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShare" xlink:href="urgn-20171231.xsd#Role_DisclosureLossPerOrdinaryShare" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShare">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalances" xlink:href="urgn-20171231.xsd#Role_DisclosureRelatedPartiesTransactionsAndBalances" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalances">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="urgn-20171231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEvents">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="urgn-20171231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="urgn-20171231.xsd#urgn_InitialPublicOfferingCostsPolicyTextBlock" xlink:type="locator" xlink:label="urgn_InitialPublicOfferingCostsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <loc xlink:href="urgn-20171231.xsd#urgn_DeferredTaxesPolicyTextBlock" xlink:type="locator" xlink:label="urgn_DeferredTaxesPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_DeferredTaxesPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_InitialPublicOfferingCostsPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables" xlink:href="urgn-20171231.xsd#Role_DisclosureSignificantAccountingPoliciesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables">
    <loc xlink:href="urgn-20171231.xsd#urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="locator" xlink:label="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="urgn-20171231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsTables" xlink:href="urgn-20171231.xsd#Role_DisclosureFinancialInstrumentsTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalTables" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalUnitsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndOtherServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndOtherServiceProvidersMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfCapitalUnitsTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeTables" xlink:href="urgn-20171231.xsd#Role_DisclosureTaxesOnIncomeTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareTables" xlink:href="urgn-20171231.xsd#Role_DisclosureLossPerOrdinaryShareTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureNatureOfOperationsAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_MilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentForLicensingAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AdditionalMilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_AdditionalMilestonePaymentForLicensingAgreement" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" xlink:type="locator" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationForSalesAndSupportingServices" xlink:type="locator" xlink:label="urgn_ConsiderationForSalesAndSupportingServices" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperationsCommencedDate1" xlink:type="locator" xlink:label="us-gaap_OperationsCommencedDate1" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:type="locator" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
    <loc xlink:href="urgn-20171231.xsd#urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="urgn_SecondaryPublicOfferingMember" />
    <loc xlink:href="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd#exch_XNCM" xlink:type="locator" xlink:label="exch_XNCM" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:type="locator" xlink:label="dei_EntityListingsExchangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" xlink:label="us-gaap_SubsidiariesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_ConsolidatedEntitiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="us-gaap_SubsidiariesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="dei_EntityListingsExchangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_ExchangeDomain" xlink:to="exch_XNCM" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_SecondaryPublicOfferingMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_OperationsCommencedDate1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_ConsiderationForSalesAndSupportingServices" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_AdditionalMilestonePaymentForLicensingAgreement" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="urgn_MilestonePaymentForLicensingAgreement" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_InitialPublicOfferingCost" xlink:type="locator" xlink:label="urgn_InitialPublicOfferingCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_MilestonePaymentForLicensingAgreement" xlink:type="locator" xlink:label="urgn_MilestonePaymentForLicensingAgreement" />
    <loc xlink:href="urgn-20171231.xsd#urgn_UpfrontFeeAllocatedToLicenseComponent" xlink:type="locator" xlink:label="urgn_UpfrontFeeAllocatedToLicenseComponent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" xlink:type="locator" xlink:label="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" />
    <loc xlink:href="urgn-20171231.xsd#urgn_DescriptionOfLicenseAgreementComponents" xlink:type="locator" xlink:label="urgn_DescriptionOfLicenseAgreementComponents" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfDeliverableLicenseAgreements" xlink:type="locator" xlink:label="urgn_NumberOfDeliverableLicenseAgreements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:type="locator" xlink:label="urgn_SummaryOfSignificantAccountingPolicyLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="urgn_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="urgn_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="urgn_SummaryOfSignificantAccountingPolicyLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_NumberOfDeliverableLicenseAgreements" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_DescriptionOfLicenseAgreementComponents" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_UpfrontFeeAllocatedToLicenseComponent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_MilestonePaymentForLicensingAgreement" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_IncreaseDecreaseInResearchAndDevelopmentExpense" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_SummaryOfSignificantAccountingPolicyLineItems" xlink:to="urgn_InitialPublicOfferingCost" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" xlink:type="locator" xlink:label="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails" xlink:href="urgn-20171231.xsd#Role_DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LaboratoryEquipmentMember" xlink:type="locator" xlink:label="urgn_LaboratoryEquipmentMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ComputersAndSoftwareMember" xlink:type="locator" xlink:label="urgn_ComputersAndSoftwareMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_ComputersAndSoftwareMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="urgn_LaboratoryEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" xlink:type="locator" xlink:label="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAOnePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTable" xlink:to="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_SuccessFeesToThirdPartiesInCash" xlink:type="locator" xlink:label="urgn_SuccessFeesToThirdPartiesInCash" />
    <loc xlink:href="urgn-20171231.xsd#urgn_FairValueOfStockOptionsIssuedToThirdParties" xlink:type="locator" xlink:label="urgn_FairValueOfStockOptionsIssuedToThirdParties" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SuccessFeesToThirdPartiesInStockOptions" xlink:type="locator" xlink:label="urgn_SuccessFeesToThirdPartiesInStockOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PercentageOfRoyaltyPayableOnGrantReceived" xlink:type="locator" xlink:label="urgn_PercentageOfRoyaltyPayableOnGrantReceived" />
    <loc xlink:href="urgn-20171231.xsd#urgn_RoyaltyFeesPercentage" xlink:type="locator" xlink:label="urgn_RoyaltyFeesPercentage" />
    <loc xlink:href="urgn-20171231.xsd#urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" xlink:type="locator" xlink:label="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementTerminationPeriod" xlink:type="locator" xlink:label="urgn_LeaseAgreementTerminationPeriod" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementCommencementPeriod" xlink:type="locator" xlink:label="urgn_LeaseAgreementCommencementPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseExpirationYear" xlink:type="locator" xlink:label="urgn_LeaseExpirationYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IsraelInnovationAuthorityMember" xlink:type="locator" xlink:label="urgn_IsraelInnovationAuthorityMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" xlink:label="us-gaap_SubsidiariesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ConsolidatedEntitiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="us-gaap_SubsidiariesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="urgn_IsraelInnovationAuthorityMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_LeaseExpirationYear" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_LeaseAgreementCommencementPeriod" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_LeaseAgreementTerminationPeriod" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_RoyaltyFeesPercentage" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_PercentageOfRoyaltyPayableOnGrantReceived" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_SuccessFeesToThirdPartiesInStockOptions" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_FairValueOfStockOptionsIssuedToThirdParties" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="urgn_SuccessFeesToThirdPartiesInCash" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:type="locator" xlink:label="us-gaap_FairValueInputsDiscountRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsProbabilityOfDefault" xlink:type="locator" xlink:label="us-gaap_FairValueInputsProbabilityOfDefault" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_InternalDevelopmentMember" xlink:type="locator" xlink:label="urgn_InternalDevelopmentMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AllerganPharmaceuticalsInternationalLimitedMember" xlink:type="locator" xlink:label="urgn_AllerganPharmaceuticalsInternationalLimitedMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LiquidationEventMember" xlink:type="locator" xlink:label="urgn_LiquidationEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_HybridMethodValuationTechniqueMember" xlink:type="locator" xlink:label="urgn_HybridMethodValuationTechniqueMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:type="locator" xlink:label="us-gaap_ValuationTechniqueAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_AOneWarrantsMember" xlink:type="locator" xlink:label="urgn_AOneWarrantsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="urgn_AOneWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="urgn_HybridMethodValuationTechniqueMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_LiquidationEventMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis" xlink:to="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:to="urgn_AllerganPharmaceuticalsInternationalLimitedMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAssetTransactionDomain" xlink:to="urgn_InternalDevelopmentMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAOnePreferredStockMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInputsProbabilityOfDefault" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfWarrantsForPreferredSharesDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfWarrantsForPreferredSharesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfWarrantsForPreferredSharesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <loc xlink:href="urgn-20171231.xsd#urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" xlink:type="locator" xlink:label="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfShareCapitalDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAAndAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAAndAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAAndAOnePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" xlink:type="locator" xlink:label="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ModificationsOfPerformanceConditionsInShares" xlink:type="locator" xlink:label="urgn_ModificationsOfPerformanceConditionsInShares" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PercentageOfOutstandingPreferredStockShares" xlink:type="locator" xlink:label="urgn_PercentageOfOutstandingPreferredStockShares" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NetProceedsRequiredForConversion" xlink:type="locator" xlink:label="urgn_NetProceedsRequiredForConversion" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PreMoneyValuation" xlink:type="locator" xlink:label="urgn_PreMoneyValuation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <loc xlink:href="urgn-20171231.xsd#urgn_InitialPublicOfferingCost" xlink:type="locator" xlink:label="urgn_InitialPublicOfferingCost" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PreferredSharesIntoOrdinarySharesConversionRatio" xlink:type="locator" xlink:label="urgn_PreferredSharesIntoOrdinarySharesConversionRatio" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" xlink:type="locator" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="urgn-20171231.xsd#urgn_PreferredStockIssuedPricePerShare" xlink:type="locator" xlink:label="urgn_PreferredStockIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndServiceProvidersMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_TwoThousandSeventeenEquityIncentivePlanMember" xlink:type="locator" xlink:label="urgn_TwoThousandSeventeenEquityIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="urgn_SecondaryPublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SeriesAOnePreferredStockMember" xlink:type="locator" xlink:label="urgn_SeriesAOnePreferredStockMember" />
    <loc xlink:href="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd#exch_XNCM" xlink:type="locator" xlink:label="exch_XNCM" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:type="locator" xlink:label="dei_EntityListingsExchangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_TelormedixSAMember" xlink:type="locator" xlink:label="urgn_TelormedixSAMember" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="urgn_TelormedixSAMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_EntityListingsExchangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_ExchangeDomain" xlink:to="exch_XNCM" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAOnePreferredStockMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="urgn_SeriesAOnePreferredStockMember_li0l2" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_RangeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_SecondaryPublicOfferingMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="urgn_TwoThousandSeventeenEquityIncentivePlanMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndServiceProvidersMember" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PreferredStockIssuedPricePerShare" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PreferredSharesIntoOrdinarySharesConversionRatio" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_InitialPublicOfferingCost" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PreMoneyValuation" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_NetProceedsRequiredForConversion" order="12700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_PercentageOfOutstandingPreferredStockShares" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="13040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_ModificationsOfPerformanceConditionsInShares" order="13130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="13320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="13840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndOtherServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndOtherServiceProvidersMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ConsultantsAndOtherServiceProvidersMember" xlink:type="locator" xlink:label="urgn_ConsultantsAndOtherServiceProvidersMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_EmployeesAndDirectorsMember" xlink:type="locator" xlink:label="urgn_EmployeesAndDirectorsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:type="locator" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_EmployeesAndDirectorsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="urgn_ConsultantsAndOtherServiceProvidersMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeFourMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeFourMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeThreeMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeThreeMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeTwoMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeTwoMember" />
    <loc xlink:href="urgn-20171231.xsd#urgn_ExercisePricePerShareRangeOneMember" xlink:type="locator" xlink:label="urgn_ExercisePricePerShareRangeOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeTwoMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeThreeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="urgn_ExercisePricePerShareRangeFourMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureTaxesOnIncomeAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_FederalAndStateNetOperatingLossesExpirationYear" xlink:type="locator" xlink:label="urgn_FederalAndStateNetOperatingLossesExpirationYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IncomeTaxLineItems" xlink:type="locator" xlink:label="urgn_IncomeTaxLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:type="locator" xlink:label="us-gaap_ScenarioForecastMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_IncomeTaxTable" xlink:type="locator" xlink:label="urgn_IncomeTaxTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="urgn_IncomeTaxTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxTable" xlink:to="us-gaap_StatementScenarioAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxTable" xlink:to="urgn_IncomeTaxLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="urgn_IncomeTaxLineItems" xlink:to="urgn_FederalAndStateNetOperatingLossesExpirationYear" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <loc xlink:href="urgn-20171231.xsd#urgn_DeferredTaxAssetsIssuanceCosts" xlink:type="locator" xlink:label="urgn_DeferredTaxAssetsIssuanceCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="urgn_DeferredTaxAssetsIssuanceCosts" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfChangeInValuationAllowanceDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureTaxesOnIncomeScheduleOfChangeInValuationAllowanceDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfChangeInValuationAllowanceDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureLossPerOrdinaryShareAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareAdditionalInformationDetails">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseCommencementDate" xlink:type="locator" xlink:label="urgn_LeaseCommencementDate" />
    <loc xlink:href="urgn-20171231.xsd#urgn_LeaseAgreementDate" xlink:type="locator" xlink:label="urgn_LeaseAgreementDate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiariesMember" xlink:type="locator" xlink:label="us-gaap_SubsidiariesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="us-gaap_ConsolidatedEntitiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ConsolidatedEntitiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidatedEntitiesAxis" xlink:to="us-gaap_ConsolidatedEntitiesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConsolidatedEntitiesDomain" xlink:to="us-gaap_SubsidiariesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="urgn_LeaseAgreementDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="urgn_LeaseCommencementDate" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="urgn-20171231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <loc xlink:href="urgn-20171231.xsd#urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" xlink:type="locator" xlink:label="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd#exch_XNCM" xlink:type="locator" xlink:label="exch_XNCM" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_ExchangeDomain" xlink:type="locator" xlink:label="dei_ExchangeDomain" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityListingsExchangeAxis" xlink:type="locator" xlink:label="dei_EntityListingsExchangeAxis" />
    <loc xlink:href="urgn-20171231.xsd#urgn_SecondaryPublicOfferingMember" xlink:type="locator" xlink:label="urgn_SecondaryPublicOfferingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="urgn_SecondaryPublicOfferingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_EntityListingsExchangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsExchangeAxis" xlink:to="dei_ExchangeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_ExchangeDomain" xlink:to="exch_XNCM" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6861946880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">URGN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">UroGen Pharma Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001668243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">13,751,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862602624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 36,999<span></span>
</td>
<td class="nump">$ 21,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">36,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Restricted deposit</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">74,472<span></span>
</td>
<td class="nump">22,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted deposit</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">75,550<span></span>
</td>
<td class="nump">23,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">4,435<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related accrued expenses</a></td>
<td class="nump">1,950<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent', window );">Proceeds from exercise of warrants for preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">7,035<span></span>
</td>
<td class="nump">3,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_WarrantsForPreferredSharesNoncurrent', window );">Warrants for preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">7,035<span></span>
</td>
<td class="nump">6,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, NIS 0.01 par value; 100,000,000 and 17,600,000 shares authorized at December 31, 2017 and 2016, respectively; 13,751,390 and 2,305,743 shares issued and outstanding as of December 31, 2017 and 2016, respectively</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">115,692<span></span>
</td>
<td class="nump">43,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(47,214)<span></span>
</td>
<td class="num">(27,214)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">68,515<span></span>
</td>
<td class="nump">16,307<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 75,550<span></span>
</td>
<td class="nump">23,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember', window );">Series A and A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A and A-1 preferred shares, NIS 0.01 par value: 0 and 14,400,000 shares authorized at December 31, 2017 and 2016, respectively; 0 and 5,193,427 shares issued and outstanding at December 31, 2017 and 2016, respectively</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of warrants for preferred shares current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_WarrantsForPreferredSharesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants for preferred shares noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_WarrantsForPreferredSharesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862666720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">13,751,390<span></span>
</td>
<td class="nump">2,305,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">13,751,390<span></span>
</td>
<td class="nump">2,305,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember', window );">Series A and A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862595920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
<td class="nump">$ 8,158<span></span>
</td>
<td class="nump">$ 17,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">7,558<span></span>
</td>
<td class="nump">17,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ResearchAndDevelopmentExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="nump">18,697<span></span>
</td>
<td class="nump">10,287<span></span>
</td>
<td class="nump">$ 10,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">8,811<span></span>
</td>
<td class="nump">6,417<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING (LOSS) INCOME</a></td>
<td class="num">(19,950)<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="num">(12,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_FinanceIncomeExpenseNet', window );">FINANCE EXPENSES, NET</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(19,981)<span></span>
</td>
<td class="num">(1,941)<span></span>
</td>
<td class="num">(12,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (20,000)<span></span>
</td>
<td class="num">$ (1,941)<span></span>
</td>
<td class="num">$ (12,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">LOSS PER ORDINARY SHARE BASIC AND DILUTED</a></td>
<td class="num">$ (2.14)<span></span>
</td>
<td class="num">$ (1.91)<span></span>
</td>
<td class="num">$ (5.88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE</a></td>
<td class="nump">9,716,790<span></span>
</td>
<td class="nump">2,305,503<span></span>
</td>
<td class="nump">2,300,959<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_FinanceIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance income expense net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_FinanceIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ResearchAndDevelopmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ResearchAndDevelopmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863867776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Preferred A Shares</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th">
<div>Ordinary Shares </div>
<div>IPO</div>
</th>
<th class="th"><div>Preferred Shares</div></th>
<th class="th">
<div>Preferred Shares </div>
<div>Preferred A Shares</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Preferred A Shares</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 3,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,584)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net of issuance costs</a></td>
<td class="nump">21,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,635,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Purchase of IP R&amp;D in consideration, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase of IP R&amp;D in consideration, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,689)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">16,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,273)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,941)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">16,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,305,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,144,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice', window );">Exercise of options into ordinary shares, net of 68,416 shares withheld to pay option price</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice', window );">Exercise of options into ordinary shares, net of 68,416 shares withheld to pay option price, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants into preferred shares</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants into preferred shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_StockIssuedDuringPeriodValuePreferredSharesExercised', window );">Exercise of preferred shares into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised', window );">Exercise of preferred shares into ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,557,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,557,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 68,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47,214)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,751,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares preferred shares exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_StockIssuedDuringPeriodSharesPreferredSharesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised net of shares withheld to pay option price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_StockIssuedDuringPeriodSharesStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_StockIssuedDuringPeriodValuePreferredSharesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value preferred shares exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_StockIssuedDuringPeriodValuePreferredSharesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock options exercised net of shares withheld to pay option price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfSharesWithheldToPayOptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862174336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Shares issuance expense and underwriters discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 579,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay option price</a></td>
<td class="nump">68,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Shares issuance expense and underwriters discounts</a></td>
<td class="nump">$ 6,105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay option price</a></td>
<td class="nump">68,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863430144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,000)<span></span>
</td>
<td class="num">$ (1,941)<span></span>
</td>
<td class="num">$ (12,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In process R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange rates differences</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants for preferred shares</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating asset and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
<td class="nump">83<span></span>
</td>
<td class="num">(83)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="num">(562)<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="num">(737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued expenses</a></td>
<td class="nump">2,534<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase in deferred revenues</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase in employee related accrued expenses</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(9,571)<span></span>
</td>
<td class="nump">4,189<span></span>
</td>
<td class="num">(7,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Short-term investments</a></td>
<td class="num">(36,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Change in restricted deposit</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(271)<span></span>
</td>
<td class="num">(695)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(36,377)<span></span>
</td>
<td class="num">(793)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options into ordinary shares</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants for preferred shares</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred equity offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of ordinary shares, net of issuance expenses</a></td>
<td class="nump">60,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred shares from 2014 Share Purchase Agreement net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Issuance cost for secondary offering</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">61,585<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">21,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">15,637<span></span>
</td>
<td class="nump">3,387<span></span>
</td>
<td class="nump">14,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</a></td>
<td class="nump">21,362<span></span>
</td>
<td class="nump">17,975<span></span>
</td>
<td class="nump">3,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE YEAR</a></td>
<td class="nump">36,999<span></span>
</td>
<td class="nump">21,362<span></span>
</td>
<td class="nump">17,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Purchase of IP R&amp;D in consideration for Preferred A Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NoncashIssuanceCost', window );">Non cash issuance cost</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NoncashExerciseOfWarrantsToPreferredShares', window );">Exercise of warrants to preferred shares</a></td>
<td class="nump">$ 4,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NoncashExerciseOfWarrantsToPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash exercise of warrants to preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NoncashExerciseOfWarrantsToPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NoncashIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NoncashIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6853244864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature Of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>1&#8212;NATURE<font style="letter-spacing:1pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>OPERATIONS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<font style="letter-spacing:0.65pt;"> </font>Pharma<font style="letter-spacing:0.65pt;"> </font>Ltd.<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>company<font style="letter-spacing:0.75pt;"> </font>incorporated<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>April<font style="letter-spacing:0.4pt;"> </font>20<font style="letter-spacing:-0.1pt;">0</font>4<font style="letter-spacing:0.45pt;"> </font>(&#8220;UPL&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UroGen<font style="letter-spacing:0.65pt;"> </font>Pharma<font style="letter-spacing:0.65pt;"> </font>Inc.,<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>subsidiary<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>UPL,<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>incorporated<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>Del<font style="letter-spacing:-0.1pt;">a</font>ware<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>October<font style="letter-spacing:0.65pt;"> </font>2015<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>began<font style="letter-spacing:0.5pt;"> </font>operati<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>February<font style="letter-spacing:0.75pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>(&#8220;UPI&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPL<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>UPI<font style="letter-spacing:0.35pt;"> </font>(together<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>&#8220;Company&#8221;)<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>clinical<font style="letter-spacing:0.55pt;"> </font>stage<font style="letter-spacing:0.45pt;"> </font>bi<font style="letter-spacing:-0.1pt;">o</font>pharmaceutical<font style="letter-spacing:1.45pt;"> </font>company<font style="letter-spacing:0.75pt;"> </font>focused<font style="letter-spacing:0.65pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>oping<font style="letter-spacing:0.85pt;"> </font>novel<font style="letter-spacing:0.45pt;"> </font>therapies<font style="letter-spacing:0.75pt;"> </font>desi<font style="letter-spacing:-0.1pt;">g</font>ned<font style="letter-spacing:0.75pt;"> </font>to change<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>standard<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>care<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>urological<font style="letter-spacing:0.8pt;"> </font>pathologies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2015 the Company entered into an agreement with Allergen Pharmaceuticals International Limited (&#8220;Allergen&#8221;), a wholly owned subsidiary of Allergan plc, pursuant to which the Company undertook to supply its gel product and supporting services to Allergan for consideration of $750, to allow Allergan to conduct certain scientific investigations aimed at testing utility of the Company&#8217;s gel product for the delivery of a certain proprietary product of Allergan. Further, the Company granted Allergan a time limited option to negotiate an exclusive, worldwide right to research, develop, make and have made, use, sell, offer to sell and import the Company&#8217;s product in combination with Allergan&#8217;s product. &#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the agreement from 2015, on October 7, 2016, the Company entered into an exclusive license agreement with Allergan to license worldwide rights to some of its products indicated for use with neurotoxins. As stipulated in the agreement, Allergan paid a non-refundable upfront fee of $17.5 million in accordance with the terms of the license agreement. Allergan shall pay the Company additional milestone payments of up to $207.5 million and tiered royalty payments as a percentage of net sales of the licensed product all as stated in the agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>described<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>Note<font style="letter-spacing:0.4pt;"> </font>8a,<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>April<font style="letter-spacing:0.4pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any&#8217;s<font style="letter-spacing:0.9pt;"> </font>board<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>shareholders<font style="letter-spacing:1.05pt;"> </font>approv<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.75pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>aggregate<font style="letter-spacing:0.8pt;"> </font>3.2-for-1<font style="letter-spacing:0.7pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>split<font style="letter-spacing:0.35pt;"> </font>of the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>ordinary,<font style="letter-spacing:0.7pt;"> </font>Preferred<font style="letter-spacing:0.75pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>Preferred<font style="letter-spacing:0.75pt;"> </font>A-1<font style="letter-spacing:0.3pt;"> </font>shares.<font style="letter-spacing:0.6pt;"> </font>All<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>reflected<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>financial statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>notes<font style="letter-spacing:0.45pt;"> </font>thereto<font style="letter-spacing:0.6pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>adjusted,<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>retroactive<font style="letter-spacing:0.85pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>is,<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>reflect this<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>split.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, the Company raised $60.8 million, net of issuance costs and underwriting discounts, in an Initial Public Offering ("IPO") on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;) (see Note 8a).</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&#8217;s submission of an Investigational New Drug (&#8220;IND&#8221;) application for the Company&#8217;s RTGel in combination with Allergan&#8217;s BOTOX for the treatment of overactive bladder to the U.S. Food and Drug Administration (&#8220;FDA&#8221;). The Company received the milestone payment in August 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market in consideration for approximately $64 million net of issuance costs. Also, see Note 12.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company&#8217;s product candidates may never achieve commercialization and it will continue to incur losses for the foreseeable future. Therefore, in order to fund the Company&#8217;s research and development expenses, general and administrative expenses and capital expenditures until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6707361952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>2&#8212;SIGNIFICANT<font style="letter-spacing:1.4pt;"> </font>ACCOUNTING<font style="letter-spacing:1.2pt;"> </font>POLICIES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Basis<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>presentation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>b<font style="letter-spacing:-0.1pt;">e</font>en<font style="letter-spacing:0.45pt;"> </font>prepared<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>account<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.85pt;"> </font>principles<font style="letter-spacing:0.75pt;"> </font>generally<font style="letter-spacing:0.75pt;"> </font>accept<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>United<font style="letter-spacing:0.55pt;"> </font>States<font style="letter-spacing:0.55pt;"> </font>of America<font style="letter-spacing:0.7pt;"> </font>(&#8220;U.S.<font style="letter-spacing:0.55pt;"> </font>GAAP&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b. Principles of consolidation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The consolidated financial statements include the financial statements of UPL and its wholly owned subsidiary, UPI. Intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c.<font style="letter-spacing:0.2pt;"> </font>Use<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>estimates<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preparation<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>financial<font style="letter-spacing:0.75pt;"> </font>statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>preparation<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>conformity<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>U.S.<font style="letter-spacing:0.4pt;"> </font>GAAP<font style="letter-spacing:0.5pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>man<font style="letter-spacing:-0.1pt;">a</font>gement<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>make<font style="letter-spacing:0.45pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>affect the<font style="letter-spacing:0.05pt;"> </font>reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>assets<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities,<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>disclosure<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cont<font style="letter-spacing:-0.1pt;">i</font>ngent<font style="letter-spacing:0.85pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>financ<font style="letter-spacing:-0.1pt;">i</font>al<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenues<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>duri<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>Actual<font style="letter-spacing:0.5pt;"> </font>results<font style="letter-spacing:0.55pt;"> </font>may<font style="letter-spacing:0.35pt;"> </font>differ<font style="letter-spacing:0.45pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>estimates.<font style="letter-spacing:0.8pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>applicable<font style="letter-spacing:0.9pt;"> </font>to these<font style="letter-spacing:0.45pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financi<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.65pt;"> </font>statements,<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>most<font style="letter-spacing:0.4pt;"> </font>significant<font style="letter-spacing:0.8pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>relate<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>compensat<font style="letter-spacing:-0.1pt;">i</font>on, the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>timing<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>recognition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d.<font style="letter-spacing:0.2pt;"> </font>Functional<font style="letter-spacing:0.9pt;"> </font>currency</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>U.S.<font style="letter-spacing:0.4pt;"> </font>dollar<font style="letter-spacing:0.45pt;"> </font>(&#8220;Dollar&#8221;)<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>primary<font style="letter-spacing:0.6pt;"> </font>economic<font style="letter-spacing:0.8pt;"> </font>environment<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>subsidiary<font style="letter-spacing:0.8pt;"> </font>are conducted.<font style="letter-spacing:0.9pt;"> </font>Therefore,<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>functional<font style="letter-spacing:0.8pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Dol<font style="letter-spacing:-0.1pt;">l</font>ar.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<font style="letter-spacing:1pt;"> </font>transactions<font style="letter-spacing:0.95pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>currencies<font style="letter-spacing:0.85pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Do<font style="letter-spacing:-0.1pt;">l</font>lar<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>functional<font style="letter-spacing:0.8pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>usi<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exchange<font style="letter-spacing:0.8pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>in effect<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>transaction.<font style="letter-spacing:0.95pt;"> </font>At<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>date,<font style="letter-spacing:0.45pt;"> </font>monetary<font style="letter-spacing:0.75pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liab<font style="letter-spacing:-0.1pt;">i</font>lities<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>denominated<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>currencies<font style="letter-spacing:0.85pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>than the<font style="letter-spacing:0.05pt;"> </font>Dollar<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>official<font style="letter-spacing:0.55pt;"> </font>exch<font style="letter-spacing:-0.1pt;">a</font>nge<font style="letter-spacing:0.8pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>effects<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>foreign<font style="letter-spacing:0.55pt;"> </font>currency<font style="letter-spacing:0.8pt;"> </font>re-measurements<font style="letter-spacing:1.45pt;"> </font>are recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>&#8220;fin<font style="letter-spacing:-0.1pt;">a</font>ncial<font style="letter-spacing:0.75pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>(expenses).&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e.<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.45pt;"> </font>equivalents</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equiv<font style="letter-spacing:-0.1pt;">a</font>lents<font style="letter-spacing:0.9pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>short-term,<font style="letter-spacing:0.85pt;"> </font>highly<font style="letter-spacing:0.5pt;"> </font>liquid<font style="letter-spacing:0.45pt;"> </font>investments,<font style="letter-spacing:1pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>incl<font style="letter-spacing:-0.1pt;">u</font>de<font style="letter-spacing:0.6pt;"> </font>short-term<font style="letter-spacing:0.8pt;"> </font>bank<font style="letter-spacing:0.4pt;"> </font>deposits<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>original maturities<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>three<font style="letter-spacing:0.45pt;"> </font>months<font style="letter-spacing:0.6pt;"> </font>or<font style="letter-spacing:0.25pt;"> </font>less<font style="letter-spacing:0.35pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>withdrawal<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>readily<font style="letter-spacing:0.55pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>to known<font style="letter-spacing:0.55pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">f.  Short-term investments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in short-term investments that consist of mutual and bond funds.&nbsp;&nbsp;While these investments are considered highly liquid and available to fund current operations, there is more than an insignificant risk of change in value due to interest rate, quoted price, or penalty on withdrawal and are therefore classified as short-term investments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We classify our short-term investments as available-for-sale in accordance with FASB ASC Topic 320, &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within stockholders&#8217; equity.&nbsp;&nbsp;There was no change in value for the period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">g.<font style="letter-spacing:0.2pt;"> </font>Property<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>stated<font style="letter-spacing:0.5pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>cost,<font style="letter-spacing:0.4pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accumulated<font style="letter-spacing:1pt;"> </font>depreciation.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>d<font style="letter-spacing:-0.1pt;">e</font>preciated<font style="letter-spacing:0.95pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>basis<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">s</font>eful<font style="letter-spacing:0.5pt;"> </font>lives.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual<font style="letter-spacing:0.6pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>depreciation<font style="letter-spacing:1pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15-30</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-15</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold<font style="letter-spacing:0.85pt;"> </font>improvements<font style="letter-spacing:1.1pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>amortized<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>strai<font style="letter-spacing:-0.1pt;">g</font>ht-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>shorter<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>term<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>useful life<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">h.<font style="letter-spacing:0.15pt;"> </font>Impairment<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>long-lived<font style="letter-spacing:0.85pt;"> </font>assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>tests<font style="letter-spacing:0.4pt;"> </font>long-lived<font style="letter-spacing:0.8pt;"> </font>assets,<font style="letter-spacing:0.6pt;"> </font>comprised<font style="letter-spacing:0.85pt;"> </font>solely<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment,<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>whenever<font style="letter-spacing:0.8pt;"> </font>ev<font style="letter-spacing:-0.1pt;">e</font>nts<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>circumstances<font style="letter-spacing:1.15pt;"> </font>present an<font style="letter-spacing:0.25pt;"> </font>indication<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>impairment.<font style="letter-spacing:0.95pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sum<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>undiscounted<font style="letter-spacing:1.05pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>less<font style="letter-spacing:0.35pt;"> </font>th<font style="letter-spacing:-0.1pt;">a</font>n<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>carrying<font style="letter-spacing:0.65pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>such assets, an<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>recognized.<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:-0.1pt;">s</font>ets<font style="letter-spacing:0.55pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>written<font style="letter-spacing:0.55pt;"> </font>down<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>values,<font style="letter-spacing:0.6pt;"> </font>calculated<font style="letter-spacing:0.8pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>ased<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the present<font style="letter-spacing:0.6pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>discounted<font style="letter-spacing:0.85pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>some<font style="letter-spacing:0.45pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>e<font style="letter-spacing:0.45pt;"> </font>measure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017 and<font style="letter-spacing:0.35pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>d<font style="letter-spacing:-0.1pt;">i</font>d<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>long-lived<font style="letter-spacing:0.8pt;"> </font>assets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i.<font style="letter-spacing:0.2pt;"> </font>Financial<font style="letter-spacing:0.8pt;"> </font>instruments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issues<font style="letter-spacing:0.55pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>A<font style="letter-spacing:-0.1pt;">S</font>C<font style="letter-spacing:0.4pt;"> </font>480<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine<font style="letter-spacing:0.8pt;"> </font>whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>should be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liability.<font style="letter-spacing:0.6pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company further<font style="letter-spacing:0.55pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument&#8217;s<font style="letter-spacing:0.95pt;"> </font>characteristics<font style="letter-spacing:1.15pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine<font style="letter-spacing:0.8pt;"> </font>whether<font style="letter-spacing:0.65pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>c<font style="letter-spacing:-0.1pt;">l</font>assified<font style="letter-spacing:0.75pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>temporary<font style="letter-spacing:0.8pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>(mezzanine)<font style="letter-spacing:1pt;"> </font>or within<font style="letter-spacing:0.5pt;"> </font>permanent<font style="letter-spacing:0.85pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ith<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.55pt;"> </font>480-10-S99.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issues<font style="letter-spacing:0.55pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>freestanding<font style="letter-spacing:1pt;"> </font>instruments,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>first<font style="letter-spacing:0.3pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>l<font style="letter-spacing:-0.1pt;">i</font>ability,<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>subsequent<font style="letter-spacing:0.95pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>va<font style="letter-spacing:-0.1pt;">l</font>ue<font style="letter-spacing:0.45pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>earnings<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>ea<font style="letter-spacing:-0.1pt;">c</font>h<font style="letter-spacing:0.4pt;"> </font>period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>further<font style="letter-spacing:0.55pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>815-40<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.3pt;"> </font>determine whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>wit<font style="letter-spacing:-0.1pt;">h</font>in<font style="letter-spacing:0.5pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>rather<font style="letter-spacing:0.5pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>liability,<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>subse<font style="letter-spacing:-0.1pt;">q</font>uent<font style="letter-spacing:0.95pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value recognized<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>earnings<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>ea<font style="letter-spacing:-0.1pt;">c</font>h<font style="letter-spacing:0.4pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>See<font style="letter-spacing:0.35pt;"> </font>note<font style="letter-spacing:0.4pt;"> </font>7<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>note<font style="letter-spacing:0.4pt;"> </font>8.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j.<font style="letter-spacing:0.15pt;"> </font>Share-based<font style="letter-spacing:1.05pt;"> </font>compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>employees&#8217;<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors&#8217;<font style="letter-spacing:0.75pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>payment<font style="letter-spacing:0.7pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>classif<font style="letter-spacing:-0.1pt;">i</font>ed<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant-date<font style="letter-spacing:0.8pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value method.<font style="letter-spacing:0.65pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>payment<font style="letter-spacing:0.7pt;"> </font>transactions<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recogni<font style="letter-spacing:-0.1pt;">z</font>ed<font style="letter-spacing:0.9pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>expense<font style="letter-spacing:0.7pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requisite<font style="letter-spacing:0.7pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>of December<font style="letter-spacing:0.65pt;"> </font>31,<font style="letter-spacing:0.1pt;"> </font>2016,<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>Company<font style="letter-spacing:0.6pt;"> </font>has<font style="letter-spacing:0.15pt;"> </font>early<font style="letter-spacing:0.25pt;"> </font>ad<font style="letter-spacing:-0.1pt;">o</font>pted<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>policy<font style="letter-spacing:0.3pt;"> </font>to account<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>forfeitures<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.2pt;"> </font>occur<font style="letter-spacing:0.25pt;"> </font>according<font style="letter-spacing:0.6pt;"> </font>to the<font style="letter-spacing:0.1pt;"> </font>FASB&#8217;s<font style="letter-spacing:0.4pt;"> </font>Accounting Standards<font style="letter-spacing:0.65pt;"> </font>Update<font style="letter-spacing:0.5pt;"> </font>(ASU)<font style="letter-spacing:0.3pt;"> </font>2016-09,<font style="letter-spacing:0.65pt;"> </font>Improvements<font style="letter-spacing:0.95pt;"> </font>to Employee<font style="letter-spacing:0.65pt;"> </font>Share-Based<font style="letter-spacing:0.85pt;"> </font>Payment<font style="letter-spacing:0.55pt;"> </font>Accounting.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:-0.1pt;">d</font>justment<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>beginning<font style="letter-spacing:0.6pt;"> </font>of the period<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>material<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>reflected<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>conso<font style="letter-spacing:-0.1pt;">l</font>idated<font style="letter-spacing:1pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>shareholders&#8217;<font style="letter-spacing:1.05pt;"> </font>e<font style="letter-spacing:-0.1pt;">q</font>uity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>elected<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>compen<font style="letter-spacing:-0.1pt;">s</font>ation<font style="letter-spacing:1.1pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>conditioned<font style="letter-spacing:0.9pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>conti<font style="letter-spacing:-0.1pt;">n</font>ued<font style="letter-spacing:0.8pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>graded<font style="letter-spacing:0.6pt;"> </font>vesting<font style="letter-spacing:0.6pt;"> </font>schedule<font style="letter-spacing:0.05pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sin<font style="letter-spacing:-0.1pt;">g</font>le-option<font style="letter-spacing:1pt;"> </font>award<font style="letter-spacing:0.5pt;"> </font>approach.<font style="letter-spacing:0.8pt;"> </font>Performance<font style="letter-spacing:1pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>wards<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>expensed<font style="letter-spacing:0.05pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requisite<font style="letter-spacing:0.7pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>hen<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>achievement<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>criteria<font style="letter-spacing:0.55pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>probable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>non-employees<font style="letter-spacing:1.3pt;"> </font>are<font style="letter-spacing:0.35pt;"> </font>re-measured<font style="letter-spacing:1.1pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>commitment<font style="letter-spacing:0.95pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>reached which<font style="letter-spacing:0.5pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>usually<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>completed.<font style="letter-spacing:0.9pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>va<font style="letter-spacing:-0.1pt;">l</font>ue<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>charged<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>service period<font style="letter-spacing:0.5pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">k.<font style="letter-spacing:0.15pt;"> </font>Revenue<font style="letter-spacing:0.75pt;"> </font>recognition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Virtually<font style="letter-spacing:0.65pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>revenues<font style="letter-spacing:0.75pt;"> </font>are<font style="letter-spacing:0.25pt;"> </font>derived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>Allergan,<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>lic<font style="letter-spacing:-0.1pt;">e</font>nse<font style="letter-spacing:0.6pt;"> </font>worldwide<font style="letter-spacing:0.8pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>some<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>products. See also Note 1. Revenue<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>hen<font style="letter-spacing:0.45pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>conditi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.8pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>met:<font style="letter-spacing:0.4pt;"> </font>(i)<font style="letter-spacing:0.2pt;"> </font>there<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>persuasive<font style="letter-spacing:0.85pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>arrangement; (ii)<font style="letter-spacing:0.25pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>occurred:<font style="letter-spacing:0.75pt;"> </font>(iii)<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable:<font style="letter-spacing:1.1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(iv)<font style="letter-spacing:0.3pt;"> </font>collectab<font style="letter-spacing:-0.1pt;">i</font>lity<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonably<font style="letter-spacing:0.9pt;"> </font>assured.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:1pt;"> </font>contains<font style="letter-spacing:0.7pt;"> </font>two<font style="letter-spacing:0.3pt;"> </font>deliverables:<font style="letter-spacing:1pt;"> </font>(a)<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>comp<font style="letter-spacing:-0.1pt;">o</font>nent<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(b)<font style="letter-spacing:0.25pt;"> </font>Allergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>require<font style="letter-spacing:0.6pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>RTGel<font style="letter-spacing:0.55pt;"> </font>vi<font style="letter-spacing:-0.1pt;">a</font>ls from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.3pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>multiple<font style="letter-spacing:0.65pt;"> </font>deliverab<font style="letter-spacing:-0.1pt;">l</font>es,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>shall<font style="letter-spacing:0.4pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>u<font style="letter-spacing:-0.1pt;">n</font>it<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the following<font style="letter-spacing:0.7pt;"> </font>criteria<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>met:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="letter-spacing:0.25pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>customer<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>is.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>sold<font style="letter-spacing:0.05pt;"> </font>separately<font style="letter-spacing:0.85pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>vendor<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>customer<font style="letter-spacing:0.75pt;"> </font>could<font style="letter-spacing:0.45pt;"> </font>resell<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s)<font style="letter-spacing:0.55pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standal<font style="letter-spacing:-0.1pt;">o</font>ne<font style="letter-spacing:0.9pt;"> </font>basis.<font style="letter-spacing:0.5pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>context<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>customer&#8217;s<font style="letter-spacing:0.85pt;"> </font>ability<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>resell<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s),<font style="letter-spacing:0.6pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>criterion<font style="letter-spacing:0.65pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>require<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>existence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>ob<font style="letter-spacing:-0.1pt;">s</font>ervable<font style="letter-spacing:0.9pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>deliverable(s),<font style="letter-spacing:1.1pt;"> </font>and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="letter-spacing:0.25pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>includes<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>general<font style="letter-spacing:0.6pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>return<font style="letter-spacing:0.5pt;"> </font>relative<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s),<font style="letter-spacing:0.6pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>unde<font style="letter-spacing:-0.1pt;">l</font>ivered<font style="letter-spacing:1.1pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or items<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>probable<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>subst<font style="letter-spacing:-0.1pt;">a</font>ntially<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>control<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>vendor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>deliverables<font style="letter-spacing:0.95pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>separab<font style="letter-spacing:-0.1pt;">l</font>e,<font style="letter-spacing:0.85pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>allocated<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>units<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>relati<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.6pt;"> </font>selling<font style="letter-spacing:0.55pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>deliverable<font style="letter-spacing:0.85pt;"> </font>(where<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>locable<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>element<font style="letter-spacing:0.65pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>limited<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amo<font style="letter-spacing:-0.1pt;">u</font>nt<font style="letter-spacing:0.6pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>contingent<font style="letter-spacing:0.85pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>future products<font style="letter-spacing:0.7pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>services)<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>appropriate<font style="letter-spacing:0.9pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>recognition<font style="letter-spacing:0.9pt;"> </font>princip<font style="letter-spacing:-0.1pt;">l</font>es<font style="letter-spacing:0.75pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>applied<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>unit. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>component<font style="letter-spacing:0.9pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>standa<font style="letter-spacing:-0.1pt;">l</font>one<font style="letter-spacing:0.9pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>(and<font style="letter-spacing:0.4pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>accounted<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>separately<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services)<font style="letter-spacing:0.75pt;"> </font>since<font style="letter-spacing:0.5pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>can<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>the license<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intended<font style="letter-spacing:0.7pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>without<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any&#8217;s<font style="letter-spacing:0.9pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services.<font style="letter-spacing:0.7pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>four<font style="letter-spacing:0.35pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>605<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ere<font style="letter-spacing:0.4pt;"> </font>met<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> 2017 and </font>2016: (1)<font style="letter-spacing:0.25pt;"> </font>persuasive<font style="letter-spacing:0.85pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>exists<font style="letter-spacing:0.5pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.45pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>engaged<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>inding<font style="letter-spacing:0.6pt;"> </font>agreement;<font style="letter-spacing:0.9pt;"> </font>(2)<font style="letter-spacing:0.25pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>has occurred<font style="letter-spacing:0.7pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>rendered<font style="letter-spacing:0.75pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>l<font style="letter-spacing:0.2pt;"> </font>documents<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>request<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.8pt;"> </font>relating<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>know-how<font style="letter-spacing:0.8pt;"> </font>were provided<font style="letter-spacing:0.7pt;"> </font>before<font style="letter-spacing:0.55pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.3pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>can<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intend<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.7pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>without<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>(except<font style="letter-spacing:0.6pt;"> </font>for immaterial<font style="letter-spacing:0.85pt;"> </font>support<font style="letter-spacing:0.6pt;"> </font>services);<font style="letter-spacing:0.8pt;"> </font>(3)<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable,<font style="letter-spacing:1.1pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>indicated<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>licen<font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:0.6pt;"> </font>agreement;<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(4)<font style="letter-spacing:0.25pt;"> </font>collectability<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonably assured.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>milestone<font style="letter-spacing:0.8pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>royalties<font style="letter-spacing:0.7pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>Allergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>reve<font style="letter-spacing:-0.1pt;">n</font>ue<font style="letter-spacing:0.65pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>product,<font style="letter-spacing:0.65pt;"> </font>which are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable<font style="letter-spacing:1.05pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>th<font style="letter-spacing:-0.1pt;">e</font>ir<font style="letter-spacing:0.4pt;"> </font>occurrence.<font style="letter-spacing:0.95pt;"> </font>Therefore,<font style="letter-spacing:0.85pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>recogniz<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.9pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>for payment<font style="letter-spacing:0.7pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>met,<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>become<font style="letter-spacing:0.65pt;"> </font>due<font style="letter-spacing:0.35pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>payable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During October<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>n<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$17.5<font style="letter-spacing:0.45pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>represented<font style="letter-spacing:0.85pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>consi<font style="letter-spacing:-0.1pt;">d</font>eration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>both the<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intellectual<font style="letter-spacing:0.85pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>well<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font><font style="letter-spacing:-0.1pt;">A</font>llergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>(which<font style="letter-spacing:0.55pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>e<font style="letter-spacing:0.25pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>future payments<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>according<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>pricing<font style="letter-spacing:0.55pt;"> </font>stipulat<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>agreement).<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.85pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>pricing<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the supply<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>represents<font style="letter-spacing:0.85pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>se<font style="letter-spacing:-0.1pt;">l</font>ling<font style="letter-spacing:0.55pt;"> </font>price.<font style="letter-spacing:0.45pt;"> </font>Accordingly,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>allo<font style="letter-spacing:-0.1pt;">c</font>ated<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>entire<font style="letter-spacing:0.45pt;"> </font>upfront<font style="letter-spacing:0.6pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>of $17.5<font style="letter-spacing:0.45pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the license<font style="letter-spacing:0.6pt;"> </font>component.<font style="letter-spacing:0.95pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>addition,<font style="letter-spacing:0.7pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>servi<font style="letter-spacing:-0.1pt;">c</font>es<font style="letter-spacing:0.65pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.3pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>equal<font style="letter-spacing:0.45pt;"> to </font>the<font style="letter-spacing:0.3pt;"> </font>consi<font style="letter-spacing:-0.1pt;">d</font>eration<font style="letter-spacing:1.05pt;"> </font>stipulated<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the agreement<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>services,<font style="letter-spacing:0.7pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>provided.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&#8217;s submission of an IND application for the Company&#8217;s RTGel in combination with Allergan&#8217;s BOTOX for the treatment of overactive bladder to the U.S. FDA. The Company received the milestone payment in August 2017. This milestone was recognized as revenue during the year ended December 31, 2017, as conditions for payment were met and the milestone payment was considered fixed or determinable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">l.<font style="letter-spacing:0.2pt;"> </font>Research<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1.1pt;"> </font>costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>expen<font style="letter-spacing:-0.1pt;">s</font>ed<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>incurred<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>consist<font style="letter-spacing:0.6pt;"> </font>primarily<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>cost<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>salaries,<font style="letter-spacing:0.7pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>compensat<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:1.1pt;"> </font>expenses,<font style="letter-spacing:0.05pt;"> </font>payroll<font style="letter-spacing:0.55pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>employee<font style="letter-spacing:0.8pt;"> </font>benefits,<font style="letter-spacing:0.7pt;"> </font>subcontractors<font style="letter-spacing:1.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>materials<font style="letter-spacing:0.75pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>evelopment<font style="letter-spacing:1pt;"> </font>activities, including preclinical studies, clinical trials, manufacturing costs<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>professional<font style="letter-spacing:0.05pt;"> </font>services. The<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>performed<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>others<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>connection<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>nd<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>activities of an<font style="letter-spacing:0.05pt;"> </font>entity,<font style="letter-spacing:0.3pt;"> </font>including<font style="letter-spacing:0.55pt;"> </font>research<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.15pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment<font style="letter-spacing:0.85pt;"> </font>conducted<font style="letter-spacing:0.65pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>others<font style="letter-spacing:0.35pt;"> </font>on behalf<font style="letter-spacing:0.35pt;"> </font>of the<font style="letter-spacing:0.1pt;"> </font>entity,<font style="letter-spacing:0.3pt;"> </font>shall<font style="letter-spacing:0.2pt;"> </font>be<font style="letter-spacing:0.05pt;"> </font>inc<font style="letter-spacing:-0.1pt;">l</font>uded<font style="letter-spacing:0.5pt;"> </font>in research<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.25pt;"> </font>development costs.<font style="letter-spacing:0.5pt;"> </font>Grants<font style="letter-spacing:0.55pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israel<font style="letter-spacing:0.45pt;"> </font>Innovation<font style="letter-spacing:0.85pt;"> </font>Authority,<font style="letter-spacing:0.75pt;"> </font>f/k/a<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Office<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Chief<font style="letter-spacing:0.45pt;"> </font>Scientist<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel&#8217;s<font style="letter-spacing:0.6pt;"> </font>Ministry<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.25pt;"> </font>Industry,<font style="letter-spacing:0.7pt;"> </font>Trade<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>Labor<font style="letter-spacing:0.5pt;"> </font>(the<font style="letter-spacing:0.35pt;"> </font>&#8220;IIA&#8221;)<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>becomes<font style="letter-spacing:0.75pt;"> </font>receiva<font style="letter-spacing:-0.1pt;">b</font>le,<font style="letter-spacing:0.85pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>there<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonable<font style="letter-spacing:0.9pt;"> </font>assurance<font style="letter-spacing:0.85pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>comply<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>attached<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>there<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reaso<font style="letter-spacing:-0.1pt;">n</font>able<font style="letter-spacing:0.9pt;"> </font>assurance<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>received.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>deducted<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:1pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>pplicable<font style="letter-spacing:0.8pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>incurred.<font style="letter-spacing:0.7pt;"> </font>In<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.4pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.75pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>n<font style="letter-spacing:0.25pt;"> </font>increase<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$175<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:1pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>decis<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.65pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pursue<font style="letter-spacing:0.55pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>programs<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>approved<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>financing<font style="letter-spacing:0.75pt;"> </font>opportunities.<font style="letter-spacing:1.05pt;"> </font>For<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">D</font>ecember<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$126<font style="font-size:12pt;">&#160;</font>was received from Allergan, in connection with the pre-clinical collaboration agreement signed in August 2015 and deducted from the research and development expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>intangibles<font style="letter-spacing:0.85pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>purchased<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>others<font style="letter-spacing:0.5pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>particular<font style="letter-spacing:0.75pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment<font style="letter-spacing:1pt;"> </font>project<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>alternative<font style="letter-spacing:0.85pt;"> </font>future uses<font style="letter-spacing:0.4pt;"> </font>(in<font style="letter-spacing:0.25pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>research<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>projects<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>otherwise)<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>s<font style="letter-spacing:-0.1pt;">e</font>parate<font style="letter-spacing:0.7pt;"> </font>economic<font style="letter-spacing:0.8pt;"> </font>values<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment costs<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>time<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>incurred. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">m.<font style="letter-spacing:0.15pt;"> </font>Income tax</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">1)<font style="letter-spacing:0.2pt;"> </font>Deferred<font style="letter-spacing:0.7pt;"> </font>taxes</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred<font style="letter-spacing:0.6pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabi<font style="letter-spacing:-0.1pt;">l</font>ity<font style="letter-spacing:0.65pt;"> </font>method.<font style="letter-spacing:0.65pt;"> </font>Under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>method,<font style="letter-spacing:0.65pt;"> </font>deferred<font style="letter-spacing:0.7pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and liabilities<font style="letter-spacing:0.7pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>bas<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>differences<font style="letter-spacing:0.9pt;"> </font>between<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>reporti<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>tax bases<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>mea<font style="letter-spacing:-0.1pt;">s</font>ured<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>enacted<font style="letter-spacing:0.65pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>laws.<font style="letter-spacing:0.45pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>llowance<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the extent<font style="letter-spacing:0.5pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>deferred<font style="letter-spacing:0.7pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>realized<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>foresee<font style="letter-spacing:-0.1pt;">a</font>ble<font style="letter-spacing:0.95pt;"> </font>future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2)<font style="letter-spacing:0.2pt;"> </font>Uncertain<font style="letter-spacing:0.8pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>positions</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>follows<font style="letter-spacing:0.55pt;"> </font>a<font style="letter-spacing:0.3pt;"> </font>two-step<font style="letter-spacing:0.8pt;"> </font>approach<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>recognizing<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>measuring<font style="letter-spacing:0.85pt;"> </font>uncertain<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>positions.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>first<font style="letter-spacing:0.3pt;"> </font>step<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>evaluate<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>position for<font style="letter-spacing:0.25pt;"> </font>recognition<font style="letter-spacing:0.9pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>determining<font style="letter-spacing:0.95pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>availab<font style="letter-spacing:-0.1pt;">l</font>e<font style="letter-spacing:0.7pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>indicates<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>position<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ill<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>sustained<font style="letter-spacing:0.8pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on technical<font style="letter-spacing:0.7pt;"> </font>merits.<font style="letter-spacing:0.55pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>threshold<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>met,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>second<font style="letter-spacing:0.6pt;"> </font>step<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>measure<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>benefit<font style="letter-spacing:0.55pt;"> </font>as<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>largest<font style="letter-spacing:0.55pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>of being<font style="letter-spacing:0.45pt;"> </font>realized<font style="letter-spacing:0.65pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>ultim<font style="letter-spacing:0.1pt;">a</font>te<font style="letter-spacing:0.65pt;"> </font>settlement. As of December 31, 2017 and 2016, the Company had not accrued a provision for uncertain tax positions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">n.<font style="letter-spacing:0.25pt;"> </font>Loss<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic<font style="letter-spacing:0.45pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>(&#8220;LPS&#8221;)<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>dividing<font style="letter-spacing:0.65pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year,<font style="letter-spacing:0.45pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>reducing<font style="letter-spacing:0.7pt;"> </font>cumulati<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.85pt;"> </font>dividends<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;">, </font>by<font style="letter-spacing:0.25pt;"> </font>the weighted<font style="letter-spacing:0.75pt;"> </font>average<font style="letter-spacing:0.75pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>peri<font style="letter-spacing:-0.1pt;">o</font>d.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>calculation<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>ex<font style="letter-spacing:-0.1pt;">c</font>ludes<font style="letter-spacing:0.7pt;"> </font>potential<font style="letter-spacing:0.7pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>issuances<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordi<font style="letter-spacing:-0.1pt;">n</font>ary<font style="letter-spacing:0.8pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>options, warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>anti-dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o.<font style="letter-spacing:0.2pt;"> </font>Fair<font style="letter-spacing:0.45pt;"> </font>value<font style="letter-spacing:0.5pt;"> </font>measurement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair<font style="letter-spacing:0.35pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>rec<font style="letter-spacing:-0.1pt;">e</font>ived<font style="letter-spacing:0.7pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sale<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>paid<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>transfer<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.3pt;"> </font>orderly transaction<font style="letter-spacing:0.9pt;"> </font>between<font style="letter-spacing:0.7pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>participants<font style="letter-spacing:0.9pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>measurement<font style="letter-spacing:1.1pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>increase<font style="letter-spacing:0.7pt;"> </font>consistency<font style="letter-spacing:0.95pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>comparability<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value measurements,<font style="letter-spacing:1.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>guidance<font style="letter-spacing:0.75pt;"> </font>establishes<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>e<font style="letter-spacing:0.45pt;"> </font>hierarchy<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>prioritizes<font style="letter-spacing:0.8pt;"> </font>observable<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>unob<font style="letter-spacing:-0.1pt;">s</font>ervable<font style="letter-spacing:1.2pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>measure<font style="letter-spacing:0.7pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value into<font style="letter-spacing:0.3pt;"> </font>three<font style="letter-spacing:0.45pt;"> </font>broad<font style="letter-spacing:0.5pt;"> </font>levels,<font style="letter-spacing:0.55pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>described<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>fo<font style="letter-spacing:-0.1pt;">l</font>lows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>1:<font style="letter-spacing:0.2pt;"> </font>Quoted<font style="letter-spacing:0.6pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>(unadjusted)<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>active<font style="letter-spacing:0.5pt;"> </font>markets<font style="letter-spacing:0.65pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>accessible<font style="letter-spacing:0.85pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>measurement<font style="letter-spacing:1.1pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>liabilities.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value hierarchy<font style="letter-spacing:0.75pt;"> </font>gives<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>highest<font style="letter-spacing:0.6pt;"> </font>priority<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Level<font style="letter-spacing:0.45pt;"> </font>1<font style="letter-spacing:0.15pt;"> </font>inputs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>2:<font style="letter-spacing:0.2pt;"> </font>Observable<font style="letter-spacing:1.05pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>quoted<font style="letter-spacing:0.55pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>active<font style="letter-spacing:0.5pt;"> </font>markets but<font style="letter-spacing:0.3pt;"> </font>corroborated<font style="letter-spacing:1pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>3:<font style="letter-spacing:0.2pt;"> </font>Unobservable<font style="letter-spacing:1.1pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>us<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.4pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>little<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>market<font style="letter-spacing:0.65pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>available.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>hierarchy<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">g</font>ives<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>lowest<font style="letter-spacing:0.55pt;"> </font>priority<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Level<font style="letter-spacing:0.45pt;"> </font>3 inputs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>determining<font style="letter-spacing:0.95pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>utilizes<font style="letter-spacing:0.55pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>ation<font style="letter-spacing:0.75pt;"> </font>techniques<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>maximize<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>observable<font style="letter-spacing:0.9pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>minimize<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>of unobservable<font style="letter-spacing:1.05pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>extent<font style="letter-spacing:0.5pt;"> </font>possib<font style="letter-spacing:-0.1pt;">l</font>e<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>counterparty<font style="letter-spacing:1pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>assessment<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">p.<font style="letter-spacing:0.2pt;"> </font>Concentration<font style="letter-spacing:1.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit<font style="letter-spacing:0.5pt;"> </font>risks</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial<font style="letter-spacing:0.75pt;"> </font>instruments<font style="letter-spacing:0.95pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>potentially<font style="letter-spacing:0.8pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>concentrati<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>consist<font style="letter-spacing:0.6pt;"> </font>principally<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equiva<font style="letter-spacing:-0.1pt;">l</font>ents and short-term investments.<font style="letter-spacing:0.95pt;"> </font>The Company<font style="letter-spacing:0.8pt;"> </font>deposits<font style="letter-spacing:0.7pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>eq<font style="letter-spacing:-0.1pt;">u</font>ivalents<font style="letter-spacing:0.9pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>highly<font style="letter-spacing:0.5pt;"> </font>rated<font style="letter-spacing:0.45pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nstitutions,<font style="letter-spacing:0.9pt;"> </font>and,<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>matter<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>policy,<font style="letter-spacing:0.55pt;"> </font>limits<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amounts<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit exposure<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>single<font style="letter-spacing:0.5pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nstitution.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>experienced<font style="letter-spacing:1pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>cre<font style="letter-spacing:-0.1pt;">d</font>it<font style="letter-spacing:0.45pt;"> </font>losses<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>belie<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.6pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is exposed<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>significant<font style="letter-spacing:0.8pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>instruments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">q.<font style="letter-spacing:0.2pt;"> </font>Segment<font style="letter-spacing:0.75pt;"> </font>reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating<font style="letter-spacing:0.8pt;"> </font>segments<font style="letter-spacing:0.8pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>reported<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>manner<font style="letter-spacing:0.65pt;"> </font>consistent<font style="letter-spacing:0.8pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>internal<font style="letter-spacing:0.6pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>ch<font style="letter-spacing:-0.1pt;">i</font>ef<font style="letter-spacing:0.4pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>decision-maker,<font style="letter-spacing:1.25pt;"> </font>who<font style="letter-spacing:0.35pt;"> </font>is responsible<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>allocating<font style="letter-spacing:0.75pt;"> </font>resources<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>assessing<font style="letter-spacing:0.8pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>segments.<font style="letter-spacing:0.85pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>o<font style="letter-spacing:-0.1pt;">p</font>erates<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>operating segment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r.<font style="letter-spacing:0.2pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>Costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>SEC<font style="letter-spacing:0.4pt;"> </font>Staff<font style="letter-spacing:0.4pt;"> </font>Accounting<font style="letter-spacing:0.9pt;"> </font>Bulletin<font style="letter-spacing:0.6pt;"> </font>Topic<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">5</font>A.<font style="letter-spacing:0.3pt;"> Costs directly attributable to a proposed or actual offering of securities are deferred and recorded against the gross proceeds of the offering upon completion. </font>During<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.4pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016, the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>$1.7<font style="letter-spacing:0.4pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>g<font style="letter-spacing:-0.1pt;">e</font>neral<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>administrative<font style="letter-spacing:1.1pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">s.<font style="letter-spacing:0.15pt;"> </font>Newly<font style="letter-spacing:0.55pt;"> </font>issued<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>recently<font style="letter-spacing:0.7pt;"> </font>adopted<font style="letter-spacing:0.7pt;"> </font>accounting<font style="letter-spacing:0.95pt;"> </font>pronouncements</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>August<font style="letter-spacing:0.6pt;"> </font>2014,<font style="letter-spacing:0.45pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> Accounting Standards Update (&#8220;</font>ASU&#8221;)<font style="letter-spacing:0.35pt;"> No. </font>2014-15&#8212;Presentation<font style="letter-spacing:1.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Financial<font style="letter-spacing:0.75pt;"> </font>Statements&#8212;Going<font style="letter-spacing:1.55pt;"> </font>Concern<font style="letter-spacing:0.7pt;"> </font>(ASC<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">S</font>ubtopic<font style="letter-spacing:0.75pt;"> </font>205-40):<font style="letter-spacing:0.8pt;"> </font>&#8220;Disclosure of<font style="letter-spacing:0.2pt;"> </font>Uncertainties<font style="letter-spacing:1.05pt;"> </font>about<font style="letter-spacing:0.45pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>Entity&#8217;s<font style="letter-spacing:0.6pt;"> </font>Ability<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Conti<font style="letter-spacing:-0.1pt;">n</font>ue<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>Going<font style="letter-spacing:0.5pt;"> </font>Concern&#8221;.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>update<font style="letter-spacing:0.55pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>managem<font style="letter-spacing:-0.1pt;">e</font>nt<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>assess<font style="letter-spacing:0.6pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>company&#8217;s ability<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>continue<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>going<font style="letter-spacing:0.45pt;"> </font>concern<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>nd<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>provide<font style="letter-spacing:0.6pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>footnote<font style="letter-spacing:0.65pt;"> </font>disclosures<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>certain<font style="letter-spacing:0.55pt;"> </font>circumstances.<font style="letter-spacing:1.2pt;"> </font>All<font style="letter-spacing:0.25pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>new<font style="letter-spacing:0.35pt;"> </font>requirements<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>annu<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.55pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>ending<font style="letter-spacing:0.55pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>per<font style="letter-spacing:-0.1pt;">i</font>ods<font style="letter-spacing:0.6pt;"> </font>thereafter.<font style="letter-spacing:0.8pt;"> </font>The adoption of the guidance did not have a material impact on the Company&#8217;s financial statements.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;, &#8220;ASU 2014-09&#8221;, or &#8220;the New Revenue Standard&#8221;). ASU 2014-09 requires entities to recognize revenue that represents the transfer of promised goods or services to customers in an amount equivalent to the consideration to which the entity expects to be entitled to in exchange for those goods or services. The following steps should be applied to determine this amount: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in ASU 605, &#8220;Revenue Recognition,&#8221; and most industry-specific guidance in the Accounting Standards Codification. The New Revenue Standard is effective for the Company for annual reporting periods, including interim periods therein, beginning January 1, 2018. The New Revenue Standard may be applied retrospectively with the cumulative effect recognized as of the date of adoption (modified retrospective method). The Company will adopt the New Revenue Standard using modified retrospective method. The Company has substantially completed its assessment of the New Revenue Standard and identified two revenue streams (1) licensing revenue and (2) revenue from clinical supply of RTGel per the license agreement with Allergan. The implementation of the New Revenue Standard will not have a material impact on the amount or timing of the Company&#8217;s current revenue recognition related to these revenue streams. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>February<font style="letter-spacing:0.75pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> No. </font>2016-02,<font style="letter-spacing:0.75pt;"> </font>Leases<font style="letter-spacing:0.6pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>842 or &#8220;ASU<font style="letter-spacing:0.5pt;"> </font>2016-02&#8221;).<font style="letter-spacing:0.95pt;"> </font>ASU<font style="letter-spacing:0.4pt;"> </font>2016-02<font style="letter-spacing:0.7pt;"> </font>supersedes<font style="letter-spacing:0.95pt;"> </font>existing<font style="letter-spacing:0.65pt;"> </font>guida<font style="letter-spacing:0.1pt;">n</font>ce<font style="letter-spacing:0.75pt;"> </font>in Leases<font style="letter-spacing:0.6pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>840).<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>revised<font style="letter-spacing:0.6pt;"> </font>standard<font style="letter-spacing:0.7pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>les<font style="letter-spacing:-0.1pt;">s</font>ees<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>ari<font style="letter-spacing:-0.1pt;">s</font>ing<font style="letter-spacing:0.55pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>leases<font style="letter-spacing:0.55pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>terms greater<font style="letter-spacing:0.6pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>twelve<font style="letter-spacing:0.55pt;"> </font>months<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet,<font style="letter-spacing:0.5pt;"> </font>including<font style="letter-spacing:0.7pt;"> </font>tho<font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:0.45pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>leases,<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>disc<font style="letter-spacing:-0.1pt;">l</font>ose<font style="letter-spacing:0.65pt;"> </font>key<font style="letter-spacing:0.3pt;"> </font>information about<font style="letter-spacing:0.45pt;"> </font>leasing<font style="letter-spacing:0.6pt;"> </font>arrangements.<font style="letter-spacing:1.15pt;"> </font>Lessees<font style="letter-spacing:0.7pt;"> </font>w<font style="letter-spacing:-0.1pt;">i</font>ll<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>li<font style="letter-spacing:-0.1pt;">a</font>bility<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.25pt;"> </font>right-of-use<font style="letter-spacing:1.05pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheets,<font style="letter-spacing:0.6pt;"> </font>while lessor<font style="letter-spacing:0.5pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>remain<font style="letter-spacing:0.55pt;"> </font>larg<font style="letter-spacing:-0.1pt;">e</font>ly<font style="letter-spacing:0.55pt;"> </font>unchanged.<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>guidance<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:-0.1pt;">n</font>ual<font style="letter-spacing:0.55pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>beginning<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>Decem<font style="letter-spacing:-0.1pt;">b</font>er<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2018,<font style="letter-spacing:0.45pt;"> </font>with early<font style="letter-spacing:0.4pt;"> </font>adoption<font style="letter-spacing:0.8pt;"> </font>permitted.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>evaluating<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>impact<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>adopt<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASU<font style="letter-spacing:0.5pt;"> </font>2016-02<font style="letter-spacing:0.7pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>consolidated financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>disclosures.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>August<font style="letter-spacing:0.6pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> No. </font>2016-15,<font style="letter-spacing:0.75pt;"> </font>&#8220;Statement<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows:<font style="letter-spacing:0.55pt;"> </font>Classification<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Certain<font style="letter-spacing:0.6pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Rec<font style="letter-spacing:-0.1pt;">e</font>ipts<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Payments,&#8221; which<font style="letter-spacing:0.5pt;"> </font>addresses<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>presentation<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>(or<font style="letter-spacing:0.25pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>generally<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>escribed<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>such)<font style="letter-spacing:0.45pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>230,<font style="letter-spacing:0.4pt;"> </font>Statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows,<font style="letter-spacing:0.55pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intent<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>reduce<font style="letter-spacing:0.55pt;"> </font>diversity<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>practi<font style="letter-spacing:-0.1pt;">c</font>e.<font style="letter-spacing:0.7pt;"> </font>Among<font style="letter-spacing:0.6pt;"> </font>others,<font style="letter-spacing:0.55pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>ASU addresses<font style="letter-spacing:0.95pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flow<font style="letter-spacing:0.35pt;"> </font>treatment<font style="letter-spacing:0.75pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>debt<font style="letter-spacing:0.4pt;"> </font>prepayment<font style="letter-spacing:0.95pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>debt<font style="letter-spacing:0.4pt;"> </font>extinguishment<font style="letter-spacing:1.2pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>proce<font style="letter-spacing:-0.1pt;">e</font>ds<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>settlement<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>insurance claims.<font style="letter-spacing:0.6pt;"> </font>Entities<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>disclose<font style="letter-spacing:0.65pt;"> </font>how<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>reconc<font style="letter-spacing:-0.1pt;">i</font>les<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.25pt;"> </font>shown separately<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>b<font style="letter-spacing:-0.1pt;">a</font>lance<font style="letter-spacing:0.65pt;"> </font>sheet.<font style="letter-spacing:0.5pt;"> </font>Entities<font style="letter-spacing:0.6pt;"> </font>must<font style="letter-spacing:0.4pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>disclose<font style="letter-spacing:0.65pt;"> </font>information<font style="letter-spacing:0.9pt;"> </font>ab<font style="letter-spacing:-0.1pt;">o</font>ut<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>nature<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the restrictions.<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>amendments<font style="letter-spacing:1.05pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>public<font style="letter-spacing:0.5pt;"> </font>business<font style="letter-spacing:0.7pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>beg<font style="letter-spacing:-0.1pt;">i</font>nning<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim periods<font style="letter-spacing:0.6pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years.<font style="letter-spacing:0.5pt;"> </font>Early<font style="letter-spacing:0.45pt;"> </font>adopti<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>permitted.<font style="letter-spacing:0.8pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>retrospective<font style="letter-spacing:1pt;"> </font>basis<font style="letter-spacing:0.45pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>required.<font style="letter-spacing:0.7pt;"> </font>The Company believes the<font style="letter-spacing:0.35pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> of the guidance will be immaterial to its financial statements</font>.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>November<font style="letter-spacing:0.85pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> </font>No.<font style="letter-spacing:0.3pt;"> </font>2016-18,<font style="letter-spacing:0.8pt;"> </font>&#8220;Statement<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows<font style="letter-spacing:0.5pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>230):<font style="letter-spacing:0.45pt;"> </font>Restricted<font style="letter-spacing:0.8pt;"> </font>Cash&#8221;<font style="letter-spacing:0.5pt;"> </font>(&#8220;ASU<font style="letter-spacing:0.5pt;"> </font>2016-18&#8221;).<font style="letter-spacing:0.95pt;"> </font>ASU 2016-18<font style="letter-spacing:0.7pt;"> </font>amends<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>classification<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>presentati<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash flows.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.45pt;"> </font>ASU<font style="letter-spacing:0.4pt;"> </font>2016-18<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>public<font style="letter-spacing:0.5pt;"> </font>business<font style="letter-spacing:0.7pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>begin<font style="letter-spacing:-0.1pt;">n</font>ing<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>periods within<font style="letter-spacing:0.5pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years.<font style="letter-spacing:0.5pt;"> </font>Early<font style="letter-spacing:0.45pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>permitted,<font style="letter-spacing:0.8pt;"> </font>inclu<font style="letter-spacing:-0.1pt;">d</font>ing<font style="letter-spacing:0.7pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>period. The<font style="letter-spacing:0.05pt;"> Company believes</font><font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> of the guidance </font>will be immaterial to its<font style="letter-spacing:0.7pt;"> financial statements</font>.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6853244864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.55pt;"> </font>3&#8212;PROPERTY<font style="letter-spacing:1.25pt;"> </font>AND<font style="letter-spacing:0.4pt;"> </font>EQUIPMENT</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DECEMBER&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Manufacturing equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,111</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less&#8212;Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(370</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation<font style="letter-spacing:1pt;"> </font>expense<font style="letter-spacing:0.7pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>$<font style="letter-spacing:-0.1pt;">207</font><font style="letter-spacing:0.45pt;">, </font>$213 and $113<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;">, </font>2016 and 2015<font style="letter-spacing:0.45pt;"> </font>respectively.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763695360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Rights Upon Retirement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_EmployeeRightsUponRetirementAbstract', window );"><strong>Employee Rights Upon Retirement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_EmployeeRightsUponRetirementTextBlock', window );">Employee Rights Upon Retirement</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>4&#8212;EMPLOYEE<font style="letter-spacing:1.25pt;"> </font>RIGHTS<font style="letter-spacing:0.7pt;"> </font>UPON<font style="letter-spacing:0.55pt;"> </font>RETIREMENT</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>law<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>make<font style="letter-spacing:0.45pt;"> </font>severance<font style="letter-spacing:0.85pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>dismissal<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>employ<font style="letter-spacing:-0.1pt;">e</font>e<font style="letter-spacing:0.8pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>termination<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>employment<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>certain other<font style="letter-spacing:0.45pt;"> </font>circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>operates<font style="letter-spacing:0.7pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>post-employment<font style="letter-spacing:1.35pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>contribution<font style="letter-spacing:0.95pt;"> </font>pl<font style="letter-spacing:-0.1pt;">a</font>ns.<font style="letter-spacing:0.5pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>contribution<font style="letter-spacing:0.95pt;"> </font>plan<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>program<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>benefits<font style="letter-spacing:0.65pt;"> </font>an employee<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>termination<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>employment,<font style="letter-spacing:1pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>re<font style="letter-spacing:-0.1pt;">g</font>ularly<font style="letter-spacing:0.7pt;"> </font>makes<font style="letter-spacing:0.55pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>indepe<font style="letter-spacing:-0.1pt;">n</font>dent<font style="letter-spacing:1pt;"> </font>entity<font style="letter-spacing:0.45pt;"> </font>so<font style="letter-spacing:0.05pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>legal<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>constructive<font style="letter-spacing:0.95pt;"> </font>obl<font style="letter-spacing:-0.1pt;">i</font>gation<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>additional<font style="letter-spacing:0.8pt;"> </font>contributi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:1pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fund<font style="letter-spacing:0.4pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>hold<font style="letter-spacing:0.35pt;"> </font>sufficient<font style="letter-spacing:0.7pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>all employees<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>benefits<font style="letter-spacing:0.65pt;"> </font>relating<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employee<font style="letter-spacing:0.8pt;"> </font>servi<font style="letter-spacing:-0.1pt;">c</font>e<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>current<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>prior<font style="letter-spacing:0.4pt;"> </font>periods.<font style="letter-spacing:0.65pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fund<font style="letter-spacing:0.4pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.4pt;"> </font>included<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s financial<font style="letter-spacing:0.65pt;"> </font>position.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>operates<font style="letter-spacing:0.7pt;"> </font>pension<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>severance<font style="letter-spacing:0.85pt;"> </font>compensation<font style="letter-spacing:1.1pt;"> </font>plans<font style="letter-spacing:0.45pt;"> </font>sub<font style="letter-spacing:-0.1pt;">j</font>ect<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>14<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israeli<font style="letter-spacing:0.6pt;"> </font>Severance<font style="letter-spacing:0.85pt;"> </font>Pay<font style="letter-spacing:0.35pt;"> </font>Law.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>plans<font style="letter-spacing:0.45pt;"> </font>are funded<font style="letter-spacing:0.55pt;"> </font>through<font style="letter-spacing:0.65pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>insurance<font style="letter-spacing:0.8pt;"> </font>compan<font style="letter-spacing:-0.1pt;">i</font>es<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>pension<font style="letter-spacing:0.65pt;"> </font>funds<font style="letter-spacing:0.45pt;"> </font>administered<font style="letter-spacing:1pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>trustees.<font style="letter-spacing:0.7pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>terms,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>plans<font style="letter-spacing:0.45pt;"> </font>meet<font style="letter-spacing:0.45pt;"> </font>the definition<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>contribution<font style="letter-spacing:0.95pt;"> </font><font style="letter-spacing:-0.1pt;">p</font>lan,<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>defined<font style="letter-spacing:0.6pt;"> </font>above.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_EmployeeRightsUponRetirementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_EmployeeRightsUponRetirementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_EmployeeRightsUponRetirementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_EmployeeRightsUponRetirementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6655747568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Proceeds from Exercise of Warrants for Preferred A-1 Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract', window );"><strong>Proceeds From Exercise Of Warrants For Preferred Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock', window );">Proceeds from Exercise of Warrants for Preferred A-1 Shares</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>5&#8212;PROCEEDS<font style="letter-spacing:1.25pt;"> </font>FROM<font style="letter-spacing:0.55pt;"> </font>EXERCISE<font style="letter-spacing:0.9pt;"> </font>OF<font style="letter-spacing:0.3pt;"> </font>WARRANTS<font style="letter-spacing:1.05pt;"> </font>FOR<font style="letter-spacing:0.4pt;"> </font>PRE<font style="letter-spacing:-0.1pt;">F</font>ERRED<font style="letter-spacing:1.1pt;"> A-1 </font>SHARES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s warrants outstanding prior to the IPO were exercisable for Series A-1 preferred shares at an exercise price of $7.81 per share. Prior to the IPO, such warrants were exercisable for 728,312 Preferred A-1 shares. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017 and 2016, the Company notified holders of these warrants that it was ready to accept an exercise notice that was conditioned on the price per share at which the Company&#8217;s shares would be sold in an anticipated IPO. Prior to the IPO, the Company received a total amount of $952 as consideration for the conditional cash exercise of these warrants. The cash received was recorded among current liabilities as proceeds from exercise of warrants for preferred shares. As of December 31, 2017, following the exercise of the warrants, the cash received was re-classified to additional paid in capital. See also Note 8.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Exercise of Warrants for Preferred Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of warrants for preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761582864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>6&#8212;COMMITMENT<font style="letter-spacing:1.5pt;"> </font>AND<font style="letter-spacing:0.4pt;"> </font>CONTINGENCIES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Lease<font style="letter-spacing:0.55pt;"> </font>agreement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>April<font style="letter-spacing:0.4pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>UPL<font style="letter-spacing:0.8pt;"> </font>signed<font style="letter-spacing:0.55pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:-0.1pt;">d</font>dendum<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>November<font style="letter-spacing:0.85pt;"> </font>2014<font style="letter-spacing:0.45pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>increase<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>s<font style="letter-spacing:-0.1pt;">p</font>ace<font style="letter-spacing:0.5pt;"> </font>rented<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to extend<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>rent<font style="letter-spacing:0.35pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:0.15pt;">lease</font><font style="letter-spacing:0.45pt;"> </font>agr<font style="letter-spacing:-0.1pt;">e</font>ement<font style="letter-spacing:0.85pt;"> is </font>effective<font style="letter-spacing:0.7pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>rent<font style="letter-spacing:0.35pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ending<font style="letter-spacing:0.55pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;">,</font><font style="letter-spacing:0.35pt;"> </font>2016 and 2015,<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>approximately<font style="letter-spacing:1.1pt;"> </font>$276<font style="letter-spacing:0.45pt;">,</font><font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">$</font>218 and $121,<font style="letter-spacing:0.45pt;"> </font>respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPI<font style="letter-spacing:0.35pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>7<font style="letter-spacing:0.15pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>commencing<font style="letter-spacing:1pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>May<font style="letter-spacing:0.35pt;"> </font>1,<font style="letter-spacing:0.2pt;"> </font>2016.<font style="letter-spacing:0.45pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>part<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>UPI<font style="letter-spacing:0.35pt;"> </font>provided the<font style="letter-spacing:0.05pt;"> </font>lessor<font style="letter-spacing:0.5pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>letter<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>renews on an annual basis.<font style="letter-spacing:0.25pt;"> </font><font style="font-size:12pt;">&#160;</font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:12pt;">&#160;</font><font style="letter-spacing:0.4pt;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:0.4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the fourth quarter, UPI entered into a new lease agreement for its New York headquarters. The lease agreement commenced in October 2017 and shall terminate in February 2021. The rent expense<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.3pt;"> </font>a<font style="letter-spacing:-0.1pt;">p</font>proximately<font style="letter-spacing:1.1pt;"> </font>$342 and rent expense for the eight months ended December 31, 2016 was $102.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>minimum<font style="letter-spacing:0.75pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>next<font style="letter-spacing:0.35pt;"> </font>seven<font style="letter-spacing:0.5pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>u<font style="letter-spacing:-0.1pt;">n</font>der<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreements<font style="letter-spacing:0.95pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>$1,115<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year 2018,<font style="letter-spacing:0.45pt;"> </font>$1,054<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2019,<font style="letter-spacing:0.55pt;"> </font>$873 in 2020, $305 in<font style="letter-spacing:0.45pt;"> </font>2021, $192 in<font style="letter-spacing:0.35pt;"> </font>2022,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>$80<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b.<font style="letter-spacing:0.2pt;"> </font>Grants<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israel<font style="letter-spacing:0.5pt;"> </font>Innovation<font style="letter-spacing:0.9pt;"> </font>Authority<font style="letter-spacing:0.8pt;"> </font>(&#8220;IIA&#8221;<font style="letter-spacing:0.1pt;">)</font>,<font style="letter-spacing:0.6pt;"> </font>formerly<font style="letter-spacing:0.75pt;"> </font>known<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Office<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Chief<font style="letter-spacing:0.45pt;"> </font>Scientist<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>State<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA<font style="letter-spacing:0.25pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>fundi<font style="letter-spacing:-0.1pt;">n</font>g.<font style="letter-spacing:0.65pt;"> </font>Up<font style="letter-spacing:0.25pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>2007,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA<font style="letter-spacing:0.35pt;"> </font>participation<font style="letter-spacing:0.95pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>funding<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>part<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Director<font style="letter-spacing:0.65pt;"> </font>General<font style="letter-spacing:0.65pt;"> </font>Directive<font style="letter-spacing:0.7pt;"> </font>8.2<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel<font style="letter-spacing:0.45pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>provi<font style="letter-spacing:-0.1pt;">d</font>ed<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Granot<font style="letter-spacing:0.55pt;"> </font>Ventures.<font style="letter-spacing:0.8pt;"> </font>Since<font style="letter-spacing:0.45pt;"> </font>2008,<font style="letter-spacing:0.45pt;"> </font>the funding<font style="letter-spacing:0.6pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>directly<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>committed<font style="letter-spacing:0.85pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>royalties<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Government<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>proceeds<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>sales<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>products<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>dev<font style="letter-spacing:-0.1pt;">e</font>lopment of<font style="letter-spacing:0.2pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA<font style="letter-spacing:0.25pt;"> </font>participates<font style="letter-spacing:0.9pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>way<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>grants.<font style="letter-spacing:0.55pt;"> </font>At<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>time<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>were<font style="letter-spacing:0.4pt;"> </font>received,<font style="letter-spacing:0.75pt;"> </font>successful<font style="letter-spacing:0.85pt;"> </font>development<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>projects<font style="letter-spacing:0.65pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not assured.<font style="letter-spacing:0.7pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>case<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>failure<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>project<font style="letter-spacing:0.55pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>partly<font style="letter-spacing:0.45pt;"> </font>financed<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>above,<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>o<font style="letter-spacing:-0.1pt;">b</font>ligated<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>royalties.<font style="letter-spacing:0.85pt;"> </font>Under the<font style="letter-spacing:0.05pt;"> </font>terms<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>funding<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>IIA,<font style="letter-spacing:0.3pt;"> </font>royalties<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>3%-4.5%<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>payable<font style="letter-spacing:0.65pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>sales<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>products<font style="letter-spacing:0.7pt;"> </font>devel<font style="letter-spacing:-0.1pt;">o</font>ped<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>project<font style="letter-spacing:0.55pt;"> </font>so<font style="letter-spacing:0.25pt;"> </font>funded,<font style="letter-spacing:0.6pt;"> </font>up<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>100% of<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>(dollar<font style="letter-spacing:0.5pt;"> </font>linked);<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>addition<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>annual<font style="letter-spacing:0.55pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nterest<font style="letter-spacing:0.6pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.35pt;"> </font>12-month<font style="letter-spacing:0.85pt;"> </font>LIBOR. The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>several<font style="letter-spacing:0.6pt;"> </font>conditions,<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:-0.1pt;">c</font>luding<font style="letter-spacing:0.7pt;"> </font>restrictions<font style="letter-spacing:0.85pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intellectual<font style="letter-spacing:0.85pt;"> </font>property.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>maximum<font style="letter-spacing:0.8pt;"> </font>royalty<font style="letter-spacing:0.55pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>payable<font style="letter-spacing:0.65pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">n</font>der<font style="letter-spacing:0.5pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>funding<font style="letter-spacing:0.6pt;"> </font>arrangements<font style="letter-spacing:1.1pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>$2,105<font style="letter-spacing:0.55pt;"> </font>(exclud<font style="letter-spacing:-0.1pt;">i</font>ng interest).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c.<font style="letter-spacing:0.2pt;"> </font>Financing<font style="letter-spacing:0.85pt;"> </font>success<font style="letter-spacing:0.7pt;"> </font>fees</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>agreements<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>third<font style="letter-spacing:0.4pt;"> </font>parties<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>shareholders<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>connect<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>fundraising<font style="letter-spacing:0.9pt;"> </font>efforts.<font style="letter-spacing:0.55pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the services<font style="letter-spacing:0.65pt;"> </font>rendered,<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>undertook<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pay<font style="letter-spacing:0.3pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>third<font style="letter-spacing:0.4pt;"> </font>parties<font style="letter-spacing:0.55pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>shareholders<font style="letter-spacing:1.05pt;"> </font>certain<font style="letter-spacing:0.55pt;"> </font>success<font style="letter-spacing:0.65pt;"> </font>fees<font style="letter-spacing:0.35pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>funds<font style="letter-spacing:0.45pt;"> </font>actually<font style="letter-spacing:0.65pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>by the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.9pt;"> </font>and/or<font style="letter-spacing:0.55pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company,<font style="letter-spacing:0.8pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>agreed<font style="letter-spacing:0.6pt;"> </font>betw<font style="letter-spacing:-0.1pt;">e</font>en<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total<font style="letter-spacing:0.25pt;"> </font>success<font style="letter-spacing:0.45pt;"> </font>fees<font style="letter-spacing:0.2pt;"> </font>to third<font style="letter-spacing:0.2pt;"> </font>parties for the year ended December 31, 2017 were $28 and payable in cash and<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>year<font style="letter-spacing:0.2pt;"> </font>ended<font style="letter-spacing:0.35pt;"> </font>December<font style="letter-spacing:0.65pt;"> </font>31,<font style="letter-spacing:0.1pt;"> </font>2016<font style="letter-spacing:0.25pt;"> </font>consisted<font style="letter-spacing:0.6pt;"> </font>of 5,726<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.4pt;"> </font>to third<font style="letter-spacing:0.2pt;"> </font>parties<font style="letter-spacing:0.35pt;"> </font>to purchase<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:-0.1pt;">d</font>inary shares<font style="letter-spacing:0.4pt;"> </font>with<font style="letter-spacing:0.2pt;"> </font>a fair<font style="letter-spacing:0.15pt;"> </font>value<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>$9.<font style="letter-spacing:0.15pt;"> </font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770708176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>7&#8212;FINANCIAL<font style="letter-spacing:1.25pt;"> </font>INSTRUMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Warrants<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.8pt;"> </font>shares</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>2014,<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>part<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>(the &#8220;2014<font style="letter-spacing:0.8pt;"> </font>SPA&#8221;),<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>arrants<font style="letter-spacing:0.7pt;"> </font>(the<font style="letter-spacing:0.5pt;"> </font>&#8220;A-1<font style="letter-spacing:0.4pt;"> </font>warrants&#8221;)<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares.<font style="margin-left:36pt;"></font><font style="font-size:12pt;">&#160;</font><font style="letter-spacing:0.4pt;"> </font><font style="letter-spacing:0.45pt;"> </font><font style="font-size:12pt;">&#160;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>warrants<font style="letter-spacing:0.8pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>exercisable<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>representing<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>pri<font style="letter-spacing:-0.1pt;">c</font>e.<font style="letter-spacing:0.45pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>event<font style="letter-spacing:0.45pt;"> </font>that the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.6pt;"> </font>were<font style="letter-spacing:0.15pt;"> </font>exercised<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>connection<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>M&amp;A<font style="letter-spacing:0.4pt;"> </font>event,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>holder<font style="letter-spacing:0.5pt;"> </font>could<font style="letter-spacing:0.35pt;"> </font>elect<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>convert<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrant<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>basis. The<font style="letter-spacing:0.4pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.15pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>freestanding<font style="letter-spacing:1pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nstruments,<font style="letter-spacing:1pt;"> </font>exercisable<font style="letter-spacing:0.9pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>Series A-1<font style="letter-spacing:0.35pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>redeemable<font style="letter-spacing:0.95pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>certain<font style="letter-spacing:0.55pt;"> </font>e<font style="letter-spacing:-0.1pt;">v</font>ents<font style="letter-spacing:0.55pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>represent<font style="letter-spacing:0.75pt;"> </font>&#8220;Deemed<font style="letter-spacing:0.75pt;"> </font>Liquidation&#8221;<font style="letter-spacing:0.95pt;"> </font>events. Accordingly,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>every<font style="letter-spacing:0.45pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period,<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cha<font style="letter-spacing:-0.1pt;">n</font>ges<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>in earnings<font style="letter-spacing:0.7pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>finance expenses, net.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accor<font style="letter-spacing:-0.1pt;">d</font>ance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Hybrid<font style="letter-spacing:0.55pt;"> </font>Method.<font style="letter-spacing:0.65pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Hybrid Method<font style="letter-spacing:0.65pt;"> </font>combines<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>probabilities<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>scenario<font style="letter-spacing:0.7pt;"> </font>w<font style="letter-spacing:-0.1pt;">h</font>ich<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>20%<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liquidation<font style="letter-spacing:0.8pt;"> </font>e<font style="letter-spacing:-0.1pt;">v</font>ent<font style="letter-spacing:0.45pt;"> </font>scenario<font style="letter-spacing:0.7pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>estimated at<font style="letter-spacing:0.05pt;"> </font>80%.<font style="letter-spacing:0.45pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>mainly<font style="letter-spacing:0.55pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:0.4pt;"> </font>estimation<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the Company&#8217;s<font style="letter-spacing:0.85pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>derived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>DCF<font style="letter-spacing:0.4pt;"> </font>calcu<font style="letter-spacing:-0.1pt;">l</font>ation<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>assumption<font style="letter-spacing:0.9pt;"> </font>relating<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>forecast,<font style="letter-spacing:0.7pt;"> </font>clini<font style="letter-spacing:-0.1pt;">c</font>al<font style="letter-spacing:0.55pt;"> </font>success probabilities,<font style="letter-spacing:1pt;"> </font>relevant<font style="letter-spacing:0.65pt;"> </font>discount<font style="letter-spacing:0.7pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>betw<font style="letter-spacing:-0.1pt;">e</font>en<font style="letter-spacing:0.75pt;"> </font>10.5%-19%<font style="letter-spacing:1.05pt;"> </font>(10.5%<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flow<font style="letter-spacing:0.35pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>derived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>19%<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>erived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.85pt;"> </font>internal<font style="letter-spacing:0.6pt;"> </font>development)<font style="letter-spacing:1.1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expect<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.75pt;"> </font>volatility<font style="letter-spacing:0.65pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.05pt;"> </font>73.93%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the IPO, the Company converted all outstanding warrants into 364,036 Preferred A-1 shares of the Company and subsequently converted all of its preferred shares, including the Preferred A-1 shares, into ordinary shares. See also Note 5 and Note 8.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b.<font style="letter-spacing:0.2pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>financial<font style="letter-spacing:0.75pt;"> </font>instruments<font style="letter-spacing:1pt;"> </font>measured<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>classified<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>Level<font style="letter-spacing:0.5pt;"> </font>3.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>below<font style="letter-spacing:0.5pt;"> </font>sets<font style="letter-spacing:0.35pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>summary<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>Lev<font style="letter-spacing:-0.1pt;">e</font>l<font style="letter-spacing:0.45pt;"> </font>3:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value of warrants for preferred shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,740</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrants for preferred shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>fi<font style="letter-spacing:-0.1pt;">n</font>ancial<font style="letter-spacing:0.65pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.75pt;"> </font>a<font style="letter-spacing:-0.1pt;">p</font>proximate<font style="letter-spacing:1pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>carrying<font style="letter-spacing:0.65pt;"> </font>amounts.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761582864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Share Capital</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>8&#8212;SHARE<font style="letter-spacing:0.9pt;"> </font>CAPITAL</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Share<font style="letter-spacing:0.5pt;"> </font>capital</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>capit<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued and Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares of NIS 0.01 par value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,600,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,751,390</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,743</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A and A-1 preferred shares of NIS 0.01 par value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,400,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,193,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Terms<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.95pt;"> </font>ordinary<font style="letter-spacing:0.75pt;"> </font>shares<font style="font-weight:normal;font-style:normal;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each<font style="letter-spacing:0.45pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>vote.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>hol<font style="letter-spacing:-0.1pt;">d</font>ers<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>receive<font style="letter-spacing:0.6pt;"> </font>dividends<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>henever<font style="letter-spacing:0.8pt;"> </font>funds<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>legally available,<font style="letter-spacing:0.75pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>if<font style="letter-spacing:0.3pt;"> </font>declared<font style="letter-spacing:0.7pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Board<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Directors.<font style="letter-spacing:0.8pt;"> </font>Since<font style="letter-spacing:0.45pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>inception,<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Comp<font style="letter-spacing:-0.1pt;">a</font>ny<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>declared<font style="letter-spacing:0.7pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>dividends.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>October<font style="letter-spacing:0.65pt;"> </font>2015<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>agr<font style="letter-spacing:-0.1pt;">e</font>ement<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>Telormedix<font style="letter-spacing:0.9pt;"> </font>SA<font style="letter-spacing:0.3pt;"> </font>(&#8220;TMX&#8221;)<font style="letter-spacing:0.65pt;"> </font>pursuant<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company purchased<font style="letter-spacing:0.85pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intellectual<font style="letter-spacing:0.85pt;"> </font>pro<font style="letter-spacing:-0.1pt;">p</font>erty<font style="letter-spacing:0.65pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>TMX<font style="letter-spacing:0.4pt;"> </font>(in<font style="letter-spacing:0.25pt;"> </font>process<font style="letter-spacing:0.65pt;"> </font>R&amp;D)<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.3pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>691,200<font style="letter-spacing:0.65pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the Company<font style="letter-spacing:0.8pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$5.94, which were subsequently converted into ordinary shares on the date of the IPO.<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:0.2pt;"> </font><font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>issue<font style="letter-spacing:0.25pt;"> </font>ad<font style="letter-spacing:-0.1pt;">d</font>itional<font style="letter-spacing:0.8pt;"> </font>shares upon the occurrence of each of three milestones as set in the agreement. The Company has deemed the probability of achieving these milestones to be remote<font style="letter-spacing:0.8pt;">. </font><font style="color:#000000;">The acquired intellectual property costs totaling $4.1&#160;million were expensed as incurred to research and development costs in accordance with ASC&#160;730, as the intellectual property is purchased from others for a particular research and development project and has no alternative future uses and therefore no separate economic value. </font><font style="font-size:11pt;letter-spacing:0.55pt;"> </font><font style="font-size:11pt;letter-spacing:0.65pt;"> </font><font style="font-size:11pt;letter-spacing:0.6pt;"> </font><font style="font-size:14pt;">&#160;</font><font style="font-size:11pt;letter-spacing:0.55pt;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On April 19, 2017, the Company&#8217;s board of directors and shareholders approved an aggregate 3.2 for-1 share split of the Company&#8217;s ordinary, Preferred A and Preferred A-1 shares. The share split was effected on April 19, 2017 by the issuance of 2.2 ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 share held immediately prior to the share split.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In May 2017, the Company completed an IPO on the Nasdaq Stock Market, in which it issued 5,144,378 ordinary shares, at a public offering price of $13.00 per share, in consideration for $60.8 million, net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&#8217; option to purchase additional 671,005 ordinary shares at the IPO price. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the completion of the IPO, the Company converted all outstanding warrants for Preferred A 1 shares into 364,036 Preferred A-1 shares of the Company. Subsequently, the Company converted all outstanding Preferred A and Preferred A-1 shares into ordinary shares at a ratio of 1:1. As of December 31, 2017, the Company&#8217;s share capital was composed entirely of ordinary shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, during the years ended December 31, 2017 and 2016, the Company recorded $0.0 and $1.7 million, respectively, in general and administrative expenses related to IPO costs, in accordance with SEC staff Bulletin Topic 5A.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Company&#8217;s convertible preferred shares included Series A and A-1 preferred shares.  The<font style="letter-spacing:0.35pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>$5.94<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the exercise<font style="letter-spacing:0.7pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>$7.81.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>holder<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>was:<font style="letter-spacing:0.45pt;"> </font>(i)<font style="letter-spacing:0.25pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>votes<font style="letter-spacing:0.45pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font><font style="letter-spacing:-0.1pt;">e</font>qual<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>which such<font style="letter-spacing:0.4pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>then<font style="letter-spacing:0.4pt;"> </font>convertible,<font style="letter-spacing:0.9pt;"> </font>(ii)<font style="letter-spacing:0.25pt;"> </font>had<font style="letter-spacing:0.4pt;"> </font>voting<font style="letter-spacing:0.5pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>powers<font style="letter-spacing:0.6pt;"> </font>equal<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>voting<font style="letter-spacing:0.5pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>powers<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>h<font style="letter-spacing:-0.1pt;">o</font>lder<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.4pt;"> </font>vote<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>single<font style="letter-spacing:0.5pt;"> </font>class<font style="letter-spacing:0.45pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font><font style="letter-spacing:-0.1pt;">h</font>olders<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(iii)<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>notice<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>meeting<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the shareholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>issuance<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>dividends<font style="letter-spacing:0.75pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>annum<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>8%<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>original<font style="letter-spacing:0.65pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>pri<font style="letter-spacing:-0.1pt;">c</font>e<font style="letter-spacing:0.45pt;"> </font>(as defined)<font style="letter-spacing:0.5pt;"> </font>per<font style="letter-spacing:0.1pt;"> </font>share<font style="letter-spacing:0.2pt;"> </font>accrued<font style="letter-spacing:0.4pt;"> </font>on<font style="letter-spacing:0.05pt;"> </font>such<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.55pt;"> </font>shares<font style="letter-spacing:0.4pt;"> </font>(sub<font style="letter-spacing:-0.1pt;">j</font>ect<font style="letter-spacing:0.45pt;"> </font>to appropriate<font style="letter-spacing:0.85pt;"> </font>adjustment<font style="letter-spacing:0.7pt;"> </font>in the<font style="letter-spacing:0.1pt;"> </font>event<font style="letter-spacing:0.3pt;"> </font>of any<font style="letter-spacing:0.15pt;"> </font>stock<font style="letter-spacing:0.25pt;"> </font>dividend,<font style="letter-spacing:0.55pt;"> </font>stock<font style="letter-spacing:0.25pt;"> </font>split, combination<font style="letter-spacing:0.95pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>similar<font style="letter-spacing:0.55pt;"> </font>recapitalization<font style="letter-spacing:1.2pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ith<font style="letter-spacing:0.35pt;"> </font>respect<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>holders<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>had<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>follo<font style="letter-spacing:-0.1pt;">w</font>ing<font style="letter-spacing:0.7pt;"> </font>conversion<font style="letter-spacing:0.85pt;"> </font>rights:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optional conversion - each preferred share was convertible, at the option of the holder thereof, at any time after the date of issuance of such share into such number of fully paid shares of ordinary shares as was determined by dividing the original purchase price by the conversion price applicable to such share, in effect on the date that the certificate was surrendered for conversion. The initial conversion price of the preferred shares was the original purchase price; provided, however, that the conversion price for the preferred shares was subject to certain adjustments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Automatic<font style="letter-spacing:0.8pt;"> </font>conversion<font style="letter-spacing:0.85pt;"> </font>-<font style="letter-spacing:0.1pt;"> </font>Each<font style="letter-spacing:0.45pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>was to be automatica<font style="letter-spacing:-0.1pt;">l</font>ly<font style="letter-spacing:0.25pt;"> </font>converted<font style="letter-spacing:0.8pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>conversion<font style="letter-spacing:0.9pt;"> </font>price<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the time<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share,<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consummation<font style="letter-spacing:1.15pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>events:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Upon<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>closing<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>IPO,<font style="letter-spacing:0.4pt;"> </font>where<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.85pt;"> </font>pre-money<font style="letter-spacing:0.95pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font>was<font style="letter-spacing:0.15pt;"> </font>$75,000<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>proceeds<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Comp<font style="letter-spacing:-0.1pt;">a</font>ny of<font style="letter-spacing:0.2pt;"> </font>$25,000<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>(a<font style="letter-spacing:0.2pt;"> </font>&#8220;Qualified<font style="letter-spacing:0.8pt;"> </font>Public<font style="letter-spacing:0.5pt;"> </font>Offering&#8221;);<font style="letter-spacing:0.85pt;"> </font>or</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>event<font style="letter-spacing:0.45pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>holders<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>majority<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>sixty<font style="letter-spacing:0.4pt;"> </font>percent<font style="letter-spacing:0.6pt;"> </font>(60%)<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>then<font style="letter-spacing:0.4pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>voting<font style="letter-spacing:0.5pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>single<font style="letter-spacing:0.5pt;"> </font>class, consent<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>such.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As noted in 8a4, in May 2017, upon completion of the IPO, all of the convertible preferred shares were converted into ordinary shares.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the<font style="letter-spacing:0.35pt;"> </font>Series<font style="letter-spacing:0.55pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>perma<font style="letter-spacing:-0.1pt;">n</font>ent<font style="letter-spacing:0.85pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>were<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.3pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>classification<font style="letter-spacing:1.15pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>meet<font style="letter-spacing:0.45pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requirements<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>classificat<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:1pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>ASC<font style="letter-spacing:0.45pt;"> </font>480-10-S99.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During 2017, the Company received $404 from a portion of the exercise of 812,222 options into 743,806 ordinary shares, which were net of 68,416 shares surrendered to pay the exercise price on the balance.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for $64 million net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&#8217; option to purchase additional 219,512 ordinary shares at the public offering price. </p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;letter-spacing:0.2pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b. Share-based<font style="letter-spacing:1.05pt;"> </font>compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>October<font style="letter-spacing:0.65pt;"> </font>2010,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>board<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>approved<font style="letter-spacing:0.75pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>option<font style="letter-spacing:0.5pt;"> </font>plan<font style="letter-spacing:0.35pt;"> </font>(the<font style="letter-spacing:0.35pt;"> </font>&#8220;Pl<font style="letter-spacing:-0.1pt;">a</font>n&#8221;)<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>employees,<font style="letter-spacing:0.9pt;"> </font>consultants, directors,<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>providers.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.4pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>su<font style="letter-spacing:-0.1pt;">b</font>ject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>terms<font style="letter-spacing:0.45pt;"> </font>stipulated<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>102<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>Income<font style="letter-spacing:0.6pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>Ordinance (&#8220;Section<font style="letter-spacing:0.75pt;"> </font>102&#8221;).<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>option<font style="letter-spacing:0.5pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>track<font style="letter-spacing:0.4pt;"> </font>chosen<font style="letter-spacing:0.6pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company,<font style="letter-spacing:0.8pt;"> </font>either<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>&#8220;regular<font style="letter-spacing:0.65pt;"> </font>income&#8221;<font style="letter-spacing:0.65pt;"> </font>track<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>&#8220;capital<font style="letter-spacing:0.6pt;"> </font>gains&#8221;<font style="letter-spacing:0.5pt;"> </font>track,<font style="letter-spacing:0.05pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>set<font style="letter-spacing:0.3pt;"> </font>out<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>102.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>registered<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>un<font style="letter-spacing:-0.1pt;">d</font>er<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>capital<font style="letter-spacing:0.55pt;"> </font>gains<font style="letter-spacing:0.45pt;"> </font>track,<font style="letter-spacing:0.45pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>offers<font style="letter-spacing:0.45pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>favorable<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the employees.<font style="letter-spacing:0.9pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result,<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>pursuant<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>terms<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>102,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>allowed<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>claim<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>ex<font style="letter-spacing:-0.1pt;">p</font>ense<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>the amounts<font style="letter-spacing:0.7pt;"> </font>credited<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>respect<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>them<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>P<font style="letter-spacing:-0.1pt;">l</font>an,<font style="letter-spacing:0.45pt;"> </font>including<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>salary<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:-0.1pt;">n</font>efits<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>accounts,<font style="letter-spacing:0.8pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exception<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>work-income<font style="letter-spacing:1pt;"> </font>b<font style="letter-spacing:-0.1pt;">e</font>nefit<font style="letter-spacing:0.55pt;"> </font>component,<font style="letter-spacing:0.95pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>any,<font style="letter-spacing:0.35pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>For<font style="letter-spacing:0.4pt;"> </font>non-employees<font style="letter-spacing:1.3pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>for non-Israeli<font style="letter-spacing:0.95pt;"> </font>employees,<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Section<font style="letter-spacing:0.6pt;"> </font>3(i)<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>Income<font style="letter-spacing:0.6pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>Ordinance.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>volatility<font style="letter-spacing:0.65pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>histori<font style="letter-spacing:-0.1pt;">c</font>al<font style="letter-spacing:0.7pt;"> </font>volatility<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>comparable<font style="letter-spacing:1pt;"> </font>companies.<font style="letter-spacing:0.9pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>risk-free<font style="letter-spacing:0.65pt;"> </font>interest<font style="letter-spacing:0.6pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>assumption<font style="letter-spacing:0.9pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on observed<font style="letter-spacing:0.75pt;"> </font>interest<font style="letter-spacing:0.6pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>appropriate<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>term<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>dol<font style="letter-spacing:-0.1pt;">l</font>ar<font style="letter-spacing:0.45pt;"> </font>terms.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>term<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>length<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>time<font style="letter-spacing:0.35pt;"> </font>until the<font style="letter-spacing:0.05pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>dates<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>exercising<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options and<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>(except<font style="letter-spacing:0.6pt;"> </font>senior<font style="letter-spacing:0.5pt;"> </font>managem<font style="letter-spacing:-0.1pt;">e</font>nt)<font style="letter-spacing:1.1pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>simplified<font style="letter-spacing:0.75pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>due<font style="letter-spacing:0.35pt;"> </font>to insufficient<font style="letter-spacing:0.85pt;"> </font>specific<font style="letter-spacing:0.6pt;"> </font>historical<font style="letter-spacing:0.7pt;"> </font>information<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>employ<font style="letter-spacing:-0.1pt;">e</font>es&#8217;<font style="letter-spacing:0.9pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>behavior,<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.3pt;"> </font>non-employees,<font style="letter-spacing:1.35pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>senior<font style="letter-spacing:0.5pt;"> </font>management<font style="letter-spacing:1.05pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.05pt;"> </font>contractual<font style="letter-spacing:0.9pt;"> </font>term.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Company&#8217;s board of directors adopted the 2017 Equity Incentive Plan ("2017 Plan"), which was approved by the shareholders in April 2017. The 2017 Plan provides for the grant of incentive stock options to the Company's employees and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of stock awards to the Company's employees, directors and consultants.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maximum number of ordinary shares that may initially be issued under the 2017 Plan is 1,400,000. In addition, the number of ordinary shares reserved for issuance under the 2017 Plan will automatically increase on January 1st of each calendar year, from January 1, 2018 through January 1, 2026, so that the number of such shares reserved for issuance will equal 12% of the total number of ordinary shares outstanding on the last day of the calendar month prior to the date of each automatic increase, or a lesser number of shares determined by our board of directors. The maximum number of ordinary shares that may be issued upon the exercise of incentive stock options under the 2017 Plan is 5,600,000.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2017 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our Ordinary Shares on the date of grant. Options granted under the 2017 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2017, the Company&#8217;s board of directors approved modifications of performance conditions for 67,200 restricted stock units and contingent options for executive management. The Company recorded an expense of $527 under general and administrative expenses with respect to these modifications.</p>
<p style="margin-top:12pt;line-height:11pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2017 and 2016, the Company granted options to certain employees and non-employees as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-style:italic;">1)</p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Options<font style="letter-spacing:0.65pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors:</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Set<font style="letter-spacing:0.3pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>below<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>grants<font style="letter-spacing:0.5pt;"> </font>made<font style="letter-spacing:0.45pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> and directors </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>20<font style="letter-spacing:-0.1pt;">1</font>7.<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>majority<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>vest<font style="letter-spacing:0.35pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>of four<font style="letter-spacing:0.35pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expire<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>seventh<font style="letter-spacing:0.65pt;"> </font>anniversary<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>grant.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a) </font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During<font style="letter-spacing:0.55pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>712,900<font style="letter-spacing:0.65pt;"> </font>options and restricted stock units<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>ra<font style="letter-spacing:-0.1pt;">n</font>ging<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>$0<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>$39.26<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share. <font style="font-size:12pt;">&#160;&#160;</font> </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">During<font style="letter-spacing:0.55pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>404,813<font style="letter-spacing:0.8pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>ra<font style="letter-spacing:-0.1pt;">n</font>ging<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>$5<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>$5.94<font style="letter-spacing:0.45pt;"> </font>per share. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="letter-spacing:-0.2pt;">During 2015, the Company granted 1,098,777 options to employees and directors with prices ranging from $0 to $5.94 per share.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of options granted to employees and directors during 2017, 2016 and 2015 was $14,249, $906 and $2,334, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>total<font style="letter-spacing:0.35pt;"> </font>unrecognized<font style="letter-spacing:1.05pt;"> </font>compensati<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:1.1pt;"> </font>cost<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>employee<font style="letter-spacing:0.8pt;"> and director </font>options<font style="letter-spacing:0.6pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>$14,131,<font style="letter-spacing:0.6pt;"> </font>whi<font style="letter-spacing:-0.1pt;">c</font>h<font style="letter-spacing:0.5pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>a weighted<font style="letter-spacing:0.75pt;"> </font>average<font style="letter-spacing:0.65pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.15pt;"> </font>3.31<font style="letter-spacing:0.4pt;"> </font>years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>irectors<font style="letter-spacing:0.7pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Black-Scholes<font style="letter-spacing:1.15pt;"> </font>mod<font style="letter-spacing:-0.1pt;">e</font>l.<font style="letter-spacing:0.55pt;"> </font>The underlying<font style="letter-spacing:0.85pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>used<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>computing<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of ordinary shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.00-39.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98-5.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98-3.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.53%-76.32%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.8%-80%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.78%-76.68%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.85%-2.47%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4%&#8211;2.13%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38%&#8211;2.08%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5-10 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1-7 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-style:italic;">2)</p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Options<font style="letter-spacing:0.65pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>providers:</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no new grants issued to consultants and service providers in 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During<font style="letter-spacing:0.55pt;"> </font>2016 and 2015,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>132,0<font style="letter-spacing:-0.1pt;">3</font>2<font style="letter-spacing:0.65pt;"> and 203,820 </font>options,<font style="letter-spacing:0.65pt;"> </font>respectively,<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>providers<font style="letter-spacing:0.75pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>an exercise<font style="letter-spacing:0.7pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>ranging<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>$0<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>$5.94<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016 and 2015<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>opt<font style="letter-spacing:-0.1pt;">i</font>ons<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>providers<font style="letter-spacing:0.75pt;"> </font>during<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">2</font>016 and 2015<font style="letter-spacing:0.45pt;"> </font>was $671 and $57, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>pro<font style="letter-spacing:-0.1pt;">v</font>iders<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">s</font>ing<font style="letter-spacing:0.45pt;"> </font>the Black-Scholes<font style="letter-spacing:1.15pt;"> </font>model.<font style="letter-spacing:0.55pt;"> </font>The<font style="letter-spacing:0.3pt;"> </font>underlying<font style="letter-spacing:0.85pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>computing<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>opt<font style="letter-spacing:-0.1pt;">i</font>ons<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of ordinary shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.58-37.21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.58-7.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.45%-74.50%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.72%-80%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.31%-76.3%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38%-2.26%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.56%-2.27%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88%-2.07%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9-5.9 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8-8.5 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.8-7 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3)</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>summarizes<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font><font style="letter-spacing:-0.1pt;">o</font>utstanding<font style="letter-spacing:0.95pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>Decem<font style="letter-spacing:-0.1pt;">b</font>er<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017, 2016<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2015,<font style="letter-spacing:0.45pt;"> </font>and related<font style="letter-spacing:0.55pt;"> </font>inform<font style="letter-spacing:0.1pt;">a</font>tion:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directors</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consultants and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service providers</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of January 1, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098,777</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.99</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,826</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.98</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,088</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,686,600</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,238</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,032</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.03</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,784</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,030,613</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634,486</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,686</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(682,184</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,038</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,021,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.70</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Including 38,400 ordinary shares issuable upon the vesting of options granted in 2016, which were contingent upon the closing of the IPO.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.5pt;"> </font>summarizes<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>outstand<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.95pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>exercisable<font style="letter-spacing:0.9pt;"> </font>options and restricted stock units<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2<font style="letter-spacing:-0.1pt;">0</font>17:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding at end</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercisable at end of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00 - 10.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,948,091</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142,310</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.98</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.01 - 20.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,501</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.01 - 30.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.01 - 40.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,520,591</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,194,811</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>aggregate<font style="letter-spacing:0.8pt;"> </font>intrinsic<font style="letter-spacing:0.65pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>total<font style="letter-spacing:0.35pt;"> </font>vested<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>e<font style="letter-spacing:-0.1pt;">x</font>ercisable<font style="letter-spacing:0.9pt;"> </font>options and restricted stock units<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>$38,308.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>illustrates<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>com<font style="letter-spacing:-0.1pt;">p</font>ensation<font style="letter-spacing:1.1pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations:</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,377</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,300</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,967</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6707631456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>9&#8212;TAXES<font style="letter-spacing:0.9pt;"> </font>ON<font style="letter-spacing:0.3pt;"> </font>INCOME</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>taxed<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>Israeli<font style="letter-spacing:0.5pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>laws:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>rates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>taxed<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>regular<font style="letter-spacing:0.6pt;"> </font>rate.<font style="letter-spacing:0.4pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>24%<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">2</font>5%.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Economic<font style="letter-spacing:0.8pt;"> </font>Efficiency<font style="letter-spacing:0.8pt;"> </font>Law<font style="letter-spacing:0.35pt;"> </font>(Legi<font style="letter-spacing:-0.1pt;">s</font>lative<font style="letter-spacing:0.9pt;"> </font>Amendments<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>Implementing<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Economic<font style="letter-spacing:0.8pt;"> </font>Policy<font style="letter-spacing:0.5pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>2018 Budget<font style="letter-spacing:0.6pt;"> </font>Year),<font style="letter-spacing:0.5pt;"> </font>2016<font style="letter-spacing:0.6pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>published,<font style="letter-spacing:0.9pt;"> </font>introducing<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>gradual<font style="letter-spacing:0.6pt;"> </font>reduction<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>n<font style="letter-spacing:0.2pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>25%<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>23%.<font style="letter-spacing:0.45pt;"> </font>However,<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>law<font style="letter-spacing:0.3pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>included<font style="letter-spacing:0.7pt;"> </font>a temporary<font style="letter-spacing:0.8pt;"> </font>provision<font style="letter-spacing:0.75pt;"> </font>setting<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>24%.<font style="letter-spacing:0.45pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>corporate<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>was<font style="letter-spacing:0.25pt;"> </font>24%<font style="letter-spacing:0.4pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>20<font style="letter-spacing:-0.1pt;">1</font>7<font style="letter-spacing:0.45pt;"> </font>and would be<font style="letter-spacing:0.35pt;"> </font>23%<font style="letter-spacing:0.4pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>2018<font style="letter-spacing:0.45pt;"> </font>and thereafter.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>change<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>mentioned<font style="letter-spacing:0.85pt;"> </font>above<font style="letter-spacing:0.5pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font><font style="letter-spacing:-0.1pt;">n</font>ot<font style="letter-spacing:0.3pt;"> </font>affected<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>date in Israel.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b.<font style="letter-spacing:0.2pt;"> </font>Tax<font style="letter-spacing:0.35pt;"> </font>assessments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>assessments<font style="letter-spacing:1.05pt;"> </font>filed<font style="letter-spacing:0.35pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>2013<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>final.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c.<font style="letter-spacing:0.2pt;"> </font>Losses<font style="letter-spacing:0.65pt;"> </font>for<font style="letter-spacing:0.3pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>purposes<font style="letter-spacing:0.8pt;"> </font>carried<font style="letter-spacing:0.6pt;"> </font>forward<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>future<font style="letter-spacing:0.55pt;"> </font>years</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font>approximately<font style="letter-spacing:1.1pt;"> </font><font style="letter-spacing:-0.1pt;">$</font>24.8<font style="letter-spacing:0.65pt;"> million </font>of<font style="letter-spacing:0.2pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>carry<font style="letter-spacing:0.45pt;"> </font>forward<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>losses<font style="letter-spacing:0.55pt;"> </font>available<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>reduce<font style="letter-spacing:0.55pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>taxable<font style="letter-spacing:0.6pt;"> </font>income without<font style="letter-spacing:0.6pt;"> </font>limitation<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d.<font style="letter-spacing:0.2pt;"> </font>Deferred<font style="letter-spacing:0.75pt;"> </font>income<font style="letter-spacing:0.65pt;"> </font>taxes:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In respect of:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forward</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,844</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,691</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Rent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance Costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-Process R&amp;D</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less&#8212;valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,725</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>change<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>lowance<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>were<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,551</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes during the year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,948</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the end of the year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,725</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The main reconciling item between the statutory tax rates of the Company (not UPI) and the effective rate is the share-based compensation and provision for full valuation allowance in respect of tax benefits from carryforward tax losses due to the uncertainty of the realization of such tax benefits.<font style="font-size:12pt;"><br /></font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regarding the Company&#8217;s US operations, as of December 31, 2017, UPI had federal tax net operating losses of $0.4 million and state tax net operating losses of $0.7 million in several jurisdictions available to carry forward and reduce future income tax liabilities. The federal and state net operating losses begin to expire after 2036.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Internal Revenue Code contains provisions that may limit the use of the net operating tax loss carryforward available if significant changes occur in the stock ownership of UPI. In the event UPI has had a change in ownership, utilization of the carry&#8209;forwards could be restricted due to the &#8220;change in ownership provisions&#8221; under Section&#160;382 of the Internal Revenue Code and similar state provisions. Such limitations could result in the expiration of the net operating carry&#8209;forwards before their utilization.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782633168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Ordinary Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Ordinary Share</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.55pt;"> </font>10&#8212;LOSS<font style="letter-spacing:0.85pt;"> </font>PER<font style="letter-spacing:0.4pt;"> </font>ORDINARY<font style="letter-spacing:0.95pt;"> </font>SHARE</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>sets<font style="letter-spacing:0.35pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>calculation<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>ic<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>indicat<font style="letter-spacing:-0.1pt;">e</font>d:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss attributable to equity holders of the Company</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,689</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend accumulated for preferred shares during the period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,467</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss attributable to equity holders of the Company, after deducting dividend</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accumulated for preferred shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,825</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,408</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,541</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,716,790</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,503</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300,959</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss per ordinary share (LPS)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.35pt;"> </font>20<font style="letter-spacing:-0.1pt;">16</font> and 2015,<font style="letter-spacing:0.45pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>underlying<font style="letter-spacing:0.85pt;"> </font>outstand<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.95pt;"> </font>options,<font style="letter-spacing:0.75pt;"> </font>A-1<font style="letter-spacing:0.35pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.45pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>preferred shares<font style="letter-spacing:0.55pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>excluded<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>calculat<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>anti-dilutive.<font style="letter-spacing:0.95pt;"> </font>Di<font style="letter-spacing:-0.1pt;">l</font>uted<font style="letter-spacing:0.6pt;"> </font>LPS<font style="letter-spacing:0.35pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>include 2,415,545,<font style="letter-spacing:0.35pt;"> </font>2,665,099<font style="letter-spacing:0.8pt;"> and 2,199,838 </font>ordi<font style="letter-spacing:-0.1pt;">n</font>ary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>underlying<font style="letter-spacing:0.85pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>opti<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017, 2016<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2<font style="letter-spacing:-0.1pt;">0</font>15,<font style="letter-spacing:0.45pt;"> </font>respectively, 728,312<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>issuable<font style="letter-spacing:0.65pt;"> </font>up<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:0.45pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> Preferred </font>A-1<font style="letter-spacing:0.35pt;"> </font>warrants, which were converted to ordinary shares upon the IPO, for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016 and 2015, and 5,193,427 shares issuable upon conversion of preferred shares for the years ended December 31, 2016 and 2015.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6707615360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties-Transactions and Balances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties-Transactions and Balances</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.55pt;"> </font>11&#8212;RELATED<font style="letter-spacing:1.2pt;"> </font>PARTIES-TRANSAC<font style="letter-spacing:0.1pt;">T</font>IONS<font style="letter-spacing:2.2pt;"> </font>AND<font style="letter-spacing:0.4pt;"> </font>BALANCES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UPI<font style="letter-spacing:0.35pt;"> </font>entered<font style="letter-spacing:0.65pt;"> </font>into<font style="letter-spacing:0.3pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement,<font style="letter-spacing:0.9pt;"> </font>dated<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>November<font style="letter-spacing:0.85pt;"> </font>20<font style="letter-spacing:-0.1pt;">1</font>5<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>commencing<font style="letter-spacing:1pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>May<font style="letter-spacing:0.35pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>space<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>New<font style="letter-spacing:0.4pt;"> </font>York.<font style="letter-spacing:0.25pt;"> </font>UPI<font style="letter-spacing:0.35pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>office<font style="letter-spacing:0.45pt;"> </font>space<font style="letter-spacing:0.5pt;"> </font>equitably<font style="letter-spacing:0.75pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>Kite<font style="letter-spacing:0.35pt;"> </font>P<font style="letter-spacing:-0.1pt;">h</font>arma,<font style="letter-spacing:0.7pt;"> </font>Inc.,<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>Delaware<font style="letter-spacing:0.75pt;"> </font>corporation,<font style="letter-spacing:0.95pt;"> </font>which<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:0.05pt;"> </font>cosignatory<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>agreement.<font style="letter-spacing:0.9pt;"> </font>Arie<font style="letter-spacing:0.35pt;"> </font>Bell<font style="letter-spacing:-0.1pt;">d</font>egrun,<font style="letter-spacing:0.9pt;"> </font>M.D.,<font style="letter-spacing:0.45pt;"> </font>UPL&#8217;s<font style="letter-spacing:0.5pt;"> </font>chairman,<font style="letter-spacing:0.8pt;"> </font>served<font style="letter-spacing:0.55pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Chairman<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>Chief<font style="letter-spacing:0.5pt;"> </font>Executive<font style="letter-spacing:0.8pt;"> </font>Officer<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Kite Pharma,<font style="letter-spacing:0.7pt;"> </font>Inc. until his resignation effective as of October 3, 2017, in connection with the acquisition of Kite Pharma, Inc. by Gilead Sciences, Inc.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6643583696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE<font style="letter-spacing:0.5pt;"> </font>12&#8212;SUBSEQUENT<font style="letter-spacing:1.6pt;"> </font>EVENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2018, the Company completed a secondary public offering on the Nasdaq Stock Market of 1,682,926 ordinary shares, at a public offering price of $41.00 per share, in consideration for approximately $64 million net of underwriting discounts and commissions and issuance costs, including exercise of the underwriters&nbsp;&nbsp;option to purchase an additional 219,512 ordinary shares at the public offering price. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6864393040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">a.<font style="letter-spacing:0.2pt;"> </font>Basis<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>presentation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>b<font style="letter-spacing:-0.1pt;">e</font>en<font style="letter-spacing:0.45pt;"> </font>prepared<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>account<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.85pt;"> </font>principles<font style="letter-spacing:0.75pt;"> </font>generally<font style="letter-spacing:0.75pt;"> </font>accept<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>United<font style="letter-spacing:0.55pt;"> </font>States<font style="letter-spacing:0.55pt;"> </font>of America<font style="letter-spacing:0.7pt;"> </font>(&#8220;U.S.<font style="letter-spacing:0.55pt;"> </font>GAAP&#8221;).</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b. Principles of consolidation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The consolidated financial statements include the financial statements of UPL and its wholly owned subsidiary, UPI. Intercompany transactions and balances have been eliminated in consolidation.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in the Preparation of Financial Statements</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c.<font style="letter-spacing:0.2pt;"> </font>Use<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>estimates<font style="letter-spacing:0.85pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preparation<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>financial<font style="letter-spacing:0.75pt;"> </font>statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>preparation<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>conformity<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>U.S.<font style="letter-spacing:0.4pt;"> </font>GAAP<font style="letter-spacing:0.5pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>man<font style="letter-spacing:-0.1pt;">a</font>gement<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>make<font style="letter-spacing:0.45pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>affect the<font style="letter-spacing:0.05pt;"> </font>reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>assets<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities,<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>disclosure<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cont<font style="letter-spacing:-0.1pt;">i</font>ngent<font style="letter-spacing:0.85pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>financ<font style="letter-spacing:-0.1pt;">i</font>al<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the reported<font style="letter-spacing:0.7pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenues<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>duri<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>Actual<font style="letter-spacing:0.5pt;"> </font>results<font style="letter-spacing:0.55pt;"> </font>may<font style="letter-spacing:0.35pt;"> </font>differ<font style="letter-spacing:0.45pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>estimates.<font style="letter-spacing:0.8pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>applicable<font style="letter-spacing:0.9pt;"> </font>to these<font style="letter-spacing:0.45pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>financi<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.65pt;"> </font>statements,<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>most<font style="letter-spacing:0.4pt;"> </font>significant<font style="letter-spacing:0.8pt;"> </font>estimates<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>assumptions<font style="letter-spacing:1pt;"> </font>relate<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>compensat<font style="letter-spacing:-0.1pt;">i</font>on, the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>timing<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>recognition.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d.<font style="letter-spacing:0.2pt;"> </font>Functional<font style="letter-spacing:0.9pt;"> </font>currency</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>U.S.<font style="letter-spacing:0.4pt;"> </font>dollar<font style="letter-spacing:0.45pt;"> </font>(&#8220;Dollar&#8221;)<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>primary<font style="letter-spacing:0.6pt;"> </font>economic<font style="letter-spacing:0.8pt;"> </font>environment<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>subsidiary<font style="letter-spacing:0.8pt;"> </font>are conducted.<font style="letter-spacing:0.9pt;"> </font>Therefore,<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>functional<font style="letter-spacing:0.8pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Dol<font style="letter-spacing:-0.1pt;">l</font>ar.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,<font style="letter-spacing:1pt;"> </font>transactions<font style="letter-spacing:0.95pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>currencies<font style="letter-spacing:0.85pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Do<font style="letter-spacing:-0.1pt;">l</font>lar<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>functional<font style="letter-spacing:0.8pt;"> </font>currency<font style="letter-spacing:0.7pt;"> </font>usi<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exchange<font style="letter-spacing:0.8pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>in effect<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>transaction.<font style="letter-spacing:0.95pt;"> </font>At<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>date,<font style="letter-spacing:0.45pt;"> </font>monetary<font style="letter-spacing:0.75pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liab<font style="letter-spacing:-0.1pt;">i</font>lities<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>denominated<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>currencies<font style="letter-spacing:0.85pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>than the<font style="letter-spacing:0.05pt;"> </font>Dollar<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>measured<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>official<font style="letter-spacing:0.55pt;"> </font>exch<font style="letter-spacing:-0.1pt;">a</font>nge<font style="letter-spacing:0.8pt;"> </font>rate<font style="letter-spacing:0.35pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>effects<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>foreign<font style="letter-spacing:0.55pt;"> </font>currency<font style="letter-spacing:0.8pt;"> </font>re-measurements<font style="letter-spacing:1.45pt;"> </font>are recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consolidated<font style="letter-spacing:1pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>&#8220;fin<font style="letter-spacing:-0.1pt;">a</font>ncial<font style="letter-spacing:0.75pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>(expenses).&#8221;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e.<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.45pt;"> </font>equivalents</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equiv<font style="letter-spacing:-0.1pt;">a</font>lents<font style="letter-spacing:0.9pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>short-term,<font style="letter-spacing:0.85pt;"> </font>highly<font style="letter-spacing:0.5pt;"> </font>liquid<font style="letter-spacing:0.45pt;"> </font>investments,<font style="letter-spacing:1pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>incl<font style="letter-spacing:-0.1pt;">u</font>de<font style="letter-spacing:0.6pt;"> </font>short-term<font style="letter-spacing:0.8pt;"> </font>bank<font style="letter-spacing:0.4pt;"> </font>deposits<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>original maturities<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>three<font style="letter-spacing:0.45pt;"> </font>months<font style="letter-spacing:0.6pt;"> </font>or<font style="letter-spacing:0.25pt;"> </font>less<font style="letter-spacing:0.35pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>purchase<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>withdrawal<font style="letter-spacing:0.85pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>readily<font style="letter-spacing:0.55pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>to known<font style="letter-spacing:0.55pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash.&nbsp;&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term Investments</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">f.  Short-term investments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests in short-term investments that consist of mutual and bond funds.&nbsp;&nbsp;While these investments are considered highly liquid and available to fund current operations, there is more than an insignificant risk of change in value due to interest rate, quoted price, or penalty on withdrawal and are therefore classified as short-term investments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We classify our short-term investments as available-for-sale in accordance with FASB ASC Topic 320, &#8220;Investments &#8212; Debt and Equity Securities&#8221;. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in other comprehensive income/loss within stockholders&#8217; equity.&nbsp;&nbsp;There was no change in value for the period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments are valued using models or other valuation methodologies that use Level 2 inputs. These models are primarily industry-standard models that consider various assumptions, including time value, yield curve, volatility factors, default rates, current market and contractual prices for the underlying financial instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace.&#160;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">g.<font style="letter-spacing:0.2pt;"> </font>Property<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>stated<font style="letter-spacing:0.5pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>cost,<font style="letter-spacing:0.4pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accumulated<font style="letter-spacing:1pt;"> </font>depreciation.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The<font style="letter-spacing:0.35pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment<font style="letter-spacing:0.85pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>d<font style="letter-spacing:-0.1pt;">e</font>preciated<font style="letter-spacing:0.95pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>basis<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">s</font>eful<font style="letter-spacing:0.5pt;"> </font>lives.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual<font style="letter-spacing:0.6pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>depreciation<font style="letter-spacing:1pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15-30</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-15</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold<font style="letter-spacing:0.85pt;"> </font>improvements<font style="letter-spacing:1.1pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>amortized<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>strai<font style="letter-spacing:-0.1pt;">g</font>ht-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.6pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>shorter<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>term<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>useful life<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>improvements.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">h.<font style="letter-spacing:0.15pt;"> </font>Impairment<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>long-lived<font style="letter-spacing:0.85pt;"> </font>assets</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>tests<font style="letter-spacing:0.4pt;"> </font>long-lived<font style="letter-spacing:0.8pt;"> </font>assets,<font style="letter-spacing:0.6pt;"> </font>comprised<font style="letter-spacing:0.85pt;"> </font>solely<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>equipment,<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>whenever<font style="letter-spacing:0.8pt;"> </font>ev<font style="letter-spacing:-0.1pt;">e</font>nts<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>circumstances<font style="letter-spacing:1.15pt;"> </font>present an<font style="letter-spacing:0.25pt;"> </font>indication<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>impairment.<font style="letter-spacing:0.95pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sum<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>undiscounted<font style="letter-spacing:1.05pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>less<font style="letter-spacing:0.35pt;"> </font>th<font style="letter-spacing:-0.1pt;">a</font>n<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>carrying<font style="letter-spacing:0.65pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>such assets, an<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>recognized.<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:-0.1pt;">s</font>ets<font style="letter-spacing:0.55pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>written<font style="letter-spacing:0.55pt;"> </font>down<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>estimated<font style="letter-spacing:0.8pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>values,<font style="letter-spacing:0.6pt;"> </font>calculated<font style="letter-spacing:0.8pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>ased<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the present<font style="letter-spacing:0.6pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>expected<font style="letter-spacing:0.75pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>discounted<font style="letter-spacing:0.85pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>some<font style="letter-spacing:0.45pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>e<font style="letter-spacing:0.45pt;"> </font>measure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017 and<font style="letter-spacing:0.35pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>d<font style="letter-spacing:-0.1pt;">i</font>d<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>impairment<font style="letter-spacing:0.9pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>long-lived<font style="letter-spacing:0.8pt;"> </font>assets.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i.<font style="letter-spacing:0.2pt;"> </font>Financial<font style="letter-spacing:0.8pt;"> </font>instruments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issues<font style="letter-spacing:0.55pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares,<font style="letter-spacing:0.6pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>A<font style="letter-spacing:-0.1pt;">S</font>C<font style="letter-spacing:0.4pt;"> </font>480<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine<font style="letter-spacing:0.8pt;"> </font>whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>should be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liability.<font style="letter-spacing:0.6pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company further<font style="letter-spacing:0.55pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument&#8217;s<font style="letter-spacing:0.95pt;"> </font>characteristics<font style="letter-spacing:1.15pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine<font style="letter-spacing:0.8pt;"> </font>whether<font style="letter-spacing:0.65pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>c<font style="letter-spacing:-0.1pt;">l</font>assified<font style="letter-spacing:0.75pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>temporary<font style="letter-spacing:0.8pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>(mezzanine)<font style="letter-spacing:1pt;"> </font>or within<font style="letter-spacing:0.5pt;"> </font>permanent<font style="letter-spacing:0.85pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ith<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.4pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.55pt;"> </font>480-10-S99.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>issues<font style="letter-spacing:0.55pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>freestanding<font style="letter-spacing:1pt;"> </font>instruments,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>first<font style="letter-spacing:0.3pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480<font style="letter-spacing:0.35pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>determine whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>l<font style="letter-spacing:-0.1pt;">i</font>ability,<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>subsequent<font style="letter-spacing:0.95pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>va<font style="letter-spacing:-0.1pt;">l</font>ue<font style="letter-spacing:0.45pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>earnings<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>ea<font style="letter-spacing:-0.1pt;">c</font>h<font style="letter-spacing:0.4pt;"> </font>period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>scope<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>480,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>further<font style="letter-spacing:0.55pt;"> </font>analyzes<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>provisi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.3pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>815-40<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.3pt;"> </font>determine whether<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>instrument<font style="letter-spacing:0.85pt;"> </font>should<font style="letter-spacing:0.55pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>wit<font style="letter-spacing:-0.1pt;">h</font>in<font style="letter-spacing:0.5pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>rather<font style="letter-spacing:0.5pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>liability,<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>subse<font style="letter-spacing:-0.1pt;">q</font>uent<font style="letter-spacing:0.95pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value recognized<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>earnings<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>ea<font style="letter-spacing:-0.1pt;">c</font>h<font style="letter-spacing:0.4pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>See<font style="letter-spacing:0.35pt;"> </font>note<font style="letter-spacing:0.4pt;"> </font>7<font style="letter-spacing:0.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>note<font style="letter-spacing:0.4pt;"> </font>8.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j.<font style="letter-spacing:0.15pt;"> </font>Share-based<font style="letter-spacing:1.05pt;"> </font>compensation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>employees&#8217;<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>directors&#8217;<font style="letter-spacing:0.75pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>payment<font style="letter-spacing:0.7pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>classif<font style="letter-spacing:-0.1pt;">i</font>ed<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant-date<font style="letter-spacing:0.8pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value method.<font style="letter-spacing:0.65pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>payment<font style="letter-spacing:0.7pt;"> </font>transactions<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recogni<font style="letter-spacing:-0.1pt;">z</font>ed<font style="letter-spacing:0.9pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>expense<font style="letter-spacing:0.7pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requisite<font style="letter-spacing:0.7pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>period.<font style="letter-spacing:0.55pt;"> </font>As<font style="letter-spacing:0.25pt;"> </font>of December<font style="letter-spacing:0.65pt;"> </font>31,<font style="letter-spacing:0.1pt;"> </font>2016,<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>Company<font style="letter-spacing:0.6pt;"> </font>has<font style="letter-spacing:0.15pt;"> </font>early<font style="letter-spacing:0.25pt;"> </font>ad<font style="letter-spacing:-0.1pt;">o</font>pted<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>policy<font style="letter-spacing:0.3pt;"> </font>to account<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>forfeitures<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.05pt;"> </font>they<font style="letter-spacing:0.2pt;"> </font>occur<font style="letter-spacing:0.25pt;"> </font>according<font style="letter-spacing:0.6pt;"> </font>to the<font style="letter-spacing:0.1pt;"> </font>FASB&#8217;s<font style="letter-spacing:0.4pt;"> </font>Accounting Standards<font style="letter-spacing:0.65pt;"> </font>Update<font style="letter-spacing:0.5pt;"> </font>(ASU)<font style="letter-spacing:0.3pt;"> </font>2016-09,<font style="letter-spacing:0.65pt;"> </font>Improvements<font style="letter-spacing:0.95pt;"> </font>to Employee<font style="letter-spacing:0.65pt;"> </font>Share-Based<font style="letter-spacing:0.85pt;"> </font>Payment<font style="letter-spacing:0.55pt;"> </font>Accounting.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.15pt;"> </font>a<font style="letter-spacing:-0.1pt;">d</font>justment<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.1pt;"> </font>beginning<font style="letter-spacing:0.6pt;"> </font>of the period<font style="letter-spacing:0.5pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>material<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>reflected<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>conso<font style="letter-spacing:-0.1pt;">l</font>idated<font style="letter-spacing:1pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>shareholders&#8217;<font style="letter-spacing:1.05pt;"> </font>e<font style="letter-spacing:-0.1pt;">q</font>uity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>elected<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>compen<font style="letter-spacing:-0.1pt;">s</font>ation<font style="letter-spacing:1.1pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>conditioned<font style="letter-spacing:0.9pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>conti<font style="letter-spacing:-0.1pt;">n</font>ued<font style="letter-spacing:0.8pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>graded<font style="letter-spacing:0.6pt;"> </font>vesting<font style="letter-spacing:0.6pt;"> </font>schedule<font style="letter-spacing:0.05pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sin<font style="letter-spacing:-0.1pt;">g</font>le-option<font style="letter-spacing:1pt;"> </font>award<font style="letter-spacing:0.5pt;"> </font>approach.<font style="letter-spacing:0.8pt;"> </font>Performance<font style="letter-spacing:1pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>wards<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>expensed<font style="letter-spacing:0.05pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>requisite<font style="letter-spacing:0.7pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>hen<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>achievement<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>criteria<font style="letter-spacing:0.55pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>probable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>non-employees<font style="letter-spacing:1.3pt;"> </font>are<font style="letter-spacing:0.35pt;"> </font>re-measured<font style="letter-spacing:1.1pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>period<font style="letter-spacing:0.5pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>commitment<font style="letter-spacing:0.95pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>reached which<font style="letter-spacing:0.5pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>usually<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>completed.<font style="letter-spacing:0.9pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>va<font style="letter-spacing:-0.1pt;">l</font>ue<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>equity<font style="letter-spacing:0.5pt;"> </font>awards<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>charged<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations<font style="letter-spacing:0.85pt;"> </font>over<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>service period<font style="letter-spacing:0.5pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>straight-line<font style="letter-spacing:0.95pt;"> </font>method.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">k.<font style="letter-spacing:0.15pt;"> </font>Revenue<font style="letter-spacing:0.75pt;"> </font>recognition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Virtually<font style="letter-spacing:0.65pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>revenues<font style="letter-spacing:0.75pt;"> </font>are<font style="letter-spacing:0.25pt;"> </font>derived<font style="letter-spacing:0.6pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>Allergan,<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>lic<font style="letter-spacing:-0.1pt;">e</font>nse<font style="letter-spacing:0.6pt;"> </font>worldwide<font style="letter-spacing:0.8pt;"> </font>rights<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>some<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>products. See also Note 1. Revenue<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>hen<font style="letter-spacing:0.45pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>conditi<font style="letter-spacing:-0.1pt;">o</font>ns<font style="letter-spacing:0.8pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>met:<font style="letter-spacing:0.4pt;"> </font>(i)<font style="letter-spacing:0.2pt;"> </font>there<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>persuasive<font style="letter-spacing:0.85pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>arrangement; (ii)<font style="letter-spacing:0.25pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>occurred:<font style="letter-spacing:0.75pt;"> </font>(iii)<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable:<font style="letter-spacing:1.1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(iv)<font style="letter-spacing:0.3pt;"> </font>collectab<font style="letter-spacing:-0.1pt;">i</font>lity<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonably<font style="letter-spacing:0.9pt;"> </font>assured.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>agreement<font style="letter-spacing:1pt;"> </font>contains<font style="letter-spacing:0.7pt;"> </font>two<font style="letter-spacing:0.3pt;"> </font>deliverables:<font style="letter-spacing:1pt;"> </font>(a)<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>comp<font style="letter-spacing:-0.1pt;">o</font>nent<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(b)<font style="letter-spacing:0.25pt;"> </font>Allergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>require<font style="letter-spacing:0.6pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>RTGel<font style="letter-spacing:0.55pt;"> </font>vi<font style="letter-spacing:-0.1pt;">a</font>ls from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.3pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>multiple<font style="letter-spacing:0.65pt;"> </font>deliverab<font style="letter-spacing:-0.1pt;">l</font>es,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>shall<font style="letter-spacing:0.4pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>u<font style="letter-spacing:-0.1pt;">n</font>it<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>all<font style="letter-spacing:0.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the following<font style="letter-spacing:0.7pt;"> </font>criteria<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>met:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="letter-spacing:0.25pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>customer<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>is.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>items<font style="letter-spacing:0.45pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>sold<font style="letter-spacing:0.05pt;"> </font>separately<font style="letter-spacing:0.85pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>vendor<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>customer<font style="letter-spacing:0.75pt;"> </font>could<font style="letter-spacing:0.45pt;"> </font>resell<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s)<font style="letter-spacing:0.55pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>standal<font style="letter-spacing:-0.1pt;">o</font>ne<font style="letter-spacing:0.9pt;"> </font>basis.<font style="letter-spacing:0.5pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>context<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>customer&#8217;s<font style="letter-spacing:0.85pt;"> </font>ability<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>resell<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s),<font style="letter-spacing:0.6pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>criterion<font style="letter-spacing:0.65pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>require<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>existence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>ob<font style="letter-spacing:-0.1pt;">s</font>ervable<font style="letter-spacing:0.9pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>deliverable(s),<font style="letter-spacing:1.1pt;"> </font>and</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="letter-spacing:0.25pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>includes<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>general<font style="letter-spacing:0.6pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>return<font style="letter-spacing:0.5pt;"> </font>relative<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>item(s),<font style="letter-spacing:0.6pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>unde<font style="letter-spacing:-0.1pt;">l</font>ivered<font style="letter-spacing:1.1pt;"> </font>item<font style="letter-spacing:0.35pt;"> </font>or items<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>probable<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>subst<font style="letter-spacing:-0.1pt;">a</font>ntially<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>control<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>vendor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When<font style="letter-spacing:0.5pt;"> </font>deliverables<font style="letter-spacing:0.95pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>separab<font style="letter-spacing:-0.1pt;">l</font>e,<font style="letter-spacing:0.85pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>allocated<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>separate<font style="letter-spacing:0.7pt;"> </font>units<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>relati<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.6pt;"> </font>selling<font style="letter-spacing:0.55pt;"> </font>price<font style="letter-spacing:0.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>deliverable<font style="letter-spacing:0.85pt;"> </font>(where<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>locable<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivered<font style="letter-spacing:0.75pt;"> </font>element<font style="letter-spacing:0.65pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>limited<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amo<font style="letter-spacing:-0.1pt;">u</font>nt<font style="letter-spacing:0.6pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>contingent<font style="letter-spacing:0.85pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>future products<font style="letter-spacing:0.7pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>services)<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>appropriate<font style="letter-spacing:0.9pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>recognition<font style="letter-spacing:0.9pt;"> </font>princip<font style="letter-spacing:-0.1pt;">l</font>es<font style="letter-spacing:0.75pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>applied<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>unit. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>component<font style="letter-spacing:0.9pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>standa<font style="letter-spacing:-0.1pt;">l</font>one<font style="letter-spacing:0.9pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>(and<font style="letter-spacing:0.4pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>accounted<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>separately<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services)<font style="letter-spacing:0.75pt;"> </font>since<font style="letter-spacing:0.5pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>can<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>the license<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intended<font style="letter-spacing:0.7pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>without<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any&#8217;s<font style="letter-spacing:0.9pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services.<font style="letter-spacing:0.7pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>four<font style="letter-spacing:0.35pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>605<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ere<font style="letter-spacing:0.4pt;"> </font>met<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> 2017 and </font>2016: (1)<font style="letter-spacing:0.25pt;"> </font>persuasive<font style="letter-spacing:0.85pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>exists<font style="letter-spacing:0.5pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.45pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>engaged<font style="letter-spacing:0.7pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>inding<font style="letter-spacing:0.6pt;"> </font>agreement;<font style="letter-spacing:0.9pt;"> </font>(2)<font style="letter-spacing:0.25pt;"> </font>delivery<font style="letter-spacing:0.65pt;"> </font>has occurred<font style="letter-spacing:0.7pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>rendered<font style="letter-spacing:0.75pt;"> </font>since<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>l<font style="letter-spacing:0.2pt;"> </font>documents<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>request<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.8pt;"> </font>relating<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company&#8217;s<font style="letter-spacing:0.9pt;"> </font>know-how<font style="letter-spacing:0.8pt;"> </font>were provided<font style="letter-spacing:0.7pt;"> </font>before<font style="letter-spacing:0.55pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.3pt;"> </font>Allergan<font style="letter-spacing:0.65pt;"> </font>can<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>intend<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.7pt;"> </font>purposes<font style="letter-spacing:0.75pt;"> </font>without<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>(except<font style="letter-spacing:0.6pt;"> </font>for immaterial<font style="letter-spacing:0.85pt;"> </font>support<font style="letter-spacing:0.6pt;"> </font>services);<font style="letter-spacing:0.8pt;"> </font>(3)<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable,<font style="letter-spacing:1.1pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>indicated<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>licen<font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:0.6pt;"> </font>agreement;<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>(4)<font style="letter-spacing:0.25pt;"> </font>collectability<font style="letter-spacing:0.95pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonably assured.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>entitled<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>milestone<font style="letter-spacing:0.8pt;"> </font>payments<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>royalties<font style="letter-spacing:0.7pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>Allergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>reve<font style="letter-spacing:-0.1pt;">n</font>ue<font style="letter-spacing:0.65pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>product,<font style="letter-spacing:0.65pt;"> </font>which are<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>considered<font style="letter-spacing:0.9pt;"> </font>fixed<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>determinable<font style="letter-spacing:1.05pt;"> </font>until<font style="letter-spacing:0.35pt;"> </font>th<font style="letter-spacing:-0.1pt;">e</font>ir<font style="letter-spacing:0.4pt;"> </font>occurrence.<font style="letter-spacing:0.95pt;"> </font>Therefore,<font style="letter-spacing:0.85pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>only<font style="letter-spacing:0.35pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>recogniz<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.9pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>for payment<font style="letter-spacing:0.7pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>met,<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>they<font style="letter-spacing:0.35pt;"> </font>become<font style="letter-spacing:0.65pt;"> </font>due<font style="letter-spacing:0.35pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>payable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During October<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>n<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$17.5<font style="letter-spacing:0.45pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>represented<font style="letter-spacing:0.85pt;"> </font>arrangement<font style="letter-spacing:1pt;"> </font>consi<font style="letter-spacing:-0.1pt;">d</font>eration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>both the<font style="letter-spacing:0.35pt;"> </font>license<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intellectual<font style="letter-spacing:0.85pt;"> </font>property<font style="letter-spacing:0.65pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>well<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font><font style="letter-spacing:-0.1pt;">A</font>llergan&#8217;s<font style="letter-spacing:0.8pt;"> </font>right<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>future<font style="letter-spacing:0.5pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>(which<font style="letter-spacing:0.55pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">b</font>e<font style="letter-spacing:0.25pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>consideration<font style="letter-spacing:1.05pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>future payments<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>according<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>pricing<font style="letter-spacing:0.55pt;"> </font>stipulat<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>agreement).<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.85pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>pricing<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the supply<font style="letter-spacing:0.05pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>represents<font style="letter-spacing:0.85pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>standalone<font style="letter-spacing:0.9pt;"> </font>se<font style="letter-spacing:-0.1pt;">l</font>ling<font style="letter-spacing:0.55pt;"> </font>price.<font style="letter-spacing:0.45pt;"> </font>Accordingly,<font style="letter-spacing:1pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>allo<font style="letter-spacing:-0.1pt;">c</font>ated<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>entire<font style="letter-spacing:0.45pt;"> </font>upfront<font style="letter-spacing:0.6pt;"> </font>fee<font style="letter-spacing:0.3pt;"> </font>of $17.5<font style="letter-spacing:0.45pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the license<font style="letter-spacing:0.6pt;"> </font>component.<font style="letter-spacing:0.95pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>addition,<font style="letter-spacing:0.7pt;"> </font>revenue<font style="letter-spacing:0.65pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>supply<font style="letter-spacing:0.55pt;"> </font>servi<font style="letter-spacing:-0.1pt;">c</font>es<font style="letter-spacing:0.65pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.3pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>equal<font style="letter-spacing:0.45pt;"> to </font>the<font style="letter-spacing:0.3pt;"> </font>consi<font style="letter-spacing:-0.1pt;">d</font>eration<font style="letter-spacing:1.05pt;"> </font>stipulated<font style="letter-spacing:0.8pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the agreement<font style="letter-spacing:0.85pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>services,<font style="letter-spacing:0.7pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>provided.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During July 2017, the Company earned a milestone payment of $7.5 million resulting from Allergan&#8217;s submission of an IND application for the Company&#8217;s RTGel in combination with Allergan&#8217;s BOTOX for the treatment of overactive bladder to the U.S. FDA. The Company received the milestone payment in August 2017. This milestone was recognized as revenue during the year ended December 31, 2017, as conditions for payment were met and the milestone payment was considered fixed or determinable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">l.<font style="letter-spacing:0.2pt;"> </font>Research<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1.1pt;"> </font>costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research<font style="letter-spacing:0.8pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>expen<font style="letter-spacing:-0.1pt;">s</font>ed<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>incurred<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>consist<font style="letter-spacing:0.6pt;"> </font>primarily<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>cost<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>salaries,<font style="letter-spacing:0.7pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>compensat<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:1.1pt;"> </font>expenses,<font style="letter-spacing:0.05pt;"> </font>payroll<font style="letter-spacing:0.55pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>employee<font style="letter-spacing:0.8pt;"> </font>benefits,<font style="letter-spacing:0.7pt;"> </font>subcontractors<font style="letter-spacing:1.15pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>materials<font style="letter-spacing:0.75pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>evelopment<font style="letter-spacing:1pt;"> </font>activities, including preclinical studies, clinical trials, manufacturing costs<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>professional<font style="letter-spacing:0.05pt;"> </font>services. The<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>services<font style="letter-spacing:0.65pt;"> </font>performed<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>others<font style="letter-spacing:0.5pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>connection<font style="letter-spacing:0.85pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>nd<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>activities of an<font style="letter-spacing:0.05pt;"> </font>entity,<font style="letter-spacing:0.3pt;"> </font>including<font style="letter-spacing:0.55pt;"> </font>research<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.15pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment<font style="letter-spacing:0.85pt;"> </font>conducted<font style="letter-spacing:0.65pt;"> </font>by<font style="letter-spacing:0.05pt;"> </font>others<font style="letter-spacing:0.35pt;"> </font>on behalf<font style="letter-spacing:0.35pt;"> </font>of the<font style="letter-spacing:0.1pt;"> </font>entity,<font style="letter-spacing:0.3pt;"> </font>shall<font style="letter-spacing:0.2pt;"> </font>be<font style="letter-spacing:0.05pt;"> </font>inc<font style="letter-spacing:-0.1pt;">l</font>uded<font style="letter-spacing:0.5pt;"> </font>in research<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.25pt;"> </font>development costs.<font style="letter-spacing:0.5pt;"> </font>Grants<font style="letter-spacing:0.55pt;"> </font>received<font style="letter-spacing:0.7pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Israel<font style="letter-spacing:0.45pt;"> </font>Innovation<font style="letter-spacing:0.85pt;"> </font>Authority,<font style="letter-spacing:0.75pt;"> </font>f/k/a<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Office<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Chief<font style="letter-spacing:0.45pt;"> </font>Scientist<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Israel&#8217;s<font style="letter-spacing:0.6pt;"> </font>Ministry<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.25pt;"> </font>Industry,<font style="letter-spacing:0.7pt;"> </font>Trade<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>Labor<font style="letter-spacing:0.5pt;"> </font>(the<font style="letter-spacing:0.35pt;"> </font>&#8220;IIA&#8221;)<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>becomes<font style="letter-spacing:0.75pt;"> </font>receiva<font style="letter-spacing:-0.1pt;">b</font>le,<font style="letter-spacing:0.85pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>there<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reasonable<font style="letter-spacing:0.9pt;"> </font>assurance<font style="letter-spacing:0.85pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Com<font style="letter-spacing:-0.1pt;">p</font>any<font style="letter-spacing:0.8pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>comply<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>conditions<font style="letter-spacing:0.8pt;"> </font>attached<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>there<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>reaso<font style="letter-spacing:-0.1pt;">n</font>able<font style="letter-spacing:0.9pt;"> </font>assurance<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>received.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>deducted<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:1pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>pplicable<font style="letter-spacing:0.8pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>incurred.<font style="letter-spacing:0.7pt;"> </font>In<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.4pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.75pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>n<font style="letter-spacing:0.25pt;"> </font>increase<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$175<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.05pt;"> </font>development<font style="letter-spacing:1pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>decis<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.65pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>pursue<font style="letter-spacing:0.55pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>programs<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>had<font style="letter-spacing:0.35pt;"> </font>been<font style="letter-spacing:0.45pt;"> </font>approved<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>result<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>other<font style="letter-spacing:0.05pt;"> </font>financing<font style="letter-spacing:0.75pt;"> </font>opportunities.<font style="letter-spacing:1.05pt;"> </font>For<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font><font style="letter-spacing:-0.1pt;">D</font>ecember<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>$126<font style="font-size:12pt;">&#160;</font>was received from Allergan, in connection with the pre-clinical collaboration agreement signed in August 2015 and deducted from the research and development expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>intangibles<font style="letter-spacing:0.85pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>purchased<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>others<font style="letter-spacing:0.5pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>particular<font style="letter-spacing:0.75pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment<font style="letter-spacing:1pt;"> </font>project<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>alternative<font style="letter-spacing:0.85pt;"> </font>future uses<font style="letter-spacing:0.4pt;"> </font>(in<font style="letter-spacing:0.25pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>research<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>development<font style="letter-spacing:1pt;"> </font>projects<font style="letter-spacing:0.65pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>otherwise)<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>therefore<font style="letter-spacing:0.75pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>s<font style="letter-spacing:-0.1pt;">e</font>parate<font style="letter-spacing:0.7pt;"> </font>economic<font style="letter-spacing:0.8pt;"> </font>values<font style="letter-spacing:0.55pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>research<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>deve<font style="letter-spacing:-0.1pt;">l</font>opment costs<font style="letter-spacing:0.45pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>time<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>incurred. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_DeferredTaxesPolicyTextBlock', window );">Deferred Taxes</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">m.<font style="letter-spacing:0.15pt;"> </font>Income tax</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">1)<font style="letter-spacing:0.2pt;"> </font>Deferred<font style="letter-spacing:0.7pt;"> </font>taxes</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred<font style="letter-spacing:0.6pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabi<font style="letter-spacing:-0.1pt;">l</font>ity<font style="letter-spacing:0.65pt;"> </font>method.<font style="letter-spacing:0.65pt;"> </font>Under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>method,<font style="letter-spacing:0.65pt;"> </font>deferred<font style="letter-spacing:0.7pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and liabilities<font style="letter-spacing:0.7pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>determined<font style="letter-spacing:0.9pt;"> </font>bas<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>differences<font style="letter-spacing:0.9pt;"> </font>between<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font>reporti<font style="letter-spacing:-0.1pt;">n</font>g<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>tax bases<font style="letter-spacing:0.5pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>mea<font style="letter-spacing:-0.1pt;">s</font>ured<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>enacted<font style="letter-spacing:0.65pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>laws.<font style="letter-spacing:0.45pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>llowance<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>recognized<font style="letter-spacing:0.9pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the extent<font style="letter-spacing:0.5pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>deferred<font style="letter-spacing:0.7pt;"> </font>taxes<font style="letter-spacing:0.45pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>realized<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>foresee<font style="letter-spacing:-0.1pt;">a</font>ble<font style="letter-spacing:0.95pt;"> </font>future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">2)<font style="letter-spacing:0.2pt;"> </font>Uncertain<font style="letter-spacing:0.8pt;"> </font>income<font style="letter-spacing:0.6pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>positions</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>follows<font style="letter-spacing:0.55pt;"> </font>a<font style="letter-spacing:0.3pt;"> </font>two-step<font style="letter-spacing:0.8pt;"> </font>approach<font style="letter-spacing:0.75pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>recognizing<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>measuring<font style="letter-spacing:0.85pt;"> </font>uncertain<font style="letter-spacing:0.75pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>positions.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>first<font style="letter-spacing:0.3pt;"> </font>step<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>evaluate<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>position for<font style="letter-spacing:0.25pt;"> </font>recognition<font style="letter-spacing:0.9pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>determining<font style="letter-spacing:0.95pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>availab<font style="letter-spacing:-0.1pt;">l</font>e<font style="letter-spacing:0.7pt;"> </font>evidence<font style="letter-spacing:0.75pt;"> </font>indicates<font style="letter-spacing:0.7pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>position<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">w</font>ill<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>sustained<font style="letter-spacing:0.8pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on technical<font style="letter-spacing:0.7pt;"> </font>merits.<font style="letter-spacing:0.55pt;"> </font>If<font style="letter-spacing:0.15pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>threshold<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>met,<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>second<font style="letter-spacing:0.6pt;"> </font>step<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>measure<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>tax<font style="letter-spacing:0.3pt;"> </font>benefit<font style="letter-spacing:0.55pt;"> </font>as<font style="letter-spacing:0.3pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>largest<font style="letter-spacing:0.55pt;"> </font>amount<font style="letter-spacing:0.6pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>more<font style="letter-spacing:0.45pt;"> </font>likely<font style="letter-spacing:0.45pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>of being<font style="letter-spacing:0.45pt;"> </font>realized<font style="letter-spacing:0.65pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>ultim<font style="letter-spacing:0.1pt;">a</font>te<font style="letter-spacing:0.65pt;"> </font>settlement. As of December 31, 2017 and 2016, the Company had not accrued a provision for uncertain tax positions.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">n.<font style="letter-spacing:0.25pt;"> </font>Loss<font style="letter-spacing:0.45pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic<font style="letter-spacing:0.45pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>(&#8220;LPS&#8221;)<font style="letter-spacing:0.6pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>dividing<font style="letter-spacing:0.65pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year,<font style="letter-spacing:0.45pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>reducing<font style="letter-spacing:0.7pt;"> </font>cumulati<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.85pt;"> </font>dividends<font style="letter-spacing:0.75pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;">, </font>by<font style="letter-spacing:0.25pt;"> </font>the weighted<font style="letter-spacing:0.75pt;"> </font>average<font style="letter-spacing:0.75pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordinary<font style="letter-spacing:0.65pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>outstanding<font style="letter-spacing:0.95pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>peri<font style="letter-spacing:-0.1pt;">o</font>d.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>calculation<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>net<font style="letter-spacing:0.3pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>ex<font style="letter-spacing:-0.1pt;">c</font>ludes<font style="letter-spacing:0.7pt;"> </font>potential<font style="letter-spacing:0.7pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>issuances<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ordi<font style="letter-spacing:-0.1pt;">n</font>ary<font style="letter-spacing:0.8pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>upon<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>exercise<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>options, warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>convertible<font style="letter-spacing:0.85pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>each<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>anti-dilutive.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o.<font style="letter-spacing:0.2pt;"> </font>Fair<font style="letter-spacing:0.45pt;"> </font>value<font style="letter-spacing:0.5pt;"> </font>measurement</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair<font style="letter-spacing:0.35pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>price<font style="letter-spacing:0.4pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>rec<font style="letter-spacing:-0.1pt;">e</font>ived<font style="letter-spacing:0.7pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>sale<font style="letter-spacing:0.35pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>would<font style="letter-spacing:0.5pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>paid<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>transfer<font style="letter-spacing:0.65pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>liability<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.3pt;"> </font>orderly transaction<font style="letter-spacing:0.9pt;"> </font>between<font style="letter-spacing:0.7pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>participants<font style="letter-spacing:0.9pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>measurement<font style="letter-spacing:1.1pt;"> </font>date.<font style="letter-spacing:0.45pt;"> </font>In<font style="letter-spacing:0.2pt;"> </font>order<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>increase<font style="letter-spacing:0.7pt;"> </font>consistency<font style="letter-spacing:0.95pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>comparability<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value measurements,<font style="letter-spacing:1.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>guidance<font style="letter-spacing:0.75pt;"> </font>establishes<font style="letter-spacing:0.9pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>e<font style="letter-spacing:0.45pt;"> </font>hierarchy<font style="letter-spacing:0.75pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>prioritizes<font style="letter-spacing:0.8pt;"> </font>observable<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>unob<font style="letter-spacing:-0.1pt;">s</font>ervable<font style="letter-spacing:1.2pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>measure<font style="letter-spacing:0.7pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value into<font style="letter-spacing:0.3pt;"> </font>three<font style="letter-spacing:0.45pt;"> </font>broad<font style="letter-spacing:0.5pt;"> </font>levels,<font style="letter-spacing:0.55pt;"> </font>which<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>described<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>fo<font style="letter-spacing:-0.1pt;">l</font>lows:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>1:<font style="letter-spacing:0.2pt;"> </font>Quoted<font style="letter-spacing:0.6pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>(unadjusted)<font style="letter-spacing:1pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>active<font style="letter-spacing:0.5pt;"> </font>markets<font style="letter-spacing:0.65pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>accessible<font style="letter-spacing:0.85pt;"> </font>at<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>measurement<font style="letter-spacing:1.1pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>liabilities.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value hierarchy<font style="letter-spacing:0.75pt;"> </font>gives<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>highest<font style="letter-spacing:0.6pt;"> </font>priority<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Level<font style="letter-spacing:0.45pt;"> </font>1<font style="letter-spacing:0.15pt;"> </font>inputs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>2:<font style="letter-spacing:0.2pt;"> </font>Observable<font style="letter-spacing:1.05pt;"> </font>prices<font style="letter-spacing:0.5pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>based<font style="letter-spacing:0.5pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>quoted<font style="letter-spacing:0.55pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>active<font style="letter-spacing:0.5pt;"> </font>markets but<font style="letter-spacing:0.3pt;"> </font>corroborated<font style="letter-spacing:1pt;"> </font>by<font style="letter-spacing:0.25pt;"> </font>market<font style="letter-spacing:0.55pt;"> </font>data.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level<font style="letter-spacing:0.45pt;"> </font>3:<font style="letter-spacing:0.2pt;"> </font>Unobservable<font style="letter-spacing:1.1pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>us<font style="letter-spacing:-0.1pt;">e</font>d<font style="letter-spacing:0.4pt;"> </font>when<font style="letter-spacing:0.45pt;"> </font>little<font style="letter-spacing:0.35pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>no<font style="letter-spacing:0.25pt;"> </font>market<font style="letter-spacing:0.65pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>available.<font style="letter-spacing:0.75pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>hierarchy<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">g</font>ives<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>lowest<font style="letter-spacing:0.55pt;"> </font>priority<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Level<font style="letter-spacing:0.45pt;"> </font>3 inputs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<font style="letter-spacing:0.2pt;"> </font>determining<font style="letter-spacing:0.95pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value,<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>utilizes<font style="letter-spacing:0.55pt;"> </font>val<font style="letter-spacing:-0.1pt;">u</font>ation<font style="letter-spacing:0.75pt;"> </font>techniques<font style="letter-spacing:0.9pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>maximize<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>observable<font style="letter-spacing:0.9pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>minimize<font style="letter-spacing:0.7pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>use<font style="letter-spacing:0.3pt;"> </font>of unobservable<font style="letter-spacing:1.05pt;"> </font>inputs<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>extent<font style="letter-spacing:0.5pt;"> </font>possib<font style="letter-spacing:-0.1pt;">l</font>e<font style="letter-spacing:0.65pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>considers<font style="letter-spacing:0.8pt;"> </font>counterparty<font style="letter-spacing:1pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>assessment<font style="letter-spacing:0.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">p.<font style="letter-spacing:0.2pt;"> </font>Concentration<font style="letter-spacing:1.2pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit<font style="letter-spacing:0.5pt;"> </font>risks</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial<font style="letter-spacing:0.75pt;"> </font>instruments<font style="letter-spacing:0.95pt;"> </font>that<font style="letter-spacing:0.35pt;"> </font>potentially<font style="letter-spacing:0.8pt;"> </font>subject<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>concentrati<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>consist<font style="letter-spacing:0.6pt;"> </font>principally<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equiva<font style="letter-spacing:-0.1pt;">l</font>ents and short-term investments.<font style="letter-spacing:0.95pt;"> </font>The Company<font style="letter-spacing:0.8pt;"> </font>deposits<font style="letter-spacing:0.7pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>eq<font style="letter-spacing:-0.1pt;">u</font>ivalents<font style="letter-spacing:0.9pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>highly<font style="letter-spacing:0.5pt;"> </font>rated<font style="letter-spacing:0.45pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nstitutions,<font style="letter-spacing:0.9pt;"> </font>and,<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>matter<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>policy,<font style="letter-spacing:0.55pt;"> </font>limits<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>amounts<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>credit exposure<font style="letter-spacing:0.75pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>single<font style="letter-spacing:0.5pt;"> </font>financial<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">i</font>nstitution.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>has<font style="letter-spacing:0.3pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>experienced<font style="letter-spacing:1pt;"> </font>any<font style="letter-spacing:0.3pt;"> </font>cre<font style="letter-spacing:-0.1pt;">d</font>it<font style="letter-spacing:0.45pt;"> </font>losses<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>does<font style="letter-spacing:0.4pt;"> </font>not<font style="letter-spacing:0.3pt;"> </font>belie<font style="letter-spacing:-0.1pt;">v</font>e<font style="letter-spacing:0.6pt;"> </font>it<font style="letter-spacing:0.15pt;"> </font>is exposed<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>significant<font style="letter-spacing:0.8pt;"> </font>credit<font style="letter-spacing:0.45pt;"> </font>risk<font style="letter-spacing:0.3pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>these<font style="letter-spacing:0.45pt;"> </font>instruments.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">q.<font style="letter-spacing:0.2pt;"> </font>Segment<font style="letter-spacing:0.75pt;"> </font>reporting</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating<font style="letter-spacing:0.8pt;"> </font>segments<font style="letter-spacing:0.8pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>reported<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>manner<font style="letter-spacing:0.65pt;"> </font>consistent<font style="letter-spacing:0.8pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>internal<font style="letter-spacing:0.6pt;"> </font>reporting<font style="letter-spacing:0.7pt;"> </font>provided<font style="letter-spacing:0.7pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>ch<font style="letter-spacing:-0.1pt;">i</font>ef<font style="letter-spacing:0.4pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>decision-maker,<font style="letter-spacing:1.25pt;"> </font>who<font style="letter-spacing:0.35pt;"> </font>is responsible<font style="letter-spacing:0.9pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>allocating<font style="letter-spacing:0.75pt;"> </font>resources<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>assessing<font style="letter-spacing:0.8pt;"> </font>performance<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>segments.<font style="letter-spacing:0.85pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>o<font style="letter-spacing:-0.1pt;">p</font>erates<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>one<font style="letter-spacing:0.35pt;"> </font>operating segment.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_InitialPublicOfferingCostsPolicyTextBlock', window );">IPO Costs</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r.<font style="letter-spacing:0.2pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>Costs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>accounts<font style="letter-spacing:0.75pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>accordance<font style="letter-spacing:0.95pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>SEC<font style="letter-spacing:0.4pt;"> </font>Staff<font style="letter-spacing:0.4pt;"> </font>Accounting<font style="letter-spacing:0.9pt;"> </font>Bulletin<font style="letter-spacing:0.6pt;"> </font>Topic<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">5</font>A.<font style="letter-spacing:0.3pt;"> Costs directly attributable to a proposed or actual offering of securities are deferred and recorded against the gross proceeds of the offering upon completion. </font>During<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>year<font style="letter-spacing:0.4pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2016, the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>recorded<font style="letter-spacing:0.7pt;"> </font>$1.7<font style="letter-spacing:0.4pt;"> </font>million<font style="letter-spacing:0.55pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>g<font style="letter-spacing:-0.1pt;">e</font>neral<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>administrative<font style="letter-spacing:1.1pt;"> </font>expenses<font style="letter-spacing:0.8pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>IPO<font style="letter-spacing:0.35pt;"> </font>costs.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Newly Issued and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">s.<font style="letter-spacing:0.15pt;"> </font>Newly<font style="letter-spacing:0.55pt;"> </font>issued<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>recently<font style="letter-spacing:0.7pt;"> </font>adopted<font style="letter-spacing:0.7pt;"> </font>accounting<font style="letter-spacing:0.95pt;"> </font>pronouncements</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>August<font style="letter-spacing:0.6pt;"> </font>2014,<font style="letter-spacing:0.45pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> Accounting Standards Update (&#8220;</font>ASU&#8221;)<font style="letter-spacing:0.35pt;"> No. </font>2014-15&#8212;Presentation<font style="letter-spacing:1.95pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Financial<font style="letter-spacing:0.75pt;"> </font>Statements&#8212;Going<font style="letter-spacing:1.55pt;"> </font>Concern<font style="letter-spacing:0.7pt;"> </font>(ASC<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">S</font>ubtopic<font style="letter-spacing:0.75pt;"> </font>205-40):<font style="letter-spacing:0.8pt;"> </font>&#8220;Disclosure of<font style="letter-spacing:0.2pt;"> </font>Uncertainties<font style="letter-spacing:1.05pt;"> </font>about<font style="letter-spacing:0.45pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>Entity&#8217;s<font style="letter-spacing:0.6pt;"> </font>Ability<font style="letter-spacing:0.5pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>Conti<font style="letter-spacing:-0.1pt;">n</font>ue<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>Going<font style="letter-spacing:0.5pt;"> </font>Concern&#8221;.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>update<font style="letter-spacing:0.55pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>managem<font style="letter-spacing:-0.1pt;">e</font>nt<font style="letter-spacing:1.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>assess<font style="letter-spacing:0.6pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>company&#8217;s ability<font style="letter-spacing:0.05pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>continue<font style="letter-spacing:0.7pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>going<font style="letter-spacing:0.45pt;"> </font>concern<font style="letter-spacing:0.65pt;"> </font><font style="letter-spacing:-0.1pt;">a</font>nd<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>provide<font style="letter-spacing:0.6pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>footnote<font style="letter-spacing:0.65pt;"> </font>disclosures<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>certain<font style="letter-spacing:0.55pt;"> </font>circumstances.<font style="letter-spacing:1.2pt;"> </font>All<font style="letter-spacing:0.25pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>apply<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>new<font style="letter-spacing:0.35pt;"> </font>requirements<font style="letter-spacing:1.05pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>annu<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.55pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>ending<font style="letter-spacing:0.55pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>per<font style="letter-spacing:-0.1pt;">i</font>ods<font style="letter-spacing:0.6pt;"> </font>thereafter.<font style="letter-spacing:0.8pt;"> </font>The adoption of the guidance did not have a material impact on the Company&#8217;s financial statements.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (&#8220;Topic 606&#8221;, &#8220;ASU 2014-09&#8221;, or &#8220;the New Revenue Standard&#8221;). ASU 2014-09 requires entities to recognize revenue that represents the transfer of promised goods or services to customers in an amount equivalent to the consideration to which the entity expects to be entitled to in exchange for those goods or services. The following steps should be applied to determine this amount: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 supersedes the revenue recognition requirements in ASU 605, &#8220;Revenue Recognition,&#8221; and most industry-specific guidance in the Accounting Standards Codification. The New Revenue Standard is effective for the Company for annual reporting periods, including interim periods therein, beginning January 1, 2018. The New Revenue Standard may be applied retrospectively with the cumulative effect recognized as of the date of adoption (modified retrospective method). The Company will adopt the New Revenue Standard using modified retrospective method. The Company has substantially completed its assessment of the New Revenue Standard and identified two revenue streams (1) licensing revenue and (2) revenue from clinical supply of RTGel per the license agreement with Allergan. The implementation of the New Revenue Standard will not have a material impact on the amount or timing of the Company&#8217;s current revenue recognition related to these revenue streams. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>February<font style="letter-spacing:0.75pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> No. </font>2016-02,<font style="letter-spacing:0.75pt;"> </font>Leases<font style="letter-spacing:0.6pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>842 or &#8220;ASU<font style="letter-spacing:0.5pt;"> </font>2016-02&#8221;).<font style="letter-spacing:0.95pt;"> </font>ASU<font style="letter-spacing:0.4pt;"> </font>2016-02<font style="letter-spacing:0.7pt;"> </font>supersedes<font style="letter-spacing:0.95pt;"> </font>existing<font style="letter-spacing:0.65pt;"> </font>guida<font style="letter-spacing:0.1pt;">n</font>ce<font style="letter-spacing:0.75pt;"> </font>in Leases<font style="letter-spacing:0.6pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>840).<font style="letter-spacing:0.45pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>revised<font style="letter-spacing:0.6pt;"> </font>standard<font style="letter-spacing:0.7pt;"> </font>requires<font style="letter-spacing:0.65pt;"> </font>les<font style="letter-spacing:-0.1pt;">s</font>ees<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>assets<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>liabilities<font style="letter-spacing:0.7pt;"> </font>ari<font style="letter-spacing:-0.1pt;">s</font>ing<font style="letter-spacing:0.55pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>leases<font style="letter-spacing:0.55pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>terms greater<font style="letter-spacing:0.6pt;"> </font>than<font style="letter-spacing:0.4pt;"> </font>twelve<font style="letter-spacing:0.55pt;"> </font>months<font style="letter-spacing:0.6pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet,<font style="letter-spacing:0.5pt;"> </font>including<font style="letter-spacing:0.7pt;"> </font>tho<font style="letter-spacing:-0.1pt;">s</font>e<font style="letter-spacing:0.45pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>operating<font style="letter-spacing:0.75pt;"> </font>leases,<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>disc<font style="letter-spacing:-0.1pt;">l</font>ose<font style="letter-spacing:0.65pt;"> </font>key<font style="letter-spacing:0.3pt;"> </font>information about<font style="letter-spacing:0.45pt;"> </font>leasing<font style="letter-spacing:0.6pt;"> </font>arrangements.<font style="letter-spacing:1.15pt;"> </font>Lessees<font style="letter-spacing:0.7pt;"> </font>w<font style="letter-spacing:-0.1pt;">i</font>ll<font style="letter-spacing:0.3pt;"> </font>be<font style="letter-spacing:0.25pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>recognize<font style="letter-spacing:0.8pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>lease<font style="letter-spacing:0.45pt;"> </font>li<font style="letter-spacing:-0.1pt;">a</font>bility<font style="letter-spacing:0.55pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>a<font style="letter-spacing:0.25pt;"> </font>right-of-use<font style="letter-spacing:1.05pt;"> </font>asset<font style="letter-spacing:0.45pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>their<font style="letter-spacing:0.4pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheets,<font style="letter-spacing:0.6pt;"> </font>while lessor<font style="letter-spacing:0.5pt;"> </font>accounting<font style="letter-spacing:0.85pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>remain<font style="letter-spacing:0.55pt;"> </font>larg<font style="letter-spacing:-0.1pt;">e</font>ly<font style="letter-spacing:0.55pt;"> </font>unchanged.<font style="letter-spacing:0.95pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>guidance<font style="letter-spacing:0.75pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>an<font style="letter-spacing:-0.1pt;">n</font>ual<font style="letter-spacing:0.55pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>beginning<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>Decem<font style="letter-spacing:-0.1pt;">b</font>er<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2018,<font style="letter-spacing:0.45pt;"> </font>with early<font style="letter-spacing:0.4pt;"> </font>adoption<font style="letter-spacing:0.8pt;"> </font>permitted.<font style="letter-spacing:0.8pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>currently<font style="letter-spacing:0.7pt;"> </font>evaluating<font style="letter-spacing:0.8pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>impact<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>adopt<font style="letter-spacing:-0.1pt;">i</font>on<font style="letter-spacing:0.7pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ASU<font style="letter-spacing:0.5pt;"> </font>2016-02<font style="letter-spacing:0.7pt;"> </font>will<font style="letter-spacing:0.3pt;"> </font>have<font style="letter-spacing:0.4pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>its<font style="letter-spacing:0.2pt;"> </font>consolidated financial<font style="letter-spacing:0.65pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>related<font style="letter-spacing:0.55pt;"> </font>disclosures.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>August<font style="letter-spacing:0.6pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> No. </font>2016-15,<font style="letter-spacing:0.75pt;"> </font>&#8220;Statement<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows:<font style="letter-spacing:0.55pt;"> </font>Classification<font style="letter-spacing:1.05pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Certain<font style="letter-spacing:0.6pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Rec<font style="letter-spacing:-0.1pt;">e</font>ipts<font style="letter-spacing:0.7pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Payments,&#8221; which<font style="letter-spacing:0.5pt;"> </font>addresses<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>presentation<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>(or<font style="letter-spacing:0.25pt;"> </font>amounts<font style="letter-spacing:0.7pt;"> </font>generally<font style="letter-spacing:0.75pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>escribed<font style="letter-spacing:0.8pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>such)<font style="letter-spacing:0.45pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>the statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>ASC<font style="letter-spacing:0.4pt;"> </font>230,<font style="letter-spacing:0.4pt;"> </font>Statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows,<font style="letter-spacing:0.55pt;"> </font>with<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>intent<font style="letter-spacing:0.45pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>reduce<font style="letter-spacing:0.55pt;"> </font>diversity<font style="letter-spacing:0.65pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>practi<font style="letter-spacing:-0.1pt;">c</font>e.<font style="letter-spacing:0.7pt;"> </font>Among<font style="letter-spacing:0.6pt;"> </font>others,<font style="letter-spacing:0.55pt;"> </font>this<font style="letter-spacing:0.3pt;"> </font>ASU addresses<font style="letter-spacing:0.95pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flow<font style="letter-spacing:0.35pt;"> </font>treatment<font style="letter-spacing:0.75pt;"> </font>such<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>debt<font style="letter-spacing:0.4pt;"> </font>prepayment<font style="letter-spacing:0.95pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>debt<font style="letter-spacing:0.4pt;"> </font>extinguishment<font style="letter-spacing:1.2pt;"> </font>costs<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>proce<font style="letter-spacing:-0.1pt;">e</font>ds<font style="letter-spacing:0.75pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>settlement<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>insurance claims.<font style="letter-spacing:0.6pt;"> </font>Entities<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>required<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>disclose<font style="letter-spacing:0.65pt;"> </font>how<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>flows<font style="letter-spacing:0.45pt;"> </font>reconc<font style="letter-spacing:-0.1pt;">i</font>les<font style="letter-spacing:0.8pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>balance<font style="letter-spacing:0.65pt;"> </font>sheet<font style="letter-spacing:0.45pt;"> </font>if<font style="letter-spacing:0.15pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>is<font style="letter-spacing:0.25pt;"> </font>shown separately<font style="letter-spacing:0.85pt;"> </font>from<font style="letter-spacing:0.4pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>b<font style="letter-spacing:-0.1pt;">a</font>lance<font style="letter-spacing:0.65pt;"> </font>sheet.<font style="letter-spacing:0.5pt;"> </font>Entities<font style="letter-spacing:0.6pt;"> </font>must<font style="letter-spacing:0.4pt;"> </font>also<font style="letter-spacing:0.35pt;"> </font>disclose<font style="letter-spacing:0.65pt;"> </font>information<font style="letter-spacing:0.9pt;"> </font>ab<font style="letter-spacing:-0.1pt;">o</font>ut<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>nature<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the restrictions.<font style="letter-spacing:0.05pt;"> </font>The<font style="letter-spacing:0.35pt;"> </font>amendments<font style="letter-spacing:1.05pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>public<font style="letter-spacing:0.5pt;"> </font>business<font style="letter-spacing:0.7pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>beg<font style="letter-spacing:-0.1pt;">i</font>nning<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim periods<font style="letter-spacing:0.6pt;"> </font>within<font style="letter-spacing:0.5pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years.<font style="letter-spacing:0.5pt;"> </font>Early<font style="letter-spacing:0.45pt;"> </font>adopti<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>permitted.<font style="letter-spacing:0.8pt;"> </font>A<font style="letter-spacing:0.15pt;"> </font>retrospective<font style="letter-spacing:1pt;"> </font>basis<font style="letter-spacing:0.45pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>required.<font style="letter-spacing:0.7pt;"> </font>The Company believes the<font style="letter-spacing:0.35pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> of the guidance will be immaterial to its financial statements</font>.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In<font style="letter-spacing:0.2pt;"> </font>November<font style="letter-spacing:0.85pt;"> </font>2016,<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>FASB<font style="letter-spacing:0.5pt;"> </font>issued<font style="letter-spacing:0.55pt;"> </font>ASU<font style="letter-spacing:0.35pt;"> </font>No.<font style="letter-spacing:0.3pt;"> </font>2016-18,<font style="letter-spacing:0.8pt;"> </font>&#8220;Statement<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>Cash<font style="letter-spacing:0.45pt;"> </font>Flows<font style="letter-spacing:0.5pt;"> </font>(Topic<font style="letter-spacing:0.5pt;"> </font>230):<font style="letter-spacing:0.45pt;"> </font>Restricted<font style="letter-spacing:0.8pt;"> </font>Cash&#8221;<font style="letter-spacing:0.5pt;"> </font>(&#8220;ASU<font style="letter-spacing:0.5pt;"> </font>2016-18&#8221;).<font style="letter-spacing:0.95pt;"> </font>ASU 2016-18<font style="letter-spacing:0.7pt;"> </font>amends<font style="letter-spacing:0.65pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>classification<font style="letter-spacing:1pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>presentati<font style="letter-spacing:-0.1pt;">o</font>n<font style="letter-spacing:1pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>or<font style="letter-spacing:0.2pt;"> </font>restricted<font style="letter-spacing:0.75pt;"> </font>cash<font style="letter-spacing:0.4pt;"> </font>equivalents<font style="letter-spacing:0.9pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statement<font style="letter-spacing:0.8pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>cash flows.<font style="letter-spacing:0.5pt;"> </font>The<font style="letter-spacing:0.45pt;"> </font>ASU<font style="letter-spacing:0.4pt;"> </font>2016-18<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>effective<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>public<font style="letter-spacing:0.5pt;"> </font>business<font style="letter-spacing:0.7pt;"> </font>entities<font style="letter-spacing:0.6pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>begin<font style="letter-spacing:-0.1pt;">n</font>ing<font style="letter-spacing:0.8pt;"> </font>after<font style="letter-spacing:0.4pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>15,<font style="letter-spacing:0.3pt;"> </font>2017,<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>periods within<font style="letter-spacing:0.5pt;"> </font>those<font style="letter-spacing:0.45pt;"> </font>fiscal<font style="letter-spacing:0.45pt;"> </font>years.<font style="letter-spacing:0.5pt;"> </font>Early<font style="letter-spacing:0.45pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>is<font style="letter-spacing:0.15pt;"> </font>permitted,<font style="letter-spacing:0.8pt;"> </font>inclu<font style="letter-spacing:-0.1pt;">d</font>ing<font style="letter-spacing:0.7pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>an<font style="letter-spacing:0.25pt;"> </font>interim<font style="letter-spacing:0.55pt;"> </font>period. The<font style="letter-spacing:0.05pt;"> Company believes</font><font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.35pt;"> </font>adoption<font style="letter-spacing:0.7pt;"> of the guidance </font>will be immaterial to its<font style="letter-spacing:0.7pt;"> financial statements</font>.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DeferredTaxesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DeferredTaxesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_InitialPublicOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_InitialPublicOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for director stock option and stock incentive plans. This disclosure may include (1) the types of director stock option or incentive plans sponsored by the entity (2) significant plan provisions and (3) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansDirectorPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6853194768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of Annual Rates of Depreciation</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual<font style="letter-spacing:0.6pt;"> </font>rates<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>depreciation<font style="letter-spacing:1pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15-30</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6-15</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of annual rates of depreciation of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ScheduleOfAnnualRatesOfDepreciationOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769627616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div>

<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DECEMBER&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">531</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">441</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and software</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Manufacturing equipment</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">234</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,382</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,111</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less&#8212;Accumulated depreciation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(577</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(370</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Property and equipment, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">805</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6853219808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Warrants for Preferred Shares</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>below<font style="letter-spacing:0.5pt;"> </font>sets<font style="letter-spacing:0.35pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>a<font style="letter-spacing:0.15pt;"> </font>summary<font style="letter-spacing:0.75pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>changes<font style="letter-spacing:0.7pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>warrants<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>preferred<font style="letter-spacing:0.75pt;"> </font>shares<font style="letter-spacing:0.55pt;"> </font>classified<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>Lev<font style="letter-spacing:-0.1pt;">e</font>l<font style="letter-spacing:0.45pt;"> </font>3:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">872</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value of warrants for preferred shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,740</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of warrants for preferred shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,780</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,612</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788980784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalUnitsTextBlock', window );">Schedule of Share Capital</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>capit<font style="letter-spacing:-0.1pt;">a</font>l<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Company<font style="letter-spacing:0.8pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued and Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ordinary shares of NIS 0.01 par value</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,600,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,751,390</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,743</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A and A-1 preferred shares of NIS 0.01 par value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,400,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,193,427</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Number of Options Outstanding Under the Plan</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>summarizes<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>number<font style="letter-spacing:0.65pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font><font style="letter-spacing:-0.1pt;">o</font>utstanding<font style="letter-spacing:0.95pt;"> </font>under<font style="letter-spacing:0.5pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Plan<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>Decem<font style="letter-spacing:-0.1pt;">b</font>er<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017, 2016<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>2015,<font style="letter-spacing:0.45pt;"> </font>and related<font style="letter-spacing:0.55pt;"> </font>inform<font style="letter-spacing:0.1pt;">a</font>tion:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Directors</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consultants and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Service providers</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of January 1, 2015</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098,777</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.99</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,826</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.98</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,088</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,686,600</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,238</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">404,813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,032</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.15</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.03</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,784</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,030,613</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.29</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634,486</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.62</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/Forfeited</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.77</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,686</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.93</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(682,184</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,038</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of December 31, 2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,021,829</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.70</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498,762</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.36%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Including 38,400 ordinary shares issuable upon the vesting of options granted in 2016, which were contingent upon the closing of the IPO.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Summary of Number of Options Outstanding and Exercisable</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.5pt;"> </font>summarizes<font style="letter-spacing:0.9pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>outstand<font style="letter-spacing:-0.1pt;">i</font>ng<font style="letter-spacing:0.95pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>exercisable<font style="letter-spacing:0.9pt;"> </font>options and restricted stock units<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2<font style="letter-spacing:-0.1pt;">0</font>17:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="8" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">share</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">outstanding at end</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercisable at end of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00 - 10.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,948,091</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.62</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,142,310</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.98</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$10.01 - 20.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">292,500</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.49</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,501</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.01 - 30.00</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.82</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.01 - 40.00</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.81</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.84%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,520,591</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,194,811</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Effect of Share-Based Compensation on Statements of Operations</a></td>
<td class="text"><div>

<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.33%;text-indent:-3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>illustrates<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>effect<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>share-based<font style="letter-spacing:1pt;"> </font>com<font style="letter-spacing:-0.1pt;">p</font>ensation<font style="letter-spacing:1.1pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>statements<font style="letter-spacing:0.9pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>operations:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,923</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,377</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,300</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,967</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Computing Fair Value of Options Granted</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>employees<font style="letter-spacing:0.85pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font><font style="letter-spacing:-0.1pt;">d</font>irectors<font style="letter-spacing:0.7pt;"> </font>on<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>date<font style="letter-spacing:0.4pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>grant<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>using<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>Black-Scholes<font style="letter-spacing:1.15pt;"> </font>mod<font style="letter-spacing:-0.1pt;">e</font>l.<font style="letter-spacing:0.55pt;"> </font>The underlying<font style="letter-spacing:0.85pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>used<font style="letter-spacing:0.55pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>computing<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of ordinary shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.00-39.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98-5.54</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98-3.01</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.53%-76.32%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.8%-80%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69.78%-76.68%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.85%-2.47%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4%&#8211;2.13%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38%&#8211;2.08%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5-10 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1-7 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember', window );">Consultants and Other Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Computing Fair Value of Options Granted</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>options<font style="letter-spacing:0.6pt;"> </font>granted<font style="letter-spacing:0.65pt;"> </font>to<font style="letter-spacing:0.2pt;"> </font>consultants<font style="letter-spacing:0.9pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>other<font style="letter-spacing:0.45pt;"> </font>service<font style="letter-spacing:0.6pt;"> </font>pro<font style="letter-spacing:-0.1pt;">v</font>iders<font style="letter-spacing:0.45pt;"> </font>was<font style="letter-spacing:0.35pt;"> </font>computed<font style="letter-spacing:0.8pt;"> </font>u<font style="letter-spacing:-0.1pt;">s</font>ing<font style="letter-spacing:0.45pt;"> </font>the Black-Scholes<font style="letter-spacing:1.15pt;"> </font>model.<font style="letter-spacing:0.55pt;"> </font>The<font style="letter-spacing:0.3pt;"> </font>underlying<font style="letter-spacing:0.85pt;"> </font>data<font style="letter-spacing:0.4pt;"> </font>used<font style="letter-spacing:0.4pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>computing<font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>fair<font style="letter-spacing:0.3pt;"> </font>value<font style="letter-spacing:0.45pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>opt<font style="letter-spacing:-0.1pt;">i</font>ons<font style="letter-spacing:0.6pt;"> </font>are<font style="letter-spacing:0.3pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of ordinary shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.58-37.21</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.58-7.96</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.98</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.45%-74.50%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72.72%-80%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.31%-76.3%</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.38%-2.26%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.56%-2.27%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.88%-2.07%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.8%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9-5.9 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8-8.5 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;">
<p style="text-align:center;line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.8-7 years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="line-height:11pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalUnitsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's capital units or capital shares, including the value of capital units or capital shares, units authorized, units outstanding and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalUnitsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6853221184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Taxes</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In respect of:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forward</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,844</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,280</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,691</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Rent</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">742</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance Costs</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,261</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-Process R&amp;D</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">806</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less&#8212;valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,725</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Change in Valuation Allowance</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>change<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.2pt;"> </font>valuation<font style="letter-spacing:0.75pt;"> </font>a<font style="letter-spacing:-0.1pt;">l</font>lowance<font style="letter-spacing:0.8pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>years<font style="letter-spacing:0.45pt;"> </font>ended<font style="letter-spacing:0.5pt;"> </font>December<font style="letter-spacing:0.85pt;"> </font>31,<font style="letter-spacing:0.3pt;"> </font>2017<font style="letter-spacing:0.45pt;"> </font>a<font style="letter-spacing:-0.1pt;">n</font>d<font style="letter-spacing:0.35pt;"> </font>2016<font style="letter-spacing:0.45pt;"> </font>were<font style="letter-spacing:0.4pt;"> </font>as<font style="letter-spacing:0.25pt;"> </font>follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,551</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes during the year</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,567</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">341</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,948</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the end of the year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,725</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,158</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770033760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Ordinary Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Calculation of Basic and Diluted Loss Per Share</a></td>
<td class="text"><div>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<font style="letter-spacing:0.35pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>table<font style="letter-spacing:0.4pt;"> </font>sets<font style="letter-spacing:0.35pt;"> </font>forth<font style="letter-spacing:0.4pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>calculation<font style="letter-spacing:0.85pt;"> </font>of<font style="letter-spacing:0.2pt;"> </font>ba<font style="letter-spacing:-0.1pt;">s</font>ic<font style="letter-spacing:0.45pt;"> </font>and<font style="letter-spacing:0.35pt;"> </font>diluted<font style="letter-spacing:0.55pt;"> </font>loss<font style="letter-spacing:0.35pt;"> </font>per<font style="letter-spacing:0.3pt;"> </font>share<font style="letter-spacing:0.45pt;"> </font>for<font style="letter-spacing:0.25pt;"> </font>the<font style="letter-spacing:0.3pt;"> </font>periods<font style="letter-spacing:0.6pt;"> </font>indicat<font style="letter-spacing:-0.1pt;">e</font>d:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss attributable to equity holders of the Company</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,941</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,689</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend accumulated for preferred shares during the period</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,467</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss attributable to equity holders of the Company, after deducting dividend</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accumulated for preferred shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,825</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,408</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,541</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of ordinary shares</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,716,790</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,305,503</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,300,959</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss per ordinary share (LPS)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.88</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862704656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 19, 2017</div></th>
<th class="th">
<div>Oct. 07, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Date of operating commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 29,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Share split, conversion ratio</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Nasdaq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember', window );">Secondary Public Offering | Nasdaq | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">UroGen Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperationsCommencedDate1', window );">Date of operating commencement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 29,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember', window );">Allergan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ConsiderationForSalesAndSupportingServices', window );">Consideration for sales and supporting services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices', window );">Consideration received for license and future supply services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MilestonePaymentForLicensingAgreement', window );">Milestone payment for licensing agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember', window );">Allergan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_AdditionalMilestonePaymentForLicensingAgreement', window );">Additional milestone payment to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_AdditionalMilestonePaymentForLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment for licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_AdditionalMilestonePaymentForLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration fee received for license and future supply services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ConsiderationForSalesAndSupportingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration for sales and supporting services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ConsiderationForSalesAndSupportingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MilestonePaymentForLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment for licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MilestonePaymentForLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperationsCommencedDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the operations of the entity commenced, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperationsCommencedDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNCM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNCM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862389072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>LicenseAgreement </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in value of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss for long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NumberOfDeliverableLicenseAgreements', window );">Number of deliverable license agreements | LicenseAgreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_DescriptionOfLicenseAgreementComponents', window );">License component, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The license component has standalone value (and therefore is accounted for separately from the supply services) since Allergan can use the license for its intended purposes without the Company&#8217;s supply services. The four conditions of ASC 605 were met as of December 31, 2017 and 2016: (1) persuasive evidence of an arrangement exists since the Company and Allergan engaged with a binding agreement; (2) delivery has occurred or services have been rendered since all documents and data Allergan has requested relating to the Company&#8217;s know-how were provided before December 31, 2016 and Allergan can use the license for its intended purposes without the supply services (except for immaterial support services); (3) the fee is fixed or determinable, as indicated in the license agreement; and (4) collectability is reasonably assured.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_UpfrontFeeAllocatedToLicenseComponent', window );">Upfront fee allocated to license component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Increase (decrease) in research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Accrued provision for uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_InitialPublicOfferingCost', window );">IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember', window );">Allergan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_SummaryOfSignificantAccountingPolicyLineItems', window );"><strong>Summary Of Significant Accounting Policy [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices', window );">Consideration received for license and future supply services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_MilestonePaymentForLicensingAgreement', window );">Milestone payment for licensing agreement</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Increase (decrease) in research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration fee received for license and future supply services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DescriptionOfLicenseAgreementComponents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of license agreement components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DescriptionOfLicenseAgreementComponents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_InitialPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_InitialPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_MilestonePaymentForLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment for licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_MilestonePaymentForLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NumberOfDeliverableLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of deliverable license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NumberOfDeliverableLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SummaryOfSignificantAccountingPolicyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SummaryOfSignificantAccountingPolicyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_UpfrontFeeAllocatedToLicenseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee allocated to license component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_UpfrontFeeAllocatedToLicenseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84241808&amp;loc=d3e92212-112881<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6788909552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Annual Rates of Depreciation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation', window );">Property and equipment, annual rates of depreciation</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation', window );">Property and equipment, annual rates of depreciation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation', window );">Property and equipment, annual rates of depreciation</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation', window );">Property and equipment, annual rates of depreciation</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation', window );">Property and equipment, annual rates of depreciation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation', window );">Property and equipment, annual rates of depreciation</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment annual rate of depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PropertyPlantAndEquipmentAnnualRateOfDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862749344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Cost</a></td>
<td class="nump">$ 1,382<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;Accumulated depreciation</a></td>
<td class="num">(577)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">805<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Cost</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember', window );">Computers and Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Cost</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Cost</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Cost</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Cost</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_ComputersAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=urgn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760843552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787069584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Proceeds from Exercise of Warrants for Preferred A-1 Shares - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems', window );"><strong>Proceeds from Exercise of Warrants for Preferred Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants for preferred shares</a></td>
<td class="nump">$ 382<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems', window );"><strong>Proceeds from Exercise of Warrants for Preferred Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 7.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercisable number of warrants for preferred shares</a></td>
<td class="nump">728,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants for preferred shares</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of warrants for preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ProceedsFromExerciseOfWarrantsForPreferredSharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862314400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Future minimum lease payments, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Future minimum lease payments, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Future minimum lease payments, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Future minimum lease payments, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Future minimum lease payments, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears', window );">Future minimum lease payments, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_SuccessFeesToThirdPartiesInStockOptions', window );">Success fees to third parties in stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_FairValueOfStockOptionsIssuedToThirdParties', window );">Fair value of stock options issued to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_SuccessFeesToThirdPartiesInCash', window );">Success fees to third parties in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember', window );">UroGen Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease agreement period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseAgreementCommencementPeriod', window );">Lease agreement, commencement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseAgreementTerminationPeriod', window );">Lease agreement, termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | IIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_RoyaltyFeesPercentage', window );">Royalty fees payable on product sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseExpirationYear', window );">Lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | IIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_RoyaltyFeesPercentage', window );">Royalty fees payable on product sales, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PercentageOfRoyaltyPayableOnGrantReceived', window );">Maximum percentage of royalty payable on grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalty amount payable excluding interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_FairValueOfStockOptionsIssuedToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock options issued to third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_FairValueOfStockOptionsIssuedToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseAgreementCommencementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement commencement period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseAgreementCommencementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseAgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement termination period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseAgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases future minimum payments due in six years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_OperatingLeasesFutureMinimumPaymentsDueInSixYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PercentageOfRoyaltyPayableOnGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payable on grant received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PercentageOfRoyaltyPayableOnGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_RoyaltyFeesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty fees percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_RoyaltyFeesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SuccessFeesToThirdPartiesInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success fees to third parties in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SuccessFeesToThirdPartiesInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_SuccessFeesToThirdPartiesInStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Success fees to third parties in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_SuccessFeesToThirdPartiesInStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=urgn_IsraelInnovationAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=urgn_IsraelInnovationAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6864383056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Series A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during period upon conversion of warrants, shares</a></td>
<td class="nump">364,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, expected volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.93%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants | Allergan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair value inputs discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants | Internal Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair value inputs discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants | IPO | Series A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during period upon conversion of warrants, shares</a></td>
<td class="nump">364,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants | Hybrid Method Valuation Technique | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Fair value inputs, probability of estimated rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants | Hybrid Method Valuation Technique | Liquidation Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsProbabilityOfDefault', window );">Fair value inputs, probability of estimated rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair value inputs discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember', window );">A-1 Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Fair value inputs discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsProbabilityOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of likelihood a loan will not be repaid and instead default, used as an input to measure fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsProbabilityOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=urgn_AOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=urgn_InternalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=urgn_InternalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=urgn_HybridMethodValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=urgn_HybridMethodValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=urgn_LiquidationEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=urgn_LiquidationEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787000336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Changes in Fair Value of Warrants for Preferred Shares (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning of year</a></td>
<td class="nump">$ 3,612<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value of warrants for preferred shares</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock', window );">Issuance of warrants for preferred shares</a></td>
<td class="num">$ (3,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability issuance of warrants for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssuanceOfWarrantsForPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6851530864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Summary of Share Capital (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">17,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">13,751,390<span></span>
</td>
<td class="nump">2,305,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">13,751,390<span></span>
</td>
<td class="nump">2,305,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember', window );">Series A and A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6779463904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Summary of Share Capital (Parenthetical) (Details) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember', window );">Series A and A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=urgn_SeriesAAndAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6869300624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 19, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Share split, conversion ratio</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Issuance of ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 shares held immediately prior to share split</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On April 19, 2017, the Company&#8217;s board of directors and shareholders approved an aggregate 3.2 for-1 share split of the Company&#8217;s ordinary, Preferred A and Preferred A-1 shares. The share split was effected on April 19, 2017 by the issuance of 2.2 ordinary shares for each outstanding ordinary, Preferred A and Preferred A-1 share held immediately prior to the share split.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividends at the rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PercentageOfOutstandingPreferredStockShares', window );">Percentage of outstanding preferred stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options into ordinary shares, amount received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of shares surrendered to pay the exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="nump">449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted', window );">Fair value of option granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,249<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
<td class="nump">$ 2,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of ordinary shares issuable upon vesting of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of the total vested and exercisable options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">682,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,900<span></span>
</td>
<td class="nump">404,813<span></span>
</td>
<td class="nump">1,098,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices ranging lower limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices ranging upper limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.26<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost of employee options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected to be recognized over a weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndServiceProvidersMember', window );">Consultants and Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">132,032<span></span>
</td>
<td class="nump">203,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices ranging lower limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices ranging upper limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted', window );">Fair value of option granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Maximum number of ordinary share isuable under the 2017 incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Number of ordinary shares reserved for issuance, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_ModificationsOfPerformanceConditionsInShares', window );">Modifications of performance conditions in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options into ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812,222<span></span>
</td>
<td class="nump">4,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Number of shares issued upon exercise of options, net of shares surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Number of shares surrendered to pay the exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PreMoneyValuation', window );">Pre-money valuation to convert automatically each preferred shares into ordinary shares upon the closing of an IPO | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NetProceedsRequiredForConversion', window );">Net proceeds required to automatically convert preferred shares to ordinary shares upon the closing of an IPO | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | 2017 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Exercise price of stock option as percentage of fair market value on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_InitialPublicOfferingCost', window );">IPO costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,377<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PreferredSharesIntoOrdinarySharesConversionRatio', window );">Preferred A and Preferred A-1 shares into ordinary shares conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,144,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Nasdaq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,144,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance of ordinary shares, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice', window );">Additional ordinary shares exercised under underwriters option to purchase at the public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">671,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember', window );">Secondary Public Offering | Nasdaq | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,682,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance of ordinary shares, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice', window );">Additional ordinary shares exercised under underwriters option to purchase at the public offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Preferred A Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PreferredStockIssuedPricePerShare', window );">Preferred stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PreferredStockIssuedPricePerShare', window );">Preferred stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember', window );">Series A-1 Preferred Shares | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued during period upon conversion of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=urgn_TelormedixSAMember', window );">TMX | Intellectual Property Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses incurred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=urgn_TelormedixSAMember', window );">TMX | Preferred A Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Purchase of IP R&amp;D in consideration, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_PreferredStockIssuedPricePerShare', window );">Preferred stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_InitialPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_InitialPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ModificationsOfPerformanceConditionsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modifications of performance conditions in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ModificationsOfPerformanceConditionsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NetProceedsRequiredForConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds required for conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NetProceedsRequiredForConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares exercised under underwriters option to purchase at the public offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PercentageOfOutstandingPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PercentageOfOutstandingPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PreMoneyValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-money valuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PreMoneyValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PreferredSharesIntoOrdinarySharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred shares into ordinary shares conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PreferredSharesIntoOrdinarySharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_PreferredStockIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock issued price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_PreferredStockIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=urgn_TwoThousandSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNCM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNCM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=urgn_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=urgn_TelormedixSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=urgn_TelormedixSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6862553472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Employees and Directors (Details) - Options - Employees and Directors - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">71.53%<span></span>
</td>
<td class="nump">74.80%<span></span>
</td>
<td class="nump">69.78%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">76.32%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">76.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.13%<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of ordinary shares</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of ordinary shares</a></td>
<td class="nump">$ 39.26<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863204880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Consultants and Other Service Providers (Details) - Options - Consultants and Other Service Providers - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">68.45%<span></span>
</td>
<td class="nump">72.72%<span></span>
</td>
<td class="nump">73.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">76.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.38%<span></span>
</td>
<td class="nump">1.56%<span></span>
</td>
<td class="nump">1.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">2.26%<span></span>
</td>
<td class="nump">2.27%<span></span>
</td>
<td class="nump">2.07%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of ordinary shares</a></td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Value of ordinary shares</a></td>
<td class="nump">$ 37.21<span></span>
</td>
<td class="nump">$ 7.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6863987664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Number of Options Outstanding Under the Plan (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding beginning balance</a></td>
<td class="nump">2,030,613<span></span>
</td>
<td class="nump">1,686,600<span></span>
</td>
<td class="nump">595,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">712,900<span></span>
</td>
<td class="nump">404,813<span></span>
</td>
<td class="nump">1,098,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Canceled/Forfeited</a></td>
<td class="num">(39,500)<span></span>
</td>
<td class="num">(60,800)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding beginning balance</a></td>
<td class="nump">2,021,829<span></span>
</td>
<td class="nump">2,030,613<span></span>
</td>
<td class="nump">1,686,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(682,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Outstanding beginning balance</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="nump">$ 3.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Granted</a></td>
<td class="nump">24.62<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="nump">2.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Canceled/Forfeited</a></td>
<td class="nump">5.77<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Outstanding beginning balance</a></td>
<td class="nump">10.70<span></span>
</td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Exercised</a></td>
<td class="nump">$ 3.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember', window );">Consultants and Other Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding beginning balance</a></td>
<td class="nump">634,486<span></span>
</td>
<td class="nump">513,238<span></span>
</td>
<td class="nump">332,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,032<span></span>
</td>
<td class="nump">203,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Canceled/Forfeited</a></td>
<td class="num">(5,686)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(23,088)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding beginning balance</a></td>
<td class="nump">498,762<span></span>
</td>
<td class="nump">634,486<span></span>
</td>
<td class="nump">513,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(130,038)<span></span>
</td>
<td class="num">(4,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Outstanding beginning balance</a></td>
<td class="nump">$ 4.27<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.15<span></span>
</td>
<td class="nump">2.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Canceled/Forfeited</a></td>
<td class="nump">2.93<span></span>
</td>
<td class="nump">1.58<span></span>
</td>
<td class="nump">2.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Outstanding beginning balance</a></td>
<td class="nump">4.64<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price Per Share, Exercised</a></td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=urgn_ConsultantsAndOtherServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6868039872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Summary of Number of Options Outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options outstanding at end of year | shares</a></td>
<td class="nump">2,520,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options outstanding at end of year | shares</a></td>
<td class="nump">1,194,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeOneMember', window );">0.00 - 10.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices ranging lower limit | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices ranging upper limit | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options outstanding at end of year | shares</a></td>
<td class="nump">1,948,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">4 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options outstanding at end of year | shares</a></td>
<td class="nump">1,142,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining contractual life</a></td>
<td class="text">3 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeTwoMember', window );">10.01 - 20.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices ranging lower limit | $ / shares</a></td>
<td class="nump">$ 10.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices ranging upper limit | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options outstanding at end of year | shares</a></td>
<td class="nump">292,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">9 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable, number of options outstanding at end of year | shares</a></td>
<td class="nump">52,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options exercisable, weighted average remaining contractual life</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeThreeMember', window );">20.01 - 30.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices ranging lower limit | $ / shares</a></td>
<td class="nump">$ 20.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices ranging upper limit | $ / shares</a></td>
<td class="nump">$ 30.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options outstanding at end of year | shares</a></td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">9 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeFourMember', window );">30.01 - 40.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices ranging lower limit | $ / shares</a></td>
<td class="nump">$ 30.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices ranging upper limit | $ / shares</a></td>
<td class="nump">$ 40.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding, number of options outstanding at end of year | shares</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">9 years 9 months 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=urgn_ExercisePricePerShareRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786881360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Effect of Share-Based Compensation on Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="nump">$ 449<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">3,923<span></span>
</td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 2,377<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6852165296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate including temporary provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net carry forward tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal tax net operating losses carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State tax net operating losses carry forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_FederalAndStateNetOperatingLossesExpirationYear', window );">Federal and state net operating losses expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate including temporary provision</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_FederalAndStateNetOperatingLossesExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal and state net operating losses expiratiuon year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_FederalAndStateNetOperatingLossesExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6851219824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income - Schedule of Deferred Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>In respect of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 5,844<span></span>
</td>
<td class="nump">$ 3,280<span></span>
</td>
<td class="nump">$ 3,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred Rent</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and Development expenses</a></td>
<td class="nump">2,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_DeferredTaxAssetsIssuanceCosts', window );">Issuance Costs</a></td>
<td class="nump">1,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">In-Process R&amp;D</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less&#8212;valuation allowance</a></td>
<td class="num">(11,725)<span></span>
</td>
<td class="num">(4,158)<span></span>
</td>
<td class="num">(4,499)<span></span>
</td>
<td class="num">$ (2,551)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_DeferredTaxAssetsIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_DeferredTaxAssetsIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6651765776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Schedule of Change in Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation Allowance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the beginning of the year</a></td>
<td class="num">$ (4,158)<span></span>
</td>
<td class="num">$ (4,499)<span></span>
</td>
<td class="num">$ (2,551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Changes during the year</a></td>
<td class="num">(7,567)<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="num">(1,948)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance at the end of the year</a></td>
<td class="num">$ (11,725)<span></span>
</td>
<td class="num">$ (4,158)<span></span>
</td>
<td class="num">$ (4,499)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787002576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Ordinary Share - Schedule of Calculation of Basic and Diluted Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss attributable to equity holders of the Company</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="nump">$ 12,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividend accumulated for preferred shares during the period</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Loss attributable to equity holders of the Company, after deducting dividend accumulated for preferred shares</a></td>
<td class="nump">$ 20,825<span></span>
</td>
<td class="nump">$ 4,408<span></span>
</td>
<td class="nump">$ 13,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of ordinary shares</a></td>
<td class="nump">9,716,790<span></span>
</td>
<td class="nump">2,305,503<span></span>
</td>
<td class="nump">2,300,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per ordinary share (LPS)</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="nump">$ 5.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6852191712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Ordinary Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Shares Issuable Upon Conversion of Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted loss per share, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
<td class="nump">5,193,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted loss per share, Shares</a></td>
<td class="nump">2,415,545<span></span>
</td>
<td class="nump">2,665,099<span></span>
</td>
<td class="nump">2,199,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Preferred A-1 Warrants Converted to Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted loss per share, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,312<span></span>
</td>
<td class="nump">728,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656319920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties-Transactions and Balances - Additional Information (Details) - UroGen Pharma Inc.<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseAgreementDate', window );">Lease agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">May 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidatedEntitiesAxis=us-gaap_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6852168640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember', window );">Secondary Public Offering | Nasdaq | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, shares</a></td>
<td class="nump">1,682,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance of ordinary shares, price per share</a></td>
<td class="nump">$ 41.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, consideration received net of underwriting discounts and commissions and issuance costs</a></td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice', window );">Additional ordinary shares exercised under underwriters option to purchase at the public offering price</a></td>
<td class="nump">219,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares exercised under underwriters option to purchase at the public offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">urgn_NumberOfAdditionalSharesExercisedUnderUnderwritersOptionToPurchaseAtPublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>urgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=urgn_SecondaryPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNCM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNCM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O)NPZ8_?V'QM?!9L:?MU%\P502P,$%     @ >(EO3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " !XB6],*529@6L"  "-"   &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'56VXZ;,!#]%<0'+-C<DH@@)5M5K=1*T5;=/CO$"6@!4]L)
MV[^O;5A*[>$%W\Z9,V-[/.0#XV^BHE1Z[VW3B;U?2=GO@D"4%6V)>&(][=3*
ME?&62#7DMT#TG)*+(;5-@,,P#5I2=WZ1F[D3+W)VETW=T1/WQ+UM"?]SI T;
M]C[R/R9>ZELE]410Y#VYT1]4_NQ/7(V"V<JE;FDG:M9YG%[W_@'MCBC5!(-X
MK>D@%GU/AW)F[$T/OE[V?J@]H@TMI39!5/.@S[1IM"7EQ^_)J#]K:N*R_V']
MLPE>!7,F@CZSYE=]D=7>W_C>A5[)O9$O;/A"IX 2WYNB_T8?M%%P[8G2*%DC
MS-<K[T*R=K*B7&G)^]C6G6F'<26.)AI,P!,!SP2,32RCD/'\$Y&DR#D;/#YN
M?D_T&:,=5GM3ZDFS%69-.2_4[*,(\^"AS4R(XXC "P2:$8&R/0M@2."('3J&
MZ1'H7V3HT8(>P?08I,>&'B_HL16>BTA@@0042!QZ:@FXB P62$&!U*%O+ $7
ML84%,E @<^C(O@(C)#&0;CS#$*U$L0%%-JX(LD0 R,I-V8(26Y<?61( )(8E
M4 AG2^A:2.Q\ 3#IBLI*3B+70F:K(.=,4)IN<+R2'@C,S@/"KI1]OR#,R@U#
M<!*CR+& G6<&P*P\- C.=>2F,L:V"H!9VS$XX9&;S]A^4R#,RJN"X*Q';E)C
M^V&9,/]=@2A+4+0-+:U@40U:RF^F#@JO9/?.%.'%[%QK#V,U^0<?"_5WPF]U
M)[PSDZHFF<IQ94Q2Y5#XI%RIU+_!/&CH5>INIOI\+)#C0+)^*O[!_ =2_ 50
M2P,$%     @ >(EO3*D&7#+# P  IA$  !@   !X;"]W;W)K<VAE971S+W-H
M965T,BYX;6R%F-MNXS80AE]%T'U7G"&I0V ;J%T4+= "P19MKQ6;CH75P964
M>/OVI63%L&>&Z8UU\#^<?RCR$ZG5I>N_#2?GQNA[4[?#.CZ-X_DI28;]R37E
M\*4[N];_<^SZIAS]9?^:#.?>E8<YJ*D35"I-FK)JX\UJOO?<;U;=VUA7K7ON
MH^&M:<K^WZVKN\LZAOCCQM?J]31.-Y+-ZER^NC_<^.?YN?=7R:V50]6X=JBZ
M-NK=<1W_"$\[K:> 6?%7Y2[#W7DTE?+2==^FBU\/ZUA-CESM]N/41.D/[V[G
MZGIJR?OX9VDTON6< N_//UK_>2[>%_-2#F[7U7]7A_&TCO,X.KAC^5:/7[O+
M+VXIR,;14OUO[MW57CXY\3GV73W,O]'^;1B[9FG%6VG*[]=CU<['R]+^1Y@<
M@$L W@+ ?!J@EP!- I*KL[G4G\JQW*SZ[A+UUZ=U+J=! 4_:=^9^NCGWW?R?
MKW;P=]\WF*V2]ZF=1;*]2O!>DC]*=H*DN$D2;^#F D47.,?KNWBMY'@MQNLY
MWMS' ZGB*DEG27N5I$51D$*X"D&G*'LQHA?#O2#Q<I78!R]*@9S%BEDLSZ))
M%LNR0$$?'-<45K:1BC92;L.0%"E+D6LY12:FR'@*2RK->']"2FQP#:A J;GH
M(^<^2(YM+O0F[7&NT44J^RA$'P7W06=LP7)DQF1D%.ZX"E&9P"@$)>-#\9F;
M!UH(  AX/04E$/ QI"QE$!=EP6ID# '^_ZQ:- _=1BDB:4S B0PTX$0SBCK1
M0A8Z^R21#; 59* !)YJA= 6.M,Q:JZ@;+D.M;&#\@XP^L&S,F0"A0:86<&P9
M]IPYMXRAY-D)*LCS4/_*@ -../H8MR#@J^#=RU5IG@7,R)0#CCE#<0N<86EP
M3,D0 TXQ0XD-'% V"Z1!&4^H>!H*RT7S,'05>]""2H,.]"W*J$/@ S< 2PRL
MDSB@#(4/<OCH% (3!&7\(,</'6Q;20/4RZ>:1R<R?)##Q]+E% KP$9X@5Z69
M"2U39?0@1X\-+&901@]R]%@ZV9%#A;[B=X(F0%&4J8.<.I9.=!2H S8MZ$I"
MT'E4JM"8D\F#G#R6+K"0D^<'O[ !^M:3=/B@>W0D0PHYI"RC!X=4FEM@@X_+
M(-4JP \MTTQSFM'EY7;1W.]@I!>QYCC[Y$6L99YIOG2S@?FD99YIOO$+S2<=
MV/EQPJ2L6+ZK YHEN=LP3U\P?B_[UZH=HI=N]'OO>8=\[+K1^?;4%]]M)U<>
M;A>U.X[3:>;/^^N7@^O%V)V7KR+)[=/,YC]02P,$%     @ >(EO3)59U1]"
M @  LP<  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R-E=N.VC 0AE\E
MR@.L<PY! :E05:W42FBK;J\-#"1:)TYM0[9O7]O)1L%V8;G I_\??V.,I^PI
M>^45@/#>&M+RE5\)T2T1XH<*&LR?: >M7#E1UF AA^R,>,< '[6I(2@*@@PU
MN&[]=:GG=FQ=THL@=0L[YO%+TV#V=P.$]BL_]-\GGNMS)=0$6I<=/L-/$+^Z
M'9,C-$4YU@VTO*:MQ^"T\C^%RVT8*(-6O-30\UG?4ZGL*7U5@V_'E1\H(B!P
M$"H$ELT5MD"(BB0Y_HQ!_6E/99SWWZ-_T<G+9/:8PY:2W_515"M_X7M'..$+
M$<^T_PIC0JGOC=E_ARL0*5<D<H\#)5Q_>X<+%[09HTB4!K\-;=WJMA]6TGRT
MN0W1:(@F0YC<-<2C(38,:"#3J7[& J]+1GN/#;]6A]6E")>Q/,R#FM1GI]=D
MMES.7M=96**KBC-*-H,DFDFBQ:UDZY 4DP1)@(DB<E)$VI_,*2*#8I#D6M)J
M2? 4&*C;!Z(;DMA)$MLDL4$R2-+9)F$P?@P<AS+/;H4W2(D3*;&1$@,IL3>*
M\S2,"Y/(%D9QD.9)[ 9*G4"I#90:0.E'@6SA7:#,"9190.E_KE_N].=V0IF1
M4/Z1Z_= =$.R<)(L;)+<(%E8)V:>J:T(D^3.M2N<*(6-8OSM-\5#%%N1AD6<
M1+F;1!8$YR,5V"R%^4H%#V$<$C<-FKV>JIS]P.Q<M]S;4R$?8OU<GB@5((,&
M3S)<)2OH-"!P$JJ;RSX;RL@P$+0;2R2:ZO3Z'U!+ P04    " !XB6],\_ 1
M11L#   ?#   &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;'V7;V^;,!#&
MOPKB?8-M_IDJB=0DFC9IDZI.VU[3Q$E0 6?@)-VWGVT();ZC;P(XSW/^W4&.
MR_PJF[?V*(3RWJNR;A?^4:G38Q"TVZ.H\G8F3Z+6W^QE4^5*7S:'H#TU(M]9
M4U4&C) DJ/*B]I=SN_;<+.?RK,JB%L^-UYZK*F_^K40IKPN?^K>%E^)P5&8A
M6,Y/^4'\%.K7Z;G15\$095=4HFX+67N-V"_\)_JXH8DQ6,7O0ES;T;EG4GF5
M\LU<?-LM?&*(1"FVRH3(]>$BUJ(L323-\;</Z@][&N/X_!;]BTU>)_.:MV(M
MRS_%3AT7/O>]G=CGYU*]R.M7T2<4^UZ?_7=Q$:66&Q*]QU:6K?WTMN=6R:J/
MHE&J_+T[%K4]7OOX-QMN8+V!#8:N.).&L#>$'X;H4T/4&R+'$'2IV-IL<I4O
MYXV\>DUW>T^Y>8KH8Z2KOS6+MMCV.UV>5J]>EBF9!Q<3IY>L.@D;2>B@"'3P
M80>&[;!BP,[X_0YK1)+=2S90DDY0A&B>H?6'8S_#_1'JCZP_&OM#ITZ=)+&2
MVDHXC=U4H8BF<4APE!A%B2%*Y*!TDGBT2T*<V[J&FM%]N<-(4(P$8L0.1@*V
M2&-0$2C2%2$3-R=%45)X<Q/<SU$_AZFD3BH<4O(D<U1K1$48=U0;#I\!$M,8
M)\Y0X@P2.W5=98"%<TH=8"A*(NKR0A'EV00N)7B;(1 X<_L, ?L\T"R+W0<7
MT:69D_T&#<8B.O%+HQ/=D0)L#MHC!3N%;ID1#4M#M\>AJFP"&&VV3Y1!8.H"
M,[3.KFZ-ZR+J4F,REO I<+P_TQ"",Q<\A _BU"YX%Z>PC7.WC5/8HA_T' 7Z
M)Z;#RH/)/BD/WO,I;/K<;?J]AM^!SVCD<B,R.LL -R*+9WSB%4'Q=P2%+PGN
MOB0H? %D*4W2#!0<"EE(XIB$+CHJ)%GLUCP834F5: YV FV]K3S7R@P;H]5A
MRGUB9LIRUE=F^K73UT>8;G3^D3>'HFZ]5ZGT#&<GK;V42FA.,M.$1SVM#Q>E
MV"MSFNKSIAM9NPLE3_TX'@S_"9;_ 5!+ P04    " !XB6],5+ZLI[$$  #N
M%@  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;(U8VW+B2 S]%8IWQE9?
MW':*4+7DPF2&J4K-UNX^.Z$3J+$Q:SMA]N^W;1S DMHD#\$V1]*16GUD>KHO
MRE_5VMIZ]#O/MM7U>%W7NZL@J)[7-D^K+\7.;MTW+T69I[6[+5^#:E?:=-4:
MY5D@PC *\G2S'<^F[;/'<C8MWNILL[6/Y:AZR_.T_&]NLV)_/8;QQX.?F]=U
MW3P(9M-=^FK_M/5?N\?2W05'+ZM-;K?5IMB.2OMR/?X#KI8B:0Q:Q-\;NZ_.
MKD=-*D]%\:NY>5A=C\.&D<WL<]VX2-W'N[VQ6=9X<CS^[9R.CS$;P_/K#^_W
M;?(NF:>TLC=%]L]F5:^OQ_%XM+(OZ5M6_RSV7VV7D!Z/NNR7]MUF#MXP<3&>
MBZQJ_X^>WZJZR#LOCDJ>_CY\;K;MY[[S_V'&&XC.0!P-8-A =@;RLP:J,U G
M@V300'<&^F00#1I$G4'TV0BF,S G S-H$'<&\=% ZD&#I#-(C@9B.((K8K=R
MX2G&<&'AN-BGU5;#M.!CN>&TWJ*-$AP:J^W4V[1.9].RV(_*PV;;I<V>ABMG
MY9PW3]O>;[]TW5JYI^^S.)H&[XVC#C(_0,0YQ/0A-PPD[D-N&4C2A]Q12!+V
M(?<,!/J0!0,1?<A7!B+[D <&HOJ0;PQ$]R'?&0BJ[I*!G*H;N,4[KJ#@5U"T
M#M2Y U3[^0$2M9!M"Y$0H8SO* A175 $*NP#18 V$JWSDJ(F('2L^+0EG[:D
M:>-^.D#T.5\9AHE&N 7%Q9&!4/)\%,]'$3X0HNZ=*TK()8Z:9J%(>1#A!]:/
MBGB^FN>K&;YX*VD21T92NU!\I(B/%#&14./<1B1G=;X AVU+0<C-=]8-\&P-
MS]8P;#$10^H2)2#.EKL7*.8#Q4P@)#'SF 12"C?#,*;').&9) P3U)3SA$1Q
M>S;"$KZ\".OQ:68D.Y1"AA$92R&)!9&(40_?=; A76,@0.8!C:9 2U2F)0.;
M""V,1TO -Y6!*8#!F<$G]8T!:DBD$IY! YY) W340!AC5H(6ROBT'3SB#E3=
MZ>8 JMN01 8OW 54GX]'W(%3=[Q%@,KR!!(%N$4NP?J,//(-G'XGF!$5<#?W
M:2/IRUN$0N@6H=&4U%CJEPQL(HP 7XMXI@HP8P5"G%G$;1%ME,3Y4>#P%O%,
M#^#&!V)UTX%Z]0Z-086Z9V" >NX;[TK[6'M&$7"S"# =.F@T*"5-[ GFF3;
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M71Y.8 \W=;'K3I>#XQ'W[']02P,$%     @ >(EO3/OY[.U2 @  NP<  !@
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6R55=N.FS 0_17$!ZPQM\"*("6I
MJE9JI6BKML\.<0):@ZGMA.W?US:$I6%H=U]B>YASSLS$X\DZ+IYE2:ER7FK6
MR+5;*M4^(B2+DM9$/O"6-OK+B8N:*'T49R1;0<G1@FJ&?,^+44VJQLTS:]N+
M/.,7Q:J&[H4C+W5-Q.\M9;Q;N]B]&9ZJ<ZF, >592\[T&U7?V[W0)S2R'*N:
M-K+BC2/H:>UN\.,.AP9@/7Y4M).3O6-2.7#^; Z?CVO7,Q%11@ME*(A>KG1'
M&3-,.HY? ZD[:AK@=']C_VB3U\D<B*0[SGY61U6NW<1UCO1$+DP]\>X3'1**
M7&?(_@N]4J;=321:H^!,VE^GN$C%ZX%%AU*3EWZM&KMV _\-!@/\ >"/ !S_
M$Q ,@. 58*N)^LALJA^((GDF>.>(_M]JB;D4^#'0Q2R,T=;.?M/92FV]YABG
M&;H:HL%GV_OX4Y_1 VGV4<*')+;^#.XG?ROL )<4E@C + *+#Z<1^MZ=1N\3
M6Y_&^D2KU/,\6"<$=4) !]]5J_>))CIQ$N(8EHE F6@FDR0P/@;Q\?_+L8UG
MY8BQ%RW68P4*K69"Z0(^ ?')&^J9O*>>*2B3 C(^3( ]N$T\@"*XNV&#TS14
MO%A0O-"/&! *%RC ?MM@_RVQ^N^)%>XZ#+5=M$ !-Q2&.FH6:SB[JT"L:/+D
MU52<[7203L$OC3)OR\0Z3J"-;Y[,._O63";[E+[2]&/M*Q'GJI'.@2O](-MG
M\\2YHCI([T&7LM23=#PP>E)FN])[T8^3_J!X.XQ*-,[K_ ]02P,$%     @
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M-;.;B4YF_.4 26#]J1B3)@9&B*,FEF.2<%H D7:&OVBD,B'+ 3@JN7S(!$)
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MUY?#U,M-6QW'@^+H>EJ]^!]02P,$%     @ >(EO3.Z9O/FW 0  TP,  !@
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MW-MQSL; FVYZ0FQ^Q_D?4$L#!!0    ( 'B);TSQ]BZRM0$  -,#   8
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MQZ>-#] 8XP%32>YPACK\8:NAH/'A>(]G.\_9;'@S+%^(K?^X_ U02P,$%
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MWQZW,-E?1<CJ4"68+HZ31;4>51SE57:9V#L:+^4=/H_[5V8ZKBRZ:.>O-EY
MJ[4#;V5WXV>H]R]L"02T+FP_^KV9YVP.G![2$R++.ZY^ U!+ P04    " !X
MB6],CL%9G;4!  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q]
M4^UNG# 0?!7+#Q#?P24YG0 IERA*I58Z)6K[VP<+6/$'L<V1OGW6AE#:HO[!
MWF5F=M9>9X.QKZX%\.1=2>URVGK?'1AS90N*NRO3@<8_M;&*>PQMPUQG@5>1
MI"1+-IL;IKC0M,AB[F2+S/1>"@TG2URO%+>_CB#-D-,M_4P\BZ;U(<&*K.,-
MO(#_WITL1FQ6J80"[831Q$*=T[OMX;@+^ CX(6!PBST)G9R->0W!ERJGFV (
M))0^*'!<+G /4@8AM/$V:=*Y9" N]Y_JC[%W[.7,'=P;^5-4OLWIGI(*:MY+
M_VR&)YCZN:9D:OXK7$ B/#C!&J61+GY)V3MOU*2"5A1_'U>AXSJ,?])THJT3
MDHF0S(1]K,/&0M'Y _>\R*P9B!W/ON/ABK>'!,^F#,EX%/$?FG>8O13;_77&
M+D%HPAQ'3++$S B&ZG.)9*W$,?F'GNS7^>FJQ33RTS\LWJP+[%8%=E%@]]\>
MUS"W?Q5ABT-58)LX3HZ4IM=QE!?9>6+ODG@IO^'CN'_CMA':D;/Q>+7Q FIC
M/*"5S17.4(LO; XDU#YL;W%OQSD; V^ZZ0FQ^1T7'U!+ P04    " !XB6],
MV&2=&+4!  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q]4W^/
ME# 0_2I-/\"595?E-D!R>\9HHLGFC.??71B@N?[ MBSGMW=:6$0E_D,[PWMO
MWK33?#3VQ74 GKPJJ5U!.^_[(V.NZD!Q=V=ZT/BG,59QCZ%MF>LM\#J2E&1I
MDKQEB@M-RSSFSK;,S>"ET'"VQ U*<?OS!-*,!=W16^))M)T/"5;F/6_A*_AO
M_=EBQ!:56BC03AA-+#0%?=@=3X> CX!G :-;[4GHY&+,2P@^U05-@B&04/F@
MP'&YPB-(&830QH]9DRXE W&]OZE_B+UC+Q?NX-'([Z+V74$S2FIH^"#]DQD_
MPMS/&TKFYC_#%23"@Q.L41GIXI=4@_-&S2IH1?'7:14ZKN/T9W^C;1/2F9 N
MA"P2V%0H.G_//2]S:T9BI[/O>;CBW3'%LZE",AY%_(?F'6:OY2[+<G8-0C/F
M-&'2-69!,%1?2J1;)4[I/_0TV^;O-RWN(W__A\7[;8'#IL A"AS^V^,&YC[Y
MJPA;':H"V\9Q<J0R@XZCO,HN$_N0QDOY#9_&_0NWK=".7(S'JXT7T!CC :TD
M=SA#';ZP)9#0^+!]AWL[S=D4>-//3X@M[[C\!5!+ P04    " !XB6],7]\4
MQ;4!  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q]4]%NG# 0
M_!7+'Q ?/II>3X"42U6U4B.=4K5]]L$"5FQ,;',D?]^U(92VJ"_8N\S,SMKK
M;#3VR;4 GKQHU;F<MM[W1\9<V8(6[L;TT.&?VE@M/(:V8:ZW(*I(THKQW>Z6
M:2$[6F0Q=[9%9@:O9 =G2]R@M;"O)U!FS&E"WQ*/LFE]2+ BZT4#W\!_[\\6
M([:H5%)#YZ3IB(4ZIW?)\90&? 3\D#"ZU9Z$3B[&/(7@2Y7373 $"DH?% 0N
M5[@'I8(0VGB>->E2,A#7^S?U3[%W[.4B'-P;]5-6OLWI@9(*:C$H_VC&SS#W
M\XZ2N?FO< 6%\. $:Y1&N?@EY>"\T;,*6M'B95IE%]=Q^I/RF;9-X#.!+X3D
M$'N9"D7G'X4716;-2.QT]KT(5YP<.9Y-&9+Q*.(_-.\P>RV2#TG&KD%HQIPF
M#%]C%@1#]:4$WRIQXO_0^6&;O]^TN(_\_1\6^;9 NBF01H'TOSUN8?9_%6&K
M0]5@FSA.CI1FZ.(HK[++Q-[%6V2_X=.X/PC;R,Z1B_%XM?$":F,\H)7=#<Y0
MBR]L"134/FS?X]Y.<S8%WO3S$V++.RY^ 5!+ P04    " !XB6],R<C1L[4!
M  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q]4]%NG# 0_!7+
M'Q#?^4AZ.0%2+E652HET2M7TV0<+6+%98ILC_?O:AE#:HKY@[S(S.VNOTP'-
MJVT ''G7JK49;9SK#HS9H@$M[!5VT/H_%1HMG ]-S6QG0)21I!7CF\T-TT*V
M-$]C[F3R%'NG9 LG0VROM3 _CZ!PR.B6?B2>9=VXD&!YVHD:OH'[WIV,C]BL
M4DH-K978$@-51N^VAV,2\!'P(F&PBST)G9P17T/PM<SH)A@"!84+"L(O%[@'
MI8*0M_$V:=*Y9" N]Q_J7V+OOI>SL'"/ZH<L79/1/24E5*)7[AF'!YCZN:9D
M:OX1+J \/#CQ-0I4-GY)T5N'>E+Q5K1X'U?9QG48__#;B;9.X!.!SX1]K,/&
M0M'Y9^%$GAH<B!G/OA/ABK<'[L^F",EX%/&?-V]]]I)O;Y.478+0A#F.&+[$
MS CFU><2?*W$D?]#Y_MU_F[5XB[R=W]8O%X72%8%DBB0_+?'-<S-7T78XE U
MF#J.DR4%]FT<Y45VGM@['B_E-WP<]R=A:ME:<D;GKS9>0(7HP%O97/D9:OP+
MFP,%E0O;3WYOQCD; X?=](38_([S7U!+ P04    " !XB6],N5SAD*P"   5
M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6QU5M&.VC 0_)4H'W".
M'0AP B2XJFJE5D)7]?KL P/1)7%J&[C^?6TGEU)G_$)L9W;&=F:77=ZD>M-G
M(4SR7E>-7J5G8]I'0O3^+&JN'V0K&OOF*%7-C9VJ$]&M$OS@@^J*L"PK2,W+
M)ETO_=I.K9?R8JJR$3N5Z$M=<_5G*RIY6Z4T_5AX+D]GXQ;(>MGRD_@AS,]V
MI^R,#"R'LA:-+F63*'%<I1OZN&7,!7C$2REN^FZ<N*.\2OGF)E\/JS1S.Q*5
MV!M'P>WC*IY$53DFNX_?/6DZ:+K ^_$'^V=_>'N85Z[%DZQ^E0=S7J7S-#F(
M([]4YEG>OHC^0-,TZ4__35Q%9>%N)U9C+ROM?Y/]11M9]RQV*S5_[YYEXY^W
M[DWQ$88#6!_ AH"Y#R"=D-_Y)V[X>JGD+5'=Y;?<?6/ZR.S=[-VBOPK_SFY>
MV]7KFBYF2W)U1#UFVV'8/69 $,L^2# DL66C<#;'\3G<8N[C\WOY8HH))I!@
MX@DF_YUQ'IP181989 I%IB,"FQJ!",)$KK* (@4@8($(PN189 9%9H!@$H@@
M3.2;S*'('! 4@0C"S+#( HHL $'XX1$F\N%IAE,H&WNG&.70&,1H%M&)I"H%
M%#3402 6T8'YNJ%L?)[9(M09@QB-V(SBO*8YH B-!D$1IU&<_G2<VXR&7H.@
MB-DHK@ 4I#<-[09!,;_A(D!!AK.PU$!0I-907 <H2'(65AL(BOD EP(*\IR-
M?(! ,1_@:D!!JK.1#Q HX@.&ZP$#J<Y"'T!0Q <,UP,&4CT/?0!!L;]O7 \8
M2/4\] $$A3X@=UU)+=3)]V,ZV<M+XYO!N]6AY]OXEH_\@W<-XW>N3F6CDU=I
M;&_D.YBCE$;8O60/-L?.MD<=)I4X&C><V;'J&K5N8F3;-Z%DZ(37?P%02P,$
M%     @ >(EO3,3,MZFX 0  TP,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL;5/M;ML@%'T5Q .4F#A9%-F6FDY5)ZU2U&GK;V)?VZA\>(#C]NT'
MV'7=SG^ >SGGW \NV:#-BVT!''J50MD<M\YU1T)LV8)D]D9WH/Q-K8UDSINF
M(;8SP*I(DH+0S69/).,*%UGTG4V1Z=X)KN!LD.VE9.;M!$(/.4[PN^.)-ZT+
M#E)D'6O@%[C?W=EXB\PJ%9>@+-<*&:AS?)L<3VG 1\ ?#H-=G%&HY*+U2S!^
M5#G>A(1 0.F" O/;%>Y B"#DT_@[:>(Y9" NS^_J][%V7\N%6;C3XIE7KLWQ
M :,*:M8+]Z2'!YCJV6$T%?\3KB \/&3B8Y1:V+BBLK=.RTG%IR+9Z[AS%?=A
MO$F3B;9.H!.!SH1#C$/&0#'S[\RQ(C-Z0&;L?<?"$R='ZGM3!F=L1;SSR5OO
MO19TFV;D&H0FS&G$T 4FF1'$J\\AZ%J($_V/3@_K_.UJBMO(WR[#[W?K NFJ
M0!H%TD\U[K[4N(;9?PE"%DV58)HX3A:5NE=QE!?>>6)O:7R4#_@X[H_,-%Q9
M=-'./VU\@%IK!SZ5S8V?H=;_L-D04+MP_.;/9IRST7"ZF[X0F?]Q\0]02P,$
M%     @ >(EO3-UNG[.X 0  TP,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL=5/M;ML@%'T5Q .4A+AM%MF6FD[3)FU2U&G=;V)?VZC@ZP&.N[<?
M8,?S.O</<"_GG/O!)1W0O-@&P)%7K5J;T<:Y[L"8+1K0PMY@!ZV_J=!HX;QI
M:F8[ Z*,)*T8WVSNF!:RI7D:?2>3I]@[)5LX&6)[K87Y?02%0T:W].IXDG7C
M@H/E:2=J^ [N1W<RWF*S2BDUM%9B2PQ4&7W8'HY)P$? LX3!+LXD5')&? G&
MES*CFY 0*"A<4!!^N\ C*!6$?!J_)DTZAPS$Y?FJ_BG6[FLY"PN/J'[*TC49
MW5-20B5ZY9YP^ Q3/;>43,5_A0LH#P^9^!@%*AM74O36H9Y4?"I:O(Z[;.,^
MC#?)E;9.X!.!SX1])+ Q4,S\HW B3PT.Q(R][T1XXNV!^]X4P1E;$>]\\M9[
M+SG?W:?L$H0FS''$\ 5F.R.85Y]#\+401_X?G>_7^;O5%'>1OUN&OWM'(%D5
M2*) \D^-^S<UKF$^O G"%DW58.HX3I84V+=QE!?>>6(?>'R4O_!QW+\)4\O6
MDC,Z_[3Q 2I$!SZ5S8V?H<;_L-E04+EPO/=G,\[9:#CLIB_$YG^<_P%02P,$
M%     @ >(EO3*4R:+ZW 0  TP,  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL;5/;;IPP$/T5RQ\0@Y=L5RM RB:J&JF15JG:/GMA "N^$-LLR=_7
M-H32E!?;,S[GS,7C?-3FQ78 #KU)H6R!.^?Z(R&VZD R>Z-[4/ZFT48RYTW3
M$ML;8'4D24%HDNR)9%SA,H^^LRES/3C!%9P-LH.4S+R?0.BQP"G^<#SSMG/!
M0<J\9RW\ />S/QMOD46EYA*4Y5HA TV![]+C*0OX"/C%8;2K,PJ57+1^"<9C
M7> D) 0"*A<4F-^N< ]"!"&?QNNLB9>0@;@^?ZA_C;7[6B[,PKT6OWGMN@(?
M,*JA88-PSWK\!G,]MQC-Q7^'*P@/#YGX&)46-JZH&JS3<E;QJ4CV-NU<Q7V<
M;O;[F;9-H#.!+H1#C$.F0#'S!^98F1L](C/UOF?AB=,C];VI@C.V(M[YY*WW
M7DN:)3FY!J$9<YHP=(5)%P3QZDL(NA7B1/^CT\,V?[>9XB[R=^OPAV1;(-L4
MR*) ]D^-Z:<:MS#T4Q"R:JH$T\9QLJC2@XJCO/(N$WM'XZ/\A4_C_L1,RY5%
M%^W\T\8':+1VX%-);OP,=?Z'+8: QH7C%W\VTYQ-AM/]_(7(\H_+/U!+ P04
M    " !XB6],7;3YSAX"  #;!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6R55=&.FS 0_!7$!YRQ@9!$!"FYJFJE5HJN:OOLD$U 9S"UG7#]^]J&
MHSFZD:XOV+N>G=DU]CKOI7K6%8 )7AK1ZDU8&=.M"=%E!0W7#[*#UJZ<I&JX
ML:8Z$]TIX$<?U C"HFA!&EZW89%[WUX5N;P84;>P5X&^- U7OW<@9+\):?CJ
M>*K/E7$.4N0=/\,W,-^[O;(6F5B.=0.MKF4;*#AMPBU=[VCL CSB1PV]OID'
MKI2#E,_.^'S<A)'+" 24QE%P.USA$81P3#:/7R-I.&FZP-OY*_M'7[PMYL U
M/$KQLSZ::A,NP^ ()WX1YDGVGV L* V#L?HO< 5AX2X3JU%*H?TW*"_:R&9D
ML:DT_&48Z]:/_;"2K<8P/("- 6P*6'H=,@CYS#]PPXM<R3Y0P^9WW/UCNF9V
M;TKG]%OAUVSRVGJO!4OBG%P=T8C9#1AV@Z$3@ECV28)A$COV3SA;XO$QFF+L
MX^,W*28X08(2))X@>4.0SFK$, M<)$5%4H0@FXE@F#M;L4!%%@C!:B:"8-((
M%\E0D0PAH#,1#,-PD24JLD0(8IQ@A1*LWG\J:(0?_0C)(9F??0R4WM&Y<\4H
M0G'G;%'T"FTI^X]J\5M$X_=4BX&RF0ZYZ2T-J+/OJCHHY:7U+?W&.W7N+?.]
MZ2]\:/M?N3K7K0X.TM@.Y_O024H#-I?HP=Z6RKXTDR'@9-PTLW,UM-O!,+(;
MGQ(RO6?%'U!+ P04    " !XB6],#*<4Y,<!   X!   &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6QM5-MNG# 0_17+'Q"#=]G2%2!E4U6MU$BK5&V>
MO3!<%!M3VRS)W]<VA)*M7_#,^,PY,[:';)+J1;< !KT*WNL<M\8,1T)TV8)@
M^DX.T-N=6BK!C'550_2@@%4^27!"H^A !.MZ7&0^=E9%)D?#NQ[."NE1"*;>
M3L#EE.,8OP>>NJ8U+D"*;& -_ 3S:S@KZY&5I>H$]+J3/5)0Y_@^/IX2A_>
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MSFDKY+,J +3W4O%:;?U"ZV83!"HOH&+J0310FR]G(2NFS5%> M5(8"?G5/&
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M&R]G(3287,('4R2%>4 ,!PYG;;>)V<MNBG8'+9K^A1 ,SY3L'U!+ P04
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MJ8:HZZCNO[,#*R2\92)K+'G1=)_.<M\(7JHLDDJ9O??7O.JN1Y7_(PP/ !4
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MVGRLVF-'LGZZD=!\+5;_ 5!+ P04    " !XB6],8PIH@=0!  #=!   &0
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M/?%]]DX1V8@>(&#:*]LG@8GT@&E/ R82P.JU.P3V[+YX":NWH.3RZ+I3HIK
M)80'I/H!I'I JM<N(<7"C;(,S6)$][N 5:]4O,3. I>*")J"!T![9>LD,#T!
M !T&5+,!<!@4#HEOX4$I4HUK\@6+(0" @@*0F,@@;_0,@"P R(+VF0-8"0%
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M,6_[PG8B6=/UO$'?>"__ 5!+ P04    " !XB6],6X-UV=T"  "%"P  &0
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M![/R,4GA;&@-\=RX; 4HM@#$YHY8 $.<"[F", [/&L(06.P4%#L%_AE.198
MAKAW%L*X-@!@1M6_$HMBV/%BGV+D-M<4-TP3?=Y,$&B*]PA_;"?+'C3V$S3)
MW+)]A+J6 [LC2@ YJ2L' !7(50.!L'.*("BYH1BV8^3[,<(W# '!7HNR_SA&
MV $18$O^,>;> 25D@KW*^3 RF>8W], FAP#G\<\1 !6IJP8"N=\[ )1XGY!H
MU(O43.QMGR>##3\VRGS11ZM#+WF/32_CK"]-CVE[G#>:KD']0<6^;&3PS)7N
ME&P_L^-<,:TQGNA3/NB>>)A4;*?,D.BQZ!K#;J)XVS>]T=!Y+_X!4$L#!!0
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MLM'I=G2D5(#,T7F2G[205]JP(' 4:AK+.>OZ>K<0M.GO+#1<G-D_4$L#!!0
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MYE7?\)YP?<--%&^[GACTC3G_"U!+ P04    " !XB6],F;W4HYD"  "%"0
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MAZ49R^%B,$RTZ,=+3W*Y>2W^ U!+ P04    " !XB6],%"KAT"X"  !&!@
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M.1I9MIAXF&8>)_.1Y2DJ&G3/&G8H!4N\<!M.G(83AV$\,IQ,^Q($\S >.7;
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MF&&"">$)]2D$L(4HP8(.TL<(6PLD>X3LEI#DB8O0FFBH^.%#HK%= %H%H!*
M#P*)42F-B16FTWGXXF-DNT0%&0R,?"T@$*>9W7%D=1Q9'!N5+S4FFH5)@?'^
MMTL,@+&1^LXB% &[V]CJ-K:X-9J@C"WU7?I=HB#TC<1W2U 01O!)2R56Q\G2
M<62\ZS)9E"5+@CC)S)Y8XD#H"[G0L&W%^5GTI#%2J_'48MSHOU)CTGF@50 -
MUTM0L,K,3EZ"HE6:&GZ]V8758GI1PX Y1W+MN/S;STZG>?,"Y(5GG)=B#NFQ
M\2&CA]@/1"]UQYP#X>(Z59?>F1".A4=_)2I:B;DY;1I\YG*9B#75TT-O..G'
MP>A-T[GX#U!+ P04    " !XB6],P50J;$L"  !3!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6R-5>V.VR 0?!7+#W 8_'UR+%T25:W42M%5;7\3
MA\368>,"B:]O7\".SW'()7\"K&>&V0TL6<?XFR@)D<Y[31NQ<$LIVV< 1%&2
M&HLGUI)&?=DS7F.IEOP 1,L)WAE230'RO C4N&K</#.Q#<\S=I2T:LB&.^)8
MUYC_6Q+*NH4+W7/@M3J44@= GK7X0'X2^:O=<+4"H\JNJDDC*M8XG.P7[@M\
M7D-#,(C?%>G$9.[H5+:,O>G%M]W"];0C0DDAM016PXFL"*5:2?GX.XBZXYZ:
M.)V?U;^8Y%4R6RS(BM$_U4Z6"S=QG1W9XR.5KZS[2H:$0M<9LO].3H0JN':B
M]B@8%>;7*8Y"LGI0459J_-Z/56/&;M _T^P$-!#02(#1IP1_(/@?A.!30C 0
M@AD!]*F8VJRQQ'G&6>?P_N]ML3Y%\#E0U2]TT!3;?%/E$2IZRL,09>"DA0;,
MLL>@"0:."*#4QRV0;8LENJ*CY'*'E0627D+6UY#XA@O?FJAO^,%%HKY=(+ *
M!$; OQ ([ *A52"T. AGA>@QH<$T/0:F?H#B637NXRX,159#D<509!>(K0+Q
MXR5)K +)_9(LDZM440#5/O/267!1%'KI_"!9<#!-$S^Q&T^MQE.+\1NUAY[]
MXGF/%P_>N+OP@1,U@*;YQBCQX>R2K^_C>DM@TEEJP@^F:PNG8,=&ZOLYB8XO
MPPO2G6D67^H7PW2L#YG^N?F!^:%JA+-E4O4]TYWVC$FB;'I/RF"I7KAQ0<E>
MZFFLYKQO\_U"LG9XPL#XCN;_ 5!+ P04    " !XB6],\W@0Q> !  "H!
M&0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q]5-N.VR 0_17$!RR.'=+=
MR+:T256U4BM%6[5])O;XH@7C HZW?U_ CM=)45\,,YPY9V;,D(Y2O>H&P* W
MP3N=X<:8?D^(+AH03#_('CI[4DDEF+&FJHGN%;#2!PE.XBC:$<':#N>I]YU4
MGLK!\+:#DT)Z$(*I/P?@<LSP!E\=+VW=&.<@>=JS&KZ#^=&?E+7(PE*V CK=
MR@XIJ#+\O-D?J<-[P,\61KW:(U?)6<I79WPI,QRYA(!#81P#L\L%CL"Y([)I
M_)XY\2+I M?[*_LG7[NMY<PT'"7_U9:FR? C1B54;.#F18Z?8:Z'8C07_Q4N
MP"W<96(U"LFU_Z)BT$:*F<6F(MC;M+:=7\>9_QH6#HCG@'@)V-#_!B1S0/(>
ML//%3YGY4C\RP_)4R1&IZ6?US-V)S3ZQS2R<T_?.G]EJM?5><DH?4W)Q1#/F
M,&'B%29^BA<,L?R+2!P2.<3_$%#Z="MR#&!V45@D"5:2>(+DAF 3)M@&";:>
M8'M#$-]E&<(D81$:%*$!@NU=OT,8>B="5C]8@*K]+&A4R*$SKHTK[S)NS[&[
M('?^@QW#:6K>::89_L94W78:G:6QU\]?DDI* S;%Z,'FV-AG8S$X5,9M/]B]
MFH9G,HSLYW>!+(]3_A=02P,$%     @ >(EO3*4TF#TU @  < 8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3 N>&ULC57;CILP$/T5Q <L8,# BB!M4E6M
MU$K15FV?'3(): VFMA.V?U_;$): M^U+; _G,N/+).\9?Q$5@'1>&]J*C5M)
MV3UZGB@K:(AX8!VTZLN)\89(M>1G3W0<R-&0&NHAW\=>0^K6+7(3V_,B9Q=)
MZQ;VW!&7IB'\]Q8HZS=NX-X"S_6YDCK@%7E'SO -Y/=NS]7*FU2.=0.MJ%GK
M<#AMW*?@<1?XFF 0/VKHQ6SNZ%(.C+WHQ>?CQO5U1D"AE%J"J.$*.Z!4*ZD\
M?HVB[N2IB?/Y3?VC*5X5<R "=HS^K(^RVKBIZQSA1"Y4/K/^$XP%Q:XS5O\%
MKD 57&>B/$I&A?EURHN0K!E55"H->1W&NC5C/^K?:'8"&@EH(BCOOQ'"D1"^
M$; I?LC,E/J!2%+DG/4.'TZK(_I2!(^AVLQ2!\W>F6^J6J&BUR+&./>N6FC$
M; <,FF%0ANXQNS4FF!">RF!* ]G2V*(5/<;)PF*-2=[Q"*VEAH8?WGFD=H'(
M*A 9@>A.(%LD.6"PP;3#7@4HCNTVL=4F7MF@-+0+8*L _O]"$ZM LLH@"M/%
MI1@P\:S0 *?J7F"[46HU2M<[FO@+HW2UH]$[QYY9/;)_G]HV6WG@R/=]NXWJ
M6M:7Y*]W+5H6,X+BN_N1Q0%:6'FS]]L /YM6)YR275K39V?1J9T^(?/^W^!#
M+_Y*^+ENA7-@4G41\]9/C$E0Z?@/*I%*M?]I0>$D]311<S[TP&$A63?V=V_Z
MDRG^ %!+ P04    " !XB6],\7]94/HR   -Z@  %    'AL+W-H87)E9%-T
M<FEN9W,N>&UL[7UI<^,VMNCGT:] Y77NLV]1:I':D[FI4FPYT3RW[6?9F4E-
MW0^T1-M,*%$AI7;WU/SX=Q8 ! E0BY.YDYGGJBRRA.4 .#C[.?ACGF_$=A7_
MLHW.TNUJ\U]?] ;^%^+3,EGE__7%\V:S_NK]^WS^'"W#O)6NHQ7\\IAFRW #
M?V9/[_-U%H6+_#F*-LOD?=!N]]\OPWCUQ3=_S.-O_KCYYCR=;Y?1:B/"U4),
M5IMX\UE,5SQ"G*[^^'[SS1_?8U-N[@?B0[K:/.?0=A$MJC^?1_.6Z/B>"-K^
M('\.LRBWFJ@)Q\X)Q5_'#_DF"^>;_Z[M>?=Y'55_#-K-B^IW8VB]H!X72?A4
M_?4Q3')K&#W'393%*0*X$.?AQFXG%]KXPQ]PJ;7#7,3Y/$S$CU&8B0OXLGX[
M9$LYK[/MQ8_5;^ZR<!&OGL3L\_(A3:J_WM]^=U7]3N[X;?04XS;#Q%?ATEK>
M?99^%ZW$#9S@,A27FT6K9IPS #T#L*> #9_$_XD^5]N=;;.LNA%UF]IL^D&S
MX]=,]><H29H_K]*7E9A%89ZNHH68YODVRJH=KM(Z:"4PM]$ZS3:T<9MP8V_T
MCS;:RA$NXB3*Q!D _Y1FUF*OTE4SG,\C: ,M%MRZ#I9TN01TGVW2^<^>F-%=
M$=?;3;Z!FPB@61MY?36[OIR>C^\FY^+;\>7XZFPB9M]/)G<ST13WLW-Q\NY4
MO!/Q2MP]I]L<1K&1S;R>NW[L6[/?W]Y.KN[$>#:#";^R?@[S9Z(@<_P0_;*-
M/X8)[+0%P>P9-KZYB;(E /HQRC=+5ZM;^"&+Y[B%"SBJ/-Y85WL^1VJ8BRR:
M1S#90V)ATQ3&7VT<IW231>LP7HCH$Y#+''8= 4\WSW"P<XD@89Y'-EAWUW?C
M2U'>"@L%KJ^:NUO<9$"F,\  G!:W:HU[X(E59*WRFH!: 58= IA[.@7,Y73\
M[?1R>C>=V,>G=W,=?L:M)-  D;-M5&R3A<?+=9)^CB(X@H2P?5^'\^@Q@E4L
MH .<S-9N #LSCZ)%+AZS= G#1-D\SB.1/HJ7,$-:!;^DF0".)@=R<YCR,1GK
MWG56.YK]^9C)SZX_?)C>?8 A9V)\=2[@VMY-K[Z;7)W!R.+D*MU$HG]:Z87L
M_*M\'<ZC__H")LBC[&/TQ3?"O; =D,Z^']].OK^^/)_<SO[C?PT#?_"UF/S?
M^^G=C]:17V= 9,+LLUR&)ZZF,]%NM7W @4S [=U&7PN_W?;:_"^AA#_P^O)/
M[B;"[09N=/PW//Z- !(2+1\ 916-H5Y(3SPX]'P=S3?QQRCY#"-WO$'/]SHC
M'CCP.NV>-^AVU+@Q$O8%W\R")@+Z(S8<.HV%YHM%C#(&\"$D $T@E?-P'6]"
MBW/"A=@NMXS6B^@QGML4B ^C?L?W'AZAQ^']9R 8P,:,::WCIB]N-";.G)AH
M=:BBKNO,OQ+RI+M>][<Y:1ZOY_FCCM<-!OL.^/"ACV&0)S<ADL_G:!.#%'(*
M#!,VN],/OA;O:^ZQ=3_T%NUM:6W8WAZ\&7N;I?72P8UUMK7PVDWW ES;Q0UX
M;?,="RB=WNP._L<T]/I"7-],;L=W4VCP*D&G9PL&\W09D>@7D>A=KW+<3GZ8
M7-W;A/;L>G:'H-7]_MWM]6PF;FZO+Z9WUK'R<JZ^$Y._W$RN9@Y^?#N93<:W
M9]\3B3B'.2ZO;W [= ^XNA-K8& R,/(E=1J??YC"[;[#F7Z8Z'[UL)Q< L2G
M8GH%#&QB*1[3*[I-.Z?' <2WDXOKVXD<1MR-_V+/6?RFQK/X\@3X,8SFG $@
M%M>WYP#1[8],/N&RSZ9GO%?3RWM ((N#3Z;??8^(-?X!UOO=1%S=?_@6Q[G@
M$0#-[N\ Z:[.<2ON9]!R>@6L^\/-_1UA'K:T9A$U\!R!VF??CT$VF.%L)B>0
M+.!@=+]+'3QL>G-=?S''-4Q#TYR#?MXYA7N$ZN_[03*X]@UR[>D*]"\WUZYM
MZ0"TOO$!(!GBP;E;//@V3,+5/)(,31.C;DV[@@CO:8\:+PT,<I"BKJ YX)^Q
M^FF>YK:.<'!'KX8CWFRS^7/(\OCT1MS^1[A<?WV.>#E/5WF\0)T7]M.KX3J'
M]G9/3N?0?( !0,=,EZA@..U35["B),VM_C7'8?&&/<=AM9\82DJZ1HB *8+6
M*5*W5' @7);^O0<NJ_WA<$D<Z ^]KM]7P[_$F^?G*%D(Z $ZH1P"),AX;IWL
M/W"JNEV;N%1#FG.?>G9XST/FKO9QKOM7#W D[EB&G3VX8[5_/;^RQ6S)OYS7
M.2\(CS09D*2_70$Q>,GB393E8A'G;)JH&>$81/T0?HJ7V^5K\;=F./%WL8=I
M%@T/9V6[SF \^UY<7%[_^7!QV.AR<7O]011BW_@,Y,,:H]#BIZVTSX'>]<LV
M1C2%;<DBH-CS.(GH/B.QQ6_Q,QG_3K9(H^/5*1Q"^A$(^T(\X+D0@4<-#]4W
MV(4HMV8\C^ ^S&,G89_BH:;S"&:3O,.)$6(_BYA\ D:T>HH$VF@1PQ[A"D:
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M-OP%#'3!. 1"B3:)Y3ML8A*"= <$;G_&U?7=1$C/<EM]",5*W-]<BE0DXDD
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MAPG<']TGA'\$4,DYTMLG6@@*"GF81%4X%P510*S#S7-N'&WL6D0"29OX $M
M';Z,#%D8XX#O^NW64,%98^TKJ]Q(!+3*[=$VKV :^ %5UNT#P H<0TIF)U],
M;ZZ_.$74Q,FOPGP1_L(!+0!7]C-,I\@L_Z:(K#C)X5#)%3X,3UOB?$OC_6F;
MN!8#MQ<)<6B?"1-"XRC@KF\36@3='.O^ 3%?PO(E#:6E&001EG@5O8CS;/ND
M 9]>G6NH0R#AB/5*%'"1@]N[[X!('D0,OKV^N_Z+'F@#NHS6+U.@J"3/@3Z;
M %8R.<)F]ZT9$,\T9<\I@3I>+.,5!7/19 KRB_.Q@KPE[DSD('T0=7GXTM[3
MV&3!@Q8BV9_"U18I.7PQ+)\-ZME)1 J7(<NN&5&T"+\#09PR%FQT!D1D"?@/
M&/&NW]4'[$1AO-=YBM1;(I4?T"61]VN!;,+L)+^?:\$(R9B6@7(M Y67"@(B
M7\0'YI%P($BKF"XFX6I%#$H)1+R.C4A 0V7&L8H^;0 RL:3PR9;X/GT!?E3F
M@!97F:.S=$%VBB7<]!7V ,KW',,'W/PE"I%AHF0]XE5(WX&"P/+@)FPC!#1>
M@>).IIHHUQ@'_P?6&!&Q?=RB3$=X B08?J"[#_25,8\6ZH)3,5>:6?)7PB*E
M='D@-*PBC! D_=] U8]1V< @(S'X2Z##6U2\@ S%<"1;%*U0$M@\AYLR L(E
MYAG@D%%6VP!7Q6-45H/R(?(F2CL6$DF3YN,JX6 LK2-^6J'TA.Q:!DHA4M\
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M@=?NH!-ST()17-#UV]Y0@@=TH@-?:' 1:QLJ[FC1:,)7S<9)UQL,NQ+Z;N\
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M'88*VEYOA"&6_@AOJ4]']*G1X[-:-WYT)R]56<[MOHQ]"@@8$2V#N?I(JWS
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MH"D/K\=7:V9S6=?<D]64]-N16/Z!V9VC_HE[AB.K ]K%""B^LE":SF!3XHW
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M]'5NC!-44G5CEE@' ]C;GPRXN^QFK3J) /;V9QR3DEW4!?M_%.$O4$L#!!0
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M23Z,61[FL^X/Z.D74$L! A0#%     @ >(EO3!\CSP/     $P(   L
M         ( !     %]R96QS+RYR96QS4$L! A0#%     @ >(EO3&;S"V""
M    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    " !XB6],L+)VT>\    K @  $0              @ &9 0  9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    " !XB6],F5R<(Q &  "<)P  $P
M            @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M 'B);TPI5)F!:P(  (T(   8              "  ?@(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !XB6],J09<,L,#  "F$0  &
M            @ &9"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ >(EO3)59U1]" @  LP<  !@              ( !D@\  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( 'B);TSS\!%%&P,  !\,
M   8              "  0H2  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " !XB6],5+ZLI[$$  #N%@  &               @ %;%0
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ >(EO3/OY[.U2
M @  NP<  !@              ( !0AH  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( 'B);TQLO5BDI 0  +D6   8              "
M <H<  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !XB6],
M[IF\^;<!  #3 P  &               @ &D(0  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ >(EO3/'V+K*U 0  TP,  !@
M     ( !D2,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M 'B);TS,"9O M $  -,#   9              "  7PE  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ >(EO3#]AULBS 0  TP,  !D
M             ( !9R<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " !XB6],GX="=;4!  #3 P  &0              @ %1*0  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( 'B);TS6<$0IM0$
M -,#   9              "  3TK  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ >(EO3*1"ASFU 0  TP,  !D              ( !
M*2T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !XB6],
M\IJ<8[0!  #3 P  &0              @ $5+P  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( 'B);TR.P5F=M0$  -,#   9
M      "  0 Q  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ >(EO3-ADG1BU 0  TP,  !D              ( ![#(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !XB6],7]\4Q;4!  #3 P
M&0              @ '8-   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( 'B);TS)R-&SM0$  -,#   9              "  <0V  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ >(EO3+E<X9"L
M @  %0L  !D              ( !L#@  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " !XB6],Q,RWJ;@!  #3 P  &0
M@ &3.P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( 'B)
M;TS=;I^SN $  -,#   9              "  8(]  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ >(EO3*4R:+ZW 0  TP,  !D
M         ( !<3\  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " !XB6],7;3YSAX"  #;!@  &0              @ %?00  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( 'B);TP,IQ3DQP$  #@$
M   9              "  ;1#  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ >(EO3,2/B0*X 0  TP,  !D              ( !LD4
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !XB6],])P>
M)OL"  !'#0  &0              @ &A1P  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( 'B);TR,;<_6PP(  *<*   9
M  "  =-*  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M>(EO3.\]S41) @  L@@  !D              ( !S4T  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " !XB6],BI!7>9 "   \"@  &0
M            @ %-4   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( 'B);TPY=EJ:[0$  -L$   9              "  113  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ >(EO3+55A3X@ @
M%@8  !D              ( !.%4  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " !XB6],WA*VYFP#   7$   &0              @ &/
M5P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( 'B);TQ/
M@%PFOP(  /L+   9              "  3);  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ >(EO3&D^^4(5 @  NP4  !D
M     ( !*%X  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M" !XB6],YK<\UB\"   B!P  &0              @ %T8   >&PO=V]R:W-H
M965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'B);TQC"FB!U $  -T$   9
M              "  =IB  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!
M A0#%     @ >(EO3-D)"XBA!@  HR<  !D              ( !Y60  'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !XB6],WWL>8MH"
M  "$"P  &0              @ &]:P  >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;%!+ 0(4 Q0    ( 'B);TQ;@W79W0(  (4+   9              "
M <YN  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ >(EO
M3)&$F>8"!   %1(  !D              ( !XG$  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " !XB6],7A@V1SX#  "##@  &0
M        @ $;=@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( 'B);TS9+KIX30(  $0'   9              "  9!Y  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ >(EO3)U:_9=8 @  I <
M !D              ( !%'P  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " !XB6],F;W4HYD"  "%"0  &0              @ &C?@
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( 'B);TP4*N'0
M+@(  $8&   9              "  7.!  !X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ >(EO3'*&TL%Q @  J0<  !D
M ( !V(,  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !X
MB6],P50J;$L"  !3!P  &0              @ & A@  >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( 'B);TSS>!#%X $  *@$   9
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( 'B);TQXE!L.\0,   (A   /
M      "  47#  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !XB6],%O],
M-MH!  ";'@  &@              @ %CQP  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !XB6],2I4EW<<!  "('@  $P
M    @ %UR0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .P [  \0  !M
%RP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>167</ContextCount>
  <ElementCount>251</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>45</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Nature Of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperations</Role>
      <ShortName>Nature Of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Employee Rights Upon Retirement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureEmployeeRightsUponRetirement</Role>
      <ShortName>Employee Rights Upon Retirement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Proceeds from Exercise of Warrants for Preferred A-1 Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1Shares</Role>
      <ShortName>Proceeds from Exercise of Warrants for Preferred A-1 Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure -  Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Loss Per Ordinary Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShare</Role>
      <ShortName>Loss Per Ordinary Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Related Parties-Transactions and Balances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalances</Role>
      <ShortName>Related Parties-Transactions and Balances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapital</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncome</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Loss Per Ordinary Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareTables</Role>
      <ShortName>Loss Per Ordinary Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Nature of Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetails</Role>
      <ShortName>Nature of Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Significant Accounting Policies - Schedule of Annual Rates of Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfAnnualRatesOfDepreciationDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Annual Rates of Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and Equipment - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Proceeds from Exercise of Warrants for Preferred A-1 Shares - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureProceedsFromExerciseOfWarrantsForPreferredA1SharesAdditionalInformationDetails</Role>
      <ShortName>Proceeds from Exercise of Warrants for Preferred A-1 Shares - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Commitment and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Financial Instruments - Summary of Changes in Fair Value of Warrants for Preferred Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfChangesInFairValueOfWarrantsForPreferredSharesDetails</Role>
      <ShortName>Financial Instruments - Summary of Changes in Fair Value of Warrants for Preferred Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Share Capital - Summary of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalDetails</Role>
      <ShortName>Share Capital - Summary of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Share Capital - Summary of Share Capital (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfShareCapitalParentheticalDetails</Role>
      <ShortName>Share Capital - Summary of Share Capital (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Share Capital - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails</Role>
      <ShortName>Share Capital - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Employees and Directors (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToEmployeesAndDirectorsDetails</Role>
      <ShortName>Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Employees and Directors (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Consultants and Other Service Providers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfAssumptionsUsedToComputingFairValueOfOptionsGrantedToConsultantsAndOtherServiceProvidersDetails</Role>
      <ShortName>Share Capital - Schedule of Assumptions Used to Computing Fair Value of Options Granted to Consultants and Other Service Providers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Share Capital - Summary of Number of Options Outstanding Under the Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingUnderPlanDetails</Role>
      <ShortName>Share Capital - Summary of Number of Options Outstanding Under the Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Share Capital - Summary of Number of Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalSummaryOfNumberOfOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Share Capital - Summary of Number of Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Share Capital - Schedule of Effect of Share-Based Compensation on Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureShareCapitalScheduleOfEffectOfShareBasedCompensationOnStatementsOfOperationsDetails</Role>
      <ShortName>Share Capital - Schedule of Effect of Share-Based Compensation on Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Taxes on Income - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeAdditionalInformationDetails</Role>
      <ShortName>Taxes on Income - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Taxes on Income - Schedule of Deferred Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfDeferredIncomeTaxesDetails</Role>
      <ShortName>Taxes on Income - Schedule of Deferred Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Taxes on Income - Schedule of Change in Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureTaxesOnIncomeScheduleOfChangeInValuationAllowanceDetails</Role>
      <ShortName>Taxes on Income - Schedule of Change in Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Loss Per Ordinary Share - Schedule of Calculation of Basic and Diluted Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareScheduleOfCalculationOfBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Loss Per Ordinary Share - Schedule of Calculation of Basic and Diluted Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Loss Per Ordinary Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureLossPerOrdinaryShareAdditionalInformationDetails</Role>
      <ShortName>Loss Per Ordinary Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Related Parties-Transactions and Balances - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureRelatedPartiesTransactionsAndBalancesAdditionalInformationDetails</Role>
      <ShortName>Related Parties-Transactions and Balances - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="urgn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.urogen.com/20171231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>urgn-20171231.xml</File>
    <File>urgn-20171231.xsd</File>
    <File>urgn-20171231_cal.xml</File>
    <File>urgn-20171231_def.xml</File>
    <File>urgn-20171231_lab.xml</File>
    <File>urgn-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/exch/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001564590-18-005876-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-18-005876-xbrl.zip
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ML>WYVGO$#VMN<0DMKB<DSOXD>'C/?Q"7'Q0O=X+8C]C3^EO2']>\Q8D9XSP
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M'3^ID)]4Y?'(+H'AUJ&R&2IWW+$T=^R0NTGDWEZ4[%"@,BMS2S&@#>;F-B'
M6I_N+H'\)7VZAVTSOG<(CB_LTVT*E&IE<8=@VI1/MRG@;I"V.P35%_?I5@G.
MU@2&6X"N:W6#%\XHV!$EH>G$ATI%T$ZB0'/>W):C RRT=A(/&C 16XX Z\7
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M=<15(*X4"E[NR1T1M9"(0#AUQ-*AZRL#=14I5N4=DUU+W*W@P^U.17OI;KU
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MH8%^F ']L ,Z-EJN!?3#%@%]*_3AEL"ZWB+PM1I(MCLILZ[G0KR6,GU>!7H
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M_))8L=@[M/'-C%I_PTW9M""_DJ$WV*8MO^_G$F"3T&\AD->)$:V-'F]2&9H
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MT%G1=SH>]:ECJU6W0TC81O9$?9(0>8W*\**@<.M<*B<.B2.-]??!%9@JW>/
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MX3P)[%N%SW.FQ08AN=<(YT]4G 4?V&0R57UB^BHI)"N+*NDK-Q;T(0DGY[P
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M54^/'365BT)O)UX:: I:[;8@!#&0M6&@,<H"*F_+5$D-]P2D7(T,^M%I-&R
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MF+DE3,J5#$[;J-+)]K18 21P&IE9)0)"H;(+(<Q]1SK5=!O#H%4W-&_*&3I
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M9>G8"+R9:4 2Z/UZ-IL0#:4?7+11B9N92M'I!24 '8RM$3$).!H[8>.YAG8
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MUJ,S'792QYAKV?96P_*M216PR'?.2[72M"OWDNA( *ABE?^JX8YK,U]02U!
M^C4X &F*;RUMD*/"490P*F96(/,T#!#-45)&'M9N4>[B%6W1L<H@-F$TID[#
M;0OV5'$</78&=B,TT*[<0"<&6SEVCHA'R^!(V;Z94$M9DSDH"=<WF!N)YODA
MG?AT3!U;P_,(>7N;LV'-^F\8$%;.3;0;SL\_T<[/.S+1\EM#+"8=!9^$RW?
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MEAB,:@F7!^-D&EHB9\<ZCT.^.]$V:FG8%QRU,D7%.NH=Y2XH/%V\.7UKX9*
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MZ8_">2[]8,>34^!#7)Y/EYQR4,#I=JVMZKP9!49L8=Z,<6^0+FD&DS2C8TQ
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MNRAPTSSBP27!6@;]%-VX^?".8>#.9N1M%G">",FW:,DDY^#J,5AH3YVW/35
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M-S 68#+DUU19:N>''N"$2U/3&<2G#!*H7=Z(2&5&SL'EB!>XOL& % /YH=]
MA,JD==DL6&Y?&NK/VC8Y.S+0,$QF+9F;;- _@JD*=R'R-W1?W6.VHZ\23CP\
M@9I4]1I'V/4]#<,FX;4=AXC@5UU ZPNBVHY"*DBB[;ZC;JAOJJ\SK'3YV5 <
MQ-3C6:(**12'CSBX@4K34^!JZ1R[/<5D,U]AP\!&KR9V_@&3=EPO3^33#E_6
M-2N2_O"H6E0?6'@M9T/W4?S]PE<YX0$*8*J,J-D>LQYR@I7SR9YDORBDH8*;
M!A7_^_(-ARQII?@Z1&2;;NZZ3&+0^=4L"8*WA%<(, )7?U2P3P%_*XS""U5K
MR8%GK.D[YCP+F2]"]3 5(CKS9*<FYD74=&QH&"#HO=0?2(LG_56X:WW2?]9Y
M:]#NT!_<4S-("+Z+ C=5*T,'#U3UV5\EJ]^R)N=S/TDC@T&/"D<L@.=Q *CT
M10\WJER5DPK &!37A[Y!O-^$36(_^7XQBZF"! /=5GX(F6AK*J/AL6Z29 LU
M#P+8O/IXE$03GKEL(*(.L?7Z9Q!5YET"FV\4?#5Q.PUU _=%=&W">D8 UQL_
MU(^43*,JQ26/@G$&"5G\=*Z6+,=::=- &!H09T##6X7XT^'3@TTF]V0ALSB4
MNI=!&5K&2$^-Q+=!YYF\ %@E4GWXS*-54P>3N(0!F3-MZR],<O!-5)[YT=?+
M/.*JJP<2&OH*ZX?R@=S0O94>!^T)?J:RR((#3<;+E*CU".FYB<\P,VNVMZ#I
M/%+0O8"0R/1E7!H1/TRRV<SW?).V>_S0E/>:TGV'PK/T]#U$/^3Q!L6QW >7
MEX)MM<F>EKLJZ*Y^U;1!=P,G=.[>,=ZOISY416B"#1!+07#9ZAWX_,&X0-W@
M]0\B=N4,#'>).+[XA/M3A#P#-LT4>!^*_3.#^&1#I->\&7'LS7]NFU4^6":B
MK0-OV+*F8^).F2G%>UJQ2_C%Y(-H*$BN0]Y.W;^CA)]\D)?/Q!_YS\]>K;ME
MN0E9=5Q834T6;1"*OO>\(<W5,F8&,K\XGVV\OLUJ)G&RGC<LW$LQ"GK][$0T
MRUD9>T7#X/6;+:.$O=2:K47#FI]NQG8N2=TT8V_[L'V_5O&1OP+33'G+G'RF
M=XOP@ K3-7QKBF_=L[W;]8<L]-/U7Y<T%BJ&5]YM7U?^B^<F\_4?^*I%Y3M?
M^T+,LBY?*7OK5AE,T<%G7=!_LN3."6GA_O 7V:(T%OQQ#R$QX7KA/JSF:0</
M?*PP[VC$L!-)11NJ%Q3I)\1I]3L=/J*HS3A@W:@HYRCX2>Q?$<(3U+=NF;3K
M$?=^$)0F&_,U,6J/*6^+%&U:33F)H%TQ?)U]B_+&4N2!NG$K;WRW_EY+=*5B
M#XFC[':^_?OND%%XM!GTO5G_9G8YM':Q3OH'D[?$Z;Y8]7A*HY3] MZ'TER!
M5=>KP&6O,G4?UBW05V^S8.CRR?*E3N"K4?#BM=>;M-Z@%GL><4E $[;B\MOD
M#]^>]!YE\0YQE\N@"J13(IAE\4;EQE>0I *H:] :%M1URIS)N]$PUF%0,(,]
M=MF^;[!)=G5-Y)3W2#+GK<5SHN-!N)5HR_DQ65'3>G=;ZQ'W&WI_W)MQQKNT
ME1Y#;FE(8\&#GAN&4<K1YM3%;Q$2W@QQ]9R9ZS.*S7NV\0%]XFZ<Q#ZO".>F
MX(!PBY*%%FJ3SP59% '4G>1QQ_3*JNT9C\B3PEW*1PX(U5I>NWL;4V'-$?<Q
MZ:<[,3A9DKLN&QG5;)^5[;*(INLVX8*VMI3UANHXH0Y'K6ZGL]L,6),I[ZS'
ML5G) WXA(T<O$[)B8XKG\JC4X52D7K*[$!X6#',A\WS0'14D4U"L>$P)77[3
MXH)$L XI4I0+R<KNL_6*3T<+/[NWLOYW1Z"0CX5-R!4HLYQ"OL7OJ4>%]._E
M.G0D]I3],-QN\;ABV9(-ZM$X=1E/;AN>6QXF9\I\ O6939 &VBCNDA YH$77
M1'%7Y]5FK\1/FGU$]RVB4O/&?71:C00_JYZ\[<L]K"5UWSS:;!+S6 OKUSM)
M(__QE.<.W>A7X;/;*YRG 6> $\J$EVZLR:!/BEF#EH4[U:\UKK7GB/89VM,R
M-M=T&P-J&W3]P@_]H/I*C6L+)Z;^=9'KRN88EX/YSM:E(_U,<).L@AJ'.]:7
MM7*GDAH%=INZ4^GG TA!Z87@8#$:^PIG?2!(S/;,%(Y*@.N%F:Q-GR;:GODP
MOH+JL"K?-1'S9>5Z%F(I-PR9^Q8G*I5O4&5$+6PY5<GX.WCV6QY1.2N?RL:Q
M"#A,W-*9(>ZK;7XYC$=M(PGF@X+DR@*0F2):J*WEZC/X32,!(Z?;NNS(3-<]
M)N F\PX(@NH::HV/44CO "2%&-5=FZ;TB,,1;8<[UI_@>JO"O0"I\$-07=OC
MN9SV03-1FT*?]R[;W:&VN%DJ>"&0?<H/IO*1.8"6ZFXI];\XPT[YI_*]R$YM
MDO^( \UL5))HIUEJITW.98":N9DV/$<SK=_IM\9.3_?QM0W.0%,,33%U4VQ0
MARDV:%_V32PQ4C*IT!AJD"I"8\A28\@[%V-(+J&[VW83ST@:[,Y(<EJ=RW%K
M-!J5<Y.V<Y(V)[4B*2S7+X1=SP5^GDG\O,,O$S)Q,TJV+8=#7<XU=(#HMU7:
MYR;?\U$6YY[MGI:'F',3=I5=-A!%$\^=?JO;OVR1YY>=_$_/NZU>K]]:Y>WY
M=S1X4,[2LW\GM4TJD7&N?746\I3*VY"]^2%FXU:PKZ*M6\@.)L&"53YU6?OM
M34L5%;K!;+R/,OT?U!5QY1M@96Z(,]*V,0T*T[ED<536#>PVLVTJ4/EVYR;M
MW@TFA?C&?3*T_0AIOUG8>5&62G 9LDE>"LGEN\F89/9X]U:_6Y1I@HLVO3 +
MWM'=-Y$7@TJ97<3,(EW!**PI;<EXAJW3ZPVH55 &VS.:3 -Q]21SU9C3I,T3
M]PJ)MQ"\W+;-#-K8U-90Y6W@>M\O;KQY%"@T-8:TP4*J@^!^'(%"7S XA3>O
MYPH>5+8/XFM&K/(44VCZFE+/0H,^'!!SYA1G\MH&5--$Q55?XK1!%8=!+0!0
M-K>VLQ1*$DNFF-SN B/#JR#]^N?*<?DB4LE+Q&E\A##]Y)9=&[&U_.6C^&?]
MB&(1%_Q<06S!ZA=?Q;85=OWJE]_X/N6_RE<PZ+7'+]X4;[K:V"0*_"G)OT>$
MF;ED!!*FI:4^MH5A2(J/Z_5M8\1_L4%I7$-TO-I!0?Z>Q\/#:7>'=>,AWNSU
M7SKB'T1GZU=O-_M: -9K.]W]B*UV<@=:8C?$XE_GHD,NXA3YJ5S\:@2H 7JK
MR%C]7*7.4C^?^!U3ZMF DC4\9H\$1&Q0_AU&_@WMX"F4?PW@,91_]F*#\D]/
M_@WLX"F4?V8\]DLY-*$2I7CW\6/GX[LC\ET>N-@!3?6@D;Y'7,=IWC_7.4K;
MC0PU&>WH0.7Z[ R!,M9=QX=F6W?Q;=977*<.YW.V6YW.Q;JXSTI =V4L(^]9
M"16*16NA0;%802QVVY?CBT%[T+<63A2*C>$\%(K60H-"L:I09/:B8RV<*!2/
M&/TX>M3Q;*,?[WW>^3^<D@>?!E-K@\*HQZR%)M=CJ*;8^W=>6(L2JJ?&,!3*
M.FNA05F'LJXY$#6 H5#660L-RCJ4=<V!"),N&@77AZ+W +F+ C?U@V*PAI61
M/=11UD*#.FJ-ULAI#WHO+D;#=J^KJZXP2HZ\A6+/?FA0[&W$7I]94!=C;0L=
M11[R%8H\^Z%!D;=&:WC9'HV%I3<<H]BS'2W,AV@47%_]Y/O%+*:4^%R8T"0E
M<='8RLKX'ZHL:Z%!E;5&RVF/!R\NNNW^""/IMF/5 ,Y"H6<M-"CT2D*O_R(?
M!C?N.LZ;;MOIH?2S';0&L!A*/VNA0>FWR9EH]\;;XJ^C':U \6<3CV$:A35P
MK=,HF$196!L*1(5E+32HL-9H#=J#"Z=#Q*0*:_%"/=48UD*I9RTT*/4V^1,H
M\!J!4P.X"@6>M="@P-M$92]0Y&D@92=;E4,1*F-TGWP R@E/*=\]J&\7<^=$
MX*=L 5[1R/:5$O>ELCG5>]90[@3[\RHJR*!J5/M9=6[08 G/,ZME6)['EIT%
M*7N\?/7 9$V3:7E1.E<9RPE<G=#XSO<4AFKNOGP91[P-2EP>G52BRY*H494T
M)2)MR$C+F))[_I\P(B%[E"#$A/A)DN7SNDOT(286%UM.UGM'_%!,[3Z5,9_Y
M%'DI24&3WK9&E\N'"A]AT%\Q]5YZ.3"@T%04.;UNJR.YNCPCL+>]?56>FV]S
MKS7N=G:.<5.8Z0R\1'FHO.PNP"#R>D5R!0#"K2OU1?FAA+'T!B-@ ?=^*A^H
M#:W>#0G]06//3^1O  Q@7<8JKP^,EV1<=ZLB=X#=F\710O?1SV7LNF=PK#:1
M/Q^T+_O:XG&I8#0 XE&T>3\59=7,F=0&LR[UIX*^IQY=3!3H!IJBVG/D^@38
MKBVC0'O;C$9Y5U (_O:U31P!CEZ-B2*=*IK NZ^N0&G=K0L/PB3W;D*>#T>.
MN-/SP:A%RK9<FZ#@;^1,9\/!S"B):I)$%83!W=:U:A)LCQ30WK)\WKH"L0 .
M=%;AG9/M=U80NGL"!N1MX'K?+VZ\>110V?L[;0>XTR*:TJ ME_[ Y4J2"=@Y
M)ESCX$%E&R C;>JF,M\7](.R1 %TX%HFL[5MVIS@3-[:(%K41&5@\+HU6<+,
MY=1=L8&S-(N"(+HO1[<KCM\S/ 9;_USYY*LX"<H/IX]P$':L"8EY2K(%4T?/
M?M*\/5-@C092GB@ZLIP5G .[>P[LR ZNPCFP#> QE( VHX,24$\"Z@X-10F(
M$A EH$WHH 34DX #.[@*): 9CV$]M37% ?_D<4P2S0BC9S]TXP<BDD3LK17
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MZK6&EXZU2)TIZV RJLWHK)JPD*]L>=:>%6!\TQ8D4(C9B@P: ANX^KI%>\A
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MH-6YO)2+E_4-A/W4<BXO6^/>^&?KI@**X38=G815I'*/?=9-A>V+M@E*_OH
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M8K6=HG,6BT0\;;+5=XA-3"A7H4T-<.V=&V3ZKZMO08C4I8N)F^BR-S]*8&:
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M-PMR(<D^KF3Q(N^"G[>:#]DFBMK[7'INYJYNYJ.76C,RYDGC+(^M<-%P3X-
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M-*0JQAXT.ZI*@[/M[&659AU@NU;M[BR>'WO9@I>B>M+\1@>4^<N8)KR45F'
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M3I6<)BA0:T28!V%H[5U/YCQL1PSB;YL^X=JOH-!;! QV:HLC/MY8- 66*V5
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MLDG-T4!)QLT1KV>#?2+'=K'GY^#7X;^1?][^)8SQ'2C8GHJ6^ 6)I\1F231
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M#&B9G)89\6;M @=US/.$*\_:KCP[U4,/+ ))D !Y)BLR8!'D"GFT(ZU;@8.
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MPIKK:0/=9%-_6Y<4H*ZTO<FWEU+'K?:7FHR'4PWZR1Z$\O>(F#GD"NA6AGI
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MMC_D-Z<6]K;!<%_\J@^UG/ZIN*H#>_H8!!&64/&<CR_QB(]_&4Z$L(:,_Z7
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MFYA=<^0YYA =/['TFY($XG0O%==6SZZ8@OTGXFPZG2Y5;2I*J%SXRO0>7!+
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M5?D-<14&U;(AK;BALD53DN!N=OY $>=$0.>W6C6/^/#)FAY*3RM91043))]
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M=BT$9-PJ- []Z6&[HO'S/U!+ P04    " !XB6],XKM(,A(2  "]PP  $0
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M@2W#L_9@C#4KYPM^#;'(0!2.TR-9(IG67F-F"-KJY+>[9<Z6,)="1$ODSE+
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MY%]8+63U(7LDXOR0.<5R@W\.>1O'AJR 0/[P!5OB%')QK*K'J0(U7XT)Y*)
M<"<I6:8AH>P69HV YBTX^<L#.VZ?2K./')$*O()"3"0"^3):D(Y41]N_GE:W
MKM;/%V<4=37T+OS4[ED<"^<Y7EC[H!SP*3!^GR_?*#'V);<('UA$K0"V@ER%
M9V%=IJ"@VL)XI'5[!8P5Y"H8\[67PC5\B^*!B_FJV35/ID(M7WE)+>Q;M Y=
MX5? 542GPBM?B,DL]EO$CK3JKP"N@ER%7[Y:4U(!:'$\RI&+@6E*U41$B\Z9
M#XF+J57W.$:E"!7>^8I/<%3#21[5@)_C7I(GXM&[H*/6#8ZU.M'VB/VEJ9PC
M7SE2K61:/_EN?B*>GV!Z%DP% ]OVL/6(78C6RR$!TR&I/<AK-&2K?$C[))&@
M"+H7DY"O )(:B.])'5JO.M;*N>BW!^)6.= >8E2^4O?H4FG#CPAZ:[WB6%ZA
M'8JTA2@\XB)?2ROUB#;PO.4AJ7U<Y9A=J!SIJ(>K6F\[JK>5'ZC2]JH]1:F\
M1^_<5NL>1W6/HIJOMF-H"U&Y1,TC8:TOO+HOS+S-!K/=9'FSQG )\I%]ARG[
M#5M>24#Q)W%=;SFP&Y4_Y0NG9?X4*"(B5: *HC82RB"I344("\)7ZWH'[G%$
MOI#\L7*U79=9Y2;Y^FQZ/R3E'IFMDA;U5T ]=5_I02Y0*$GE#_GZ;7U_2-\2
MV_K'H?ZA7[FMRZSR@H)";<8+VB3DE>:$N%+*N;?9RNV2;Z#6W($EPM83JX)$
MGC#Q"7X5P5G0A#=VB0.=0\J(X3JL,C/Y7GVK/*Z@K)N==Y)%W%@_)!1$KH,B
M%3.I2Z F"O04I)&F<JT5Z=IZ[QM[+ZQZN6>Y(M$$'YI *&$S_R'V4^8\49-\
M-U_6T$3EV05'-%_/LQ-Z2]^6FJ- =13IWGKZT7*W!V^S("SRH(GGBN> BU<\
M?+-AJ*<6KAVR]Y&I\+X/!8='R_,YO]^D:R6Z1K)O! Z%A *M"WT'%Q+['GXA
M69R-.:(?%0M6.5.^Z+VW,\G=EEB#UIN.%WIOETO(9X*UX!<,FHD 0FPNC9W8
MT4-P>/+4CWY@/:P?E:_E2^158=/7)5J3=J0Z**F/.#$8:Y0YCM1ZWZ''/K77
MJO6Y59Z2KYQGCXBVR]57PSV>#H9!43@\WOM271+7EZ+R _51X?2<$785MOK4
MK4L<SR7\[821+58LTL"!93G/XD[0/3Q#+4SE(/E:=[6#^#V*S9"H3Q1UVCK*
ML0Z>)R".QV:RA!!.#5E*LCQ8W0:<DJ/*>X[;@\JE:M_@GG6MQ&L%X*O4)"A&
M25U\,5NQ=O</Q[?.=AQGT\Y3M(6H7"9?6R]WF39M^<Z/3=!VC\.EJOPE7QFO
M_;B%UH..N]S./&Q!?W].1X#*+PKJRMDG.?S_QO]3-_G2*/B6?JG4I^ -E1(H
M\3Z4/ZI>_3%8<)?!->:_TNKS63U:_P4G\@VDU_ ;M5<CEVR$CF>( UK Z F.
M7YGC;4-""B1GR/\,&0!US+D48WI^N0)4H)8EJF:?SUSF@2@<=!A^[Y886/^,
MK'^PYT:^+2ZR>6_VY#!L'!M<C^T.& C_59MNU3@LL25?>2-Y%_YT^/G, -6H
M6SX^Y:8\.+:1'HQZM*=B^0PZ@3@%WCR8V"0VR'6,/^^)*.2&=M>A]*WV7[1\
M;3H;3.TW]7OQ/FC,C+7(]<D3L1QYQO_V110'R0.),%73'1G/.J85 VJ2116>
M_ED_XB]K\X:6-C?&/J7#"G\;<>X1<^B)B74JN_6O0-D8[#J$$Y4)]@6U:OX[
M===K8IES9XIW/MV44?'NWL#'7T=X*AI(VN\SM)IC*/>77VD(#Y3]W^&>8>B(
M;*_E=P5<I^10ND:7,?UWN$ F9=#SA'+F4W*(/8= P7LR[B&R1,S7PD#!<./P
M*#H7-C7&,$7F$2B?7Q_ ;)Y&+6-N+8Y3&86JY_7/R8O[Q0+G#@>@)G$JJW;#
MW]_V J]2/;MDKD=[XDOF'+@'"&@BX+KF9)U@?_Z&.4:X>RRW$.6S)G8Y[*MI
MF@CO2)3:L#7U%J#L9 GJPSB+ %1FH@9#$^VM\6"2R3)\1( X]NCF'OB8&Y+C
MRFSBJ!6>]$^7B2I)FE8?JG':.VV=!D/3;)VP%;;I?Z04809<I:9?M;;-Y.NZ
M)\OH?M'XV-R8VD1H'^5NQY+6L,G](+/D%7R4 0HD[3$XIGN]AG9F> LYQ*\S
M3 /+(L*^*83J#3:()^_\XR/;)<S&_K;3F&X )S-]_>S!V+3K:$8,QS9A^9$.
M?=EB>251TVP2#BHF+RD&<K$9MN0$/O.V6X>).U""68XG)\*Z'*>R=DO;!.L5
M8A#Z1$PP;PR6V)R @7>>*S=TMUMK5STH6@).98SB;>5["HB[H.H4[P1-9*2X
MRV#%2/!.N^"ZUV4[E?TSK5%X&]M?L=(9W7U>^@S 72YST&1J6()00_OP ?\:
M!L<LC0WYI>N6>*V37NHD%OZZC$%XA-@HS +2MUWU^+=A0FHOXINS=)\Q(]EE
M03E%TV+]&"\<D.&P781$VI@*@J;9$M[G-B06Q%DF1(2!-IQ.XVIS+=KD]4<A
M*UT1]K;.-R3<8'3K+Q6R"@N_@P"1L+(V^7>?5Q5V?MLNF0,AD1!QTM[ \F[L
MP(!([]#*FL2GDD2,;*# G R)___(KCR0$I?@--D:DU@HDLS2VJ*R^'@Z-NK6
MPW-YU $"&I93:>^4)+.K/9D;FV<%Q^SJ'<8[F8-X8S$_P3Q$?4'_AEDJ2C>*
MFI+PK,1/;[P[PADFULBVG2>_AN>Y:X=1=Y=&14G62%B2Z0'\9\C/_IF+%$:5
M=#G [B$^K]\6M;36<\(VU*\Q5AE70-9$VX)[V.V5U)[[1:5[:M.-MPFJ"WSH
M04HPHR]"Y;APK\]X*FG4H[/#EKN#K%#<N"76C7@5Q8F2QH8M-6/5)LM 8P!%
MB)K8\FD_84DQ"G_U&1IFZLPS#,*Y &3NS->4A?=2@>LESHG&592:Y$T["I=X
MV%124?^ 6]J4Z)2V#DL*5IGC-!;7&\S7-?#TR1J3R*NF'9&%A?EF9K>KH*5I
M*<#7W8)1\YY IF)&=[O/B;&VZ5]>ILQ5C[9I%HY!N6#O5=X=EZEVE;0VS8I@
MB]1*K.LSR6<Y0=-LB>:W>\A!//\@H#C[_\UV%IRP)R%S9&\]ES^*?52#6GYE
M&+YY3*S5Q&WSL*#%"VAQ=^%YV9)EGYLXHO,6/3=F(E-6)))Z^\%&WGX1/ALA
M7G(K"9L6E.9P2; -S.,OLT'ZLBEJ:=KU,G^&".EX'-OFC(A)BA!;U.;%S:<B
MD8/\3NRN9 S38VJ:S>F35CJGLD[E0%:X(1'OC6=N:I#/791_GAD5NTM^'CAW
MIAXSUF+1ZJ8KH*D;L5Y-?-,2[$R!#^*@DWIH!P?W> +SQ#0N^LI/8W7Y&K:"
M @/N(9[LHE0L85FVX52"T -QPXKN(X'9BLG3,S$2D7<KZ4[%XN0*/O&@S'20
M3=\XH\5R3*>M7[HI/2_CF/((A%S03I9@B7QZ@KS;R?8G*K&B3YFKQ].TZ:GX
M*9D#D2ZN).F774P25. &SYB9I4^ICI;0KR"Y,5>-:M4=AK%4XODH+(=%=^9(
M>AW2IF4'Y4I#8E?7O@3I"=FW9J0V@BGBT['QSO%871.3M$VS,'I:9VY[NJBE
M8?O.D8JI#>7LKXW=*4[<9#;@G+@\>=]PXD!0-553-G=4SS4AXERU)99WXBX)
M\="(:"/+ ;MX\>:R-EO#-I[3>Y-#,*%XU])O22IOPB\-T#VY5YQ3/]_X=A9\
MZG)C33;XE_\#4$L#!!0    ( 'B);TRE1(P0, L  (21   5    =7)G;BTR
M,#$W,3(S,5]C86PN>&UL[5U;<^(X%G[?JOT/7N9EIG8!$Y+N3BJ9*0)DABHZ
MI )S>9M2;#G1MK$8R4["_/J5?,&8&-N2D8E2VP_=:<<Z.M_1D71NDB]_>EVZ
MQC,D%&'OJM7KF"T#>A:VD?=XU0IH&U +H=9//_[S'Y?_:K>-T<W<&%@^>H8C
M1"T7TX# [^=??S#^N+Z?&E/D?7L %!HC; 5+Z/E&VWCR_=5%M_OR\M*Q'6KA
MCH6770=YP+,0<-L4DF=D0=HUVNVDDR&!P&?\&"/@0R/\<V&<F+TO;;/?[ITM
M>N<79N^B=][Y=/J9/3[[MVE>F.86@=\B/,;6'T:@PQI\,L\ZO7Z_O_7R';"^
M@4=H3$9;+SOGI\[#B7-NGO<?3LU^#YR<.6;_"S@S'>>\_^5TFUN\6A/T^.0;
MWUL_A&PR^)X'71>NC9L$Z'^,Z738,0:N:]SSEZEQ#SEV:'=B6FXB/#8B'KUJ
M;0GN]8&X'4P>NR>FV>\F+[:B-R]>*<J\_=)/WNUU__@ZG5M/< G:R*,^8R5M
MQ<GDM>N=GY]WP]^R5RFZH&'[*;;",:G E['W#?Z_=O):FS]J]T[:_5[GE=HM
M)@/#N"38A??0,4(&+OSU"EZU*%JN7,YX^.R)0(>I)GGT&(7>Y]Y)U/Z[!61O
M,869AIQS.K_>3S+L!@0_0B]4P*1EE[_7S3;M9CFI2LD'K]C#RW5$<NXS>GP*
M#&>W\]ET,AHLQJ/KP71P.QS/?QF/%_,R//>,S)_5R61%%6.P@&L%;CAP'%OF
M5?CJ0\^&=D* LWUXD"$?C!,76QF\<3^A?CB /H1*PM:;1P!687==Z/HT>1)*
MIFWV8EWY+G[\YQV!*X#L\>L*>A0./'OF/T$RH!3Z=!@0PEC+RL?E:HQ)\M %
M#] -U[GJY+IJ(4V\9]8-)NM;*,1[MIUB)@>6A0//I_?0@N@9/+B0]2HA\&(Z
MBD&P!=@GR/*AS65'?:[(,EI33$<QB/D3)OX"DN56WR+,Y[=7S/00T"<VN_@_
MX[\"-O N[W;@#P$A:V9Y_ ;< (J@J$A0,:RMU>(6>Y:X)NTA<(QY( >@E)1B
M*'<$KR#QUW<N\'RF$%P95IP)P<6TF([JQ55V^VIVHXIZ$^>O@+&W1A!_PD?#
M@M"F-P0OQZ^06(C"F?,[F]ML=.@-)FS?=B!#;<^? (%"HJM%7[&$1W&O]Y!M
M[0&4T(A]%!0S/F9&*%Y#9CYSJ]J>(O" 7.0CL:&I3JPA:^<.K+F)PM8#]H0$
M=8$)D16=,_NU5W!EKTY,\2C4$_81U.8>^@!YT!X#XC$;A++1#99!J,1L7B(+
M"6ZMY=14SP/;1MR5!.X=\Y(FWA"LD ]<(9W?1T*Y89"HK8^M;\+V96YSU48R
M7BZQ)\?OV[:JW1#>U1-V;4@H-Y;\M9 3DM.ZN=5$<AEI1 %09$)SWP9[/IOW
MT+,$62XDTYR46=_UE*2<U@;,5MAK0*Q,'X!8"7WVXYN85S9>&;_1I<%R&5)K
M(Q\ND_8.,Q=%V(O9P!6'!A/6^*K5,\V>V3'-EK$B"!-&Z:IUTC("RAC'JV@M
M;1DOD >5PP"^J:$@,M,J!7[RX8'GO97B[VN%O[K.9[>F%._I!\2;:SJDD,\^
M(.2]1EX*^],'A%W%0D\E\%DK">292_GK]\:[2J%^^1!0JSO"*?)S79'O>MA8
M,FRQ$043QL<318705"H ;:VX @'LBR^FJ+4UX?)0UPH6IS+1RZS;B?/CW=_D
M -3+CML/L#@-E.+5RXC;C[<T?9="ULN VP]Y3\HU!:J7G9:?.]QVOZIERE/\
M>AEOI?CSZQU2N'I9;*5PBVM3-K!/]++.2F$7UQ6EL/6RR4IA9VO 4IAZ&6&E
M,"N5Z:7H)<VMR^Y.]:2RLM#Y@OW]=7R[F,]N9G?C^\%BPGXK7Q]:3._=%(KN
M85-U4H7Z,R?V5\32*)F&RG/'83]"B9ZTC6+F?H8>),#EGK^]1!YB6PS@1P+B
M"2G"<RDIT;H'7E7/%AMNXXR8/%P<VNLQN:I58-4(J98RP90R#\01JQ/(-!.5
M7G1< 4X\-I>AA-#VME==><G<-,"39U'/4R8"H;K+O.;*Z[QY5POP&HOIFLT$
MP:'>2Z(1UKF4>! D2EL&3'JQ&+%'KZ&#"=SP!^GXE4ULMB4S_2#K"=L+0F^+
MM63;@QL*WH>$V:?B\!6QH5B$;%+(J>I.PZ,::OD@<$,CI&M^O*+4<J:U5&*\
M_0X@-[%@X)+E7->L>E.R*]R^=4W1%]D%>(_-I&MNO@QK-:-6*D7_'M:8JD-=
MYG!(9>C?@P#R_ 6<YQWJFI@O ;CCH$LEX=O'#P -!_-?;J:SWP\4_WE#[EV&
M?U(NE7LN! (*1S#Z=^+M3^$+NB("=-6[9SO,[*3IZR%[0ZQQ.%4J4.IAK-9#
MX\#CP'<R KD!\'K J_5PM!%/\SF'&=]M>HV#2K(UM;4U0T@QC!N 2)@C'MC_
M#:)\8EK](@*CA)!J&,QC0H]>E"VRU@O6*P46W_]^!LCCQF/D53%_2@B4"%GE
M-P,  J^9@MA#O.33.-S>1=#LHZ#^/'J.D\+7)FQ!L6A9*2GE)WA7!%I(6/+9
M=KK%(A4=X0/KL'IA@0?67P$B<&]UE@@&$:J-[Q!I]0:OUZFW2>S2:GJTZEY4
M4I%@0[!F3GRSE_?(_4XI)&]IJ+\=8U.Z.J$TX+&^F9,]H,(T/GK ]B\8/A&"
M)MG#48!OG42JCS%#K#$E#/M+F*BAB'ET&AR3V.Q+RJG%0!32:1!$*,-9&%*B
M"0>V+)(]Q-1; GQS8(P\(QO:U^M?*2\<W"Q3X<V/PNZU"-7C (QVD$,#S*5Z
M'(";X/A! >92/<K587>0(&SO&CU"Y5U"=(\:!Y<2 98;35V3[(IDE#NE=3VO
MKDA&N>NZKMEWB1T1"^WHNF;6#R>8MT:;KAGXFC(IM,:US<L?3E'V.%NZ'JE7
M(9AR3UO7Y/^AYM9NR*5^F<#[$DB1*Y,CD))HFM3Q??VE4QX]E3K6K[]@1*+E
M4G< O&,1%?G06:LXM^Q4LU/_]820S5_I>C% /1F4YAYUO3^@GECV)95UO5J@
MGC2$"@:D+B70?T4MJ131]:J">D(IJ0*2NM! ?U6I5NDE=>W!1Q1.M6H_J>L2
M/J*XJE6%ZGKMPJ&E]:9.N/:-#!]$,$6EX:F,)$UE)8<6TF_])?[>MJN7]XS)
M;,2OPW0W,BD\QG"(#HYQL*$6W\H_6I'>/IIZ8^QG%X;3AZU>2TQ\]'?X_"#%
M=(?K\UC?"0K/& D6;112^E@?/#K&\EL)8I5+^^(1T36E+2J'PTW&^N?.%>]*
MX:GGF1?%W?CW3NW A3,GL4"VCD;+;4K2](^[)XFSW<SWK%B7D6_!O?IH$KDN
M?HF_3EMYS:I$KJ%/=&UX"#VG6BAB"DTSSG[8\0/C#Q33Q,\!+JUWSNYP?38M
MG$W4-C^H6TL(I;1%+W%ZVX-P@7 5,L=7T.T ,A-:?$\*S8\P<ZX/K*P2_1]!
M:$/V?Q3=[^I@\@*(O=&TNO(H)'U\_<A93-*@1,U9*]%;XUM1$J#@:83,(-7;
MGPK(-@U1T,O);W]4J[X04LY-^Y6&05<71UH8$K-1UZK=.C(J7*]U+=$]H-)(
M;.BZUN^62JV*":AKH:ZTRI3:ZKI^X4KMREN8)M.L;%=^PX[\>ET+<*5QYT5E
MWNGE7&GHC!M5=Y#,XDL4PQT@C: -TZYG#ML8D,77 >0&/)T7M0Q;R$4;E?1]
MW$CD82&I3JELU]"/$$_Z>C:-HZC)36:3Y0I8@BD6$;K_O_/C36^#9S;ZO/!B
M@;<.@,2?90S51AI(%=+'KD&0$D2%PF3-?,0#2$)L)JK)?EUV.5L/S*GX\7]0
M2P,$%     @ >(EO3&:Z#W0*,0  MH8# !4   !U<F=N+3(P,3<Q,C,Q7V1E
M9BYX;6SM?5MSX[:3[_NI.M_!9_XONW5VQM>9S*22W9)OB:L\EM?6Y/(T19.0
MQ U%*"!I6_GT"Y 204F\H$$"!&GF(5%DL='=;#0:C1^Z?_JOUX5W\(Q(X&+_
MYW?''X[>'2#?QH[KSWY^%P7OK<!VW7?_]9__]__\]/_>OS^XO'X\&-FA^XPN
MW<#V<! 1]&^/7__]X(_SA]N#6]?_Z\D*T,$EMJ,%\L.#]P?S,%S^>'CX\O+R
MP9D&-OY@X\7AU/4MWW8M[WV R+-KH^#PX/W[S2 7!%DAY>?@T@K10?S/CP<G
M1\>?WQ^=OC_^.#G^\N/1\8_'7SY\.ON!?OWQ_Q\=_7ATE"'P6R+/0>8?2N #
M?>#3T<</QZ>GIYD?WUOV7]8,'=Q<9GX\_7(V?3J9?CGZ<OIT=G1Z;)U\G!Z=
M?K8^'DVG7TX_GV6YQ<L5<6?S\.#?['^/V:3B^S[R/+0ZN-X(^A\'M[<7'PY&
MGG?PP'X<'#P@)CMR/JQI>1OET3?B!S^_RRCN]8EX'S"9'9X<'9T>;G[X+OGE
MCZ^!N_7KE]/-;X\/__AZ^VC/T<)Z[_I!2%GA3S$R><\=?_GRY3#^:_I3.KP3
MIK_-<O/Q,/DC_6G@_AC$0]UB.WY] B(<%/Z"_=_[S<_>LZ_>'Y^\/SW^\!HX
M[ZBZ#@Y^LHA-L(<>T/0@9O?'<+5$/[\+W,728V+&W\T)FA8RLN&>T?_(*/_+
M\KQW!VO"WQYN]F5V_?#0<1>'Z]\<Q@\<JF.(CH5\9LSO'32U(B^$L9?SN!YF
M\<)R?6E>UT^K9#4>XOT"+9X0 ?*Y_:A")N>4!+&C)_0^U0V,U5P":X9%N8W(
MS*<L'?]P?)),OW]-$/T5=<VWL8_898:)%1$\0W[LZC=/'L8,;3^ZPXDHI=!Z
MQ3Y>K!*2CR&EQQ:;B_'=X_CVYG(TN;H\']V.[BZN'G^]NIH\5LGS0,E\%R>S
MK:JU#'1ZN;[+W!X3;>N7Z#5$OH.<S?.,Z^9EC-F@C'C8SC.VV$2F5O 4VPE=
MV&>6M8R'.T1>&&R^B17S_NAX[6G_M?[Z^ZUK/;D>E0\%(]]Y#+']UQQ[#EUG
MK_Z.W'"UK1N/K0"8;+[TK"?DQ=&$(*U#M<+48[\%AA]02#T.<JXLXM/ +!C9
M-+R*V#QR+JG=V6X($4"$FF*!1HX3SQ7+N[=<Y\:_L)9N:'D0*0I)*&;]GM)"
MA*#$<'^SO A!V,Y]7#'+%WBQP+X<O_O/:I^<HZ<@))8-LO$R*HH%R+@W2:^H
MQ2#<D*TGS -?8#^D?H!N^X LEY(I%&%__67??/_=(L2BE*XQX7-D;A$4W&'?
MCNC_^F(6($Y,GR'P466,N8*0/C$N *^AY&FH:=P3;"/D!-<$+ZY>:4#K!F@\
M+7['$#9KT5>L^<OUJ _H&?D1DM!^$07%C%_1T!BO$ WJXZBBG@4)$%,=K=@V
MCJ@EW%LKZ\E#U-?1;TA45S 06>V3O*:CVJ.B3X#<345-<2IHJC; ($ A:&G>
M/*&8L7$X1R09"[A*EQ-0OI^B+\ZUJ3>Y\9_IYSB$D1.@DI3R[0A>(A*N[CVZ
M5E$K99:Y9$S<(9 <Y72TV'>](*F8AA;F9?S_]H/J]ZU+NE&^>ETB/V"+36;J
M23 O1$ZQ2&S&^93%%=#6MY_3%#P\(!NYSVRAIZ/6B!;RZ;3A,"6$**>C.K,P
MQR2<(++(C W**>0^KWJK;@5SMKFF_V$N^=GRXNUV>$%W)RNZW88G=,0(ZG2:
M\NY>=Y29C"K/KP"C!7O@1T18&,HV"6,?;6<1OZY/H@2WNR*D5%NU9P7!>!H/
M>;D^[ .8<,[3'6/X^XF&1.KFS"@S^NC5A?F\8B*ZV)^PM4Z*Y_63NAB]=7UT
M0S_**3CS=,HP/U0<$7N+J$7L#<'U6:\@5"%Y9DKPHIR']6"X6*V8T)WPS^^.
MCT[.CCX<';T[6!(7$[HM_OD=->XHH!SA97)"0\G%)]L_VM@/T6MXY<6$?GX7
MH-DB"2'6?_=P@)R?WX5D:PUJ5@^YA^*E>MDVP3R=[$\/KIX?JM6C2-(<]$>I
MG(6> E?Y,B[M9Q.DW?+0C0J;$?7TJ#U1MR$H>7*6K%@8$ AP:4],EE;,A>T&
M85RXCR8+5Q!U[@FV%PVG\IV=FB]?T68 @_<NJ=@?CWLA=O[&DTO9 >,5D+(\
M-\"E_=(+:<O3.:FTG_HQ<;<S;ERZ%D.C!J43RH6F0O_0#Z=4*%X'O%&U7'GG
M"%S$#KB@DL.4+<LM._5)!?[<@7DJ)G#E<5TJ\Y<.3%,QF0O.6+FDO9BQ68&,
MGI]B6Q5Q[,%&;+8A-5AL,$ C7QF%>QSZ3T?$!T2'0M @K@&C[1ZF 0'45RKW
M25<,7T#N(L0>%];HM5A0V%JHRU05ISV:\:4&;G9ZJB'/7A9R'Y]VQ;55A&3B
MX/14]+.N3'BQ:+3TTD JM-F9.[#06Y<[N)"]G=9"\:K9F3R8P/O7I%(QS4YR
MP<3,O;V62FIV9@LF:>'U0BZMT;,7)JW(E5 N>(_F;=YEWE30SUW95]0)NPJN
M8',E"+NOGPZW+\'KN=Q_;['%=XY"U^87B&O>],^E:>2U_VU.==Y\3B+6<12R
MLC*L7! $]51)2NLE[F3\FR"(^-N2E6)#I04!1E$XIU/TG_I"9"EI%82:\YC$
M5N_$P<4](C%'\@(54]1WZ;[65"FGHUL(^"0I)*&;=;GI44I&GPA-3 PA<@,N
MO5.X] 'D/8"\M8"\CP3V]F\8Y'TD@('O">SYR.A\5M.PYR/#DQTBDUIHX4\E
M/FX1P:] XOVHC=]5Z &DO3"\YE)^ZJ&46YN@CMS($!-5=/O*A6YQZ5$C=,F4
M/>V!<RI+&_$;&SWP3959/BZML(_2EF1^G-!_?[VZFSR.KR]^'=W]<O5X<_?X
MZ^CAZM?Q[>75P^/5?W^[F?PIGW$&#F!*^EF4;;7[L3L4WOB4=72+ ]!6;.=!
M<+J#67(R62\C0HV8.F07K^$;.VB.#:A)+-]4@WI#0B0+C"(9*H@W^AXV )N&
M7T .V28UWSC71525U_;]GV@-K)_@@F/T6*&LLK]#(SMV:R9N&/" _H[<P W1
M8](4(A'C =EXEC@Y<+$3];PT:KCQ'\?QBL=?&/58=#^;6* ;SN?(<R;XWEHE
MO[LGKBVF$H6C-SD-VM)!S<%U5$4&O3A8?A).O1V!B]]2 _*6$6_S_=Y'Q)Y;
M#!T-+P0))-SB6U4@90'=-M_E'7J)_]3<2\Q0;/'M-2G7+D'E=>'D3K:U'F=W
MKF?%S?T8</Z[_Y!J?5H>6A\3W%D+^G%"P^3 LIG?AY_\BE#KF4 Z*IA%3X'K
MN!999=@!'VX7$U'-?G+.)(V)$"$SX"%ZA8?8Q6'#K:6(0CL-?>#\5Q#2BD:$
M<]_.).6'8W".<QY6W1PBCC]8K@7[=([!W4H!@4ZRK;,.Z X#@;1;S"<T0,4&
MJ-@ %2N=(H;!Q81J@I9Z#2S@WKC0+5Z8@V'D:LG<&:A<^8J6C[[I&#Y.6,0*
M%."QT3<!A:6L"*ZYN/VPVZ*]$)>S/>/5782Z162<9GRRV=6 *O#)(CD?+FE[
M"VJ3YEN<H#,"PRH8+U7F*K,B"V57#:L@7S9YFQ4^*[K1X04@YYXMALL/.3BN
MU?#2&6(;PN(R KU *1= =4][ + 7/(GE5;A[@+07/57G0O< DPU#2O!*W?VU
M\2(H#)>]!W<.)!!/O/IS?\V^%.'&%=#EM4L=Y)'76^[R!%$(B^65F7NP6JJ'
M4O,ZQGV>;SF ?%[EM,MV(G-_@DO>Y35&_MH++_+:Y?BJQM4EKH NKR'K7^W<
M+>,50(6-V[3;C0T5UZLS6L?N/>HLR+>>7'0%OL9D8KW&D0CVV-U:^D7\U_/=
MQ1B$19"BKQJB9:WB(&2==V,NQ_)M=($#V)6!<CK#[98!"]YA+'BW@=,] 9,.
MN$RMB.]NPQN_TGAF$2W@AK+SH&HVK5=)-K<?5(VCM_P9D@#/9Q\SGD4-V.%X
M-.A$RCPT8(('3/!;QP1GID.'\+_[,W]7).Z$NH/P%96J,QC>O%4$%ZZZ'4'M
M5@FU'?%P-&<_X'""5PB.C8#$Z433F]W>LA$T_8G1,+#&<>8M0G5U UB-6/#;
M@7 :O8 V!^$T'*JJ'";4Z2-<H4.!7A5GE3O<D<!"JCC3O'0#M@V,"(H97:\O
ML8=.A2T]IA0AT,+)8RE;BE,4]APY$7.&F];;:[A.OBF,O#AG03^-IVLHSS_(
M2=Q%/%TF5!WG]#=_@3(=ZIC0441JGT&&>)G%D_%\Q7^R=C.C%XLX:X_Z&PI"
MY(Q\Y^IUB6SZ<8+95YERR?'?8K?+S"&V"3D=M\RIZA>1FE"^H-EE;$27^6?J
MO&HHLX'16E!(]K5F660+?6(.=.5;)-\UJYPZ(VM3U-KO?J..OJX?*R %K9AZ
M0=41>:&5=,T>AW-$-FA*@I]==N4&V&T+0!'*[,9W,\*7+J%. H/9*Z6AV! F
M;LA>W0UU9E01D>6QV.@!>;%]!G-W.<%7?DAG,OR,%$SZS8BJX31KCR/HR58!
M@997M,S2'12MW? #LN8&-37RDCN+:V T[6=WS6D(*[&0-W!,V/@<QI5NJ4.G
MC>6>N4S4ZD6E.Z>3JK30F=-,V6@$BP2-'3G\K*L#0%QOPLFI2#Y3\?)5L$7K
M2D-$;8M[G:V["4=^1BD3FB3BQRQO48$MIRR[TGY0L?4VGI/G!VK"1JWV-.G.
M"NF_Q],Q#>N3!9=#&6[\*2:+^-M+5EC.@YXTR1%O]10*R#(P3_C5]>@LQ#Y:
MV^(U)K?4KFB@3"?DC""TWM")90P%J0T]4III/W*'PP02\+CTW)!&G<_T3]06
M'IA%'(,E!-&&)J2YT39K<F"Z,FE_%K+'L^P:41]G(_<9.2EY1!>NZXA-TL=H
MN?16:]<L9F$U1Z@G#"8,>L/V*(PN)B'55$WNRTDJGB'<13* '_)M.E^M$(%F
M0C$-(>8#9'^8X6>Z0KJ,[S/V@;%[EF&7?O4]V3^RJ^J$:BGQX'08MNG,?"7"
M.(2:ACN/Z.^(X4V?Z;\D^JSD$]#+]H0R*G'EM)A(I]G7U&-H9VR9B[*Y),!M
M,6FX[#L66=U'3YYKCZ=3Q!9\X,EI!160)T&O]GRM2_II5X?LN^]_W%U\%>$M
M\^-FG1FER_8WXF:7]Y1Q+ F;/LSIW[H!6Q6#S6"BMEY%82@@,!00,*> P'"9
MVJR;RMV]IURTH?0\1&:6?S^WR,*R4127^PEN_! 1WTJVA+?NP@V1 UR])2CK
M\@4NDNA'E_>T\KH;?H ]UZ&;$"=>L^C0$LT+2ZAT7  -877>X-#Y64P#.EW'
M;$:Y_\33AU-ER6K?N2<HH%'[.F-][?J6;[N6EUZB",2A4TT-I56\_=R_4A%O
M6X!!*= 1;O!U]QC]U/#DPR+.H4.PITHO62%P%T%.S<C<&4B3P%J>=Y4X$RUU
M!+<D**ADC&L"5*E-=Y=71.:DQ5NHJJJMM-C22EVU%;-OP$M66VGQNGN;$U&D
MV$.;9=Q;+O9@.#JMN7Y=;VL9JDK_&]$+JSSF%CP#P46',5Q$4[OQU9$P*Y^1
M86;)N1K>.ESDF$*C:RD!79' P2XOS?%V5^;<8WC>R,N(=;FJBV@9&J%<W!QG
M]:G%22 <BM25."NOV?%')5JF6-R]:?[)S*V2FF0K!&AF>N,^1>GH2@QAJI<?
MS&PSI3!-#\&)<C69N6W7IB80&-CT;I$*M09&@9O>6%*M@X+#_;F^C-R:Z- 7
MH#7SES=E5(";/UQ#PF:DN':A._/=J6M;?CBR;1SY;"&ZITJQV9E8<Q?/:H_3
M;B5$:>Z!,(H;)HWE;>^NV95%861$"07%>)N[B$VY]*(>BV=B0  (<%-"1#'[
MWWR27A6=6*_GR*?&!6.^D 0434-W$P19 ;I$R7]O_ ?JF:B+F[.J$N@9>7@9
MES5_97=>Q9%!8+I0QLVZ3EG Y+<E70\H-836%X799>QU<)E6%A=F4I#:F[YV
M=XD"F[C+9%W=$-^\0%Z57YAU87I01C?NYQ)Y5!6$Y?EVR8MS*49,];6%Q=)R
M"1N+:@K[LUOVBD=!@,+@5^2QE_U-T(' "&KPUI;''.TO--QCS6['_@T-VM?M
MP:%>NY248E%^H<L$L3PZV4;.@H8S0<BFY#-:.V$XWEF0H&K#B]L0\T+@ZXH,
M<!!Q!:%>B*$!#ETP/A0174IFN,-0<C\$+2,::%E;*U7$^%E:)%RQ$SBX40&(
M]EH\+=<)M@>&7R7(>QY\/S=:+"RR&D]+MZ2P^P(@F@H87NVG51I@.4M5*\Q?
M3F(L\S)Z#MN7,79<->,ZA<TO<3E8TDUV":;?L/B=0>S#%],F<.TM@ONU^(/2
MT-4P2'N96Q")Y*O%SO$(;1;&%/((34K>&<2_V X4@_?_IM\-J!=+B29WC$#,
MJ]:"8,[.!&BY.EV(IV1-;[)77P_""72NBCXZB:8 1^*="#NF','#+:Z(%N]>
M*%4$%-]A* BXOB+ 1\A=@,(V$F;DGOQS)&<?E]1JT$87,)EU)T0AX(8++[QX
MMHCVXD761[X?6=X#]?8!"Y66U+9=5=@O^*CF(L$ L@"SZ/<$T[D5KNX]-K#O
M,-!J[&;Y0-OC"&?2)2@/)>DZ5.#O+5?.:\H>_6AJV6$,?+ZV;->C'ES&.DO(
M*!;A.B+4.5+WQ;8R[BO[)%%'KXP*]%CPUGIBEZ4P6:4.!WC"7T(!CK5;+*,0
MD?@Z#IZ&+Q:!3)DJ$HI?;J$'EZN$+42N=R)I ! 4<G&^DBGY+41.=5W.-. I
M5K%\U]<JFFV]K_V]0)W7==L"3 $N86XSIJH7U&-X@NP$P, )W"&T L2_B:BA
MH)R \; %=7KH#'X!LGYC@0C*!(B"(K%+PEA><-#H,C)0J05V$UQR,]/H]20O
MW0EVH\ID \M?7CG)8R-*=S5;3O+8:)<E6WG1:(\D6R.SF\ZF^&A"(K?+E2$\
M%=4>66QDR+*?]]T="N5.)^0':/4@0H+MEK;+E(-&-LHQ'<5[_I%M1XO(8SB'
M[5,;^HK712)&"U:M)RD@4<@K1.#FQFPK(?(+P4$SR9 UI?ZFPWMP)#%D]%6_
MWEL&K&'EB6X62X*?$U@B_/66DNE=!G_(WP_Y^R%_KRA_+[ S&O+WY?E[TU,;
M>M+61B=#)/-YI>ML3Y.XPAG[?F5PA3/V9J)]M>2M>W4R!3JLZ*9S*PT6JG;J
M1ER;525\<YD9?HW*S LR:FPDSMCQNT'"%RR59Y1MA)S@FHI^]4KC1#>@\=_O
M%B&4_> :DWNZ"4&$(&=T_#BG:UJ3=5#5#-YV)KI)D91O"E-FURQN>(9N!TOH
MJ"Y%Y%E!D*IX3![<V3S<7,)Y1#9=H%GKPPNZ<43.^6KS*M8_A%4MJCM4&ZK8
MO(E[XMH94]PP=5Q; =4#@,LD(=9O<S3V43I;XJ+;P*1E%1D];R,>4J);>,[3
MJA-@FZH*V;&AF;P2(E S$/>EB2>%%?J2I*Y:"%@^KN8(6DN!U=<$KO?J>HS
MK3]=L- 4-@R!6];'JM*9X7)GVQ%T:<DJ@P770=,3DLTYCWIAC!'(O-;U!(EW
MN<;,+7?0J,;*=T(\/V3([I]U)'/#! 3G7.#X_C;R&^YV4F^05G?SDJR#J\+:
M-@J":T379#R9N\2YMPB;6#?^A17,Q?<[572@L>NUY9*XK=%Z?1G'QADDO8^V
MAQ!F$D037E^W4 /9P9K0Z#8]]4@\&E\Z#WAE>;''C:@_BHWR#OMV\C] E)T
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MU;5>S.UN4>Z M=4Q,;17AI8U/>]H>S]JZ6H'CN;G6%XUS3:OJ:NJIGEL--Q
MLIKFL=%( ,EJFAUK)-+\E*RHI'-T,E32.6JQLITIE71,[YR@)CC/)']319A]
M&56A(M1F_WD-=:/ON'=(O[O'5;R"M-&W!#JKX?2HE5?X-?H:2G<5O7LM[+C-
M+FB]4'0^ZH77VQS6/(58+5ZH<UCZ%.(->5'(M[K^*4+)IHK](KS>=0;@OEUB
M<QS.$=FML]DZW!W.8U_ [P#)!RC\ (4W#JW=1?3K (4?L-L#=GO ;@] 8V.
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M$;I#+_%?@/@2(8(Z6@<$"1M;M5=!HA03:>>M) PU^5KV*&K8"6=<@-QF.(>
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MD?P"#+H[F9W$[D=.<(*?6-=L3O?5_&9V<WYI9@>VFI 6C"X2T8+-4V^WE?I
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MWD5LQ!XP HE>F9DN/@OU@9P45-#BM#1PM*R),1X?HUSC=I$VDT=0TE*GQ%T
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M;\M.B^19L=;N?;W+Q5/K6'_WONK>+5(K&7A]O:O3WZHHYW#RJ:\'LM)0M\F
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MII?KS5*DOP@KNMMVJ"Z@V*S$H^_8N:VX8>JD-0#- T"=D_R'*#E",#=[RQ'
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MO;;12X#^BJAJDV\&"UB<<@)ZV:9P">RK:B+ZV0<G*E61@&>MV=B;6OZZ:*
M)ZS54M&7U C?P24?:\F3HL(,>V3MX#NW@H"N!+NMX0/A)+MR0D.M4FNWB!"
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M,#$W,3(S,2YX;6Q02P$"% ,4    " !XB6],XKM(,A(2  "]PP  $0
M        @ %&7P$ =7)G;BTR,#$W,3(S,2YX<V102P$"% ,4    " !XB6],
MI42,$# +  "$D0  %0              @ &'<0$ =7)G;BTR,#$W,3(S,5]C
M86PN>&UL4$L! A0#%     @ >(EO3&:Z#W0*,0  MH8# !4
M ( !ZGP! '5R9VXM,C Q-S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( 'B);TPA
MIGJZ*F4  ':P!0 5              "  2>N 0!U<F=N+3(P,3<Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " !XB6],%.(<_09$   :.04 %0
M@ &$$P( =7)G;BTR,#$W,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  +U7
$ @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
